drug_name_id,drugname,odrugname,Brand,Brand0,Brand1,Brand2,Brand3,Brand4,Brand5,Brand6,Brand7,Brand8,Brand9,Brand10,Brand11,Brand12,Brand13,Brand14,Brand15,Brand16,Brand17,Brand18,Brand19,Brand20,Brand21,Brand22,Brand23,Brand24,Brand25,Brand26,Brand27,Brand28,Brand29,Brand30,applno1,DrugName1,applno2,DrugName2,applno3,DrugName3,applno4,DrugName4,applno5,DrugName5,applno6,DrugName6,applno7,DrugName7,applno8,DrugName8,applno9,DrugName9,applno10,DrugName10,applno11,DrugName11,date,year,month,brandname,indication,action,otheraction,tech,_merge,nda/bla number,nda/bla,submission date,submission date source,priority review,accelerated,fast track,orphan drug,breakthrough,brkthru date,manufacturer,firmtype/symbol,firm_public,firm_revenue,firm_revenue_lag_1,firm_revenue_lag_2,firm_revenue_lag_3,firm_revenue_lag_4,firm_revenue_lag_5,firm_grossprofit,firm_rd,firm_rd_supplemental,acquired firm revenue in year of acqusition,acquired firm date last revenue reported,acquired firm year last revenue reported,jv_dummy,firm_notes,in_cancerfile,drug_notes,bbw,url,index,indicationID,icd9,ccs,ccs_label,nccs,cancer
548,OROCHOL,"CVD 103-HGR; MUTACOL BERNA; OROCHOL; OROCHOL BERNA; OROCHOL E BERNA; PXVX-0200; PXVX-200; VAXCHORA; CHOLERA VACCINE (ORAL), BERNA; VACCINE (VIBRIO CHOLERAE), BERNA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-06-10T00:00:00Z,2016,6,Vaxchora,vibrio cholerae infection,,LIVE ATTENUATED BACTERIAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; ORAL FORMULATION,using only (2),125597,BLA,2015-10-15T00:00:00Z,fda,1,0,1,0,0,,paxvax,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125597,707,343,1,135,Intestinal infection,1,0
526,NP-018,"H-BAT; HEPTAVALENT EQUINE-DERIVED BOTULINUM ANTITOXIN; NP-018; BOTULINUM TOXIN IMMUNE GLOBULIN, CANGENE; BOTULINUM TOXIN IMMUNE GLOBULIN, EMERGENT BIOSOLUTIONS; BOTULISM ANTITOXIN (BAT), CANGENE; BOTULISM ANTITOXIN (BAT), EMERGENT BIOSOLUTIONS; IMMUNE GLOBULIN (BOTULISM), CANGENE; IMMUNE GLOBULIN (BOTULISM), EMERGENT BIOSOLUTIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-03-22T00:00:00Z,2013,3,BAT,clostridium botulinum infection,BOTULINUM TOXIN INHIBITOR,ANTIBACTERIAL,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN; INTRAVENOUS FORMULATION,using only (2),125462,BLA,2012-09-20T00:00:00Z,fda,1,0,0,1,0,,cangene,TSX: CNJ,1,129.8,118.4,141.5,135.7,220.6,145,60.6,22,37.2,,,,,acquired by emergent biosolutions in 2014; cangene revenues for 12 months prior to following january are reported with exception of 2013 in which revenue dated 2/1/13 - 7/31/13 is reported scaled by a factor of 2,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125462,702,71,5,135,Intestinal infection,1,0
96,BEZLOTOXUMAB,"C DIFFICILE THERAPY (ANTI TOXIN-A AND TOXIN-B ANTIBODY COMBINATION), MEDAREX; CDA-1 + CDB-1; GS-CDA1 + MDX-1388; MBL-CDA1 + MBL-CDB1; MBL-CDB1; MDX-066 + MDX-1388; MDX-1388; MK-3415 + MK-6072; MK-3415A; MK-6072; ZINPLAVA; ACTOXUMAB + BEZLOTOXUMAB; BEZLOTOXUMAB; HUMANIZED MONOCLONAL ANTIBODY COMBINATION (C DIFFICILE ENTEROTOXINS A AND B, ULTIMAB), MERCK & CO/MEDAREX/MASSACHUSETTS BIOLOGIC LABORATORIES","C DIFFICILE THERAPY (ANTI TOXIN-A AND TOXIN-B ANTIBODY COMBINATION), MEDAREX; CDA-1 + CDB-1; GS-CDA1 + MDX-1388; MBL-CDA1 + MBL-CDB1; MBL-CDB1; MDX-066 + MDX-1388; MDX-1388; MK-3415 + MK-6072; MK-3415A; MK-6072; ZINPLAVA; ACTOXUMAB + BEZLOTOXUMAB; BEZLOTOXUMAB; HUMANIZED MONOCLONAL ANTIBODY COMBINATION (C DIFFICILE ENTEROTOXINS A AND B, ULTIMAB), MERCK & CO/MEDAREX/MASSACHUSETTS BIOLOGIC LABORATORIES",BEZLOTOXUMAB,"C DIFFICILE THERAPY (ANTI TOXIN-A AND TOXIN-B ANTIBODY COMBINATION), MEDAREX",CDA-1 + CDB-1,GS-CDA1 + MDX-1388,MBL-CDA1 + MBL-CDB1,MBL-CDB1,MDX-066 + MDX-1388,MDX-1388,MK-3415 + MK-6072,MK-3415A,MK-6072,ZINPLAVA,ACTOXUMAB + BEZLOTOXUMAB,BEZLOTOXUMAB,"HUMANIZED MONOCLONAL ANTIBODY COMBINATION (C DIFFICILE ENTEROTOXINS A AND B, ULTIMAB), MERCK & CO/MEDAREX/MASSACHUSETTS BIOLOGIC LABORATORIES",,,,,,,,,,,,,,,,,761046,BEZLOTOXUMAB,,,,,,,,,,,,,,,,,,,,,2016-10-21T00:00:00Z,2016,10,Zinplava,clostridium difficile infection,CLOSTRIDIUM DIFFICILE TOXIN B INHIBITOR,ANTIBACTERIAL; ANTIDIARRHOEAL,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; TOXIN BINDING PROTEIN,matched (3),761046,BLA,2015-11-17T00:00:00Z,fda,1,0,1,0,0,,merck,NYSE: MRK,1,39807,39498,42237,44033,47267,48047,26444,10065,6524,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761046,626,995,8,135,Intestinal infection,1,0
645,ROTARIX,"444563; GSK-357941-A; GSK-444563; RIX-4414; ROTARIX; ROTARNIX; SB-444563; ROTAVIRUS VACCINE, AVANT/GSK; ROTAVIRUS VACCINE, AVANT/GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-04-03T00:00:00Z,2008,4,Rotarix,rotavirus infection,,LIVE ATTENUATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; CELL CULTURE; FREEZE DRYING; ORAL FORMULATION; ORAL LIQUID FORMULATION; ORAL SUSPENSION FORMULATION,using only (2),125265,BLA,2007-06-04T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35480.4,45147.6,45499.1,37229.2,38293.2,37593.1,27064.9,5108.18,5363.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125265,716,294,8,135,Intestinal infection,1,0
646,ROTATEQ,"ROTATEQ; V-260; ROTAVIRUS VACCINE, AVENTIS PASTEUR MSD; ROTAVIRUS VACCINE, MERCK & CO; ROTAVIRUS VACCINE, SANOFI PASTEUR MSD; VACCINE (ROTAVIRUS), MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2006-02-03T00:00:00Z,2006,2,RotaTeq,rotavirus infection,,LIVE ATTENUATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; ORAL FORMULATION; ORAL LIQUID FORMULATION; SOLUTION; VIRUS RECOMBINANT,using only (2),125122,BLA,2005-04-06T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,22636,22011.9,22972.8,22485.9,21445.8,21199,17371.3,3963.6,4020.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125122,717,294,8,135,Intestinal infection,1,0
84,BEDAQUILINE,"JNJ-16175328-AAA; R-126987; R-207910; SIRTURO; TMC-207; ANTIBACTERIAL DIARYLQUINOLINES, JOHNSON & JOHNSON; ANTIBACTERIAL DIARYLQUINOLINES, TIBOTEC; BEDAQUILINE","JNJ-16175328-AAA; R-126987; R-207910; SIRTURO; TMC-207; ANTIBACTERIAL DIARYLQUINOLINES, JOHNSON & JOHNSON; ANTIBACTERIAL DIARYLQUINOLINES, TIBOTEC; BEDAQUILINE",BEDAQUILINE,JNJ-16175328-AAA,R-126987,R-207910,SIRTURO,TMC-207,"ANTIBACTERIAL DIARYLQUINOLINES, JOHNSON & JOHNSON","ANTIBACTERIAL DIARYLQUINOLINES, TIBOTEC",BEDAQUILINE,,,,,,,,,,,,,,,,,,,,,,,204384,BEDAQUILINE FUMARATE,,,,,,,,,,,,,,,,,,,,,2012-12-28T00:00:00Z,2012,12,Sirturo,mycobacterium tuberculosis infection,ATP SYNTHASE INHIBITOR,ANTIBACTERIAL MULTIDRUG RESISTANCE INHIBITOR,ANTIBIOTIC; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204384,NDA,2012-06-28T00:00:00Z,fda,1,1,1,1,0,,johnson and johnson,NYSE: JNJ,1,67224,65030,61587,61897,63747,61095,45566,7665,7665,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204384,196,221,11,1,Tuberculosis,1,0
624,RAXIBACUMAB,"ABTHRAX; GSK-3068483; ANTI-ANTHRAX MONOCLONAL, HUMAN GENOME SCIENCES; RAXIBACUMAB","ABTHRAX; GSK-3068483; ANTI-ANTHRAX MONOCLONAL, HUMAN GENOME SCIENCES; RAXIBACUMAB",RAXIBACUMAB,ABTHRAX,GSK-3068483,"ANTI-ANTHRAX MONOCLONAL, HUMAN GENOME SCIENCES",RAXIBACUMAB,,,,,,,,,,,,,,,,,,,,,,,,,,,125349,RAXIBACUMAB,125349,RAXIBACUMAB,,,,,,,,,,,,,,,,,,,2012-12-14T00:00:00Z,2012,12,raxibacumab,bacillus anthracis infection,ANTHRAX PROTECTIVE ANTIGEN INHIBITOR,ANTIBACTERIAL,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INTRAVENOUS FORMULATION; LIQUID FORMULATION; MONOCLONAL ANTIBODY HUMAN,matched (3),125349,BLA,2012-06-15T00:00:00Z,fda,0,0,1,1,0,,glaxosmithkline,NYSE: GSK,1,42959.8,131,157.4,275.7,48.4,41.9,29874,6467.3,6467.3,215,2012-06-30T00:00:00Z,2012,,acquired by GSK in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125349,28,39,22,3,Bacterial infection; unspecified site,5,0
48,"ANTHRAX IMMUNE GLOBULIN INTRAVENOUS, EMERGENT BIOSOLUTIONS (CANGENE)","AIGIV, EMERGENT BIOSOLUTIONS (CANGENE); ANTHRASIL; NP-015; ANTHRAX IMMUNE GLOBULIN (INTRAVENOUS), CANGENE; ANTHRAX IMMUNE GLOBULIN INTRAVENOUS, EMERGENT BIOSOLUTIONS (CANGENE); IMMUNE GLOBULIN (ANTHRAX), CANGENE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-03-24T00:00:00Z,2015,3,Anthrasil,bacillus anthracis infection,ANTHRAX TOXIN INHIBITOR,ANTIBACTERIAL,ANTIBODY POLYCLONAL; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INTRAVENOUS FORMULATION,using only (2),125562,BLA,2014-07-25T00:00:00Z,fda,1,0,1,1,0,,emergent biosolutions,NYSE: EBS,1,489.3,404.5,129.8,118.4,141.5,135.7,272.5,,109.4,,,2014,,acquired by emergent biosolutions in 2014; cangene revenues for 12 months prior to following january are reported with exception of 2013 in which revenue dated 2/1/13 - 7/31/13 is reported scaled by a factor of 2,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125562,638,39,22,3,Bacterial infection; unspecified site,5,0
409,KINRIX,INFANRIX-DTPA-IPV; INFANRIX-IPV; KINRIX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-06-24T00:00:00Z,2008,6,Kinrix,bordetella pertussis infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE; TOXOID VACCINE,BIOLOGICAL THERAPEUTIC; DRUG COMBINATION; INTRAMUSCULAR FORMULATION,using only (2),125260,BLA,2007-04-09T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35480.4,45147.6,45499.1,37229.2,38293.2,37593.1,27064.9,5108.18,5363.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125260,693,47,33,3,Bacterial infection; unspecified site,1,0
95,BEXSERO,"4CMENB; BEXSERO; MB1 MENINGOCOCCAL B VACCINE, CHIRON; MB1 MENINGOCOCCAL B VACCINE, NOVARTIS; MB2 MENINGOCOCCAL B VACCINE, CHIRON; MB2 MENINGOCOCCAL B VACCINE, NOVARTIS; FIRST-GENERATION MENB VACCINE, CHIRON; FIRST-GENERATION MENB VACCINE, NOVARTIS; MENINGITIS B VACCINE, NOVARTIS; RMENB+OMV NZ; RECOMBINANT MENINGOCOCCAL B VACCINE (MENINGITIS B), CHIRON; RECOMBINANT MENINGOCOCCAL B VACCINE (MENINGITIS B), NOVARTIS; SECOND-GENERATION MENB VACCINE, CHIRON; SECOND-GENERATION MENB VACCINE, NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-01-23T00:00:00Z,2015,1,Bexsero,neisseria meningitidis meningitis,,PROPHYLACTIC VACCINE; SUBUNIT VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PROTEIN FUSION; PROTEIN RECOMBINANT; SUSPENSION,using only (2),125546,BLA,2014-06-17T00:00:00Z,cortellis,1,1,1,0,1,2014-04-07T00:00:00Z,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125546,642,1811,36,3,Bacterial infection; unspecified site,6,0
351,HIB-MENCY-TT,"792014; 92014; GSK-792014; HIB-MENCY; HIB-MENCY-TT; MENHIBRIX; N MENINGITIDIS C/Y, H INFLUENZAE TYPE B (VIRAL INFECTIONS), SMITHKLINE BEECHAM; CONJUGATED PEDIATRIC VACCINE (N MENINGITIDIS C/Y, H INFLUENZAE TYPE B), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-06-14T00:00:00Z,2012,6,MenHibrix,neisseria meningitidis infection,,POLYSACCHARIDE SUBUNIT VACCINE; PROPHYLACTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAMUSCULAR FORMULATION; OLIGOSACCHARIDE; SOLUTION,using only (2),125363,BLA,2009-08-12T00:00:00Z,fda,0,0,1,0,0,,glaxosmithkline,NYSE: GSK,1,42959.8,42629,44331.3,45825.1,35480.4,45147.6,29874,6467.29,6467.29,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125363,681,389,36,3,Bacterial infection; unspecified site,6,0
463,"MENINGOCOCCAL B RLP2086 VACCINE, PFIZER","MENB-FHBP; MNB RLP2086; PF-05212366; PF-5212366; TRUMENBA; MENINGOCOCCAL B RLP2086 VACCINE, PFIZER; MENINGOCOCCAL B RLP2086 VACCINE, WYETH; RECOMBINANT LIPIDATED PROTEIN 2086 VACCINE (MENINGOCOCCAL B), PFIZER; RECOMBINANT LIPIDATED PROTEIN 2086 VACCINE (MENINGOCOCCAL B), WYETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-10-29T00:00:00Z,2014,10,Trumenba,neisseria meningitidis meningitis,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; LIPID; PROTEIN RECOMBINANT; SUSPENSION,using only (2),125549,BLA,2014-06-16T00:00:00Z,fda,1,1,0,0,1,2014-03-20T00:00:00Z,pfizer,NYSE: PFE,1,49605,51584,54657,61035,65165,49269,22833.9,7150,8393,22144.2,2009-06-30T00:00:00Z,2009,,acquired by Pfizer in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125549,696,1811,36,3,Bacterial infection; unspecified site,6,0
464,MENVEO,"MEN ACWY CONJUGATE VACCINE, NOVARTIS; MENACWY, NOVARTIS; MENACWY-CRM; MENVEO; MENINGOCOCCAL ACWY CONJUGATE VACCINE, NOVARTIS; MENINGOCOCCAL ACWY VACCINE, CHIRON; MENINGOCOCCAL ACWY VACCINE, NOVARTIS; MENINGOCOCCAL CONJUGATE ACWY VACCINE, NOVARTIS; MENINGOCOCCAL MENINGITIS ACYW VACCINE, NOVARTIS; SEROGROUPS ACWY MENINGOCOCCAL VACCINE, NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-02-19T00:00:00Z,2010,2,Menveo,neisseria meningitidis meningitis,,POLYSACCHARIDE SUBUNIT VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; FREEZE DRYING; INTRAMUSCULAR FORMULATION; LIQUID FORMULATION; OLIGOSACCHARIDE,using only (2),125300,BLA,2008-08-29T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,51561,45075,42535,38947,35105,29753,37456,8149,9070,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125300,697,1811,36,3,Bacterial infection; unspecified site,6,0
142,CEFTAROLINE FOSAMIL,DSP-5990; PPI-0903; PPI-0903M; T-91825; TAK-599; TEFLARO; ZINFORO; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAROLINE FOSAMIL (USAN); CEFTAROLINE FOSAMIL ACETATE; CEFTAROLINE FOSAMIL MONOACETATE MONOHYDRATE,DSP-5990; PPI-0903; PPI-0903M; T-91825; TAK-599; TEFLARO; ZINFORO; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAROLINE FOSAMIL (USAN); CEFTAROLINE FOSAMIL ACETATE; CEFTAROLINE FOSAMIL MONOACETATE MONOHYDRATE,CEFTAROLINE FOSAMIL,DSP-5990,PPI-0903,PPI-0903M,T-91825,TAK-599,TEFLARO,ZINFORO,CEFTAROLINE,CEFTAROLINE FOSAMIL,CEFTAROLINE FOSAMIL (USAN),CEFTAROLINE FOSAMIL ACETATE,CEFTAROLINE FOSAMIL MONOACETATE MONOHYDRATE,,,,,,,,,,,,,,,,,,,200327,CEFTAROLINE FOSAMIL,,,,,,,,,,,,,,,,,,,,,2010-10-29T00:00:00Z,2010,10,Teflaro,bacterial skin infection,PENICILLIN BINDING PROTEIN 2X INHIBITOR,ANTIBACTERIAL; CEPHALOSPORIN; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; INFUSION; INTRAVENOUS FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),200327,NDA,2009-12-29T00:00:00Z,fda,0,0,1,0,0,,forest laboratories,NYSE: FRX,1,4308.4,4060.6,3863.8,3621.4,3242.3,,3343.2,984.7,984.7,,,2006,,acquired by forest labs in 2006,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200327,72,485,41,3,Bacterial infection; unspecified site,1,0
736,"TOBRAMYCIN (DRY POWDER INHALER, INHANCE), NOVARTIS/NEKTAR","TBM-100; TBM-100C; TIP; TMB-100; TOBI DRY POWDER; TOBI DRY POWDER INHALER; TOBI PODHALER; TOBI-TIP; TPI; ZOTEON PODHALER; TOBRAMYCIN; TOBRAMYCIN (DRY POWDER INHALER, INHANCE), NOVARTIS/NEKTAR; TOBRAMYCIN (INHALED, INHANCE), CHIRON/INHALE; TOBRAMYCIN (INHALED, INHANCE), CHIRON/NEKTAR","TBM-100; TBM-100C; TIP; TMB-100; TOBI DRY POWDER; TOBI DRY POWDER INHALER; TOBI PODHALER; TOBI-TIP; TPI; ZOTEON PODHALER; TOBRAMYCIN; TOBRAMYCIN (DRY POWDER INHALER, INHANCE), NOVARTIS/NEKTAR; TOBRAMYCIN (INHALED, INHANCE), CHIRON/INHALE; TOBRAMYCIN (INHALED, INHANCE), CHIRON/NEKTAR","TOBRAMYCIN (DRY POWDER INHALER, INHANCE), NOVARTIS/NEKTAR",TBM-100,TBM-100C,TIP,TMB-100,TOBI DRY POWDER,TOBI DRY POWDER INHALER,TOBI PODHALER,TOBI-TIP,TPI,ZOTEON PODHALER,TOBRAMYCIN,"TOBRAMYCIN (DRY POWDER INHALER, INHANCE), NOVARTIS/NEKTAR","TOBRAMYCIN (INHALED, INHANCE), CHIRON/INHALE","TOBRAMYCIN (INHALED, INHANCE), CHIRON/NEKTAR",,,,,,,,,,,,,,,,,201688,TOBRAMYCIN,50789,TOBRAMYCIN SULFATE,,,,,,,,,,,,,,,,,,,2013-03-22T00:00:00Z,2013,3,Tobi Podhaler,pseudomonas aeruginosa infection,,AMINOGLYCOSIDE ANTIBIOTIC; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; RIBOSOME BINDING AGENT,ANTIBIOTIC; CAPSULE FORMULATION; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; RIBOSOME INACTIVATOR; SMALL MOLECULE THERAPEUTIC,matched (3),201688,NDA,2011-12-21T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,52716,51971,59375,51561,45075,42535,36177,8946,9681,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201688,89,280,41,3,Bacterial infection; unspecified site,1,0
737,"TOBRAMYCIN (INHALED), CHIESI","ACTITOB; BETHKIS; BRAMITOB; TOBRINEB; TOBRAMYCIN; TOBRAMYCIN (INHALED), CHIESI","ACTITOB; BETHKIS; BRAMITOB; TOBRINEB; TOBRAMYCIN; TOBRAMYCIN (INHALED), CHIESI","TOBRAMYCIN (INHALED), CHIESI",ACTITOB,BETHKIS,BRAMITOB,TOBRINEB,TOBRAMYCIN,"TOBRAMYCIN (INHALED), CHIESI",,,,,,,,,,,,,,,,,,,,,,,,,201820,TOBRAMYCIN,50789,TOBRAMYCIN SULFATE,,,,,,,,,,,,,,,,,,,2012-10-12T00:00:00Z,2012,10,Bethkis,pseudomonas aeruginosa infection,,AMINOGLYCOSIDE ANTIBIOTIC; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; RIBOSOME BINDING AGENT,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),201820,NDA,2010-10-22T00:00:00Z,fda,0,0,0,0,0,,chiesi pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201820,91,280,41,3,Bacterial infection; unspecified site,1,0
711,TEDIZOLID PHOSPHATE,"BAY-1192631; DA-70157; DA-70218; DA-7157; DA-7218; DA-7686; DA-7867; MK-1986; SIVEXTRO; TR-700; TR-701; TR-701FA; OXAZOLIDINONES (ANTIBACTERIAL), CUBIST; OXAZOLIDINONES (ANTIBACTERIAL), TRIUS/DONG-A; TEDIZOLID PHOSPHATE; TOREZOLID; TOREZOLID PHOSPHATE","BAY-1192631; DA-70157; DA-70218; DA-7157; DA-7218; DA-7686; DA-7867; MK-1986; SIVEXTRO; TR-700; TR-701; TR-701FA; OXAZOLIDINONES (ANTIBACTERIAL), CUBIST; OXAZOLIDINONES (ANTIBACTERIAL), TRIUS/DONG-A; TEDIZOLID PHOSPHATE; TOREZOLID; TOREZOLID PHOSPHATE",TEDIZOLID PHOSPHATE,BAY-1192631,DA-70157,DA-70218,DA-7157,DA-7218,DA-7686,DA-7867,MK-1986,SIVEXTRO,TR-700,TR-701,TR-701FA,"OXAZOLIDINONES (ANTIBACTERIAL), CUBIST","OXAZOLIDINONES (ANTIBACTERIAL), TRIUS/DONG-A",TEDIZOLID PHOSPHATE,TOREZOLID,TOREZOLID PHOSPHATE,,,,,,,,,,,,,,205435,TEDIZOLID PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2014-06-20T00:00:00Z,2014,6,Sivextro,bacterial skin infection,,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; FILM COATING; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205435,NDA,2013-10-18T00:00:00Z,fda,1,0,1,0,0,,cubist pharmaceuticals,NASDAQ: CBST,1,1153.06666666667,1054.4,926.4,754,636.5,562.1,810.266666666667,388.666666666667,388.666666666667,,,,,acquired by merck in 2015; financials for the first 9 months of 2014 are reported scaled by a factor of 12/9,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205435,239,485,41,3,Bacterial infection; unspecified site,1,0
221,"DOXYCYCLINE HYCLATE (EASY-TO-SWALLOW, ACNE, BACTERIAL INFECTION), AQUA PHARMACEUTICALS","AQ-101; ACTICLATE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; DOXYCYCLINE HYCLATE (EASY-TO-SWALLOW, ACNE, BACTERIAL INFECTION), AQUA PHARMACEUTICALS","AQ-101; ACTICLATE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; DOXYCYCLINE HYCLATE (EASY-TO-SWALLOW, ACNE, BACTERIAL INFECTION), AQUA PHARMACEUTICALS","DOXYCYCLINE HYCLATE (EASY-TO-SWALLOW, ACNE, BACTERIAL INFECTION), AQUA PHARMACEUTICALS",AQ-101,ACTICLATE,DOXYCYCLINE,DOXYCYCLINE HYCLATE,"DOXYCYCLINE HYCLATE (EASY-TO-SWALLOW, ACNE, BACTERIAL INFECTION), AQUA PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,205931,DOXYCYCLINE HYCLATE,,,,,,,,,,,,,,,,,,,,,2014-07-25T00:00:00Z,2014,7,Acticlate,bacterial infection,,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT; TETRACYCLINE,ANTIBIOTIC; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205931,NDA,2013-09-25T00:00:00Z,fda,0,0,0,0,0,,almirall,BME: ALM,1,1001.8,,,,,,765.5,,121.8,,,2013,,acquired by almirall in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205931,266,40,41,3,Bacterial infection; unspecified site,1,0
547,ORITAVANCIN,LY-307599; LY-309174; LY-309360; LY-309687; LY-329332; LY-333328; NUVOCID; ORBACTIV; RAMVOCID; ORITAVANCIN,LY-307599; LY-309174; LY-309360; LY-309687; LY-329332; LY-333328; NUVOCID; ORBACTIV; RAMVOCID; ORITAVANCIN,ORITAVANCIN,LY-307599,LY-309174,LY-309360,LY-309687,LY-329332,LY-333328,NUVOCID,ORBACTIV,RAMVOCID,ORITAVANCIN,,,,,,,,,,,,,,,,,,,,,206334,ORITAVANCIN DIPHOSPHATE,,,,,,,,,,,,,,,,,,,,,2014-08-06T00:00:00Z,2014,8,Orbactiv,viridans group streptococcus infection,,ANTIBACTERIAL; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INFUSION; INTRAVENOUS FORMULATION; LIPID; LIPOPROTEIN; PEPTIDE; SMALL MOLECULE THERAPEUTIC,matched (3),206334,NDA,2013-12-06T00:00:00Z,fda,1,0,0,0,0,,the medicines company,NASDAQ: MDCO,1,659.7,624.6,558.6,484.7,437.6,404.2,447.9,139.5,149,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206334,278,3303,41,3,Bacterial infection; unspecified site,1,0
144,CEFTOLOZANE SULFATE + TAZOBACTAM,"CXA-101 + TAZOBACTAM; CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CALIXA; CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CUBIST; CXA-201; CXA/TAZ; MK-7625A; ZERBAXA; CEFTOLOZANE SULFATE + TAZOBACTAM","CXA-101 + TAZOBACTAM; CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CALIXA; CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CUBIST; CXA-201; CXA/TAZ; MK-7625A; ZERBAXA; CEFTOLOZANE SULFATE + TAZOBACTAM",CEFTOLOZANE SULFATE + TAZOBACTAM,CXA-101 + TAZOBACTAM,"CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CALIXA","CXA-101 + TAZOBACTAM (BACTERIAL INFECTION), CUBIST",CXA-201,CXA/TAZ,MK-7625A,ZERBAXA,CEFTOLOZANE SULFATE + TAZOBACTAM,,,,,,,,,,,,,,,,,,,,,,,206829,CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM,,,,,,,,,,,,,,,,,,,,,2014-12-19T00:00:00Z,2014,12,Zerbaxa,gram negative bacterium infection,BETA LACTAMASE INHIBITOR,ANTI-INFLAMMATORY; ANTIBACTERIAL; CEPHALOSPORIN,ANTIBIOTIC; DRUG COMBINATION; FORMULATION POWDER; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),206829,NDA,2014-04-21T00:00:00Z,fda,1,0,1,0,0,,cubist pharmaceuticals,NASDAQ: CBST,1,1153.06666666667,1054.4,926.4,754,636.5,562.1,810.266666666667,388.666666666667,388.666666666667,,,,,acquired by merck in 2015; financials for the first 9 months of 2014 are reported scaled by a factor of 12/9,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206829,290,137,41,3,Bacterial infection; unspecified site,1,0
182,DALBAVANCIN,"A-40926; A-40926 ANALOG, VERSICOR; ANTIBIOTIC A-40926 AGLYCONE; ANTIBIOTIC A-40926A; BI-397; DALVANCE; EXULETT; MDL-62476; MDL-63042; MDL-63246; MDL-63397; RQ-00000002; V-GLYCOPEPTIDE; VGE, BIOSEARCH; VGE, VICURON; XYDALBA; XYDALBA; ZEVEN; DALBAVANCIN; DALBAVANCIN HYDROCHLORIDE","A-40926; A-40926 ANALOG, VERSICOR; ANTIBIOTIC A-40926 AGLYCONE; ANTIBIOTIC A-40926A; BI-397; DALVANCE; EXULETT; MDL-62476; MDL-63042; MDL-63246; MDL-63397; RQ-00000002; V-GLYCOPEPTIDE; VGE, BIOSEARCH; VGE, VICURON; XYDALBA; XYDALBA; ZEVEN; DALBAVANCIN; DALBAVANCIN HYDROCHLORIDE",DALBAVANCIN,A-40926,"A-40926 ANALOG, VERSICOR",ANTIBIOTIC A-40926 AGLYCONE,ANTIBIOTIC A-40926A,BI-397,DALVANCE,EXULETT,MDL-62476,MDL-63042,MDL-63246,MDL-63397,RQ-00000002,V-GLYCOPEPTIDE,"VGE, BIOSEARCH","VGE, VICURON",XYDALBA,XYDALBA,ZEVEN,DALBAVANCIN,DALBAVANCIN HYDROCHLORIDE,,,,,,,,,,,21883,DALBAVANCIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-05-23T00:00:00Z,2014,5,Dalvance,streptococcus infection,,ANTI-INFLAMMATORY; ANTIBACTERIAL; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INFUSION; INTRAVENOUS FORMULATION; LIPOPROTEIN; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),021883,NDA,2013-09-26T00:00:00Z,fda,1,0,1,0,0,,actavis (allergan plc),NYSE: AGN,1,4676.5,,,,,,3693,583.8,605.7,,,2014,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883,401,312,41,3,Bacterial infection; unspecified site,1,0
631,RETAPAMULIN,275833; ALTABAX; ALTAGO; ALTARGO; SB-275833; RETAPAMULIN,275833; ALTABAX; ALTAGO; ALTARGO; SB-275833; RETAPAMULIN,RETAPAMULIN,275833,ALTABAX,ALTAGO,ALTARGO,SB-275833,RETAPAMULIN,,,,,,,,,,,,,,,,,,,,,,,,,22055,RETAPAMULIN,,,,,,,,,,,,,,,,,,,,,2007-04-12T00:00:00Z,2007,4,Altabax,bacterial skin infection,,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; RIBOSOME BINDING AGENT; TOPICAL DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,matched (3),022055,NDA,2006-06-12T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45147.6,45499.1,37229.2,38293.2,37593.1,34140.7,34800.8,6433.47,6612.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022055,455,485,41,3,Bacterial infection; unspecified site,1,0
217,DORIPENEM,DORIBAX; FINIBAX; S-4661; DORIPENEM,DORIBAX; FINIBAX; S-4661; DORIPENEM,DORIPENEM,DORIBAX,FINIBAX,S-4661,DORIPENEM,,,,,,,,,,,,,,,,,,,,,,,,,,,22106,DORIPENEM,,,,,,,,,,,,,,,,,,,,,2007-10-12T00:00:00Z,2007,10,Doribax,bacterial infection,PENICILLIN BINDING PROTEIN INHIBITOR,ANTI-INFLAMMATORY; ANTIBACTERIAL; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; BETA LACTAM ANTIBIOTIC; CARBAPENEM; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022106,NDA,2006-12-12T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61095,53324,50514,47348,41862,36298,43344,7680,7680,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022106,467,40,41,3,Bacterial infection; unspecified site,1,0
714,TELAVANCIN,ASP-9809; ARBELIC; TD-6424; VIBATIV; TELAVANCIN; TELAVANCIN HYDROCHLORIDE,ASP-9809; ARBELIC; TD-6424; VIBATIV; TELAVANCIN; TELAVANCIN HYDROCHLORIDE,TELAVANCIN,ASP-9809,ARBELIC,TD-6424,VIBATIV,TELAVANCIN,TELAVANCIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,22407,TELAVANCIN,,,,,,,,,,,,,,,,,,,,,2009-09-11T00:00:00Z,2009,9,Vibativ,bacterial skin infection,,ANTIBACTERIAL; ANTIMICROBIAL PERMEABILITY ENHANCER; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; BIOLOGICAL THERAPEUTIC; DAILY DOSING; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INFUSION; INTRAVENOUS FORMULATION; LIPID,matched (3),022110,NDA,2006-12-06T00:00:00Z,fda,0,0,1,0,0,,theravance,private,0,24.4,23.1,22,19.6,12.1,8.9,-53.2,,77.5,,,,,IPO in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022110,553,485,41,3,Bacterial infection; unspecified site,1,0
97,"BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HCL (H PYLORI INFECTION), APTALIS/ NEWBRIDGE/ NOVAMEDICA","H PYLORI COMBINATION THERAPY, AXCAN; HELICIDE; HELIZIDE; PYLERA; BISKALCITRATE + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HCL (H PYLORI INFECTION), APTALIS/ NEWBRIDGE/ NOVAMEDICA; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS/ NEWBRIDGE; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), AXCAN; BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE; BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE (H PYLORI INFECTION), AXCAN; BISMUTH SUBCITRATE POTASSIUM; BISMUTH SUBCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE; TETRACYCLINE","H PYLORI COMBINATION THERAPY, AXCAN; HELICIDE; HELIZIDE; PYLERA; BISKALCITRATE + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HCL (H PYLORI INFECTION), APTALIS/ NEWBRIDGE/ NOVAMEDICA; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS/ NEWBRIDGE; BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), AXCAN; BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE; BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE (H PYLORI INFECTION), AXCAN; BISMUTH SUBCITRATE POTASSIUM; BISMUTH SUBCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE; TETRACYCLINE","BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HCL (H PYLORI INFECTION), APTALIS/ NEWBRIDGE/ NOVAMEDICA","H PYLORI COMBINATION THERAPY, AXCAN",HELICIDE,HELIZIDE,PYLERA,BISKALCITRATE + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE,"BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HCL (H PYLORI INFECTION), APTALIS/ NEWBRIDGE/ NOVAMEDICA","BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS","BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), APTALIS/ NEWBRIDGE","BISKALCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE (H PYLORI INFECTION), AXCAN",BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE,"BISMUTH CITRATE + METRONIDAZOLE + TETRACYCLINE (H PYLORI INFECTION), AXCAN",BISMUTH SUBCITRATE POTASSIUM,BISMUTH SUBCITRATE POTASSIUM + METRONIDAZOLE + TETRACYCLINE HYDROCHLORIDE,TETRACYCLINE,,,,,,,,,,,,,,,,,50786,BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE,,,,,,,,,,,,,,,,,,,,,2006-09-28T00:00:00Z,2006,9,Pylera,helicobacter pylori infection,H+ K+ ATPASE INHIBITOR,ANTIBACTERIAL; MUCOSAL PROTECTIVE,ANTIBIOTIC; CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),050786,NDA,2001-09-28T00:00:00Z,fda,0,0,0,0,0,,axcan pharma,NASDAQ: AXCA,1,292.3,251.3,243.6,179.1,133.2,104.5,219.5,39.8,39.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050786,610,149,41,3,Bacterial infection; unspecified site,1,0
78,"AZTREONAM LYSINE (NEBULIZED), GILEAD","CAYSTON; CORUS-1020; GS-9268; GILEAD AZLI; AZTREONAM; AZTREONAM (INHALED, BACTERIAL LUNG INFECTION), CORUS; AZTREONAM LYSINATE; AZTREONAM LYSINE; AZTREONAM LYSINE (INHALED, BACTERIAL LUNG INFECTION), CORUS; AZTREONAM LYSINE (NEBULIZED), GILEAD","CAYSTON; CORUS-1020; GS-9268; GILEAD AZLI; AZTREONAM; AZTREONAM (INHALED, BACTERIAL LUNG INFECTION), CORUS; AZTREONAM LYSINATE; AZTREONAM LYSINE; AZTREONAM LYSINE (INHALED, BACTERIAL LUNG INFECTION), CORUS; AZTREONAM LYSINE (NEBULIZED), GILEAD","AZTREONAM LYSINE (NEBULIZED), GILEAD",CAYSTON,CORUS-1020,GS-9268,GILEAD AZLI,AZTREONAM,"AZTREONAM (INHALED, BACTERIAL LUNG INFECTION), CORUS",AZTREONAM LYSINATE,AZTREONAM LYSINE,"AZTREONAM LYSINE (INHALED, BACTERIAL LUNG INFECTION), CORUS","AZTREONAM LYSINE (NEBULIZED), GILEAD",,,,,,,,,,,,,,,,,,,,,50814,AZTREONAM,,,,,,,,,,,,,,,,,,,,,2010-02-22T00:00:00Z,2010,2,Cayston,pseudomonas aeruginosa infection,PENICILLIN BINDING PROTEIN INHIBITOR,ANTIBACTERIAL; BACTERIAL CELL WALL SYNTHESIS INHIBITOR; BETA LACTAM ANTIBIOTIC; MONOBACTAM,ANTIBIOTIC; FREEZE DRYING; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),050814,NDA,2007-11-16T00:00:00Z,fda,0,0,1,1,0,,gilead sciences,NASDAQ: GILD,1,7949.42,7011.38,5335.75,4230.05,3026.14,2028.4,6079.54,1072.93,936.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050814,617,280,41,3,Bacterial infection; unspecified site,1,0
341,GSK-208108,GSK-208108; HIBERIX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-08-19T00:00:00Z,2009,8,Hiberix,haemophilus influenzae infection,,PROPHYLACTIC VACCINE; TOXOID VACCINE,BIOLOGICAL THERAPEUTIC; INJECTABLE FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; PROTEIN CONJUGATED,using only (2),125347,BLA,2009-03-17T00:00:00Z,fda,1,1,0,0,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125347,674,145,41,3,Bacterial infection; unspecified site,1,0
636,RILPIVIRINE HYDROCHLORIDE,EDURANT; R-278474; TMC-278; RILPIVIRINE; RILPIVIRINE HYDROCHLORIDE,EDURANT; R-278474; TMC-278; RILPIVIRINE; RILPIVIRINE HYDROCHLORIDE,RILPIVIRINE HYDROCHLORIDE,EDURANT,R-278474,TMC-278,RILPIVIRINE,RILPIVIRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,202022,RILPIVIRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-05-20T00:00:00Z,2011,5,Edurant,hiv-1 infection,HIV-1 REVERSE TRANSCRIPTASE INHIBITOR; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,DAILY DOSING; FILM COATING; GRANULE; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),202022,NDA,2010-07-23T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,65030,61587,61897,63747,61095,53324,44757,7548,7548,,,2002,,acquired by J&J in 2002,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202022,96,159,42,5,HIV infection,1,0
722,"TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES","COMPLERA; EVIPLERA; TMC-278FDC; TRUVADA + TMC-278 (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES; TRUVADA + RILPIVIRINE (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + TMC-278 (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES","COMPLERA; EVIPLERA; TMC-278FDC; TRUVADA + TMC-278 (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES; TRUVADA + RILPIVIRINE (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + TMC-278 (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES","TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES",COMPLERA,EVIPLERA,TMC-278FDC,"TRUVADA + TMC-278 (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES","TRUVADA + RILPIVIRINE (HIV-1 INFECTION, FIXED DOSE), TIBOTEC/GILEAD SCIENCES","TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + TMC-278 (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES",TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE,"TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE (HIV-1 INFECTION, FIXED DOSE), GILEAD SCIENCES",,,,,,,,,,,,,,,,,,,,,,,202123,EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE,,,,,,,,,,,,,,,,,,,,,2011-08-10T00:00:00Z,2011,8,Complera,hiv-1 infection,HIV-1 REVERSE TRANSCRIPTASE INHIBITOR; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DAILY DOSING; DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202123,NDA,2011-02-10T00:00:00Z,fda,1,0,0,0,0,,gilead sciences,NASDAQ: GILD,1,8385.39,7949.42,7011.38,5335.75,4230.05,3026.14,6260.98,1229.15,1202.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202123,102,159,42,5,HIV infection,1,0
240,ELVITEGRAVIR,GS-9137; JTK-303; VITEKTA; ELVITEGRAVIR,GS-9137; JTK-303; VITEKTA; ELVITEGRAVIR,ELVITEGRAVIR,GS-9137,JTK-303,VITEKTA,ELVITEGRAVIR,,,,,,,,,,,,,,,,,,,,,,,,,,,203093,ELVITEGRAVIR,,,,,,,,,,,,,,,,,,,,,2014-09-24T00:00:00Z,2014,9,Vitekta,hiv-1 infection,HIV INTEGRASE INHIBITOR; HIV-1 INTEGRASE INHIBITOR,ANTIVIRAL,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203093,NDA,2012-06-27T00:00:00Z,fda,0,0,1,0,0,,gilead sciences,NASDAQ: GILD,1,24890,11202,9702,8385.39,7949.42,7011.38,21102,2854,2854,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203093,139,159,42,5,HIV infection,1,0
164,COBICISTAT,"GS-9350; TYBOST; ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES; ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES/ JAPAN TOBACCO; COBICISTAT","GS-9350; TYBOST; ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES; ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES/ JAPAN TOBACCO; COBICISTAT",COBICISTAT,GS-9350,TYBOST,"ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES","ANTIRETROVIRAL BOOSTING AGENT, GILEAD SCIENCES/ JAPAN TOBACCO",COBICISTAT,,,,,,,,,,,,,,,,,,,,,,,,,,203094,COBICISTAT,,,,,,,,,,,,,,,,,,,,,2014-09-24T00:00:00Z,2014,9,Tybost,hiv-1 infection,CYTOCHROME P450 3 INHIBITOR,ANTIVIRAL; SYNERGIST,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203094,NDA,2012-06-27T00:00:00Z,fda,0,0,1,0,0,,gilead sciences,NASDAQ: GILD,1,24890,11202,9702,8385.39,7949.42,7011.38,21102,2854,2854,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203094,140,159,42,5,HIV infection,1,0
245,"EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT (SINGLE TABLET REGIMEN, HIV/AIDS), GILEAD SCIENCES","EMTRIVA + VIREAD + ELVITEGRAVIR + GS-9350; EMTRIVA + VIREAD + ELVITEGRAVIR + COBICISTAT; QUAD; STRIBILD; TRUVADA + ELVITEGRAVIR + COBICISTAT, GILEAD SCIENCES; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350, GILEAD SCIENCES; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT (SINGLE TABLET REGIMEN, HIV/AIDS), GILEAD SCIENCES","EMTRIVA + VIREAD + ELVITEGRAVIR + GS-9350; EMTRIVA + VIREAD + ELVITEGRAVIR + COBICISTAT; QUAD; STRIBILD; TRUVADA + ELVITEGRAVIR + COBICISTAT, GILEAD SCIENCES; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350, GILEAD SCIENCES; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT; EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT (SINGLE TABLET REGIMEN, HIV/AIDS), GILEAD SCIENCES","EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT (SINGLE TABLET REGIMEN, HIV/AIDS), GILEAD SCIENCES",EMTRIVA + VIREAD + ELVITEGRAVIR + GS-9350,EMTRIVA + VIREAD + ELVITEGRAVIR + COBICISTAT,QUAD,STRIBILD,"TRUVADA + ELVITEGRAVIR + COBICISTAT, GILEAD SCIENCES",EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350,"EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + GS-9350, GILEAD SCIENCES",EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT,"EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE + ELVITEGRAVIR + COBICISTAT (SINGLE TABLET REGIMEN, HIV/AIDS), GILEAD SCIENCES",,,,,,,,,,,,,,,,,,,,,,203100,COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,,,,,,,,,,,2012-08-27T00:00:00Z,2012,8,Stribild,hiv-1 infection,CYTOCHROME P450 3 INHIBITOR; HIV INTEGRASE INHIBITOR; HIV-1 INTEGRASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203100,NDA,2011-10-26T00:00:00Z,fda,0,0,1,0,0,,gilead sciences,NASDAQ: GILD,1,9702,8385.39,7949.42,7011.38,5335.75,4230.05,7231,1652,1760,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203100,141,159,42,5,HIV infection,1,0
215,DOLUTEGRAVIR,"1349572; 572; GSK-1349572; HIV INTEGRASE INHIBITOR (ORAL), SHIONOGI/GLAXOSMITHKLINE; S-1349572; S-349572; S/GSK-1349572; TIVICAY; DOLUTEGRAVIR; DOLUTEGRAVIR SODIUM","1349572; 572; GSK-1349572; HIV INTEGRASE INHIBITOR (ORAL), SHIONOGI/GLAXOSMITHKLINE; S-1349572; S-349572; S/GSK-1349572; TIVICAY; DOLUTEGRAVIR; DOLUTEGRAVIR SODIUM",DOLUTEGRAVIR,1349572,572,GSK-1349572,"HIV INTEGRASE INHIBITOR (ORAL), SHIONOGI/GLAXOSMITHKLINE",S-1349572,S-349572,S/GSK-1349572,TIVICAY,DOLUTEGRAVIR,DOLUTEGRAVIR SODIUM,,,,,,,,,,,,,,,,,,,,,204790,DOLUTEGRAVIR SODIUM,,,,,,,,,,,,,,,,,,,,,2013-08-12T00:00:00Z,2013,8,Tivicay,hiv-1 infection,HIV-1 INTEGRASE INHIBITOR,ANTIVIRAL,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204790,NDA,2012-12-16T00:00:00Z,fda,1,0,1,0,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,1,"joint venture of GSK, pfizer, and shionogi",,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204790,217,159,42,5,HIV infection,1,0
188,"DARUNAVIR + COBICISTAT (FIXED DOSE, HIV INFECTION), JANSSEN R&D/ GILEAD","G-006; G-006; PREZCOBIX; PREZCOBIX; REZOLSTA; REZOLSTA; DARUNAVIR + COBICISTAT; DARUNAVIR + COBICISTAT (FIXED DOSE, HIV INFECTION), JANSSEN R&D/ GILEAD; DARUNAVIR + COBICISTAT (FIXED DOSE, HIV), TIBOTEC PHARMACEUTICALS/ GILEAD","G-006; G-006; PREZCOBIX; PREZCOBIX; REZOLSTA; REZOLSTA; DARUNAVIR + COBICISTAT; DARUNAVIR + COBICISTAT (FIXED DOSE, HIV INFECTION), JANSSEN R&D/ GILEAD; DARUNAVIR + COBICISTAT (FIXED DOSE, HIV), TIBOTEC PHARMACEUTICALS/ GILEAD","DARUNAVIR + COBICISTAT (FIXED DOSE, HIV INFECTION), JANSSEN R&D/ GILEAD",G-006,G-006,PREZCOBIX,PREZCOBIX,REZOLSTA,REZOLSTA,DARUNAVIR + COBICISTAT,"DARUNAVIR + COBICISTAT (FIXED DOSE, HIV INFECTION), JANSSEN R&D/ GILEAD","DARUNAVIR + COBICISTAT (FIXED DOSE, HIV), TIBOTEC PHARMACEUTICALS/ GILEAD",,,,,,,,,,,,,,,,,,,,,,205395,COBICISTAT; DARUNAVIR ETHANOLATE,,,,,,,,,,,,,,,,,,,,,2015-01-29T00:00:00Z,2015,1,Prezcobix,hiv infection,CYTOCHROME P450 3 INHIBITOR; HIV-1 PROTEASE INHIBITOR,,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205395,NDA,2014-03-31T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,70074,74331,71312,67224,65030,61587,48619,9046,9046,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205395,236,158,42,5,HIV infection,1,0
216,"DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR (HIV), VIIV","572-TRII; GSK-1349572 + EPZICOM (HIV), SHIONOGI-VIIV; GSK-1349572 + LAMIVUDINE + ABACAVIR; GSK-1349572 + LAMIVUDINE + ABACAVIR (HIV), VIIV; TRIUMEQ; DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR; DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR (HIV), VIIV; DOLUTEGRAVIR-TRII","572-TRII; GSK-1349572 + EPZICOM (HIV), SHIONOGI-VIIV; GSK-1349572 + LAMIVUDINE + ABACAVIR; GSK-1349572 + LAMIVUDINE + ABACAVIR (HIV), VIIV; TRIUMEQ; DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR; DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR (HIV), VIIV; DOLUTEGRAVIR-TRII","DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR (HIV), VIIV",572-TRII,"GSK-1349572 + EPZICOM (HIV), SHIONOGI-VIIV",GSK-1349572 + LAMIVUDINE + ABACAVIR,"GSK-1349572 + LAMIVUDINE + ABACAVIR (HIV), VIIV",TRIUMEQ,DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR,"DOLUTEGRAVIR + LAMIVUDINE + ABACAVIR (HIV), VIIV",DOLUTEGRAVIR-TRII,,,,,,,,,,,,,,,,,,,,,,,205551,ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE,,,,,,,,,,,,,,,,,,,,,2014-08-22T00:00:00Z,2014,8,Triumeq,hiv infection,HIV-1 INTEGRASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205551,NDA,2013-10-22T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35854.4,43907.9,42959.8,42629,44331.3,45825.1,24441.7,5376.8,5376.8,,,,1,"joint venture of GSK, pfizer, and shionogi",,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205551,242,158,42,5,HIV infection,1,0
65,"ATAZANAVIR SULFATE + COBICISTAT (FIXED-DOSE COMBINATION, HIV INFECTION), BRISTOL-MYERS SQUIBB","EVOTAZ; ATAZANAVIR + GS-9350 (FDC, HIV INFECTION), BMS/GILEAD; ATAZANAVIR + COBICISTAT COMBINATION (HIV-1 INFECTION), BMS/GILEAD; ATAZANAVIR SULFATE + COBICISTAT; ATAZANAVIR SULFATE + COBICISTAT (FIXED-DOSE COMBINATION, HIV INFECTION), BRISTOL-MYERS SQUIBB","EVOTAZ; ATAZANAVIR + GS-9350 (FDC, HIV INFECTION), BMS/GILEAD; ATAZANAVIR + COBICISTAT COMBINATION (HIV-1 INFECTION), BMS/GILEAD; ATAZANAVIR SULFATE + COBICISTAT; ATAZANAVIR SULFATE + COBICISTAT (FIXED-DOSE COMBINATION, HIV INFECTION), BRISTOL-MYERS SQUIBB","ATAZANAVIR SULFATE + COBICISTAT (FIXED-DOSE COMBINATION, HIV INFECTION), BRISTOL-MYERS SQUIBB",EVOTAZ,"ATAZANAVIR + GS-9350 (FDC, HIV INFECTION), BMS/GILEAD","ATAZANAVIR + COBICISTAT COMBINATION (HIV-1 INFECTION), BMS/GILEAD",ATAZANAVIR SULFATE + COBICISTAT,"ATAZANAVIR SULFATE + COBICISTAT (FIXED-DOSE COMBINATION, HIV INFECTION), BRISTOL-MYERS SQUIBB",,,,,,,,,,,,,,,,,,,,,,,,,,206041,ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE,206041,ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE,206041,ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE,206353,ATAZANAVIR SULFATE; COBICISTAT,,,,,,,,,,,,,,,2015-01-29T00:00:00Z,2015,1,Evotaz,hiv-1 infection,CYTOCHROME P450 3 INHIBITOR; HIV PROTEASE INHIBITOR,ANTIVIRAL; SYNERGIST,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; PEPTIDOMIMETIC; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206353,NDA,2014-04-04T00:00:00Z,fda,0,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,16560,15879,16385,17621,21244,19484,12735,4037,5760,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206353,279,159,42,5,HIV infection,1,0
718,"TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (FDC, HIV), GILEAD/ JAPAN TOBACCO","E/C/F/TAF; GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES; GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR; GENVOYA; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (FDC, HIV), GILEAD/ JAPAN TOBACCO; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD/ JAPAN TOBACCO","E/C/F/TAF; GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES; GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR; GENVOYA; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (FDC, HIV), GILEAD/ JAPAN TOBACCO; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD/ JAPAN TOBACCO","TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (FDC, HIV), GILEAD/ JAPAN TOBACCO",E/C/F/TAF,"GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES",GS-7340 + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR,GENVOYA,TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR,"TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (FDC, HIV), GILEAD/ JAPAN TOBACCO","TENOFOVIR ALAFENAMIDE + EMTRICITABINE + COBICISTAT + ELVITEGRAVIR (SINGLE TABLET REGIMEN, HIV), GILEAD/ JAPAN TOBACCO",,,,,,,,,,,,,,,,,,,,,,,,207561,COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE,,,,,,,,,,,,,,,,,,,,,2015-11-05T00:00:00Z,2015,11,Genvoya,hiv-1 infection,CYTOCHROME P450 3 INHIBITOR; HIV INTEGRASE INHIBITOR; HIV-1 INTEGRASE INHIBITOR; HIV-1 PROTEASE INHIBITOR; HIV-1 REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207561,NDA,2014-11-05T00:00:00Z,fda,0,0,1,0,0,,gilead sciences,NASDAQ: GILD,1,32639,24890,11202,9702,8385.39,7949.42,28633,3014,3014,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207561,303,159,42,5,HIV infection,1,0
244,"EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD/ JAPAN TOBACCO","DESCOVY; DESCOVY; DESCOVY COMBINATION TABLETS HT; DESCOVY COMBINATION TABLETS HT; DESCOVY COMBINATION TABLETS LT; DESCOVY COMBINATION TABLETS LT; F/TAF; EMTRICITABINE + TENOFOVIR ALAFENAMIDE; EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD; EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD/ JAPAN TOBACCO","DESCOVY; DESCOVY; DESCOVY COMBINATION TABLETS HT; DESCOVY COMBINATION TABLETS HT; DESCOVY COMBINATION TABLETS LT; DESCOVY COMBINATION TABLETS LT; F/TAF; EMTRICITABINE + TENOFOVIR ALAFENAMIDE; EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD; EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD/ JAPAN TOBACCO","EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD/ JAPAN TOBACCO",DESCOVY,DESCOVY,DESCOVY COMBINATION TABLETS HT,DESCOVY COMBINATION TABLETS HT,DESCOVY COMBINATION TABLETS LT,DESCOVY COMBINATION TABLETS LT,F/TAF,EMTRICITABINE + TENOFOVIR ALAFENAMIDE,"EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD","EMTRICITABINE + TENOFOVIR ALAFENAMIDE (FIXED DOSE, HIV INFECTION), GILEAD/ JAPAN TOBACCO",,,,,,,,,,,,,,,,,,,,,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,206042,EMTRICITABINE;TENOFOVIR DISOPROXIL FUMARATE;NEVIRAPINE,208215,EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE,208215,EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE,,,,,,,,,,,2016-04-04T00:00:00Z,2016,4,Descovy,hiv-1 infection,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208215,NDA,2015-04-06T00:00:00Z,fda,0,0,0,0,0,,gilead sciences,NASDAQ: GILD,1,30390,32639,24890,11202,9702,8385.39,26129,4666,4666,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208215,332,159,42,5,HIV infection,1,0
719,"TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (FDC, HIV), GILEAD/ JANSSEN","ODEFSEY; R/F/TAF; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (FDC, HIV), GILEAD/ JANSSEN; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES/ JANSSEN","ODEFSEY; R/F/TAF; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (FDC, HIV), GILEAD/ JANSSEN; TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES/ JANSSEN","TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (FDC, HIV), GILEAD/ JANSSEN",ODEFSEY,R/F/TAF,TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE,"TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (FDC, HIV), GILEAD/ JANSSEN","TENOFOVIR ALAFENAMIDE + EMTRICITABINE + RILPIVIRINE (SINGLE TABLET REGIMEN, HIV), GILEAD SCIENCES/ JANSSEN",,,,,,,,,,,,,,,,,,,,,,,,,,208351,EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE,,,,,,,,,,,,,,,,,,,,,2016-03-01T00:00:00Z,2016,3,Odefsey,hiv-1 infection,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DAILY DOSING; DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208351,NDA,2015-07-01T00:00:00Z,fda,1,0,0,0,0,,gilead sciences,NASDAQ: GILD,1,30390,32639,24890,11202,9702,8385.39,26129,4666,4666,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208351,340,159,42,5,HIV infection,1,0
721,"TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ, GILEAD/BMS/MERCK & CO","ATRIPLA; VIREAD + EMTRIVA + STOCRIN, GILEAD/BMS/MERCK & CO; VIREAD + EMTRIVA + SUSTIVA, GILEAD/BMS/MERCK & CO; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ, GILEAD/BMS/MERCK & CO","ATRIPLA; VIREAD + EMTRIVA + STOCRIN, GILEAD/BMS/MERCK & CO; VIREAD + EMTRIVA + SUSTIVA, GILEAD/BMS/MERCK & CO; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ; TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ, GILEAD/BMS/MERCK & CO","TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ, GILEAD/BMS/MERCK & CO",ATRIPLA,"VIREAD + EMTRIVA + STOCRIN, GILEAD/BMS/MERCK & CO","VIREAD + EMTRIVA + SUSTIVA, GILEAD/BMS/MERCK & CO",TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ,"TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE + EFAVIRENZ, GILEAD/BMS/MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,,,21937,EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE,,,,,,,,,,,,,,,,,,,,,2006-07-12T00:00:00Z,2006,7,Atripla,hiv infection,HIV-1 REVERSE TRANSCRIPTASE INHIBITOR; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,DAILY DOSING; DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021937,NDA,2006-04-25T00:00:00Z,fda,1,0,1,0,0,,gilead sciences,NASDAQ: GILD,1,3026.14,2028.4,1324.62,867.864,466.79,233.769,2592.82,383.861,383.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021937,413,158,42,5,HIV infection,1,0
187,DARUNAVIR,"HIV-1 PROTEASE INHIBITOR, TIBOTEC; PREZISTA; PREZISTA NAIVE; TMC-114; TMC-126; UIC-94003; UIC-94017; UIC-PI (RES); DARUNAVIR; DARUNAVIR ETHANOLATE","HIV-1 PROTEASE INHIBITOR, TIBOTEC; PREZISTA; PREZISTA NAIVE; TMC-114; TMC-126; UIC-94003; UIC-94017; UIC-PI (RES); DARUNAVIR; DARUNAVIR ETHANOLATE",DARUNAVIR,"HIV-1 PROTEASE INHIBITOR, TIBOTEC",PREZISTA,PREZISTA NAIVE,TMC-114,TMC-126,UIC-94003,UIC-94017,UIC-PI (RES),DARUNAVIR,DARUNAVIR ETHANOLATE,,,,,,,,,,,,,,,,,,,,,21976,DARUNAVIR ETHANOLATE,,,,,,,,,,,,,,,,,,,,,2006-06-23T00:00:00Z,2006,6,Prezista,hiv-1 infection,HIV-1 PROTEASE INHIBITOR,ANTIVIRAL,FILM COATING; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021976,NDA,2005-12-22T00:00:00Z,fda,1,1,1,0,0,,johnson and johnson,NYSE: JNJ,1,53324,50514,47348,41862,36298,,38267,7125,7125,,,2002,,acquired by J&J in 2002,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021976,421,159,42,5,HIV infection,1,0
455,MARAVIROC,"CCR5 ANTAGONIST (RHEUMATOID ARTHRITIS), PFIZER; CCR5 ANTAGONISTS (HIV INFECTION), PFIZER; CELSENTRI; DIN-02299844; SELZENTRY; UK-107543; UK-179645; UK-370907; UK-372677; UK-374503; UK-378995; UK-382055; UK-387170; UK-395859; UK-408030; UK-418526; UK-427857; UK-440103; MARAVIROC","CCR5 ANTAGONIST (RHEUMATOID ARTHRITIS), PFIZER; CCR5 ANTAGONISTS (HIV INFECTION), PFIZER; CELSENTRI; DIN-02299844; SELZENTRY; UK-107543; UK-179645; UK-370907; UK-372677; UK-374503; UK-378995; UK-382055; UK-387170; UK-395859; UK-408030; UK-418526; UK-427857; UK-440103; MARAVIROC",MARAVIROC,"CCR5 ANTAGONIST (RHEUMATOID ARTHRITIS), PFIZER","CCR5 ANTAGONISTS (HIV INFECTION), PFIZER",CELSENTRI,DIN-02299844,SELZENTRY,UK-107543,UK-179645,UK-370907,UK-372677,UK-374503,UK-378995,UK-382055,UK-387170,UK-395859,UK-408030,UK-418526,UK-427857,UK-440103,MARAVIROC,,,,,,,,,,,,203382,MARAVIROC,203382,MARAVIROC,22128,MARAVIROC,,,,,,,,,,,,,,,,,2007-08-06T00:00:00Z,2007,8,Selzentry,hiv infection,CCR5 CHEMOKINE ANTAGONIST; HIV-1 GP120 PROTEIN INHIBITOR,ANTIVIRAL; CD4 AGONIST; HIV FUSION INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022128,NDA,2006-12-19T00:00:00Z,fda,1,0,1,0,0,,pfizer,NYSE: PFE,1,48418,48371,47405,48988,44736,32294,40479,7573,8089,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022128,476,158,42,5,HIV infection,1,0
618,RALTEGRAVIR,"HIV-1 INTEGRASE INHIBITOR, MERCK & CO; ICENTRIS; ISENTRESS; MK-0518; MK-518; RALTEGRAVIR; RALTEGRAVIR POTASSIUM","HIV-1 INTEGRASE INHIBITOR, MERCK & CO; ICENTRIS; ISENTRESS; MK-0518; MK-518; RALTEGRAVIR; RALTEGRAVIR POTASSIUM",RALTEGRAVIR,"HIV-1 INTEGRASE INHIBITOR, MERCK & CO",ICENTRIS,ISENTRESS,MK-0518,MK-518,RALTEGRAVIR,RALTEGRAVIR POTASSIUM,,,,,,,,,,,,,,,,,,,,,,,,22145,RALTEGRAVIR POTASSIUM,,,,,,,,,,,,,,,,,,,,,2007-10-12T00:00:00Z,2007,10,Isentress,hiv-1 infection,HIV-1 INTEGRASE INHIBITOR,ANTIVIRAL,BUCCAL FORMULATION SYSTEMIC; FILM COATING; GRANULE; INJECTABLE CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION; TABLET FORMULATION,matched (3),022145,NDA,2007-04-13T00:00:00Z,fda,1,1,0,0,0,,merck,NYSE: MRK,1,24197.7,22636,22011.9,22972.8,22485.9,21445.8,18540.1,4557.8,4557.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022145,478,159,42,5,HIV infection,1,0
263,ETRAVIRINE,"INTELENCE; NNRTI, JANSSEN/TIBOTEC-VIRCO; NNRTI, TIBOTEC/JANSSEN; R-165335; TMC-125; DIARYLPYRIMIDINE ANALOGS (HIV), JANSSEN/TIBOTEC; DIARYLTRIAZINE ANALOGS (HIV), JANSSEN/TIBOTEC; ETRAVIRINE; IMIDOYL THIOUREA ANALOGS (HIV), JANSSEN/TIBOTEC; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (HIV), TIBOTEC; PYRAZINONE ANALOGS (HIV), JANSSEN/TIBOTEC","INTELENCE; NNRTI, JANSSEN/TIBOTEC-VIRCO; NNRTI, TIBOTEC/JANSSEN; R-165335; TMC-125; DIARYLPYRIMIDINE ANALOGS (HIV), JANSSEN/TIBOTEC; DIARYLTRIAZINE ANALOGS (HIV), JANSSEN/TIBOTEC; ETRAVIRINE; IMIDOYL THIOUREA ANALOGS (HIV), JANSSEN/TIBOTEC; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (HIV), TIBOTEC; PYRAZINONE ANALOGS (HIV), JANSSEN/TIBOTEC",ETRAVIRINE,INTELENCE,"NNRTI, JANSSEN/TIBOTEC-VIRCO","NNRTI, TIBOTEC/JANSSEN",R-165335,TMC-125,"DIARYLPYRIMIDINE ANALOGS (HIV), JANSSEN/TIBOTEC","DIARYLTRIAZINE ANALOGS (HIV), JANSSEN/TIBOTEC",ETRAVIRINE,"IMIDOYL THIOUREA ANALOGS (HIV), JANSSEN/TIBOTEC","NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (HIV), TIBOTEC","PYRAZINONE ANALOGS (HIV), JANSSEN/TIBOTEC",,,,,,,,,,,,,,,,,,,,22187,ETRAVIRINE,,,,,,,,,,,,,,,,,,,,,2008-01-18T00:00:00Z,2008,1,Intelence,hiv-1 infection,HIV-1 REVERSE TRANSCRIPTASE INHIBITOR; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022187,NDA,2007-07-17T00:00:00Z,fda,1,1,1,0,0,,johnson and johnson,NYSE: JNJ,1,63747,61095,53324,50514,47348,41862,45236,7577,7577,,,2002,,acquired by J&J in 2002,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022187,489,159,42,5,HIV infection,1,0
582,PENTACEL,"PEDIACEL; PENTACEL; PENTAVALENT PEDIATRIC VACCINE, AVENTIS PASTEUR; PENTAVALENT VACCINE, PMC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-06-20T00:00:00Z,2008,6,Pentacel,poliovirus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE; SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125145,BLA,2005-07-26T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,40266.9,42651,38911.4,33775.2,21301.1,10143.7,30017.5,6392.79,6392.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125145,709,272,45,78,Other CNS infection and poliomyelitis,1,0
612,QUADRACEL,"QUADRACEL; DIPHTHERIA, TETANUS, PERTUSSIS, POLIO VACCINE (2), AVENTIS PASTEUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-03-24T00:00:00Z,2015,3,Quadracel,poliovirus infection,,PROPHYLACTIC VACCINE; SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PARENTERAL FORMULATION UNSPECIFIED,using only (2),125525,BLA,2014-03-24T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,37861.5,38732.7,43091.6,47408.5,45544.7,45640,26002.7,5519.41,5519.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125525,712,272,45,78,Other CNS infection and poliomyelitis,1,0
320,GADOBUTROL,BAY-86-4875; DE-05040; GADAVIST; GADOGRAF; GADOVIST; GADOVIST 1.0; SH-L-562; SHL-562BB; ZK-135079; GADOBUTROL,BAY-86-4875; DE-05040; GADAVIST; GADOGRAF; GADOVIST; GADOVIST 1.0; SH-L-562; SHL-562BB; ZK-135079; GADOBUTROL,GADOBUTROL,BAY-86-4875,DE-05040,GADAVIST,GADOGRAF,GADOVIST,GADOVIST 1.0,SH-L-562,SHL-562BB,ZK-135079,GADOBUTROL,,,,,,,,,,,,,,,,,,,,,201277,GADOBUTROL,201277,GADOBUTROL,,,,,,,,,,,,,,,,,,,2011-03-14T00:00:00Z,2011,3,Gadavist,central nervous system disease,,CNS DIAGNOSTIC AGENT; CARDIOVASCULAR DIAGNOSTIC AGENT; ENDOCRINE DIAGNOSTIC AGENT; MRI IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),201277,NDA,2010-05-13T00:00:00Z,fda,0,0,0,0,0,,bayer,ETR: BAYN,1,47454.4,47050.6,44669.3,45997.3,47291.9,38208.1,24102.6,3809.03,3809,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201277,81,60,46,78,Other CNS infection and poliomyelitis,2,0
322,GADOTERATE MEGLUMINE,ARTIREM; DOTAREM; EK-5504; GADOLINIUM-DOTA MEGLUMINE; GD-DOTA; MAGNESCOPE; MAGNESCOPE SYRINGE; GADOLIUM-DOTA MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIC ACID MEGLUMINE; MEGLUMINE GADOTERATE,ARTIREM; DOTAREM; EK-5504; GADOLINIUM-DOTA MEGLUMINE; GD-DOTA; MAGNESCOPE; MAGNESCOPE SYRINGE; GADOLIUM-DOTA MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIC ACID MEGLUMINE; MEGLUMINE GADOTERATE,GADOTERATE MEGLUMINE,ARTIREM,DOTAREM,EK-5504,GADOLINIUM-DOTA MEGLUMINE,GD-DOTA,MAGNESCOPE,MAGNESCOPE SYRINGE,GADOLIUM-DOTA MEGLUMINE,GADOTERATE MEGLUMINE,GADOTERIC ACID,GADOTERIC ACID MEGLUMINE,MEGLUMINE GADOTERATE,,,,,,,,,,,,,,,,,,,204781,GADOTERATE MEGLUMINE,,,,,,,,,,,,,,,,,,,,,2013-03-20T00:00:00Z,2013,3,Dotarem,central nervous system disease,,CNS DIAGNOSTIC AGENT; CARDIOVASCULAR DIAGNOSTIC AGENT; MRI IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT,INTRAVENOUS FORMULATION; PARENTERAL FORMULATION UNSPECIFIED,matched (3),204781,NDA,2012-09-20T00:00:00Z,fda,1,0,0,0,0,,guerbet,EPA: GBT,1,537.9,533,492.2,474.3,583,449.6,392.1,,50.6,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204781,216,60,46,78,Other CNS infection and poliomyelitis,2,0
5,ACAM-2000,"ACAM-2000; ACAMBIS 2000; SMALLPOX VACCINE, ACAMBIS/BAXTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-08-31T00:00:00Z,2007,8,"Smallpox (Vaccinia) Vaccine, Live",variola virus infection,,LIVE ATTENUATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INJECTABLE FORMULATION; PARENTERAL FORMULATION UNSPECIFIED,using only (2),125158,BLA,2006-01-18T00:00:00Z,cortellis,0,0,1,0,0,,acambis,NASDAQ: ACAM,1,18.9,60.5,70.3,163.8,301.7,128.3,-2.2,43.9,47.9,,,,,acquired by sanofi in 2008,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125158,632,1270,50,7,Viral infection,1,0
318,"GABAPENTIN (ACUFORM CONTROLLED-RELEASE, GASTRIC RETENTION SYSTEM), DEPOMED","DM-1796; DM-5689; GABAPENTIN ER; GABAPENTIN GR; GRALISE; SEFELSA; SERADA; GABAPENTIN; GABAPENTIN (ACUFORM CONTROLLED-RELEASE, GASTRIC RETENTION SYSTEM), DEPOMED","DM-1796; DM-5689; GABAPENTIN ER; GABAPENTIN GR; GRALISE; SEFELSA; SERADA; GABAPENTIN; GABAPENTIN (ACUFORM CONTROLLED-RELEASE, GASTRIC RETENTION SYSTEM), DEPOMED","GABAPENTIN (ACUFORM CONTROLLED-RELEASE, GASTRIC RETENTION SYSTEM), DEPOMED",DM-1796,DM-5689,GABAPENTIN ER,GABAPENTIN GR,GRALISE,SEFELSA,SERADA,GABAPENTIN,"GABAPENTIN (ACUFORM CONTROLLED-RELEASE, GASTRIC RETENTION SYSTEM), DEPOMED",,,,,,,,,,,,,,,,,,,,,,22544,GABAPENTIN,,,,,,,,,,,,,,,,,,,,,2011-01-28T00:00:00Z,2011,1,Gralise,postherpetic neuralgia,,ANALGESIC; ANTICONVULSANT AGENT; GABA MODULATOR,ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022544,NDA,2010-03-30T00:00:00Z,fda,0,0,0,1,0,,abbott laboratories,NYSE: ABT,1,21407,35166.7,30764.7,29527.6,25914.2,22476.3,11436,1512,1512,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022544,596,3300,53,7,Viral infection,3,0
775,VARIZIG,"PAB (VZV), CANGENE; PAB (VZV), EMERGENT BIOSOLUTIONS; VZIG; VARIZIG; VARICELLA ZOSTER ANTIBODY, CANGENE; VARICELLA ZOSTER ANTIBODY, EMERGENT BIOSOLUTIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-12-20T00:00:00Z,2012,12,Varizig,varicella zoster virus infection,,ANTIVIRAL; UNSPECIFIED DRUG TARGET,ANTIBODY POLYCLONAL; BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125430,BLA,2012-06-29T00:00:00Z,fda,1,0,0,1,0,,cangene,TSX: CNJ,1,118.4,141.5,135.7,220.6,145,119.9,31.4,19.2,29.9,,,,,acquired by emergent biosolutions in 2014; cangene revenues for 12 months prior to following january are reported with exception of 2013 in which revenue dated 2/1/13 - 7/31/13 is reported scaled by a factor of 2,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125430,728,392,53,7,Viral infection,3,0
10,"ACICLOVIR (BUCCAL, LAURIAD), ONXEO","BA-021; LABIRIAD; SITAVIG; SITAVIR; ACICLOVIR; ACICLOVIR (BUCCAL, LAURIAD), BIOALLIANCE; ACICLOVIR (BUCCAL, LAURIAD), ONXEO; ACYCLOVIR; ACYCLOVIR (BUCCAL, LAURIAD), BIOALLIANCE; ACYCLOVIR LAURIAD","BA-021; LABIRIAD; SITAVIG; SITAVIR; ACICLOVIR; ACICLOVIR (BUCCAL, LAURIAD), BIOALLIANCE; ACICLOVIR (BUCCAL, LAURIAD), ONXEO; ACYCLOVIR; ACYCLOVIR (BUCCAL, LAURIAD), BIOALLIANCE; ACYCLOVIR LAURIAD","ACICLOVIR (BUCCAL, LAURIAD), ONXEO",BA-021,LABIRIAD,SITAVIG,SITAVIR,ACICLOVIR,"ACICLOVIR (BUCCAL, LAURIAD), BIOALLIANCE","ACICLOVIR (BUCCAL, LAURIAD), ONXEO",ACYCLOVIR,"ACYCLOVIR (BUCCAL, LAURIAD), BIOALLIANCE",ACYCLOVIR LAURIAD,,,,,,,,,,,,,,,,,,,,,203791,ACYCLOVIR,203791,ACYCLOVIR,,,,,,,,,,,,,,,,,,,2013-04-12T00:00:00Z,2013,4,Sitavig,hsv-1 infection,DNA POLYMERASE INHIBITOR; THYMIDINE KINASE INHIBITOR,VIRAL REPLICATION INHIBITOR,BUCCAL FORMULATION LOCAL; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203791,NDA,2012-03-12T00:00:00Z,fda,0,0,0,0,0,,bioalliance pharma,EPA: ONXEO,1,2.02,5.311,4.197,30.214,10.801,11.422,1.656,,13.7,,,,,merged with topotarget to become onxeo in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203791,171,164,54,7,Viral infection,5,0
325,"GANCICLOVIR (0.15% OPHTHALMIC GEL, EYE INFECTION), SIRION/LABORATORIES THEA","GV-550; ST-605; VIRGAN; ZIRGAN; GANCICLOVIR (0.15% OPHTHALMIC GEL, EYE INFECTION), SIRION/LABORATORIES THEA","GV-550; ST-605; VIRGAN; ZIRGAN; GANCICLOVIR (0.15% OPHTHALMIC GEL, EYE INFECTION), SIRION/LABORATORIES THEA","GANCICLOVIR (0.15% OPHTHALMIC GEL, EYE INFECTION), SIRION/LABORATORIES THEA",GV-550,ST-605,VIRGAN,ZIRGAN,"GANCICLOVIR (0.15% OPHTHALMIC GEL, EYE INFECTION), SIRION/LABORATORIES THEA",,,,,,,,,,,,,,,,,,,,,,,,,,209347,GANCICLOVIR,209347,GANCICLOVIR,22211,GANCICLOVIR,,,,,,,,,,,,,,,,,2009-09-15T00:00:00Z,2009,9,Zirgan,herpetic keratitis,DNA POLYMERASE INHIBITOR; TRANSFERASE INHIBITOR,VIRAL REPLICATION INHIBITOR,OPHTHALMIC FORMULATION; OPHTHALMIC GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022211,NDA,2008-11-14T00:00:00Z,fda,0,0,0,1,0,,sirion therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022211,499,3145,54,7,Viral infection,5,0
11,"ACICLOVIR + HYDROCORTISONE (DERMATOLOGICAL), MEDIVIR","GERCLEAR; LIPSOVIR; ME-609; XERCLEAR; XERESE; ZOVIDUO; ZOVIRAX DUO; ACICLOVIR + HYDROCORTISONE; ACICLOVIR + HYDROCORTISONE (DERMATOLOGICAL), MEDIVIR; ACICLOVIR + HYDROCORTISONE (HERPES), ASTRA/MEDIVIR; ANTIVIRALS (HERPES), ASTRA/MEDIVIR","GERCLEAR; LIPSOVIR; ME-609; XERCLEAR; XERESE; ZOVIDUO; ZOVIRAX DUO; ACICLOVIR + HYDROCORTISONE; ACICLOVIR + HYDROCORTISONE (DERMATOLOGICAL), MEDIVIR; ACICLOVIR + HYDROCORTISONE (HERPES), ASTRA/MEDIVIR; ANTIVIRALS (HERPES), ASTRA/MEDIVIR","ACICLOVIR + HYDROCORTISONE (DERMATOLOGICAL), MEDIVIR",GERCLEAR,LIPSOVIR,ME-609,XERCLEAR,XERESE,ZOVIDUO,ZOVIRAX DUO,ACICLOVIR + HYDROCORTISONE,"ACICLOVIR + HYDROCORTISONE (DERMATOLOGICAL), MEDIVIR","ACICLOVIR + HYDROCORTISONE (HERPES), ASTRA/MEDIVIR","ANTIVIRALS (HERPES), ASTRA/MEDIVIR",,,,,,,,,,,,,,,,,,,,22436,ACYCLOVIR; HYDROCORTISONE,,,,,,,,,,,,,,,,,,,,,2009-07-31T00:00:00Z,2009,7,Xerese,herpes simplex virus infection,DNA POLYMERASE INHIBITOR; GLUCOCORTICOID AGONIST,ANTIVIRAL; HSV REPLICATION INHIBITOR; STEROIDAL ANTI-INFLAMMATORY,DERMATOLOGICAL FORMULATION; DRUG COMBINATION; EMULSION DERMATOLOGICAL; NUCLEOSIDE SYNTHESIS; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),022436,NDA,2008-09-30T00:00:00Z,fda,0,0,0,0,0,,medivir,STO: MVIR-B,1,5,13,39.2,18.9,13.2,12.8,5,,17.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022436,563,157,54,7,Viral infection,5,0
367,IC-51,"IC-51; IXIARO; JE-PIV; JEVAL; JAPANESE ENCEPHALITIS VIRUS VACCINE, VACCGEN/INTERCELL; JEEV; JESPECT",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-03-30T00:00:00Z,2009,3,Ixiaro,japanese encephalitis virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; SUSPENSION,using only (2),125280,BLA,2007-12-18T00:00:00Z,fda,0,0,0,0,0,,intercell,WBAG: ICLL,1,88.4,77.9,77.9,30.9,10,6.2,70.6,89.6,90,,,,,acquired by vivalis in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125280,686,1283,62,77,Encephalitis (except that caused by tuberculosis or sexually transmitted disease),1,0
713,TELAPREVIR,"HCV NS3 PROTEASE INHIBITORS (HCV INFECTION), VERTEX/JANSSEN/MITSUBISHI TANABE; HCV PROTEASE INHIBITORS, VERTEX; HCV PROTEASE INHIBITORS, VERTEX/LILLY; INCIVEK; INCIVO; LY-570310; MP-424; NS3 PROTEASE INHIBITORS (HEPATITIS C VIRUS), VERTEX/LILLY; TELAVIC; VX-950; TELAPREVIR","HCV NS3 PROTEASE INHIBITORS (HCV INFECTION), VERTEX/JANSSEN/MITSUBISHI TANABE; HCV PROTEASE INHIBITORS, VERTEX; HCV PROTEASE INHIBITORS, VERTEX/LILLY; INCIVEK; INCIVO; LY-570310; MP-424; NS3 PROTEASE INHIBITORS (HEPATITIS C VIRUS), VERTEX/LILLY; TELAVIC; VX-950; TELAPREVIR",TELAPREVIR,"HCV NS3 PROTEASE INHIBITORS (HCV INFECTION), VERTEX/JANSSEN/MITSUBISHI TANABE","HCV PROTEASE INHIBITORS, VERTEX","HCV PROTEASE INHIBITORS, VERTEX/LILLY",INCIVEK,INCIVO,LY-570310,MP-424,"NS3 PROTEASE INHIBITORS (HEPATITIS C VIRUS), VERTEX/LILLY",TELAVIC,VX-950,TELAPREVIR,,,,,,,,,,,,,,,,,,,,201917,TELAPREVIR,,,,,,,,,,,,,,,,,,,,,2011-05-23T00:00:00Z,2011,5,Incivek,hepatitis c virus infection,HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR; P-GLYCOPROTEIN INHIBITOR,HEPATITIS C VIRUS REPLICATION INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),201917,NDA,2010-11-22T00:00:00Z,fda,1,0,1,0,0,,vertex pharmaceuticals,NASDAQ: VRTX,1,1410.6,143.4,101.9,175.5,199,216.4,622.4,,707.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201917,92,153,70,6,Hepatitis,1,0
100,BOCEPREVIR,DIN-02370816; MK-3034; SCH-503034; VICTRELIS; BOCEPREVIR,DIN-02370816; MK-3034; SCH-503034; VICTRELIS; BOCEPREVIR,BOCEPREVIR,DIN-02370816,MK-3034,SCH-503034,VICTRELIS,BOCEPREVIR,,,,,,,,,,,,,,,,,,,,,,,,,,202258,BOCEPREVIR,,,,,,,,,,,,,,,,,,,,,2011-05-13T00:00:00Z,2011,5,Victrelis,hepatitis c virus infection,HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR; HEPATITIS C VIRUS PROTEASE INHIBITOR; HEPATITIS C VIRUS PROTEIN NS4B INHIBITOR,ANTI-INFLAMMATORY; ANTIVIRAL; HEPATITIS C VIRUS REPLICATION INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202258,NDA,2010-11-10T00:00:00Z,fda,1,0,1,0,0,,merck,NYSE: MRK,1,48047,45987,27428,18502,12690,10594,31731,7742,7880,18052,2009-09-30T00:00:00Z,2009,,acquired by merck in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202258,107,153,70,6,Hepatitis,1,0
678,SOFOSBUVIR,"GS-7977; PSI-7977; SOVALDI; HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR (ORAL PRODRUG), PHARMASSET; SOFODELEVIER; SOFOSBUVIR","GS-7977; PSI-7977; SOVALDI; HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR (ORAL PRODRUG), PHARMASSET; SOFODELEVIER; SOFOSBUVIR",SOFOSBUVIR,GS-7977,PSI-7977,SOVALDI,"HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR (ORAL PRODRUG), PHARMASSET",SOFODELEVIER,SOFOSBUVIR,,,,,,,,,,,,,,,,,,,,,,,,,204671,SOFOSBUVIR,,,,,,,,,,,,,,,,,,,,,2013-12-06T00:00:00Z,2013,12,Sovaldi,hepatitis c virus infection,HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR,ANTI-INFLAMMATORY; ANTIVIRAL,FILM COATING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY; TABLET FORMULATION,matched (3),204671,NDA,2013-04-08T00:00:00Z,fda,1,0,1,0,1,2013-10-25T00:00:00Z,gilead sciences,NASDAQ: GILD,1,11202,9702,8385.39,7949.42,7011.38,5335.75,8343,2120,2120,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204671,209,153,70,6,Hepatitis,1,0
668,SIMEPREVIR,"GALEXOS; HCV NS3/4A PROTEASE INHIBITORS, TIBOTEC/MEDIVIR; HCV-PI; OLYSIO; SOVRIAD; TMC-435; TMC-435350; HEPATITIS C VIRUS THERAPIES, TIBOTEC; SIMEPREVIR","GALEXOS; HCV NS3/4A PROTEASE INHIBITORS, TIBOTEC/MEDIVIR; HCV-PI; OLYSIO; SOVRIAD; TMC-435; TMC-435350; HEPATITIS C VIRUS THERAPIES, TIBOTEC; SIMEPREVIR",SIMEPREVIR,GALEXOS,"HCV NS3/4A PROTEASE INHIBITORS, TIBOTEC/MEDIVIR",HCV-PI,OLYSIO,SOVRIAD,TMC-435,TMC-435350,"HEPATITIS C VIRUS THERAPIES, TIBOTEC",SIMEPREVIR,,,,,,,,,,,,,,,,,,,,,,205123,SIMEPREVIR SODIUM,,,,,,,,,,,,,,,,,,,,,2013-11-22T00:00:00Z,2013,11,Olysio,hepatitis c virus infection,HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR,ANTI-INFLAMMATORY; ANTIVIRAL; HEPATITIS C VIRUS REPLICATION INHIBITOR; SYNERGIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205123,NDA,2013-03-28T00:00:00Z,fda,1,0,1,0,0,,johnson and johnson,NYSE: JNJ,1,71312,67224,65030,61587,61897,63747,49070,8183,8183,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205123,228,153,70,6,Hepatitis,1,0
679,"SOFOSBUVIR + LEDIPASVIR (FIXED-COMBINATION, HCV), GILEAD","GS-7977 + GS-5885; GS-7977 + GS-5885 (FIXED-COMBINATION, HCV), GILEAD; HARVONI; LDV/SOF; SOFOSBUVIR + LEDIPASVIR; SOFOSBUVIR + LEDIPASVIR (FIXED-COMBINATION, HCV), GILEAD","GS-7977 + GS-5885; GS-7977 + GS-5885 (FIXED-COMBINATION, HCV), GILEAD; HARVONI; LDV/SOF; SOFOSBUVIR + LEDIPASVIR; SOFOSBUVIR + LEDIPASVIR (FIXED-COMBINATION, HCV), GILEAD","SOFOSBUVIR + LEDIPASVIR (FIXED-COMBINATION, HCV), GILEAD",GS-7977 + GS-5885,"GS-7977 + GS-5885 (FIXED-COMBINATION, HCV), GILEAD",HARVONI,LDV/SOF,SOFOSBUVIR + LEDIPASVIR,"SOFOSBUVIR + LEDIPASVIR (FIXED-COMBINATION, HCV), GILEAD",,,,,,,,,,,,,,,,,,,,,,,,,205834,LEDIPASVIR; SOFOSBUVIR,,,,,,,,,,,,,,,,,,,,,2014-10-10T00:00:00Z,2014,10,Harvoni,hepatitis c virus infection,HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR; HEPATITIS C VIRUS PROTEIN NS5A INHIBITOR,ANTI-INFLAMMATORY; ANTIVIRAL,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205834,NDA,2014-02-07T00:00:00Z,fda,1,0,1,0,1,2013-07-25T00:00:00Z,gilead sciences,NASDAQ: GILD,1,24890,11202,9702,8385.39,7949.42,7011.38,21102,2854,2854,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205834,261,153,70,6,Hepatitis,1,0
573,"PARITAPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE","ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBVIE; ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBOTT; ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBVIE; ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBOTT; HOLKIRA PAK; HOLKIRA PAK; TECHNIVIE; VIEKIRA PAK; VIEKIRA PAK; VIEKIRA PAK; VIEKIRAX; VIEKIRAX + EXVIERA; VIEKIRAX + EXVIERA; PARITAPREVIR + OMBITASVIR + DASABUVIR, ABBVIE; PARITAPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE; PARITAPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE; PARITAPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE; VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT; VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE; VERUPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE; VERUPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE; VERUPREVIR/R + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT","ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBVIE; ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBOTT; ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBVIE; ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBOTT; HOLKIRA PAK; HOLKIRA PAK; TECHNIVIE; VIEKIRA PAK; VIEKIRA PAK; VIEKIRA PAK; VIEKIRAX; VIEKIRAX + EXVIERA; VIEKIRAX + EXVIERA; PARITAPREVIR + OMBITASVIR + DASABUVIR, ABBVIE; PARITAPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE; PARITAPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE; PARITAPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE; VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT; VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE; VERUPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE; VERUPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE; VERUPREVIR/R + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT","PARITAPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE","ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBVIE","ABT-450 + RITONAVIR + ABT-267 (ORAL, HCV INFECTION), ABBOTT","ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBVIE","ABT-450/R + ABT-267 (ORAL, HCV INFECTION), ABBOTT",HOLKIRA PAK,HOLKIRA PAK,TECHNIVIE,VIEKIRA PAK,VIEKIRA PAK,VIEKIRA PAK,VIEKIRAX,VIEKIRAX + EXVIERA,VIEKIRAX + EXVIERA,"PARITAPREVIR + OMBITASVIR + DASABUVIR, ABBVIE","PARITAPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE",PARITAPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE,PARITAPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE,"VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT","VERUPREVIR + RITONAVIR + OMBITASVIR (ORAL, HCV INFECTION) ABBVIE",VERUPREVIR DIHYDRATE + RITONAVIR + ABT-267 HYDRATE,VERUPREVIR DIHYDRATE + RITONAVIR + OMBITASVIR HYDRATE,"VERUPREVIR/R + OMBITASVIR (ORAL, HCV INFECITON), ABBOTT",,,,,,,,,206619,DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR,207931,OMBITASVIR; PARITAPREVIR; RITONAVIR,,,,,,,,,,,,,,,,,,,2015-07-24T00:00:00Z,2015,7,Technivie,hepatitis c virus infection,HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR; HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR; HEPATITIS C VIRUS PROTEIN NS5A INHIBITOR,ANTI-INFLAMMATORY; ANTIVIRAL; HEPATITIS C VIRUS REPLICATION INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207931,NDA,2015-02-25T00:00:00Z,fda,1,0,1,0,1,,abbvie,NYSE: ABBV,1,22859,19960,18790,18380,17444,15638,18620,4101,4285,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207931,288,153,70,6,Hepatitis,1,0
180,DACLATASVIR,"BMS-790052; BMS-790052-05; DAKLINZA; HCV NS5A INHIBITOR (HEPATITIS C VIRUS INFECTION), BMS; NS5A INHIBITOR (HCV INFECTION), BRISTOL-MYERS SQUIBB; DACLATASVIR; DACLATASVIR DIHYDROCHLORIDE","BMS-790052; BMS-790052-05; DAKLINZA; HCV NS5A INHIBITOR (HEPATITIS C VIRUS INFECTION), BMS; NS5A INHIBITOR (HCV INFECTION), BRISTOL-MYERS SQUIBB; DACLATASVIR; DACLATASVIR DIHYDROCHLORIDE",DACLATASVIR,BMS-790052,BMS-790052-05,DAKLINZA,"HCV NS5A INHIBITOR (HEPATITIS C VIRUS INFECTION), BMS","NS5A INHIBITOR (HCV INFECTION), BRISTOL-MYERS SQUIBB",DACLATASVIR,DACLATASVIR DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,206843,DACLATASVIR DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-07-24T00:00:00Z,2015,7,Daklinza,hepatitis c virus infection,HEPATITIS C VIRUS PROTEIN NS5A INHIBITOR,ANTIVIRAL,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206843,NDA,2014-03-31T00:00:00Z,fda,1,0,1,0,0,,bristol-myers squibb,NYSE: BMY,1,16560,15879,16385,17621,21244,19484,12735,4037,5760,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206843,291,153,70,6,Hepatitis,1,0
340,"GRAZOPREVIR + ELBASVIR (ORAL/FDC TABLET, HCV INFECTION), MERCK","MK-5172 + MK-8742; MK-5172 + MK-8742 (HCV INFECTION), MERCK; MK-5172A; ZEPATIER; GRAZOPREVIR + ELBASVIR; GRAZOPREVIR + ELBASVIR (ORAL/FDC TABLET, HCV INFECTION), MERCK","MK-5172 + MK-8742; MK-5172 + MK-8742 (HCV INFECTION), MERCK; MK-5172A; ZEPATIER; GRAZOPREVIR + ELBASVIR; GRAZOPREVIR + ELBASVIR (ORAL/FDC TABLET, HCV INFECTION), MERCK","GRAZOPREVIR + ELBASVIR (ORAL/FDC TABLET, HCV INFECTION), MERCK",MK-5172 + MK-8742,"MK-5172 + MK-8742 (HCV INFECTION), MERCK",MK-5172A,ZEPATIER,GRAZOPREVIR + ELBASVIR,"GRAZOPREVIR + ELBASVIR (ORAL/FDC TABLET, HCV INFECTION), MERCK",,,,,,,,,,,,,,,,,,,,,,,,,208261,ELBASVIR; GRAZOPREVIR,,,,,,,,,,,,,,,,,,,,,2016-01-28T00:00:00Z,2016,1,Zepatier,hepatitis c virus infection,HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR; HEPATITIS C VIRUS PROTEIN NS5A INHIBITOR,ANTIVIRAL,DAILY DOSING; DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208261,NDA,2015-05-28T00:00:00Z,fda,1,0,0,0,1,2015-04-08T00:00:00Z,merck,NYSE: MRK,1,39807,39498,42237,44033,47267,48047,26444,10065,6524,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208261,335,153,70,6,Hepatitis,1,0
680,"SOFOSBUVIR + VELPATASVIR (FIXED DOSE COMBINATION, HCV), GILEAD","EPCLUSA; EPCLUSA; GS-5816 + SOFOSBUVIR; GS-7977 + GS-5816; GS-7977 + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD; SOF/VEL; SOFOSBUVIR + GS-5816; SOFOSBUVIR + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD; SOFOSBUVIR + VELPATASVIR; SOFOSBUVIR + VELPATASVIR (FIXED DOSE COMBINATION, HCV), GILEAD","EPCLUSA; EPCLUSA; GS-5816 + SOFOSBUVIR; GS-7977 + GS-5816; GS-7977 + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD; SOF/VEL; SOFOSBUVIR + GS-5816; SOFOSBUVIR + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD; SOFOSBUVIR + VELPATASVIR; SOFOSBUVIR + VELPATASVIR (FIXED DOSE COMBINATION, HCV), GILEAD","SOFOSBUVIR + VELPATASVIR (FIXED DOSE COMBINATION, HCV), GILEAD",EPCLUSA,EPCLUSA,GS-5816 + SOFOSBUVIR,GS-7977 + GS-5816,"GS-7977 + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD",SOF/VEL,SOFOSBUVIR + GS-5816,"SOFOSBUVIR + GS-5816 (FIXED DOSE COMBINATION, HCV), GILEAD",SOFOSBUVIR + VELPATASVIR,"SOFOSBUVIR + VELPATASVIR (FIXED DOSE COMBINATION, HCV), GILEAD",,,,,,,,,,,,,,,,,,,,,208341,SOFOSBUVIR; VELPATASVIR,208341,SOFOSBUVIR; VELPATASVIR,,,,,,,,,,,,,,,,,,,2016-06-28T00:00:00Z,2016,6,Epclusa,hepatitis c virus infection,HEPATITIS C VIRUS NS5B POLYMERASE INHIBITOR; HEPATITIS C VIRUS PROTEIN NS5A INHIBITOR,ANTIVIRAL,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208341,NDA,2015-10-28T00:00:00Z,fda,1,0,1,0,1,,gilead sciences,NASDAQ: GILD,1,30390,32639,24890,11202,9702,8385.39,26129,4666,4666,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208341,339,153,70,6,Hepatitis,1,0
720,TENOFOVIR ALAFENAMIDE FUMARATE,GS-7340; GS-7340 FUMARATE; GS-7340 HEMIFUMARATE; VEMLIDY; VEMLIDY; TENOFOVIR ALAFENAMIDE; TENOFOVIR ALAFENAMIDE FUMARATE; TENOFOVIR ALAFENAMIDE MONOFUMARATE,GS-7340; GS-7340 FUMARATE; GS-7340 HEMIFUMARATE; VEMLIDY; VEMLIDY; TENOFOVIR ALAFENAMIDE; TENOFOVIR ALAFENAMIDE FUMARATE; TENOFOVIR ALAFENAMIDE MONOFUMARATE,TENOFOVIR ALAFENAMIDE FUMARATE,GS-7340,GS-7340 FUMARATE,GS-7340 HEMIFUMARATE,VEMLIDY,VEMLIDY,TENOFOVIR ALAFENAMIDE,TENOFOVIR ALAFENAMIDE FUMARATE,TENOFOVIR ALAFENAMIDE MONOFUMARATE,,,,,,,,,,,,,,,,,,,,,,,208464,TENOFOVIR ALAFENAMIDE FUMARATE,,,,,,,,,,,,,,,,,,,,,2016-11-10T00:00:00Z,2016,11,Vemlidy,hepatitis b virus infection,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,ANTIVIRAL; HIV REPLICATION INHIBITOR,ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208464,NDA,2016-01-11T00:00:00Z,fda,0,0,0,0,0,,gilead sciences,NASDAQ: GILD,1,30390,32639,24890,11202,9702,8385.39,26129,4666,4666,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208464,345,152,70,6,Hepatitis,1,0
715,TELBIVUDINE,".BETA.-L-THYMIDINE; L-2-DEOXYADENOSINE; L-2-DEOXYTHYMIDINE; L-THYMIDINE; L-DA; L-DT; LDT-600; NV-02 PROGRAM, NOVIRIO; NV-02A; NV-02B; NV-06, IDENIX; SEBIVO; SEVIBO; TYZEKA; ANTI-HBV L-NUCLEOSIDES, IDENIX; ANTI-HBV L-NUCLEOSIDES, NOVIRIO; BETA-L-DDA; BETA-L-THYMIDINE; EPAVUDINE; TELBIVUDINE",".BETA.-L-THYMIDINE; L-2-DEOXYADENOSINE; L-2-DEOXYTHYMIDINE; L-THYMIDINE; L-DA; L-DT; LDT-600; NV-02 PROGRAM, NOVIRIO; NV-02A; NV-02B; NV-06, IDENIX; SEBIVO; SEVIBO; TYZEKA; ANTI-HBV L-NUCLEOSIDES, IDENIX; ANTI-HBV L-NUCLEOSIDES, NOVIRIO; BETA-L-DDA; BETA-L-THYMIDINE; EPAVUDINE; TELBIVUDINE",TELBIVUDINE,.BETA.-L-THYMIDINE,L-2-DEOXYADENOSINE,L-2-DEOXYTHYMIDINE,L-THYMIDINE,L-DA,L-DT,LDT-600,"NV-02 PROGRAM, NOVIRIO",NV-02A,NV-02B,"NV-06, IDENIX",SEBIVO,SEVIBO,TYZEKA,"ANTI-HBV L-NUCLEOSIDES, IDENIX","ANTI-HBV L-NUCLEOSIDES, NOVIRIO",BETA-L-DDA,BETA-L-THYMIDINE,EPAVUDINE,TELBIVUDINE,,,,,,,,,,,22011,TELBIVUDINE,,,,,,,,,,,,,,,,,,,,,2006-10-25T00:00:00Z,2006,10,Tyzeka,hepatitis b virus infection,DNA POLYMERASE INHIBITOR,ANTIVIRAL; DNA SYNTHESIS INHIBITOR; VIRAL REPLICATION INHIBITOR,FILM COATING; NUCLEOSIDE SYNTHESIS; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),022011,NDA,2005-12-30T00:00:00Z,fda,0,0,0,0,0,,idenix pharmaceuticals,NASDAQ: IDIX,1,67.4,64.7,95.4,29.6,3.5,1.3,28.8,,96.1,,,,,acquired by merck in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022011,440,152,70,6,Hepatitis,1,0
349,HEPAGAM B,"HEPAGAM B; HEPAGAM BT; IMMUNOGAM; ANTI-HEPATITIS B HYPERIMMUNE, CANGENE; ANTI-HEPATITIS B HYPERIMMUNE, EMERGENT BIOSOLUTIONS; HEPATITIS B THERAPY, CANGENE; HEPATITIS B THERAPY, EMERGENT BIOSOLUTIONS; POLYCLONAL ANTIBODY (HEPATITIS B), CANGENE; POLYCLONAL ANTIBODY (HEPATITIS B), EMERGENT BIOSOLUTIONS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2006-01-27T00:00:00Z,2006,1,HepaGam B,hepatitis b virus infection,,ANTIVIRAL; UNSPECIFIED DRUG TARGET,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INTRAVENOUS FORMULATION,using only (2),125035,BLA,2001-09-25T00:00:00Z,fda,0,0,0,0,0,,cangene,TSX: CNJ,1,85.5,89.8,101.7,145.5,78.7,53.3,43.4,4.5,20.4,,,,,acquired by emergent biosolutions in 2014; cangene revenues for 12 months prior to following january are reported with exception of 2013 in which revenue dated 2/1/13 - 7/31/13 is reported scaled by a factor of 2,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125035,679,152,70,6,Hepatitis,1,0
780,VEREGEN,"POLYPHENON E; POLYPHENON E (TOPICAL); SB-03; VEREGEN; SINECATECHINS (WARTS), EPITOME/MEDIGENE/MITSUI; TOPICAL POLYPHENOLS, EPITOME/MEDIGENE/MITSUI","POLYPHENON E; POLYPHENON E (TOPICAL); SB-03; VEREGEN; SINECATECHINS (WARTS), EPITOME/MEDIGENE/MITSUI; TOPICAL POLYPHENOLS, EPITOME/MEDIGENE/MITSUI",VEREGEN,POLYPHENON E,POLYPHENON E (TOPICAL),SB-03,VEREGEN,"SINECATECHINS (WARTS), EPITOME/MEDIGENE/MITSUI","TOPICAL POLYPHENOLS, EPITOME/MEDIGENE/MITSUI",,,,,,,,,,,,,,,,,,,,,,,,,21902,SINECATECHINS,21902,SINECATECHINS,,,,,,,,,,,,,,,,,,,2006-10-31T00:00:00Z,2006,10,Veregen,papillomavirus infection,,ANTICANCER; ANTIVIRAL; TOPICAL DERMATOLOGICAL ANTIVIRAL PRODUCT; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC,matched (3),021902,NDA,2005-09-23T00:00:00Z,fda,0,0,0,0,0,,medigene,ETR: MDG1,1,41.2,23.2,16.9,2.2,3.6,6.7,27.1,28.1,28.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021902,404,396,79,7,Viral infection,2,0
102,BR-01,"BR-01; RNA POLYMERASE MODULATOR (DNA VIRUS INFECTION), INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY OF THE ACADEMY OF MILITARY MEDICAL SCIENCES",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-10-12T00:00:00Z,2014,10,BR-01,adenovirus infection,DNA POLYMERASE INHIBITOR,ANTIVIRAL,SMALL MOLECULE THERAPEUTIC; SYSTEMIC FORMULATION UNSPECIFIED,using only (2),not identified,not identified,,,,,,,,,sihuan pharmaceutical holdings,HKG: 0460,1,497.3,427.2,488.1,355.7,157.3,103.8,340.4,,24,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,644,7,79,7,Viral infection,2,0
147,CERVARIX,"580299; CERVARIX; GSK-580299; HPV VACCINE, MEDIMMUNE/GSK; HPV VACCINE, MEDIMMUNE/SB; HPV-16/18 L1 AS04 VACCINE; MEDI-501; MEDI-503; MEDI-503 + MEDI-504, MEDIMMUNE/GSK; MEDI-504; MEDI-517; HUMAN PAPILLOMAVIRUS VACCINE (HPV-16 + HPV-18), MEDIMMUNE/GSK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-10-16T00:00:00Z,2009,10,Cervarix,papillomavirus infection,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; INTRAMUSCULAR FORMULATION; PROTEIN RECOMBINANT; SUSPENSION,using only (2),125259,BLA,2007-03-29T00:00:00Z,cortellis,0,0,1,0,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125259,647,396,79,7,Viral infection,2,0
223,DR-5001,"DR-5001; US MILITARY ORAL PROPHYLCATIC ADENOVIRUS VACCINE (TYPES 4 AND 7), DURAMED/BARR; ORAL PROPHYLACTIC ADENOVIRUS INFECTION VACCINE (TYPES 4 AND 7), DURAMED/BARR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2011-03-16T00:00:00Z,2011,3,"Adenovirus Type 4 and Type 7 Vaccine, Live, Oral",adenovirus infection,,LIVE ATTENUATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; ENTERIC COATED FORMULATION; ORAL FORMULATION; TABLET FORMULATION,using only (2),125296,BLA,2008-12-11T00:00:00Z,cortellis,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,18312,16121,13899,11085,9408,8408,9867,1095,1095,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125296,652,7,79,7,Viral infection,2,0
326,GARDASIL,"GARDASIL; HPV VACCINE (QUADRIVALENT), AVENTIS PASTEUR MSD/CSL; HPV VACCINE (QUADRIVALENT), MERCK & CO; HPV VACCINE (QUADRIVALENT), SANOFI PASTEUR MSD/CSL; HPV VACCINE, CSL/MERCK & CO; SILGARD; V-501, UNIQUEST; HUMAN PAPILLOMA VIRUS VACCINE, CSL/MERCK & CO; HUMAN PAPILLOMAVIRUS VACCINE, CSL/MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2006-06-08T00:00:00Z,2006,6,Gardasil,papillomavirus infection,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PROTEIN RECOMBINANT; SUSPENSION; VIRAL COAT PROTEIN,using only (2),125126,BLA,2005-12-07T00:00:00Z,fda,1,0,0,0,0,,merck,NYSE: MRK,1,22636,22011.9,22972.8,22485.9,21445.8,21199,17371.3,3963.6,4020.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125126,669,396,79,7,Viral infection,2,0
327,GARDASIL 9,"9-VALENT HPV VACCINE, MERCK; GARDASIL 9; V-503; HUMAN PAPILLOMAVIRUS VACCINE (NONAVALENT), MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-12-10T00:00:00Z,2014,12,Gardasil 9,papillomavirus infection,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PROTEIN RECOMBINANT; SUSPENSION,using only (2),125508,BLA,2013-12-10T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125508,670,396,79,7,Viral infection,2,0
489,MILTEFOSINE,IMPAVIDO; MILTEX; MILTEFOSINE,IMPAVIDO; MILTEX; MILTEFOSINE,MILTEFOSINE,IMPAVIDO,MILTEX,MILTEFOSINE,,,,,,,,,,,,,,,,,,,,,,,,,,,,204684,MILTEFOSINE,,,,,,,,,,,,,,,,,,,,,2014-03-19T00:00:00Z,2014,3,Impavido,leishmania infection,,ANTICANCER PERMEABILITY ENHANCER; ANTIMICROBIAL PERMEABILITY ENHANCER; ANTIPARASITIC; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204684,NDA,2013-04-19T00:00:00Z,fda,1,0,1,1,0,,endo,NASDAQ: ENDP,1,2380.7,260.6,210.9,139.2,128.7,104.7,1214.8,112.7,112.7,,,2014,,acquired by endo in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204684,212,1136,85,8,Other infections; including parasitic,1,0
51,APIXABAN,"BMS-562247; ELIQUIS; FACTOR XA ANTAGONIST (FOLLOW-ON), BRISTOL-MYERS SQUIBB/PFIZER; APIXABAN; RAZAXABAN FOLLOW-ON COMPOUND, BRISTOL-MYERS SQUIBB/PFIZER","BMS-562247; ELIQUIS; FACTOR XA ANTAGONIST (FOLLOW-ON), BRISTOL-MYERS SQUIBB/PFIZER; APIXABAN; RAZAXABAN FOLLOW-ON COMPOUND, BRISTOL-MYERS SQUIBB/PFIZER",APIXABAN,BMS-562247,ELIQUIS,"FACTOR XA ANTAGONIST (FOLLOW-ON), BRISTOL-MYERS SQUIBB/PFIZER",APIXABAN,"RAZAXABAN FOLLOW-ON COMPOUND, BRISTOL-MYERS SQUIBB/PFIZER",,,,,,,,,,,,,,,,,,,,,,,,,,202155,APIXABAN,,,,,,,,,,,,,,,,,,,,,2012-12-28T00:00:00Z,2012,12,Eliquis,thromboembolism,FACTOR XA ANTAGONIST,ANTIARRHYTHMIC AGENT; COAGULATION INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202155,NDA,2011-09-28T00:00:00Z,fda,1,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,17621,21244,19484,18808,17715,15617,13067,3688,3762,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202155,104,325,88,8,Other infections; including parasitic,1,0
788,VORAPAXAR,"MK-5348; SCH-530348; TRA (ATHEROTHROMBOSIS), SCHERING-PLOUGH; ZONTIVITY; THROMBIN RECEPTOR ANTAGONIST, SCHERING-PLOUGH; VORAPAXAR; VORAPAXAR SULFATE","MK-5348; SCH-530348; TRA (ATHEROTHROMBOSIS), SCHERING-PLOUGH; ZONTIVITY; THROMBIN RECEPTOR ANTAGONIST, SCHERING-PLOUGH; VORAPAXAR; VORAPAXAR SULFATE",VORAPAXAR,MK-5348,SCH-530348,"TRA (ATHEROTHROMBOSIS), SCHERING-PLOUGH",ZONTIVITY,"THROMBIN RECEPTOR ANTAGONIST, SCHERING-PLOUGH",VORAPAXAR,VORAPAXAR SULFATE,,,,,,,,,,,,,,,,,,,,,,,,204886,VORAPAXAR SULFATE,,,,,,,,,,,,,,,,,,,,,2014-05-08T00:00:00Z,2014,5,Zontivity,thromboembolism,PROTEASE-ACTIVATED RECEPTOR-1 ANTAGONIST,ANTI-INFLAMMATORY; ANTIVIRAL; PLATELET AGGREGATION INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204886,NDA,2013-05-10T00:00:00Z,fda,0,0,1,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204886,221,325,88,8,Other infections; including parasitic,1,0
231,EDOXABAN,"DU-176; DU-176B; FACTOR XA INHIBITOR (ORAL FORMULATION), DAIICHI SEIYAKU; FACTOR XA INHIBITOR (ORAL, VENOUS THROMBOEMBOLISM/ ATRIAL FIBRILLATION), DAIICHI SEIYAKU; LIXIANA; RIXIANA; SAVAYSA; EDOXABAN; EDOXABAN TOSYLATE; EDOXABAN TOSYLATE MONOHYDRATE","DU-176; DU-176B; FACTOR XA INHIBITOR (ORAL FORMULATION), DAIICHI SEIYAKU; FACTOR XA INHIBITOR (ORAL, VENOUS THROMBOEMBOLISM/ ATRIAL FIBRILLATION), DAIICHI SEIYAKU; LIXIANA; RIXIANA; SAVAYSA; EDOXABAN; EDOXABAN TOSYLATE; EDOXABAN TOSYLATE MONOHYDRATE",EDOXABAN,DU-176,DU-176B,"FACTOR XA INHIBITOR (ORAL FORMULATION), DAIICHI SEIYAKU","FACTOR XA INHIBITOR (ORAL, VENOUS THROMBOEMBOLISM/ ATRIAL FIBRILLATION), DAIICHI SEIYAKU",LIXIANA,RIXIANA,SAVAYSA,EDOXABAN,EDOXABAN TOSYLATE,EDOXABAN TOSYLATE MONOHYDRATE,,,,,,,,,,,,,,,,,,,,,206316,EDOXABAN TOSYLATE,,,,,,,,,,,,,,,,,,,,,2015-01-08T00:00:00Z,2015,1,Savaysa,thromboembolism,FACTOR XA ANTAGONIST,ANTIARRHYTHMIC AGENT; COAGULATION INHIBITOR; PLATELET AGGREGATION INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206316,NDA,2014-01-08T00:00:00Z,fda,0,0,0,0,0,,daiichi sankyo,TYO: 4568,1,6986.3,9593.4,10074.1,11421.5,11901.6,12010.8,4746.9,1552.5,1552.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206316,276,325,88,8,Other infections; including parasitic,1,0
7,"ACETYLSALICYLIC ACID (81 MG, DELAYED RELEASE) + OMEPRAZOLE (40 MG, QUICK RELEASE) (CARDIOVASCULAR DISEASE), ARALEZ","PA-08140; PA-8140; YOSPRALA 81/40; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID (81 MG, DELAYED RELEASE) + OMEPRAZOLE (40 MG, QUICK RELEASE) (CARDIOVASCULAR DISEASE), ARALEZ; ACETYLSALICYLIC ACID (81 MG, DELAYED RELEASE) + OMEPRAZOLE (40 MG, QUICK RELEASE) (CARDIOVASCULAR DISEASE), POZEN; ACETYLSALICYLIC ACID + OMEPRAZOLE; ASPIRIN (81 MG, DELAYED RELEASE) + OMEPRAZOLE (40 MG, QUICK RELEASE) (CARDIOVASCULAR DISEASE), POZEN; ASPIRIN + OMEPRAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-09-14T00:00:00Z,2016,9,Yosprala,thromboembolism,H+ K+ ATPASE INHIBITOR,ANTIARTERIOSCLEROTIC; CARDIOPROTECTANT; NON-STEROIDAL ANTI-INFLAMMATORY,DRUG COMBINATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,using only (2),205103,NDA,2013-03-25T00:00:00Z,fda,0,0,0,0,0,,aralez pharmaceuticals,NASDAQ: ARLZ,1,54.3,21.4,32.4,10.3,5.3,15.1,44,8.8,8.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205103,633,325,88,8,Other infections; including parasitic,1,0
502,"NAFTIFINE HYDROCHLORIDE GEL (TINEA PEDIS/TINEA CAPITIS), MERZ NORTH AMERICA","NAFTIN; NAFTIN; NAFTIFINE; NAFTIFINE HYDROCHLORIDE; NAFTIFINE HYDROCHLORIDE GEL (TINEA PEDIS/TINEA CAPITIS), MERZ NORTH AMERICA","NAFTIN; NAFTIN; NAFTIFINE; NAFTIFINE HYDROCHLORIDE; NAFTIFINE HYDROCHLORIDE GEL (TINEA PEDIS/TINEA CAPITIS), MERZ NORTH AMERICA","NAFTIFINE HYDROCHLORIDE GEL (TINEA PEDIS/TINEA CAPITIS), MERZ NORTH AMERICA",NAFTIN,NAFTIN,NAFTIFINE,NAFTIFINE HYDROCHLORIDE,"NAFTIFINE HYDROCHLORIDE GEL (TINEA PEDIS/TINEA CAPITIS), MERZ NORTH AMERICA",,,,,,,,,,,,,,,,,,,,,,,,,,19356,NAFTIFINE HYDROCHLORIDE,19356,NAFTIFINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2013-06-27T00:00:00Z,2013,6,Naftin,tinea pedis,,FUNGICIDE; TOPICAL DERMATOLOGICAL ANTIFUNGAL PRODUCT; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204286,NDA,2012-08-30T00:00:00Z,fda,0,0,0,0,0,,merz pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204286,67,2429,110,4,Mycoses,1,0
232,EFINACONAZOLE,CLENAFIN; IDP-108; JUBLIA; KP-103; EFINACONAZOLE,CLENAFIN; IDP-108; JUBLIA; KP-103; EFINACONAZOLE,EFINACONAZOLE,CLENAFIN,IDP-108,JUBLIA,KP-103,EFINACONAZOLE,,,,,,,,,,,,,,,,,,,,,,,,,,203567,EFINACONAZOLE,,,,,,,,,,,,,,,,,,,,,2014-06-06T00:00:00Z,2014,6,Jublia,trichophyton infection,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE; TOPICAL DERMATOLOGICAL ANTIFUNGAL PRODUCT,DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),203567,NDA,2012-07-25T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,8200,5765.6,3480.4,2427.5,1181.2,820.4,5997,246,246,,,2009,,acquired by valeant in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203567,163,334,110,4,Mycoses,1,0
451,LULICONAZOLE,33525; BAY-38-9502; JA-004; JA-005; LUCONAC; LUCONAC; LUCONAC SOLUTION 5 %; LULICON; LULIFIN; LUZU; NND-502; PR-2699; LULICONAZOLE,33525; BAY-38-9502; JA-004; JA-005; LUCONAC; LUCONAC; LUCONAC SOLUTION 5 %; LULICON; LULIFIN; LUZU; NND-502; PR-2699; LULICONAZOLE,LULICONAZOLE,33525,BAY-38-9502,JA-004,JA-005,LUCONAC,LUCONAC,LUCONAC SOLUTION 5 %,LULICON,LULIFIN,LUZU,NND-502,PR-2699,LULICONAZOLE,,,,,,,,,,,,,,,,,,204153,LULICONAZOLE,,,,,,,,,,,,,,,,,,,,,2013-11-14T00:00:00Z,2013,11,Luzu,tinea corporis,,FUNGICIDE; TOPICAL DERMATOLOGICAL ANTIFUNGAL PRODUCT; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),204153,NDA,2012-12-11T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,5765.6,3480.4,721.1,695.9,570.6,517.8,4236.9,156.8,156.8,771.333333333333,2012-09-30T00:00:00Z,2012,,acquired by valeant in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204153,185,2427,110,4,Mycoses,1,0
708,TAVABOROLE,"AN-2690; KERYDIN; SCH-900340; TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH; TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO; FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH; FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), MERCK & CO/ANACOR; TAVABOROLE; TOPICAL ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO","AN-2690; KERYDIN; SCH-900340; TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH; TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO; FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH; FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), MERCK & CO/ANACOR; TAVABOROLE; TOPICAL ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO",TAVABOROLE,AN-2690,KERYDIN,SCH-900340,"TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH","TRICHOPHYTON-TARGETING ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO","FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), ANACOR PHARMACEUTICALS/SCHERING-PLOUGH","FUNGAL LEUCYL-TRNA SYNTHETASE INHIBITOR (ONYCHOMYCOSIS), MERCK & CO/ANACOR",TAVABOROLE,"TOPICAL ANTIFUNGAL (ONYCHOMYCOSIS), MERCK & CO",,,,,,,,,,,,,,,,,,,,,,204427,TAVABOROLE,,,,,,,,,,,,,,,,,,,,,2014-07-07T00:00:00Z,2014,7,Kerydin,onychomycosis,LEUCYL TRNA SYNTHETASE INHIBITOR,FUNGICIDE; TOPICAL DERMATOLOGICAL ANTIFUNGAL PRODUCT,DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),204427,NDA,2013-07-26T00:00:00Z,fda,0,0,0,0,0,,anacor pharmaceuticals,NASDAQ: ANAC,1,20.7,17.2,10.7,20.3,27.8,18.6,-59.4,,72.5,,,,,acquired by Pfizer in 2016,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204427,200,1775,110,4,Mycoses,1,0
229,"ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), EXELTIS USA DERMATOLOGY","ECOZA; ECONAZOLE; ECONAZOLE NITRATE; ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), EXELTIS USA DERMATOLOGY; ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), QUINNOVA","ECOZA; ECONAZOLE; ECONAZOLE NITRATE; ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), EXELTIS USA DERMATOLOGY; ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), QUINNOVA","ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), EXELTIS USA DERMATOLOGY",ECOZA,ECONAZOLE,ECONAZOLE NITRATE,"ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), EXELTIS USA DERMATOLOGY","ECONAZOLE NITRATE 1% (TOPICAL FOAM, TINEA PEDIS), QUINNOVA",,,,,,,,,,,,,,,,,,,,,,,,,,205175,ECONAZOLE NITRATE,,,,,,,,,,,,,,,,,,,,,2013-10-24T00:00:00Z,2013,10,Ecoza,tinea pedis,,FUNGICIDE; TOPICAL DERMATOLOGICAL ANTIFUNGAL PRODUCT; UNSPECIFIED DRUG TARGET,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,matched (3),205175,NDA,2012-12-21T00:00:00Z,fda,0,0,0,0,0,,amderma pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205175,229,2429,110,4,Mycoses,1,0
396,"ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), MERZ","HYPHANOX; ONMEL; SPORAMELT; ITRACONAZOLE; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), BARRIER THERAPEUTICS; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), MERZ; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), STIEFEL","HYPHANOX; ONMEL; SPORAMELT; ITRACONAZOLE; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), BARRIER THERAPEUTICS; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), MERZ; ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), STIEFEL","ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), MERZ",HYPHANOX,ONMEL,SPORAMELT,ITRACONAZOLE,"ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), BARRIER THERAPEUTICS","ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), MERZ","ITRACONAZOLE (ONCE-DAILY ORAL FORMULATION), STIEFEL",,,,,,,,,,,,,,,,,,,,,,,,22484,ITRACONAZOLE,,,,,,,,,,,,,,,,,,,,,2010-04-29T00:00:00Z,2010,4,Onmel,onychomycosis,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGAL CELL WALL SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIFUNGAL PRODUCT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022484,NDA,2009-03-31T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,44331.3,45825.1,,,,,32308.5,5992.7,6959.2,,,2009,,acquired by GSK in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022484,575,1775,110,4,Mycoses,1,0
485,"MICONAZOLE (TOPICAL), BARRIER THERAPEUTICS","BEBEKTIN; DAKTOZIN; VUSION; ZIMYCAN; MICONAZOLE; MICONAZOLE (TOPICAL), BARRIER THERAPEUTICS","BEBEKTIN; DAKTOZIN; VUSION; ZIMYCAN; MICONAZOLE; MICONAZOLE (TOPICAL), BARRIER THERAPEUTICS","MICONAZOLE (TOPICAL), BARRIER THERAPEUTICS",BEBEKTIN,DAKTOZIN,VUSION,ZIMYCAN,MICONAZOLE,"MICONAZOLE (TOPICAL), BARRIER THERAPEUTICS",,,,,,,,,,,,,,,,,,,,,,,,,21026,"MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE",,,,,,,,,,,,,,,,,,,,,2006-02-16T00:00:00Z,2006,2,Vusion,candida infection,,DERMATOLOGICAL AGENT; ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,matched (3),021026,NDA,1998-08-24T00:00:00Z,fda,0,0,0,0,0,,barrier therapeutics,NASDAQ: BTRX,1,6.738,2.54,0.897,0.367,,,5.307,25.895,25.895,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021026,360,1308,112,4,Mycoses,4,0
47,ANIDULAFUNGIN,ECB; ECALTA; ERACSIS; ERAXIS; LY-303366; LY-329960; LY-333006; V-ECHINOCANDIN; VER-002; ANIDULAFUNGIN,ECB; ECALTA; ERACSIS; ERAXIS; LY-303366; LY-329960; LY-333006; V-ECHINOCANDIN; VER-002; ANIDULAFUNGIN,ANIDULAFUNGIN,ECB,ECALTA,ERACSIS,ERAXIS,LY-303366,LY-329960,LY-333006,V-ECHINOCANDIN,VER-002,ANIDULAFUNGIN,,,,,,,,,,,,,,,,,,,,,21632,ANIDULAFUNGIN,21632,ANIDULAFUNGIN,,,,,,,,,,,,,,,,,,,2006-02-17T00:00:00Z,2006,2,Eraxis,candida infection,"1,3 BETA GLUCAN SYNTHASE INHIBITOR",ANTIPARASITIC; FUNGAL CELL WALL SYNTHESIS INHIBITOR; FUNGICIDE,ANTIBIOTIC; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021632,NDA,2003-04-25T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,48371,47405,8.4,9.6,6.3,6.4,41123,7423,7599,5.8,2005-06-30T00:00:00Z,2005,,acquired by pfizer in 2005,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021632,376,1308,112,4,Mycoses,4,0
600,POSACONAZOLE,"MK-5592 (ORAL SUSPENSION), MERCK & CO; NOXAFIL; POSACONAZOLE SP; POSANOL; SCH 056592; SCH-207962; SCH-56588; SCH-56592; SCH-56984; SPRIAFIL; ANTIFUNGAL, SCHERING-PLOUGH; POSACONAZOLE; TRIAZOLE (ORAL), SCHERING-PLOUGH","MK-5592 (ORAL SUSPENSION), MERCK & CO; NOXAFIL; POSACONAZOLE SP; POSANOL; SCH 056592; SCH-207962; SCH-56588; SCH-56592; SCH-56984; SPRIAFIL; ANTIFUNGAL, SCHERING-PLOUGH; POSACONAZOLE; TRIAZOLE (ORAL), SCHERING-PLOUGH",POSACONAZOLE,"MK-5592 (ORAL SUSPENSION), MERCK & CO",NOXAFIL,POSACONAZOLE SP,POSANOL,SCH 056592,SCH-207962,SCH-56588,SCH-56592,SCH-56984,SPRIAFIL,"ANTIFUNGAL, SCHERING-PLOUGH",POSACONAZOLE,"TRIAZOLE (ORAL), SCHERING-PLOUGH",,,,,,,,,,,,,,,,,,22003,POSACONAZOLE,,,,,,,,,,,,,,,,,,,,,2006-09-15T00:00:00Z,2006,9,Noxafil (oral suspension),candida infection,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE; SYSTEMIC DERMATOLOGICAL ANTIFUNGAL PRODUCT,CONTROLLED RELEASE FORMULATION; INTRAVENOUS FORMULATION; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022003,NDA,2005-12-21T00:00:00Z,fda,1,0,0,0,0,,schering-plough,NYSE: SGP,1,10594,9508,8272,8334,10180,9762,7043,2188,2188,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022003,434,1308,112,4,Mycoses,4,0
486,"MICONAZOLE NITRATE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE","BA-001; LORAMYC; LORAMYC-DELETED; ORAVIG; ORAVIG-DELETED; SO-1105; SITAMIC; MICONAZOLE; MICONAZOLE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE; MICONAZOLE LAURIAD; MICONAZOLE LAURIAD-DELETED; MICONAZOLE NITRATE; MICONAZOLE NITRATE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE","BA-001; LORAMYC; LORAMYC-DELETED; ORAVIG; ORAVIG-DELETED; SO-1105; SITAMIC; MICONAZOLE; MICONAZOLE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE; MICONAZOLE LAURIAD; MICONAZOLE LAURIAD-DELETED; MICONAZOLE NITRATE; MICONAZOLE NITRATE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE","MICONAZOLE NITRATE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE",BA-001,LORAMYC,LORAMYC-DELETED,ORAVIG,ORAVIG-DELETED,SO-1105,SITAMIC,MICONAZOLE,"MICONAZOLE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE",MICONAZOLE LAURIAD,MICONAZOLE LAURIAD-DELETED,MICONAZOLE NITRATE,"MICONAZOLE NITRATE (TABLET, LAURIAD, CANDIDIASIS), BIOALLIANCE",,,,,,,,,,,,,,,,,,22404,MICONAZOLE,,,,,,,,,,,,,,,,,,,,,2010-04-16T00:00:00Z,2010,4,Oravig,candida infection,,ANTIMICROBIAL PERMEABILITY ENHANCER; ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,BUCCAL FORMULATION LOCAL; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022404,NDA,2009-08-11T00:00:00Z,fda,0,0,0,0,0,,bioalliance pharma,EPA: ONXEO,1,30.214,10.801,11.422,5.154,0.607,,29.062,,11.5,,,,,merged with topotarget to become onxeo in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022404,550,1308,112,4,Mycoses,4,0
393,"ISAVUCONAZONIUM CHLORIDE/SULFATE (INTRAVENOUS), BASILEA/ASTELLAS","BAL-4815; BAL-8349; BAL-8557; BAL-8557 (INTRAVENOUS), BASILEA; BAL-8728; CRESEMBA; CRESEMBA; RO-0098557; ANTIFUNGALS, BASILEA; ISAVUCONAZOLE; ISAVUCONAZONIUM; ISAVUCONAZONIUM CHLORIDE; ISAVUCONAZONIUM CHLORIDE/SULFATE (INTRAVENOUS), BASILEA/ASTELLAS; ISAVUCONAZONIUM SULFATE","BAL-4815; BAL-8349; BAL-8557; BAL-8557 (INTRAVENOUS), BASILEA; BAL-8728; CRESEMBA; CRESEMBA; RO-0098557; ANTIFUNGALS, BASILEA; ISAVUCONAZOLE; ISAVUCONAZONIUM; ISAVUCONAZONIUM CHLORIDE; ISAVUCONAZONIUM CHLORIDE/SULFATE (INTRAVENOUS), BASILEA/ASTELLAS; ISAVUCONAZONIUM SULFATE","ISAVUCONAZONIUM CHLORIDE/SULFATE (INTRAVENOUS), BASILEA/ASTELLAS",BAL-4815,BAL-8349,BAL-8557,"BAL-8557 (INTRAVENOUS), BASILEA",BAL-8728,CRESEMBA,CRESEMBA,RO-0098557,"ANTIFUNGALS, BASILEA",ISAVUCONAZOLE,ISAVUCONAZONIUM,ISAVUCONAZONIUM CHLORIDE,"ISAVUCONAZONIUM CHLORIDE/SULFATE (INTRAVENOUS), BASILEA/ASTELLAS",ISAVUCONAZONIUM SULFATE,,,,,,,,,,,,,,,,,207500,ISAVUCONAZONIUM SULFATE,,,,,,,,,,,,,,,,,,,,,2015-03-06T00:00:00Z,2015,3,Cresemba (intravenous),zygomycete infection,,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE; SYNERGIST,INFUSION; INTRAVENOUS FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),207501,NDA,2014-07-08T00:00:00Z,fda,1,0,0,1,0,,astellas pharma,TYO: 4503,1,11315.7,10060.3,10821,11107,12783.1,11541,8452.1,1860.1,1860.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207501,300,1370,117,4,Mycoses,1,0
394,"ISAVUCONAZONIUM CHLORIDE/SULFATE (ORAL), BASILEA/ASTELLAS","ASP-9766; BAL-4815; BAL-8349; BAL-8557; BAL-8557 (ORAL), BASILEA; BAL-8728; BMS-207147 PRODRUGS, NIPPON ROCHE; CRESEMBA; CRESEMBA; RO-0094815; RO-0098557; RO-0098246; ANTIFUNGALS, BASILEA; ISAVUCONAZOLE; ISAVUCONAZONIUM; ISAVUCONAZONIUM CHLORIDE; ISAVUCONAZONIUM CHLORIDE/SULFATE (ORAL), BASILEA/ASTELLAS; ISAVUCONAZONIUM SULFATE; RAVUCONAZOLE PRODRUGS, NIPPON ROCHE","ASP-9766; BAL-4815; BAL-8349; BAL-8557; BAL-8557 (ORAL), BASILEA; BAL-8728; BMS-207147 PRODRUGS, NIPPON ROCHE; CRESEMBA; CRESEMBA; RO-0094815; RO-0098557; RO-0098246; ANTIFUNGALS, BASILEA; ISAVUCONAZOLE; ISAVUCONAZONIUM; ISAVUCONAZONIUM CHLORIDE; ISAVUCONAZONIUM CHLORIDE/SULFATE (ORAL), BASILEA/ASTELLAS; ISAVUCONAZONIUM SULFATE; RAVUCONAZOLE PRODRUGS, NIPPON ROCHE","ISAVUCONAZONIUM CHLORIDE/SULFATE (ORAL), BASILEA/ASTELLAS",ASP-9766,BAL-4815,BAL-8349,BAL-8557,"BAL-8557 (ORAL), BASILEA",BAL-8728,"BMS-207147 PRODRUGS, NIPPON ROCHE",CRESEMBA,CRESEMBA,RO-0094815,RO-0098557,RO-0098246,"ANTIFUNGALS, BASILEA",ISAVUCONAZOLE,ISAVUCONAZONIUM,ISAVUCONAZONIUM CHLORIDE,"ISAVUCONAZONIUM CHLORIDE/SULFATE (ORAL), BASILEA/ASTELLAS",ISAVUCONAZONIUM SULFATE,"RAVUCONAZOLE PRODRUGS, NIPPON ROCHE",,,,,,,,,,,,207500,ISAVUCONAZONIUM SULFATE,,,,,,,,,,,,,,,,,,,,,2015-03-06T00:00:00Z,2015,3,Cresemba (oral),aspergillus infection,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE; SYNERGIST,CAPSULE FORMULATION; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),207500,NDA,2014-07-08T00:00:00Z,fda,1,0,0,1,0,,astellas pharma,TYO: 4503,1,11315.7,10060.3,10821,11107,12783.1,11541,8452.1,1860.1,1860.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500,301,29,117,4,Mycoses,1,0
601,"POSACONAZOLE (DELAYED RELEASE/ORAL TABLET), MERCK & CO","MK-5592 (SOLID ORAL TABLET), MERCK & CO; NOXAFIL; NOXAFIL GASTRO RESISTANT; SPRIAFIL; POSACONAZOLE; POSACONAZOLE (DELAYED RELEASE/ORAL TABLET), MERCK & CO; POSACONAZOLE (SOLID ORAL TABLET), MERCK & CO","MK-5592 (SOLID ORAL TABLET), MERCK & CO; NOXAFIL; NOXAFIL GASTRO RESISTANT; SPRIAFIL; POSACONAZOLE; POSACONAZOLE (DELAYED RELEASE/ORAL TABLET), MERCK & CO; POSACONAZOLE (SOLID ORAL TABLET), MERCK & CO","POSACONAZOLE (DELAYED RELEASE/ORAL TABLET), MERCK & CO","MK-5592 (SOLID ORAL TABLET), MERCK & CO",NOXAFIL,NOXAFIL GASTRO RESISTANT,SPRIAFIL,POSACONAZOLE,"POSACONAZOLE (DELAYED RELEASE/ORAL TABLET), MERCK & CO","POSACONAZOLE (SOLID ORAL TABLET), MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,22003,POSACONAZOLE,,,,,,,,,,,,,,,,,,,,,2013-11-25T00:00:00Z,2013,11,Noxafil (oral tablet),fungal infection,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,FORMULATION SOLID ORAL; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205053,NDA,2013-01-24T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,44033,47267,48047,45987,27428,23850,28052,7123,7224,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205053,435,124,117,4,Mycoses,1,0
602,"POSACONAZOLE (IV FORMULATION, CAPTISOL-ENABLED), MERCK & CO","MK-5592 (IV FORMULATION), MERCK & CO; NOXAFIL; NOXAFIL (IV FORMULATION), SCHERING-PLOUGH; NOXAFIL-IV; SCH-56592; SCH-56592 (IV PRODRUG), SCHERING-PLOUGH; SCH-59884; POSACONAZOLE; POSACONAZOLE (INTRAVENOUS FORMULATION), SCHERING-PLOUGH; POSACONAZOLE (IV FORMULATION), MERCK & CO; POSACONAZOLE (IV FORMULATION), SCHERING-PLOUGH; POSACONAZOLE (IV FORMULATION, CAPTISOL-ENABLED), MERCK & CO; POSACONAZOLE (IV PRODRUG), SCHERING-PLOUGH","MK-5592 (IV FORMULATION), MERCK & CO; NOXAFIL; NOXAFIL (IV FORMULATION), SCHERING-PLOUGH; NOXAFIL-IV; SCH-56592; SCH-56592 (IV PRODRUG), SCHERING-PLOUGH; SCH-59884; POSACONAZOLE; POSACONAZOLE (INTRAVENOUS FORMULATION), SCHERING-PLOUGH; POSACONAZOLE (IV FORMULATION), MERCK & CO; POSACONAZOLE (IV FORMULATION), SCHERING-PLOUGH; POSACONAZOLE (IV FORMULATION, CAPTISOL-ENABLED), MERCK & CO; POSACONAZOLE (IV PRODRUG), SCHERING-PLOUGH","POSACONAZOLE (IV FORMULATION, CAPTISOL-ENABLED), MERCK & CO","MK-5592 (IV FORMULATION), MERCK & CO",NOXAFIL,"NOXAFIL (IV FORMULATION), SCHERING-PLOUGH",NOXAFIL-IV,SCH-56592,"SCH-56592 (IV PRODRUG), SCHERING-PLOUGH",SCH-59884,POSACONAZOLE,"POSACONAZOLE (INTRAVENOUS FORMULATION), SCHERING-PLOUGH","POSACONAZOLE (IV FORMULATION), MERCK & CO","POSACONAZOLE (IV FORMULATION), SCHERING-PLOUGH","POSACONAZOLE (IV FORMULATION, CAPTISOL-ENABLED), MERCK & CO","POSACONAZOLE (IV PRODRUG), SCHERING-PLOUGH",,,,,,,,,,,,,,,,,,22003,POSACONAZOLE,,,,,,,,,,,,,,,,,,,,,2014-03-13T00:00:00Z,2014,3,Noxafil (IV),fungal infection,LANOSTEROL-14 DEMETHYLASE INHIBITOR,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),205596,NDA,2013-09-13T00:00:00Z,fda,1,0,0,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205596,436,124,117,4,Mycoses,1,0
686,"SPINOSAD CREME RINSE (HEAD LICE), PARAPRO","NATROVA; NATROBA; SPINOSAD; SPINOSAD CREME RINSE (HEAD LICE), PARAPRO; SPINOSAD CREME RINSE (PEDICULOSIS CAPITIS INFECTOION), PARAPRO; SPINOSYN A + SPINOSYN D (TOPICAL SHAMPOO, HEAD LICE), PARAPRO","NATROVA; NATROBA; SPINOSAD; SPINOSAD CREME RINSE (HEAD LICE), PARAPRO; SPINOSAD CREME RINSE (PEDICULOSIS CAPITIS INFECTOION), PARAPRO; SPINOSYN A + SPINOSYN D (TOPICAL SHAMPOO, HEAD LICE), PARAPRO","SPINOSAD CREME RINSE (HEAD LICE), PARAPRO",NATROVA,NATROBA,SPINOSAD,"SPINOSAD CREME RINSE (HEAD LICE), PARAPRO","SPINOSAD CREME RINSE (PEDICULOSIS CAPITIS INFECTOION), PARAPRO","SPINOSYN A + SPINOSYN D (TOPICAL SHAMPOO, HEAD LICE), PARAPRO",,,,,,,,,,,,,,,,,,,,,,,,,22408,SPINOSAD,22408,SPINOSAD,,,,,,,,,,,,,,,,,,,2011-01-18T00:00:00Z,2011,1,Natroba,pediculosis capitis infestation,UNSPECIFIED ION CHANNEL MODULATOR,INSECTICIDE,DERMATOLOGICAL FORMULATION; DRUG COMBINATION; EMULSION DERMATOLOGICAL; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC; SUSPENSION,matched (3),022408,NDA,2009-01-21T00:00:00Z,fda,0,0,0,0,0,,parapro,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022408,554,699,132,8,Other infections; including parasitic,1,0
400,"IVERMECTIN (TOPICAL, HEAD LICE), SANOFI-TOPAZ","SKLICE LOTION; HEAD LICE THERAPY (TOPICAL), TOPAZ; IVERMECTIN; IVERMECTIN (TOPICAL, HEAD LICE), SANOFI-TOPAZ; IVERMECTIN (TOPICAL, HEAD LICE), TOPAZ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-02-07T00:00:00Z,2012,2,Sklice,pediculosis capitis infestation,CHLORIDE CHANNEL MODULATOR,,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,using only (2),202736,NDA,2011-04-07T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,47408.5,45544.7,45640,44761,40266.9,42651,32806.4,6467.14,6467.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202736,690,699,132,8,Other infections; including parasitic,1,0
620,RAMUCIRUMAB,"CYRAMZA; IMC-1121; IMC-1121B; IMC-2C6; LY-3009806; ANTI-KDR ANTIBODIES, IMCLONE; ANTI-VEGFR2 ANTIBODIES, IMCLONE; RAMUCIRUMAB","CYRAMZA; IMC-1121; IMC-1121B; IMC-2C6; LY-3009806; ANTI-KDR ANTIBODIES, IMCLONE; ANTI-VEGFR2 ANTIBODIES, IMCLONE; RAMUCIRUMAB",RAMUCIRUMAB,CYRAMZA,IMC-1121,IMC-1121B,IMC-2C6,LY-3009806,"ANTI-KDR ANTIBODIES, IMCLONE","ANTI-VEGFR2 ANTIBODIES, IMCLONE",RAMUCIRUMAB,,,,,,,,,,,,,,,,,,,,,,,125477,RAMUCIRUMAB,,,,,,,,,,,,,,,,,,,,,2014-04-21T00:00:00Z,2014,4,Cyramza,metastatic stomach cancer,VEGF-2 RECEPTOR ANTAGONIST; VEGF-A LIGAND INHIBITOR; VEGF-C LIGAND INHIBITOR; VEGF-D LIGAND INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; PROTEIN RECOMBINANT; SOLUTION,matched (3),125477,BLA,2013-08-23T00:00:00Z,fda,1,0,1,1,0,,eli lilly,NYSE: LLY,1,19615.6,23113.1,22603.4,24286.5,23076,21836,14683.1,4733.6,4733.6,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,45,3666,151,13,Cancer of stomach,1,1
511,NECITUMUMAB,"HUMAN EGF ANTIBODY VACCINE, IMCLONE; IMC-11F8; LY-3012211; LY-3012211; PORTRAZZA; PORTRAZZA; HUMAN EGF ANTIBODY, IMCLONE; NECITUMUMAB","HUMAN EGF ANTIBODY VACCINE, IMCLONE; IMC-11F8; LY-3012211; LY-3012211; PORTRAZZA; PORTRAZZA; HUMAN EGF ANTIBODY, IMCLONE; NECITUMUMAB",NECITUMUMAB,"HUMAN EGF ANTIBODY VACCINE, IMCLONE",IMC-11F8,LY-3012211,LY-3012211,PORTRAZZA,PORTRAZZA,"HUMAN EGF ANTIBODY, IMCLONE",NECITUMUMAB,,,,,,,,,,,,,,,,,,,,,,,125547,NECITUMUMAB,,,,,,,,,,,,,,,,,,,,,2015-11-24T00:00:00Z,2015,11,Portrazza,metastatic non small cell lung cancer,EPIDERMAL GROWTH FACTOR ANTAGONIST,ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SOLUTION,matched (3),125547,BLA,2014-12-02T00:00:00Z,fda,0,0,1,1,0,,eli lilly,NYSE: LLY,1,19958.7,19615.6,23113.1,22603.4,24286.5,23076,15074.5,4796.4,4796.4,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125547,59,3665,151,13,Cancer of stomach,1,1
172,CRIZOTINIB,NSC-749005; PF-02341066; PF-06260182; PF-1066; PF-2341066; XALKORI; CRIZOTINIB,NSC-749005; PF-02341066; PF-06260182; PF-1066; PF-2341066; XALKORI; CRIZOTINIB,CRIZOTINIB,NSC-749005,PF-02341066,PF-06260182,PF-1066,PF-2341066,XALKORI,CRIZOTINIB,,,,,,,,,,,,,,,,,,,,,,,,202570,CRIZOTINIB,,,,,,,,,,,,,,,,,,,,,2011-08-26T00:00:00Z,2011,8,Xalkori,metastatic non small cell lung cancer,ALK TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; ANAPLASTIC LYMPHOMA KINASE RECEPTOR INHIBITOR; ECHINODERM MICROTUBULE LIKE PROTEIN 4 INHIBITOR; HEPATOCYTE GROWTH FACTOR ANTAGONIST; MET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; ROS1 TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR,CAPSULE FORMULATION; MICROPARTICLE FORMULATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202570,NDA,2011-03-30T00:00:00Z,fda,1,1,1,1,0,,pfizer,NYSE: PFE,1,61035,65165,49269,48296,48418,48371,49335,8004,8681,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,124,3665,151,13,Cancer of stomach,1,1
145,CERITINIB,"ALK INHIBITOR (ORAL, CANCER), NOVARTIS; LDK-378; ZYKADIA; CERITINIB","ALK INHIBITOR (ORAL, CANCER), NOVARTIS; LDK-378; ZYKADIA; CERITINIB",CERITINIB,"ALK INHIBITOR (ORAL, CANCER), NOVARTIS",LDK-378,ZYKADIA,CERITINIB,,,,,,,,,,,,,,,,,,,,,,,,,,,205755,CERITINIB,,,,,,,,,,,,,,,,,,,,,2014-04-29T00:00:00Z,2014,4,Zykadia,metastatic non small cell lung cancer,ALK TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; ANAPLASTIC LYMPHOMA KINASE RECEPTOR INHIBITOR; INSULIN RECEPTOR FAMILY TYROSINE KINASE INHIBITOR; INSULIN-LIKE GROWTH FACTOR 1 ANTAGONIST; ROS1 TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; SYNERGIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205755,NDA,2013-12-24T00:00:00Z,fda,1,0,1,1,1,2013-03-15T00:00:00Z,novartis,NYSE: NVS,1,53634,52716,51971,59375,51561,45075,36289,9086,9086,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205755,254,3665,151,13,Cancer of stomach,1,1
392,"IRINOTECAN SUCROSOFATE (NANOLIPOSOMAL, CANCER), PHARMAENGINE/MERRIMACK/SHIRE","BAX-2398; MM-398; ONIVYDE; ONIVYDE; PEP-02; PEP-02 (NANOLIPOSOMAL); CAMPOTHECIN DERIVATIVE (CANCER), PHARMAENGINE; CAMPTOTHECIN DERIVATIVE (CANCER), PHARMAENGINE/HERMES; IRINOTECAN; IRINOTECAN SUCROSOFATE; IRINOTECAN SUCROSOFATE (NANOLIPOSOMAL, CANCER), PHARMAENGINE/MERRIMACK/SHIRE; NAL-IRI","BAX-2398; MM-398; ONIVYDE; ONIVYDE; PEP-02; PEP-02 (NANOLIPOSOMAL); CAMPOTHECIN DERIVATIVE (CANCER), PHARMAENGINE; CAMPTOTHECIN DERIVATIVE (CANCER), PHARMAENGINE/HERMES; IRINOTECAN; IRINOTECAN SUCROSOFATE; IRINOTECAN SUCROSOFATE (NANOLIPOSOMAL, CANCER), PHARMAENGINE/MERRIMACK/SHIRE; NAL-IRI","IRINOTECAN SUCROSOFATE (NANOLIPOSOMAL, CANCER), PHARMAENGINE/MERRIMACK/SHIRE",BAX-2398,MM-398,ONIVYDE,ONIVYDE,PEP-02,PEP-02 (NANOLIPOSOMAL),"CAMPOTHECIN DERIVATIVE (CANCER), PHARMAENGINE","CAMPTOTHECIN DERIVATIVE (CANCER), PHARMAENGINE/HERMES",IRINOTECAN,IRINOTECAN SUCROSOFATE,"IRINOTECAN SUCROSOFATE (NANOLIPOSOMAL, CANCER), PHARMAENGINE/MERRIMACK/SHIRE",NAL-IRI,,,,,,,,,,,,,,,,,,,207793,IRINOTECAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-10-22T00:00:00Z,2015,10,Onivyde,metastatic pancreas cancer,TOPOISOMERASE I INHIBITOR,ANTICANCER; ENDOCRINE DIAGNOSTIC AGENT; GASTROINTESTINAL DIAGNOSTIC AGENT; NEOPLASM DIAGNOSTIC AGENT,INFUSION; INTRAVENOUS FORMULATION; LIPOSOME FORMULATION; NANOPARTICLE FORMULATION; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC,matched (3),207793,NDA,2015-04-24T00:00:00Z,fda,1,0,1,1,0,,merrimack pharmaceuticals,NASDAQ: MACK,1,89.3,102.8,47.8,48.9,34.2,20.3,-71.8,,161,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207793,306,3669,151,13,Cancer of stomach,1,1
549,OSIMERTINIB,"AZ-5104; AZ-7550; AZD-9291; TAGRISSO; TAGRISSO; MERELETINIB; OSIMERTINIB; OSIMERTINIB (T790M-MUTATION-TARGETING, NSCLC), ASTRAZENECA; OSIMERTINIB MESYLATE","AZ-5104; AZ-7550; AZD-9291; TAGRISSO; TAGRISSO; MERELETINIB; OSIMERTINIB; OSIMERTINIB (T790M-MUTATION-TARGETING, NSCLC), ASTRAZENECA; OSIMERTINIB MESYLATE",OSIMERTINIB,AZ-5104,AZ-7550,AZD-9291,TAGRISSO,TAGRISSO,MERELETINIB,OSIMERTINIB,"OSIMERTINIB (T790M-MUTATION-TARGETING, NSCLC), ASTRAZENECA",OSIMERTINIB MESYLATE,,,,,,,,,,,,,,,,,,,,,,208065,OSIMERTINIB MESYLATE,,,,,,,,,,,,,,,,,,,,,2015-11-13T00:00:00Z,2015,11,Tagrisso,metastatic non small cell lung cancer,EPIDERMAL GROWTH FACTOR ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR,DAILY DOSING; DRUG COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208065,NDA,2015-06-05T00:00:00Z,fda,1,1,1,1,1,2014-04-24T00:00:00Z,astrazeneca,NYSE: AZN,1,24708,26547,25806,27973,33591,33269,20248,5660,5861,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,323,3665,151,13,Cancer of stomach,1,1
22,ALECTINIB,"AF-802; ALK INHIBITOR (NSCLC), CHUGAI; ALECENSA; ALECENSARO; ALECENSARO; CH-5424802; RG-7853; RO-5424802; ALECTINIB","AF-802; ALK INHIBITOR (NSCLC), CHUGAI; ALECENSA; ALECENSARO; ALECENSARO; CH-5424802; RG-7853; RO-5424802; ALECTINIB",ALECTINIB,AF-802,"ALK INHIBITOR (NSCLC), CHUGAI",ALECENSA,ALECENSARO,ALECENSARO,CH-5424802,RG-7853,RO-5424802,ALECTINIB,,,,,,,,,,,,,,,,,,,,,,208434,ALECTINIB HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-12-11T00:00:00Z,2015,12,Alecensa,metastatic non small cell lung cancer,ALK TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; ANAPLASTIC LYMPHOMA KINASE RECEPTOR INHIBITOR; RET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208434,NDA,2015-07-06T00:00:00Z,fda,1,1,0,1,1,2013-09-23T00:00:00Z,roche,SIX: ROG,1,50342.1,50199.3,54589.6,51820.8,47194.8,52624.4,36105.3,9443.6,9569.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,343,3665,151,13,Cancer of stomach,1,1
264,EVEROLIMUS,AFINITOR; AFINITOR DISPERZ; APINITO; CERTICAN; RAD-001; RAD-001A; RAD001C; SDZ-RAD; VOTUBIA; ZORTRESS; EVEROLIMUS,AFINITOR; AFINITOR DISPERZ; APINITO; CERTICAN; RAD-001; RAD-001A; RAD001C; SDZ-RAD; VOTUBIA; ZORTRESS; EVEROLIMUS,EVEROLIMUS,AFINITOR,AFINITOR DISPERZ,APINITO,CERTICAN,RAD-001,RAD-001A,RAD001C,SDZ-RAD,VOTUBIA,ZORTRESS,EVEROLIMUS,,,,,,,,,,,,,,,,,,,,203985,EVEROLIMUS,21560,EVEROLIMUS,22334,EVEROLIMUS,,,,,,,,,,,,,,,,,2009-03-30T00:00:00Z,2009,3,Afinitor,metastatic renal cancer,MTOR COMPLEX 1 INHIBITOR; MTOR INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; ANTICONVULSANT AGENT; ANTIVIRAL; IMMUNOSUPPRESSANT,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022334,NDA,2008-06-27T00:00:00Z,fda,1,0,0,0,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,533,3467,151,13,Cancer of stomach,1,1
571,PANITUMUMAB,"ABX-EGF; VECTIBIX; ANTI-EGFR ANTIBODY, ABGENIX/AMGEN; ANTI-EGFR ANTIBODY, ABGENIX/IMMUNEX; PANITUMUMAB; RHUMAB-EGFR, AMGEN/ ABGENIX","ABX-EGF; VECTIBIX; ANTI-EGFR ANTIBODY, ABGENIX/AMGEN; ANTI-EGFR ANTIBODY, ABGENIX/IMMUNEX; PANITUMUMAB; RHUMAB-EGFR, AMGEN/ ABGENIX",PANITUMUMAB,ABX-EGF,VECTIBIX,"ANTI-EGFR ANTIBODY, ABGENIX/AMGEN","ANTI-EGFR ANTIBODY, ABGENIX/IMMUNEX",PANITUMUMAB,"RHUMAB-EGFR, AMGEN/ ABGENIX",,,,,,,,,,,,,,,,,,,,,,,,,125147,PANITUMUMAB,,,,,,,,,,,,,,,,,,,,,2006-09-27T00:00:00Z,2006,9,Vectibix,colorectal tumor,EGFR FAMILY TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE; DNA TECHNOLOGY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; PROTEIN RECOMBINANT,matched (3),125147,BLA,2006-02-21T00:00:00Z,cortellis,1,1,1,0,0,,amgen,NASDAQ: AMGN,1,14268,12430,10550,8356,5523,4015.7,12173,3366,3366,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147,5,989,153,14,Cancer of colon,1,1
16,"AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI","AVE-0005; AFLITIV; LIDAVEG; VEGF TRAP, REGENERON/AVENTIS; VEGF TRAP, REGENERON/SANOFI-AVENTIS; VEGF ANTAGONIST (CANCER), REGENERON/AVENTIS; VEGF ANTAGONIST (CANCER), REGENERON/SANOFI-AVENTIS; VEGF TRAP; ZALTRAP; AFLIBERCEPT; AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI; AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI-AVENTIS; SYSTEMIC VEGF TRAP (CANCER), REGENERON/SANOFI-AVENTIS; ZIV-AFLIBERCEPT","AVE-0005; AFLITIV; LIDAVEG; VEGF TRAP, REGENERON/AVENTIS; VEGF TRAP, REGENERON/SANOFI-AVENTIS; VEGF ANTAGONIST (CANCER), REGENERON/AVENTIS; VEGF ANTAGONIST (CANCER), REGENERON/SANOFI-AVENTIS; VEGF TRAP; ZALTRAP; AFLIBERCEPT; AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI; AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI-AVENTIS; SYSTEMIC VEGF TRAP (CANCER), REGENERON/SANOFI-AVENTIS; ZIV-AFLIBERCEPT","AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI",AVE-0005,AFLITIV,LIDAVEG,"VEGF TRAP, REGENERON/AVENTIS","VEGF TRAP, REGENERON/SANOFI-AVENTIS","VEGF ANTAGONIST (CANCER), REGENERON/AVENTIS","VEGF ANTAGONIST (CANCER), REGENERON/SANOFI-AVENTIS",VEGF TRAP,ZALTRAP,AFLIBERCEPT,"AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI","AFLIBERCEPT (INTRAVENOUS, CANCER), REGENERON/SANOFI-AVENTIS","SYSTEMIC VEGF TRAP (CANCER), REGENERON/SANOFI-AVENTIS",ZIV-AFLIBERCEPT,,,,,,,,,,,,,,,,,125418,ZIV-AFLIBERCEPT,,,,,,,,,,,,,,,,,,,,,2012-08-03T00:00:00Z,2012,8,Zaltrap,metastatic colorectal cancer,PLACENTA GROWTH FACTOR LIGAND INHIBITOR; VEGF-A LIGAND INHIBITOR; VEGF-B LIGAND INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER PROTEIN KINASE INHIBITOR; METASTASIS INHIBITOR,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; PROTEIN FUSION; PROTEIN RECOMBINANT; RECEPTOR FUSION; SOLUTION,matched (3),125418,BLA,2012-02-03T00:00:00Z,fda,1,0,0,0,0,,sanofi,NYSE: SNY,1,47408.5,45544.7,45640,44761,40266.9,42651,32806.4,6467.14,6467.1,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125418,37,3658,153,14,Cancer of colon,1,1
628,REGORAFENIB,"BAY-73-4506; BAY-81-1557; DAST (CANCER), BAYER; DAST INHIBITOR; DAST INHIBITOR (CANCER), BAYER; STIVARGA; DUAL ACTING KINASE INHIBITOR (CANCER), BAYER; DUAL ACTING MULTIKINASE INHIBITOR (CANCER), BAYER; DUAL ACTING SIGNAL TRANSDUCTION INHIBITOR (CANCER), BAYER; FLUORO-SORAFENIB; REGORAFENIB","BAY-73-4506; BAY-81-1557; DAST (CANCER), BAYER; DAST INHIBITOR; DAST INHIBITOR (CANCER), BAYER; STIVARGA; DUAL ACTING KINASE INHIBITOR (CANCER), BAYER; DUAL ACTING MULTIKINASE INHIBITOR (CANCER), BAYER; DUAL ACTING SIGNAL TRANSDUCTION INHIBITOR (CANCER), BAYER; FLUORO-SORAFENIB; REGORAFENIB",REGORAFENIB,BAY-73-4506,BAY-81-1557,"DAST (CANCER), BAYER",DAST INHIBITOR,"DAST INHIBITOR (CANCER), BAYER",STIVARGA,"DUAL ACTING KINASE INHIBITOR (CANCER), BAYER","DUAL ACTING MULTIKINASE INHIBITOR (CANCER), BAYER","DUAL ACTING SIGNAL TRANSDUCTION INHIBITOR (CANCER), BAYER",FLUORO-SORAFENIB,REGORAFENIB,,,,,,,,,,,,,,,,,,,,203085,REGORAFENIB,,,,,,,,,,,,,,,,,,,,,2012-09-27T00:00:00Z,2012,9,Stivarga,metastatic colorectal cancer,CASPASE-3 STIMULATOR; CASPASE-9 STIMULATOR; FGF RECEPTOR ANTAGONIST; KIT TYROSINE KINASE INHIBITOR; PDGF RECEPTOR BETA MODULATOR; RET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; RAF 1 PROTEIN KINASE INHIBITOR; RAF B PROTEIN KINASE INHIBITOR; TIE TYROSINE KINASE RECEPTOR INHIBITOR; TEK TYROSINE KINASE RECEPTOR INHIBITOR; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; SYNERGIST,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203085,NDA,2012-04-27T00:00:00Z,fda,1,0,1,0,0,,bayer,ETR: BAYN,1,52397.7,47454.4,47050.6,44669.3,45997.3,47291.9,27254.3,3972.58,3972.6,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085,138,3658,153,14,Cancer of colon,1,1
761,"TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE (ORAL), TAIHO","LONSURF; MUP-98156 + F3DTHD, TAIHO; S-95005; TAS-102; TRIFLURIDINE + MUP-98156; TRIFLURIDINE + MUP-98156 (ORAL COMBINATION), TAIHO; TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE (ORAL), TAIHO","LONSURF; MUP-98156 + F3DTHD, TAIHO; S-95005; TAS-102; TRIFLURIDINE + MUP-98156; TRIFLURIDINE + MUP-98156 (ORAL COMBINATION), TAIHO; TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE (ORAL), TAIHO","TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE (ORAL), TAIHO",LONSURF,"MUP-98156 + F3DTHD, TAIHO",S-95005,TAS-102,TRIFLURIDINE + MUP-98156,"TRIFLURIDINE + MUP-98156 (ORAL COMBINATION), TAIHO",TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE,"TRIFLURIDINE + TIPIRACIL HYDROCHLORIDE (ORAL), TAIHO",,,,,,,,,,,,,,,,,,,,,,,207981,TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE,,,,,,,,,,,,,,,,,,,,,2015-09-22T00:00:00Z,2015,9,Lonsurf,metastatic colorectal cancer,THYMIDINE PHOSPHORYLASE INHIBITOR; THYMIDYLATE SYNTHASE INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER; DNA SYNTHESIS INHIBITOR; NUCLEIC ACID METABOLISM MODULATOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207981,NDA,2014-12-19T00:00:00Z,fda,0,0,1,0,0,,otsuka,TYO: 4578,1,12023.5,13350.2,13344,13476.7,14733.1,13618.6,8285.8,1672.3,1672.3,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207981,316,3658,153,14,Cancer of colon,1,1
323,GADOXETATE DISODIUM,BAY-86-4873; EOB PRIMOVIST; EOVIST; GD-EOB-DTPA; PRIMOVIST; SH-L-569; ZK-139834; GADOXETATE DISODIUM; GADOXETIC ACID; GADOXETIC ACID DISODIUM,BAY-86-4873; EOB PRIMOVIST; EOVIST; GD-EOB-DTPA; PRIMOVIST; SH-L-569; ZK-139834; GADOXETATE DISODIUM; GADOXETIC ACID; GADOXETIC ACID DISODIUM,GADOXETATE DISODIUM,BAY-86-4873,EOB PRIMOVIST,EOVIST,GD-EOB-DTPA,PRIMOVIST,SH-L-569,ZK-139834,GADOXETATE DISODIUM,GADOXETIC ACID,GADOXETIC ACID DISODIUM,,,,,,,,,,,,,,,,,,,,,22090,GADOXETATE DISODIUM,,,,,,,,,,,,,,,,,,,,,2008-07-03T00:00:00Z,2008,7,Eovist,liver tumor,,GASTROINTESTINAL DIAGNOSTIC AGENT; MRI IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022090,NDA,2007-06-29T00:00:00Z,fda,0,0,0,0,0,,bayer,ETR: BAYN,1,45997.3,47291.9,38208.1,29259.7,28330.6,28254.3,23002.9,3707.12,3707.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022090,464,202,155,16,Cancer of liver and intrahepatic bile duct,1,1
15,AFATINIB,"BIBW-2992; GILOTRIF; GILOTRIF; GIOTRIF; TOMTOVOK; TOVOK; XOVOLTIB; AFATINIB; AFATINIB DIMALEATE; DUAL EGFR/HER2 RECEPTOR TYROSINE KINASE INHIBITOR (SOLID TUMORS), BOEHRINGER INGELHEIM","BIBW-2992; GILOTRIF; GILOTRIF; GIOTRIF; TOMTOVOK; TOVOK; XOVOLTIB; AFATINIB; AFATINIB DIMALEATE; DUAL EGFR/HER2 RECEPTOR TYROSINE KINASE INHIBITOR (SOLID TUMORS), BOEHRINGER INGELHEIM",AFATINIB,BIBW-2992,GILOTRIF,GILOTRIF,GIOTRIF,TOMTOVOK,TOVOK,XOVOLTIB,AFATINIB,AFATINIB DIMALEATE,"DUAL EGFR/HER2 RECEPTOR TYROSINE KINASE INHIBITOR (SOLID TUMORS), BOEHRINGER INGELHEIM",,,,,,,,,,,,,,,,,,,,,201292,AFATINIB DIMALEATE,,,,,,,,,,,,,,,,,,,,,2013-07-12T00:00:00Z,2013,7,Gilotrif,non-small-cell lung cancer,EPIDERMAL GROWTH FACTOR ANTAGONIST; ERBB2 TYROSINE KINASE RECEPTOR INHIBITOR; ERBB3 TYROSINE KINASE RECEPTOR INHIBITOR; ERBB4 TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),201292,NDA,2012-11-14T00:00:00Z,fda,1,0,1,1,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292,84,1262,162,19,Cancer of bronchus; lung,2,1
745,"TOPOTECAN HYDROCHLORIDE (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS","HYCAMTIN; TOPOTECAN; TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), GLAXOSMITHKLINE; TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS; TOPOTECAN HYDROCHLORIDE; TOPOTECAN HYDROCHLORIDE (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS","HYCAMTIN; TOPOTECAN; TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), GLAXOSMITHKLINE; TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS; TOPOTECAN HYDROCHLORIDE; TOPOTECAN HYDROCHLORIDE (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS","TOPOTECAN HYDROCHLORIDE (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS",HYCAMTIN,TOPOTECAN,"TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), GLAXOSMITHKLINE","TOPOTECAN (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS",TOPOTECAN HYDROCHLORIDE,"TOPOTECAN HYDROCHLORIDE (ORAL, SMALL-CELL LUNG CANCER), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,200199,TOPOTECAN HYDROCHLORIDE,20671,TOPOTECAN HYDROCHLORIDE,22453,TOPOTECAN HYDROCHLORIDE,22453,TOPOTECAN HYDROCHLORIDE,22453,TOPOTECAN HYDROCHLORIDE,,,,,,,,,,,,,2007-10-11T00:00:00Z,2007,10,Hycamtin,small-cell lung cancer,TOPOISOMERASE I INHIBITOR,ANTICANCER,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),020981,NDA,2007-04-11T00:00:00Z,fda,1,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45147.6,45499.1,37229.2,38293.2,37593.1,34140.7,34800.8,6433.47,6612.3,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020981,631,1261,162,19,Cancer of bronchus; lung,2,1
746,TRABECTEDIN,"ET-743, UNIVERSITY OF ILLINOIS; ECT-743; PT-650; YONDELIS; ECTEINASCIDIN-743; PHTHALASCIDIN; TRABECTEDIN","ET-743, UNIVERSITY OF ILLINOIS; ECT-743; PT-650; YONDELIS; ECTEINASCIDIN-743; PHTHALASCIDIN; TRABECTEDIN",TRABECTEDIN,"ET-743, UNIVERSITY OF ILLINOIS",ECT-743,PT-650,YONDELIS,ECTEINASCIDIN-743,PHTHALASCIDIN,TRABECTEDIN,,,,,,,,,,,,,,,,,,,,,,,,207953,TRABECTEDIN,,,,,,,,,,,,,,,,,,,,,2015-10-23T00:00:00Z,2015,10,Yondelis,liposarcoma,,ANTICANCER; ANTICANCER ALKYLATING AGENT; CELL CYCLE INHIBITOR; DNA MODULATOR,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC,matched (3),207953,NDA,2014-11-24T00:00:00Z,fda,1,0,0,1,0,,johnson and johnson,NYSE: JNJ,1,70074,74331,71312,67224,65030,61587,48619,9046,9046,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207953,313,2447,171,21,Cancer of bone and connective tissue,1,1
165,COBIMETINIB,"COTELLIC; COTELLIC; GDC-0973; MEK INHIBITOR (ORAL, CANCER), EXELIXIS/GENENTECH; RG-7420 (GDC-0973); RG-7421; RO-5514041; XL-518; [14C]-GDC-0973; COBIMETINIB; COBIMETINIB BUTYRATE; COBIMETINIB FUMARATE","COTELLIC; COTELLIC; GDC-0973; MEK INHIBITOR (ORAL, CANCER), EXELIXIS/GENENTECH; RG-7420 (GDC-0973); RG-7421; RO-5514041; XL-518; [14C]-GDC-0973; COBIMETINIB; COBIMETINIB BUTYRATE; COBIMETINIB FUMARATE",COBIMETINIB,COTELLIC,COTELLIC,GDC-0973,"MEK INHIBITOR (ORAL, CANCER), EXELIXIS/GENENTECH",RG-7420 (GDC-0973),RG-7421,RO-5514041,XL-518,[14C]-GDC-0973,COBIMETINIB,COBIMETINIB BUTYRATE,COBIMETINIB FUMARATE,,,,,,,,,,,,,,,,,,,206192,COBIMETINIB FUMARATE,206192,COBIMETINIB FUMARATE,,,,,,,,,,,,,,,,,,,2015-11-10T00:00:00Z,2015,11,Cotellic,stage iv melanoma,MEK PROTEIN KINASE INHIBITOR; MEK-1 PROTEIN KINASE INHIBITOR; MEK-2 PROTEIN KINASE INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; SYNERGIST,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206192,NDA,2014-12-11T00:00:00Z,fda,1,0,1,1,0,,roche,SIX: ROG,1,50342.1,50199.3,54589.6,51820.8,47194.8,52624.4,36105.3,9433.6,9569.4,,,2009,,acquired by roche in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,2,3257,172,22,Melanomas of skin,1,1
581,PEMBROLIZUMAB,"KEYTRUDA; KEYTRUDA; MK-3475; SCH-900475; LAMBROLIZUMAB; LAMBROLIZUMAB, MERCK; PEMBROLIZUMAB","KEYTRUDA; KEYTRUDA; MK-3475; SCH-900475; LAMBROLIZUMAB; LAMBROLIZUMAB, MERCK; PEMBROLIZUMAB",PEMBROLIZUMAB,KEYTRUDA,KEYTRUDA,MK-3475,SCH-900475,LAMBROLIZUMAB,"LAMBROLIZUMAB, MERCK",PEMBROLIZUMAB,,,,,,,,,,,,,,,,,,,,,,,,125514,PEMBROLIZUMAB,125514,PEMBROLIZUMAB,,,,,,,,,,,,,,,,,,,2014-09-04T00:00:00Z,2014,9,Keytruda,stage iv melanoma,PROGRAMMED CELL DEATH PROTEIN 1 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; ANTIVIRAL; APOPTOSIS STIMULATOR; IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED,matched (3),125514,BLA,2014-02-27T00:00:00Z,fda,1,1,0,1,1,2013-04-24T00:00:00Z,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,52,3257,172,22,Melanomas of skin,1,1
179,DABRAFENIB,"DRB-436; GSK-2118435; GSK-2118436; GSK-2118436A; GSK-2118436J; GSK-436; NSC-763760; SB-244649; SB-477790; SB-590885; SB-602330; SB-699393; TAFINLAR; B-RAF INHIBITORS (CANCER), GLAXOSMITHKLINE; DABRAFENIB; DABRAFENIB MESYLATE","DRB-436; GSK-2118435; GSK-2118436; GSK-2118436A; GSK-2118436J; GSK-436; NSC-763760; SB-244649; SB-477790; SB-590885; SB-602330; SB-699393; TAFINLAR; B-RAF INHIBITORS (CANCER), GLAXOSMITHKLINE; DABRAFENIB; DABRAFENIB MESYLATE",DABRAFENIB,DRB-436,GSK-2118435,GSK-2118436,GSK-2118436A,GSK-2118436J,GSK-436,NSC-763760,SB-244649,SB-477790,SB-590885,SB-602330,SB-699393,TAFINLAR,"B-RAF INHIBITORS (CANCER), GLAXOSMITHKLINE",DABRAFENIB,DABRAFENIB MESYLATE,,,,,,,,,,,,,,,202806,DABRAFENIB MESYLATE,,,,,,,,,,,,,,,,,,,,,2013-05-29T00:00:00Z,2013,5,Tafinlar,stage iv melanoma,RAF B PROTEIN KINASE INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202806,NDA,2012-07-29T00:00:00Z,fda,0,1,1,1,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,129,3257,172,22,Melanomas of skin,1,1
749,TRAMETINIB,"ERK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE; GSK-1120212; GSK-1120212B; GSK-212; JTP-74057 DMSO; MEK INHIBITOR (CANCER, INFLAMMATION), GLAXOSMITHKLINE; MEK INHIBITOR (ORAL, CANCER), GLAXOSMITHKLINE; MARK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE; MEKINIST; NSC-763093; TMT-212; TRAMETINIB; TRAMETINIB DMSO; TRAMETINIB DIMETHYL SULFOXIDE","ERK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE; GSK-1120212; GSK-1120212B; GSK-212; JTP-74057 DMSO; MEK INHIBITOR (CANCER, INFLAMMATION), GLAXOSMITHKLINE; MEK INHIBITOR (ORAL, CANCER), GLAXOSMITHKLINE; MARK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE; MEKINIST; NSC-763093; TMT-212; TRAMETINIB; TRAMETINIB DMSO; TRAMETINIB DIMETHYL SULFOXIDE",TRAMETINIB,"ERK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE",GSK-1120212,GSK-1120212B,GSK-212,JTP-74057 DMSO,"MEK INHIBITOR (CANCER, INFLAMMATION), GLAXOSMITHKLINE","MEK INHIBITOR (ORAL, CANCER), GLAXOSMITHKLINE","MARK INHIBITOR (CANCER, INFLAMMATION), JAPAN TOBACCO/GLAXOSMITHKLINE",MEKINIST,NSC-763093,TMT-212,TRAMETINIB,TRAMETINIB DMSO,TRAMETINIB DIMETHYL SULFOXIDE,,,,,,,,,,,,,,,,,204114,TRAMETINIB DIMETHYL SULFOXIDE,,,,,,,,,,,,,,,,,,,,,2013-05-29T00:00:00Z,2013,5,Mekinist,stage iv melanoma,MEK-1 PROTEIN KINASE INHIBITOR; MEK-2 PROTEIN KINASE INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; SYNERGIST,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204114,NDA,2012-08-02T00:00:00Z,fda,0,0,1,1,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204114,184,3257,172,22,Melanomas of skin,1,1
704,TALIMOGENE LAHERPAREPVEC,"ICP34.5-NULL HERPES SIMPLEX VIRUS-1, BIOVEX; IMLYGIC; IMLYGIC; JS1 34.5-HGMCSF 47-PA-; ONCOVEX; ONCOVEX GM-CSF VACCINE; ONCOVEX THERAPIES (CANCER), AMGEN; ONCOVEX-TNF-ALPHA; ONCOVEX-TNF-ALPHA+GM-CSF; T-VEC; TALIMOGENE LAHERPAREPVEC; TALMINOGENE LAHERPAREPVEC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-10-27T00:00:00Z,2015,10,Imlygic,stage iv melanoma,CSF2 GENE STIMULATOR,ANTICANCER; LIVE ATTENUATED VIRAL VACCINE; RECOMBINANT VIRAL VECTOR VACCINE; THERAPEUTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRATUMORAL FORMULATION; SUSPENSION; VIRUS RECOMBINANT,using only (2),125518,BLA,2014-07-28T00:00:00Z,fda,0,0,0,1,0,,amgen,NASDAQ: AMGN,1,21662,20063,18676,17265,15582,15053,17487,4006,4160,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125518,722,3257,172,22,Melanomas of skin,1,1
391,IPILIMUMAB,"BMS-734016; MDX-010; MDX-101; MDX-CTLA4; WINGLORE; YERVOY; ANTI-CTLA4, MEDAREX; IPILIMUMAB","BMS-734016; MDX-010; MDX-101; MDX-CTLA4; WINGLORE; YERVOY; ANTI-CTLA4, MEDAREX; IPILIMUMAB",IPILIMUMAB,BMS-734016,MDX-010,MDX-101,MDX-CTLA4,WINGLORE,YERVOY,"ANTI-CTLA4, MEDAREX",IPILIMUMAB,,,,,,,,,,,,,,,,,,,,,,,125377,IPILIMUMAB,,,,,,,,,,,,,,,,,,,,,2011-03-25T00:00:00Z,2011,3,Yervoy,melanoma,CYTOTOXIC T-LYMPHOCYTE PROTEIN-4 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; ANTIVIRAL; IMMUNOSTIMULANT,BIOLOGICAL THERAPEUTIC; DNA TECHNOLOGY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; SOLUTION,matched (3),125377,BLA,2010-06-25T00:00:00Z,fda,1,0,1,1,0,,bristol-myers squibb,NYSE: BMY,1,21244,19484,18808,17715,15617,16208,15721,3604,3811,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,32,205,173,23,Other non-epithelial cancer of skin,1,1
521,NIVOLUMAB,"89ZR-NIVOLUMAB; BMS-936558; MDX-1106; MDX-1106-04; ONO-4538; OPDIVO; ANTI-PD-1 ANTIBODY (CANCER), ONO/MEDAREX/BMS; NIVOLUMAB","89ZR-NIVOLUMAB; BMS-936558; MDX-1106; MDX-1106-04; ONO-4538; OPDIVO; ANTI-PD-1 ANTIBODY (CANCER), ONO/MEDAREX/BMS; NIVOLUMAB",NIVOLUMAB,89ZR-NIVOLUMAB,BMS-936558,MDX-1106,MDX-1106-04,ONO-4538,OPDIVO,"ANTI-PD-1 ANTIBODY (CANCER), ONO/MEDAREX/BMS",NIVOLUMAB,,,,,,,,,,,,,,,,,,,,,,,125527,NIVOLUMAB,,,,,,,,,,,,,,,,,,,,,2014-12-22T00:00:00Z,2014,12,Opdivo,melanoma,PROGRAMMED CELL DEATH PROTEIN 1 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; ANTIVIRAL,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; SOLUTION,matched (3),125554,BLA,2014-07-30T00:00:00Z,fda,1,1,1,1,1,2014-09-26T00:00:00Z,bristol-myers squibb,NYSE: BMY,1,15879,16385,17621,21244,19484,18808,12098,3913,4191,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,57,205,173,23,Other non-epithelial cancer of skin,1,1
778,VEMURAFENIB,"B-RAF INHIBITORS (CANCER), PLEXXIKON; B-RAF INHIBITORS (CANCER), PLEXXIKON/ROCHE; PLX-3204; PLX-3331; PLX-4032; PLX-4718; PLX-4720; PLX-4735; R-7204; RG-7204; RO-5185426; ZELBORAF; VEMURAFENIB","B-RAF INHIBITORS (CANCER), PLEXXIKON; B-RAF INHIBITORS (CANCER), PLEXXIKON/ROCHE; PLX-3204; PLX-3331; PLX-4032; PLX-4718; PLX-4720; PLX-4735; R-7204; RG-7204; RO-5185426; ZELBORAF; VEMURAFENIB",VEMURAFENIB,"B-RAF INHIBITORS (CANCER), PLEXXIKON","B-RAF INHIBITORS (CANCER), PLEXXIKON/ROCHE",PLX-3204,PLX-3331,PLX-4032,PLX-4718,PLX-4720,PLX-4735,R-7204,RG-7204,RO-5185426,ZELBORAF,VEMURAFENIB,,,,,,,,,,,,,,,,,,202429,VEMURAFENIB,,,,,,,,,,,,,,,,,,,,,2011-08-17T00:00:00Z,2011,8,Zelboraf,melanoma,RAF B PROTEIN KINASE INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR,CAPSULE FORMULATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202429,NDA,2011-04-27T00:00:00Z,fda,0,0,0,1,0,,roche,SIX: ROG,1,47194.8,52624.4,49411.7,45026.8,42678.4,35608.8,34768.4,8655.2,8907.7,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,119,205,173,23,Other non-epithelial cancer of skin,1,1
785,VISMODEGIB,"ERIVEDGE; GDC-0449; HEDGEHOG ANTAGONIST GDC-0449; HEDGEHOG ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH/ROCHE; HH ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH//ROCHE; NSC-747691; R-3616; RG-3616; RO-5450815; SMALL-MOLECULE HEDGEHOG ANTAGONIST (CANCER), CURIS/GENENTECH//ROCHE; VISMODEGIB","ERIVEDGE; GDC-0449; HEDGEHOG ANTAGONIST GDC-0449; HEDGEHOG ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH/ROCHE; HH ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH//ROCHE; NSC-747691; R-3616; RG-3616; RO-5450815; SMALL-MOLECULE HEDGEHOG ANTAGONIST (CANCER), CURIS/GENENTECH//ROCHE; VISMODEGIB",VISMODEGIB,ERIVEDGE,GDC-0449,HEDGEHOG ANTAGONIST GDC-0449,"HEDGEHOG ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH/ROCHE","HH ANTAGONISTS (SYSTEMIC FORMULATION, CANCER), CURIS/GENENTECH//ROCHE",NSC-747691,R-3616,RG-3616,RO-5450815,"SMALL-MOLECULE HEDGEHOG ANTAGONIST (CANCER), CURIS/GENENTECH//ROCHE",VISMODEGIB,,,,,,,,,,,,,,,,,,,,203388,VISMODEGIB,,,,,,,,,,,,,,,,,,,,,2012-01-30T00:00:00Z,2012,1,Erivedge,basal cell carcinoma,HEDGEHOG PROTEIN INHIBITOR; SMOOTHENED RECEPTOR ANTAGONIST,ANTICANCER; APOPTOSIS STIMULATOR,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203388,NDA,2011-09-08T00:00:00Z,fda,1,0,0,0,0,,roche,SIX: ROG,1,51820.8,47194.8,52624.4,49411.7,13418,11724,38789.1,9297.2,10433.2,,,2009,,acquired by roche in 2009,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203388,154,1764,173,23,Other non-epithelial cancer of skin,1,1
684,"SONIDEGIB (ORAL), NOVARTIS","LAB-687; LDE-225; LDE-225 (ORAL), NOVARTIS; LDE-255; NVP-LDE-225; NVP-LDE-225 (ORAL), NOVARTIS; ODOMZO; ODOMZO; SMO INHIBITOR (CANCER), NOVARTIS; ERISMODEGIB; ERISMODEGIB (ORAL), NOVARTIS; SMOOTHENED INHIBITOR (CANCER), NOVARTIS; SONIDEGIB; SONIDEGIB (ORAL), NOVARTIS; SONIDEGIB PHOSPHATE","LAB-687; LDE-225; LDE-225 (ORAL), NOVARTIS; LDE-255; NVP-LDE-225; NVP-LDE-225 (ORAL), NOVARTIS; ODOMZO; ODOMZO; SMO INHIBITOR (CANCER), NOVARTIS; ERISMODEGIB; ERISMODEGIB (ORAL), NOVARTIS; SMOOTHENED INHIBITOR (CANCER), NOVARTIS; SONIDEGIB; SONIDEGIB (ORAL), NOVARTIS; SONIDEGIB PHOSPHATE","SONIDEGIB (ORAL), NOVARTIS",LAB-687,LDE-225,"LDE-225 (ORAL), NOVARTIS",LDE-255,NVP-LDE-225,"NVP-LDE-225 (ORAL), NOVARTIS",ODOMZO,ODOMZO,"SMO INHIBITOR (CANCER), NOVARTIS",ERISMODEGIB,"ERISMODEGIB (ORAL), NOVARTIS","SMOOTHENED INHIBITOR (CANCER), NOVARTIS",SONIDEGIB,"SONIDEGIB (ORAL), NOVARTIS",SONIDEGIB PHOSPHATE,,,,,,,,,,,,,,,,205266,SONIDEGIB PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2015-07-24T00:00:00Z,2015,7,Odomzo,basal cell carcinoma,HEDGEHOG PROTEIN INHIBITOR; SMOOTHENED RECEPTOR ANTAGONIST,ANTICANCER,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205266,NDA,2014-09-26T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205266,231,1764,173,23,Other non-epithelial cancer of skin,1,1
587,PERTUZUMAB,"2C4; HERCEPTIN-LIKE ANTIBODY, GENENTECH; OMNITARG; PERJETA; R-1273; RG-1273; RO-4368451; ANTI-2C4, GENENTECH; PERTUZUMAB; RHUHAB 2C4; RHUMAB 2C4","2C4; HERCEPTIN-LIKE ANTIBODY, GENENTECH; OMNITARG; PERJETA; R-1273; RG-1273; RO-4368451; ANTI-2C4, GENENTECH; PERTUZUMAB; RHUHAB 2C4; RHUMAB 2C4",PERTUZUMAB,2C4,"HERCEPTIN-LIKE ANTIBODY, GENENTECH",OMNITARG,PERJETA,R-1273,RG-1273,RO-4368451,"ANTI-2C4, GENENTECH",PERTUZUMAB,RHUHAB 2C4,RHUMAB 2C4,,,,,,,,,,,,,,,,,,,,125409,PERTUZUMAB,,,,,,,,,,,,,,,,,,,,,2012-06-08T00:00:00Z,2012,6,Perjeta,metastatic breast cancer,EPIDERMAL GROWTH FACTOR ANTAGONIST; ERBB2 TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; CELL CYCLE INHIBITOR; SYNERGIST,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; LIQUID FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT,matched (3),125409,BLA,2011-12-06T00:00:00Z,fda,1,0,0,0,0,,roche,SIX: ROG,1,51820.8,47194.8,52624.4,49411.7,13418,11724,38789.1,9297.2,10433.2,,,2009,,acquired by roche in 2009,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,36,3657,174,24,Cancer of breast,1,1
753,TRASTUZUMAB EMTANSINE,"HERCEPTIN-DM1 CONJUGATE, IMMUNOGEN/GENENTECH; KADCYLA; KADCYLA; PRO-132365; R-3502; RG-3502; RO-5304020; T-DM1; TMAB-MCC-DM1; ADO-TRASTUZUMAB EMTANSINE; ADO-TRASTUZUMAB EMTANSINE; TRASTUZUMAB MCC MERTANSINE; TRASTUZUMAB EMTANSINE; TRASTUZUMAB-DM1; TRASTUZUMAB-MCC-DM1","HERCEPTIN-DM1 CONJUGATE, IMMUNOGEN/GENENTECH; KADCYLA; KADCYLA; PRO-132365; R-3502; RG-3502; RO-5304020; T-DM1; TMAB-MCC-DM1; ADO-TRASTUZUMAB EMTANSINE; ADO-TRASTUZUMAB EMTANSINE; TRASTUZUMAB MCC MERTANSINE; TRASTUZUMAB EMTANSINE; TRASTUZUMAB-DM1; TRASTUZUMAB-MCC-DM1",TRASTUZUMAB EMTANSINE,"HERCEPTIN-DM1 CONJUGATE, IMMUNOGEN/GENENTECH",KADCYLA,KADCYLA,PRO-132365,R-3502,RG-3502,RO-5304020,T-DM1,TMAB-MCC-DM1,ADO-TRASTUZUMAB EMTANSINE,ADO-TRASTUZUMAB EMTANSINE,TRASTUZUMAB MCC MERTANSINE,TRASTUZUMAB EMTANSINE,TRASTUZUMAB-DM1,TRASTUZUMAB-MCC-DM1,,,,,,,,,,,,,,,,125427,ADO-TRASTUZUMAB EMTANSINE,,,,,,,,,,,,,,,,,,,,,2013-02-22T00:00:00Z,2013,2,Kadcyla,metastatic breast cancer,ERBB2 TYROSINE KINASE RECEPTOR MODULATOR; TUBULIN ANTAGONIST,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; IMMUNOTOXIN; MICROTUBULE INHIBITOR,ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY; BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY CONJUGATED; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT,matched (3),125427,BLA,2012-08-24T00:00:00Z,fda,1,0,0,0,0,,roche,SIX: ROG,1,54589.6,51820.8,47194.8,52624.4,49411.7,13418,40688.4,9832.7,10409.9,,,2009,,acquired by roche in 2009,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,39,3657,174,24,Cancer of breast,1,1
562,PALBOCICLIB,"IBRANCE; PD-0205606; PD-0332991; PD-0332991-00; PD-332991; PD-991; PF-0332991; PF-332991; CELL CYCLE REGULATORS, ONYX/PARKE-DAVIS; CELL CYCLE REGULATORS, ONYX/PFIZER; CELL CYCLE REGULATORS, PFIZER; PALBOCICLIB; PALBOCICLIB ISETHIONATE","IBRANCE; PD-0205606; PD-0332991; PD-0332991-00; PD-332991; PD-991; PF-0332991; PF-332991; CELL CYCLE REGULATORS, ONYX/PARKE-DAVIS; CELL CYCLE REGULATORS, ONYX/PFIZER; CELL CYCLE REGULATORS, PFIZER; PALBOCICLIB; PALBOCICLIB ISETHIONATE",PALBOCICLIB,IBRANCE,PD-0205606,PD-0332991,PD-0332991-00,PD-332991,PD-991,PF-0332991,PF-332991,"CELL CYCLE REGULATORS, ONYX/PARKE-DAVIS","CELL CYCLE REGULATORS, ONYX/PFIZER","CELL CYCLE REGULATORS, PFIZER",PALBOCICLIB,PALBOCICLIB ISETHIONATE,,,,,,,,,,,,,,,,,,207103,PALBOCICLIB,,,,,,,,,,,,,,,,,,,,,2015-02-03T00:00:00Z,2015,2,Ibrance,metastatic breast cancer,CYCLIN-DEPENDENT KINASE-4 INHIBITOR; CYCLIN-DEPENDENT KINASE-6 INHIBITOR; RETINOBLASTOMA ASSOCIATED PROTEIN MODULATOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; CELL CYCLE INHIBITOR,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207103,NDA,2014-08-13T00:00:00Z,fda,1,1,0,0,1,2013-04-10T00:00:00Z,pfizer,NYSE: PFE,1,48851,49605,51584,54657,61035,65165,39490,7646,7690,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,295,3657,174,24,Cancer of breast,1,1
633,RIBOCICLIB,"CDK4/6 INHIBITOR (CANCER), NOVARTIS/ASTREX; KISQALI; KISQALI; LEE-011; CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR (CANCER), ASTREX/NOVARTIS; RIBOCICLIB; RIBOCICLIB SUCCINATE","CDK4/6 INHIBITOR (CANCER), NOVARTIS/ASTREX; KISQALI; KISQALI; LEE-011; CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR (CANCER), ASTREX/NOVARTIS; RIBOCICLIB; RIBOCICLIB SUCCINATE",RIBOCICLIB,"CDK4/6 INHIBITOR (CANCER), NOVARTIS/ASTREX",KISQALI,KISQALI,LEE-011,"CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR (CANCER), ASTREX/NOVARTIS",RIBOCICLIB,RIBOCICLIB SUCCINATE,,,,,,,,,,,,,,,,,,,,,,,,209092,RIBOCICLIB,,,,,,,,,,,,,,,,,,,,,2017-03-13T00:00:00Z,2017,3,Kisquali,metastatic breast cancer,CYCLIN-DEPENDENT KINASE-4 INHIBITOR; CYCLIN-DEPENDENT KINASE-6 INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; CELL CYCLE INHIBITOR; SYNERGIST,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),209092,NDA,2016-08-29T00:00:00Z,fda,1,0,0,0,1,2016-08-03T00:00:00Z,novartis,NYSE: NVS,1,47140,49386,50359,53634,52716,51971,30888,8004,8676,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,356,3657,174,24,Cancer of breast,1,1
414,LAPATINIB,572016; GW-2016; GW-572016; GW-572016F; TYKERB; TYVERB; LAPATINIB; LAPATINIB DITOSYLATE; LAPATINIB DITOSYLATE (USAN); LAPATINIB DITOSYLATE MONOHYDRATE,572016; GW-2016; GW-572016; GW-572016F; TYKERB; TYVERB; LAPATINIB; LAPATINIB DITOSYLATE; LAPATINIB DITOSYLATE (USAN); LAPATINIB DITOSYLATE MONOHYDRATE,LAPATINIB,572016,GW-2016,GW-572016,GW-572016F,TYKERB,TYVERB,LAPATINIB,LAPATINIB DITOSYLATE,LAPATINIB DITOSYLATE (USAN),LAPATINIB DITOSYLATE MONOHYDRATE,,,,,,,,,,,,,,,,,,,,,22059,LAPATINIB DITOSYLATE,,,,,,,,,,,,,,,,,,,,,2007-03-13T00:00:00Z,2007,3,Tykerb,metastatic breast cancer,EPIDERMAL GROWTH FACTOR ANTAGONIST; ERBB2 TYROSINE KINASE RECEPTOR INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022059,NDA,2006-09-13T00:00:00Z,fda,1,0,1,0,0,,glaxosmithkline,NYSE: GSK,1,45147.6,45499.1,37229.2,38293.2,37593.1,34140.7,34800.8,6433.47,6612.3,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,457,3657,174,24,Cancer of breast,1,1
536,OLARATUMAB,"3G3 MAB (CANCER), IMCLONE; IMC-3G3; LY-3012207; LARTRUVO; PDGF MAB (CANCER), IMCLONE; PDGF-ALPHA MONOCLONAL ANTIBODY (CANCER), IMCLONE/ELI LILLY; PDGFRA MAB (CANCER), ELI LILLY; OLARATUMAB","3G3 MAB (CANCER), IMCLONE; IMC-3G3; LY-3012207; LARTRUVO; PDGF MAB (CANCER), IMCLONE; PDGF-ALPHA MONOCLONAL ANTIBODY (CANCER), IMCLONE/ELI LILLY; PDGFRA MAB (CANCER), ELI LILLY; OLARATUMAB",OLARATUMAB,"3G3 MAB (CANCER), IMCLONE",IMC-3G3,LY-3012207,LARTRUVO,"PDGF MAB (CANCER), IMCLONE","PDGF-ALPHA MONOCLONAL ANTIBODY (CANCER), IMCLONE/ELI LILLY","PDGFRA MAB (CANCER), ELI LILLY",OLARATUMAB,,,,,,,,,,,,,,,,,,,,,,,761038,OLARATUMAB,,,,,,,,,,,,,,,,,,,,,2016-10-19T00:00:00Z,2016,10,Lartruvo,soft tissue sarcoma,PDGF RECEPTOR ALPHA ANTAGONIST,ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN,matched (3),761038,BLA,2016-02-24T00:00:00Z,fda,1,1,1,1,1,2015-06-08T00:00:00Z,eli lilly,NYSE: LLY,1,21222.1,19958.7,19615.6,23113.1,22603.4,24286.5,15567.2,5243.9,5243.9,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038,625,3378,176,41,Cancer; other and unspecified primary,1,1
535,OLAPARIB,"AZD-2281; KU-0051529; KU-0058684; KU-0058948; KU-0059436; KU-0687; KU-56186; KU-58948; KU-59436; KU-59449; LYNPARZA; MRU-687; MRU-868; NU-1025; NU-1040; NU-1051; NU-1056; NU-1057; NU-1068; NU-1070; NU-1085; PARP INHIBITORS (CANCER), ASTRAZENECA; PARP INHIBITORS (CANCER), KUDOS; TBI-361; NU-1091; OLAPARIB","AZD-2281; KU-0051529; KU-0058684; KU-0058948; KU-0059436; KU-0687; KU-56186; KU-58948; KU-59436; KU-59449; LYNPARZA; MRU-687; MRU-868; NU-1025; NU-1040; NU-1051; NU-1056; NU-1057; NU-1068; NU-1070; NU-1085; PARP INHIBITORS (CANCER), ASTRAZENECA; PARP INHIBITORS (CANCER), KUDOS; TBI-361; NU-1091; OLAPARIB",OLAPARIB,AZD-2281,KU-0051529,KU-0058684,KU-0058948,KU-0059436,KU-0687,KU-56186,KU-58948,KU-59436,KU-59449,LYNPARZA,MRU-687,MRU-868,NU-1025,NU-1040,NU-1051,NU-1056,NU-1057,NU-1068,NU-1070,NU-1085,"PARP INHIBITORS (CANCER), ASTRAZENECA","PARP INHIBITORS (CANCER), KUDOS",TBI-361,NU-1091,OLAPARIB,,,,,206162,OLAPARIB,,,,,,,,,,,,,,,,,,,,,2014-12-19T00:00:00Z,2014,12,Lynparza,ovary tumor,PARP INHIBITOR; POLY ADP RIBOSE POLYMERASE 1 INHIBITOR; POLY ADP RIBOSE POLYMERASE 2 INHIBITOR; POLY ADP RIBOSE POLYMERASE 3 INHIBITOR,ANTICANCER,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206162,NDA,2014-02-03T00:00:00Z,fda,1,1,0,1,0,,astrazeneca,NYSE: AZN,1,26547,25806,27973,33591,33269,32804,20812,5001,5438,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206162,272,799,183,28,Cancer of other female genital organs,2,1
648,"RUCAPARIB CAMSYLATE (ORAL, SOLID TUMORS), CLOVIS","CO-338; RUBRACA; RUBRACA; RUCAPARIB; RUCAPARIB CAMSYLATE; RUCAPARIB CAMSYLATE (ORAL, SOLID TUMORS), CLOVIS","CO-338; RUBRACA; RUBRACA; RUCAPARIB; RUCAPARIB CAMSYLATE; RUCAPARIB CAMSYLATE (ORAL, SOLID TUMORS), CLOVIS","RUCAPARIB CAMSYLATE (ORAL, SOLID TUMORS), CLOVIS",CO-338,RUBRACA,RUBRACA,RUCAPARIB,RUCAPARIB CAMSYLATE,"RUCAPARIB CAMSYLATE (ORAL, SOLID TUMORS), CLOVIS",,,,,,,,,,,,,,,,,,,,,,,,,209115,RUCAPARIB CAMSYLATE,,,,,,,,,,,,,,,,,,,,,2016-12-19T00:00:00Z,2016,12,Rubraca,ovary tumor,PARP INHIBITOR; POLY ADP RIBOSE POLYMERASE 1 INHIBITOR; POLY ADP RIBOSE POLYMERASE 2 INHIBITOR; POLY ADP RIBOSE POLYMERASE 3 INHIBITOR,ANTICANCER,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),209115,NDA,2016-06-23T00:00:00Z,fda,1,1,0,1,1,2016-04-06T00:00:00Z,clovis,NASDAQ: CLVS,1,0.1,,13.6,,,,,251.1,260.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,357,799,183,28,Cancer of other female genital organs,2,1
3,ABIRATERONE,CB-7598; CB-7630; JNJ-212082; JNJ-589485; ZYTIGA; ABIRATERONE; ABIRATERONE ACETATE; PIRATERONE,CB-7598; CB-7630; JNJ-212082; JNJ-589485; ZYTIGA; ABIRATERONE; ABIRATERONE ACETATE; PIRATERONE,ABIRATERONE,CB-7598,CB-7630,JNJ-212082,JNJ-589485,ZYTIGA,ABIRATERONE,ABIRATERONE ACETATE,PIRATERONE,,,,,,,,,,,,,,,,,,,,,,,202379,ABIRATERONE ACETATE,,,,,,,,,,,,,,,,,,,,,2011-04-28T00:00:00Z,2011,4,Zytiga,hormone refractory prostate cancer,CYTOCHROME P450 17 INHIBITOR,ANDROGEN SYNTHESIS INHIBITOR; ANTICANCER,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; STEROID; TABLET FORMULATION,matched (3),202379,NDA,2010-12-18T00:00:00Z,fda,1,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61897,63747,61095,,,,43563,6986,6986,,,2009,,acquired by J&J in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379,118,3246,185,29,Cancer of prostate,1,1
248,ENZALUTAMIDE,"ASP-9785; MDV-300; MDV-3100; MDVN-300; MDVN-311; MDVN-312; RD-162; RD-162'; XTANDI; ENZALUTAMIDE; PROSTATE CANCER THERAPEUTICS, MEDIVATION","ASP-9785; MDV-300; MDV-3100; MDVN-300; MDVN-311; MDVN-312; RD-162; RD-162'; XTANDI; ENZALUTAMIDE; PROSTATE CANCER THERAPEUTICS, MEDIVATION",ENZALUTAMIDE,ASP-9785,MDV-300,MDV-3100,MDVN-300,MDVN-311,MDVN-312,RD-162,RD-162',XTANDI,ENZALUTAMIDE,"PROSTATE CANCER THERAPEUTICS, MEDIVATION",,,,,,,,,,,,,,,,,,,,203415,ENZALUTAMIDE,,,,,,,,,,,,,,,,,,,,,2012-08-31T00:00:00Z,2012,8,Xtandi,hormone refractory prostate cancer,ANDROGEN RECEPTOR ANTAGONIST; CYTOCHROME P450 3A4 STIMULATOR; DNA BINDING PROTEIN INHIBITOR; PROSTATE SPECIFIC ANTIGEN MODULATOR; TRANSLOCATION ASSOCIATED PROTEIN INHIBITOR,ANTICANCER; APOPTOSIS STIMULATOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203415,NDA,2012-05-21T00:00:00Z,fda,1,0,1,0,0,,medivation,NASDAQ: MDVN,1,181.7,60.4,62.5,69.3,12.6,,86.1,,144.8,,,,,acquired by pfizer in 2016,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415,157,3246,185,29,Cancer of prostate,1,1
617,RADIUM RA 223 DICHLORIDE,"223RA-BASED ALPHA-PARTICLE EMITTING THERAPY (BONE METASTASES), ALGETA; 223RA-CHLORIDE; ATI-BC-2; ALPHARADIN; BAY-88-8223; RADIUM-223-CHLORIDE; XOFIGO; BONE METASTASES THERAPY, ANTICANCER THERAPEUTIC INVENTIONS; RADIUM RA 223 DICHLORIDE; RADIUM-223 (BONE METASTASES), ALGETA; RADIUM-223 DICHLORIDE","223RA-BASED ALPHA-PARTICLE EMITTING THERAPY (BONE METASTASES), ALGETA; 223RA-CHLORIDE; ATI-BC-2; ALPHARADIN; BAY-88-8223; RADIUM-223-CHLORIDE; XOFIGO; BONE METASTASES THERAPY, ANTICANCER THERAPEUTIC INVENTIONS; RADIUM RA 223 DICHLORIDE; RADIUM-223 (BONE METASTASES), ALGETA; RADIUM-223 DICHLORIDE",RADIUM RA 223 DICHLORIDE,"223RA-BASED ALPHA-PARTICLE EMITTING THERAPY (BONE METASTASES), ALGETA",223RA-CHLORIDE,ATI-BC-2,ALPHARADIN,BAY-88-8223,RADIUM-223-CHLORIDE,XOFIGO,"BONE METASTASES THERAPY, ANTICANCER THERAPEUTIC INVENTIONS",RADIUM RA 223 DICHLORIDE,"RADIUM-223 (BONE METASTASES), ALGETA",RADIUM-223 DICHLORIDE,,,,,,,,,,,,,,,,,,,,203971,RADIUM RA-223 DICHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-05-15T00:00:00Z,2013,5,Xofigo,hormone refractory prostate cancer,,ANTICANCER; BONE SYNTHESIS INHIBITOR; RADIOTHERAPEUTIC,INTRAVENOUS FORMULATION; RADIOLABELING; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),203971,NDA,2012-12-14T00:00:00Z,fda,1,0,1,0,0,,bayer,ETR: BAYN,1,55301.2,52397.7,47454.4,47050.6,44669.3,45997.3,28539.6,4691.87,4690.5,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203971,175,3246,185,29,Cancer of prostate,1,1
123,CABAZITAXEL,"106258; 116258; JEVTANA; RPR-116258A; TXD-258; XRP-6258; CABAZITAXEL; TAXOID (CANCER), SANOFI-AVENTIS","106258; 116258; JEVTANA; RPR-116258A; TXD-258; XRP-6258; CABAZITAXEL; TAXOID (CANCER), SANOFI-AVENTIS",CABAZITAXEL,106258,116258,JEVTANA,RPR-116258A,TXD-258,XRP-6258,CABAZITAXEL,"TAXOID (CANCER), SANOFI-AVENTIS",,,,,,,,,,,,,,,,,,,,,,,207949,CABAZITAXEL,207949,CABAZITAXEL,,,,,,,,,,,,,,,,,,,2010-06-17T00:00:00Z,2010,6,Jevtana,hormone refractory prostate cancer,,ANTICANCER; CELL CYCLE INHIBITOR; MICROTUBULE INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; INTRAVESICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),201023,NDA,2010-03-31T00:00:00Z,fda,1,0,1,0,0,,sanofi,NYSE: SNY,1,45640,44761,40266.9,42651,38911.4,33775.2,33228.3,6097.22,6097.2,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201023,312,3246,185,29,Cancer of prostate,1,1
300,FLUCICLOVINE (18F),"18F-FACBC; 18F-GE-148; 18F-LABELED PET TRACERS (IMAGING AGENT), EMORY; AXUMIN; AXUMIN; FACBC-[18F]; GE-148-[18F]; NMK-36; [18F]-FLUCICLOVINE; ANTI-18F-FACBC; FLUCICLOVINE (18F); FLUCICLOVINE F18; FLUORINE-18-FACBC; FLUORINE-18-GE-148; FLUORINE-18-FLUCICLOVINE; FLUORINE-18-LABELED PET TRACERS (IMAGING AGENT), EMORY; FLUORINE-18-SYN-FACBC; SYN-18F-FACBC","18F-FACBC; 18F-GE-148; 18F-LABELED PET TRACERS (IMAGING AGENT), EMORY; AXUMIN; AXUMIN; FACBC-[18F]; GE-148-[18F]; NMK-36; [18F]-FLUCICLOVINE; ANTI-18F-FACBC; FLUCICLOVINE (18F); FLUCICLOVINE F18; FLUORINE-18-FACBC; FLUORINE-18-GE-148; FLUORINE-18-FLUCICLOVINE; FLUORINE-18-LABELED PET TRACERS (IMAGING AGENT), EMORY; FLUORINE-18-SYN-FACBC; SYN-18F-FACBC",FLUCICLOVINE (18F),18F-FACBC,18F-GE-148,"18F-LABELED PET TRACERS (IMAGING AGENT), EMORY",AXUMIN,AXUMIN,FACBC-[18F],GE-148-[18F],NMK-36,[18F]-FLUCICLOVINE,ANTI-18F-FACBC,FLUCICLOVINE (18F),FLUCICLOVINE F18,FLUORINE-18-FACBC,FLUORINE-18-GE-148,FLUORINE-18-FLUCICLOVINE,"FLUORINE-18-LABELED PET TRACERS (IMAGING AGENT), EMORY",FLUORINE-18-SYN-FACBC,SYN-18F-FACBC,,,,,,,,,,,,,208054,FLUCICLOVINE F-18,,,,,,,,,,,,,,,,,,,,,2016-05-27T00:00:00Z,2016,5,Axumin,prostate tumor,,ANTICANCER; ENDOCRINE DIAGNOSTIC AGENT; NEOPLASM DIAGNOSTIC AGENT; PET CONTRAST AGENT; RADIODIAGNOSTIC,IMAGING; RADIOLABELING; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),208054,NDA,2015-09-28T00:00:00Z,fda,1,0,0,0,0,,blue earth diagnostics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208054,322,276,185,29,Cancer of prostate,1,1
193,DEGARELIX,ASP-3550; FE-200486; FIRMAGON; GONAX; DEGARELIX; DEGARELIX ART; DEGARELIX ACETATE,ASP-3550; FE-200486; FIRMAGON; GONAX; DEGARELIX; DEGARELIX ART; DEGARELIX ACETATE,DEGARELIX,ASP-3550,FE-200486,FIRMAGON,GONAX,DEGARELIX,DEGARELIX ART,DEGARELIX ACETATE,,,,,,,,,,,,,,,,,,,,,,,,22201,DEGARELIX ACETATE,,,,,,,,,,,,,,,,,,,,,2008-12-24T00:00:00Z,2008,12,Firmagon,hormone dependent prostate cancer,GNRH ANTAGONIST,ANTICANCER; ANTICANCER HORMONE ANTAGONIST,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAMUSCULAR FORMULATION; MONTHLY DOSING; PEPTIDE; SUBCUTANEOUS FORMULATION,matched (3),022201,NDA,2008-02-14T00:00:00Z,fda,0,0,0,0,0,,ferring pharmaceuticals,private,0,,,,,,,,,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022201,494,3247,185,29,Cancer of prostate,1,1
214,"DOCETAXEL (ALCOHOL FREE), TEIKOKU/EAGLE","DOCETAXEL INJECTION; TPU-004DO; DOCETAXEL; DOCETAXEL (ALCOHOL FREE), TEIKOKU/EAGLE","DOCETAXEL INJECTION; TPU-004DO; DOCETAXEL; DOCETAXEL (ALCOHOL FREE), TEIKOKU/EAGLE","DOCETAXEL (ALCOHOL FREE), TEIKOKU/EAGLE",DOCETAXEL INJECTION,TPU-004DO,DOCETAXEL,"DOCETAXEL (ALCOHOL FREE), TEIKOKU/EAGLE",,,,,,,,,,,,,,,,,,,,,,,,,,,22234,DOCETAXEL,,,,,,,,,,,,,,,,,,,,,2015-12-22T00:00:00Z,2015,12,Docetaxel,prostate tumor,,ANTICANCER; CELL CYCLE INHIBITOR; MICROTUBULE INHIBITOR,INTRAVENOUS FORMULATION; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC,matched (3),205934,NDA,2015-02-26T00:00:00Z,fda,0,0,0,0,0,,teikoku,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205934,506,276,185,29,Cancer of prostate,1,1
670,SIPULEUCEL-T,"APC-8015; PROVENGE; DENDRITIC CELL THERAPY (PROSTATE CANCER), DENDREON; DENDRITIC CELL THERAPY (PROSTATE CANCER), VALEANT; SIPULEUCEL-T",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-04-29T00:00:00Z,2010,4,Provenge,hormone refractory prostate cancer,PROSTATIC ACID PHOSPHATASE MODULATOR,ANTICANCER; GENETICALLY ENGINEERED AUTOLOGOUS CELL THERAPY; THERAPEUTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; CELL THERAPY; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; TUMOR ANTIGEN,using only (2),125197,BLA,2009-10-30T00:00:00Z,fda,1,0,1,0,0,,dendreon,NASDAQ: DNDN,1,48.1,0.1,0.1,0.7,0.3,0.2,19.5,75.9,75.9,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125197,720,3246,185,29,Cancer of prostate,1,1
67,ATEZOLIZUMAB,"MPDL-3280A; MPDL-3280A; RG-7446; RG-7746; RG-7746; RO-5541267; RO-5541267; TECENTRIQ; TECENTRIQ; ANTI-PDL1 MAB (SOLID TUMORS), GENENTECH; ATEZOLIZUMAB","MPDL-3280A; MPDL-3280A; RG-7446; RG-7746; RG-7746; RO-5541267; RO-5541267; TECENTRIQ; TECENTRIQ; ANTI-PDL1 MAB (SOLID TUMORS), GENENTECH; ATEZOLIZUMAB",ATEZOLIZUMAB,MPDL-3280A,MPDL-3280A,RG-7446,RG-7746,RG-7746,RO-5541267,RO-5541267,TECENTRIQ,TECENTRIQ,"ANTI-PDL1 MAB (SOLID TUMORS), GENENTECH",ATEZOLIZUMAB,,,,,,,,,,,,,,,,,,,,761034,ATEZOLIZUMAB,,,,,,,,,,,,,,,,,,,,,2016-05-18T00:00:00Z,2016,5,Tecentriq,metastatic bladder cancer,PROGRAMMED CELL DEATH LIGAND 1 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; IMMUNOSTIMULANT,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; PROTEIN RECOMBINANT,matched (3),761034,BLA,2016-01-12T00:00:00Z,fda,1,1,0,0,1,2014-05-31T00:00:00Z,roche,SIX: ROG,1,51818.3,50342.1,50199.3,54589.6,51820.8,47194.8,36947,9899.8,11352.9,,,2009,,acquired by roche in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,622,3466,188,32,Cancer of bladder,1,1
73,AXITINIB,"AG-013736; AG-13736; INLYTA; VEGF/PDGF INHIBITOR, AGOURON/PFIZER; AXITINIB","AG-013736; AG-13736; INLYTA; VEGF/PDGF INHIBITOR, AGOURON/PFIZER; AXITINIB",AXITINIB,AG-013736,AG-13736,INLYTA,"VEGF/PDGF INHIBITOR, AGOURON/PFIZER",AXITINIB,,,,,,,,,,,,,,,,,,,,,,,,,,202324,AXITINIB,,,,,,,,,,,,,,,,,,,,,2012-01-27T00:00:00Z,2012,1,Inlyta,renal cell carcinoma,BCR PROTEIN INHIBITOR; CD79 ANTAGONIST; CSF-1 ANTAGONIST; PDGF RECEPTOR ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE PROTEIN KINASE ABL1 INHIBITOR; VEGF RECEPTOR ANTAGONIST; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202324,NDA,2011-04-14T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,54657,61035,65165,49269,48296,48418,45164,6705,7482,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202324,113,1766,189,34,Cancer of other urinary organs,2,1
694,SUNITINIB,"PDGF TK ANTAGONIST (CANCER), SUGEN; PHA-290940AD; SU-010398; SU-011248; SU-012487; SU-012662; SU-11248; SU-11248J; SU-12662; SUTENE; SUTENT; SUNITINIB; SUNITINIB MALATE","PDGF TK ANTAGONIST (CANCER), SUGEN; PHA-290940AD; SU-010398; SU-011248; SU-012487; SU-012662; SU-11248; SU-11248J; SU-12662; SUTENE; SUTENT; SUNITINIB; SUNITINIB MALATE",SUNITINIB,"PDGF TK ANTAGONIST (CANCER), SUGEN",PHA-290940AD,SU-010398,SU-011248,SU-012487,SU-012662,SU-11248,SU-11248J,SU-12662,SUTENE,SUTENT,SUNITINIB,SUNITINIB MALATE,,,,,,,,,,,,,,,,,,21938,SUNITINIB MALATE,,,,,,,,,,,,,,,,,,,,,2006-01-26T00:00:00Z,2006,1,Sutent,renal cell carcinoma,CSF-1 ANTAGONIST; FLT3 TYROSINE KINASE INHIBITOR; KIT TYROSINE KINASE INHIBITOR; PDGF RECEPTOR ALPHA ANTAGONIST; PDGF RECEPTOR BETA ANTAGONIST; RET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER PROTEIN KINASE INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021938,NDA,2005-08-10T00:00:00Z,fda,1,1,1,0,0,,pfizer,NYSE: PFE,1,48371,47405,48988,44736,32294,29024,41123,7423,7599,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021938,414,1766,189,34,Cancer of other urinary organs,2,1
717,TEMSIROLIMUS,CCI-779; NSC-683864; TORISEL; TEMSIROLIMUS,CCI-779; NSC-683864; TORISEL; TEMSIROLIMUS,TEMSIROLIMUS,CCI-779,NSC-683864,TORISEL,TEMSIROLIMUS,,,,,,,,,,,,,,,,,,,,,,,,,,,22088,TEMSIROLIMUS,,,,,,,,,,,,,,,,,,,,,2007-05-30T00:00:00Z,2007,5,Torisel,renal cell carcinoma,FK506 BINDING PROTEIN-12 MODULATOR; MTOR INHIBITOR,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022088,NDA,2006-10-05T00:00:00Z,fda,1,0,1,1,0,,wyeth,NYSE: WYE,1,22399.8,20350.7,18755.8,17358,15850.6,14584,16330.5,3256.52,3256.8,,,,,acquired by Pfizer in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022088,463,1766,189,34,Cancer of other urinary organs,2,1
577,PAZOPANIB,"786034; ARMALA; GW-786034; GW-786034B; PZP-115891; PATORMA; VOTRIENT; PAZOPANIB; PAZOPANIB (ORAL, CANCER), NOVARTIS; PAZOPANIB HYDROCHLORIDE","786034; ARMALA; GW-786034; GW-786034B; PZP-115891; PATORMA; VOTRIENT; PAZOPANIB; PAZOPANIB (ORAL, CANCER), NOVARTIS; PAZOPANIB HYDROCHLORIDE",PAZOPANIB,786034,ARMALA,GW-786034,GW-786034B,PZP-115891,PATORMA,VOTRIENT,PAZOPANIB,"PAZOPANIB (ORAL, CANCER), NOVARTIS",PAZOPANIB HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,22465,PAZOPANIB HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-10-19T00:00:00Z,2009,10,Votrient,renal tumor,FGF1 RECEPTOR ANTAGONIST; FGF3 RECEPTOR ANTAGONIST; ITK TYROSINE KINASE INHIBITOR; KIT TYROSINE KINASE INHIBITOR; LCK TYROSINE KINASE INHIBITOR; LTK TYROSINE KINASE RECEPTOR INHIBITOR; PDGF RECEPTOR ALPHA ANTAGONIST; PDGF RECEPTOR BETA ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022465,NDA,2008-12-18T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022465,571,999,189,34,Cancer of other urinary organs,2,1
,CABOZANTINIB S-MALATE (RCC),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-04-25T00:00:00Z,2016,4,Cabometyx,renal cell carcinoma,,,,,208692,NDA,2015-12-22T00:00:00Z,fda,1,0,1,0,1,2015-08-24T00:00:00Z,exelixis,NASDAQ: EXEL,1,191.5,37.2,25.1,31.3,47.5,289.6,185.4,96,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692,732,1766,189,34,Cancer of other urinary organs,2,1
124,CABOZANTINIB S-MALATE,BMS-907351; CABOMETYX; CABOMETYX; COMETRIQ; XL-184; CABOZANTINIB; CABOZANTINIB S-MALATE,BMS-907351; CABOMETYX; CABOMETYX; COMETRIQ; XL-184; CABOZANTINIB; CABOZANTINIB S-MALATE,CABOZANTINIB S-MALATE,BMS-907351,CABOMETYX,CABOMETYX,COMETRIQ,XL-184,CABOZANTINIB,CABOZANTINIB S-MALATE,,,,,,,,,,,,,,,,,,,,,,,,203756,CABOZANTINIB S-MALATE,208692,CABOZANTINIB S-MALATE,,,,,,,,,,,,,,,,,,,2012-11-29T00:00:00Z,2012,11,Cometriq,medullary thyroid cancer,AXL TYROSINE KINASE RECEPTOR INHIBITOR; FLT3 TYROSINE KINASE INHIBITOR; HEPATOCYTE GROWTH FACTOR ANTAGONIST; KIT TYROSINE KINASE INHIBITOR; MET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; RET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; TEK TYROSINE KINASE RECEPTOR INHIBITOR; TRKB RECEPTOR ANTAGONIST; VEGF RECEPTOR ANTAGONIST; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; METASTASIS INHIBITOR; SYNERGIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203756,NDA,2012-05-21T00:00:00Z,fda,1,0,1,1,0,,exelixis,NASDAQ: EXEL,1,47.5,289.6,185,151.8,117.9,113.5,47.5,128.9,128.9,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203756,170,3240,193,36,Cancer of thyroid,1,1
772,VANDETANIB,AZD-6474; CAPRELSA; ZD-6474; ZACTIMA; ZICTIFA; VANDETANIB,AZD-6474; CAPRELSA; ZD-6474; ZACTIMA; ZICTIFA; VANDETANIB,VANDETANIB,AZD-6474,CAPRELSA,ZD-6474,ZACTIMA,ZICTIFA,VANDETANIB,,,,,,,,,,,,,,,,,,,,,,,,,22405,VANDETANIB,,,,,,,,,,,,,,,,,,,,,2011-04-06T00:00:00Z,2011,4,Caprelsa,medullary thyroid cancer,EGFR FAMILY TYROSINE KINASE RECEPTOR INHIBITOR; EPH FAMILY TYROSINE KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR ANTAGONIST; PROTEIN TYROSINE KINASE 6 INHIBITOR; RET TYROSINE KINASE RECEPTOR FAMILY INHIBITOR; SRC TYROSINE KINASE INHIBITOR; TEK TYROSINE KINASE RECEPTOR INHIBITOR; VEGF RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER PROTEIN KINASE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022405,NDA,2010-07-07T00:00:00Z,fda,1,0,1,1,0,,astrazeneca,NYSE: AZN,1,33591,33269,32804,31601,29559,26475,27488,4506,5523,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405,551,3240,193,36,Cancer of thyroid,1,1
213,DINUTUXIMAB,"UNITUXIN; CH14.18 (INTRAVENOUS), UNITED THERAPEUTICS/NATIONAL CANCER INSTITUTE; CH14.18-UTC; DINUTUXIMAB","UNITUXIN; CH14.18 (INTRAVENOUS), UNITED THERAPEUTICS/NATIONAL CANCER INSTITUTE; CH14.18-UTC; DINUTUXIMAB",DINUTUXIMAB,UNITUXIN,"CH14.18 (INTRAVENOUS), UNITED THERAPEUTICS/NATIONAL CANCER INSTITUTE",CH14.18-UTC,DINUTUXIMAB,,,,,,,,,,,,,,,,,,,,,,,,,,,125516,DINUTUXIMAB,,,,,,,,,,,,,,,,,,,,,2015-03-10T00:00:00Z,2015,3,Unituxin,neuroblastoma,,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; GANGLIOSIDE GD2 INHIBITOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; CHIMERIC MONOCLONAL ANTIBODY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; SOLUTION,matched (3),125516,BLA,2014-04-11T00:00:00Z,fda,1,0,0,1,0,,united therapeutics,NASDAQ: UTHR,1,1465.8,1288.5,1117,916.1,743.2,592.9,1396.8,245.1,245.1,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125516,53,2726,194,41,Cancer; other and unspecified primary,1,1
364,IBRUTINIB,"(S)-IBRUTINIB; B-CELL ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), PHARMACYCLICS; B-CELL-ASSOCIATED TYROSINE KINASE INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH; B-CELL-ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), CELERA; BTK INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH; BTK INHIBITORS (AUTOIMMUNE DISEASE, LYMPHOMA), PHARMACYCLICS; CRA-032765; IMBRUVICA; JNJ-54179060; JNJ-54179060; PCI-31523; PCI-32765; PCI-45261; IBRUTINIB","(S)-IBRUTINIB; B-CELL ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), PHARMACYCLICS; B-CELL-ASSOCIATED TYROSINE KINASE INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH; B-CELL-ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), CELERA; BTK INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH; BTK INHIBITORS (AUTOIMMUNE DISEASE, LYMPHOMA), PHARMACYCLICS; CRA-032765; IMBRUVICA; JNJ-54179060; JNJ-54179060; PCI-31523; PCI-32765; PCI-45261; IBRUTINIB",IBRUTINIB,(S)-IBRUTINIB,"B-CELL ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), PHARMACYCLICS","B-CELL-ASSOCIATED TYROSINE KINASE INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH","B-CELL-ASSOCIATED TYROSINE KINASE INHIBITORS (LYMPHOMA, AUTOIMMUNE DISEASE), CELERA","BTK INHIBITOR (CANCER), PHARMACYCLICS/JANSSEN BIOTECH","BTK INHIBITORS (AUTOIMMUNE DISEASE, LYMPHOMA), PHARMACYCLICS",CRA-032765,IMBRUVICA,JNJ-54179060,JNJ-54179060,PCI-31523,PCI-32765,PCI-45261,IBRUTINIB,,,,,,,,,,,,,,,,,205552,IBRUTINIB,,,,,,,,,,,,,,,,,,,,,2013-11-13T00:00:00Z,2013,11,Imbruvica,mantle cell lymphoma,BTK TYROSINE KINASE INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; B-LYMPHOCYTE ADHESION INHIBITOR; B-LYMPHOCYTE MIGRATION INHIBITOR; CELL CYCLE INHIBITOR; CHEMOTAXIS INHIBITOR; SYNERGIST,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION,matched (3),205552,NDA,2013-06-28T00:00:00Z,fda,1,1,1,1,1,2013-02-12T00:00:00Z,pharmacyclics,NASDAQ: PCYC,1,260.2,164.7,8.2,9.3,,,171.5,,219.1,,,,,acquired by abbvie 2015,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205552,243,1744,200,38,Non-Hodgkin`s lymphoma,1,1
103,BRENTUXIMAB VEDOTIN,"1F6-SGD-1269; 1F6-MAFODOTIN; 1F6-MC-MMAF; ADCETRIS; NSC-749710; SGN-35; ANTI-CD30 MAB/AURISTATIN E CONJUGATES, SEATTLE; ANTI-CD30 MAB/AURISTATIN F CONJUGATES, SEATTLE; ANTIBODY-DRUG CONJUGATES (ANTICANCER), SEATTLE GENETICS; AURISTATIN E ADCS, SEATTLE GENETICS; AURISTATIN E CONJUGATES, SEATTLE GENETICS; BRENTUXIMAB VEDOTIN; CAC10 FRAGMENT MMAE CONJUGATE (CANCER), SEATTLE; CAC10-SGD-1269; CAC10-MAFODOTIN; CAC10-MC-MMAF; CAC10-MC-VC-PAB-MMAE; CAC10-MC-VC-PAB-MONOMETHYL AURISTATIN E; CBR96-VAL-CIT-MMAF; CBR96-VC-MMAF","1F6-SGD-1269; 1F6-MAFODOTIN; 1F6-MC-MMAF; ADCETRIS; NSC-749710; SGN-35; ANTI-CD30 MAB/AURISTATIN E CONJUGATES, SEATTLE; ANTI-CD30 MAB/AURISTATIN F CONJUGATES, SEATTLE; ANTIBODY-DRUG CONJUGATES (ANTICANCER), SEATTLE GENETICS; AURISTATIN E ADCS, SEATTLE GENETICS; AURISTATIN E CONJUGATES, SEATTLE GENETICS; BRENTUXIMAB VEDOTIN; CAC10 FRAGMENT MMAE CONJUGATE (CANCER), SEATTLE; CAC10-SGD-1269; CAC10-MAFODOTIN; CAC10-MC-MMAF; CAC10-MC-VC-PAB-MMAE; CAC10-MC-VC-PAB-MONOMETHYL AURISTATIN E; CBR96-VAL-CIT-MMAF; CBR96-VC-MMAF",BRENTUXIMAB VEDOTIN,1F6-SGD-1269,1F6-MAFODOTIN,1F6-MC-MMAF,ADCETRIS,NSC-749710,SGN-35,"ANTI-CD30 MAB/AURISTATIN E CONJUGATES, SEATTLE","ANTI-CD30 MAB/AURISTATIN F CONJUGATES, SEATTLE","ANTIBODY-DRUG CONJUGATES (ANTICANCER), SEATTLE GENETICS","AURISTATIN E ADCS, SEATTLE GENETICS","AURISTATIN E CONJUGATES, SEATTLE GENETICS",BRENTUXIMAB VEDOTIN,"CAC10 FRAGMENT MMAE CONJUGATE (CANCER), SEATTLE",CAC10-SGD-1269,CAC10-MAFODOTIN,CAC10-MC-MMAF,CAC10-MC-VC-PAB-MMAE,CAC10-MC-VC-PAB-MONOMETHYL AURISTATIN E,CBR96-VAL-CIT-MMAF,CBR96-VC-MMAF,,,,,,,,,,,125388,BRENTUXIMAB VEDOTIN,,,,,,,,,,,,,,,,,,,,,2011-08-19T00:00:00Z,2011,8,Adcetris,hodgkins disease,CD30 ANTAGONIST; TUBULIN ANTAGONIST,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; IMMUNOTOXIN; MICROTUBULE INHIBITOR,BIOLOGICAL THERAPEUTIC; CHIMERIC ANTIBODY; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY CONJUGATED,matched (3),125388,BLA,2011-02-25T00:00:00Z,fda,1,1,1,1,0,,seattle genetics,NASDAQ: SGEN,1,94.8,107.5,52,35.2,22.4,10,-71.7,,163.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388,34,161,201,37,Hodgkin`s disease,1,1
458,"MECHLORETHAMINE HYDROCHLORIDE (TOPICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON","CLEARAZIDE; LEDAGA; LEDAGA; VALCHLOR; CHLORMETHINE; CHLORMETHINE HYDROCHLORIDE; MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), CEPTARIS; MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON; MECHLORETHAMINE (TOPICAL, CTCL), YAUPON; MECHLORETHAMINE HYDROCHLORIDE; MECHLORETHAMINE HYDROCHLORIDE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), ACTELION; MECHLORETHAMINE HYDROCHLORIDE (TOPICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON; MECLORETHAMINE","CLEARAZIDE; LEDAGA; LEDAGA; VALCHLOR; CHLORMETHINE; CHLORMETHINE HYDROCHLORIDE; MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), CEPTARIS; MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON; MECHLORETHAMINE (TOPICAL, CTCL), YAUPON; MECHLORETHAMINE HYDROCHLORIDE; MECHLORETHAMINE HYDROCHLORIDE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), ACTELION; MECHLORETHAMINE HYDROCHLORIDE (TOPICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON; MECLORETHAMINE","MECHLORETHAMINE HYDROCHLORIDE (TOPICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON",CLEARAZIDE,LEDAGA,LEDAGA,VALCHLOR,CHLORMETHINE,CHLORMETHINE HYDROCHLORIDE,"MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), CEPTARIS","MECHLORETHAMINE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON","MECHLORETHAMINE (TOPICAL, CTCL), YAUPON",MECHLORETHAMINE HYDROCHLORIDE,"MECHLORETHAMINE HYDROCHLORIDE (DERMATOLOGICAL GEL, CTCL/MYCOSIS FUNGOIDES), ACTELION","MECHLORETHAMINE HYDROCHLORIDE (TOPICAL GEL, CTCL/MYCOSIS FUNGOIDES), YAUPON",MECLORETHAMINE,,,,,,,,,,,,,,,,,,202317,MECHLORETHAMINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-08-23T00:00:00Z,2013,8,Valchlor,mycosis fungoides,,ANTICANCER ALKYLATING AGENT; DERMATOLOGICAL AGENT,DAILY DOSING; DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202317,NDA,2013-02-27T00:00:00Z,fda,0,0,1,1,0,,actelion,NASDAQ: ATLN,1,2005.3,,,,,,1318.4,708.1,455.1,,,2013,,acquired by actelion in 2013; private in years prior,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202317,112,1115,202,38,Non-Hodgkin`s lymphoma,3,1
89,"BENDAMUSTINE HYDROCHLORIDE (READY-TO-DILUTE, IV, CHRONIC LYMPHOCYTIC LEUKEMIA/NON-HODGKINS LYMPHOMA), EAGLE PHARMACEUTICALS","BENDEKA; BENDAMUSTINE RTD; BENDEKA; EP-3101; EP-3102; BENDAMUSTINE; BENDAMUSTINE HYDROCHLORIDE; BENDAMUSTINE HYDROCHLORIDE (READY-TO-DILUTE, IV, CHRONIC LYMPHOCYTIC LEUKEMIA/NON-HODGKINS LYMPHOMA), EAGLE PHARMACEUTICALS","BENDEKA; BENDAMUSTINE RTD; BENDEKA; EP-3101; EP-3102; BENDAMUSTINE; BENDAMUSTINE HYDROCHLORIDE; BENDAMUSTINE HYDROCHLORIDE (READY-TO-DILUTE, IV, CHRONIC LYMPHOCYTIC LEUKEMIA/NON-HODGKINS LYMPHOMA), EAGLE PHARMACEUTICALS","BENDAMUSTINE HYDROCHLORIDE (READY-TO-DILUTE, IV, CHRONIC LYMPHOCYTIC LEUKEMIA/NON-HODGKINS LYMPHOMA), EAGLE PHARMACEUTICALS",BENDEKA,BENDAMUSTINE RTD,BENDEKA,EP-3101,EP-3102,BENDAMUSTINE,BENDAMUSTINE HYDROCHLORIDE,"BENDAMUSTINE HYDROCHLORIDE (READY-TO-DILUTE, IV, CHRONIC LYMPHOCYTIC LEUKEMIA/NON-HODGKINS LYMPHOMA), EAGLE PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,205580,BENDAMUSTINE HYDROCHLORIDE,205580,BENDAMUSTINE HYDROCHLORIDE,205580,BENDAMUSTINE HYDROCHLORIDE,205580,BENDAMUSTINE HYDROCHLORIDE,208194,BENDAMUSTINE HYDROCHLORIDE,208194,BENDAMUSTINE HYDROCHLORIDE,,,,,,,,,,,2015-12-07T00:00:00Z,2015,12,Bendeka,non-hodgkin lymphoma,PARP MODULATOR,ANTICANCER ALKYLATING AGENT,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),208194,NDA,2015-02-13T00:00:00Z,fda,0,0,0,1,0,,eagle pharmaceuticals,NASDAQ: EGRX,1,66.2,19.6,17.7,2.5,9.5,,50.6,27.9,27.9,,,,,IPO in 2014; revenues for 2011 and 2012 are for 12 months preceding september of that year,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208194,245,319,202,38,Non-Hodgkin`s lymphoma,3,1
87,"BELINOSTAT (IV, CANCER), ONXEO/SPECTRUM","BELEODAQ; HDAC INHIBITORS, TOPOTARGET/CURAGEN; PX-089344; PXD-101; PXD-101 (IV, CANCER), TOPOTARGET/ CURAGEN; BELINOSTAT; BELINOSTAT (IV, CANCER), BIOALLIANCE PHARMA/SPECTRUM; BELINOSTAT (IV, CANCER), ONXEO/SPECTRUM; BELINOSTAT (IV, CANCER), TOPOTARGET/CURAGEN; BELINOSTAT (IV, CANCER), TOPOTARGET/SPECTRUM; HISTONE DEACETYLASE INHIBITORS, PROLIFIX; HISTONE DEACETYLASE INHIBITORS, TOPOTARGET/CURAGEN","BELEODAQ; HDAC INHIBITORS, TOPOTARGET/CURAGEN; PX-089344; PXD-101; PXD-101 (IV, CANCER), TOPOTARGET/ CURAGEN; BELINOSTAT; BELINOSTAT (IV, CANCER), BIOALLIANCE PHARMA/SPECTRUM; BELINOSTAT (IV, CANCER), ONXEO/SPECTRUM; BELINOSTAT (IV, CANCER), TOPOTARGET/CURAGEN; BELINOSTAT (IV, CANCER), TOPOTARGET/SPECTRUM; HISTONE DEACETYLASE INHIBITORS, PROLIFIX; HISTONE DEACETYLASE INHIBITORS, TOPOTARGET/CURAGEN","BELINOSTAT (IV, CANCER), ONXEO/SPECTRUM",BELEODAQ,"HDAC INHIBITORS, TOPOTARGET/CURAGEN",PX-089344,PXD-101,"PXD-101 (IV, CANCER), TOPOTARGET/ CURAGEN",BELINOSTAT,"BELINOSTAT (IV, CANCER), BIOALLIANCE PHARMA/SPECTRUM","BELINOSTAT (IV, CANCER), ONXEO/SPECTRUM","BELINOSTAT (IV, CANCER), TOPOTARGET/CURAGEN","BELINOSTAT (IV, CANCER), TOPOTARGET/SPECTRUM","HISTONE DEACETYLASE INHIBITORS, PROLIFIX","HISTONE DEACETYLASE INHIBITORS, TOPOTARGET/CURAGEN",,,,,,,,,,,,,,,,,,,206256,BELINOSTAT,,,,,,,,,,,,,,,,,,,,,2014-07-03T00:00:00Z,2014,7,Beleodaq,peripheral t-cell lymphoma,HISTONE DEACETYLASE INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER; APOPTOSIS STIMULATOR; CELL DIFFERENTIATION STIMULATOR,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),206256,NDA,2013-12-08T00:00:00Z,fda,1,1,1,1,0,,spectrum pharmaceuticals,NASDAQ: SPPI,1,186.8,155.9,267.7,193,74.1,38,159.8,69.7,74.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206256,274,1753,202,38,Non-Hodgkin`s lymphoma,3,1
789,"VORINOSTAT (ORAL), MERCK & CO","L-001079038; MK-0683; MSK-390; NSC-701852; SAHA; SAHA (ORAL), MERCK; SUBEROYLANILIDE HYDROXAMIC ACID; ZOLINZA; SUBERANILOHYDROXAMIC ACID (ORAL), ATON PHARMA; SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), ATON PHARMA; SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), MERCK; VORINOSTAT; VORINOSTAT (ORAL), ATON PHARMA; VORINOSTAT (ORAL), MERCK & CO","L-001079038; MK-0683; MSK-390; NSC-701852; SAHA; SAHA (ORAL), MERCK; SUBEROYLANILIDE HYDROXAMIC ACID; ZOLINZA; SUBERANILOHYDROXAMIC ACID (ORAL), ATON PHARMA; SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), ATON PHARMA; SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), MERCK; VORINOSTAT; VORINOSTAT (ORAL), ATON PHARMA; VORINOSTAT (ORAL), MERCK & CO","VORINOSTAT (ORAL), MERCK & CO",L-001079038,MK-0683,MSK-390,NSC-701852,SAHA,"SAHA (ORAL), MERCK",SUBEROYLANILIDE HYDROXAMIC ACID,ZOLINZA,"SUBERANILOHYDROXAMIC ACID (ORAL), ATON PHARMA","SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), ATON PHARMA","SUBEROYLANILIDE HYDROXAMIC ACID (ORAL), MERCK",VORINOSTAT,"VORINOSTAT (ORAL), ATON PHARMA","VORINOSTAT (ORAL), MERCK & CO",,,,,,,,,,,,,,,,,21991,VORINOSTAT,,,,,,,,,,,,,,,,,,,,,2006-10-06T00:00:00Z,2006,10,Zolinza,cutaneous t-cell lymphoma,HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASE-1 INHIBITOR; HISTONE DEACETYLASE-2 INHIBITOR; HISTONE DEACETYLASE-3 INHIBITOR; HISTONE DEACETYLASE-6 INHIBITOR,ANTICANCER; ANTIVIRAL,CAPSULE FORMULATION; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021991,NDA,2006-04-05T00:00:00Z,fda,1,0,1,1,0,,merck,NYSE: MRK,1,22636,22011.9,22972.8,22485.9,21445.8,21199,17371.3,3963.6,4020.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021991,428,1754,202,38,Non-Hodgkin`s lymphoma,3,1
642,ROMIDEPSIN,"FK-228; FR-901228; ISTODAX; NSC-630176; DEPSIPEPTIDE, NCI/FUJISAWA; ROMIDEPSIN","FK-228; FR-901228; ISTODAX; NSC-630176; DEPSIPEPTIDE, NCI/FUJISAWA; ROMIDEPSIN",ROMIDEPSIN,FK-228,FR-901228,ISTODAX,NSC-630176,"DEPSIPEPTIDE, NCI/FUJISAWA",ROMIDEPSIN,,,,,,,,,,,,,,,,,,,,,,,,,22393,ROMIDEPSIN,,,,,,,,,,,,,,,,,,,,,2009-11-05T00:00:00Z,2009,11,Istodax,cutaneous t-cell lymphoma,HISTONE DEACETYLASE INHIBITOR,ANTICANCER; APOPTOSIS STIMULATOR; CELL CYCLE INHIBITOR; SYNERGIST,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; NATURAL PRODUCT; PEPTIDE; PRODRUG,matched (3),022393,NDA,2009-01-12T00:00:00Z,fda,0,0,1,1,0,,celgene,NASDAQ: CELG,1,2689.9,,,,,,2473.6,794.8,794.8,,,2009,,acquired by celgene in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022393,545,1754,202,38,Non-Hodgkin`s lymphoma,3,1
603,PRALATREXATE,"10-PROPARGYL-10-DEAZAAMINOPTERIN; DHFR INHIBITOR (ANTICANCER), ALLOS; DHFR INHIBITOR (ANTICANCER), MEMORIAL SLOAN-KETTERING; FOLOTYN; PDX, ALLOS; PRALATREXATE","10-PROPARGYL-10-DEAZAAMINOPTERIN; DHFR INHIBITOR (ANTICANCER), ALLOS; DHFR INHIBITOR (ANTICANCER), MEMORIAL SLOAN-KETTERING; FOLOTYN; PDX, ALLOS; PRALATREXATE",PRALATREXATE,10-PROPARGYL-10-DEAZAAMINOPTERIN,"DHFR INHIBITOR (ANTICANCER), ALLOS","DHFR INHIBITOR (ANTICANCER), MEMORIAL SLOAN-KETTERING",FOLOTYN,"PDX, ALLOS",PRALATREXATE,,,,,,,,,,,,,,,,,,,,,,,,,22468,PRALATREXATE,,,,,,,,,,,,,,,,,,,,,2009-09-24T00:00:00Z,2009,9,Folotyn,peripheral t-cell lymphoma,DHFR INHIBITOR; FOLATE ANTAGONIST; FOLATE TRANSPORTER 1 MODULATOR,ANTICANCER; APOPTOSIS STIMULATOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022468,NDA,2009-03-23T00:00:00Z,fda,1,1,1,1,0,,allos therapeutics,NASDAQ: ALTH,1,3.6,,,,,,3.2,33.5,32.6,,,,,acquired by spectrum pharmaceuticals in 2012,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022468,572,1753,202,38,Non-Hodgkin`s lymphoma,3,1
136,CARFILZOMIB,"KYPROLIS; ONO-7057; PR-171; CARFILZOMIB; CARFILZOMIB (INTRAVENOUS/CAPTISOL-ENABLED, CANCER), ONYX/LIGAND; EPOXOMICIN DERIVATIVE (ANTICANCER), PROTEOLIX; PROTEASOME INHIBITORS (HEMATOLOGICAL MALIGNANCIES), PROTEOLIX","KYPROLIS; ONO-7057; PR-171; CARFILZOMIB; CARFILZOMIB (INTRAVENOUS/CAPTISOL-ENABLED, CANCER), ONYX/LIGAND; EPOXOMICIN DERIVATIVE (ANTICANCER), PROTEOLIX; PROTEASOME INHIBITORS (HEMATOLOGICAL MALIGNANCIES), PROTEOLIX",CARFILZOMIB,KYPROLIS,ONO-7057,PR-171,CARFILZOMIB,"CARFILZOMIB (INTRAVENOUS/CAPTISOL-ENABLED, CANCER), ONYX/LIGAND","EPOXOMICIN DERIVATIVE (ANTICANCER), PROTEOLIX","PROTEASOME INHIBITORS (HEMATOLOGICAL MALIGNANCIES), PROTEOLIX",,,,,,,,,,,,,,,,,,,,,,,,202714,CARFILZOMIB,,,,,,,,,,,,,,,,,,,,,2012-07-20T00:00:00Z,2012,7,Kyprolis,multiple myeloma,PROTEASOME INHIBITOR; UBIQUITIN INHIBITOR,ANTICANCER; SYNERGIST,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PEPTIDE; SMALL MOLECULE THERAPEUTIC,matched (3),202714,NDA,2011-09-26T00:00:00Z,fda,0,1,1,1,0,,onyx pharmaceuticals,NASDAQ: ONXX,1,362.2,447.2,324.5,251.4,194.3,90.4,35.6,,335.3,,,,,acquired by amgen in 2013,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202714,126,1828,203,40,Multiple myeloma,2,1
598,POMALIDOMIDE,ACTIMID; ACTIMID (CURRENT LEAD); CC-4047; ENMD-0995; IMID-1; IMNOVID; POMALYST; S-3APG; POMALIDOMIDE,ACTIMID; ACTIMID (CURRENT LEAD); CC-4047; ENMD-0995; IMID-1; IMNOVID; POMALYST; S-3APG; POMALIDOMIDE,POMALIDOMIDE,ACTIMID,ACTIMID (CURRENT LEAD),CC-4047,ENMD-0995,IMID-1,IMNOVID,POMALYST,S-3APG,POMALIDOMIDE,,,,,,,,,,,,,,,,,,,,,,204026,POMALIDOMIDE,,,,,,,,,,,,,,,,,,,,,2013-02-08T00:00:00Z,2013,2,Pomalyst,multiple myeloma,,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTIVIRAL; IMMUNOMODULATOR; TNF ALPHA SYNTHESIS INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204026,NDA,2012-04-10T00:00:00Z,fda,0,1,1,1,0,,celgene,NASDAQ: CELG,1,6493.9,5506.7,4842.1,3625.7,2689.9,2254.8,5507.4,1580.1,2226.2,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204026,177,1828,203,40,Multiple myeloma,2,1
572,"PANOBINOSTAT (ORAL), NOVARTIS","FARIDAK; FARYDAK; LBH-589; LBH-589 (ORAL), NOVARTIS; LBH-589B; NVP-LBH-589; PANOBINOSTAT; PANOBINOSTAT (ORAL), NOVARTIS","FARIDAK; FARYDAK; LBH-589; LBH-589 (ORAL), NOVARTIS; LBH-589B; NVP-LBH-589; PANOBINOSTAT; PANOBINOSTAT (ORAL), NOVARTIS","PANOBINOSTAT (ORAL), NOVARTIS",FARIDAK,FARYDAK,LBH-589,"LBH-589 (ORAL), NOVARTIS",LBH-589B,NVP-LBH-589,PANOBINOSTAT,"PANOBINOSTAT (ORAL), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,205353,PANOBINOSTAT LACTATE,205353,PANOBINOSTAT LACTATE,,,,,,,,,,,,,,,,,,,2015-02-23T00:00:00Z,2015,2,Farydak,multiple myeloma,CYTOCHROME P450 2D6 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASE-1 INHIBITOR; HISTONE DEACETYLASE-2 INHIBITOR; HISTONE DEACETYLASE-3 INHIBITOR; HISTONE DEACETYLASE-6 INHIBITOR; JAK2 GENE INHIBITOR; ORPHAN NUCLEAR HORMONE RECEPTOR NR4A1 AGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTIVIRAL; APOPTOSIS STIMULATOR; CELL CYCLE INHIBITOR; SYNERGIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205353,NDA,2014-03-22T00:00:00Z,fda,1,0,0,1,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205353,232,1828,203,40,Multiple myeloma,2,1
460,"MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM / CASI PHARMACEUTICALS","CDX-353; CE MELPHALAN; CE MELPHALAN; CAPTISOL-ENABLED MELPHALAN; CAPTISOL-ENABLED MELPHALAN; EVOMELA; EVOMELA; MELPHALAN; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), CYDEX PHARMACEUTICALS; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM / CASI PHARMACEUTICALS; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM PHARMACEUTICALS; MELPHALAN HYDROCHLORIDE","CDX-353; CE MELPHALAN; CE MELPHALAN; CAPTISOL-ENABLED MELPHALAN; CAPTISOL-ENABLED MELPHALAN; EVOMELA; EVOMELA; MELPHALAN; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), CYDEX PHARMACEUTICALS; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM / CASI PHARMACEUTICALS; MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM PHARMACEUTICALS; MELPHALAN HYDROCHLORIDE","MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM / CASI PHARMACEUTICALS",CDX-353,CE MELPHALAN,CE MELPHALAN,CAPTISOL-ENABLED MELPHALAN,CAPTISOL-ENABLED MELPHALAN,EVOMELA,EVOMELA,MELPHALAN,"MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), CYDEX PHARMACEUTICALS","MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM / CASI PHARMACEUTICALS","MELPHALAN (INTRAVENOUS/CAPTISOL, MULTIPLE MYELOMA), SPECTRUM PHARMACEUTICALS",MELPHALAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,207155,MELPHALAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2016-03-10T00:00:00Z,2016,3,Evomela,multiple myeloma,,ANTICANCER ALKYLATING AGENT; DNA SYNTHESIS INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),207155,NDA,2014-12-23T00:00:00Z,fda,0,0,0,1,0,,spectrum pharmaceuticals,NASDAQ: SPPI,1,146.4,162.6,186.8,155.9,267.7,193,110.6,58.9,60.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207155,297,1828,203,40,Multiple myeloma,2,1
402,"IXAZOMIB CITRATE (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM","MLN-9708; MLN-9708 (ORAL, CANCER), MILLENNIUM; MLN-9708 (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM; NINLARO; NINLARO; IXAZOMIB CITRATE; IXAZOMIB CITRATE (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM; PROTEASOME INHIBITOR (ORAL, CANCER), MILLENNIUM","MLN-9708; MLN-9708 (ORAL, CANCER), MILLENNIUM; MLN-9708 (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM; NINLARO; NINLARO; IXAZOMIB CITRATE; IXAZOMIB CITRATE (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM; PROTEASOME INHIBITOR (ORAL, CANCER), MILLENNIUM","IXAZOMIB CITRATE (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM",MLN-9708,"MLN-9708 (ORAL, CANCER), MILLENNIUM","MLN-9708 (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM",NINLARO,NINLARO,IXAZOMIB CITRATE,"IXAZOMIB CITRATE (ORAL, MULTIPLE MYELOMA/AMYLOIDOSIS), MILLENNIUM","PROTEASOME INHIBITOR (ORAL, CANCER), MILLENNIUM",,,,,,,,,,,,,,,,,,,,,,,208462,IXAZOMIB CITRATE,,,,,,,,,,,,,,,,,,,,,2015-11-20T00:00:00Z,2015,11,Ninlaro,multiple myeloma,PROTEASOME INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; ANTIVIRAL; OSTEOCLAST INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),208462,NDA,2015-07-10T00:00:00Z,fda,1,0,0,1,0,,takeda pharmaceuticals,TYO: 4502,1,15233.7,14563.6,15739.7,18156.3,19052,17491.2,10766,3217.7,3217.7,,,2008,,acquired by takeda in 2008,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208462,344,1828,203,40,Multiple myeloma,2,1
237,ELOTUZUMAB,"BMS-901608; BMS-901608; CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB; CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), FACET; CS1 TARGETING HUMANIZED MONOCLONAL ANTIBODY (MAB, MULTIPLE MYELOMA), PDL; EMPLICITI; EMPLICITI; HULUC63; PDL-063; ANTI-CD37 MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB; ANTI-CS1 ANTIBODY (CANCER), BMS/PDL; ELOTUZUMAB","BMS-901608; BMS-901608; CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB; CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), FACET; CS1 TARGETING HUMANIZED MONOCLONAL ANTIBODY (MAB, MULTIPLE MYELOMA), PDL; EMPLICITI; EMPLICITI; HULUC63; PDL-063; ANTI-CD37 MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB; ANTI-CS1 ANTIBODY (CANCER), BMS/PDL; ELOTUZUMAB",ELOTUZUMAB,BMS-901608,BMS-901608,"CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB","CS1 TARGETING HUMANIZED MAB (MULTIPLE MYELOMA), FACET","CS1 TARGETING HUMANIZED MONOCLONAL ANTIBODY (MAB, MULTIPLE MYELOMA), PDL",EMPLICITI,EMPLICITI,HULUC63,PDL-063,"ANTI-CD37 MAB (MULTIPLE MYELOMA), BRISTOL-MYERS SQUIBB","ANTI-CS1 ANTIBODY (CANCER), BMS/PDL",ELOTUZUMAB,,,,,,,,,,,,,,,,,,,761035,ELOTUZUMAB,,,,,,,,,,,,,,,,,,,,,2015-11-30T00:00:00Z,2015,11,Empliciti,multiple myeloma,LYMPHOCYTE FUNCTION ANTIGEN-3 RECEPTOR MODULATOR; SLAM FAMILY MEMBER 7 INHIBITOR,ANTICANCER MONOCLONAL ANTIBODY,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED,matched (3),761035,BLA,2015-06-27T00:00:00Z,fda,1,0,0,1,1,2014-05-19T00:00:00Z,bristol-myers squibb,NYSE: BMY,1,16560,15879,16385,17621,21244,19484,12735,4037,5760,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761035,623,1828,203,40,Multiple myeloma,2,1
186,DARATUMUMAB,"3003-005; DARZALEX; DARZALEX; HUMAX, MULTIPLE MYELOMA; HUMAX-CD38; IGG1KAPPA ANTIBODY (MULTIPLE MYELOMA), GENMAB; JNJ-54767414; DARATUMUMAB","3003-005; DARZALEX; DARZALEX; HUMAX, MULTIPLE MYELOMA; HUMAX-CD38; IGG1KAPPA ANTIBODY (MULTIPLE MYELOMA), GENMAB; JNJ-54767414; DARATUMUMAB",DARATUMUMAB,3003-005,DARZALEX,DARZALEX,"HUMAX, MULTIPLE MYELOMA",HUMAX-CD38,"IGG1KAPPA ANTIBODY (MULTIPLE MYELOMA), GENMAB",JNJ-54767414,DARATUMUMAB,,,,,,,,,,,,,,,,,,,,,,,761036,DARATUMUMAB,,,,,,,,,,,,,,,,,,,,,2015-11-16T00:00:00Z,2015,11,Darzalex,multiple myeloma,ADP RIBOSYL CYCLASE-1 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; APOPTOSIS STIMULATOR,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; SOLUTION,matched (3),761036,BLA,2015-07-09T00:00:00Z,fda,1,1,1,1,1,2013-05-01T00:00:00Z,johnson and johnson,NYSE: JNJ,1,70074,74331,71312,67224,65030,61587,48619,9046,9046,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036,624,1828,203,40,Multiple myeloma,2,1
534,OFATUMUMAB,"2F2; ARZERRA; GSK-1841157; HUMAX-CD20; ANTI-CD20 HUMAN MONOCLONAL ANTIBODY (INTRAVENOUS), GLAXOSMITHKLINE/ GENMAB; OFATUMUMAB","2F2; ARZERRA; GSK-1841157; HUMAX-CD20; ANTI-CD20 HUMAN MONOCLONAL ANTIBODY (INTRAVENOUS), GLAXOSMITHKLINE/ GENMAB; OFATUMUMAB",OFATUMUMAB,2F2,ARZERRA,GSK-1841157,HUMAX-CD20,"ANTI-CD20 HUMAN MONOCLONAL ANTIBODY (INTRAVENOUS), GLAXOSMITHKLINE/ GENMAB",OFATUMUMAB,,,,,,,,,,,,,,,,,,,,,,,,,125326,OFATUMUMAB,,,,,,,,,,,,,,,,,,,,,2009-10-26T00:00:00Z,2009,10,Arzerra,chronic lymphocytic leukemia,B-LYMPHOCYTE ANTIGEN CD20 INHIBITOR,ANTICANCER MONOCLONAL ANTIBODY,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; LIQUID FORMULATION; MONOCLONAL ANTIBODY HUMAN,matched (3),125326,BLA,2009-01-30T00:00:00Z,cortellis,1,1,1,1,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326,25,1734,204,39,Leukemias,1,1
171,"CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), JAZZ PHARMACEUTICALS","ERWINASE; ERWINAZE; ERWINIA CHRYSANTHEMI L-ASPARAGINASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA; OP-01; ASPARAGINASE (ERWINIA CHRYSANTHEMI); CRISANTASPASE; CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), JAZZ PHARMACEUTICALS; CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA","ERWINASE; ERWINAZE; ERWINIA CHRYSANTHEMI L-ASPARAGINASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA; OP-01; ASPARAGINASE (ERWINIA CHRYSANTHEMI); CRISANTASPASE; CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), JAZZ PHARMACEUTICALS; CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA","CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), JAZZ PHARMACEUTICALS",ERWINASE,ERWINAZE,"ERWINIA CHRYSANTHEMI L-ASPARAGINASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA",OP-01,ASPARAGINASE (ERWINIA CHRYSANTHEMI),CRISANTASPASE,"CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), JAZZ PHARMACEUTICALS","CRISANTASPASE (ACUTE LYMPHOBLASTIC LEUKEMIA), OPI/HPA",,,,,,,,,,,,,,,,,,,,,,,125359,asparaginase Erwinia chrysanthemi,125359,asparaginase Erwinia chrysanthemi,,,,,,,,,,,,,,,,,,,2011-11-18T00:00:00Z,2011,11,Erwinaze,acute lymphoblastic leukemia,ASPARAGINASE STIMULATOR,ANTICANCER,BIOLOGICAL THERAPEUTIC; ENZYME; FORMULATION POWDER; FREEZE DRYING; INTRAMUSCULAR FORMULATION; INTRAVENOUS FORMULATION,matched (3),125359,BLA,2010-10-29T00:00:00Z,fda,1,0,1,1,0,,eusa pharma,private,0,,,,,,,,,,,,,,acquired by jazz pharmaceuticals in 2012,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125359,29,1728,204,39,Leukemias,1,1
529,OBINUTUZUMAB,"GA-101; GASSEBA; GAZYVA; GAZYVARO; R-7159; RG-7159; RO-5072759; AFUTUZUMAB; ANTI-CD20 HUMANIZED MAB (GLYCOMAB), GLYCART; OBINUTUZUMAB","GA-101; GASSEBA; GAZYVA; GAZYVARO; R-7159; RG-7159; RO-5072759; AFUTUZUMAB; ANTI-CD20 HUMANIZED MAB (GLYCOMAB), GLYCART; OBINUTUZUMAB",OBINUTUZUMAB,GA-101,GASSEBA,GAZYVA,GAZYVARO,R-7159,RG-7159,RO-5072759,AFUTUZUMAB,"ANTI-CD20 HUMANIZED MAB (GLYCOMAB), GLYCART",OBINUTUZUMAB,,,,,,,,,,,,,,,,,,,,,125486,OBINUTUZUMAB,,,,,,,,,,,,,,,,,,,,,2013-11-01T00:00:00Z,2013,11,Gazyva,chronic lymphocytic leukemia,B-LYMPHOCYTE ANTIGEN CD20 INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; APOPTOSIS STIMULATOR; IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; GLYCOPROTEIN; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED,matched (3),125486,BLA,2013-04-22T00:00:00Z,fda,1,0,0,1,1,2013-05-15T00:00:00Z,roche,SIX: ROG,1,54589.6,51820.8,47194.8,52624.4,49411.7,13418,40688.4,9832.7,10409.9,,,2009,,acquired by roche in 2009,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486,46,1734,204,39,Leukemias,1,1
99,BLINATUMOMAB,"AMG-103; BLINCYTO; CD19XCD3; MEDI-538; MT-103 (CANCER, BITE), AMGEN; MT-103 (CANCER, BITE), MICROMET/MEDIMMUNE; MT-103, MEDIMMUNE; ANTI-CD19/ANTI-CD3 SINGLE-CHAIN BISPECIFIC ANTIBODY; BLINATUMOMAB; BLINATUMOMAB (CANCER, BITE), MICROMET/MEDIMMUNE; BSCCD19XCD3 (CANCER, BITE), AMGEN; BSCCD19XCD3 (CANCER, BITE), MICROMET/MEDIMMUNE","AMG-103; BLINCYTO; CD19XCD3; MEDI-538; MT-103 (CANCER, BITE), AMGEN; MT-103 (CANCER, BITE), MICROMET/MEDIMMUNE; MT-103, MEDIMMUNE; ANTI-CD19/ANTI-CD3 SINGLE-CHAIN BISPECIFIC ANTIBODY; BLINATUMOMAB; BLINATUMOMAB (CANCER, BITE), MICROMET/MEDIMMUNE; BSCCD19XCD3 (CANCER, BITE), AMGEN; BSCCD19XCD3 (CANCER, BITE), MICROMET/MEDIMMUNE",BLINATUMOMAB,AMG-103,BLINCYTO,CD19XCD3,MEDI-538,"MT-103 (CANCER, BITE), AMGEN","MT-103 (CANCER, BITE), MICROMET/MEDIMMUNE","MT-103, MEDIMMUNE",ANTI-CD19/ANTI-CD3 SINGLE-CHAIN BISPECIFIC ANTIBODY,BLINATUMOMAB,"BLINATUMOMAB (CANCER, BITE), MICROMET/MEDIMMUNE","BSCCD19XCD3 (CANCER, BITE), AMGEN","BSCCD19XCD3 (CANCER, BITE), MICROMET/MEDIMMUNE",,,,,,,,,,,,,,,,,,,125557,BLINATUMOMAB,,,,,,,,,,,,,,,,,,,,,2014-12-03T00:00:00Z,2014,12,Blincyto,acute lymphoblastic leukemia,B-LYMPHOCYTE ANTIGEN CD19 INHIBITOR; CD3 ANTAGONIST,ANTICANCER MONOCLONAL ANTIBODY,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; MULTIVALENT MONOCLONAL ANTIBODY; PROTEIN FUSION; PROTEIN RECOMBINANT; SOLUTION,matched (3),125557,BLA,2014-09-19T00:00:00Z,fda,1,1,0,1,1,2014-07-01T00:00:00Z,amgen,NASDAQ: AMGN,1,20063,18676,17265,15582,15053,14642,15745,4248,4405,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557,61,1728,204,39,Leukemias,1,1
599,PONATINIB,"AP-23464; AP-24283; AP-24534; ICLUSIG; DUAL ABL/SRC INHIBITORS (CANCER), ARIAD; ONCOGENIC KINASE INHIBITORS (CANCER), ARIAD; PONATINIB; PONATINIB HYDROCHLORIDE","AP-23464; AP-24283; AP-24534; ICLUSIG; DUAL ABL/SRC INHIBITORS (CANCER), ARIAD; ONCOGENIC KINASE INHIBITORS (CANCER), ARIAD; PONATINIB; PONATINIB HYDROCHLORIDE",PONATINIB,AP-23464,AP-24283,AP-24534,ICLUSIG,"DUAL ABL/SRC INHIBITORS (CANCER), ARIAD","ONCOGENIC KINASE INHIBITORS (CANCER), ARIAD",PONATINIB,PONATINIB HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,203469,PONATINIB HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2012-12-14T00:00:00Z,2012,12,Iclusig,acute lymphoblastic leukemia,ABL FAMILY TYROSINE KINASE INHIBITOR; BCR PROTEIN INHIBITOR; EPH FAMILY TYROSINE KINASE INHIBITOR; FGF RECEPTOR ANTAGONIST; FLT3 TYROSINE KINASE INHIBITOR; KIT TYROSINE KINASE INHIBITOR; PDGF RECEPTOR ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; RET GENE INHIBITOR; RET TYROSINE KINASE RECEPTOR INHIBITOR; SRC TYROSINE KINASE INHIBITOR; TEK TYROSINE KINASE RECEPTOR INHIBITOR; VEGF RECEPTOR ANTAGONIST,ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203469,NDA,2012-07-30T00:00:00Z,fda,1,1,0,1,0,,ariad pharmaceuticals,NASDAQ: ARIA,1,0.6,25.3,179,8.3,7.1,3.6,0.6,139.9,144.7,,,,,acquired by takeda in 2017,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,158,1728,204,39,Leukemias,1,1
371,IDELALISIB,"CAL-101; GS-1101; IC-87114; IC-980033; P13K DELTA INHIBITORS (INFLAMMATION/CANCER), ELI LILLY; PI3K DELTA INHIBITORS (INFLAMMATION/CANCER), ICOS/CALISTOGA; ZYDELIG; IDELALISIB; IDELALISIB (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS; LIPID KINASE INHIBITORS (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS; LIPID KINASE INHIBITORS, ICOS; P110 DELTA PI3 KINASE INHIBITORS (INFLAMMATION/CANCER), ICOS","CAL-101; GS-1101; IC-87114; IC-980033; P13K DELTA INHIBITORS (INFLAMMATION/CANCER), ELI LILLY; PI3K DELTA INHIBITORS (INFLAMMATION/CANCER), ICOS/CALISTOGA; ZYDELIG; IDELALISIB; IDELALISIB (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS; LIPID KINASE INHIBITORS (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS; LIPID KINASE INHIBITORS, ICOS; P110 DELTA PI3 KINASE INHIBITORS (INFLAMMATION/CANCER), ICOS",IDELALISIB,CAL-101,GS-1101,IC-87114,IC-980033,"P13K DELTA INHIBITORS (INFLAMMATION/CANCER), ELI LILLY","PI3K DELTA INHIBITORS (INFLAMMATION/CANCER), ICOS/CALISTOGA",ZYDELIG,IDELALISIB,"IDELALISIB (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS","LIPID KINASE INHIBITORS (INFLAMMATION/AUTOIMMUNITY/CANCER), ICOS","LIPID KINASE INHIBITORS, ICOS","P110 DELTA PI3 KINASE INHIBITORS (INFLAMMATION/CANCER), ICOS",,,,,,,,,,,,,,,,,,,205858,IDELALISIB,,,,,,,,,,,,,,,,,,,,,2014-07-23T00:00:00Z,2014,7,Zydelig,chronic lymphocytic leukemia,PHOSPHOINOSITIDE-3 KINASE DELTA INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER PROTEIN KINASE INHIBITOR; APOPTOSIS STIMULATOR; CELL CYCLE INHIBITOR; SYNERGIST,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205858,NDA,2013-09-11T00:00:00Z,fda,0,0,0,1,1,2013-11-18T00:00:00Z,gilead sciences,NASDAQ: GILD,1,24890,11202,9702,8385.39,7949.42,7011.38,21102,2854,2854,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205858,263,1734,204,39,Leukemias,1,1
468,"MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA","ALLMERCAP; PURIXAN; XALUPRINE; MERCAPTOPURINE; MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA; MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA/LINK HEALTHCARE","ALLMERCAP; PURIXAN; XALUPRINE; MERCAPTOPURINE; MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA; MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA/LINK HEALTHCARE","MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA",ALLMERCAP,PURIXAN,XALUPRINE,MERCAPTOPURINE,"MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA","MERCAPTOPURINE (ORAL SUSPENSION, ACUTE LYMPHOBLASTIC LEUKEMIA), NOVA/LINK HEALTHCARE",,,,,,,,,,,,,,,,,,,,,,,,,205919,MERCAPTOPURINE,,,,,,,,,,,,,,,,,,,,,2014-04-28T00:00:00Z,2014,4,Purixan,acute lymphoblastic leukemia,,ANTICANCER ANTIMETABOLITE,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205919,NDA,2013-07-09T00:00:00Z,fda,0,0,0,1,0,,rare disease therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205919,265,1728,204,39,Leukemias,1,1
779,VENETOCLAX,ABT-199; GDC-0199; RG-7601; RO-5537382; RO-5537382; VENCLEXTA; VENCLEXTA; VENCLYXTO; VENCLYXTO; VENETOCLAX,ABT-199; GDC-0199; RG-7601; RO-5537382; RO-5537382; VENCLEXTA; VENCLEXTA; VENCLYXTO; VENCLYXTO; VENETOCLAX,VENETOCLAX,ABT-199,GDC-0199,RG-7601,RO-5537382,RO-5537382,VENCLEXTA,VENCLEXTA,VENCLYXTO,VENCLYXTO,VENETOCLAX,,,,,,,,,,,,,,,,,,,,,208573,VENETOCLAX,,,,,,,,,,,,,,,,,,,,,2016-04-11T00:00:00Z,2016,4,Venclexta,chronic lymphocytic leukemia,BCL-2 PROTEIN INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; APOPTOSIS STIMULATOR; SYNERGIST,FILM COATING; ORAL FORMULATION; PEPTIDOMIMETIC; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208573,NDA,2015-10-29T00:00:00Z,fda,1,1,0,1,1,2015-05-06T00:00:00Z,abbvie,NYSE: ABBV,1,25638,22859,19960,18790,18380,17444,19844,4226,4366,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208573,349,1734,204,39,Leukemias,1,1
88,BENDAMUSTINE,BENDA; BENDA; CYTOSTASAN; CYTOSTASAN; INNO-P08001; INNOMUSTINE; INNOMUSTINE; LEVACT; RIBOMUSTIN; RIBOMUSTIN; RIBOVACT; RIBOVACT; SDX-105; SYB L-0501; SYBL-0501; SYMBENDA; SYMBENDA; TREAKISYM; TREANDA; BENDAMUSTINE; BENDAMUSTINE HYDROCHLORIDE,BENDA; BENDA; CYTOSTASAN; CYTOSTASAN; INNO-P08001; INNOMUSTINE; INNOMUSTINE; LEVACT; RIBOMUSTIN; RIBOMUSTIN; RIBOVACT; RIBOVACT; SDX-105; SYB L-0501; SYBL-0501; SYMBENDA; SYMBENDA; TREAKISYM; TREANDA; BENDAMUSTINE; BENDAMUSTINE HYDROCHLORIDE,BENDAMUSTINE,BENDA,BENDA,CYTOSTASAN,CYTOSTASAN,INNO-P08001,INNOMUSTINE,INNOMUSTINE,LEVACT,RIBOMUSTIN,RIBOMUSTIN,RIBOVACT,RIBOVACT,SDX-105,SYB L-0501,SYBL-0501,SYMBENDA,SYMBENDA,TREAKISYM,TREANDA,BENDAMUSTINE,BENDAMUSTINE HYDROCHLORIDE,,,,,,,,,,205580,BENDAMUSTINE HYDROCHLORIDE,205580,BENDAMUSTINE HYDROCHLORIDE,205580,BENDAMUSTINE HYDROCHLORIDE,22249,BENDAMUSTINE HYDROCHLORIDE,,,,,,,,,,,,,,,2008-03-20T00:00:00Z,2008,3,Treanda,chronic lymphocytic leukemia,PARP MODULATOR,ANTICANCER; ANTICANCER ALKYLATING AGENT,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022249,NDA,2007-09-19T00:00:00Z,fda,1,0,0,1,0,,cephalon,NASDAQ: CEPH,1,1974.6,1772.6,1764.1,1211.9,1015.4,714.8,1574.7,362.2,362.2,,,,,acquired by teva in 2011,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022249,509,1734,204,39,Leukemias,1,1
783,VINCRISTINE SULFATE,"MARQIBO; ONCO-TCS; VSLI, HANA; VSLI, INEX; TRANSMEMBRANE CARRIER SYSTEM (VINCRISTINE), HANA; TRANSMEMBRANE CARRIER SYSTEM (VINCRISTINE), INEX; VINCRISTINE; VINCRISTINE SULFATE; VINCRISTINE SULFATE (LIPOSOMAL INJECTION), HANA; VINCRISTINE SULFATE (LIPOSOMAL INJECTION), SPECTRUM / CASI PHARMACEUTICALS; VINCRISTINE SULFATE (LIPOSOMAL INJECTION), SPECTRUM PHARMACEUTICALS; VINCRISTINE SULFATE (LIPOSOMAL INJECTION), TALON; VINCRISTINE SULFATE (LIPOSOMAL INJECTION, OPTISOME), INEX; VINCRISTINE SULFATE LIPOSOMES FOR INJECTION, HANA; VINCRISTINE SULFATE LIPOSOMES FOR INJECTION, INEX; VINCRISTINE-TCS, HANA; VINCRISTINE-TCS, INEX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-08-09T00:00:00Z,2012,8,Marqibo,acute lymphoblastic leukemia,,ANTICANCER; CELL CYCLE INHIBITOR; MICROTUBULE INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; LIPOSOME FORMULATION INJECTABLE; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC,using only (2),202497,NDA,2011-07-12T00:00:00Z,fda,0,1,1,1,0,,talon therapeutics,OTCBB: TLON,1,,,,,,1.2,,12.9,12.9,,,,,acquired by spectrum pharmaceuticals in 2013,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202497,729,1728,204,39,Leukemias,1,1
101,BOSUTINIB,"BCR-ABL KINASE INHIBITORS, PFIZER; BCR-ABL KINASE INHIBITORS, WYETH; BOSLIF; BOSULIF; PF-5208763; SKI-015; SKI-606; SKI-758; SKI-971; SRC KINASE INHIBITORS (ORAL), PFIZER; SRC KINASE INHIBITORS (ORAL), WYETH; SRC KINASE INHIBITORS (ORAL), WYETH-AYERST; BOSUTINIB","BCR-ABL KINASE INHIBITORS, PFIZER; BCR-ABL KINASE INHIBITORS, WYETH; BOSLIF; BOSULIF; PF-5208763; SKI-015; SKI-606; SKI-758; SKI-971; SRC KINASE INHIBITORS (ORAL), PFIZER; SRC KINASE INHIBITORS (ORAL), WYETH; SRC KINASE INHIBITORS (ORAL), WYETH-AYERST; BOSUTINIB",BOSUTINIB,"BCR-ABL KINASE INHIBITORS, PFIZER","BCR-ABL KINASE INHIBITORS, WYETH",BOSLIF,BOSULIF,PF-5208763,SKI-015,SKI-606,SKI-758,SKI-971,"SRC KINASE INHIBITORS (ORAL), PFIZER","SRC KINASE INHIBITORS (ORAL), WYETH","SRC KINASE INHIBITORS (ORAL), WYETH-AYERST",BOSUTINIB,,,,,,,,,,,,,,,,,,203341,BOSUTINIB MONOHYDRATE,,,,,,,,,,,,,,,,,,,,,2012-09-04T00:00:00Z,2012,9,Bosulif,chronic myelocytic leukemia,ABL TYROSINE KINASE INHIBITOR; DNA GYRASE INHIBITOR; SRC TYROSINE KINASE INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203341,NDA,2011-11-17T00:00:00Z,fda,0,0,0,1,0,,pfizer,NYSE: PFE,1,54657,61035,65165,49269,22833.9,22399.8,20350.7,6705,7482,22144.2,2009-06-30T00:00:00Z,2009,,acquired by Pfizer in 2009,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341,153,1735,205,39,Leukemias,1,1
542,"OMACETAXINE MEPESUCCINATE (INJECTABLE, CANCER), CHEMGENEX/HOSPIRA","CGX-635; CEFLATONIN; MYELOSTAT; OMAPRO; SYNRIBO; TEKINEX; HOMOHARRINGTONINE; HOMOHARRINGTONINE (INJECTABLE), CHEMGENEX; OMACETAXINE MEPESUCCINATE; OMACETAXINE MEPESUCCINATE (INJECTABLE), CHEMGENEX; OMACETAXINE MEPESUCCINATE (INJECTABLE, CANCER), CHEMGENEX/HOSPIRA","CGX-635; CEFLATONIN; MYELOSTAT; OMAPRO; SYNRIBO; TEKINEX; HOMOHARRINGTONINE; HOMOHARRINGTONINE (INJECTABLE), CHEMGENEX; OMACETAXINE MEPESUCCINATE; OMACETAXINE MEPESUCCINATE (INJECTABLE), CHEMGENEX; OMACETAXINE MEPESUCCINATE (INJECTABLE, CANCER), CHEMGENEX/HOSPIRA","OMACETAXINE MEPESUCCINATE (INJECTABLE, CANCER), CHEMGENEX/HOSPIRA",CGX-635,CEFLATONIN,MYELOSTAT,OMAPRO,SYNRIBO,TEKINEX,HOMOHARRINGTONINE,"HOMOHARRINGTONINE (INJECTABLE), CHEMGENEX",OMACETAXINE MEPESUCCINATE,"OMACETAXINE MEPESUCCINATE (INJECTABLE), CHEMGENEX","OMACETAXINE MEPESUCCINATE (INJECTABLE, CANCER), CHEMGENEX/HOSPIRA",,,,,,,,,,,,,,,,,,,,203585,OMACETAXINE MEPESUCCINATE,,,,,,,,,,,,,,,,,,,,,2012-10-26T00:00:00Z,2012,10,Synribo,chronic myelocytic leukemia,BCR GENE INHIBITOR; MCL1 GENE INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER; APOPTOSIS STIMULATOR; PROTEIN SYNTHESIS INHIBITOR,FORMULATION POWDER; FREEZE DRYING; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION,matched (3),203585,NDA,2012-03-30T00:00:00Z,fda,1,1,1,1,0,,teva pharmaceuticals,NYSE: TEVA,1,20317,18312,16121,13899,11085,9408,10715,1356,1283,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203585,165,1735,205,39,Leukemias,1,1
189,DASATINIB,"BMS-354825; NSC-732517; SPRAICELL; SPRICEL; SPRYCEL; SRC/ABL KINASE INHIBITOR (CANCER), BMS; DASATINIB; DASATINIB (USAN)","BMS-354825; NSC-732517; SPRAICELL; SPRICEL; SPRYCEL; SRC/ABL KINASE INHIBITOR (CANCER), BMS; DASATINIB; DASATINIB (USAN)",DASATINIB,BMS-354825,NSC-732517,SPRAICELL,SPRICEL,SPRYCEL,"SRC/ABL KINASE INHIBITOR (CANCER), BMS",DASATINIB,DASATINIB (USAN),,,,,,,,,,,,,,,,,,,,,,,21986,DASATINIB,21986,DASATINIB,,,,,,,,,,,,,,,,,,,2006-06-28T00:00:00Z,2006,6,Sprycel,chronic myelocytic leukemia,ABL TYROSINE KINASE INHIBITOR; BCR PROTEIN INHIBITOR; EPH FAMILY TYROSINE KINASE INHIBITOR; FYN TYROSINE KINASE INHIBITOR; KIT TYROSINE KINASE INHIBITOR; LCK TYROSINE KINASE INHIBITOR; PDGF-B LIGAND INHIBITOR; SRC TYROSINE KINASE INHIBITOR; YES TYROSINE KINASE INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER PROTEIN KINASE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021986,NDA,2005-12-28T00:00:00Z,fda,1,1,1,1,0,,bristol-myers squibb,NYSE: BMY,1,16208,18605,19380,18653,16208,18044,10955,2866,2951,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,426,1735,205,39,Leukemias,1,1
515,NILOTINIB,AFG-210; AHT-202; AMN-107; BBT-594; BCG-463; TASIGNA; NILOTINIB; NILOTINIB HYDROCHLORIDE MONOHYDRATE,AFG-210; AHT-202; AMN-107; BBT-594; BCG-463; TASIGNA; NILOTINIB; NILOTINIB HYDROCHLORIDE MONOHYDRATE,NILOTINIB,AFG-210,AHT-202,AMN-107,BBT-594,BCG-463,TASIGNA,NILOTINIB,NILOTINIB HYDROCHLORIDE MONOHYDRATE,,,,,,,,,,,,,,,,,,,,,,,22068,NILOTINIB HYDROCHLORIDE MONOHYDRATE,,,,,,,,,,,,,,,,,,,,,2007-10-29T00:00:00Z,2007,10,Tasigna,chronic myelocytic leukemia,ABL TYROSINE KINASE INHIBITOR; BCR PROTEIN INHIBITOR; DDR TYROSINE KINASE RECEPTOR INHIBITOR; KIT TYROSINE KINASE INHIBITOR; PDGF RECEPTOR ANTAGONIST,ANTICANCER PROTEIN KINASE INHIBITOR; ANTIPARKINSONIAN,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022068,NDA,2006-09-29T00:00:00Z,fda,0,0,1,1,0,,novartis,NYSE: NVS,1,38947,35105,29753,27277,24930,20877,28342,6430,6430,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,459,1735,205,39,Leukemias,1,1
289,"FILGRASTIM BIOSIMILAR, SANDOZ","EP-2006; FILGRASTIM BS; FILGRASTIM BS; FILGRASTIM HEXAL; ZARXIO; ZARXIO; ZARZIO; FILGRASTIM; FILGRASTIM BIOSIMILAR, HEXAL; FILGRASTIM BIOSIMILAR, SANDOZ; FILGRASTIM-SNDZ; FILGRASTIM-SNDZ","EP-2006; FILGRASTIM BS; FILGRASTIM BS; FILGRASTIM HEXAL; ZARXIO; ZARXIO; ZARZIO; FILGRASTIM; FILGRASTIM BIOSIMILAR, HEXAL; FILGRASTIM BIOSIMILAR, SANDOZ; FILGRASTIM-SNDZ; FILGRASTIM-SNDZ","FILGRASTIM BIOSIMILAR, SANDOZ",EP-2006,FILGRASTIM BS,FILGRASTIM BS,FILGRASTIM HEXAL,ZARXIO,ZARXIO,ZARZIO,FILGRASTIM,"FILGRASTIM BIOSIMILAR, HEXAL","FILGRASTIM BIOSIMILAR, SANDOZ",FILGRASTIM-SNDZ,FILGRASTIM-SNDZ,,,,,,,,,,,,,,,,,,,125553,FILGRASTIM-SNDZ,,,,,,,,,,,,,,,,,,,,,2015-03-06T00:00:00Z,2015,3,Zarxio,stem cell transplantation,GCSF LIGAND; GCSF RECEPTOR AGONIST,HEMATOPOIETIC STIMULANT; NEUTROPHIL STIMULATOR,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125553,BLA,2014-05-08T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125553,60,2990,208,39,Leukemias,1,1
730,"THIOTEPA (HEMATOPOIETIC STEM CELL TRANSPLANTATION/SOLID TUMORS), ADIENNE","52-24-4; TEPADINA; TEPADINA; THIOTEPA; THIOTEPA (HEMATOPOIETIC STEM CELL TRANSPLANTATION/SOLID TUMORS), ADIENNE; TRIETHYLENETHIOPHOSPHORAMIDE","52-24-4; TEPADINA; TEPADINA; THIOTEPA; THIOTEPA (HEMATOPOIETIC STEM CELL TRANSPLANTATION/SOLID TUMORS), ADIENNE; TRIETHYLENETHIOPHOSPHORAMIDE","THIOTEPA (HEMATOPOIETIC STEM CELL TRANSPLANTATION/SOLID TUMORS), ADIENNE",52-24-4,TEPADINA,TEPADINA,THIOTEPA,"THIOTEPA (HEMATOPOIETIC STEM CELL TRANSPLANTATION/SOLID TUMORS), ADIENNE",TRIETHYLENETHIOPHOSPHORAMIDE,,,,,,,,,,,,,,,,,,,,,,,,,11683,THIOTEPA,208264,THIOTEPA,,,,,,,,,,,,,,,,,,,2017-01-26T00:00:00Z,2017,1,Tepadina,stem cell transplantation,,ANTICANCER,FORMULATION POWDER; INJECTABLE FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC,matched (3),208264,NDA,2016-03-31T00:00:00Z,fda,0,0,0,1,0,,adienne,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208264,630,2990,208,39,Leukemias,1,1
2,"68GA-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS","68 GALLIUM-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS; 68GA-DOTA-[3-TYR]-OCTREOTATE; 68GA-DOTATATE; 68GA-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS; DOTA-[3-TYR]-OCTREOTATE-[68GA]; NETSPOT; SOMAKIT; SOMAKIT-TATE; GALLIUM-68-DOTA-[3-TYR]-OCTREOTATE","68 GALLIUM-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS; 68GA-DOTA-[3-TYR]-OCTREOTATE; 68GA-DOTATATE; 68GA-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS; DOTA-[3-TYR]-OCTREOTATE-[68GA]; NETSPOT; SOMAKIT; SOMAKIT-TATE; GALLIUM-68-DOTA-[3-TYR]-OCTREOTATE","68GA-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS","68 GALLIUM-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS",68GA-DOTA-[3-TYR]-OCTREOTATE,68GA-DOTATATE,"68GA-DOTATATE (NEUROENDOCRINE TUMORS), ADVANCED ACCELERATOR APPLICATIONS",DOTA-[3-TYR]-OCTREOTATE-[68GA],NETSPOT,SOMAKIT,SOMAKIT-TATE,GALLIUM-68-DOTA-[3-TYR]-OCTREOTATE,,,,,,,,,,,,,,,,,,,,,,208547,GALLIUM DOTATATE GA-68,,,,,,,,,,,,,,,,,,,,,2016-06-01T00:00:00Z,2016,6,Netspot,neuroendocrine tumor,SOMATOSTATIN RECEPTOR AGONIST,ENDOCRINE DIAGNOSTIC AGENT; GROWTH HORMONE RELEASE INHIBITOR; NEOPLASM DIAGNOSTIC AGENT; PET CONTRAST AGENT; RADIODIAGNOSTIC,IMAGING; INTRAVENOUS FORMULATION; PEPTIDE,matched (3),208547,NDA,2015-07-01T00:00:00Z,fda,1,0,0,1,0,,advanced accelerator applications,NASDAQ: AAAP,1,115.4,96.2,84.6,74.1,53.8,44,83.7,,14.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208547,348,1128,209,47,Other and unspecified benign neoplasm,11,0
389,IOBENGUANE SULFATE I 123,"123I-IOBENGUANE; 123I-IOBENGUANE SULFATE; ADREVIEW; ADREVIEW; IODINE-123-IOBENGUANE SULFATE; [123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR), GE HEALTHCARE; [123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR/HEART DISEASE), GE HEALTHCARE; IOBENGUANE (123I); IOBENGUANE SULFATE I 123; NEUROENDOCRINE TUMOR IMAGING AGENT (SPECT, IV), GE HEALTHCARE","123I-IOBENGUANE; 123I-IOBENGUANE SULFATE; ADREVIEW; ADREVIEW; IODINE-123-IOBENGUANE SULFATE; [123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR), GE HEALTHCARE; [123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR/HEART DISEASE), GE HEALTHCARE; IOBENGUANE (123I); IOBENGUANE SULFATE I 123; NEUROENDOCRINE TUMOR IMAGING AGENT (SPECT, IV), GE HEALTHCARE",IOBENGUANE SULFATE I 123,123I-IOBENGUANE,123I-IOBENGUANE SULFATE,ADREVIEW,ADREVIEW,IODINE-123-IOBENGUANE SULFATE,"[123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR), GE HEALTHCARE","[123I]MIBG (SPECT, IV, NEUROENDOCRINE TUMOR/HEART DISEASE), GE HEALTHCARE",IOBENGUANE (123I),IOBENGUANE SULFATE I 123,"NEUROENDOCRINE TUMOR IMAGING AGENT (SPECT, IV), GE HEALTHCARE",,,,,,,,,,,,,,,,,,,,,20084,IOBENGUANE SULFATE I-131,20084,IOBENGUANE SULFATE I-131,22290,IOBENGUANE SULFATE I-123,,,,,,,,,,,,,,,,,2008-09-19T00:00:00Z,2008,9,Adreview,neuroendocrine tumor,,CARDIOVASCULAR DIAGNOSTIC AGENT; ENDOCRINE DIAGNOSTIC AGENT; IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT; RADIODIAGNOSTIC; SPECT CONTRAST AGENT,IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING,matched (3),022290,NDA,2008-03-20T00:00:00Z,fda,1,0,0,1,0,,GE,NYSE: GE,1,181581,172488,151568,136218,132709,112284,62698,,4400,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022290,523,1128,209,47,Other and unspecified benign neoplasm,11,0
70,AVELUMAB,"BAVENCIO; MSB-0010718C; MSB0010682; PF-06834635; PF-06834635; ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO; ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO/ PFIZER; AVELUMAB; PROGRAMMED CELL DEATH LIGAND 1 MAB (SOLID TUMORS), MERCK SERONO","BAVENCIO; MSB-0010718C; MSB0010682; PF-06834635; PF-06834635; ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO; ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO/ PFIZER; AVELUMAB; PROGRAMMED CELL DEATH LIGAND 1 MAB (SOLID TUMORS), MERCK SERONO",AVELUMAB,BAVENCIO,MSB-0010718C,MSB0010682,PF-06834635,PF-06834635,"ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO","ANTI-PD-L1 MAB (SOLID TUMORS), MERCK SERONO/ PFIZER",AVELUMAB,"PROGRAMMED CELL DEATH LIGAND 1 MAB (SOLID TUMORS), MERCK SERONO",,,,,,,,,,,,,,,,,,,,,,761049,AVELUMAB,,,,,,,,,,,,,,,,,,,,,2017-03-23T00:00:00Z,2017,3,Bavencio,merkel cell carcinoma,PROGRAMMED CELL DEATH LIGAND 1 INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN,matched (3),761049,BLA,2016-09-23T00:00:00Z,fda,1,1,1,1,1,2015-11-18T00:00:00Z,merck,NYSE: MRK,1,37736,39807,39498,42237,44033,47267,26232,7184,7184,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761049,627,3235,209,47,Other and unspecified benign neoplasm,11,0
610,"PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE/ MARUHO","HEMANGEOL; HEMANGIOL; PROPRANOLOL; PROPRANOLOL (INFANT HEMANGIOMA), UNIVERSITY OF BORDEAUX; PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE; PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE/ MARUHO","HEMANGEOL; HEMANGIOL; PROPRANOLOL; PROPRANOLOL (INFANT HEMANGIOMA), UNIVERSITY OF BORDEAUX; PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE; PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE/ MARUHO","PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE/ MARUHO",HEMANGEOL,HEMANGIOL,PROPRANOLOL,"PROPRANOLOL (INFANT HEMANGIOMA), UNIVERSITY OF BORDEAUX","PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE","PROPRANOLOL (ORAL SOLUTION, INFANT HEMANGIOMA), PIERRE FABRE/ MARUHO",,,,,,,,,,,,,,,,,,,,,,,,,16419,PROPRANOLOL HYDROCHLORIDE,205410,PROPRANOLOL HYDROCHLORIDE,205410,PROPRANOLOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,2014-03-14T00:00:00Z,2014,3,Hemangeol,hemangioma,BETA ADRENOCEPTOR ANTAGONIST,ANTICANCER; VASOCONSTRICTOR,ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205410,NDA,2013-05-17T00:00:00Z,fda,0,0,0,1,0,,pierre fabre,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205410,237,1121,228,47,Other and unspecified benign neoplasm,1,0
190,DECITABINE,"5-CDR; 5-AZA-2'-DEOXYCYTIDINE; 5-AZA-2-DEOXYCYTIDINE; 5-AZA-CDR; 5-AZADEOXYCYTIDINE; AZA-DC; DAC; DACOGEN; DAKOGEN; E-7373; IND-50733; JNJ-30979754; NSC-127716; DECITABINE; DECITABINE (INTRAVENOUS, MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA), EISAI","5-CDR; 5-AZA-2'-DEOXYCYTIDINE; 5-AZA-2-DEOXYCYTIDINE; 5-AZA-CDR; 5-AZADEOXYCYTIDINE; AZA-DC; DAC; DACOGEN; DAKOGEN; E-7373; IND-50733; JNJ-30979754; NSC-127716; DECITABINE; DECITABINE (INTRAVENOUS, MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA), EISAI",DECITABINE,5-CDR,5-AZA-2'-DEOXYCYTIDINE,5-AZA-2-DEOXYCYTIDINE,5-AZA-CDR,5-AZADEOXYCYTIDINE,AZA-DC,DAC,DACOGEN,DAKOGEN,E-7373,IND-50733,JNJ-30979754,NSC-127716,DECITABINE,"DECITABINE (INTRAVENOUS, MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA), EISAI",,,,,,,,,,,,,,,,205582,DECITABINE,205582,DECITABINE,205582,DECITABINE,21790,DECITABINE,21790,DECITABINE,,,,,,,,,,,,,2006-05-02T00:00:00Z,2006,5,Dacogen,myelodysplastic syndrome,CYTOSINE DNA METHYLTRANSFERASE INHIBITOR,ANTICANCER; ANTICANCER ANTIMETABOLITE,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021790,NDA,2005-11-14T00:00:00Z,fda,0,0,1,1,0,,MGI pharma,NASDAQ: MOGN,1,342.8,279.4,195.7,49.4,28.2,33,219.4,100.1,100.1,,,,,acquired by eisai in 2007,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021790,387,1272,238,44,Neoplasms of unspecified nature or uncertain behavior,1,1
709,TECHNETIUM TC 99M TILMANOCEPT,"99M-TC-TILMANOCEPT; 99M-TC-TILMANOCEPT; 99MTC-DTPA-MANNOSYL-DEXTRAN; 99MTC-PENTETATE-MANNOSYL-DEXTRAN; CY3-TILMANOCEPT; LYMPHOSEEK; LYMPHATIC TARGETING AGENT, NAVIDEA; LYMPHATIC TARGETING AGENT, NEOPROBE; TECHNETIUM TC 99M TILMANOCEPT; TILMANOCEPT; TILMANOCEPT-CY3","99M-TC-TILMANOCEPT; 99M-TC-TILMANOCEPT; 99MTC-DTPA-MANNOSYL-DEXTRAN; 99MTC-PENTETATE-MANNOSYL-DEXTRAN; CY3-TILMANOCEPT; LYMPHOSEEK; LYMPHATIC TARGETING AGENT, NAVIDEA; LYMPHATIC TARGETING AGENT, NEOPROBE; TECHNETIUM TC 99M TILMANOCEPT; TILMANOCEPT; TILMANOCEPT-CY3",TECHNETIUM TC 99M TILMANOCEPT,99M-TC-TILMANOCEPT,99M-TC-TILMANOCEPT,99MTC-DTPA-MANNOSYL-DEXTRAN,99MTC-PENTETATE-MANNOSYL-DEXTRAN,CY3-TILMANOCEPT,LYMPHOSEEK,"LYMPHATIC TARGETING AGENT, NAVIDEA","LYMPHATIC TARGETING AGENT, NEOPROBE",TECHNETIUM TC 99M TILMANOCEPT,TILMANOCEPT,TILMANOCEPT-CY3,,,,,,,,,,,,,,,,,,,,18141,TECHNETIUM TC-99M MEDRONATE KIT,18141,TECHNETIUM TC-99M MEDRONATE KIT,202207,TECHNETIUM TC-99M TILMANOCEPT,,,,,,,,,,,,,,,,,2013-03-13T00:00:00Z,2013,3,Lymphoseek Kit,breast tumor,MACROPHAGE MANNOSE RECEPTOR 1 MODULATOR,AUTOIMMUNE DIAGNOSTIC AGENT; CARDIOVASCULAR DIAGNOSTIC AGENT; ENDOCRINE DIAGNOSTIC AGENT; GASTROINTESTINAL DIAGNOSTIC AGENT; NEOPLASM DIAGNOSTIC AGENT; RADIODIAGNOSTIC; ULTRASOUND CONTRAST AGENT,FLUORESCENCE; IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING; SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),202207,NDA,2012-10-30T00:00:00Z,fda,0,0,0,0,0,,navidea biopharmaceuticals,NYSEMKT: NAVB,1,1.1,0.1,0.6,0.6,,7.6,0.8,23.7,23.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202207,65,49,239,44,Neoplasms of unspecified nature or uncertain behavior,1,1
253,ERIBULIN MESYLATE,"B-1793; B-1939; BOLD; E-7389; ER-076349; ER-086526; ER-094039; HALAVEN; NSC-707389; NSC-707390; ANTICANCER AGENT, EISAI/NCI; ERIBULIN; ERIBULIN MESILATE; ERIBULIN MESYLATE; HALICHONDRIN B ANALOGS, EISAI","B-1793; B-1939; BOLD; E-7389; ER-076349; ER-086526; ER-094039; HALAVEN; NSC-707389; NSC-707390; ANTICANCER AGENT, EISAI/NCI; ERIBULIN; ERIBULIN MESILATE; ERIBULIN MESYLATE; HALICHONDRIN B ANALOGS, EISAI",ERIBULIN MESYLATE,B-1793,B-1939,BOLD,E-7389,ER-076349,ER-086526,ER-094039,HALAVEN,NSC-707389,NSC-707390,"ANTICANCER AGENT, EISAI/NCI",ERIBULIN,ERIBULIN MESILATE,ERIBULIN MESYLATE,"HALICHONDRIN B ANALOGS, EISAI",,,,,,,,,,,,,,,,201532,ERIBULIN MESYLATE,,,,,,,,,,,,,,,,,,,,,2010-11-15T00:00:00Z,2010,11,Halaven,breast tumor,,ANTICANCER; CELL CYCLE INHIBITOR; MICROTUBULE INHIBITOR,INTRAVENOUS FORMULATION; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),201532,NDA,2010-03-30T00:00:00Z,fda,1,0,0,0,0,,eisai,TYO: 4523,1,10014.4,8460.4,8530.6,6546.8,5478,4907.5,7961.7,1782,1782,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201532,87,49,239,44,Neoplasms of unspecified nature or uncertain behavior,1,1
415,LENVATINIB MESYLATE,E-7080; ER-203492-00; HOPE; KISPLYX; KISPLYX; LENVIMA; LENVIMA; LENVATINIB; LENVATINIB MESYLATE,E-7080; ER-203492-00; HOPE; KISPLYX; KISPLYX; LENVIMA; LENVIMA; LENVATINIB; LENVATINIB MESYLATE,LENVATINIB MESYLATE,E-7080,ER-203492-00,HOPE,KISPLYX,KISPLYX,LENVIMA,LENVIMA,LENVATINIB,LENVATINIB MESYLATE,,,,,,,,,,,,,,,,,,,,,,206947,LENVATINIB MESYLATE,,,,,,,,,,,,,,,,,,,,,2015-02-13T00:00:00Z,2015,2,Lenvima,thyroid tumor,FGF1 RECEPTOR ANTAGONIST; FGF2 RECEPTOR ANTAGONIST; FGF3 RECEPTOR ANTAGONIST; FGF4 RECEPTOR ANTAGONIST; KIT TYROSINE KINASE INHIBITOR; PDGF RECEPTOR ALPHA ANTAGONIST; PDGF RECEPTOR BETA ANTAGONIST; RET TYROSINE KINASE RECEPTOR INHIBITOR; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),206947,NDA,2014-08-14T00:00:00Z,fda,1,0,0,1,0,,eisai,TYO: 4523,1,4712.4,4680.9,5612.5,6644.7,8576.2,10014.4,3050.3,1043.2,1043.2,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206947,294,1134,239,44,Neoplasms of unspecified nature or uncertain behavior,1,1
350,HEXAMINOLEVULINATE HYDROCHLORIDE,CERVIX; CYSVIEW; HEXVIX; HEXVIX PD; HEXAMINOLEVULINATE; HEXAMINOLEVULINATE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-05-28T00:00:00Z,2010,5,Cysview,bladder tumor,,ANTICANCER; IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT; PHOTOSENSITIZER,IMAGING; INTRAVESICAL FORMULATION,using only (2),022555,NDA,2010-03-31T00:00:00Z,fda,1,0,0,0,0,,photocure,OSE: PHO,1,30.5,8.9,5.3,18.2,33.8,8,28.9,15.5,15.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022555,680,42,239,44,Neoplasms of unspecified nature or uncertain behavior,1,1
401,IXABEPILONE,"BMS-247550; BMS-747550; IXEMPRA; NSC-710428; NSC-710468; ANTICANCER AGENTS, BMS/GBF; EPOTHILONE, BMS/GBF; IXABEPILONE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-10-16T00:00:00Z,2007,10,Ixempra,breast tumor,TUBULIN MODULATOR,ANTICANCER; CELL CYCLE INHIBITOR; MICROTUBULE INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),022065,NDA,2007-04-16T00:00:00Z,fda,1,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,15617,16208,18605,19380,18653,16208,10877,2998,3160,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022065,691,49,239,44,Neoplasms of unspecified nature or uncertain behavior,1,1
19,ALBIGLUTIDE,"716155; ALBUGON; EPERZAN; GSK-716155; SYNCRIA; TANZEUM; ALBIGLUTIDE; ALBUMIN-GLP-1 FUSION PROTEIN (DIABETES), HUMAN GENOME SCIENCES; RECOMBINANT GLUCAGON-LIKE PEPTIDE 1 (GLP, LONG ACTING), HUMAN GENOME SCIENCES","716155; ALBUGON; EPERZAN; GSK-716155; SYNCRIA; TANZEUM; ALBIGLUTIDE; ALBUMIN-GLP-1 FUSION PROTEIN (DIABETES), HUMAN GENOME SCIENCES; RECOMBINANT GLUCAGON-LIKE PEPTIDE 1 (GLP, LONG ACTING), HUMAN GENOME SCIENCES",ALBIGLUTIDE,716155,ALBUGON,EPERZAN,GSK-716155,SYNCRIA,TANZEUM,ALBIGLUTIDE,"ALBUMIN-GLP-1 FUSION PROTEIN (DIABETES), HUMAN GENOME SCIENCES","RECOMBINANT GLUCAGON-LIKE PEPTIDE 1 (GLP, LONG ACTING), HUMAN GENOME SCIENCES",,,,,,,,,,,,,,,,,,,,,,125431,ALBIGLUTIDE,,,,,,,,,,,,,,,,,,,,,2014-04-15T00:00:00Z,2014,4,Tanzeum,non-insulin dependent diabetes,GLUCAGON-LIKE PEPTIDE 1 AGONIST,HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; LIQUID FORMULATION; PROTEIN FUSION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION; WEEKLY DOSING,matched (3),125431,BLA,2013-01-14T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35854.4,43907.9,42959.8,42629,44331.3,45825.1,24441.7,5376.76,5376.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125431,40,837,250,50,Diabetes mellitus with complications,2,0
226,DULAGLUTIDE,"GLP-1 FC; GLP-1 ANALOG (TYPE 2 DIABETES), ELI LILLY; GLP-FC; LY-2189265; TRULICITY; TRULICITY ATEOS; TRULICITY ATEOS; DULAGLUTIDE","GLP-1 FC; GLP-1 ANALOG (TYPE 2 DIABETES), ELI LILLY; GLP-FC; LY-2189265; TRULICITY; TRULICITY ATEOS; TRULICITY ATEOS; DULAGLUTIDE",DULAGLUTIDE,GLP-1 FC,"GLP-1 ANALOG (TYPE 2 DIABETES), ELI LILLY",GLP-FC,LY-2189265,TRULICITY,TRULICITY ATEOS,TRULICITY ATEOS,DULAGLUTIDE,,,,,,,,,,,,,,,,,,,,,,,125469,DULAGLUTIDE,,,,,,,,,,,,,,,,,,,,,2014-09-18T00:00:00Z,2014,9,Trulicity,non-insulin dependent diabetes,GLUCAGON-LIKE PEPTIDE 1 AGONIST,HYPOGLYCEMIC AGENT,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; PROTEIN FUSION; SOLUTION; SUBCUTANEOUS FORMULATION; WEEKLY DOSING,matched (3),125469,BLA,2013-09-18T00:00:00Z,fda,0,0,0,0,0,,eli lilly,NYSE: LLY,1,19615.6,23113.1,22603.4,24286.5,23076,21836,14683.1,4733.6,4733.6,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469,43,837,250,50,Diabetes mellitus with complications,2,0
659,"SAXAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS","KOMBIGLYZE XR; RIAX-M; METFORMIN HYDROCHLORIDE + ONGLYZA; METFORMIN HYDROCHLORIDE + SAXAGLIPTIN HYDROCHLORIDE; SAXAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA; SAXAGLIPTIN HYDROCHLORIDE + EXTENDED-RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN HYDROCHLORIDE + METFORMIN HYDROCHLORIDE","KOMBIGLYZE XR; RIAX-M; METFORMIN HYDROCHLORIDE + ONGLYZA; METFORMIN HYDROCHLORIDE + SAXAGLIPTIN HYDROCHLORIDE; SAXAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA; SAXAGLIPTIN HYDROCHLORIDE + EXTENDED-RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN HYDROCHLORIDE + METFORMIN HYDROCHLORIDE","SAXAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS",KOMBIGLYZE XR,RIAX-M,METFORMIN HYDROCHLORIDE + ONGLYZA,METFORMIN HYDROCHLORIDE + SAXAGLIPTIN HYDROCHLORIDE,"SAXAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS","SAXAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA","SAXAGLIPTIN HYDROCHLORIDE + EXTENDED-RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ASTRAZENECA/BMS",SAXAGLIPTIN HYDROCHLORIDE + METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,200678,METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-11-05T00:00:00Z,2010,11,Kombiglyze XR,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200678,NDA,2009-12-29T00:00:00Z,fda,0,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,19484,18808,17715,15617,16208,18605,14320,3424,3556,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200678,78,837,250,50,Diabetes mellitus with complications,2,0
434,LINAGLIPTIN,BI-1356; BI-1356-BS; ONDERO; TRADJENTA; TRAJENTA; TRAYENTA; TRAZENTA; LINAGLIPTIN; LINAGLIPTINE,BI-1356; BI-1356-BS; ONDERO; TRADJENTA; TRAJENTA; TRAYENTA; TRAZENTA; LINAGLIPTIN; LINAGLIPTINE,LINAGLIPTIN,BI-1356,BI-1356-BS,ONDERO,TRADJENTA,TRAJENTA,TRAYENTA,TRAZENTA,LINAGLIPTIN,LINAGLIPTINE,,,,,,,,,,,,,,,,,,,,,,201280,LINAGLIPTIN,,,,,,,,,,,,,,,,,,,,,2011-05-02T00:00:00Z,2011,5,Tradjenta,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT; VULNERARY AGENT,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),201280,NDA,2010-07-02T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201280,82,837,250,50,Diabetes mellitus with complications,2,0
435,"LINAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM/ELI LILLY","BI-1356 + METFORMIN; BI-1356 + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; JENTADUETO; ONDERO + METFORMIN; ONDERO + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; ONDERO MET; ONDERO MET; TRAJENTA DUO; TRAJENTAMET; LINAGLIPTIN + METFORMIN; LINAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM/ELI LILLY; LINAGLIPTIN + METFORMIN IR; METFORMIN + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; METFORMIN + ONDERO (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; METFORMIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM","BI-1356 + METFORMIN; BI-1356 + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; JENTADUETO; ONDERO + METFORMIN; ONDERO + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; ONDERO MET; ONDERO MET; TRAJENTA DUO; TRAJENTAMET; LINAGLIPTIN + METFORMIN; LINAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM/ELI LILLY; LINAGLIPTIN + METFORMIN IR; METFORMIN + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; METFORMIN + ONDERO (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; METFORMIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM","LINAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM/ELI LILLY",BI-1356 + METFORMIN,"BI-1356 + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",JENTADUETO,ONDERO + METFORMIN,"ONDERO + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",ONDERO MET,ONDERO MET,TRAJENTA DUO,TRAJENTAMET,LINAGLIPTIN + METFORMIN,"LINAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM/ELI LILLY",LINAGLIPTIN + METFORMIN IR,"METFORMIN + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM","METFORMIN + ONDERO (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM","METFORMIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",,,,,,,,,,,,,,,,201281,LINAGLIPTIN; METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2012-01-30T00:00:00Z,2012,1,Jentadueto,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),201281,NDA,2011-01-19T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201281,83,837,250,50,Diabetes mellitus with complications,2,0
304,"FLUOCINOLONE ACETONIDE (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA","DIABETIC RETINOPATHY THERAPY (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA; ILUVIEN; MEDIDUR; MEDIDUR FA; DIABETIC MACULAR EDEMA THERAPY, ALIMERA/CONTROL DELIVERY SYSTEMS; FLUOCINOLONE ACETONIDE; FLUOCINOLONE ACETONIDE (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA","DIABETIC RETINOPATHY THERAPY (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA; ILUVIEN; MEDIDUR; MEDIDUR FA; DIABETIC MACULAR EDEMA THERAPY, ALIMERA/CONTROL DELIVERY SYSTEMS; FLUOCINOLONE ACETONIDE; FLUOCINOLONE ACETONIDE (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA","FLUOCINOLONE ACETONIDE (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA","DIABETIC RETINOPATHY THERAPY (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA",ILUVIEN,MEDIDUR,MEDIDUR FA,"DIABETIC MACULAR EDEMA THERAPY, ALIMERA/CONTROL DELIVERY SYSTEMS",FLUOCINOLONE ACETONIDE,"FLUOCINOLONE ACETONIDE (INTRAOCULAR IMPLANT, MEDIDUR), ALIMERA/PSIVIDA",,,,,,,,,,,,,,,,,,,,,,,,201923,FLUOCINOLONE ACETONIDE,,,,,,,,,,,,,,,,,,,,,2014-09-26T00:00:00Z,2014,9,Iluvien,diabetic macular edema,GLUCOCORTICOID AGONIST,ANTI-INFLAMMATORY; OPHTHALMOLOGICAL CORTICOSTEROID; STEROIDAL ANTI-INFLAMMATORY,CONTROLLED RELEASE FORMULATION; OPHTHALMIC DRUG IMPLANT; OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; SUSTAINED RELEASE FORMULATION,matched (3),201923,NDA,2010-06-30T00:00:00Z,fda,1,0,1,0,0,,alimera sciences,NASDAQ: ALIM,1,8.423,1.872,,,,,6.981,11.811,7.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201923,93,2659,250,50,Diabetes mellitus with complications,2,0
672,"SITAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES, MERCK & CO","JANUMET XR; MK-0431A XR; SITAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES, MERCK & CO","JANUMET XR; MK-0431A XR; SITAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES, MERCK & CO","SITAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES, MERCK & CO",JANUMET XR,MK-0431A XR,"SITAGLIPTIN + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES, MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,,,,,,202270,METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2012-02-02T00:00:00Z,2012,2,Janumet XR,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202270,NDA,2010-09-23T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,47267,48047,45987,27428,23850,24197.7,31009,7911,7968,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202270,108,837,250,50,Diabetes mellitus with complications,2,0
185,DAPAGLIFLOZIN PROPANEDIOL,"APPEBB; BMS-512148; BMS-512148-05; EDISTRIDE; FARXIGA; FORXIGA; OXRA; OXRA; SGLT-2 INHIBITOR (DIABETES), BMS; DAPAGLIFLOZIN; DAPAGLIFLOZIN PROPANEDIOL; DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE; SODIUM-GLUCOSE COTRANSPORTER INHIBITOR, BRISTOL-MYERS SQUIBB","APPEBB; BMS-512148; BMS-512148-05; EDISTRIDE; FARXIGA; FORXIGA; OXRA; OXRA; SGLT-2 INHIBITOR (DIABETES), BMS; DAPAGLIFLOZIN; DAPAGLIFLOZIN PROPANEDIOL; DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE; SODIUM-GLUCOSE COTRANSPORTER INHIBITOR, BRISTOL-MYERS SQUIBB",DAPAGLIFLOZIN PROPANEDIOL,APPEBB,BMS-512148,BMS-512148-05,EDISTRIDE,FARXIGA,FORXIGA,OXRA,OXRA,"SGLT-2 INHIBITOR (DIABETES), BMS",DAPAGLIFLOZIN,DAPAGLIFLOZIN PROPANEDIOL,DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE,"SODIUM-GLUCOSE COTRANSPORTER INHIBITOR, BRISTOL-MYERS SQUIBB",,,,,,,,,,,,,,,,,,202293,DAPAGLIFLOZIN PROPANEDIOL,202293,DAPAGLIFLOZIN PROPANEDIOL,,,,,,,,,,,,,,,,,,,2014-01-08T00:00:00Z,2014,1,Farxiga,non-insulin dependent diabetes,SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,HYPOGLYCEMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202293,NDA,2010-12-27T00:00:00Z,fda,0,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,15879,16385,17621,21244,19484,18808,12098,3913,4191,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202293,111,837,250,50,Diabetes mellitus with complications,2,0
674,"SITAGLIPTIN + SIMVASTATIN (DIABETES), MERCK & CO","JUVICOR; JUVISYNC; MK-0431D; MK-431D; TESOZOR; XELEZOR; SIMVASTATIN + JANUVIA; SIMVASTATIN + SITAGLIPTIN; SIMVASTATIN + SITAGLIPTIN PHOSPHATE; SITAGLIPTIN + SIMVASTATIN (DIABETES), MERCK & CO","JUVICOR; JUVISYNC; MK-0431D; MK-431D; TESOZOR; XELEZOR; SIMVASTATIN + JANUVIA; SIMVASTATIN + SITAGLIPTIN; SIMVASTATIN + SITAGLIPTIN PHOSPHATE; SITAGLIPTIN + SIMVASTATIN (DIABETES), MERCK & CO","SITAGLIPTIN + SIMVASTATIN (DIABETES), MERCK & CO",JUVICOR,JUVISYNC,MK-0431D,MK-431D,TESOZOR,XELEZOR,SIMVASTATIN + JANUVIA,SIMVASTATIN + SITAGLIPTIN,SIMVASTATIN + SITAGLIPTIN PHOSPHATE,"SITAGLIPTIN + SIMVASTATIN (DIABETES), MERCK & CO",,,,,,,,,,,,,,,,,,,,,202343,SIMVASTATIN; SITAGLIPTIN PHOSPHATE,21961,SIMVASTATIN,21961,SIMVASTATIN,21961,SIMVASTATIN,,,,,,,,,,,,,,,2011-10-07T00:00:00Z,2011,10,Juvisync,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR; HMG COA REDUCTASE INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT; LIPID METABOLISM MODULATOR,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202343,NDA,2010-12-06T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,48047,45987,27428,23850,24197.7,22636,31731,7742,7880,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202343,116,837,250,50,Diabetes mellitus with complications,2,0
382,INSULIN DEGLUDEC,"DEGLUDEC; NN-1250; SIBA; TRESIBA; TRESIBA; TRESIBA FLEXTOUCH; TRESIBA FLEXTOUCH; TRESIBA PENFIL; TRESIBA PENFIL; INSULIN DEGLUDEC; INSULIN-454; NEXT-GENERATION INSULIN ANALOG (DIABETES), NOVO NORDISK; SOLUBLE INSULIN BASAL ANALOG","DEGLUDEC; NN-1250; SIBA; TRESIBA; TRESIBA; TRESIBA FLEXTOUCH; TRESIBA FLEXTOUCH; TRESIBA PENFIL; TRESIBA PENFIL; INSULIN DEGLUDEC; INSULIN-454; NEXT-GENERATION INSULIN ANALOG (DIABETES), NOVO NORDISK; SOLUBLE INSULIN BASAL ANALOG",INSULIN DEGLUDEC,DEGLUDEC,NN-1250,SIBA,TRESIBA,TRESIBA,TRESIBA FLEXTOUCH,TRESIBA FLEXTOUCH,TRESIBA PENFIL,TRESIBA PENFIL,INSULIN DEGLUDEC,INSULIN-454,"NEXT-GENERATION INSULIN ANALOG (DIABETES), NOVO NORDISK",SOLUBLE INSULIN BASAL ANALOG,,,,,,,,,,,,,,,,,,203314,INSULIN DEGLUDEC,,,,,,,,,,,,,,,,,,,,,2015-09-25T00:00:00Z,2015,9,Tresiba,insulin dependent diabetes,INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN LONG ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; DAILY DOSING; PEPTIDE; SOLUTION; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),203314,NDA,2011-09-29T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,15706.8,14434,15428.3,13788.5,11595.7,10933.9,13350.9,1945.03,1980.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203314,150,836,250,50,Diabetes mellitus with complications,2,0
31,"ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","INISYNC; INISYNC; KAZANO; KAZANO; NESINA MET; NESINA MET; SYR-322 + METFORMIN (TYPE 2 DIABETES), TAKEDA; SYR-322 + METFORMIN HYDROCHLORIDE; SYR-322MET; VIPDOMET; VIPDOMET; ALOGLIPTIN + METFORMIN; ALOGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), TAKEDA; ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE; ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","INISYNC; INISYNC; KAZANO; KAZANO; NESINA MET; NESINA MET; SYR-322 + METFORMIN (TYPE 2 DIABETES), TAKEDA; SYR-322 + METFORMIN HYDROCHLORIDE; SYR-322MET; VIPDOMET; VIPDOMET; ALOGLIPTIN + METFORMIN; ALOGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), TAKEDA; ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE; ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA",INISYNC,INISYNC,KAZANO,KAZANO,NESINA MET,NESINA MET,"SYR-322 + METFORMIN (TYPE 2 DIABETES), TAKEDA",SYR-322 + METFORMIN HYDROCHLORIDE,SYR-322MET,VIPDOMET,VIPDOMET,ALOGLIPTIN + METFORMIN,"ALOGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), TAKEDA",ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE,"ALOGLIPTIN BENZOATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA",,,,,,,,,,,,,,,,203414,ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-01-25T00:00:00Z,2013,1,Kazano,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203414,NDA,2011-11-22T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15739.7,18156.3,19052,17491.2,15722.4,16561.7,11337.5,101,3147,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203414,156,837,250,50,Diabetes mellitus with complications,2,0
129,CANAGLIFLOZIN,"CANA; CANAGLU; INVOKANA; JNJ-28431754; SGLT-2 INHIBITOR (ORAL, DIABETES), JOHNSON & JOHNSON; SGLT-2 INHIBITORS (DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON; SGLT-2 INHIBITORS (DIABETES/OBESITY), TANABE/JOHNSON & JOHNSON; TA-7284; CANAGLIFLOZIN; CANAGLIFLOZIN (USAN); SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR (ORAL, DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON","CANA; CANAGLU; INVOKANA; JNJ-28431754; SGLT-2 INHIBITOR (ORAL, DIABETES), JOHNSON & JOHNSON; SGLT-2 INHIBITORS (DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON; SGLT-2 INHIBITORS (DIABETES/OBESITY), TANABE/JOHNSON & JOHNSON; TA-7284; CANAGLIFLOZIN; CANAGLIFLOZIN (USAN); SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR (ORAL, DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON",CANAGLIFLOZIN,CANA,CANAGLU,INVOKANA,JNJ-28431754,"SGLT-2 INHIBITOR (ORAL, DIABETES), JOHNSON & JOHNSON","SGLT-2 INHIBITORS (DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON","SGLT-2 INHIBITORS (DIABETES/OBESITY), TANABE/JOHNSON & JOHNSON",TA-7284,CANAGLIFLOZIN,CANAGLIFLOZIN (USAN),"SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR (ORAL, DIABETES/OBESITY), MITSUBISHI TANABE/JOHNSON & JOHNSON",,,,,,,,,,,,,,,,,,,,204042,CANAGLIFLOZIN,,,,,,,,,,,,,,,,,,,,,2013-03-29T00:00:00Z,2013,3,Invokana,non-insulin dependent diabetes,SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,HYPOGLYCEMIC AGENT,CAPSULE FORMULATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204042,NDA,2012-05-31T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,71312,67224,65030,61587,61897,63747,49070,8183,8183,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204042,179,837,250,50,Diabetes mellitus with complications,2,0
130,"CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT","INVOKAMET; VOKANAMET; CANAGLIFLOZIN + IMMEDIATE-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT; CANAGLIFLOZIN + METFORMIN; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), J&J PRD; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), MITSUBISHI TANABE PHARMA; METFORMIN IR + CANAGLIFLOZIN (ORAL, TYPE 2 DIABETES), J&J PRD","INVOKAMET; VOKANAMET; CANAGLIFLOZIN + IMMEDIATE-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT; CANAGLIFLOZIN + METFORMIN; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), J&J PRD; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT; CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), MITSUBISHI TANABE PHARMA; METFORMIN IR + CANAGLIFLOZIN (ORAL, TYPE 2 DIABETES), J&J PRD","CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT",INVOKAMET,VOKANAMET,"CANAGLIFLOZIN + IMMEDIATE-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT",CANAGLIFLOZIN + METFORMIN,"CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), J&J PRD","CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT","CANAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), MITSUBISHI TANABE PHARMA","METFORMIN IR + CANAGLIFLOZIN (ORAL, TYPE 2 DIABETES), J&J PRD",,,,,,,,,,,,,,,,,,,,,,,204353,CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-08-08T00:00:00Z,2014,8,Invokamet,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204353,NDA,2012-12-12T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,74331,71312,67224,65030,61587,61897,51585,8494,8494,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204353,194,837,250,50,Diabetes mellitus with complications,2,0
241,EMPAGLIFLOZIN,"BI-10773; GIBTULIO; GIBTULIO; JARDIANCE; SGLT-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM","BI-10773; GIBTULIO; GIBTULIO; JARDIANCE; SGLT-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM",EMPAGLIFLOZIN,BI-10773,GIBTULIO,GIBTULIO,JARDIANCE,"SGLT-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM",EMPAGLIFLOZIN,"SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR (DIABETES), BOEHRINGER INGELHEIM",,,,,,,,,,,,,,,,,,,,,,,,204629,EMPAGLIFLOZIN,,,,,,,,,,,,,,,,,,,,,2014-08-01T00:00:00Z,2014,8,Jardiance,non-insulin dependent diabetes,SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,HYPOGLYCEMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204629,NDA,2013-03-05T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204629,207,837,250,50,Diabetes mellitus with complications,2,0
184,"DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA","EBYMECT; OXRAMET; XIGDUO XR; XIGDUO; DAPAGLIFLOZIN + METFORMIN; DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA; DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB; DAPAGLIFLOZIN + METFORMIN IR (DIABETES), ASTRAZENECA/BMS; DAPAGLIFLOZIN + METFORMIN XR (DIABETES), ASTRAZENECA/BMS","EBYMECT; OXRAMET; XIGDUO XR; XIGDUO; DAPAGLIFLOZIN + METFORMIN; DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA; DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB; DAPAGLIFLOZIN + METFORMIN IR (DIABETES), ASTRAZENECA/BMS; DAPAGLIFLOZIN + METFORMIN XR (DIABETES), ASTRAZENECA/BMS","DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA",EBYMECT,OXRAMET,XIGDUO XR,XIGDUO,DAPAGLIFLOZIN + METFORMIN,"DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA","DAPAGLIFLOZIN + METFORMIN (DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB","DAPAGLIFLOZIN + METFORMIN IR (DIABETES), ASTRAZENECA/BMS","DAPAGLIFLOZIN + METFORMIN XR (DIABETES), ASTRAZENECA/BMS",,,,,,,,,,,,,,,,,,,,,,205649,DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-10-29T00:00:00Z,2014,10,Xigduo XR,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205649,NDA,2013-10-29T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,26547,25806,27973,33591,33269,32804,20812,5001,5438,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205649,248,837,250,50,Diabetes mellitus with complications,2,0
387,"INSULIN GLARGINE BIOSIMILAR, ELI LILLY/BOEHRINGER","ABASAGLAR; ABASRIA; BASAGLAR; LY IGLAR; LY-2963016; INSULIN GLARGINE; INSULIN GLARGINE BIOSIMILAR, ELI LILLY/BOEHRINGER; INSULIN GLARGINE PRODUCT (BASAL INSULIN, DIABETES, SC), ELI LILLY/BOEHRINGER INGELHEIM","ABASAGLAR; ABASRIA; BASAGLAR; LY IGLAR; LY-2963016; INSULIN GLARGINE; INSULIN GLARGINE BIOSIMILAR, ELI LILLY/BOEHRINGER; INSULIN GLARGINE PRODUCT (BASAL INSULIN, DIABETES, SC), ELI LILLY/BOEHRINGER INGELHEIM","INSULIN GLARGINE BIOSIMILAR, ELI LILLY/BOEHRINGER",ABASAGLAR,ABASRIA,BASAGLAR,LY IGLAR,LY-2963016,INSULIN GLARGINE,"INSULIN GLARGINE BIOSIMILAR, ELI LILLY/BOEHRINGER","INSULIN GLARGINE PRODUCT (BASAL INSULIN, DIABETES, SC), ELI LILLY/BOEHRINGER INGELHEIM",,,,,,,,,,,,,,,,,,,,,,,205692,INSULIN GLARGINE,,,,,,,,,,,,,,,,,,,,,2015-12-16T00:00:00Z,2015,12,Basaglar,insulin dependent diabetes,INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN LONG ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),205692,NDA,2014-10-17T00:00:00Z,fda,0,0,0,0,0,,eli lilly,NYSE: LLY,1,19958.7,19615.6,23113.1,22603.4,24286.5,23076,15074.5,4796.4,4796.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205692,250,836,250,50,Diabetes mellitus with complications,2,0
242,"EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","BI-10773 + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; BI-10773 + LINAGLIPTIN; BI-10773 + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM; BI-10773 + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; GLYXAMBI; EMPAGLIFLOZIN + LINAGLIPTIN; EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","BI-10773 + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; BI-10773 + LINAGLIPTIN; BI-10773 + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM; BI-10773 + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; GLYXAMBI; EMPAGLIFLOZIN + LINAGLIPTIN; EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","BI-10773 + BI-1356 (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",BI-10773 + LINAGLIPTIN,"BI-10773 + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM","BI-10773 + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",GLYXAMBI,EMPAGLIFLOZIN + LINAGLIPTIN,"EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, FIXED-DOSE COMBINATION), BOEHRINGER INGELHEIM","EMPAGLIFLOZIN + LINAGLIPTIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY",,,,,,,,,,,,,,,,,,,,,,,206073,EMPAGLIFLOZIN; LINAGLIPTIN,,,,,,,,,,,,,,,,,,,,,2015-01-30T00:00:00Z,2015,1,Glyxambi,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206073,NDA,2014-01-29T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206073,268,837,250,50,Diabetes mellitus with complications,2,0
243,"EMPAGLIFLOZIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","BI-10773 + METFORMIN; BI-10773 + METFORMIN IR (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; JARDIANCE DUO; SYNJARDY; EMPAGLIFLOZIN + METFORMIN; EMPAGLIFLOZIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY; EMPAGLIFLOZIN + METFORMIN (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY; EMPAGLIFLOZIN + METFORMIN IMMEDIATE-RELEASE (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","BI-10773 + METFORMIN; BI-10773 + METFORMIN IR (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; JARDIANCE DUO; SYNJARDY; EMPAGLIFLOZIN + METFORMIN; EMPAGLIFLOZIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY; EMPAGLIFLOZIN + METFORMIN (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM; EMPAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY; EMPAGLIFLOZIN + METFORMIN IMMEDIATE-RELEASE (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","EMPAGLIFLOZIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY",BI-10773 + METFORMIN,"BI-10773 + METFORMIN IR (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM",JARDIANCE DUO,SYNJARDY,EMPAGLIFLOZIN + METFORMIN,"EMPAGLIFLOZIN + METFORMIN (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","EMPAGLIFLOZIN + METFORMIN (TABLET, TYPE 2 DIABETES), BOEHRINGER INGELHEIM","EMPAGLIFLOZIN + METFORMIN IR (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY","EMPAGLIFLOZIN + METFORMIN IMMEDIATE-RELEASE (ORAL, TYPE 2 DIABETES), BOEHRINGER/ELI LILLY",,,,,,,,,,,,,,,,,,,,,,206111,EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-08-26T00:00:00Z,2015,8,Synjardy,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206111,NDA,2014-08-04T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206111,270,837,250,50,Diabetes mellitus with complications,2,0
385,"INSULIN GLARGINE (NEW FORMULATION), SANOFI","EDOMLUS; GLA-300; GLARGINE U300; HOE901-U300; LAMBETO; LANTUS XR; LANTUS XR; LANTUS XR INJECTION SOLOSTAR; LANTUS XR INJECTION SOLOSTAR; LANTUX XR SOLOSTAR; LANTUX XR SOLOSTAR; TOUJEO; TOUJEO; TOUJEO SOLOSTAR; TOUJEO SOLOSTAR; INSULIN GLARGINE; INSULIN GLARGINE (NEW FORMULATION), SANOFI; NEW INSULIN U300","EDOMLUS; GLA-300; GLARGINE U300; HOE901-U300; LAMBETO; LANTUS XR; LANTUS XR; LANTUS XR INJECTION SOLOSTAR; LANTUS XR INJECTION SOLOSTAR; LANTUX XR SOLOSTAR; LANTUX XR SOLOSTAR; TOUJEO; TOUJEO; TOUJEO SOLOSTAR; TOUJEO SOLOSTAR; INSULIN GLARGINE; INSULIN GLARGINE (NEW FORMULATION), SANOFI; NEW INSULIN U300","INSULIN GLARGINE (NEW FORMULATION), SANOFI",EDOMLUS,GLA-300,GLARGINE U300,HOE901-U300,LAMBETO,LANTUS XR,LANTUS XR,LANTUS XR INJECTION SOLOSTAR,LANTUS XR INJECTION SOLOSTAR,LANTUX XR SOLOSTAR,LANTUX XR SOLOSTAR,TOUJEO,TOUJEO,TOUJEO SOLOSTAR,TOUJEO SOLOSTAR,INSULIN GLARGINE,"INSULIN GLARGINE (NEW FORMULATION), SANOFI",NEW INSULIN U300,,,,,,,,,,,,,206538,INSULIN GLARGINE RECOMBINANT,,,,,,,,,,,,,,,,,,,,,2015-02-25T00:00:00Z,2015,2,Toujeo Solostar,insulin dependent diabetes,INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN INTERMEDIATE ACTING PRODUCT; HUMAN INSULIN LONG ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),206538,NDA,2014-04-25T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,37861.5,38732.7,43091.6,47408.5,45544.7,45640,26002.7,5519.41,5519.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206538,287,836,250,50,Diabetes mellitus with complications,2,0
440,LIXISENATIDE,"AQVE-0010; AVE-0010; AVE-0010 IR; AVE-010; ADLYXIN; ADLYXIN; GLP-1 ANALOGS, ZEALAND/ELAN; GLP-1 THERAPY, AVENTIS; GLP-1 THERAPY, ZEALAND/ELAN; GLP-1 THERAPY, SANOFI-AVENTIS; LYXUMIA; LYXUMIA PEN; ZP-10; DES-PRO36-EXENDIN-4(1-39)-LYS6-NH2; LIXISENATIDE; ZP-10A","AQVE-0010; AVE-0010; AVE-0010 IR; AVE-010; ADLYXIN; ADLYXIN; GLP-1 ANALOGS, ZEALAND/ELAN; GLP-1 THERAPY, AVENTIS; GLP-1 THERAPY, ZEALAND/ELAN; GLP-1 THERAPY, SANOFI-AVENTIS; LYXUMIA; LYXUMIA PEN; ZP-10; DES-PRO36-EXENDIN-4(1-39)-LYS6-NH2; LIXISENATIDE; ZP-10A",LIXISENATIDE,AQVE-0010,AVE-0010,AVE-0010 IR,AVE-010,ADLYXIN,ADLYXIN,"GLP-1 ANALOGS, ZEALAND/ELAN","GLP-1 THERAPY, AVENTIS","GLP-1 THERAPY, ZEALAND/ELAN","GLP-1 THERAPY, SANOFI-AVENTIS",LYXUMIA,LYXUMIA PEN,ZP-10,DES-PRO36-EXENDIN-4(1-39)-LYS6-NH2,LIXISENATIDE,ZP-10A,,,,,,,,,,,,,,,208471,LIXISENATIDE,,,,,,,,,,,,,,,,,,,,,2016-07-27T00:00:00Z,2016,7,Adlyxin,non-insulin dependent diabetes,EXENDIN 4 LIGAND; GLUCAGON-LIKE PEPTIDE 1 AGONIST,HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; DAILY DOSING; PEPTIDE; SUBCUTANEOUS FORMULATION,matched (3),208471,NDA,2015-07-27T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,36638.9,37861.5,38732.7,43091.6,47408.5,45544.7,25341.5,5459.73,5459.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471,346,837,250,50,Diabetes mellitus with complications,2,0
384,"INSULIN DEGLUDEC + LIRAGLUTIDE (DIABETES), NOVO NORDISK","IDEGLIRA; NN-1250 + VICTOZA (DIABETES), NOVO NORDISK; NN-9068; XULTOPHY; XULTOPHY; XULTOPHY 100/3.6; INSULIN DEGLUDEC + LIRAGLUTIDE; INSULIN DEGLUDEC + LIRAGLUTIDE (DIABETES), NOVO NORDISK","IDEGLIRA; NN-1250 + VICTOZA (DIABETES), NOVO NORDISK; NN-9068; XULTOPHY; XULTOPHY; XULTOPHY 100/3.6; INSULIN DEGLUDEC + LIRAGLUTIDE; INSULIN DEGLUDEC + LIRAGLUTIDE (DIABETES), NOVO NORDISK","INSULIN DEGLUDEC + LIRAGLUTIDE (DIABETES), NOVO NORDISK",IDEGLIRA,"NN-1250 + VICTOZA (DIABETES), NOVO NORDISK",NN-9068,XULTOPHY,XULTOPHY,XULTOPHY 100/3.6,INSULIN DEGLUDEC + LIRAGLUTIDE,"INSULIN DEGLUDEC + LIRAGLUTIDE (DIABETES), NOVO NORDISK",,,,,,,,,,,,,,,,,,,,,,,208583,INSULIN DEGLUDEC; LIRAGLUTIDE,,,,,,,,,,,,,,,,,,,,,2016-11-21T00:00:00Z,2016,11,Xultophy 100/3.6,non-insulin dependent diabetes,GLUCAGON-LIKE PEPTIDE 1 AGONIST; INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN LONG ACTING PRODUCT; HYPOGLYCEMIC AGENT; INSULIN RELEASE STIMULATOR,BIOLOGICAL THERAPEUTIC; DRUG COMBINATION; PEPTIDE; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),208583,NDA,2016-09-12T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,15871.3,15706.8,14434,15428.3,13788.5,11595.7,13431.5,2008.69,2067.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208583,350,837,250,50,Diabetes mellitus with complications,2,0
110,"BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), VEROSCIENCE","CYCLOSET; ERGOSET; PLD-165; BROMOCRIPTINE; BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), PLIVA; BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), VEROSCIENCE; BROMOCRIPTINE, ERGO SCIENCE","CYCLOSET; ERGOSET; PLD-165; BROMOCRIPTINE; BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), PLIVA; BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), VEROSCIENCE; BROMOCRIPTINE, ERGO SCIENCE","BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), VEROSCIENCE",CYCLOSET,ERGOSET,PLD-165,BROMOCRIPTINE,"BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), PLIVA","BROMOCRIPTINE (ORAL IMMEDIATE RELEASE, DIABETES), VEROSCIENCE","BROMOCRIPTINE, ERGO SCIENCE",,,,,,,,,,,,,,,,,,,,,,,,20866,BROMOCRIPTINE MESYLATE,,,,,,,,,,,,,,,,,,,,,2009-05-05T00:00:00Z,2009,5,Cycloset,non-insulin dependent diabetes,ADRENOCEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR AGONIST,HYPOGLYCEMIC AGENT; INSULIN RELEASE INHIBITOR,ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),020866,NDA,1997-08-22T00:00:00Z,fda,0,0,0,0,0,,veroscience,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020866,351,837,250,50,Diabetes mellitus with complications,2,0
658,"SAXAGLIPTIN + DAPAGLIFLOZIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA","ONGLYZA + FORXIGA FDC; QTERN; SAXADAPA; SAXAGLIPTIN + DAPAGLIFLOZIN; SAXAGLIPTIN + DAPAGLIFLOZIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA; SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB; SAXAGLIPTIN HYDROCHLORIDE + DAPAGLIFLOZIN PROPANEDIOL","ONGLYZA + FORXIGA FDC; QTERN; SAXADAPA; SAXAGLIPTIN + DAPAGLIFLOZIN; SAXAGLIPTIN + DAPAGLIFLOZIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA; SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BMS; SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB; SAXAGLIPTIN HYDROCHLORIDE + DAPAGLIFLOZIN PROPANEDIOL","SAXAGLIPTIN + DAPAGLIFLOZIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA",ONGLYZA + FORXIGA FDC,QTERN,SAXADAPA,SAXAGLIPTIN + DAPAGLIFLOZIN,"SAXAGLIPTIN + DAPAGLIFLOZIN (ORAL, TYPE 2 DIABETES), ASTRAZENECA","SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BMS","SAXAGLIPTIN + DAPAGLIFLOZIN (TYPE 2 DIABETES), ASTRAZENECA/BRISTOL-MYERS SQUIBB",SAXAGLIPTIN HYDROCHLORIDE + DAPAGLIFLOZIN PROPANEDIOL,,,,,,,,,,,,,,,,,,,,,,,209091,DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2017-02-27T00:00:00Z,2017,2,Qtern,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN SENSITIZER; SODIUM GLUCOSE TRANSPORTER-2 INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),209091,NDA,2016-04-27T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,21620,23002,24708,26547,25806,27973,18196,5396,5812,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209091,355,837,250,50,Diabetes mellitus with complications,2,0
593,"PIOGLITAZONE + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA","ACTOPLUS MET XR; ACTOS + FORTAMET; COMPETACT; METACT; PIOGLITAZONE + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA; PIOGLITAZONE + METFORMIN (EXTENDED RELEASE), ANDRX/TAKEDA; PIOGLITAZONE HYDROCHLORIDE + EXTENDED RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA; PIOGLITAZONE HYDROCHLORIDE + METFORMIN HYDROCHLORIDE","ACTOPLUS MET XR; ACTOS + FORTAMET; COMPETACT; METACT; PIOGLITAZONE + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA; PIOGLITAZONE + METFORMIN (EXTENDED RELEASE), ANDRX/TAKEDA; PIOGLITAZONE HYDROCHLORIDE + EXTENDED RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA; PIOGLITAZONE HYDROCHLORIDE + METFORMIN HYDROCHLORIDE","PIOGLITAZONE + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA",ACTOPLUS MET XR,ACTOS + FORTAMET,COMPETACT,METACT,"PIOGLITAZONE + EXTENDED-RELEASE METFORMIN (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA","PIOGLITAZONE + METFORMIN (EXTENDED RELEASE), ANDRX/TAKEDA","PIOGLITAZONE HYDROCHLORIDE + EXTENDED RELEASE METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), ANDRX/TAKEDA",PIOGLITAZONE HYDROCHLORIDE + METFORMIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,21842,METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-05-12T00:00:00Z,2009,5,Actoplus Met XR,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; PPAR GAMMA AGONIST,BIGUANIDE ANTIDIABETIC PRODUCT; GLITAZONE COMBINATION ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022024,NDA,2006-03-31T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15722.4,16561.7,12303.5,10759.3,10070.7,10838.9,12683.2,-1808.2,1341.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022024,393,837,250,50,Diabetes mellitus with complications,2,0
671,SITAGLIPTIN,"DPP-IV INHIBITORS, MERCK & CO; GLACTIVE; JANUVIA; MK-0431; MK-431; ONO-5345; ONO-5435; RISTABEN; TESAVEL; XELEVIA; DIPEPTIDYL PEPTIDASE IV INHIBITORS, MERCK & CO; SITAGLIPTIN; SITAGLIPTIN PHOSPHATE; SITAGLIPTIN PHOSPHATE MONOHYDRATE","DPP-IV INHIBITORS, MERCK & CO; GLACTIVE; JANUVIA; MK-0431; MK-431; ONO-5345; ONO-5435; RISTABEN; TESAVEL; XELEVIA; DIPEPTIDYL PEPTIDASE IV INHIBITORS, MERCK & CO; SITAGLIPTIN; SITAGLIPTIN PHOSPHATE; SITAGLIPTIN PHOSPHATE MONOHYDRATE",SITAGLIPTIN,"DPP-IV INHIBITORS, MERCK & CO",GLACTIVE,JANUVIA,MK-0431,MK-431,ONO-5345,ONO-5435,RISTABEN,TESAVEL,XELEVIA,"DIPEPTIDYL PEPTIDASE IV INHIBITORS, MERCK & CO",SITAGLIPTIN,SITAGLIPTIN PHOSPHATE,SITAGLIPTIN PHOSPHATE MONOHYDRATE,,,,,,,,,,,,,,,,,21995,SITAGLIPTIN PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2006-10-16T00:00:00Z,2006,10,Januvia,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; GLUCAGON-LIKE PEPTIDE 1 METABOLISM MODULATOR; HYPOGLYCEMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021995,NDA,2005-12-16T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,22636,22011.9,22972.8,22485.9,21445.8,21199,17371.3,3963.6,4020.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021995,430,837,250,50,Diabetes mellitus with complications,2,0
673,"SITAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), MERCK & CO","EFFICIB; GLACTIV + METFORMIN (ORAL), ONO PHARMACEUTICAL/MERCK & CO; GLACTIV + METFORMIN HYDROCHLORIDE; JANUMET; MK-0431A; MK-431 + METFORMIN (ORAL), MERCK & CO; MK-431A; ONO-5435A; RISTFOR; VELMETIA; SITAGLIPTIN + METFORMIN (ORAL), MERCK & CO; SITAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), MERCK & CO; SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), MERCK & CO","EFFICIB; GLACTIV + METFORMIN (ORAL), ONO PHARMACEUTICAL/MERCK & CO; GLACTIV + METFORMIN HYDROCHLORIDE; JANUMET; MK-0431A; MK-431 + METFORMIN (ORAL), MERCK & CO; MK-431A; ONO-5435A; RISTFOR; VELMETIA; SITAGLIPTIN + METFORMIN (ORAL), MERCK & CO; SITAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), MERCK & CO; SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), MERCK & CO","SITAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), MERCK & CO",EFFICIB,"GLACTIV + METFORMIN (ORAL), ONO PHARMACEUTICAL/MERCK & CO",GLACTIV + METFORMIN HYDROCHLORIDE,JANUMET,MK-0431A,"MK-431 + METFORMIN (ORAL), MERCK & CO",MK-431A,ONO-5435A,RISTFOR,VELMETIA,"SITAGLIPTIN + METFORMIN (ORAL), MERCK & CO","SITAGLIPTIN + METFORMIN (ORAL, TYPE 2 DIABETES), MERCK & CO",SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE,"SITAGLIPTIN PHOSPHATE + METFORMIN HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), MERCK & CO",,,,,,,,,,,,,,,,,22044,METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2007-03-30T00:00:00Z,2007,3,Janumet,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR,BIGUANIDE ANTIDIABETIC PRODUCT; DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022044,NDA,2006-05-31T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,24197.7,22636,22011.9,22972.8,22485.9,21445.8,18540.1,4557.8,4557.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022044,451,837,250,50,Diabetes mellitus with complications,2,0
266,"EXENATIDE (CONTROLLED-RELEASE, MEDISORB), ASTRAZENECA","AC-2993 LAR; BYDUREON; BYETTA EQW; BYETTA LAR; MEDISORB (AC-2993); EXENATIDE; EXENATIDE (CONTROLLED-RELEASE, MEDISORB), ASTRAZENECA; EXENATIDE LAR; EXENATIDE ONCE WEEKLY; EXENDIN-4 (CONTROLLED-RELEASE, MEDISORB), ALKERMES/AMYLIN","AC-2993 LAR; BYDUREON; BYETTA EQW; BYETTA LAR; MEDISORB (AC-2993); EXENATIDE; EXENATIDE (CONTROLLED-RELEASE, MEDISORB), ASTRAZENECA; EXENATIDE LAR; EXENATIDE ONCE WEEKLY; EXENDIN-4 (CONTROLLED-RELEASE, MEDISORB), ALKERMES/AMYLIN","EXENATIDE (CONTROLLED-RELEASE, MEDISORB), ASTRAZENECA",AC-2993 LAR,BYDUREON,BYETTA EQW,BYETTA LAR,MEDISORB (AC-2993),EXENATIDE,"EXENATIDE (CONTROLLED-RELEASE, MEDISORB), ASTRAZENECA",EXENATIDE LAR,EXENATIDE ONCE WEEKLY,"EXENDIN-4 (CONTROLLED-RELEASE, MEDISORB), ALKERMES/AMYLIN",,,,,,,,,,,,,,,,,,,,,22200,EXENATIDE SYNTHETIC,,,,,,,,,,,,,,,,,,,,,2012-01-27T00:00:00Z,2012,1,Bydureon,non-insulin dependent diabetes,EXENDIN 4 LIGAND; GLUCAGON-LIKE PEPTIDE 1 AGONIST,HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; INJECTABLE CONTROLLED RELEASE FORMULATION; PEPTIDE; SUBCUTANEOUS FORMULATION; SUSPENSION; SUSTAINED RELEASE FORMULATION; WEEKLY DOSING,matched (3),022200,NDA,2009-05-04T00:00:00Z,fda,0,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,17621,650.7,668.8,758.4,769.6,720.7,13067,3688,3762,,,2012,,acquired by bristol-myers squibb in 2012  and then acquired by astrazeneca in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022200,493,837,250,50,Diabetes mellitus with complications,2,0
30,ALOGLIPTIN BENZOATE,"DPP-IV INHIBITORS (DIABETES), SYRRX/PPD; DPP-INHIBITORS (DIABETES), TAKEDA SAN DIEGO; NESINA; SYR-085; SYR-110085A; SYR-110322; SYR-111791; SYR-11792; SYR-322; SYR-619; TAK-322; VIPIDIA; ALOGLIPTIN; ALOGLIPTIN BENZOATE; DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), SYRRX/PPD; DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), TAKEDA SAN DIEGO","DPP-IV INHIBITORS (DIABETES), SYRRX/PPD; DPP-INHIBITORS (DIABETES), TAKEDA SAN DIEGO; NESINA; SYR-085; SYR-110085A; SYR-110322; SYR-111791; SYR-11792; SYR-322; SYR-619; TAK-322; VIPIDIA; ALOGLIPTIN; ALOGLIPTIN BENZOATE; DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), SYRRX/PPD; DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), TAKEDA SAN DIEGO",ALOGLIPTIN BENZOATE,"DPP-IV INHIBITORS (DIABETES), SYRRX/PPD","DPP-INHIBITORS (DIABETES), TAKEDA SAN DIEGO",NESINA,SYR-085,SYR-110085A,SYR-110322,SYR-111791,SYR-11792,SYR-322,SYR-619,TAK-322,VIPIDIA,ALOGLIPTIN,ALOGLIPTIN BENZOATE,"DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), SYRRX/PPD","DIPEPTIDYL PEPTIDASE-IV INHIBITORS (DIABETES), TAKEDA SAN DIEGO",,,,,,,,,,,,,,,22271,ALOGLIPTIN BENZOATE,,,,,,,,,,,,,,,,,,,,,2013-01-25T00:00:00Z,2013,1,Nesina,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022271,NDA,2007-12-27T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15739.7,18156.3,19052,17491.2,15722.4,16561.7,11337.5,101,3147,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022271,518,837,250,50,Diabetes mellitus with complications,2,0
436,LIRAGLUTIDE,"GLP-1 ANALOG, SCIOS/NOVO NORDISK; LATIN T1D; NN-2211; NN-8022; NN-9211; NNC-90-1170; SAXENDA; SAXENDA; VICTOZA; INSULINOTROPIN ANALOG, SCIOS/NOVO NORDISK; LIRAGLUTIDE; RECOMBINANT GLUCAGON-LIKE PEPTIDE 1, SCIOS/NOVO NORDISK","GLP-1 ANALOG, SCIOS/NOVO NORDISK; LATIN T1D; NN-2211; NN-8022; NN-9211; NNC-90-1170; SAXENDA; SAXENDA; VICTOZA; INSULINOTROPIN ANALOG, SCIOS/NOVO NORDISK; LIRAGLUTIDE; RECOMBINANT GLUCAGON-LIKE PEPTIDE 1, SCIOS/NOVO NORDISK",LIRAGLUTIDE,"GLP-1 ANALOG, SCIOS/NOVO NORDISK",LATIN T1D,NN-2211,NN-8022,NN-9211,NNC-90-1170,SAXENDA,SAXENDA,VICTOZA,"INSULINOTROPIN ANALOG, SCIOS/NOVO NORDISK",LIRAGLUTIDE,"RECOMBINANT GLUCAGON-LIKE PEPTIDE 1, SCIOS/NOVO NORDISK",,,,,,,,,,,,,,,,,,,206321,LIRAGLUTIDE RECOMBINANT,22341,LIRAGLUTIDE RECOMBINANT,,,,,,,,,,,,,,,,,,,2010-01-25T00:00:00Z,2010,1,Victoza,non-insulin dependent diabetes,GLUCAGON-LIKE PEPTIDE 1 AGONIST,ANTI-INFLAMMATORY; ANTIARTERIOSCLEROTIC; ANTIPARKINSONIAN; CARDIOPROTECTANT; HYPOGLYCEMIC AGENT; NEUROPROTECTANT,BIOLOGICAL THERAPEUTIC; PEPTIDE; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),022341,NDA,2008-03-23T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,10933.9,9837.83,8546.85,8188.19,6856.93,5360.01,8832.6,1727.44,1727.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341,534,837,250,50,Diabetes mellitus with complications,2,0
657,SAXAGLIPTIN,"BMS-477118; BMS-510849; DPP-IV INHIBITORS, BMS; DPP-IV INHIBITORS, BRISTOL-MYERS SQUIBB; OPC-262; ONGLYZA; RIAX; DIPEPTIDYL PEPTIDASE IV INHIBITORS, BRISTOL-MYERS SQUIBB; SAXAGLIPTIN; SAXAGLIPTIN (USAN); SAXAGLIPTIN HYDRATE; SAXAGLIPTIN HYDROCHLORIDE","BMS-477118; BMS-510849; DPP-IV INHIBITORS, BMS; DPP-IV INHIBITORS, BRISTOL-MYERS SQUIBB; OPC-262; ONGLYZA; RIAX; DIPEPTIDYL PEPTIDASE IV INHIBITORS, BRISTOL-MYERS SQUIBB; SAXAGLIPTIN; SAXAGLIPTIN (USAN); SAXAGLIPTIN HYDRATE; SAXAGLIPTIN HYDROCHLORIDE",SAXAGLIPTIN,BMS-477118,BMS-510849,"DPP-IV INHIBITORS, BMS","DPP-IV INHIBITORS, BRISTOL-MYERS SQUIBB",OPC-262,ONGLYZA,RIAX,"DIPEPTIDYL PEPTIDASE IV INHIBITORS, BRISTOL-MYERS SQUIBB",SAXAGLIPTIN,SAXAGLIPTIN (USAN),SAXAGLIPTIN HYDRATE,SAXAGLIPTIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,22350,SAXAGLIPTIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-07-31T00:00:00Z,2009,7,Onglyza,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN SENSITIZER,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022350,NDA,2008-06-30T00:00:00Z,fda,0,0,0,0,0,,bristol-myers squibb,NYSE: BMY,1,18808,17715,15617,16208,18605,19380,13791,3300,3647,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022350,537,837,250,50,Diabetes mellitus with complications,2,0
629,"REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/SHIONOGI PHARMA","METPRANDIN; NN-4440; NOVOGARD; NOVOMET; PRANDIMET; PRANDIN + METFORMIN (ORAL, DIABETES), NOVO NORDISK; REPAGLINIDE + METFORMIN; REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/ SCIELE PHARMA; REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/SHIONOGI PHARMA","METPRANDIN; NN-4440; NOVOGARD; NOVOMET; PRANDIMET; PRANDIN + METFORMIN (ORAL, DIABETES), NOVO NORDISK; REPAGLINIDE + METFORMIN; REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/ SCIELE PHARMA; REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/SHIONOGI PHARMA","REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/SHIONOGI PHARMA",METPRANDIN,NN-4440,NOVOGARD,NOVOMET,PRANDIMET,"PRANDIN + METFORMIN (ORAL, DIABETES), NOVO NORDISK",REPAGLINIDE + METFORMIN,"REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/ SCIELE PHARMA","REPAGLINIDE + METFORMIN (ORAL, DIABETES), NOVO NORDISK/SHIONOGI PHARMA",,,,,,,,,,,,,,,,,,,,,,22386,METFORMIN HYDROCHLORIDE; REPAGLINIDE,,,,,,,,,,,,,,,,,,,,,2008-06-23T00:00:00Z,2008,6,Prandimet,non-insulin dependent diabetes,AMP ACTIVATED PROTEIN KINASE STIMULATOR,HYPOGLYCEMIC AGENT; INSULIN RELEASE STIMULATOR; OTHER ORAL ANTIDIABETIC PRODUCT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022386,NDA,2008-05-23T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,8546.85,8188.19,6856.93,5360.01,5284.13,4422.32,6650.16,1473.98,1562.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022386,543,837,250,50,Diabetes mellitus with complications,2,0
32,"ALOGLIPTIN BENZOATE + PIOGLITAZONE HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","ACTOS + SYR-322, TAKEDA; INCRESYNC; LIOVEL; NESINA ACT; OSENI; SYR-322 + ACTOS; SYR-322-4833; ALOGLIPTIN + PIOGLITAZONE (ORAL, TYPE 2 DIABETES), TAKEDA; ALOGLIPTIN BENZOATE + PIOGLITAZONE HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA; PIOGLITAZONE + ALOGLIPTIN (DIABETES), TAKEDA","ACTOS + SYR-322, TAKEDA; INCRESYNC; LIOVEL; NESINA ACT; OSENI; SYR-322 + ACTOS; SYR-322-4833; ALOGLIPTIN + PIOGLITAZONE (ORAL, TYPE 2 DIABETES), TAKEDA; ALOGLIPTIN BENZOATE + PIOGLITAZONE HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA; PIOGLITAZONE + ALOGLIPTIN (DIABETES), TAKEDA","ALOGLIPTIN BENZOATE + PIOGLITAZONE HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","ACTOS + SYR-322, TAKEDA",INCRESYNC,LIOVEL,NESINA ACT,OSENI,SYR-322 + ACTOS,SYR-322-4833,"ALOGLIPTIN + PIOGLITAZONE (ORAL, TYPE 2 DIABETES), TAKEDA","ALOGLIPTIN BENZOATE + PIOGLITAZONE HYDROCHLORIDE (ORAL, TYPE 2 DIABETES), TAKEDA","PIOGLITAZONE + ALOGLIPTIN (DIABETES), TAKEDA",,,,,,,,,,,,,,,,,,,,,22426,ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-01-25T00:00:00Z,2013,1,Oseni,non-insulin dependent diabetes,DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN SENSITIZER; PPAR GAMMA AGONIST,DPP IV INHIBITOR ANTIDIABETIC PRODUCT; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022426,NDA,2008-09-19T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15739.7,18156.3,19052,17491.2,15722.4,16561.7,11337.5,101,3147,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022426,560,837,250,50,Diabetes mellitus with complications,2,0
381,"INSULIN (INHALED, TECHNOSPHERE), MANNKIND/SANOFI","AFRESA; AFREZZA; SAR-439065; TECHNOSPHERE INSULIN; HUMAN INSULIN RDNA; INSULIN; INSULIN (INHALED, TECHNOSPHERE), MANNKIND/SANOFI; INSULIN (INHALED, TECHNOSPHERE), PHARMACEUTICAL DISCOVERY","AFRESA; AFREZZA; SAR-439065; TECHNOSPHERE INSULIN; HUMAN INSULIN RDNA; INSULIN; INSULIN (INHALED, TECHNOSPHERE), MANNKIND/SANOFI; INSULIN (INHALED, TECHNOSPHERE), PHARMACEUTICAL DISCOVERY","INSULIN (INHALED, TECHNOSPHERE), MANNKIND/SANOFI",AFRESA,AFREZZA,SAR-439065,TECHNOSPHERE INSULIN,HUMAN INSULIN RDNA,INSULIN,"INSULIN (INHALED, TECHNOSPHERE), MANNKIND/SANOFI","INSULIN (INHALED, TECHNOSPHERE), PHARMACEUTICAL DISCOVERY",,,,,,,,,,,,,,,,,,,,,,,17926,INSULIN PORK,22472,INSULIN RECOMBINANT HUMAN,,,,,,,,,,,,,,,,,,,2014-06-27T00:00:00Z,2014,6,Afrezza,insulin dependent diabetes,INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN FAST ACTING PRODUCT; HUMAN INSULIN INTERMEDIATE ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; INHALANT FORMULATION; MICROPARTICLE FORMULATION; POWDER FORMULATION INHALANT; PROTEIN RECOMBINANT,matched (3),022472,NDA,2009-03-16T00:00:00Z,fda,0,0,0,0,0,,mannkind,NASDAQ: MNKD,1,,,0,0.1,0.1,,,100.2,101.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022472,573,836,250,50,Diabetes mellitus with complications,2,0
383,INSULIN DEGLUDEC + INSULIN ASPART,INSULIN DEGLUDEC + INSULIN ASPART,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-09-25T00:00:00Z,2015,9,Ryzodeg 70/30,non-insulin dependent diabetes,INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN INTERMEDIATE ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; DAILY DOSING; DRUG COMBINATION; PEPTIDE; SOLUTION; SUBCUTANEOUS FORMULATION,using only (2),203313,NDA,2011-09-29T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,15706.8,14434,15428.3,13788.5,11595.7,10933.9,13350.9,1945.03,1980.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203313,688,837,250,50,Diabetes mellitus with complications,2,0
386,"INSULIN GLARGINE + LIXISENATIDE (DIABETES), SANOFI/ZEALAND PHARMA","LANTUS + AVE-0010; LANTUS + AVE-0010 (DIABETES), SANOFI; LANTUS + ZP-10; LANTUS + ZP-10 (DIABETES), SANOFI; LIXILAN; SOLIQUA; SOLIQUA; SULIQUA; SULIQUA; IGLARLIXI; IGLARLIXI; INSULIN GLARGINE; INSULIN GLARGINE + LIXISENATIDE; INSULIN GLARGINE + LIXISENATIDE (DIABETES), SANOFI/ZEALAND PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-11-21T00:00:00Z,2016,11,Soliqua 100/33,non-insulin dependent diabetes,EXENDIN 4 LIGAND; GLUCAGON-LIKE PEPTIDE 1 AGONIST; INSULIN LIGAND; INSULIN RECEPTOR AGONIST,HUMAN INSULIN LONG ACTING PRODUCT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; DAILY DOSING; DRUG COMBINATION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,using only (2),208673,NDA,2015-12-21T00:00:00Z,fda,1,0,0,0,0,,sanofi,NYSE: SNY,1,36638.9,37861.5,38732.7,43091.6,47408.5,45544.7,25341.5,5459.73,5459.7,,,,,,,priority review granted thru voucher,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208673,689,837,250,50,Diabetes mellitus with complications,2,0
625,"RECOMBINANT HUMAN PARATHYROID HORMONE (PTH) 1-84 (SC, OSTEOPOROSIS), NPS/SHIRE","ALX-1-11; NPSP-558; NATPAR; NATPARA; PREOS; PTH; PTH(1-84); PTH(1-84), NPS; PREOTACT; PARATHYROID HORMONE; PARATHYROID HORMONE, ALLELIX; PARATHYROID HORMONE, NPS/SHIRE; RECOMBINANT HUMAN PARATHYROID HORMONE; RECOMBINANT HUMAN PARATHYROID HORMONE (PTH) 1-84 (SC, OSTEOPOROSIS), NPS/SHIRE; RHPTH; RHPTH (1-84); RHPTH, ALLELIX; RHPTH, NPS","ALX-1-11; NPSP-558; NATPAR; NATPARA; PREOS; PTH; PTH(1-84); PTH(1-84), NPS; PREOTACT; PARATHYROID HORMONE; PARATHYROID HORMONE, ALLELIX; PARATHYROID HORMONE, NPS/SHIRE; RECOMBINANT HUMAN PARATHYROID HORMONE; RECOMBINANT HUMAN PARATHYROID HORMONE (PTH) 1-84 (SC, OSTEOPOROSIS), NPS/SHIRE; RHPTH; RHPTH (1-84); RHPTH, ALLELIX; RHPTH, NPS","RECOMBINANT HUMAN PARATHYROID HORMONE (PTH) 1-84 (SC, OSTEOPOROSIS), NPS/SHIRE",ALX-1-11,NPSP-558,NATPAR,NATPARA,PREOS,PTH,PTH(1-84),"PTH(1-84), NPS",PREOTACT,PARATHYROID HORMONE,"PARATHYROID HORMONE, ALLELIX","PARATHYROID HORMONE, NPS/SHIRE",RECOMBINANT HUMAN PARATHYROID HORMONE,"RECOMBINANT HUMAN PARATHYROID HORMONE (PTH) 1-84 (SC, OSTEOPOROSIS), NPS/SHIRE",RHPTH,RHPTH (1-84),"RHPTH, ALLELIX","RHPTH, NPS",,,,,,,,,,,,,125511,PARATHYROID HORMONE,125511,PARATHYROID HORMONE,,,,,,,,,,,,,,,,,,,2015-01-23T00:00:00Z,2015,1,Natpara,hypoparathyroidism,PARATHYROID HORMONE LIGAND,BONE METABOLISM MODULATOR; BONE SYNTHESIS STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; PROTEIN FUSION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125511,BLA,2013-10-23T00:00:00Z,fda,0,0,0,1,0,,shire,NASDAQ: SHPG,1,6416.7,224.1,155.6,105.6,101.6,84.1,5478.8,920.3,920.3,,,2015,,acquired by shire 2015,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511,50,1118,252,51,Other endocrine disorders,1,0
575,"PASIREOTIDE PAMOATE (SUSTAINED RELEASE), NOVARTIS","SOM-230C; SOM-230C; SIGNIFOR LAR; PASIREOTIDE; PASIREOTIDE LAR; PASIREOTIDE LAR; PASIREOTIDE PAMOATE; PASIREOTIDE PAMOATE (SUSTAINED RELEASE), NOVARTIS","SOM-230C; SOM-230C; SIGNIFOR LAR; PASIREOTIDE; PASIREOTIDE LAR; PASIREOTIDE LAR; PASIREOTIDE PAMOATE; PASIREOTIDE PAMOATE (SUSTAINED RELEASE), NOVARTIS","PASIREOTIDE PAMOATE (SUSTAINED RELEASE), NOVARTIS",SOM-230C,SOM-230C,SIGNIFOR LAR,PASIREOTIDE,PASIREOTIDE LAR,PASIREOTIDE LAR,PASIREOTIDE PAMOATE,"PASIREOTIDE PAMOATE (SUSTAINED RELEASE), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,203255,PASIREOTIDE PAMOATE,,,,,,,,,,,,,,,,,,,,,2014-12-15T00:00:00Z,2014,12,Signifor LAR,acromegaly,SOMATOSTATIN 1 RECEPTOR AGONIST; SOMATOSTATIN 2 RECEPTOR AGONIST; SOMATOSTATIN 3 RECEPTOR AGONIST; SOMATOSTATIN 5 RECEPTOR AGONIST,ACTH RELEASE INHIBITOR; ANTICANCER; GROWTH HORMONE RELEASE INHIBITOR,BIOLOGICAL THERAPEUTIC; CONTROLLED RELEASE FORMULATION; INTRAMUSCULAR FORMULATION; PEPTIDE; SUSTAINED RELEASE FORMULATION,matched (3),203255,NDA,2013-11-15T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,53634,52716,51971,59375,51561,45075,36289,9086,9086,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203255,147,5,253,51,Other endocrine disorders,1,0
683,"SOMATROPIN BIOSIMILAR, SANDOZ","OMNITROPE; PROMNITROPE; SOMATROPIN BS S.C. INJECTION 5MG / 10MG (SANDOZ); SOMATROPIN; SOMATROPIN BIOSIMILAR, SANDOZ","OMNITROPE; PROMNITROPE; SOMATROPIN BS S.C. INJECTION 5MG / 10MG (SANDOZ); SOMATROPIN; SOMATROPIN BIOSIMILAR, SANDOZ","SOMATROPIN BIOSIMILAR, SANDOZ",OMNITROPE,PROMNITROPE,SOMATROPIN BS S.C. INJECTION 5MG / 10MG (SANDOZ),SOMATROPIN,"SOMATROPIN BIOSIMILAR, SANDOZ",,,,,,,,,,,,,,,,,,,,,,,,,,21426,SOMATROPIN RECOMBINANT,,,,,,,,,,,,,,,,,,,,,2006-05-30T00:00:00Z,2006,5,Omnitrope,growth disorder,GROWTH HORMONE LIGAND; GROWTH HORMONE RECEPTOR AGONIST,,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; LIQUID FORMULATION; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),021426,NDA,2001-12-27T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,35105,29753,27277,24930,20877,18762,25694,5321,5321,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021426,368,140,253,51,Other endocrine disorders,1,0
682,"SOMATROPIN BIOSIMILAR, LG LIFE SCIENCES","EUTROPIN; VALTROPIN; GROWTH HORMONE, LG CHEM; HUMAN GROWTH HORMONE, LG CHEM; HUMAN GROWTH HORMONE, LG LIFE SCIENCES; SOMATROPIN; SOMATROPIN BIOSIMILAR, LG LIFE SCIENCES","EUTROPIN; VALTROPIN; GROWTH HORMONE, LG CHEM; HUMAN GROWTH HORMONE, LG CHEM; HUMAN GROWTH HORMONE, LG LIFE SCIENCES; SOMATROPIN; SOMATROPIN BIOSIMILAR, LG LIFE SCIENCES","SOMATROPIN BIOSIMILAR, LG LIFE SCIENCES",EUTROPIN,VALTROPIN,"GROWTH HORMONE, LG CHEM","HUMAN GROWTH HORMONE, LG CHEM","HUMAN GROWTH HORMONE, LG LIFE SCIENCES",SOMATROPIN,"SOMATROPIN BIOSIMILAR, LG LIFE SCIENCES",,,,,,,,,,,,,,,,,,,,,,,,21905,SOMATROPIN RECOMBINANT,,,,,,,,,,,,,,,,,,,,,2007-04-19T00:00:00Z,2007,4,Valtropin,growth disorder,GROWTH HORMONE LIGAND,,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),021905,NDA,2005-11-30T00:00:00Z,fda,0,0,0,0,0,,LG life sciences,068870.KS,1,274,237.6,211.1,506.4,150.2,117.5,151.4,48,51.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021905,405,140,253,51,Other endocrine disorders,1,0
413,LANREOTIDE,"ANGIOPEPTIN; BIM-23014C; BN-52030; DC13-116; ITM-014; ITM-014N; SOMATULINE AUTOGEL; SOMATULINE DEPOT; SOMATULINE SA; DERMOPEPTIN; IPSTYL; LANREOTIDE; LANREOTIDE (DEPOT FORMULATION), TULANE UNIVERSITY/IPSEN; LANREOTIDE ACETATE; SOMATULINE","ANGIOPEPTIN; BIM-23014C; BN-52030; DC13-116; ITM-014; ITM-014N; SOMATULINE AUTOGEL; SOMATULINE DEPOT; SOMATULINE SA; DERMOPEPTIN; IPSTYL; LANREOTIDE; LANREOTIDE (DEPOT FORMULATION), TULANE UNIVERSITY/IPSEN; LANREOTIDE ACETATE; SOMATULINE",LANREOTIDE,ANGIOPEPTIN,BIM-23014C,BN-52030,DC13-116,ITM-014,ITM-014N,SOMATULINE AUTOGEL,SOMATULINE DEPOT,SOMATULINE SA,DERMOPEPTIN,IPSTYL,LANREOTIDE,"LANREOTIDE (DEPOT FORMULATION), TULANE UNIVERSITY/IPSEN",LANREOTIDE ACETATE,SOMATULINE,,,,,,,,,,,,,,,,22074,LANREOTIDE ACETATE,22074,LANREOTIDE ACETATE,,,,,,,,,,,,,,,,,,,2007-08-30T00:00:00Z,2007,8,Somatuline Depot,acromegaly,INSULIN-LIKE GROWTH FACTOR 1 ANTAGONIST; SOMATOSTATIN RECEPTOR AGONIST,ANTI-INFLAMMATORY; ANTICANCER; ANTIHYPERTENSIVE; GROWTH HORMONE RELEASE INHIBITOR; VASOPROTECTANT,BIOLOGICAL THERAPEUTIC; GEL FORMULATION; INTRAMUSCULAR FORMULATION; PEPTIDE; SOLUTION; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),022074,NDA,2006-10-27T00:00:00Z,fda,0,0,0,1,0,,ipsen biopharm,EPA: IPN,1,1451.2,1247.3,1011.3,1103.2,929.2,731.8,1160.6,269.6,269.6,,,,,biomeasure changed name to ipsen,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022074,460,5,253,51,Other endocrine disorders,1,0
574,PASIREOTIDE DIASPARTATE,"SOM-230; SOM-230B; SIGNIFOR; PASIREOTIDE; PASIREOTIDE DIASPARTATE; SOMATOSTATIN ANALOG (NEUROENDOCRINE TUMORS/ACROMEGALY/CUSHING'S DISEASE), NOVARTIS","SOM-230; SOM-230B; SIGNIFOR; PASIREOTIDE; PASIREOTIDE DIASPARTATE; SOMATOSTATIN ANALOG (NEUROENDOCRINE TUMORS/ACROMEGALY/CUSHING'S DISEASE), NOVARTIS",PASIREOTIDE DIASPARTATE,SOM-230,SOM-230B,SIGNIFOR,PASIREOTIDE,PASIREOTIDE DIASPARTATE,"SOMATOSTATIN ANALOG (NEUROENDOCRINE TUMORS/ACROMEGALY/CUSHING'S DISEASE), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,200677,PASIREOTIDE DIASPARTATE,,,,,,,,,,,,,,,,,,,,,2012-12-14T00:00:00Z,2012,12,Signifor,cushings disease,SOMATOSTATIN 1 RECEPTOR AGONIST; SOMATOSTATIN 2 RECEPTOR AGONIST; SOMATOSTATIN 3 RECEPTOR AGONIST; SOMATOSTATIN 5 RECEPTOR AGONIST,ANALGESIC; ANTICANCER; GROWTH HORMONE RELEASE INHIBITOR,BIOLOGICAL THERAPEUTIC; PEPTIDE; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),200677,NDA,2012-02-17T00:00:00Z,fda,0,0,0,1,0,,novartis,NYSE: NVS,1,51971,59375,51561,45075,42535,38947,36385,8465,8588,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677,77,87,255,51,Other endocrine disorders,1,0
487,"MIFEPRISTONE (CUSHING'S SYNDROME/CANCER), CORCEPT THERAPEUTICS","C-1073; CORLUX; CORLUXIN; KORLYM; RU-009; RU-044; RU-39009; RU-43044; MIFEPRISTONE; MIFEPRISTONE (ALZHEIMER'S DISEASE), CORCEPT; MIFEPRISTONE (CUSHING'S SYNDROME/CANCER), CORCEPT THERAPEUTICS; MIFEPRISTONE (CUSHING'S SYNDROME/PSYCHOTIC MAJOR DEPRESSION), CORCEPT; MIFEPRISTONE (PSYCHOTIC MAJOR DEPRESSION/ WEIGHT GAIN PREVENTION/ CUSHING'S SYNDROME), CORCEPT","C-1073; CORLUX; CORLUXIN; KORLYM; RU-009; RU-044; RU-39009; RU-43044; MIFEPRISTONE; MIFEPRISTONE (ALZHEIMER'S DISEASE), CORCEPT; MIFEPRISTONE (CUSHING'S SYNDROME/CANCER), CORCEPT THERAPEUTICS; MIFEPRISTONE (CUSHING'S SYNDROME/PSYCHOTIC MAJOR DEPRESSION), CORCEPT; MIFEPRISTONE (PSYCHOTIC MAJOR DEPRESSION/ WEIGHT GAIN PREVENTION/ CUSHING'S SYNDROME), CORCEPT","MIFEPRISTONE (CUSHING'S SYNDROME/CANCER), CORCEPT THERAPEUTICS",C-1073,CORLUX,CORLUXIN,KORLYM,RU-009,RU-044,RU-39009,RU-43044,MIFEPRISTONE,"MIFEPRISTONE (ALZHEIMER'S DISEASE), CORCEPT","MIFEPRISTONE (CUSHING'S SYNDROME/CANCER), CORCEPT THERAPEUTICS","MIFEPRISTONE (CUSHING'S SYNDROME/PSYCHOTIC MAJOR DEPRESSION), CORCEPT","MIFEPRISTONE (PSYCHOTIC MAJOR DEPRESSION/ WEIGHT GAIN PREVENTION/ CUSHING'S SYNDROME), CORCEPT",,,,,,,,,,,,,,,,,,202107,MIFEPRISTONE,,,,,,,,,,,,,,,,,,,,,2012-02-17T00:00:00Z,2012,2,Korlym,cushings disease,GLUCOCORTICOID ANTAGONIST; PROGESTERONE RECEPTOR ANTAGONIST,ANTICANCER; ANTIDEPRESSANT; ANTIPSYCHOTIC; NOOTROPIC AGENT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202107,NDA,2011-04-15T00:00:00Z,fda,0,0,0,1,0,,corcept therapeutics,NASDAQ: CORT,1,3.3,,,,0.2,0.5,3.2,14.1,14.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202107,101,87,255,51,Other endocrine disorders,1,0
404,KEDBUMIN,"ALBITAL; ALBUKED; HUMAN ALBUMIN; KEDBUMIN; KEDRIALB; PLASBUMIN; UMAN ALBUMIN; UMAN SERUM, KEDRION; HUMAN ALBUMIN, KEDRION",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2011-06-03T00:00:00Z,2011,6,Kedbumin,ovarian hyperstimulation syndrome,ALBUMIN AGONIST,FREE RADICAL SCAVENGER,BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; INTRAVENOUS FORMULATION; PEPTIDE; SOLUTION,using only (2),125384,BLA,2010-08-03T00:00:00Z,fda,0,0,0,0,0,,kedrion biopharma,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125384,692,1701,256,51,Other endocrine disorders,2,0
726,"TESTOSTERONE GEL (MALE HYPOGONADISM), ANI PHARMACEUTICALS/TEVA","BIO-T-GEL; TESTOSTERONE; TESTOSTERONE GEL (MALE HYPOGONADISM), ANI PHARMACEUTICALS/TEVA; TESTOSTERONE GEL (MALE HYPOGONADISM), BIOSANTE/TEVA","BIO-T-GEL; TESTOSTERONE; TESTOSTERONE GEL (MALE HYPOGONADISM), ANI PHARMACEUTICALS/TEVA; TESTOSTERONE GEL (MALE HYPOGONADISM), BIOSANTE/TEVA","TESTOSTERONE GEL (MALE HYPOGONADISM), ANI PHARMACEUTICALS/TEVA",BIO-T-GEL,TESTOSTERONE,"TESTOSTERONE GEL (MALE HYPOGONADISM), ANI PHARMACEUTICALS/TEVA","TESTOSTERONE GEL (MALE HYPOGONADISM), BIOSANTE/TEVA",,,,,,,,,,,,,,,,,,,,,,,,,,,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,,,,,,,,,,,,,,,2012-02-14T00:00:00Z,2012,2,testosterone gel,male hypogonadism,ANDROGEN RECEPTOR AGONIST,,SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),202763,NDA,2011-01-13T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,20317,18312,16121,13899,11085,9408,10715,1356,1283,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202763,127,3494,257,51,Other endocrine disorders,1,0
751,"TRANSDERMAL TESTOSTERONE GEL, KYOWA KIRIN","EN-3350; FORTESTA; FORTIGEL; ITNOGEN; TOSTRAN; TOSTRELLE; TOSTREX; TESTOSTERONE; TRANSDERMAL TESTOSTERONE GEL (HYPOGONADISM), CELLEGY/PROSTRAKAN; TRANSDERMAL TESTOSTERONE GEL, CELLEGY; TRANSDERMAL TESTOSTERONE GEL, KYOWA KIRIN; TRANSDERMAL TESTOSTERONE GEL, PROSTRAKAN","EN-3350; FORTESTA; FORTIGEL; ITNOGEN; TOSTRAN; TOSTRELLE; TOSTREX; TESTOSTERONE; TRANSDERMAL TESTOSTERONE GEL (HYPOGONADISM), CELLEGY/PROSTRAKAN; TRANSDERMAL TESTOSTERONE GEL, CELLEGY; TRANSDERMAL TESTOSTERONE GEL, KYOWA KIRIN; TRANSDERMAL TESTOSTERONE GEL, PROSTRAKAN","TRANSDERMAL TESTOSTERONE GEL, KYOWA KIRIN",EN-3350,FORTESTA,FORTIGEL,ITNOGEN,TOSTRAN,TOSTRELLE,TOSTREX,TESTOSTERONE,"TRANSDERMAL TESTOSTERONE GEL (HYPOGONADISM), CELLEGY/PROSTRAKAN","TRANSDERMAL TESTOSTERONE GEL, CELLEGY","TRANSDERMAL TESTOSTERONE GEL, KYOWA KIRIN","TRANSDERMAL TESTOSTERONE GEL, PROSTRAKAN",,,,,,,,,,,,,,,,,,,202763,TESTOSTERONE,21463,TESTOSTERONE,,,,,,,,,,,,,,,,,,,2010-12-29T00:00:00Z,2010,12,Fortesta,hypogonadism,ANDROGEN RECEPTOR AGONIST,,SMALL MOLECULE THERAPEUTIC; STEROID; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),021463,NDA,2002-05-31T00:00:00Z,fda,0,0,0,0,0,,endo pharmaceuticals,NASDAQ: ENDP,1,1716.23,1460.84,1260.54,1085.61,909.659,820.164,1211.47,144.525,144.525,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021463,369,981,257,51,Other endocrine disorders,1,0
81,BAY-86-5037,"AVEED; BAY-86-5037; NEBIDO; TESTOSTERONE (INTRAMUSCULAR, CONTROLLED RELEASE, HYPOGONADISM), BAYER SCHERING PHARMA/ENDO; TESTOSTERONE DEPOT, SCHERING/INDEVUS; TESTOSTERONE UNDECANOATE; TESTOSTERONE UNDECANOATE DEPOT (HYPOGONADISM), SCHERING/INDEVUS","AVEED; BAY-86-5037; NEBIDO; TESTOSTERONE (INTRAMUSCULAR, CONTROLLED RELEASE, HYPOGONADISM), BAYER SCHERING PHARMA/ENDO; TESTOSTERONE DEPOT, SCHERING/INDEVUS; TESTOSTERONE UNDECANOATE; TESTOSTERONE UNDECANOATE DEPOT (HYPOGONADISM), SCHERING/INDEVUS",BAY-86-5037,AVEED,BAY-86-5037,NEBIDO,"TESTOSTERONE (INTRAMUSCULAR, CONTROLLED RELEASE, HYPOGONADISM), BAYER SCHERING PHARMA/ENDO","TESTOSTERONE DEPOT, SCHERING/INDEVUS",TESTOSTERONE UNDECANOATE,"TESTOSTERONE UNDECANOATE DEPOT (HYPOGONADISM), SCHERING/INDEVUS",,,,,,,,,,,,,,,,,,,,,,,,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,22219,TESTOSTERONE UNDECANOATE,,,,,,,,,,,,,2014-03-05T00:00:00Z,2014,3,Aveed,male hypogonadism,ANDROGEN RECEPTOR AGONIST,,INJECTABLE CONTROLLED RELEASE FORMULATION; INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022219,NDA,2007-08-24T00:00:00Z,fda,0,0,0,0,0,,endo pharmaceuticals,NASDAQ: ENDP,1,2380.68,2124.68,2815.74,2524.92,1716.23,1460.84,1214.77,112.708,112.708,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022219,501,3494,257,51,Other endocrine disorders,1,0
72,AXIRON,"AXERON; AXIRON; LY-900011; TESTOSTERONE MD-LOTION; TESTOSTERONE; TESTOSTERONE (MD-LOTION), ELI LILLY/ACRUX; TESTOSTERONE (METERED-DOSE LOTION), ACRUX/LILLY","AXERON; AXIRON; LY-900011; TESTOSTERONE MD-LOTION; TESTOSTERONE; TESTOSTERONE (MD-LOTION), ELI LILLY/ACRUX; TESTOSTERONE (METERED-DOSE LOTION), ACRUX/LILLY",AXIRON,AXERON,AXIRON,LY-900011,TESTOSTERONE MD-LOTION,TESTOSTERONE,"TESTOSTERONE (MD-LOTION), ELI LILLY/ACRUX","TESTOSTERONE (METERED-DOSE LOTION), ACRUX/LILLY",,,,,,,,,,,,,,,,,,,,,,,,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,22504,TESTOSTERONE,22504,TESTOSTERONE,22504,TESTOSTERONE,,,,,,,,,2010-11-23T00:00:00Z,2010,11,Axiron,hypogonadism,ANDROGEN RECEPTOR AGONIST,,SMALL MOLECULE THERAPEUTIC; SOLUTION; TRANSDERMAL FORMULATION,matched (3),022504,NDA,2010-01-25T00:00:00Z,fda,0,0,0,0,0,,acrux pharma,ASX: ACR,1,146.8,0.9,0.8,4.9,2.5,2.3,141.7,1,1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022504,580,981,257,51,Other endocrine disorders,1,0
725,"TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU/ HYUNDAI","COMPLEO; COMPLEOTRT; MPP-10; NASOBOL; NATESTO; TBS-1; URG-201; TESTOSTERONE; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU/ HYUNDAI; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ENDO; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), M ET P PHARMA/TRIMEL; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), TRIMEL/ ENDO; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), MATTERN; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN/MATTERN","COMPLEO; COMPLEOTRT; MPP-10; NASOBOL; NATESTO; TBS-1; URG-201; TESTOSTERONE; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU/ HYUNDAI; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ENDO; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), M ET P PHARMA/TRIMEL; TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), TRIMEL/ ENDO; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), MATTERN; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN; TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN/MATTERN","TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU/ HYUNDAI",COMPLEO,COMPLEOTRT,MPP-10,NASOBOL,NATESTO,TBS-1,URG-201,TESTOSTERONE,"TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU","TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ACERUS/ AYTU/ HYUNDAI","TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), ENDO","TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), M ET P PHARMA/TRIMEL","TESTOSTERONE (INTRANASAL SUSTAINED-RELEASE, HYPOGONADISM), TRIMEL/ ENDO","TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), MATTERN","TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN","TESTOSTERONE (INTRANASAL/SUSTAINED-RELEASE, HYPOGONADISM), URIGEN/MATTERN",,,,,,,,,,,,,,,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,202763,TESTOSTERONE,205488,TESTOSTERONE,2014-05-28T00:00:00Z,2014,5,Natesto,male hypogonadism,ANDROGEN RECEPTOR AGONIST,,NASAL GEL FORMULATION; NASAL SYSTEMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; SUSTAINED RELEASE FORMULATION,matched (3),205488,NDA,2013-04-29T00:00:00Z,fda,0,0,0,0,0,,acerus pharmaceuticals,TSX: ASP,1,4.313,,,,0.009,,-2.043,9.001,9.1,,,,,formerly known as trimel pharmaceuticals,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205488,629,3494,257,51,Other endocrine disorders,1,0
716,TELOTRISTAT ETIPRATE,"LP-778902; LX-01606; LX-1032; LX-1606; XERMELO; XERMELO; SEROTONIN MODULATOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON; TELOTRISTAT; TELOTRISTAT BESYLATE; TELOTRISTAT ETHYL; TELOTRISTAT ETIPRATE; TRYPTOPHAN HYDROXYLASE INHIBITOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON","LP-778902; LX-01606; LX-1032; LX-1606; XERMELO; XERMELO; SEROTONIN MODULATOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON; TELOTRISTAT; TELOTRISTAT BESYLATE; TELOTRISTAT ETHYL; TELOTRISTAT ETIPRATE; TRYPTOPHAN HYDROXYLASE INHIBITOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON",TELOTRISTAT ETIPRATE,LP-778902,LX-01606,LX-1032,LX-1606,XERMELO,XERMELO,"SEROTONIN MODULATOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON",TELOTRISTAT,TELOTRISTAT BESYLATE,TELOTRISTAT ETHYL,TELOTRISTAT ETIPRATE,"TRYPTOPHAN HYDROXYLASE INHIBITOR (ORAL, GI DISORDER/HYPERTENSION/CARCINOID SYNDROME), LEXICON",,,,,,,,,,,,,,,,,,,208794,TELOTRISTAT ETIPRATE,,,,,,,,,,,,,,,,,,,,,2017-02-28T00:00:00Z,2017,2,Xermelo,carcinoid syndrome,TRYPTOPHAN 5-HYDROXYLASE INHIBITOR,5-HT RELEASE INHIBITOR; ANTICANCER,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208794,NDA,2016-03-30T00:00:00Z,fda,1,0,1,1,0,,lexicon pharmaceuticals,NASDAQ: LXRX,1,73.2,83.3,130,22.9,2.2,1.1,-102,,174.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208794,353,2966,259,51,Other endocrine disorders,1,0
432,LIFITEGRAST,"SAR-1118; SHP-606; SPD-606; XIIDRA; XIIDRA; DUAL LFA-1/ICAM-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE; DUAL LFA-1/ICAM-1 INHIBITORS, SUNESIS; DUAL LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1/INTRACELLULAR ADHESION MOLECULE-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE; LIFITEGRAST; LIFITEGRAST SODIUM","SAR-1118; SHP-606; SPD-606; XIIDRA; XIIDRA; DUAL LFA-1/ICAM-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE; DUAL LFA-1/ICAM-1 INHIBITORS, SUNESIS; DUAL LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1/INTRACELLULAR ADHESION MOLECULE-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE; LIFITEGRAST; LIFITEGRAST SODIUM",LIFITEGRAST,SAR-1118,SHP-606,SPD-606,XIIDRA,XIIDRA,"DUAL LFA-1/ICAM-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE","DUAL LFA-1/ICAM-1 INHIBITORS, SUNESIS","DUAL LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1/INTRACELLULAR ADHESION MOLECULE-1 INHIBITORS (INFLAMMATORY DISEASES), SARCODE",LIFITEGRAST,LIFITEGRAST SODIUM,,,,,,,,,,,,,,,,,,,,,208073,LIFITEGRAST,,,,,,,,,,,,,,,,,,,,,2016-07-11T00:00:00Z,2016,7,Xiidra,xerophthalmia,CD11A ANTAGONIST; ICAM-1 INHIBITOR,ANTI-INFLAMMATORY; IMMUNOMODULATOR; OPHTHALMOLOGICAL AGENT,OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),208073,NDA,2015-02-25T00:00:00Z,fda,1,0,0,0,0,,shire,NASDAQ: SHPG,1,11396.6,6416.7,6022.1,4934.3,4527.4,4158.1,8698.1,1430.9,1430.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208073,324,3016,267,52,Nutritional deficiencies,1,0
175,"CTAP-101 (ORAL), OPKO HEALTH","CTAP-101 (ORAL), CYTOCHROMA; CTAP-101 (ORAL), OPKO HEALTH; RAYALDEE; RAYALDEE; RAYALDY; REPLIDEA; CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), CYTOCHROMA; CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), OPKO; HYPOVITAMINOSIS D THERAPY, CYTOCHROMA; VITAMIN D INSUFFICIENCY THERAPY, CYTOCHROMA; VITAMIN D PROHORMONE (VITAMIN D INSUFFICIENCY), CYTOCHROMA","CTAP-101 (ORAL), CYTOCHROMA; CTAP-101 (ORAL), OPKO HEALTH; RAYALDEE; RAYALDEE; RAYALDY; REPLIDEA; CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), CYTOCHROMA; CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), OPKO; HYPOVITAMINOSIS D THERAPY, CYTOCHROMA; VITAMIN D INSUFFICIENCY THERAPY, CYTOCHROMA; VITAMIN D PROHORMONE (VITAMIN D INSUFFICIENCY), CYTOCHROMA","CTAP-101 (ORAL), OPKO HEALTH","CTAP-101 (ORAL), CYTOCHROMA","CTAP-101 (ORAL), OPKO HEALTH",RAYALDEE,RAYALDEE,RAYALDY,REPLIDEA,"CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), CYTOCHROMA","CALCIFEDIOL (ORAL, VITAMIN D INSUFFICIENCY), OPKO","HYPOVITAMINOSIS D THERAPY, CYTOCHROMA","VITAMIN D INSUFFICIENCY THERAPY, CYTOCHROMA","VITAMIN D PROHORMONE (VITAMIN D INSUFFICIENCY), CYTOCHROMA",,,,,,,,,,,,,,,,,,,,208010,CALCIFEDIOL,208010,CALCIFEDIOL,,,,,,,,,,,,,,,,,,,2016-06-17T00:00:00Z,2016,6,Rayaldee,vitamin d deficiency,,ANTICANCER; VITAMIN D AGONIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),208010,NDA,2015-05-29T00:00:00Z,fda,0,0,0,0,0,,opko health,NASDAQ: OPK,1,1221.7,491.7,91.1,96.5,47,28,558.4,40.6,113.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208010,320,3790,268,52,Nutritional deficiencies,1,0
330,GLYCEROL PHENYLBUTYRATE,GT4P; HPN-100; RAVICTI; GLYCEROL PHENYLBUTYRATE; GLYCERYL TRI-(4-PHENYLBUTYRATE),GT4P; HPN-100; RAVICTI; GLYCEROL PHENYLBUTYRATE; GLYCERYL TRI-(4-PHENYLBUTYRATE),GLYCEROL PHENYLBUTYRATE,GT4P,HPN-100,RAVICTI,GLYCEROL PHENYLBUTYRATE,GLYCERYL TRI-(4-PHENYLBUTYRATE),,,,,,,,,,,,,,,,,,,,,,,,,,203284,GLYCEROL PHENYLBUTYRATE,,,,,,,,,,,,,,,,,,,,,2013-02-01T00:00:00Z,2013,2,Ravicti,hyperammonemia,,NITROGEN METABOLISM MODULATOR,ORAL FORMULATION; ORAL LIQUID FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),203284,NDA,2011-12-23T00:00:00Z,fda,0,0,1,1,0,,hyperion therapeutics,NASDAQ: HPTX,1,42.2,,,,,,35.5,10,10,,,,,acquired by horizon pharma in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203284,148,3144,270,58,Other nutritional; endocrine; and metabolic disorders,1,0
467,"MERCAPTAMINE (ENTERIC-COATED), HORIZON PHARMA","DR CYSTEAMINE; EC CYSTEAMINE; PROCYSBI; RP-103; RP-104; CYSTEAMINE; CYSTEAMINE BITARTRATE; CYSTEAMINE BITARTRATE (ENTERIC-COATED), BENNU; CYSTEAMINE BITARTRATE (ENTERIC-COATED), RAPTOR; DELAYED RELEASE ENTERIC COATED CYSTEAMINE BITARTRATE; ENTERIC-COATED CYSTEAMINE BITARTRATE; MERCAPTAMINE; MERCAPTAMINE (ENTERIC-COATED); MERCAPTAMINE (ENTERIC-COATED), BENNU; MERCAPTAMINE (ENTERIC-COATED), HORIZON PHARMA; MERCAPTAMINE (ENTERIC-COATED), RAPTOR","DR CYSTEAMINE; EC CYSTEAMINE; PROCYSBI; RP-103; RP-104; CYSTEAMINE; CYSTEAMINE BITARTRATE; CYSTEAMINE BITARTRATE (ENTERIC-COATED), BENNU; CYSTEAMINE BITARTRATE (ENTERIC-COATED), RAPTOR; DELAYED RELEASE ENTERIC COATED CYSTEAMINE BITARTRATE; ENTERIC-COATED CYSTEAMINE BITARTRATE; MERCAPTAMINE; MERCAPTAMINE (ENTERIC-COATED); MERCAPTAMINE (ENTERIC-COATED), BENNU; MERCAPTAMINE (ENTERIC-COATED), HORIZON PHARMA; MERCAPTAMINE (ENTERIC-COATED), RAPTOR","MERCAPTAMINE (ENTERIC-COATED), HORIZON PHARMA",DR CYSTEAMINE,EC CYSTEAMINE,PROCYSBI,RP-103,RP-104,CYSTEAMINE,CYSTEAMINE BITARTRATE,"CYSTEAMINE BITARTRATE (ENTERIC-COATED), BENNU","CYSTEAMINE BITARTRATE (ENTERIC-COATED), RAPTOR",DELAYED RELEASE ENTERIC COATED CYSTEAMINE BITARTRATE,ENTERIC-COATED CYSTEAMINE BITARTRATE,MERCAPTAMINE,MERCAPTAMINE (ENTERIC-COATED),"MERCAPTAMINE (ENTERIC-COATED), BENNU","MERCAPTAMINE (ENTERIC-COATED), HORIZON PHARMA","MERCAPTAMINE (ENTERIC-COATED), RAPTOR",,,,,,,,,,,,,,,203389,CYSTEAMINE BITARTRATE,,,,,,,,,,,,,,,,,,,,,2013-04-30T00:00:00Z,2013,4,Procysbi,nephropathic cystinosis,METHYL CPG BINDING PROTEIN 2 MODULATOR; TRANSGLUTAMINASE INHIBITOR,ANTICANCER; ANTIPARKINSONIAN; GASTRIC SECRETION STIMULATOR; NEUROPROTECTANT; RENAL SYSTEM AGENT,CAPSULE FORMULATION; ENTERIC COATED FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203389,NDA,2012-03-30T00:00:00Z,fda,0,0,0,1,0,,raptor therapeutics,NASDAQ: RPTP,1,16.9,,,,,,15.2,29.2,29.2,,,,,acquired by horizon in 2016,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203389,155,3539,270,58,Other nutritional; endocrine; and metabolic disorders,1,0
655,"SAPROPTERIN DIHYDROCHLORIDE (ORAL, PHENYLKETONURIA), BIOMARIN/MERCK SERONO","6R-BH4; 6R-BH4 (PHENYLKETONURIA), BIOMARIN/MERCK SERONO; 6R-TETRAHYDRO-L-BIOPTERIN; 6R-TETRAHYDRO-L-BIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO; KUVAN; PHENOPTIN; T-1401; PHENYLKETONURIA THERAPY (ENZYME CO-FACTOR), BIOMARIN/MERCK SERONO; SAPROPTERIN; SAPROPTERIN (HYPERTENSION), BIOMARIN/MERCK SERONO; SAPROPTERIN (VASCULAR DISEASE), BIOMARIN/MERCK SERONO; SAPROPTERIN DIHYDROCHLORIDE; SAPROPTERIN DIHYDROCHLORIDE (ORAL, PHENYLKETONURIA), BIOMARIN/MERCK SERONO; TETRAHYDROBIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO","6R-BH4; 6R-BH4 (PHENYLKETONURIA), BIOMARIN/MERCK SERONO; 6R-TETRAHYDRO-L-BIOPTERIN; 6R-TETRAHYDRO-L-BIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO; KUVAN; PHENOPTIN; T-1401; PHENYLKETONURIA THERAPY (ENZYME CO-FACTOR), BIOMARIN/MERCK SERONO; SAPROPTERIN; SAPROPTERIN (HYPERTENSION), BIOMARIN/MERCK SERONO; SAPROPTERIN (VASCULAR DISEASE), BIOMARIN/MERCK SERONO; SAPROPTERIN DIHYDROCHLORIDE; SAPROPTERIN DIHYDROCHLORIDE (ORAL, PHENYLKETONURIA), BIOMARIN/MERCK SERONO; TETRAHYDROBIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO","SAPROPTERIN DIHYDROCHLORIDE (ORAL, PHENYLKETONURIA), BIOMARIN/MERCK SERONO",6R-BH4,"6R-BH4 (PHENYLKETONURIA), BIOMARIN/MERCK SERONO",6R-TETRAHYDRO-L-BIOPTERIN,"6R-TETRAHYDRO-L-BIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO",KUVAN,PHENOPTIN,T-1401,"PHENYLKETONURIA THERAPY (ENZYME CO-FACTOR), BIOMARIN/MERCK SERONO",SAPROPTERIN,"SAPROPTERIN (HYPERTENSION), BIOMARIN/MERCK SERONO","SAPROPTERIN (VASCULAR DISEASE), BIOMARIN/MERCK SERONO",SAPROPTERIN DIHYDROCHLORIDE,"SAPROPTERIN DIHYDROCHLORIDE (ORAL, PHENYLKETONURIA), BIOMARIN/MERCK SERONO","TETRAHYDROBIOPTERIN (PHENYLKETONURIA), BIOMARIN/MERCK SERONO",,,,,,,,,,,,,,,,,22181,SAPROPTERIN DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2007-12-13T00:00:00Z,2007,12,Kuvan,phenylketonuria,PHENYLALANINE HYDROXYLASE STIMULATOR,ANTIHYPERTENSIVE,FORMULATION POWDER; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; STEREOCHEMISTRY; TABLET FORMULATION,matched (3),022181,NDA,2007-05-25T00:00:00Z,fda,1,0,1,1,0,,biomarin pharmaceutical,NASDAQ: BMRN,1,121.6,84.2,25.7,18.6,12.1,,24.6,,78.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022181,488,263,270,58,Other nutritional; endocrine; and metabolic disorders,1,0
137,CARGLUMIC ACID,CARBAGLU; OE-312; CARGLUMIC ACID,CARBAGLU; OE-312; CARGLUMIC ACID,CARGLUMIC ACID,CARBAGLU,OE-312,CARGLUMIC ACID,,,,,,,,,,,,,,,,,,,,,,,,,,,,22562,CARGLUMIC ACID,,,,,,,,,,,,,,,,,,,,,2010-03-18T00:00:00Z,2010,3,Carbaglu,hyperammonemia,N ACETYLGLUTAMATE SYNTHASE STIMULATOR,,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022562,NDA,2009-06-17T00:00:00Z,fda,1,0,1,1,0,,orphan europe,private,0,58.4,55.6,49,54.4,44.5,43,35.8,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022562,601,3144,270,58,Other nutritional; endocrine; and metabolic disorders,1,0
24,ALGLUCOSIDASE ALFA,"CHO-CELL ENZYME REPLACEMENT THERAPY (POMPE DISEASE), SYNPAC; LUMIZYME; MYOZYME; POMPASE; ALGLUCOSIDASE ALFA; ALPHA-GLUCOSIDASE (POMPE DISEASE), GENZYME","CHO-CELL ENZYME REPLACEMENT THERAPY (POMPE DISEASE), SYNPAC; LUMIZYME; MYOZYME; POMPASE; ALGLUCOSIDASE ALFA; ALPHA-GLUCOSIDASE (POMPE DISEASE), GENZYME",ALGLUCOSIDASE ALFA,"CHO-CELL ENZYME REPLACEMENT THERAPY (POMPE DISEASE), SYNPAC",LUMIZYME,MYOZYME,POMPASE,ALGLUCOSIDASE ALFA,"ALPHA-GLUCOSIDASE (POMPE DISEASE), GENZYME",,,,,,,,,,,,,,,,,,,,,,,,,125141,ALGLUCOSIDASE ALFA,125291,ALGLUCOSIDASE ALFA,,,,,,,,,,,,,,,,,,,2006-04-28T00:00:00Z,2006,4,Myozyme,pompes disease,ALPHA-GLUCOSIDASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME,matched (3),125141,BLA,2005-07-29T00:00:00Z,cortellis,1,0,1,1,0,,genzyme,NASDAQ: GENZ,1,3187.01,2734.84,2201.14,1713.87,1329.47,1223.63,2451.34,649.951,649.951,,,,,acquired by sanofi in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125141,4,2261,271,58,Other nutritional; endocrine; and metabolic disorders,1,0
483,METRELEPTIN,"AC-164594; AC-164594; MYALEPT; MYALEPTA; LEPTIN; LEPTIN, AMGEN; METRELEPTIN; OBESITY GENE PRODUCT, AMGEN; R-METHULEPTIN; R-METHULEPTIN, AMGEN; R-METHULEPTIN, AMYLIN; RECOMBINANT METHIONYL HUMAN LEPTIN, AMGEN","AC-164594; AC-164594; MYALEPT; MYALEPTA; LEPTIN; LEPTIN, AMGEN; METRELEPTIN; OBESITY GENE PRODUCT, AMGEN; R-METHULEPTIN; R-METHULEPTIN, AMGEN; R-METHULEPTIN, AMYLIN; RECOMBINANT METHIONYL HUMAN LEPTIN, AMGEN",METRELEPTIN,AC-164594,AC-164594,MYALEPT,MYALEPTA,LEPTIN,"LEPTIN, AMGEN",METRELEPTIN,"OBESITY GENE PRODUCT, AMGEN",R-METHULEPTIN,"R-METHULEPTIN, AMGEN","R-METHULEPTIN, AMYLIN","RECOMBINANT METHIONYL HUMAN LEPTIN, AMGEN",,,,,,,,,,,,,,,,,,,125390,METRELEPTIN,125390,METRELEPTIN,,,,,,,,,,,,,,,,,,,2014-02-24T00:00:00Z,2014,2,Myalept,lipodystrophy,LEPTIN AGONIST,ANTIHYPERTRIGLYCERIDEMIC AGENT; APPETITE SUPPRESSANT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; DAILY DOSING; FREEZE DRYING; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125390,BLA,2010-12-15T00:00:00Z,fda,1,0,1,1,0,,astrazeneca,NYSE: AZN,1,26547,16385,17621,650.7,668.8,758.4,20812,5001,5438,15879,2014-12-31T00:00:00Z,2014,,acquired by bristol-myers squibb in 2012  and then acquired by astrazeneca in 2014; 2014 revenue is for AZN; 2012-13 revenue is for BMS; acquired firm revenue is for BMS,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390,35,2641,272,53,Disorders of lipid metabolism,2,0
265,EVOLOCUMAB,"AMG-145; REPATHA; REPATHA; ANTI-PCSK9 MAB (HYPERCHOLESTEROLEMIA), AMGEN; EVOLOCUMAB","AMG-145; REPATHA; REPATHA; ANTI-PCSK9 MAB (HYPERCHOLESTEROLEMIA), AMGEN; EVOLOCUMAB",EVOLOCUMAB,AMG-145,REPATHA,REPATHA,"ANTI-PCSK9 MAB (HYPERCHOLESTEROLEMIA), AMGEN",EVOLOCUMAB,,,,,,,,,,,,,,,,,,,,,,,,,,125522,EVOLOCUMAB,,,,,,,,,,,,,,,,,,,,,2015-08-27T00:00:00Z,2015,8,Repatha,familial hypercholesterolemia,PROPROTEIN CONVERTASE PC9 INHIBITOR,ANTIHYPERCHOLESTEROLEMIC AGENT; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMAN; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125522,BLA,2014-08-27T00:00:00Z,fda,0,0,0,1,0,,amgen,NASDAQ: AMGN,1,21662,20063,18676,17265,15582,15053,17487,4006,4160,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522,55,3204,272,53,Disorders of lipid metabolism,2,0
25,ALIROCUMAB,"ELIRIDUC; GOLYRA; PRALUENT; PRALUENT; REGN-727; RENG-727; SAR-236553; ALIROCUMAB; ANTI-PCSK9 ANTIBODY (HYPERCHOLESTEROLEMIA), REGENERON/SANOFI-AVENTIS","ELIRIDUC; GOLYRA; PRALUENT; PRALUENT; REGN-727; RENG-727; SAR-236553; ALIROCUMAB; ANTI-PCSK9 ANTIBODY (HYPERCHOLESTEROLEMIA), REGENERON/SANOFI-AVENTIS",ALIROCUMAB,ELIRIDUC,GOLYRA,PRALUENT,PRALUENT,REGN-727,RENG-727,SAR-236553,ALIROCUMAB,"ANTI-PCSK9 ANTIBODY (HYPERCHOLESTEROLEMIA), REGENERON/SANOFI-AVENTIS",,,,,,,,,,,,,,,,,,,,,,125559,ALIROCUMAB,,,,,,,,,,,,,,,,,,,,,2015-07-24T00:00:00Z,2015,7,Praluent,familial hypercholesterolemia,PROPROTEIN CONVERTASE PC9 INHIBITOR,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTIHYPERLIPIDEMIC AGENT,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMAN; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125559,BLA,2014-11-24T00:00:00Z,fda,1,0,0,0,0,,sanofi,NYSE: SNY,1,37861.5,38732.7,43091.6,47408.5,45544.7,45640,26002.7,5519.41,5519.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125559,62,3204,272,53,Disorders of lipid metabolism,2,0
660,SEBELIPASE ALFA,"KANUMA; SBC-102; ENZYME REPLACEMENT THERAPY (PROTEIN RECOMBINANT, LYSOSOMAL ACID LIPASE DEFICIENCY), SYNAGEVA BIOPHARMA; SEBELIPASE ALFA","KANUMA; SBC-102; ENZYME REPLACEMENT THERAPY (PROTEIN RECOMBINANT, LYSOSOMAL ACID LIPASE DEFICIENCY), SYNAGEVA BIOPHARMA; SEBELIPASE ALFA",SEBELIPASE ALFA,KANUMA,SBC-102,"ENZYME REPLACEMENT THERAPY (PROTEIN RECOMBINANT, LYSOSOMAL ACID LIPASE DEFICIENCY), SYNAGEVA BIOPHARMA",SEBELIPASE ALFA,,,,,,,,,,,,,,,,,,,,,,,,,,,125561,SEBELIPASE ALFA,,,,,,,,,,,,,,,,,,,,,2015-12-08T00:00:00Z,2015,12,Kanuma,lysosomal acid lipase deficiency,LYSOSOMAL ACID LIPASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; RECOMBINANT ENZYME; SOLUTION; TRANSGENIC ANIMAL,matched (3),125561,BLA,2015-01-08T00:00:00Z,fda,0,0,1,1,1,2013-05-20T00:00:00Z,alexion pharmaceuticals,NASDAQ: ALXN,1,2604,2234,1551.35,1134.11,783.431,540.957,2371,709,709,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125561,63,3523,272,53,Disorders of lipid metabolism,2,0
268,"EZETIMIBE + ATORVASTATIN, MERCK & CO","ATOZET; LIPTRUZET; MK-0653C; SCH-900068; ZETEZE; EZETIMIBE + ATORVASTATIN; EZETIMIBE + ATORVASTATIN, MERCK & CO; EZETIMIBE + ATORVASTATIN, SCHERING-PLOUGH/MERCK & CO","ATOZET; LIPTRUZET; MK-0653C; SCH-900068; ZETEZE; EZETIMIBE + ATORVASTATIN; EZETIMIBE + ATORVASTATIN, MERCK & CO; EZETIMIBE + ATORVASTATIN, SCHERING-PLOUGH/MERCK & CO","EZETIMIBE + ATORVASTATIN, MERCK & CO",ATOZET,LIPTRUZET,MK-0653C,SCH-900068,ZETEZE,EZETIMIBE + ATORVASTATIN,"EZETIMIBE + ATORVASTATIN, MERCK & CO","EZETIMIBE + ATORVASTATIN, SCHERING-PLOUGH/MERCK & CO",,,,,,,,,,,,,,,,,,,,,,,200153,ATORVASTATIN CALCIUM; EZETIMIBE,,,,,,,,,,,,,,,,,,,,,2013-05-03T00:00:00Z,2013,5,Liptruzet,hypercholesterolemia,HMG COA REDUCTASE INHIBITOR,ANTIHYPERCHOLESTEROLEMIC AGENT; LDL CHOLESTEROL INHIBITOR; LIPID UPTAKE INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200153,NDA,2009-09-02T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,44033,47267,48047,45987,27428,23850,28052,7123,7224,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200153,70,174,272,53,Disorders of lipid metabolism,2,0
369,"ICOSAPENT ETHYL, AMARIN","AMR-101; LAX-101; LAX-101A; LAX-101B; LAX-101C; LAX-101D; LX-101; LYXIA; MIRAXION; SC-111; VASCEPA; ETHYL EICOSOPENTAENOATE; ETHYLEICOSAPENTAENOIC ACID, AMARIN; ICOSAPENT ETHYL ESTER; ICOSAPENT ETHYL, AMARIN","AMR-101; LAX-101; LAX-101A; LAX-101B; LAX-101C; LAX-101D; LX-101; LYXIA; MIRAXION; SC-111; VASCEPA; ETHYL EICOSOPENTAENOATE; ETHYLEICOSAPENTAENOIC ACID, AMARIN; ICOSAPENT ETHYL ESTER; ICOSAPENT ETHYL, AMARIN","ICOSAPENT ETHYL, AMARIN",AMR-101,LAX-101,LAX-101A,LAX-101B,LAX-101C,LAX-101D,LX-101,LYXIA,MIRAXION,SC-111,VASCEPA,ETHYL EICOSOPENTAENOATE,"ETHYLEICOSAPENTAENOIC ACID, AMARIN",ICOSAPENT ETHYL ESTER,"ICOSAPENT ETHYL, AMARIN",,,,,,,,,,,,,,,,202057,ICOSAPENT ETHYL,,,,,,,,,,,,,,,,,,,,,2012-07-26T00:00:00Z,2012,7,Vascepa,hypertriglyceridemia,APOLIPOPROTEIN B ANTAGONIST; PHOSPHOLIPASE A2 INHIBITOR,ANTIDEPRESSANT; ANTIHYPERLIPIDEMIC AGENT; ANTIHYPERTRIGLYCERIDEMIC AGENT; ESSENTIAL FATTY ACID; LIPID METABOLISM MODULATOR,CAPSULE FORMULATION; LIPID; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202057,NDA,2011-09-25T00:00:00Z,fda,0,0,0,0,0,,amarin,NASDAQ: AMRN,1,,,,,,,,59,59,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202057,97,2236,272,53,Disorders of lipid metabolism,2,0
493,"MIPOMERSEN (HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA), KASTLE","ISIS-147764; ISIS-281625; ISIS-301012; ISIS-301012 (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; ISIS-301027; KYNAMRO; ANTISENSE OLIGONUCLEOTIDE (INJECTABLE, CARDIOVASCULAR), ISIS; APOB-100 INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; APOLIPOPROTEIN B INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; MIPOMERSEN; MIPOMERSEN (HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA), KASTLE; MIPOMERSEN (SC, HYPERCHOLESTEROLEMIA), ISIS/GENZYME","ISIS-147764; ISIS-281625; ISIS-301012; ISIS-301012 (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; ISIS-301027; KYNAMRO; ANTISENSE OLIGONUCLEOTIDE (INJECTABLE, CARDIOVASCULAR), ISIS; APOB-100 INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; APOLIPOPROTEIN B INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS; MIPOMERSEN; MIPOMERSEN (HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA), KASTLE; MIPOMERSEN (SC, HYPERCHOLESTEROLEMIA), ISIS/GENZYME","MIPOMERSEN (HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA), KASTLE",ISIS-147764,ISIS-281625,ISIS-301012,"ISIS-301012 (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS",ISIS-301027,KYNAMRO,"ANTISENSE OLIGONUCLEOTIDE (INJECTABLE, CARDIOVASCULAR), ISIS","APOB-100 INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS","APOLIPOPROTEIN B INHIBITOR (INJECTABLE, HYPERCHOLESTEROLEMIA), ISIS",MIPOMERSEN,"MIPOMERSEN (HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA), KASTLE","MIPOMERSEN (SC, HYPERCHOLESTEROLEMIA), ISIS/GENZYME",,,,,,,,,,,,,,,,,,,203568,MIPOMERSEN SODIUM,,,,,,,,,,,,,,,,,,,,,2013-01-29T00:00:00Z,2013,1,Kynamro,familial hypercholesterolemia,APOB GENE INHIBITOR; APOLIPOPROTEIN B100 ANTAGONIST,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE INHIBITOR,BIOLOGICAL THERAPEUTIC; OLIGONUCLEOTIDE ANTISENSE; SOLUTION; SUBCUTANEOUS FORMULATION; WEEKLY DOSING,matched (3),203568,NDA,2012-03-29T00:00:00Z,fda,0,0,0,1,0,,sanofi,NYSE: SNY,1,43091.6,47408.5,45544.7,4048.7,3977.3,4127.4,28915.5,6341.7,6341.7,,,2011,,acquired by sanofi in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203568,164,3204,272,53,Disorders of lipid metabolism,2,0
441,LOMITAPIDE,"AEGR-733; BMS-201038; JUXTAPID; LOJUXTA; MJ-3980; MTP INHIBITORS (HYPERLIPIDEMIA), AEGERION; LOMITAPIDE; LOMITAPIDE MESYLATE; MICROSOMAL TRANSFER PROTEIN INHIBITORS (HYPERLIPIDEMIA), AEGERION","AEGR-733; BMS-201038; JUXTAPID; LOJUXTA; MJ-3980; MTP INHIBITORS (HYPERLIPIDEMIA), AEGERION; LOMITAPIDE; LOMITAPIDE MESYLATE; MICROSOMAL TRANSFER PROTEIN INHIBITORS (HYPERLIPIDEMIA), AEGERION",LOMITAPIDE,AEGR-733,BMS-201038,JUXTAPID,LOJUXTA,MJ-3980,"MTP INHIBITORS (HYPERLIPIDEMIA), AEGERION",LOMITAPIDE,LOMITAPIDE MESYLATE,"MICROSOMAL TRANSFER PROTEIN INHIBITORS (HYPERLIPIDEMIA), AEGERION",,,,,,,,,,,,,,,,,,,,,,203858,LOMITAPIDE MESYLATE,,,,,,,,,,,,,,,,,,,,,2012-12-21T00:00:00Z,2012,12,Juxtapid,familial hypercholesterolemia,MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTIHYPERTRIGLYCERIDEMIC AGENT,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203858,NDA,2012-02-28T00:00:00Z,fda,0,0,0,1,0,,aegerion pharmaceuticals,NASDAQ: AEGR,1,,,,,,,,25.2,25.2,,,,,acquired by QLT in 2016,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203858,172,3204,272,53,Disorders of lipid metabolism,2,0
235,ELIGLUSTAT TARTRATE,"CERDELGA; CEREDELGA; D-THREO-ET-P4; GENZ-11268; GZ-385660; GENZ-112638; GENZ-78132; GENZ-99067; ELIGLUSTAT; ELIGLUSTAT TARTRATE; SUBSTRATE INHIBITORS (GAUCHER DISEASE), GENZYME; SUBSTRATE INHIBITORS (LYSOSOMAL STORAGE DISEASE), GENZYME","CERDELGA; CEREDELGA; D-THREO-ET-P4; GENZ-11268; GZ-385660; GENZ-112638; GENZ-78132; GENZ-99067; ELIGLUSTAT; ELIGLUSTAT TARTRATE; SUBSTRATE INHIBITORS (GAUCHER DISEASE), GENZYME; SUBSTRATE INHIBITORS (LYSOSOMAL STORAGE DISEASE), GENZYME",ELIGLUSTAT TARTRATE,CERDELGA,CEREDELGA,D-THREO-ET-P4,GENZ-11268,GZ-385660,GENZ-112638,GENZ-78132,GENZ-99067,ELIGLUSTAT,ELIGLUSTAT TARTRATE,"SUBSTRATE INHIBITORS (GAUCHER DISEASE), GENZYME","SUBSTRATE INHIBITORS (LYSOSOMAL STORAGE DISEASE), GENZYME",,,,,,,,,,,,,,,,,,,205494,ELIGLUSTAT TARTRATE,205494,ELIGLUSTAT TARTRATE,,,,,,,,,,,,,,,,,,,2014-08-19T00:00:00Z,2014,8,Cerdelga,gauchers disease type i,GLUCOSYLCERAMIDE SYNTHASE INHIBITOR,GLYCOLIPID INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205494,NDA,2013-09-19T00:00:00Z,fda,1,0,0,1,0,,sanofi,NYSE: SNY,1,38737.7,43091.6,47408.5,45544.7,4048.7,3977.3,26349.9,5649.1,5649.1,,,2011,,acquired by sanofi in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205494,241,2245,272,53,Disorders of lipid metabolism,2,0
148,"CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), RETROPHIN","CHOLBAM; CHOLBAM; KOLBAM; XEBAM; CHOLIC ACID; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS), ASKLEPION; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), ASKLEPION; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), RETROPHIN","CHOLBAM; CHOLBAM; KOLBAM; XEBAM; CHOLIC ACID; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS), ASKLEPION; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), ASKLEPION; CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), RETROPHIN","CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), RETROPHIN",CHOLBAM,CHOLBAM,KOLBAM,XEBAM,CHOLIC ACID,"CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS), ASKLEPION","CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), ASKLEPION","CHOLIC ACID (ORAL CAPSULE, BILE ACID METABOLISM DEFICITS/PEROXISOMAL DISORDERS), RETROPHIN",,,,,,,,,,,,,,,,,,,,,,,205750,CHOLIC ACID,205750,CHOLIC ACID,,,,,,,,,,,,,,,,,,,2015-03-17T00:00:00Z,2015,3,Cholbam,lysosomal acid lipase deficiency,,BILE ACID MODULATOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205750,NDA,2013-11-21T00:00:00Z,fda,1,0,0,1,0,,asklepion,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205750,253,3523,272,53,Disorders of lipid metabolism,2,0
273,"FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), VELOXIS","FENOGLIDE; FENOFIBRATE; FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), VELOXIS; FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), LIFECYCLE PHARMA","FENOGLIDE; FENOFIBRATE; FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), VELOXIS; FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), LIFECYCLE PHARMA","FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), VELOXIS",FENOGLIDE,FENOFIBRATE,"FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), VELOXIS","FENOFIBRATE (IMPROVED TABLET FORMULATION, MELTDOSE), LIFECYCLE PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,,22118,FENOFIBRATE,,,,,,,,,,,,,,,,,,,,,2007-08-10T00:00:00Z,2007,8,Fenoglide,hypertriglyceridemia,PPAR ALPHA AGONIST,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTIHYPERLIPIDEMIC AGENT; ANTIHYPERTRIGLYCERIDEMIC AGENT,ORAL ABSORPTION ENHANCER; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022118,NDA,2006-09-28T00:00:00Z,fda,0,0,0,0,0,,veloxis pharmaceuticals,CPH: VELO,1,12.7,1.7,0.4,0.2,,,12.7,35.9,35.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022118,473,2236,272,53,Disorders of lipid metabolism,2,0
149,CHOLINE FENOFIBRATE,"ABT-335; HEXA, SOLVAY; SLV-348; TRILIPIX; CHOLINE FENOFIBRATE; FENOFIBRIC ACID; LIPID METABOLISM MODULATOR (MIXED DYSLIPIDEMIA), ABBOTT; NEXT-GENERATION TRICOR, ABBOTT","ABT-335; HEXA, SOLVAY; SLV-348; TRILIPIX; CHOLINE FENOFIBRATE; FENOFIBRIC ACID; LIPID METABOLISM MODULATOR (MIXED DYSLIPIDEMIA), ABBOTT; NEXT-GENERATION TRICOR, ABBOTT",CHOLINE FENOFIBRATE,ABT-335,"HEXA, SOLVAY",SLV-348,TRILIPIX,CHOLINE FENOFIBRATE,FENOFIBRIC ACID,"LIPID METABOLISM MODULATOR (MIXED DYSLIPIDEMIA), ABBOTT","NEXT-GENERATION TRICOR, ABBOTT",,,,,,,,,,,,,,,,,,,,,,,22224,CHOLINE FENOFIBRATE,,,,,,,,,,,,,,,,,,,,,2008-12-15T00:00:00Z,2008,12,Trilipix,lipid metabolism disorder,PPAR ALPHA AGONIST,LIPID METABOLISM MODULATOR,CAPSULE FORMULATION; CONTROLLED RELEASE FORMULATION; ENTERIC COATED FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022224,NDA,2007-12-07T00:00:00Z,fda,0,0,0,0,0,,abbott laboratories,NYSE: ABT,1,29527.6,25914.2,22476.3,22337.8,19680,17280.3,17044.5,2688.8,2688.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022224,504,584,272,53,Disorders of lipid metabolism,2,0
595,PITAVASTATIN,1-PC-002; ALIPZA; KN-104; LIVALO; LIVALO OD; LIVAZO; NK-104; NK-104 (LACTONE); NKS-104; P-872441; PITAVA; PIVASTA; REDEVANT; ITABASTATIN; ITAVASTATIN; NISVASTATIN; PITAVASTATIN; PITAVASTATIN CALCIUM,1-PC-002; ALIPZA; KN-104; LIVALO; LIVALO OD; LIVAZO; NK-104; NK-104 (LACTONE); NKS-104; P-872441; PITAVA; PIVASTA; REDEVANT; ITABASTATIN; ITAVASTATIN; NISVASTATIN; PITAVASTATIN; PITAVASTATIN CALCIUM,PITAVASTATIN,1-PC-002,ALIPZA,KN-104,LIVALO,LIVALO OD,LIVAZO,NK-104,NK-104 (LACTONE),NKS-104,P-872441,PITAVA,PIVASTA,REDEVANT,ITABASTATIN,ITAVASTATIN,NISVASTATIN,PITAVASTATIN,PITAVASTATIN CALCIUM,,,,,,,,,,,,,22363,PITAVASTATIN CALCIUM,,,,,,,,,,,,,,,,,,,,,2009-08-03T00:00:00Z,2009,8,Livalo,hypercholesterolemia,HMG COA REDUCTASE INHIBITOR,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTIHYPERTRIGLYCERIDEMIC AGENT,FILM COATING; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022363,NDA,2008-10-01T00:00:00Z,fda,0,0,0,0,0,,kowa pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022363,539,174,272,53,Disorders of lipid metabolism,2,0
274,"FENOFIBRIC ACID (TABLET, DYSLIPIDEMIA), AR SCIENTIFIC/URL PHARMA","FIBRICOR; FENOFIBRIC ACID; FENOFIBRIC ACID (TABLET, DYSLIPIDEMIA), AR SCIENTIFIC/URL PHARMA","FIBRICOR; FENOFIBRIC ACID; FENOFIBRIC ACID (TABLET, DYSLIPIDEMIA), AR SCIENTIFIC/URL PHARMA","FENOFIBRIC ACID (TABLET, DYSLIPIDEMIA), AR SCIENTIFIC/URL PHARMA",FIBRICOR,FENOFIBRIC ACID,"FENOFIBRIC ACID (TABLET, DYSLIPIDEMIA), AR SCIENTIFIC/URL PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,22418,FENOFIBRIC ACID,,,,,,,,,,,,,,,,,,,,,2009-08-14T00:00:00Z,2009,8,Fibricor,lipid metabolism disorder,PPAR ALPHA AGONIST,ANTIHYPERCHOLESTEROLEMIC AGENT; ANTIHYPERTRIGLYCERIDEMIC AGENT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022418,NDA,2008-08-15T00:00:00Z,fda,0,0,0,0,0,,sun pharmaceutical,NSE: SUNPHARMA,1,889.5,904.1,671.8,452,342.1,252.2,607.2,62.5,53,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022418,557,584,272,53,Disorders of lipid metabolism,2,0
703,TALIGLUCERASE ALFA,"ELELYSO; UPLYSO; ALFATALIGLICERASE; ALPHATALIGLICERASE; GLUCOCEREBROSIDASE ENZYME REPLACEMENT THERAPY (IV /INFUSION/PROTEIN RECOMBINANT), GAUCHERS DISEASE), PROTALIX; PLANT CELL CULTURE-DERIVED ENZYME REPLACEMENT THERAPY (PRGCD), PROTALIX; PRGCD; TALIGLUCERASE ALFA","ELELYSO; UPLYSO; ALFATALIGLICERASE; ALPHATALIGLICERASE; GLUCOCEREBROSIDASE ENZYME REPLACEMENT THERAPY (IV /INFUSION/PROTEIN RECOMBINANT), GAUCHERS DISEASE), PROTALIX; PLANT CELL CULTURE-DERIVED ENZYME REPLACEMENT THERAPY (PRGCD), PROTALIX; PRGCD; TALIGLUCERASE ALFA",TALIGLUCERASE ALFA,ELELYSO,UPLYSO,ALFATALIGLICERASE,ALPHATALIGLICERASE,"GLUCOCEREBROSIDASE ENZYME REPLACEMENT THERAPY (IV /INFUSION/PROTEIN RECOMBINANT), GAUCHERS DISEASE), PROTALIX","PLANT CELL CULTURE-DERIVED ENZYME REPLACEMENT THERAPY (PRGCD), PROTALIX",PRGCD,TALIGLUCERASE ALFA,,,,,,,,,,,,,,,,,,,,,,,22458,TALIGLUCERASE ALFA,,,,,,,,,,,,,,,,,,,,,2012-05-01T00:00:00Z,2012,5,Elelyso,gauchers disease type i,GLUCOSYLCERAMIDASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; ENZYME; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME,matched (3),022458,NDA,2010-04-26T00:00:00Z,fda,0,0,1,1,0,,protalix,AMEX: PLX,1,34.4,3,11.2,0.4,,,26.3,28.7,36.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022458,568,2245,272,53,Disorders of lipid metabolism,2,0
724,TESAMORELIN,"EGRIFTA; GRF1-44, STABILIZED, SAKAI; GRF1-44, STABILIZED, THERATECHNOLOGIES; TH-9507; TH-9507 ACETATE; THGRF; THGRF1-44 (STABILIZED), THERATECHNOLOGIES; TESAMORELIN; TESAMORELIN ACETATE; TRUNCATED SOMATORELIN (STABILIZED), THERATECHNOLOGIES","EGRIFTA; GRF1-44, STABILIZED, SAKAI; GRF1-44, STABILIZED, THERATECHNOLOGIES; TH-9507; TH-9507 ACETATE; THGRF; THGRF1-44 (STABILIZED), THERATECHNOLOGIES; TESAMORELIN; TESAMORELIN ACETATE; TRUNCATED SOMATORELIN (STABILIZED), THERATECHNOLOGIES",TESAMORELIN,EGRIFTA,"GRF1-44, STABILIZED, SAKAI","GRF1-44, STABILIZED, THERATECHNOLOGIES",TH-9507,TH-9507 ACETATE,THGRF,"THGRF1-44 (STABILIZED), THERATECHNOLOGIES",TESAMORELIN,TESAMORELIN ACETATE,"TRUNCATED SOMATORELIN (STABILIZED), THERATECHNOLOGIES",,,,,,,,,,,,,,,,,,,,,22505,TESAMORELIN ACETATE,,,,,,,,,,,,,,,,,,,,,2010-11-10T00:00:00Z,2010,11,Egrifta,hiv-associated lipodystrophy,GHRH RECEPTOR AGONIST,GROWTH HORMONE RELEASE STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; PEPTIDE; SUBCUTANEOUS FORMULATION,matched (3),022505,NDA,2009-05-29T00:00:00Z,fda,0,0,0,0,0,,theratechnologies,TSX: TH,1,31,16.5,0.2,0.6,0.2,12.7,16.9,,14.6,,,,,financials are for 12 months ending november 30th,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505,581,2642,272,53,Disorders of lipid metabolism,2,0
777,VELAGLUCERASE ALFA,"CERAMIDASE, GLUCOSYL-(HUMAN HT-1080 CELL); DRX-008A; GA-GCB; GAUCHERS DISEASE THERAPY, TKT; HUMAN GLUCOSYLCERAMIDASE (EC 3.2.1.45 OR BETA-GLUCOCEREBROSIDASE), GLYCOFORM ALPHA; VPRIV; ENZYME REPLACEMENT THERAPY (GAUCHER DISEASE), TKT; GENE-ACTIVATED GLUCOCEREBROSIDASE REPLACEMENT THERAPY (GAUCHER DISEASE), TKT; VELAGLUCERASE ALFA","CERAMIDASE, GLUCOSYL-(HUMAN HT-1080 CELL); DRX-008A; GA-GCB; GAUCHERS DISEASE THERAPY, TKT; HUMAN GLUCOSYLCERAMIDASE (EC 3.2.1.45 OR BETA-GLUCOCEREBROSIDASE), GLYCOFORM ALPHA; VPRIV; ENZYME REPLACEMENT THERAPY (GAUCHER DISEASE), TKT; GENE-ACTIVATED GLUCOCEREBROSIDASE REPLACEMENT THERAPY (GAUCHER DISEASE), TKT; VELAGLUCERASE ALFA",VELAGLUCERASE ALFA,"CERAMIDASE, GLUCOSYL-(HUMAN HT-1080 CELL)",DRX-008A,GA-GCB,"GAUCHERS DISEASE THERAPY, TKT","HUMAN GLUCOSYLCERAMIDASE (EC 3.2.1.45 OR BETA-GLUCOCEREBROSIDASE), GLYCOFORM ALPHA",VPRIV,"ENZYME REPLACEMENT THERAPY (GAUCHER DISEASE), TKT","GENE-ACTIVATED GLUCOCEREBROSIDASE REPLACEMENT THERAPY (GAUCHER DISEASE), TKT",VELAGLUCERASE ALFA,,,,,,,,,,,,,,,,,,,,,,22575,VELAGLUCERASE ALFA,,,,,,,,,,,,,,,,,,,,,2010-02-26T00:00:00Z,2010,2,Vpriv,gauchers disease type i,GLUCOSYLCERAMIDASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME,matched (3),022575,NDA,2009-08-31T00:00:00Z,fda,1,0,1,1,0,,shire,NASDAQ: SHPG,1,3471.1,3007.7,3022.2,2436.3,1796.5,1599.3,3007.7,661.5,661.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022575,608,2245,272,53,Disorders of lipid metabolism,2,0
33,"ALPHA-1 ANTITRYPSIN (IV, IMMUNE/RESPIRATORY DISEASE/TYPE 1 DIABETES), SHIRE/KAMADA","AAT-IV; D1-AAT; G1-AAT IV; GLASSIA; ALPHA 1 PROTEINASE INHIBITOR (IV, AAT DEFICIENCY), BAXTER; ALPHA 1 PROTEINASE INHIBITOR (IV, AAT DEFICIENCY), KAMADA; ALPHA 1 PROTEINASE INHIBITOR (IV, IMMUNE/RESPIRATORY DISEASE/TYPE 1 DIABETES), BAXTER/KAMADA; ALPHA-1 ANTITRYPSIN (IV, IMMUNE/RESPIRATORY DISEASE/TYPE 1 DIABETES), BAXALTA/KAMADA; ALPHA-1 ANTITRYPSIN (IV, IMMUNE/RESPIRATORY DISEASE/TYPE 1 DIABETES), BAXTER/KAMADA; ALPHA-1 ANTITRYPSIN (IV, IMMUNE/RESPIRATORY DISEASE/TYPE 1 DIABETES), SHIRE/KAMADA; ALPHA-1-ANTITRYPSIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-07-01T00:00:00Z,2010,7,Glassia,alpha-1 antitrypsin deficiency,ALPHA 1 ANTITRYPSIN STIMULATOR,HYPOGLYCEMIC AGENT; RESPIRATORY SYSTEM AGENT,INTRAVENOUS FORMULATION; LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),125325,BLA,2009-05-15T00:00:00Z,cortellis,0,0,0,0,0,,kamada,private,0,34.5,15,15.2,13.4,13.8,11.3,5.8,9,9.3,,,,,NASDAQ IPO in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125325,636,1298,273,58,Other nutritional; endocrine; and metabolic disorders,1,0
580,PEGLOTICASE,"KRYSTEXXA; PEG-URICASE; PURICASE; PEGLOTICASE; RECOMBINANT URICASE, BIO-TECHNOLOGY GENERAL; RECOMBINANT URICASE, CREALTA PHARMACEUTICALS; RECOMBINANT URICASE, HORIZON PHARMA; RECOMBINANT URICASE, SAVIENT","KRYSTEXXA; PEG-URICASE; PURICASE; PEGLOTICASE; RECOMBINANT URICASE, BIO-TECHNOLOGY GENERAL; RECOMBINANT URICASE, CREALTA PHARMACEUTICALS; RECOMBINANT URICASE, HORIZON PHARMA; RECOMBINANT URICASE, SAVIENT",PEGLOTICASE,KRYSTEXXA,PEG-URICASE,PURICASE,PEGLOTICASE,"RECOMBINANT URICASE, BIO-TECHNOLOGY GENERAL","RECOMBINANT URICASE, CREALTA PHARMACEUTICALS","RECOMBINANT URICASE, HORIZON PHARMA","RECOMBINANT URICASE, SAVIENT",,,,,,,,,,,,,,,,,,,,,,,125293,PEGLOTICASE,,,,,,,,,,,,,,,,,,,,,2010-09-14T00:00:00Z,2010,9,Krystexxa,gout,URICASE STIMULATOR,RENAL SYSTEM AGENT; URIC ACID MODULATOR,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PEGYLATED FORMULATION; RECOMBINANT ENZYME; SOLUTION,matched (3),125293,BLA,2008-10-31T00:00:00Z,fda,1,0,0,1,0,,savient pharmaceuticals,NASDAQ: SVNT,1,4,3,3.2,14,47.5,49.5,1.4,25.6,32.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125293,21,136,274,54,Gout and other crystal arthropathies,1,0
167,"COLCHICINE (CAPSULE, GOUT FLARES), HIKMA PHARMACEUTICALS","MITIGARE; COLCHICINE; COLCHICINE (CAPSULE, GOUT FLARES), HIKMA PHARMACEUTICALS","MITIGARE; COLCHICINE; COLCHICINE (CAPSULE, GOUT FLARES), HIKMA PHARMACEUTICALS","COLCHICINE (CAPSULE, GOUT FLARES), HIKMA PHARMACEUTICALS",MITIGARE,COLCHICINE,"COLCHICINE (CAPSULE, GOUT FLARES), HIKMA PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,,204820,COLCHICINE,,,,,,,,,,,,,,,,,,,,,2014-09-26T00:00:00Z,2014,9,Mitigare,gout,,ANTI-INFLAMMATORY; CELL CYCLE INHIBITOR,CAPSULE FORMULATION; NATURAL PRODUCT; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204820,NDA,2012-10-05T00:00:00Z,fda,0,0,0,0,0,,hikma pharmaceuticals,LON: HIK,1,1489,1365,1109,918,730.9,636.9,819,55,55,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204820,219,136,274,54,Gout and other crystal arthropathies,1,0
416,LESINURAD,"RDEA-594; URAT1 INHIBITOR (HYPERURICEMIA/GOUT), ARDEA; ZURAMPIC; ZURAMPIC; LESINURAD; LESINURAD SODIUM; URATE TRANSPORTER 1 INHIBITOR (ORAL, HYPERURICEMIA/GOUT), ARDEA","RDEA-594; URAT1 INHIBITOR (HYPERURICEMIA/GOUT), ARDEA; ZURAMPIC; ZURAMPIC; LESINURAD; LESINURAD SODIUM; URATE TRANSPORTER 1 INHIBITOR (ORAL, HYPERURICEMIA/GOUT), ARDEA",LESINURAD,RDEA-594,"URAT1 INHIBITOR (HYPERURICEMIA/GOUT), ARDEA",ZURAMPIC,ZURAMPIC,LESINURAD,LESINURAD SODIUM,"URATE TRANSPORTER 1 INHIBITOR (ORAL, HYPERURICEMIA/GOUT), ARDEA",,,,,,,,,,,,,,,,,,,,,,,,207988,LESINURAD,,,,,,,,,,,,,,,,,,,,,2015-12-22T00:00:00Z,2015,12,Zurampic,gout,URATE ANION EXCHANGER 1 INHIBITOR; XANTHINE OXIDASE INHIBITOR,ANTI-INFLAMMATORY; URICOSURIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207988,NDA,2014-12-25T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,24708,26547,25806,27973,7.3,27.4,20248,5660,5861,,,2012,,acquired by astrazeneca in 2012,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207988,318,136,274,54,Gout and other crystal arthropathies,1,0
271,FEBUXOSTAT,"ADENURIC; FEBRIC; FEBRIC; FEBURIC; FEBURIC; TEI-6720; TMX-67; TMX-67TLS; TMX-67TLS; ULORIC; ULORIC; FEBUXOSTAT; NON-PURINE SELECTIVE INHIBITOR OF XANTHINE OXIDASE (NP-SIXO, ORAL, GOUT), TEIJIN/ TAP/ IPSEN/ SK","ADENURIC; FEBRIC; FEBRIC; FEBURIC; FEBURIC; TEI-6720; TMX-67; TMX-67TLS; TMX-67TLS; ULORIC; ULORIC; FEBUXOSTAT; NON-PURINE SELECTIVE INHIBITOR OF XANTHINE OXIDASE (NP-SIXO, ORAL, GOUT), TEIJIN/ TAP/ IPSEN/ SK",FEBUXOSTAT,ADENURIC,FEBRIC,FEBRIC,FEBURIC,FEBURIC,TEI-6720,TMX-67,TMX-67TLS,TMX-67TLS,ULORIC,ULORIC,FEBUXOSTAT,"NON-PURINE SELECTIVE INHIBITOR OF XANTHINE OXIDASE (NP-SIXO, ORAL, GOUT), TEIJIN/ TAP/ IPSEN/ SK",,,,,,,,,,,,,,,,,,21856,FEBUXOSTAT,,,,,,,,,,,,,,,,,,,,,2009-02-13T00:00:00Z,2009,2,Uloric,gout,XANTHINE OXIDASE INHIBITOR,,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021856,NDA,2004-12-15T00:00:00Z,cortellis,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15722.4,16561.7,12303.5,10759.3,10070.7,10838.9,12683.2,-1808.2,1341.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021856,395,136,274,54,Gout and other crystal arthropathies,1,0
168,"COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), TAKEDA","COLCRYS; MPC-004; COLCHICINE; COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), TAKEDA; COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), URL PHARMA","COLCRYS; MPC-004; COLCHICINE; COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), TAKEDA; COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), URL PHARMA","COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), TAKEDA",COLCRYS,MPC-004,COLCHICINE,"COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), TAKEDA","COLCHICINE (ORAL, GOUT/FAMILIAL MEDITERRANEAN FEVER), URL PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,22351,COLCHICINE,,,,,,,,,,,,,,,,,,,,,2009-07-30T00:00:00Z,2009,7,Colcrys,gout,,ANTI-INFLAMMATORY; ANTIARRHYTHMIC AGENT; MICROTUBULE INHIBITOR; URIC ACID MODULATOR,FILM COATING; NATURAL PRODUCT; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022351,NDA,2008-09-30T00:00:00Z,fda,0,0,0,0,0,,sun pharmaceutical,NSE: SUNPHARMA,1,889.5,904.1,671.8,452,342.1,252.2,607.2,62.5,53,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022351,538,136,274,54,Gout and other crystal arthropathies,1,0
64,ASFOTASE ALFA,"ALXN-1215; ENB-0040; PHEX-BASED ENZYME REPLACEMENT THERAPY, ALEXION; PHEX-BASED ENZYME REPLACEMENT THERAPY, BIOMEP; PHEX-BASED ENZYME REPLACEMENT THERAPY, ENOBIA; STRENSIQ; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ALEXION; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, BIOMEP; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ENOBIA; ASFOTASE ALFA; SPHEX, ALEXION; SPHEX, BIOMEP; SPHEX, ENOBIA","ALXN-1215; ENB-0040; PHEX-BASED ENZYME REPLACEMENT THERAPY, ALEXION; PHEX-BASED ENZYME REPLACEMENT THERAPY, BIOMEP; PHEX-BASED ENZYME REPLACEMENT THERAPY, ENOBIA; STRENSIQ; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ALEXION; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, BIOMEP; X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ENOBIA; ASFOTASE ALFA; SPHEX, ALEXION; SPHEX, BIOMEP; SPHEX, ENOBIA",ASFOTASE ALFA,ALXN-1215,ENB-0040,"PHEX-BASED ENZYME REPLACEMENT THERAPY, ALEXION","PHEX-BASED ENZYME REPLACEMENT THERAPY, BIOMEP","PHEX-BASED ENZYME REPLACEMENT THERAPY, ENOBIA",STRENSIQ,"X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ALEXION","X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, BIOMEP","X-LINKED HYPOPHOSPHATEMIC RICKETS THERAPY, ENOBIA",ASFOTASE ALFA,"SPHEX, ALEXION","SPHEX, BIOMEP","SPHEX, ENOBIA",,,,,,,,,,,,,,,,,,125513,ASFOTASE ALFA,,,,,,,,,,,,,,,,,,,,,2015-10-23T00:00:00Z,2015,10,Strensiq,hypophosphatasia,ALKALINE PHOSPHATASE STIMULATOR; MATRIX METALLOPROTEASE STIMULATOR; PHOSPHATE REGULATING ENDOPEPTIDASE STIMULATOR; TISSUE NONSPECIFIC ALKALINE PHOSPHATASE MODULATOR,ANTICANCER; PHOSPHATE METABOLISM MODULATOR,BIOLOGICAL THERAPEUTIC; ENZYME; GLYCOPROTEIN; PROTEIN FUSION; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125513,BLA,2014-12-23T00:00:00Z,fda,1,0,1,1,1,2013-05-28T00:00:00Z,alexion pharmaceuticals,NASDAQ: ALXN,1,2604,2234,1551.35,1134.11,783.431,540.957,2371,709,709,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125513,51,3791,275,58,Other nutritional; endocrine; and metabolic disorders,1,0
688,SUCROFERRIC OXYHYDROXIDE,"P-TOL, KISSEI; PA-21, VIFOR; PA-21, VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA; PEATLE; PIETLE; VELPHORO; VELPHORO; IRON BASED-PHOSPHATE BINDER (ORAL/CHEWABLE, HYPERPHOSPHATEMIA), VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA LTD; PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR; PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR/FRESENIUS/KISSEI; SUCROFERRIC OXYHYDROXIDE","P-TOL, KISSEI; PA-21, VIFOR; PA-21, VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA; PEATLE; PIETLE; VELPHORO; VELPHORO; IRON BASED-PHOSPHATE BINDER (ORAL/CHEWABLE, HYPERPHOSPHATEMIA), VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA LTD; PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR; PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR/FRESENIUS/KISSEI; SUCROFERRIC OXYHYDROXIDE",SUCROFERRIC OXYHYDROXIDE,"P-TOL, KISSEI","PA-21, VIFOR","PA-21, VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA",PEATLE,PIETLE,VELPHORO,VELPHORO,"IRON BASED-PHOSPHATE BINDER (ORAL/CHEWABLE, HYPERPHOSPHATEMIA), VIFOR-FRESENIUS MEDICAL CARE RENAL PHARMA LTD","PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR","PHOSPHATE LOWERING AGENT (ORAL, CHRONIC KIDNEY DISEASE), VIFOR/FRESENIUS/KISSEI",SUCROFERRIC OXYHYDROXIDE,,,,,,,,,,,,,,,,,,,,205109,SUCROFERRIC OXYHYDROXIDE,,,,,,,,,,,,,,,,,,,,,2013-11-27T00:00:00Z,2013,11,Velphoro,hyperphosphatemia,,PHOSPHATE LOWERING AGENT,BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205109,NDA,2013-01-31T00:00:00Z,fda,0,0,0,0,0,,galenica,VTX: GALN,1,3978.9,3882.1,3662.2,3640,3132.1,2903,1499.9,,141.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205109,226,1003,275,58,Other nutritional; endocrine; and metabolic disorders,1,0
282,"FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANACOR/KERYX/JAPAN TOBACCO/TORII/3SBIO","AURYXIA; AURYXIA; FEXERIC; FEXERIC; JTT-751; KRX-0502; NEPHOXIL; PBF-1681; RIONA; SERENE; ZERENEX; FERRIC CITRATE; FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANACOR/KERYX/JAPAN TOBACCO/TORII/3SBIO; FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANION & BF/KERYX/JAPAN TOBACCO/TORII/3SBIO; HYPERPHOSPHATEMIA THERAPY, PANION/KERYX","AURYXIA; AURYXIA; FEXERIC; FEXERIC; JTT-751; KRX-0502; NEPHOXIL; PBF-1681; RIONA; SERENE; ZERENEX; FERRIC CITRATE; FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANACOR/KERYX/JAPAN TOBACCO/TORII/3SBIO; FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANION & BF/KERYX/JAPAN TOBACCO/TORII/3SBIO; HYPERPHOSPHATEMIA THERAPY, PANION/KERYX","FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANACOR/KERYX/JAPAN TOBACCO/TORII/3SBIO",AURYXIA,AURYXIA,FEXERIC,FEXERIC,JTT-751,KRX-0502,NEPHOXIL,PBF-1681,RIONA,SERENE,ZERENEX,FERRIC CITRATE,"FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANACOR/KERYX/JAPAN TOBACCO/TORII/3SBIO","FERRIC CITRATE (ORAL, HYPERPHOSPHATEMIA), PANION & BF/KERYX/JAPAN TOBACCO/TORII/3SBIO","HYPERPHOSPHATEMIA THERAPY, PANION/KERYX",,,,,,,,,,,,,,,,205874,FERRIC CITRATE,205874,FERRIC CITRATE,,,,,,,,,,,,,,,,,,,2014-09-05T00:00:00Z,2014,9,Auryxia,hyperphosphatemia,,ANTI-INFLAMMATORY; PHOSPHATE LOWERING AGENT,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205874,NDA,2013-08-07T00:00:00Z,fda,0,0,0,0,0,,keryx biopharmaceuticals,NASDAQ: KERX,1,10.8,7,,5,,21.6,10.3,51.5,51.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205874,264,1003,275,58,Other nutritional; endocrine; and metabolic disorders,1,0
191,DEFERIPRONE,CGP-37391; CP-20; DEFERRUM; FERRIPROX; KELFER; L1; L1NALL; DEFERIPRONE,CGP-37391; CP-20; DEFERRUM; FERRIPROX; KELFER; L1; L1NALL; DEFERIPRONE,DEFERIPRONE,CGP-37391,CP-20,DEFERRUM,FERRIPROX,KELFER,L1,L1NALL,DEFERIPRONE,,,,,,,,,,,,,,,,,,,,,,,21825,DEFERIPRONE,,,,,,,,,,,,,,,,,,,,,2011-10-14T00:00:00Z,2011,10,Ferriprox,iron overload,,ANTIPARKINSONIAN; IRON CHELATOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021825,NDA,2009-01-29T00:00:00Z,fda,0,1,1,1,0,,apotex,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021825,390,1252,275,58,Other nutritional; endocrine; and metabolic disorders,1,0
665,"SEVELAMER CARBONATE (TABLET, RENAL DISEASE/HYPERPHOSPHATEMIA), GENZYME","GT-335-012; RENVELA; SECOND GENERATION SEVELAMER, GENZYME; SEVELAMER; SEVELAMER CARBONATE; SEVELAMER CARBONATE (TABLET, RENAL DISEASE/HYPERPHOSPHATEMIA), GENZYME","GT-335-012; RENVELA; SECOND GENERATION SEVELAMER, GENZYME; SEVELAMER; SEVELAMER CARBONATE; SEVELAMER CARBONATE (TABLET, RENAL DISEASE/HYPERPHOSPHATEMIA), GENZYME","SEVELAMER CARBONATE (TABLET, RENAL DISEASE/HYPERPHOSPHATEMIA), GENZYME",GT-335-012,RENVELA,"SECOND GENERATION SEVELAMER, GENZYME",SEVELAMER,SEVELAMER CARBONATE,"SEVELAMER CARBONATE (TABLET, RENAL DISEASE/HYPERPHOSPHATEMIA), GENZYME",,,,,,,,,,,,,,,,,,,,,,,,,22127,SEVELAMER CARBONATE,,,,,,,,,,,,,,,,,,,,,2007-10-19T00:00:00Z,2007,10,Renvela,hyperphosphatemia,,HYPOGLYCEMIC AGENT; PHOSPHATE LOWERING AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022127,NDA,2006-12-20T00:00:00Z,fda,1,0,0,0,0,,genzyme,NASDAQ: GENZ,1,3813.52,3187.01,2734.84,2201.14,1713.87,1329.47,2886.19,737.685,737.685,,,,,acquired by sanofi in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022127,475,1003,275,58,Other nutritional; endocrine; and metabolic disorders,1,0
576,PATIROMER CALCIUM,"PATIROMER FOS; RLY-5016; VELTASSA; VELTASSA; PATIROMER; PATIROMER CALCIUM; POTASSIUM BINDER (HYPERKALEMIA), RELYPSA; POTASSIUM BINDER (ORAL SUSPENSION FORMULATION, HYPERKALEMIA), RELYPSA","PATIROMER FOS; RLY-5016; VELTASSA; VELTASSA; PATIROMER; PATIROMER CALCIUM; POTASSIUM BINDER (HYPERKALEMIA), RELYPSA; POTASSIUM BINDER (ORAL SUSPENSION FORMULATION, HYPERKALEMIA), RELYPSA",PATIROMER CALCIUM,PATIROMER FOS,RLY-5016,VELTASSA,VELTASSA,PATIROMER,PATIROMER CALCIUM,"POTASSIUM BINDER (HYPERKALEMIA), RELYPSA","POTASSIUM BINDER (ORAL SUSPENSION FORMULATION, HYPERKALEMIA), RELYPSA",,,,,,,,,,,,,,,,,,,,,,,205739,PATIROMER SORBITEX CALCIUM,,,,,,,,,,,,,,,,,,,,,2015-10-21T00:00:00Z,2015,10,Veltassa,hyperkalemia,,ALDOSTERONE MODULATOR; ANTIHYPERTENSIVE; POTASSIUM METABOLISM MODULATOR,BEAD FORMULATION; FORMULATION POWDER; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205739,NDA,2014-10-21T00:00:00Z,fda,0,0,0,0,0,,relypsa,NASDAQ: RLYP,1,18.6,,,,,,-74.7,,93.3,,,,,acquired by galenica in 2016,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205739,252,2738,276,55,Fluid and electrolyte disorders,2,0
742,TOLVAPTAN,JINARC; OPC-41061; SAMSCA; SAMSKA; TOLVAPTAN,JINARC; OPC-41061; SAMSCA; SAMSKA; TOLVAPTAN,TOLVAPTAN,JINARC,OPC-41061,SAMSCA,SAMSKA,TOLVAPTAN,,,,,,,,,,,,,,,,,,,,,,,,,,22275,TOLVAPTAN,22275,TOLVAPTAN,,,,,,,,,,,,,,,,,,,2009-05-19T00:00:00Z,2009,5,Samsca,hyponatremia,VASOPRESSIN V2 ANTAGONIST,DIURETIC AGENT,GRANULE; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022275,NDA,2007-10-23T00:00:00Z,fda,0,0,0,0,0,,otsuka,private,0,11975.7333333333,,,,,,8062.93333333333,1529.6,1529.6,,,,,IPO in 2010; financials for 2009 are estimated from reported financials from the last 9 months of the year,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022275,519,1256,276,55,Fluid and electrolyte disorders,2,0
372,IDURSULFASE,"E.C. 3.1.6.13; ELAPRASE; I2S (IV), TKT; NICHE PROTEIN (IV, HUNTER DISEASE), TKT; ZIPRALASE; ENZYME REPLACEMENT THERAPY (IV, HUNTER SYNDROME), TKT; IDURONATE-2-SULFATASE; IDURONATE-2-SULFATASE (IV), TKT; IDURSULFASE","E.C. 3.1.6.13; ELAPRASE; I2S (IV), TKT; NICHE PROTEIN (IV, HUNTER DISEASE), TKT; ZIPRALASE; ENZYME REPLACEMENT THERAPY (IV, HUNTER SYNDROME), TKT; IDURONATE-2-SULFATASE; IDURONATE-2-SULFATASE (IV), TKT; IDURSULFASE",IDURSULFASE,E.C. 3.1.6.13,ELAPRASE,"I2S (IV), TKT","NICHE PROTEIN (IV, HUNTER DISEASE), TKT",ZIPRALASE,"ENZYME REPLACEMENT THERAPY (IV, HUNTER SYNDROME), TKT",IDURONATE-2-SULFATASE,"IDURONATE-2-SULFATASE (IV), TKT",IDURSULFASE,,,,,,,,,,,,,,,,,,,,,,125151,IDURSULFASE,,,,,,,,,,,,,,,,,,,,,2006-07-24T00:00:00Z,2006,7,Elaprase,hunter syndrome,IDURONATE 2-SULFATASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; CELL CULTURE; DNA TECHNOLOGY; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME; SOLUTION,matched (3),125151,BLA,2005-11-24T00:00:00Z,cortellis,1,0,1,1,0,,shire,NASDAQ: SHPG,1,1796.5,1599.3,1363.2,1331.48,1121.1,852.956,1584.8,385.4,385.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125151,6,2254,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
635,RILONACEPT,"ARCALYST; IL-1 TRAP; IL-1 TRAP, REGENERON; RGN-303; RILONACEPT","ARCALYST; IL-1 TRAP; IL-1 TRAP, REGENERON; RGN-303; RILONACEPT",RILONACEPT,ARCALYST,IL-1 TRAP,"IL-1 TRAP, REGENERON",RGN-303,RILONACEPT,,,,,,,,,,,,,,,,,,,,,,,,,,125249,RILONACEPT,,,,,,,,,,,,,,,,,,,,,2008-02-27T00:00:00Z,2008,2,Arcalyst,familial cold autoinflammatory syndrome,IL-1 ANTAGONIST; INTERLEUKIN-1 BETA LIGAND INHIBITOR,ANTI-INFLAMMATORY,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; PROTEIN FUSION; SUBCUTANEOUS FORMULATION,matched (3),125249,BLA,2007-05-25T00:00:00Z,fda,1,0,1,1,0,,regeneron pharmaceuticals,NASDAQ: REGN,1,238.5,125,63.4,66.2,174,57.5,-37.4,,274.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125249,11,3602,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
228,ECALLANTIDE,"CB-500929; DX-88; KALBITOR; ECALLANTIDE; KALLIKREIN INHIBITOR (HEREDITARY ANGIOEDEMA), DYAX","CB-500929; DX-88; KALBITOR; ECALLANTIDE; KALLIKREIN INHIBITOR (HEREDITARY ANGIOEDEMA), DYAX",ECALLANTIDE,CB-500929,DX-88,KALBITOR,ECALLANTIDE,"KALLIKREIN INHIBITOR (HEREDITARY ANGIOEDEMA), DYAX",,,,,,,,,,,,,,,,,,,,,,,,,,125277,ECALLANTIDE,,,,,,,,,,,,,,,,,,,,,2009-12-01T00:00:00Z,2009,12,Kalibitor,hereditary angioedema,KALLIKREIN INHIBITOR,BLOOD CLOTTING MODULATOR,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; INFUSION; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125277,BLA,2008-09-23T00:00:00Z,fda,1,0,1,1,0,,dyax,NASDAQ: DYAX,1,21.6,43.4,26.1,12.8,19.9,16.6,21.6,46.6,46.6,,,,,acquired by shire in 2016,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125277,17,156,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
131,CANAKINUMAB,"ACZ-885; ILARIS; ANTI-IL-1 BETA MONOCLONAL ANTIBODY (INFLAMMATION), NOVARTIS; CANAKINUMAB","ACZ-885; ILARIS; ANTI-IL-1 BETA MONOCLONAL ANTIBODY (INFLAMMATION), NOVARTIS; CANAKINUMAB",CANAKINUMAB,ACZ-885,ILARIS,"ANTI-IL-1 BETA MONOCLONAL ANTIBODY (INFLAMMATION), NOVARTIS",CANAKINUMAB,,,,,,,,,,,,,,,,,,,,,,,,,,,125319,CANAKINUMAB,,,,,,,,,,,,,,,,,,,,,2009-06-17T00:00:00Z,2009,6,Ilaris,muckle wells syndrome,IMMUNOGLOBULIN G1 AGONIST; INTERLEUKIN-1 BETA LIGAND INHIBITOR,ANTI-INFLAMMATORY; IMMUNOMODULATOR; IMMUNOSUPPRESSANT,BIOLOGICAL THERAPEUTIC; DNA TECHNOLOGY; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRA-ARTICULAR FORMULATION; LIQUID FORMULATION; MONOCLONAL ANTIBODY HUMAN; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125319,BLA,2008-12-15T00:00:00Z,fda,1,0,0,1,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125319,23,3222,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
236,ELOSULFASE ALFA,"BMN-110; N-ACETYLGALACTOSAMINE-6-SULFATASE (GALNS) (MORQUIO A SYNDROME), BIOMARIN; VIMIZIM; ELOSULFASE ALFA; ENZYME REPLACEMENT THERAPY (IV INFUSION, MPS IVA), BIOMARIN; ENZYME REPLACEMENT THERAPY (IV INFUSION, MORQUIO A SYNDROME), BIOMARIN; ENZYME REPLACEMENT THERAPY (IV INFUSION, MUCOPOLYSACCHARIDOSIS IVA), BIOMARIN; RHGALNS","BMN-110; N-ACETYLGALACTOSAMINE-6-SULFATASE (GALNS) (MORQUIO A SYNDROME), BIOMARIN; VIMIZIM; ELOSULFASE ALFA; ENZYME REPLACEMENT THERAPY (IV INFUSION, MPS IVA), BIOMARIN; ENZYME REPLACEMENT THERAPY (IV INFUSION, MORQUIO A SYNDROME), BIOMARIN; ENZYME REPLACEMENT THERAPY (IV INFUSION, MUCOPOLYSACCHARIDOSIS IVA), BIOMARIN; RHGALNS",ELOSULFASE ALFA,BMN-110,"N-ACETYLGALACTOSAMINE-6-SULFATASE (GALNS) (MORQUIO A SYNDROME), BIOMARIN",VIMIZIM,ELOSULFASE ALFA,"ENZYME REPLACEMENT THERAPY (IV INFUSION, MPS IVA), BIOMARIN","ENZYME REPLACEMENT THERAPY (IV INFUSION, MORQUIO A SYNDROME), BIOMARIN","ENZYME REPLACEMENT THERAPY (IV INFUSION, MUCOPOLYSACCHARIDOSIS IVA), BIOMARIN",RHGALNS,,,,,,,,,,,,,,,,,,,,,,,125460,ELOSULFASE ALFA,,,,,,,,,,,,,,,,,,,,,2014-02-14T00:00:00Z,2014,2,Vimizim,morquio syndrome,N-ACETYLGALACTOSAMINE 6 SULFATASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME,matched (3),125460,BLA,2013-03-29T00:00:00Z,fda,1,0,1,1,0,,biomarin pharmaceutical,NASDAQ: BMRN,1,749.3,548.5,500.7,441.4,376.3,324.7,165.5,,461.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125460,42,2256,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
398,IVACAFTOR,"CFTR CHANNEL POTENTIATORS (CYSTIC FIBROSIS), VERTEX/CFFT; KALYDECO; VRT-159; VRT-484; VX-770; IVACAFTOR","CFTR CHANNEL POTENTIATORS (CYSTIC FIBROSIS), VERTEX/CFFT; KALYDECO; VRT-159; VRT-484; VX-770; IVACAFTOR",IVACAFTOR,"CFTR CHANNEL POTENTIATORS (CYSTIC FIBROSIS), VERTEX/CFFT",KALYDECO,VRT-159,VRT-484,VX-770,IVACAFTOR,,,,,,,,,,,,,,,,,,,,,,,,,203188,IVACAFTOR,,,,,,,,,,,,,,,,,,,,,2012-01-31T00:00:00Z,2012,1,Kalydeco,cystic fibrosis,CFTR STIMULATOR,RESPIRATORY SYSTEM AGENT,FILM COATING; GRANULE; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203188,NDA,2011-10-18T00:00:00Z,fda,1,0,1,1,0,,vertex pharmaceuticals,NASDAQ: VRTX,1,1527,1410.6,143.4,101.9,175.5,199,481.3,,765.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203188,144,88,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
452,"LUMACAFTOR + IVACAFTOR (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS","ORKAMBI; ORKAMBI; ORKAMBI; VX-809 + VX-770 (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS; LUMACAFTOR + IVACAFTOR; LUMACAFTOR + IVACAFTOR (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS","ORKAMBI; ORKAMBI; ORKAMBI; VX-809 + VX-770 (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS; LUMACAFTOR + IVACAFTOR; LUMACAFTOR + IVACAFTOR (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS","LUMACAFTOR + IVACAFTOR (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS",ORKAMBI,ORKAMBI,ORKAMBI,"VX-809 + VX-770 (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS",LUMACAFTOR + IVACAFTOR,"LUMACAFTOR + IVACAFTOR (CYSTIC FIBROSIS), VERTEX/CYSTIC FIBROSIS FOUNDATION THERAPEUTICS",,,,,,,,,,,,,,,,,,,,,,,,,206038,IVACAFTOR; LUMACAFTOR,206038,IVACAFTOR; LUMACAFTOR,,,,,,,,,,,,,,,,,,,2015-07-02T00:00:00Z,2015,7,Orkambi,cystic fibrosis,CFTR STIMULATOR,RESPIRATORY SYSTEM AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206038,NDA,2014-11-05T00:00:00Z,fda,1,0,1,1,1,2014-01-29T00:00:00Z,vertex pharmaceuticals,NASDAQ: VRTX,1,1032.3,580.4,1212,1527,1410.6,143.4,-88.1,,1018.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206038,267,88,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
368,ICATIBANT,"FIRAZYR; HOE-140; JE-049; BRADYKININ B2 ANTAGONIST (ANGIOEDEMA), JERINI/ABBOTT; ICATIBANT; ICATIBANT ACETATE","FIRAZYR; HOE-140; JE-049; BRADYKININ B2 ANTAGONIST (ANGIOEDEMA), JERINI/ABBOTT; ICATIBANT; ICATIBANT ACETATE",ICATIBANT,FIRAZYR,HOE-140,JE-049,"BRADYKININ B2 ANTAGONIST (ANGIOEDEMA), JERINI/ABBOTT",ICATIBANT,ICATIBANT ACETATE,,,,,,,,,,,,,,,,,,,,,,,,,22150,ICATIBANT ACETATE,,,,,,,,,,,,,,,,,,,,,2011-08-25T00:00:00Z,2011,8,Firazyr,hereditary angioedema,BRADYKININ B2 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY,BIOLOGICAL THERAPEUTIC; PEPTIDE; PEPTIDE SYNTHESIS; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),022150,NDA,2007-10-22T00:00:00Z,fda,1,0,1,1,0,,shire,NASDAQ: SHPG,1,4158.1,3471.1,3007.7,3022.2,2436.3,1796.5,3606.4,748.5,748.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022150,479,156,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
141,CE-1145,"BERINERT; BERINERT P; C1 ESTERASE INHIBITOR CONCENTRATE (HEREDITARY ANGIOEDEMA), CSL BEHRING; C1 ESTERASE INHIBITOR CONCENTRATE (HEREDITARY ANGIOEDEMA), ZLB BEHRING; C1-INH (HEREDITARY ANGIOEDEMA), CSL BEHRING; C1-INH (HEREDITARY ANGIOEDEMA), ZLB BEHRING; CE-1145; CSL-830; CSL-842",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-10-09T00:00:00Z,2009,10,Berinert,hereditary angioedema,COMPLEMENT C1S SUBCOMPONENT INHIBITOR,COAGULATION MODULATOR; FIBRINOLYSIS MODULATOR,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125287,BLA,2008-03-06T00:00:00Z,cortellis,0,0,0,1,0,,CSL Behring,ASX: CSL,1,4246.3,2797.9,2991.4,2341.7,1900,1895.2,2178.5,274.1,274.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125287,646,156,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
152,CINRYZE,"C1-INH (HEREDITARY ANGIOEDEMA), LEV PHARMACEUTICALS; C1-INH, SANQUIN BLOOD SUPPLY FOUNDATION; C1-ESTERASE INHIBITOR (HEREDITARY ANGIOEDEMA/TRANSPLANT REJECTION), SANQUIN/VIROPHARMA; C1-ESTERASE INHIBITOR, SANQUIN BLOOD SUPPLY FOUNDATION; C1INH-NF; CETOR; CINRYZE; CINRYZE-N; SHP-616; HEREDITARY ANGIOEDEMA THERAPY, LEV PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-10-10T00:00:00Z,2008,10,Cinryze,hereditary angioedema,COMPLEMENT C1S SUBCOMPONENT INHIBITOR,ANTI-INFLAMMATORY,BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125267,BLA,2007-07-31T00:00:00Z,cortellis,1,0,1,1,0,,viropharma,NASDAQ: VPHM,1,232.3,,,,,,223.4,64.4,64.4,,,2008,,acquired by viropharma in 2008,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125267,648,156,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
170,CONESTAT ALFA,"HAE THERAPY, PHARMING; RHUCIN; RUCONEST; COMPLEMENT C1 ESTERASE INHIBITOR; CONESTAT ALFA; HEREDITARY ANGIOEDEMA THERAPY, PHARMING; HUMAN C1 ESTERASE INHIBITOR, PHARMING; HUMAN COMPLEMENT 1 ESTERASE INHIBITOR, PHARMING; HUMAN RECOMBINANT C1 ESTERASE INHIBITOR (ANGIOEDEMA), PHARMING/ESTEVE; RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (HEREDITARY ANGIOEDEMA), PHARMING/ ESTEVE; RECOMBINANT HUMAN C1 INHIBITOR, PHARMING/HYLAND; RHC1INH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-07-16T00:00:00Z,2014,7,Ruconest,hereditary angioedema,COMPLEMENT C1S SUBCOMPONENT INHIBITOR; KALLIKREIN MODULATOR; MANNAN-BINDING LECTIN SERINE PROTEASE INHIBITOR,COAGULATION MODULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION; TRANSGENIC ANIMAL,using only (2),125495,BLA,2013-04-17T00:00:00Z,cortellis,0,0,1,1,0,,pharming NV,AMS: PHARM,1,25.6,9.4,14,3.9,0.8,0.5,21.5,14.1,14.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125495,650,156,277,58,Other nutritional; endocrine; and metabolic disorders,3,0
121,"BUPROPION + NALTREXONE (OBESITY), OREXIGEN/TAKEDA","CONTRAVE; MYSIMBA; NB-32; AMFEBUTAMONE + NALTREXONE; BUPROPION + NALTREXONE; BUPROPION + NALTREXONE (OBESITY), OREXIGEN/TAKEDA; NALTREXONE + BUPROPION (OBESITY), OREXIGEN","CONTRAVE; MYSIMBA; NB-32; AMFEBUTAMONE + NALTREXONE; BUPROPION + NALTREXONE; BUPROPION + NALTREXONE (OBESITY), OREXIGEN/TAKEDA; NALTREXONE + BUPROPION (OBESITY), OREXIGEN","BUPROPION + NALTREXONE (OBESITY), OREXIGEN/TAKEDA",CONTRAVE,MYSIMBA,NB-32,AMFEBUTAMONE + NALTREXONE,BUPROPION + NALTREXONE,"BUPROPION + NALTREXONE (OBESITY), OREXIGEN/TAKEDA","NALTREXONE + BUPROPION (OBESITY), OREXIGEN",,,,,,,,,,,,,,,,,,,,,,,,200063,BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-09-10T00:00:00Z,2014,9,Contrave,obesity,DOPAMINE RECEPTOR ANTAGONIST; OPIOID RECEPTOR ANTAGONIST; PROOPIOMELANOCORTIN STIMULATOR,ANTIDEPRESSANT; APPETITE SUPPRESSANT; ENERGY METABOLISM MODULATOR; HYPOGLYCEMIC AGENT,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200063,NDA,2010-03-31T00:00:00Z,fda,0,0,0,0,0,,orexigen,NASDAQ: OREX,1,55.5,3.4,3.4,4.4,1.2,0.1,-1.9,,57.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200063,69,238,278,58,Other nutritional; endocrine; and metabolic disorders,1,0
444,"LORCASERIN HYDROCHLORIDE (EXTENDED-RELEASE, OBESITY), ARENA/EISAI","BELVIQ-XR; BELVIQ-XR; LORCASERIN; LORCASERIN HYDROCHLORIDE (EXTENDED-RELEASE, OBESITY), ARENA/EISAI","BELVIQ-XR; BELVIQ-XR; LORCASERIN; LORCASERIN HYDROCHLORIDE (EXTENDED-RELEASE, OBESITY), ARENA/EISAI","LORCASERIN HYDROCHLORIDE (EXTENDED-RELEASE, OBESITY), ARENA/EISAI",BELVIQ-XR,BELVIQ-XR,LORCASERIN,"LORCASERIN HYDROCHLORIDE (EXTENDED-RELEASE, OBESITY), ARENA/EISAI",,,,,,,,,,,,,,,,,,,,,,,,,,,208524,LORCASERIN HYDROCHLORIDE,208524,LORCASERIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2016-07-15T00:00:00Z,2016,7,Belviq XR,obesity,5-HT 2C RECEPTOR AGONIST,APPETITE SUPPRESSANT,ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208524,NDA,2015-09-18T00:00:00Z,fda,0,0,0,0,0,,arena pharmaceuticals,NASDAQ: ARNA,1,124,38.3,37,81.4,27.6,12.7,44.6,,66.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208524,347,238,278,58,Other nutritional; endocrine; and metabolic disorders,1,0
443,LORCASERIN,"5HT2C AGONISTS (DIABETES/OBESITY), ARENA; APD-356; AR-10A; BELVIQ; LORQESS; LORQESS; VENESPRI; VENESPRI; LORCASERIN; LORCASERIN HYDROCHLORIDE","5HT2C AGONISTS (DIABETES/OBESITY), ARENA; APD-356; AR-10A; BELVIQ; LORQESS; LORQESS; VENESPRI; VENESPRI; LORCASERIN; LORCASERIN HYDROCHLORIDE",LORCASERIN,"5HT2C AGONISTS (DIABETES/OBESITY), ARENA",APD-356,AR-10A,BELVIQ,LORQESS,LORQESS,VENESPRI,VENESPRI,LORCASERIN,LORCASERIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,22529,LORCASERIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2012-06-27T00:00:00Z,2012,6,Belviq,obesity,5-HT 2C RECEPTOR AGONIST,APPETITE SUPPRESSANT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022529,NDA,2009-12-18T00:00:00Z,fda,0,0,0,0,0,,arena pharmaceuticals,NASDAQ: ARNA,1,27.6,12.7,16.6,10.4,9.8,19.3,-30.2,,54.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022529,593,238,278,58,Other nutritional; endocrine; and metabolic disorders,1,0
589,"PHENTERMINE + TOPIRAMATE (ORAL, OBESITY/TYPE 2 DIABETES), VIVUS","QNEXA; QSIVA; QSYMIA; VI-0521; PHENTERMINE + TOPIRAMATE; PHENTERMINE + TOPIRAMATE (ORAL, OBESITY/TYPE 2 DIABETES), VIVUS","QNEXA; QSIVA; QSYMIA; VI-0521; PHENTERMINE + TOPIRAMATE; PHENTERMINE + TOPIRAMATE (ORAL, OBESITY/TYPE 2 DIABETES), VIVUS","PHENTERMINE + TOPIRAMATE (ORAL, OBESITY/TYPE 2 DIABETES), VIVUS",QNEXA,QSIVA,QSYMIA,VI-0521,PHENTERMINE + TOPIRAMATE,"PHENTERMINE + TOPIRAMATE (ORAL, OBESITY/TYPE 2 DIABETES), VIVUS",,,,,,,,,,,,,,,,,,,,,,,,,22580,PHENTERMINE HYDROCHLORIDE; TOPIRAMATE,,,,,,,,,,,,,,,,,,,,,2012-07-17T00:00:00Z,2012,7,Qsymia,obesity,ADRENOCEPTOR AGONIST,APPETITE SUPPRESSANT; GABA MODULATOR; HYPOGLYCEMIC AGENT; PSYCHOSTIMULANT,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),022580,NDA,2009-12-28T00:00:00Z,fda,0,0,0,0,0,,vivus,NASDAQ: VVUS,1,2,,,31.4,83.7,54.7,1.8,31.2,31.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022580,609,238,278,58,Other nutritional; endocrine; and metabolic disorders,1,0
98,BIVIGAM,"BIVIGAM; NABI-IGIV; POLYSPECIFIC IMMUNOGLOBULIN (ANTIBODY DEFICIENCY), BIOTEST",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-12-19T00:00:00Z,2012,12,Bivigam,immune deficiency,,IMMUNOMODULATOR; UNSPECIFIED DRUG TARGET,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN; INTRAVENOUS FORMULATION,using only (2),125389,BLA,2010-11-03T00:00:00Z,cortellis,0,0,0,0,0,,biotest,ETR: BIO,1,580.1,548.3,553.1,559,539.1,476.7,243.5,67.8,67.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125389,643,504,279,57,Immunity disorders,3,0
324,GAMMAPLEX,"GAMMAPLEX; INTRAVENOUS IMMUNOGLOBULIN THERAPY (PRIMARY IMMUNODEFICIENCY), BPL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-09-17T00:00:00Z,2009,9,Gammaplex,immune deficiency,IMMUNOGLOBULIN G AGONIST,IMMUNOMODULATOR,ANTIBODY POLYCLONAL; BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; IMMUNOGLOBULIN-G; INTRAVENOUS FORMULATION,using only (2),125329,BLA,2008-11-18T00:00:00Z,fda,0,0,0,0,0,,bio products laboratory,private,0,,,,,,,,,,,,,,owned by bain capital private equity,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125329,668,504,279,57,Immunity disorders,3,0
352,HIZENTRA,"20% LIQUID SUBCUTANEOUS IMMUNOGLOBULIN THERAPY (PRIMARY IMMUNODEFICIENCY), CSL BEHRING; HIZENTRA; IGPRO20",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-03-04T00:00:00Z,2010,3,Hizentra,immune deficiency,IMMUNOGLOBULIN AGONIST,,ANTIBODY POLYCLONAL; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN; LIQUID FORMULATION; SUBCUTANEOUS FORMULATION,using only (2),125350,BLA,2009-04-30T00:00:00Z,fda,0,0,0,0,0,,CSL Behring,ASX: CSL,1,4354.7,4246.3,2797.9,2991.4,2341.7,1900,2157.3,320.9,320.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125350,682,504,279,57,Immunity disorders,3,0
374,"IMMUNOGLOBULIN + HUMAN RECOMBINANT HYALURONIDASE (RHUPH20) (IMMUNE DEFICIENCY, ENHANZE), SHIRE","HYQ; HYQVIA; IGHY-10; IMMUNOGLOBULIN + HUMAN RECOMBINANT HYALURONIDASE (RHUPH20) (IMMUNE DEFICIENCY, ENHANZE), BAXALTA; IMMUNOGLOBULIN + HUMAN RECOMBINANT HYALURONIDASE (RHUPH20) (IMMUNE DEFICIENCY, ENHANZE), BAXTER; IMMUNOGLOBULIN + HUMAN RECOMBINANT HYALURONIDASE (RHUPH20) (IMMUNE DEFICIENCY, ENHANZE), SHIRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-09-12T00:00:00Z,2014,9,HyQvia,immune deficiency,HYALURONIDASE STIMULATOR,IMMUNOMODULATOR; IMMUNOSTIMULANT,BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; IMMUNOGLOBULIN-G; INFUSION; PEPTIDE; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,using only (2),125402,BLA,2011-06-30T00:00:00Z,fda,0,0,0,0,0,,baxter,NYSE: BAX,1,10719,9413,13936,13893,12843,12562,4634,608,610,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125402,687,504,279,57,Immunity disorders,3,0
281,FERRIC CARBOXYMALTOSE,FERINJECT; INJECTAFER; IROPREM; RENEGY; VIT-45; Z-213; FERRIC CARBOXYMALTOSE,FERINJECT; INJECTAFER; IROPREM; RENEGY; VIT-45; Z-213; FERRIC CARBOXYMALTOSE,FERRIC CARBOXYMALTOSE,FERINJECT,INJECTAFER,IROPREM,RENEGY,VIT-45,Z-213,FERRIC CARBOXYMALTOSE,,,,,,,,,,,,,,,,,,,,,,,,203565,FERRIC CARBOXYMALTOSE,,,,,,,,,,,,,,,,,,,,,2013-07-25T00:00:00Z,2013,7,Injectafer,iron deficiency anemia,,BLOOD SYSTEM AGENT; IRON UPTAKE STIMULATOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),203565,NDA,2011-09-30T00:00:00Z,fda,0,0,0,0,0,,luitpold pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203565,162,3191,280,59,Deficiency and other anemia,1,0
681,"SOLUBLE FERRIC PYROPHOSPHATE CITRATE (ANEMIA), ROCKWELL MEDICAL","SFP (ANEMIA), ROCKWELL MEDICAL; TRIFERIC; FERRIC PYROPHOSPHATE CITRATE; SOLUBLE FERRIC PYROPHOSPHATE (ANEMIA), ROCKWELL MEDICAL; SOLUBLE FERRIC PYROPHOSPHATE CITRATE (ANEMIA), ROCKWELL MEDICAL","SFP (ANEMIA), ROCKWELL MEDICAL; TRIFERIC; FERRIC PYROPHOSPHATE CITRATE; SOLUBLE FERRIC PYROPHOSPHATE (ANEMIA), ROCKWELL MEDICAL; SOLUBLE FERRIC PYROPHOSPHATE CITRATE (ANEMIA), ROCKWELL MEDICAL","SOLUBLE FERRIC PYROPHOSPHATE CITRATE (ANEMIA), ROCKWELL MEDICAL","SFP (ANEMIA), ROCKWELL MEDICAL",TRIFERIC,FERRIC PYROPHOSPHATE CITRATE,"SOLUBLE FERRIC PYROPHOSPHATE (ANEMIA), ROCKWELL MEDICAL","SOLUBLE FERRIC PYROPHOSPHATE CITRATE (ANEMIA), ROCKWELL MEDICAL",,,,,,,,,,,,,,,,,,,,,,,,,,206317,FERRIC PYROPHOSPHATE CITRATE,,,,,,,,,,,,,,,,,,,,,2015-01-23T00:00:00Z,2015,1,Triferic,iron deficiency anemia,,BLOOD SYSTEM AGENT; IRON ABSORPTION MODULATOR,INFUSION; INTRAVENOUS FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),206317,NDA,2014-03-24T00:00:00Z,fda,0,0,0,0,0,,rockwell medical,NASDAQ: RMTI,1,55.4,54.2,52.4,49.8,49,59.6,8.9,5,5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206317,277,3191,280,59,Deficiency and other anemia,1,0
283,FERUMOXYTOL,AMI-7228; CODE 7228; FERAHEME; RIENSO; USPIO; FERUMOXYTOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE,AMI-7228; CODE 7228; FERAHEME; RIENSO; USPIO; FERUMOXYTOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE,FERUMOXYTOL,AMI-7228,CODE 7228,FERAHEME,RIENSO,USPIO,FERUMOXYTOL,ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE,,,,,,,,,,,,,,,,,,,,,,,,22180,FERUMOXYTOL,,,,,,,,,,,,,,,,,,,,,2009-06-30T00:00:00Z,2009,6,Feraheme,iron deficiency anemia,,ANTICANCER; IRON METABOLISM MODULATOR,DRUG COATING; INFUSION; INTRAVENOUS FORMULATION; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC,matched (3),022180,NDA,2007-12-18T00:00:00Z,fda,0,0,0,0,0,,AMAG pharmacetuicals,NASDAQ: AMAG,1,17.2,1.9,2.6,2.7,2.4,3.8,3,23.1,36.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022180,487,3191,280,59,Deficiency and other anemia,1,0
473,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,"CERA, ROCHE/NEKTAR; CERA, ROCHE/SHEARWATER; MIRCERA; R-744; RG-744; RO-50-3821; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; EPOETIN BETA PEGOL; EPOETIN BETA PEGOL (GENETIC RECOMBINANT); METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA; MONOPEGYLATED EPOETIN BETA; SECOND GENERATION EPO, ROCHE","CERA, ROCHE/NEKTAR; CERA, ROCHE/SHEARWATER; MIRCERA; R-744; RG-744; RO-50-3821; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; EPOETIN BETA PEGOL; EPOETIN BETA PEGOL (GENETIC RECOMBINANT); METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA; MONOPEGYLATED EPOETIN BETA; SECOND GENERATION EPO, ROCHE",METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,"CERA, ROCHE/NEKTAR","CERA, ROCHE/SHEARWATER",MIRCERA,R-744,RG-744,RO-50-3821,CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR,EPOETIN BETA PEGOL,EPOETIN BETA PEGOL (GENETIC RECOMBINANT),METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,MONOPEGYLATED EPOETIN BETA,"SECOND GENERATION EPO, ROCHE",,,,,,,,,,,,,,,,,,,125164,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,,,,,,,,,,,,,,,,,,,,,2007-11-14T00:00:00Z,2007,11,Mircera,anemia,ERYTHROPOIETIN RECEPTOR AGONIST,ANTI-INFLAMMATORY; HEMATOPOIETIC STIMULANT,BIOLOGICAL THERAPEUTIC; GLYCOPROTEIN; INTRAVENOUS FORMULATION; MONTHLY DOSING; PEGYLATED FORMULATION; SOLUTION; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),125164,BLA,2006-04-20T00:00:00Z,cortellis,0,0,0,0,0,,roche,SIX: ROG,1,42678.4,35608.8,28109.2,27245,25218.1,18843.3,30558.4,7346.3,7397.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125164,9,17,281,59,Deficiency and other anemia,1,0
768,URIDINE TRIACETATE,PN-401; VISTOGARD; VISTOGARD; XURIDEN; XURIDEN; TRIACETYLURIDINE; URIDINE TRIACETATE; VISTONURIDINE,PN-401; VISTOGARD; VISTOGARD; XURIDEN; XURIDEN; TRIACETYLURIDINE; URIDINE TRIACETATE; VISTONURIDINE,URIDINE TRIACETATE,PN-401,VISTOGARD,VISTOGARD,XURIDEN,XURIDEN,TRIACETYLURIDINE,URIDINE TRIACETATE,VISTONURIDINE,,,,,,,,,,,,,,,,,,,,,,,208159,URIDINE TRIACETATE,208169,URIDINE TRIACETATE,,,,,,,,,,,,,,,,,,,2015-09-04T00:00:00Z,2015,9,Xuriden,anemia,,ANTIDOTE; CHEMOPROTECTANT; NEUROPROTECTANT; URACIL METABOLISM MODULATOR,GRANULE; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),208169,NDA,2015-01-08T00:00:00Z,fda,1,0,0,1,1,2014-04-30T00:00:00Z,wellstat therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208169,331,17,281,59,Deficiency and other anemia,1,0
,URIDINE TRIACETATE (EMERGENCY TREATMENT),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-12-11T00:00:00Z,2015,12,Vistogard,anemia,,,,,208159,NDA,2015-07-10T00:00:00Z,fda,1,0,0,1,0,,wellstat therapeutics,private,0,,,,,,,,,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208159,734,17,281,59,Deficiency and other anemia,1,0
230,ECULIZUMAB,"5G1.1; C5 COMPLEMENT INHIBITOR (2), ALEXION; SOLIRIS; ECULIZUMAB; H5G1.1; H5G1.1SCFV","5G1.1; C5 COMPLEMENT INHIBITOR (2), ALEXION; SOLIRIS; ECULIZUMAB; H5G1.1; H5G1.1SCFV",ECULIZUMAB,5G1.1,"C5 COMPLEMENT INHIBITOR (2), ALEXION",SOLIRIS,ECULIZUMAB,H5G1.1,H5G1.1SCFV,,,,,,,,,,,,,,,,,,,,,,,,,125166,ECULIZUMAB,,,,,,,,,,,,,,,,,,,,,2007-03-16T00:00:00Z,2007,3,Soliris,paroxysmal nocturnal hemoglobinuria,COMPLEMENT C5 FACTOR INHIBITOR,IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SOLUTION,matched (3),125166,BLA,2006-09-20T00:00:00Z,cortellis,1,0,0,1,0,,alexion pharmaceuticals,NASDAQ: ALXN,1,72.041,1.558,1.5936,4.609,0.877,6.536,65.345,64.94,69,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166,10,1297,283,59,Deficiency and other anemia,1,0
62,"ARTEMETHER + LUMEFANTRINE, NOVARTIS","CGP-56697; COA-566; COA-566; COARTEM; COARTEM DISPERSIBLE; COARTEMA; COARTEMA; RIAMET; ARTEMETHER + BENFLUMETOL; ARTEMETHER + BENFLUMETOL, NOVARTIS; ARTEMETHER + LUMEFANTRINE; ARTEMETHER + LUMEFANTRINE, NOVARTIS; COARTEMETHER; COARTEMETHER, NOVARTIS","CGP-56697; COA-566; COA-566; COARTEM; COARTEM DISPERSIBLE; COARTEMA; COARTEMA; RIAMET; ARTEMETHER + BENFLUMETOL; ARTEMETHER + BENFLUMETOL, NOVARTIS; ARTEMETHER + LUMEFANTRINE; ARTEMETHER + LUMEFANTRINE, NOVARTIS; COARTEMETHER; COARTEMETHER, NOVARTIS","ARTEMETHER + LUMEFANTRINE, NOVARTIS",CGP-56697,COA-566,COA-566,COARTEM,COARTEM DISPERSIBLE,COARTEMA,COARTEMA,RIAMET,ARTEMETHER + BENFLUMETOL,"ARTEMETHER + BENFLUMETOL, NOVARTIS",ARTEMETHER + LUMEFANTRINE,"ARTEMETHER + LUMEFANTRINE, NOVARTIS",COARTEMETHER,"COARTEMETHER, NOVARTIS",,,,,,,,,,,,,,,,,22268,ARTEMETHER; LUMEFANTRINE,22268,ARTEMETHER; LUMEFANTRINE,,,,,,,,,,,,,,,,,,,2009-04-07T00:00:00Z,2009,4,Coartem,plasmodium infection,,ANTIPARASITIC; UNSPECIFIED DRUG TARGET,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022268,NDA,2008-06-27T00:00:00Z,fda,1,0,1,1,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022268,517,268,283,59,Deficiency and other anemia,1,0
20,ALBUTREPENONACOG ALFA,"CSL-654; IDELVION; ALBUTREPENONACOG ALFA; RIX - FP; RECOMBINANT COAGULATION FACTOR IX (EXTENDED HALF-LIFE, HEMOPHILIA B), CSL BEHRING; RECOMBINANT COAGULATION FACTOR IX (IV, HEMOPHILIA B), CSL BEHRING; RECOMBINANT COAGULATION FACTORS, CSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-03-04T00:00:00Z,2016,3,Idelvion,factor ix deficiency,COAGULATION FACTOR MODULATOR; FACTOR IX AGONIST,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PROTEIN FUSION; PROTEIN RECOMBINANT; SUSTAINED RELEASE FORMULATION,using only (2),125582,BLA,2014-12-16T00:00:00Z,cortellis,0,0,0,1,0,,CSL Behring,ASX: CSL,1,6452,5843.1,5504.7,5042.3,4774.7,4448.9,3272.5,616.9,616.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125582,635,1228,286,62,Coagulation and hemorrhagic disorders,1,0
91,BERIPLEX P/N,"4-PCC; 4F-PCC; BE-1116; BERIPLEX; BERIPLEX P/N; CONFIDEX; KCENTRA; PCC CSL LTD; PROTHROMBIN COMPLEX CONCENTRATE, AVENTIS BEHRING",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-04-29T00:00:00Z,2013,4,Kcentra,blood clotting disorder,FACTOR IIA MODULATOR; FACTOR IX MODULATOR; FACTOR VII MODULATOR; FACTOR X MODULATOR; VITAMIN K DEPENDENT PROTEIN C MODULATOR,ANTIDOTE; BLOOD SYSTEM AGENT; COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; INFUSION; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125421,BLA,2012-05-29T00:00:00Z,cortellis,0,0,0,1,0,,CSL Behring,ASX: CSL,1,5042.3,4774.7,4448.9,4354.7,4246.3,2797.9,2608.6,465.9,465.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125421,641,75,286,62,Coagulation and hemorrhagic disorders,1,0
140,CATRIDECACOG,"FACTOR XIII, ZYMOGENETICS; NN-1810; NN-1841; NN-8717; NOVOTHIRTEEN; TRETTEN; CATRIDECACOG; RFXIII; RFACTOR XIII, NOVO NORDISK; RFACTOR XIII, ZYMOGENETICS; RHFXIII, NOVO NORDISK; RECOMBINANT FACTOR XIII (CONGENTIAL DEFICIENCY), NOVO NORDISK; RECOMBINANT HUMAN FACTOR XIII (CONGENTIAL DEFICIENCY, CARDIAC SURGERY), NOVO NORDISK; RHFACTOR XIII, NOVO NORDISK; RHFACTOR XIII, ZYMOGENETICS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-12-23T00:00:00Z,2013,12,Tretten,factor xiii deficiency,FACTOR XIII AGONIST,ANTI-INFLAMMATORY; ANTICANCER; COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125398,BLA,2011-02-23T00:00:00Z,cortellis,0,0,0,1,0,,novo nordisk,NYSE: NVO,1,15428.3,13788.5,11595.7,10933.9,9837.83,8546.85,12817.9,2166.03,2166,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125398,645,3423,286,62,Coagulation and hemorrhagic disorders,1,0
233,EFMOROCTOCOG ALFA,"BIIB-031; BIIB-031; ELOCTA; ELOCTA; ELOCTATE; ELOCTATE; FVIII:FC; FVIII:FC; FVIIIFC; FACTOR VIII FC FUSION PROTEIN (HEMOPHILIA A), BIOGEN/SWEDISH ORPHAN BIOVITRUM; FACTOR VIII FC FUSION PROTEIN (HEMOPHILIA A), BIOVERATIV/SWEDISH ORPHAN BIOVITRUM; FACTOR VIII FUSION (HEMOPHILIA A), SYNTONIX/BIOVITRUM; EFMOROCTOCOG ALFA; RFVIIIFC; RFVIIIFC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-06-06T00:00:00Z,2014,6,Eloctate,factor viii deficiency,FACTOR VIII AGONIST; FACTOR VIII MODULATOR,BLOOD CLOTTING MODULATOR,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INJECTABLE CONTROLLED RELEASE FORMULATION; PROTEIN FUSION; PROTEIN RECOMBINANT,using only (2),125487,BLA,2013-03-12T00:00:00Z,cortellis,0,0,0,1,0,,biogen,NASDAQ: BIIB,1,9703.3,6932.2,5514.86,5037.63,4716.42,4377.35,8532.3,1893.4,1893.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125487,653,121,286,62,Coagulation and hemorrhagic disorders,1,0
234,EFTRENONACOG ALFA,"ALPROLIX; BIIB-029; BIVV-002; FIX:FC FUSION; FIXFC; FIXFC (HEMOPHILIA B), SYNTONIX/BIOVITRUM; FACTOR IX FUSION (HEMOPHILIA B), BIOGEN/SWEDISH ORPHAN BIOVITRUM; FACTOR IX FUSION (HEMOPHILIA B), BIOVERATIV/SWEDISH ORPHAN BIOVITRUM; FACTOR IX FUSION (HEMOPHILIA B), SYNTONIX/BIOVITRUM; EFTRENONACOG ALFA; EFTRENONACOG ALFA (HEMOPHILIA B), BIOGEN; HEMOPHILIA B THERAPY, SYNTONIX/BIOVITRUM; RFIXFC; RFIXFC-XTEN; RFACTOR IX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-03-28T00:00:00Z,2014,3,Alprolix,factor ix deficiency,FACTOR IX AGONIST,,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INJECTABLE CONTROLLED RELEASE FORMULATION; INTRAVENOUS FORMULATION; PROTEIN FUSION,using only (2),125444,BLA,2012-11-15T00:00:00Z,cortellis,0,0,1,1,0,,biogen,NASDAQ: BIIB,1,9703.3,6932.2,5514.86,5037.63,4716.42,4377.35,8532.3,1893.4,1893.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125444,654,1228,286,62,Coagulation and hemorrhagic disorders,1,0
269,"FACTOR XIII CONCENTRATE, CSL","CLUVOT; CORIFACT; FACTOR XIII CONCENTRATE, CSL; FIBROGAMMIN; FIBROGAMMIN P",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2011-02-15T00:00:00Z,2011,2,Corifact,factor xiii deficiency,FACTOR XIII AGONIST,,BIOLOGICAL THERAPEUTIC; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125385,BLA,2010-08-18T00:00:00Z,fda,1,1,1,1,0,,CSL Behring,ASX: CSL,1,4448.9,4354.7,4246.3,2797.9,2991.4,2341.7,2099.1,353.4,353.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125385,657,3423,286,62,Coagulation and hemorrhagic disorders,1,0
285,"FIBRINOGEN (INTRAVENOUS, FACTOR I DEFICIENCY/BLEEDING), CSL","HAEMOCOMPLETTAN P; RIASTAP; FIBRINOGEN (INTRAVENOUS, FACTOR I DEFICIENCY/BLEEDING), CSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-01-16T00:00:00Z,2009,1,RiaSTAP,factor i deficiency,FACTOR I STIMULATOR,,BIOLOGICAL THERAPEUTIC; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125317,BLA,2008-07-18T00:00:00Z,fda,1,1,0,1,0,,CSL Behring,ASX: CSL,1,4246.3,2797.9,2991.4,2341.7,1900,1895.2,2178.5,274.1,274.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125317,658,2762,286,62,Coagulation and hemorrhagic disorders,1,0
442,LONOCTOCOG ALFA,"AFSTYLA; CSL-627; NBP-601; SK-NBP601; LONOCTOCOG ALFA; RVIII-SC; RVIII-SINGLECHAIN; RECOMBINANT FACTOR VIII (HEMOPHILIA A), CSL; SINGLE-CHAIN RECOMBINANT FACTOR VIII (HEMOPHILIA A), CSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-05-25T00:00:00Z,2016,5,Afstyla,factor viii deficiency,FACTOR VIII AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; INFUSION; PARENTERAL FORMULATION UNSPECIFIED; PROTEIN RECOMBINANT,using only (2),125591,BLA,2015-05-29T00:00:00Z,fda,0,0,0,0,0,,CSL Behring,ASX: CSL,1,6452,5843.1,5504.7,5042.3,4774.7,4448.9,3272.5,616.9,616.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125591,695,121,286,62,Coagulation and hemorrhagic disorders,1,0
522,NONACOG GAMMA,"BAX-326; FIXTERA; RIXUBIS; NONACOG GAMMA; RFIX, BAXTER; RECOMBINANT FACTOR IX, BAXALTA; RECOMBINANT FACTOR IX, BAXTER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-06-26T00:00:00Z,2013,6,Rixubis,factor ix deficiency,FACTOR IX AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SOLUTION,using only (2),125446,BLA,2012-08-30T00:00:00Z,fda,0,0,0,1,0,,baxter,NYSE: BAX,1,9413,13936,13893,12843,12562,12348,4289,534,582,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125446,701,1228,286,62,Coagulation and hemorrhagic disorders,1,0
532,"OCTOCOG ALFA (PLASMA-FREE, SUCROSE-FORMULATED), BAYER","BAY-81-8973; BAY-81-8973; KOGENATE PF; KOVALTRY; OCTOCOG ALFA; OCTOCOG ALFA (PLASMA-FREE, SUCROSE-FORMULATED), BAYER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-03-16T00:00:00Z,2016,3,Kovaltry,factor viii deficiency,FACTOR VIII AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION OTHER; PARENTERAL FORMULATION UNSPECIFIED; PEPTIDE; PROTEIN RECOMBINANT,using only (2),125574,BLA,2014-12-16T00:00:00Z,fda,0,0,0,0,0,,bayer,ETR: BAYN,1,49370.8,50051.6,50038.1,55301.2,52397.7,47454.4,28381.7,4836.9,4925.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125574,703,121,286,62,Coagulation and hemorrhagic disorders,1,0
626,"RECOMBINANT MOROCTOCOG ALFA (PLASMA/ALBUMIN-FREE, HEMOPHILIA A), WYETH","FUSENGO; REFACTO AF; XYNTHA; XYNTHA SOLOFUSE; RECOMBINANT FACTOR VIII (PLASMA/ALBUMIN-FREE, HEMOPHILIA A), WYETH; RECOMBINANT MOROCTOCOG ALFA (PLASMA/ALBUMIN-FREE, HEMOPHILIA A), WYETH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-02-21T00:00:00Z,2008,2,Xyntha,factor viii deficiency,FACTOR VIII AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125264,BLA,2007-04-25T00:00:00Z,,0,0,0,0,0,,wyeth,NYSE: WYE,1,22833.9,22399.8,20350.7,18755.8,17358,15850.6,16828.6,3340.08,3373.2,,,,,acquired by Pfizer in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125264,714,121,286,62,Coagulation and hemorrhagic disorders,1,0
651,RURIOCTOCOG ALFA PEGOL,"ADYNOVATE; ADYNOVATE; ADYNOVI; ADYNOVI; BAX-855; BAX-855; FACTOR VIII + VON WILLEBRAND FACTOR (PEGYLATED), BAXTER; PEGYLATED ADVATE, BAXTER; PEGYLATED RFVIII (HEMOPHILIA A), BAXALTA; PEGYLATED RFVIII (HEMOPHILIA A), BAXTER; PEGYLATED RECOMBINANT FACTOR VIII (HEMOPHILIA A), BAXTER; RURIOCTOCOG ALFA PEGOL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-11-13T00:00:00Z,2015,11,Adynovate,factor viii deficiency,FACTOR VIII AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; PEGYLATED FORMULATION; PROTEIN RECOMBINANT; SUSTAINED RELEASE FORMULATION,using only (2),125566,BLA,2014-11-25T00:00:00Z,fda,0,0,0,0,0,,baxalta,NYSE: BXLT,1,6148,10719,9413,13936,13893,12843,3782,699,1095,,,,,spun off from baxter intl in 2015; lagged revenues are for baxter intl,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125566,718,121,286,62,Coagulation and hemorrhagic disorders,1,0
669,SIMOCTOCOG ALFA,"NUWIQ; VIHUMA; RECOMBINANT FACTOR VIII (HUMAN CELL LINE PRODUCTION), OCTAPHARMA; SIMOCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-09-04T00:00:00Z,2015,9,Nuwiq,factor viii deficiency,FACTOR VIII AGONIST; FACTOR VIII MODULATOR,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125555,BLA,2014-06-05T00:00:00Z,fda,0,0,0,0,0,,octapharma,private,0,1643.3,1548.9,1589.3,1207.3,951.2,962.5,632.5,79.1,79.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125555,719,121,286,62,Coagulation and hemorrhagic disorders,1,0
695,SUSOCTOCOG ALFA,"BAX-802; OBI-1; OBIZUR; OBIZUR; PORCINE RFVIII, IPSEN/INSPIRATION; PORCINE RFVIII, OCTAGEN/IPSEN; PORCINE RFACTOR VIII, IPSEN/INSPIRATION; PORCINE RFACTOR VIII, OCTAGEN/IPSEN; RECOMBINANT PORCINE FACTOR VIII, BAXALTA; RECOMBINANT PORCINE FACTOR VIII, IPSEN/INSPIRATION; RECOMBINANT PORCINE FACTOR VIII, OCTAGEN/IPSEN; RPFVIII; SUSOCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-10-23T00:00:00Z,2014,10,Obizur,factor viii deficiency,FACTOR VIII AGONIST,,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125512,BLA,2013-11-25T00:00:00Z,fda,1,0,1,1,0,,baxter,NYSE: BAX,1,10719,9413,13936,13893,12843,12562,4634,608,610,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125512,721,121,286,62,Coagulation and hemorrhagic disorders,1,0
755,TRENONACOG ALFA,"IB-1001; IXINITY; RECOMBINANT FACTOR IX (INTRAVENOUS, HEMOPHILIA B), INSPIRATION BIOPHARMACEUTICALS/CELTIC PHARMA; RECOMBINANT FACTOR IX (IV, FACTOR IX DEFICIENCY), INSPIRATION BIOPHARMACEUTICALS; TRENONACOG ALFA; TRENONACOG ALFA (INTRAVENOUS, HEMOPHILIA B), CANGENE; TRENONACOG ALFA (INTRAVENOUS, HEMOPHILIA B), EMERGENT BIOSOLUTIONS; TRENONACOG ALFA (INTRAVENOUS, HEMOPHILIA B), INSPIRATION BIOPHARMACEUTICALS/CELTIC PHARMA; TRENONACOG ALPHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-04-29T00:00:00Z,2015,4,Ixinity,factor ix deficiency,FACTOR IX AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125426,BLA,2012-04-06T00:00:00Z,fda,0,0,0,0,0,,emergent biosolutions,NYSE: EBS,1,489.3,404.5,129.8,118.4,141.5,135.7,272.5,,109.4,,,2014,,acquired by emergent biosolutions in 2014; cangene revenues for 12 months prior to following january are reported with exception of 2013 in which revenue dated 2/1/13 - 7/31/13 is reported scaled by a factor of 2,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125426,726,1228,286,62,Coagulation and hemorrhagic disorders,1,0
764,TUROCTOCOG ALFA,"N-8; NN-7008; NNC-0155-0000-0004; NOVOEIGHT; ZONOVATE; RECOMBINANT FACTOR VIII (THIRD GENERATION), NOVO NORDISK; TUROCTOCOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-10-15T00:00:00Z,2013,10,Novoeight,factor viii deficiency,FACTOR VIII AGONIST,,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),125466,BLA,2012-10-16T00:00:00Z,fda,0,0,0,0,0,,novo nordisk,NYSE: NVO,1,15428.3,13788.5,11595.7,10933.9,9837.83,8546.85,12817.9,2166.03,2166,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125466,727,121,286,62,Coagulation and hemorrhagic disorders,1,0
786,"VON WILLEBRAND FACTOR/FACTOR VIII (IV, PLASMA-DERIVED), OCTAPHARMA","WILOCTIN; VON WILLEBRAND FACTOR/FACTOR VIII (IV, PLASMA-DERIVED), OCTAPHARMA; WILATE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-12-04T00:00:00Z,2009,12,Wilate,von willebrands disease,FACTOR VIII AGONIST; VON WILLEBRAND FACTOR LIGAND,,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; PEPTIDE,using only (2),125251,BLA,2006-12-12T00:00:00Z,fda,0,0,0,1,0,,octapharma,private,0,1445.8,1237.8,1098.3,721.7,482.8,449.2,594.5,55.2,55.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125251,730,1229,286,62,Coagulation and hemorrhagic disorders,1,0
787,VONICOG ALFA,"BAX-111; PSA-RVWF; VONVENDI; RECOMBINANT VWF (VON WILLEBRAND DISEASE), BAXTER; RECOMBINANT GLYCOSYLATED VON WILLEBRAND FACTOR, BAXTER; RHVWF, BAXALTA; RHVWF, BAXTER; RVWF (VON WILLEBRAND DISEASE), BAXTER; VONICOG ALFA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-12-08T00:00:00Z,2015,12,Vonvendi,von willebrands disease,VON WILLEBRAND FACTOR LIGAND,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; FORMULATION POWDER; FREEZE DRYING; GLYCOPROTEIN; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SOLUTION,using only (2),125577,BLA,2014-12-19T00:00:00Z,fda,0,0,0,1,0,,baxalta,NYSE: BXLT,1,6148,10719,9413,13936,13893,12843,3782,699,1095,,,,,spun off from baxter intl in 2015; lagged revenues are for baxter intl,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125577,731,1229,286,62,Coagulation and hemorrhagic disorders,1,0
643,ROMIPLOSTIM,"AMG-531; MPL-BINDING PEPTIBODY (THROMBOCYTOPENIA), AMGEN; NPLATE; NPLATE; ROMIPLATE; ROMIPLOSTIM; THROMBOPOIETIN AGONIST PEPTIBODY (THROMBOCYTOPENIA), AMGEN","AMG-531; MPL-BINDING PEPTIBODY (THROMBOCYTOPENIA), AMGEN; NPLATE; NPLATE; ROMIPLATE; ROMIPLOSTIM; THROMBOPOIETIN AGONIST PEPTIBODY (THROMBOCYTOPENIA), AMGEN",ROMIPLOSTIM,AMG-531,"MPL-BINDING PEPTIBODY (THROMBOCYTOPENIA), AMGEN",NPLATE,NPLATE,ROMIPLATE,ROMIPLOSTIM,"THROMBOPOIETIN AGONIST PEPTIBODY (THROMBOCYTOPENIA), AMGEN",,,,,,,,,,,,,,,,,,,,,,,,125268,ROMIPLOSTIM,,,,,,,,,,,,,,,,,,,,,2008-08-22T00:00:00Z,2008,8,Nplate,immune thrombocytopenic purpura,THROMBOPOIETIN RECEPTOR AGONIST,ANTICANCER; HEMATOPOIETIC STIMULANT,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; CELL CULTURE; FORMULATION POWDER; FREEZE DRYING; PEPTIDE; PROTEIN FUSION; SUBCUTANEOUS FORMULATION,matched (3),125268,BLA,2007-08-23T00:00:00Z,fda,1,0,1,1,0,,amgen,NASDAQ: AMGN,1,15003,14771,14268,12430,10550,8356,12791,3030,3112,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125268,13,2259,287,62,Coagulation and hemorrhagic disorders,2,0
238,ELTROMBOPAG,"497115; PROMACTA; REVOLADE; SB-394725; SB-497115; SB-497115-GR; SB-497117GR; ELTROMBOPAG; ELTROMBOPAG OLAMINE; HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/GLAXOSMITHKLINE; HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/SB; THROMBOPOIETIN PEPTIDE MIMETICS, GLAXOSMITHKLINE/LIGAND","497115; PROMACTA; REVOLADE; SB-394725; SB-497115; SB-497115-GR; SB-497117GR; ELTROMBOPAG; ELTROMBOPAG OLAMINE; HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/GLAXOSMITHKLINE; HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/SB; THROMBOPOIETIN PEPTIDE MIMETICS, GLAXOSMITHKLINE/LIGAND",ELTROMBOPAG,497115,PROMACTA,REVOLADE,SB-394725,SB-497115,SB-497115-GR,SB-497117GR,ELTROMBOPAG,ELTROMBOPAG OLAMINE,"HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/GLAXOSMITHKLINE","HEMATOPOIETIC GROWTH FACTOR MIMETICS, LIGAND/SB","THROMBOPOIETIN PEPTIDE MIMETICS, GLAXOSMITHKLINE/LIGAND",,,,,,,,,,,,,,,,,,,22291,ELTROMBOPAG OLAMINE,,,,,,,,,,,,,,,,,,,,,2008-11-20T00:00:00Z,2008,11,Promacta,immune thrombocytopenic purpura,THROMBOPOIETIN RECEPTOR AGONIST,ANTI-INFLAMMATORY; ANTICANCER; ANTIVIRAL; HEMATOPOIETIC STIMULANT,FILM COATING; FORMULATION POWDER; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022291,NDA,2007-12-18T00:00:00Z,fda,1,1,0,1,0,,glaxosmithkline,NYSE: GSK,1,35480.4,45147.6,45499.1,37229.2,38293.2,37593.1,27064.9,5108.18,5363.2,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291,524,2259,287,62,Coagulation and hemorrhagic disorders,2,0
608,PRIVIGEN,10% LIQUID INTRAVENOUS IMMUNOGLOBULIN THERAPY (PRIMARY IMMUNODEFIENCY SYNDROME/ITP) CSL BEHRING; 10% LIQUID INTRAVENOUS IMMUNOGLOBULIN THERAPY (PRIMARY IMMUNODEFIENCY SYNDROME/ITP/SCLERODERMA) CSL BEHRING; IVIG-F10; IGPRO10; NEXGEN; PRIVIGEN; PRIVIGEN ISOLO; PRIVIGEN SANDOGLOBULINA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-07-26T00:00:00Z,2007,7,Privigen,immune thrombocytopenic purpura,,IMMUNOMODULATOR; NEUROPROTECTANT; UNSPECIFIED DRUG TARGET,ANTIBODY POLYCLONAL; BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN; INFUSION; INTRAVENOUS FORMULATION,using only (2),125201,BLA,,,0,0,0,0,0,,CSL Behring,ASX: CSL,1,2991.4,2341.7,1900,1895.2,979.9,776.3,1371.7,171.5,171.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125201,711,2259,287,62,Coagulation and hemorrhagic disorders,2,0
290,"FILGRASTIM BIOSIMILAR, TEVA/NIPPON KAYAKU","FILGRASTIM-MEPHA; FILGRASTIM-TEVA; GRANIX; NEUTROVAL; TKN-732; TEVAGRASTIM; FILGRASTIM; FILGRASTIM BIOSIMILAR, TEVA; FILGRASTIM BIOSIMILAR, TEVA/NIPPON KAYAKU; TBO-FILGRASTIM","FILGRASTIM-MEPHA; FILGRASTIM-TEVA; GRANIX; NEUTROVAL; TKN-732; TEVAGRASTIM; FILGRASTIM; FILGRASTIM BIOSIMILAR, TEVA; FILGRASTIM BIOSIMILAR, TEVA/NIPPON KAYAKU; TBO-FILGRASTIM","FILGRASTIM BIOSIMILAR, TEVA/NIPPON KAYAKU",FILGRASTIM-MEPHA,FILGRASTIM-TEVA,GRANIX,NEUTROVAL,TKN-732,TEVAGRASTIM,FILGRASTIM,"FILGRASTIM BIOSIMILAR, TEVA","FILGRASTIM BIOSIMILAR, TEVA/NIPPON KAYAKU",TBO-FILGRASTIM,,,,,,,,,,,,,,,,,,,,,125294,TBO-FILGRASTIM,,,,,,,,,,,,,,,,,,,,,2012-08-29T00:00:00Z,2012,8,Granix,neutropenia,GCSF LIGAND; GCSF RECEPTOR AGONIST,HEMATOPOIETIC STIMULANT; NEUTROPHIL STIMULATOR,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125294,BLA,2009-11-30T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,20317,18312,16121,13899,11085,9408,10715,1356,1283,,,2004,,acquired by teva in 2004,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125294,22,1991,288,63,Diseases of white blood cells,1,0
652,"RUXOLITINIB (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS","INC-424; INC-424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; INCB-000020; INCB-018424; INCB-18424; INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS; INCB-20; JAK INHIBITORS (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; JAKAFI; JAKAVI; RUXOLITINIB; RUXOLITINIB (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS; RUXOLITINIB PHOSPHATE","INC-424; INC-424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; INCB-000020; INCB-018424; INCB-18424; INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS; INCB-20; JAK INHIBITORS (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE; JAKAFI; JAKAVI; RUXOLITINIB; RUXOLITINIB (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS; RUXOLITINIB PHOSPHATE","RUXOLITINIB (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS",INC-424,"INC-424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE",INCB-000020,INCB-018424,INCB-18424,"INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE","INCB-18424 (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS",INCB-20,"JAK INHIBITORS (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE",JAKAFI,JAKAVI,RUXOLITINIB,"RUXOLITINIB (ORAL, MYELOPROLIFERATIVE DISORDERS), INCYTE/NOVARTIS",RUXOLITINIB PHOSPHATE,,,,,,,,,,,,,,,,,202192,RUXOLITINIB PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2011-11-16T00:00:00Z,2011,11,Jakafi,myelofibrosis,EXTRACELLULAR SIGNAL RELATED KINASE-1 INHIBITOR; EXTRACELLULAR SIGNAL RELATED KINASE-2 INHIBITOR; JAK1 TYROSINE KINASE INHIBITOR; JAK2 TYROSINE KINASE INHIBITOR; STAT-5A INHIBITOR; STAT-5B INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; IMMUNOMODULATOR; SYNERGIST,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202192,NDA,2011-06-03T00:00:00Z,fda,1,0,1,1,0,,incyte,NASDAQ: INCY,1,94.5,169.9,9.3,3.9,34.4,27.6,-84.3,,182.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202192,105,2436,289,64,Other hematologic conditions,4,0
481,"METHYLTHIONINIUM CHLORIDE SOLUTION (IV, METHEMOGLOBINEMIA), PROVEPHARM/DAIICHI SANKYO/DR FRANZ KOHLER","PROVAYBLUE; PROVAYBLUE; PROVEBLUE; METHYLENE BLUE; METHYLTHIONINIUM CHLORIDE; METHYLTHIONINIUM CHLORIDE SOLUTION (IV, METHEMOGLOBINEMIA), PROVEPHARM/DAIICHI SANKYO/DR FRANZ KOHLER; METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), DAIICHI SANKYO; METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), PROVEPHARM","PROVAYBLUE; PROVAYBLUE; PROVEBLUE; METHYLENE BLUE; METHYLTHIONINIUM CHLORIDE; METHYLTHIONINIUM CHLORIDE SOLUTION (IV, METHEMOGLOBINEMIA), PROVEPHARM/DAIICHI SANKYO/DR FRANZ KOHLER; METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), DAIICHI SANKYO; METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), PROVEPHARM","METHYLTHIONINIUM CHLORIDE SOLUTION (IV, METHEMOGLOBINEMIA), PROVEPHARM/DAIICHI SANKYO/DR FRANZ KOHLER",PROVAYBLUE,PROVAYBLUE,PROVEBLUE,METHYLENE BLUE,METHYLTHIONINIUM CHLORIDE,"METHYLTHIONINIUM CHLORIDE SOLUTION (IV, METHEMOGLOBINEMIA), PROVEPHARM/DAIICHI SANKYO/DR FRANZ KOHLER","METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), DAIICHI SANKYO","METHYLTHIONINIUM CHLORIDE SOLUTION (METHEMOGLOBINEMIA), PROVEPHARM",,,,,,,,,,,,,,,,,,,,,,,204630,METHYLENE BLUE,204630,METHYLENE BLUE,,,,,,,,,,,,,,,,,,,2016-04-08T00:00:00Z,2016,4,ProvayBlue,methemoglobinemia,HEMOGLOBIN MODULATOR,ANTIDOTE; ANTIPARASITIC; ANTIVIRAL,INTRAVENOUS FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; SOLUTION; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),204630,NDA,2015-10-09T00:00:00Z,fda,0,0,0,0,0,,provepharm,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630,208,5400,289,64,Other hematologic conditions,4,0
55,"ARGATROBAN (READY-TO-USE, THROMBOSIS), CHIESI","ARGATROBAN 50 ML; EP-1101; ARGATROBAN; ARGATROBAN (READY-TO-USE, THROMBOSIS), CHIESI; ARGATROBAN (READY-TO-USE, THROMBOSIS), EAGLE/THE MEDICINES COMPANY","ARGATROBAN 50 ML; EP-1101; ARGATROBAN; ARGATROBAN (READY-TO-USE, THROMBOSIS), CHIESI; ARGATROBAN (READY-TO-USE, THROMBOSIS), EAGLE/THE MEDICINES COMPANY","ARGATROBAN (READY-TO-USE, THROMBOSIS), CHIESI",ARGATROBAN 50 ML,EP-1101,ARGATROBAN,"ARGATROBAN (READY-TO-USE, THROMBOSIS), CHIESI","ARGATROBAN (READY-TO-USE, THROMBOSIS), EAGLE/THE MEDICINES COMPANY",,,,,,,,,,,,,,,,,,,,,,,,,,20883,ARGATROBAN,20883,ARGATROBAN,20883,ARGATROBAN,20883,ARGATROBAN,20883,ARGATROBAN,,,,,,,,,,,,,2011-06-29T00:00:00Z,2011,6,argatroban in sodium chloride,heparin induced thrombocytopenia,FACTOR IIA ANTAGONIST,COAGULATION INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),22434,NDA,2011-01-12T00:00:00Z,fda,0,0,0,0,0,,eagle pharmaceuticals,private,0,9.5,,,,,,7.7,8.7,9.8,,,,,IPO in 2014; financials are for 12 months ending september 30,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=22434,354,1271,289,64,Other hematologic conditions,4,0
353,"HUMAN PROTEIN C, SHIRE","CEPROTIN; HUMAN PROTEIN C, BAXALTA; HUMAN PROTEIN C, BAXTER; HUMAN PROTEIN C, SHIRE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-03-30T00:00:00Z,2007,3,Ceprotin,protein c deficiency,VITAMIN K DEPENDENT PROTEIN C STIMULATOR,COAGULATION INHIBITOR,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SYSTEMIC FORMULATION UNSPECIFIED,using only (2),125234,BLA,2006-09-28T00:00:00Z,fda,1,0,0,0,0,,baxter,NYSE: BAX,1,11263,10378,9849,9509,8904,8099,5533,710,699,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125234,683,3469,289,64,Other hematologic conditions,4,0
592,PIMAVANSERIN,"5-HT 2A INVERSE AGONISTS, ACADIA; AC-165024; AC-165043; AC-89725; AC-90179; ACP-103; AMI-193 ANALOGS, ACADIA; BVF-036; BVF-040; BVF-048; NUPLAZID; ANTIPSYCHOTICS, ACADIA; PIMAVANSERIN; PIMAVANSERIN TARTRATE; SPIPERONE ANALOGS, ACADIA","5-HT 2A INVERSE AGONISTS, ACADIA; AC-165024; AC-165043; AC-89725; AC-90179; ACP-103; AMI-193 ANALOGS, ACADIA; BVF-036; BVF-040; BVF-048; NUPLAZID; ANTIPSYCHOTICS, ACADIA; PIMAVANSERIN; PIMAVANSERIN TARTRATE; SPIPERONE ANALOGS, ACADIA",PIMAVANSERIN,"5-HT 2A INVERSE AGONISTS, ACADIA",AC-165024,AC-165043,AC-89725,AC-90179,ACP-103,"AMI-193 ANALOGS, ACADIA",BVF-036,BVF-040,BVF-048,NUPLAZID,"ANTIPSYCHOTICS, ACADIA",PIMAVANSERIN,PIMAVANSERIN TARTRATE,"SPIPERONE ANALOGS, ACADIA",,,,,,,,,,,,,,,,207318,PIMAVANSERIN TARTRATE,,,,,,,,,,,,,,,,,,,,,2016-04-29T00:00:00Z,2016,4,Nuplazid,psychotic disorder,5-HT 2A RECEPTOR INVERSE AGONIST,ANTIPSYCHOTIC,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207318,NDA,2015-09-01T00:00:00Z,fda,1,0,0,0,1,2014-09-02T00:00:00Z,acadia pharmaceuticals,NASDAQ: ACAD,1,17.331,0.061,0.12,1.145,4.907,2.067,-86.359,,99.3,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207318,299,282,292,661,Substance-related disorders,1,0
1,123I-IOFLUPANE,"123I-IOFLUPANE; DATSCAN; FP-CIT; NMA-78; PARKINSONS DIAGNOSTIC, AMERSHAM/RBI; PARKINSONS DIAGNOSTIC, GE HEALTHCARE/RBI; V-09AB03; IODEIN-123-IOFLUPANE; IOFLUPANE; IOFLUPANE (123I); IOFLUPANE I 123","123I-IOFLUPANE; DATSCAN; FP-CIT; NMA-78; PARKINSONS DIAGNOSTIC, AMERSHAM/RBI; PARKINSONS DIAGNOSTIC, GE HEALTHCARE/RBI; V-09AB03; IODEIN-123-IOFLUPANE; IOFLUPANE; IOFLUPANE (123I); IOFLUPANE I 123",123I-IOFLUPANE,123I-IOFLUPANE,DATSCAN,FP-CIT,NMA-78,"PARKINSONS DIAGNOSTIC, AMERSHAM/RBI","PARKINSONS DIAGNOSTIC, GE HEALTHCARE/RBI",V-09AB03,IODEIN-123-IOFLUPANE,IOFLUPANE,IOFLUPANE (123I),IOFLUPANE I 123,,,,,,,,,,,,,,,,,,,,22454,IOFLUPANE I-123,,,,,,,,,,,,,,,,,,,,,2011-01-14T00:00:00Z,2011,1,Datscan,neurodegenerative disease,DOPAMINE TRANSPORTER MODULATOR,CNS DIAGNOSTIC AGENT; IMAGING AGENT; RADIODIAGNOSTIC,IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING,matched (3),022454,NDA,2009-03-06T00:00:00Z,fda,1,0,0,0,0,,GE,NYSE: GE,1,142837,149567,154438,181581,172488,151568,53957,,5389,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022454,567,233,294,653,"Delirium, dementia, and amnestic and other cognitive disorders",1,0
639,"RIVASTIGMINE (TRANSDERMAL), NOVARTIS","ENA-713D; EXELON PATCH; EXELON PATCH 10; EXELON TDS; ONO-2540; PROMETAX PATCH; RIVASTACH PATCH; RIVASTACH TAPE; RIVASTOUCH; RIVASTIGMINE; RIVASTIGMINE (TRANSDERMAL), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-07-06T00:00:00Z,2007,7,Exelon,dementia,ACETYLCHOLINESTERASE INHIBITOR; CHOLINESTERASE INHIBITOR,NEUROPROTECTANT; NOOTROPIC AGENT,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,using only (2),022083,NDA,2006-09-08T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,38947,35105,29753,27277,24930,20877,28342,6430,6430,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022083,715,90,294,653,"Delirium, dementia, and amnestic and other cognitive disorders",1,0
453,LURASIDONE,"5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), DAINIPPON; 5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), SUMITOMO DAINIPPON; LATUDA; MK-3756; SM-13496; LURASIDONE; LURASIDONE HYDROCHLORIDE","5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), DAINIPPON; 5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), SUMITOMO DAINIPPON; LATUDA; MK-3756; SM-13496; LURASIDONE; LURASIDONE HYDROCHLORIDE",LURASIDONE,"5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), DAINIPPON","5-HT/DOPAMINE D2 ANTAGONIST (ORAL, SCHIZOPHRENIA), SUMITOMO DAINIPPON",LATUDA,MK-3756,SM-13496,LURASIDONE,LURASIDONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,200603,LURASIDONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-10-28T00:00:00Z,2010,10,Latuda,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; 5-HT 7 RECEPTOR ANTAGONIST; ALPHA 2C ADRENOCEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIDEPRESSANT; ANTIPSYCHOTIC,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200603,NDA,2009-12-30T00:00:00Z,fda,0,0,0,0,0,,dainippon sumitomo,TSE: 4506,1,4601.2,2856.3,1292.3,1225.2,1183.1,801.1,3159.7,764.6,764.6,1312.8,2009-06-30T00:00:00Z,2009,,formerly Sepracor; acquired by Dainippon Sumitomo pharma in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200603,75,299,295,659,Schizophrenia and other psychotic disorders,1,0
59,"ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA/H LUNDBECK","ABILIFY IM DEPOT; ABILIFY MAINTENA; IM DEPOT ARIPIPRAZOLE; LU-AF41155; OPC-14597-IMD; ARIPIPRAZOLE; ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA; ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA/H LUNDBECK; INTRAMUSCULAR DEPOT ARIPIPRAZOLE","ABILIFY IM DEPOT; ABILIFY MAINTENA; IM DEPOT ARIPIPRAZOLE; LU-AF41155; OPC-14597-IMD; ARIPIPRAZOLE; ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA; ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA/H LUNDBECK; INTRAMUSCULAR DEPOT ARIPIPRAZOLE","ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA/H LUNDBECK",ABILIFY IM DEPOT,ABILIFY MAINTENA,IM DEPOT ARIPIPRAZOLE,LU-AF41155,OPC-14597-IMD,ARIPIPRAZOLE,"ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA","ARIPIPRAZOLE (INTRAMUSCULAR DEPOT, SCHIZOPHRENIA), OTSUKA/H LUNDBECK",INTRAMUSCULAR DEPOT ARIPIPRAZOLE,,,,,,,,,,,,,,,,,,,,,,202971,ARIPIPRAZOLE,,,,,,,,,,,,,,,,,,,,,2013-02-28T00:00:00Z,2013,2,Abilify Maintena,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR PARTIAL AGONIST,ANTIPSYCHOTIC,FORMULATION POWDER; FREEZE DRYING; INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),202971,NDA,2011-09-26T00:00:00Z,fda,0,0,0,0,0,,otsuka,TYO: 4578,1,13344,13476.7,14733.1,13618.6,11975.7333333333,,9276.9,2300.7,2300.7,,,,,IPO in 2010; financials for 2009 are estimated from reported financials from the last 9 months of the year,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202971,136,299,295,659,Schizophrenia and other psychotic disorders,1,0
162,"CLOZAPINE (ORAL SUSPENSION, SCHIZOPHRENIA), JAZZ PHARMACEUTICALS","VERSACLOZ; CLOZAPINE; CLOZAPINE (ORAL SUSPENSION, SCHIZOPHRENIA), JAZZ PHARMACEUTICALS; CLOZAPINE OS","VERSACLOZ; CLOZAPINE; CLOZAPINE (ORAL SUSPENSION, SCHIZOPHRENIA), JAZZ PHARMACEUTICALS; CLOZAPINE OS","CLOZAPINE (ORAL SUSPENSION, SCHIZOPHRENIA), JAZZ PHARMACEUTICALS",VERSACLOZ,CLOZAPINE,"CLOZAPINE (ORAL SUSPENSION, SCHIZOPHRENIA), JAZZ PHARMACEUTICALS",CLOZAPINE OS,,,,,,,,,,,,,,,,,,,,,,,,,,,203479,CLOZAPINE,,,,,,,,,,,,,,,,,,,,,2013-02-06T00:00:00Z,2013,2,Versacloz,schizophrenia,DOPAMINE D4 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203479,NDA,2011-12-28T00:00:00Z,fda,0,0,0,0,0,,douglas pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203479,159,299,295,659,Schizophrenia and other psychotic disorders,1,0
138,CARIPRAZINE,MP-214; RGH-188; VRAYLAR; VRAYLAR; CARIPRAZINE,MP-214; RGH-188; VRAYLAR; VRAYLAR; CARIPRAZINE,CARIPRAZINE,MP-214,RGH-188,VRAYLAR,VRAYLAR,CARIPRAZINE,,,,,,,,,,,,,,,,,,,,,,,,,,204370,CARIPRAZINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-09-17T00:00:00Z,2015,9,Vraylar,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR PARTIAL AGONIST; DOPAMINE D3 RECEPTOR PARTIAL AGONIST,ANTIPSYCHOTIC,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204370,NDA,2012-11-19T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,12688.1,3646.9,3094,4547.76,4390.13,4157.39,11221.3,2067,2358.5,4518,2014-06-30T00:00:00Z,2014,,acquired by actavis (now allergan plc) in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370,195,299,295,659,Schizophrenia and other psychotic disorders,1,0
104,BREXPIPRAZOLE,LU AF-41156; LU AF-41156; OPC-34712; REXULTI; REXULTI; BREXPIPRAZOLE,LU AF-41156; LU AF-41156; OPC-34712; REXULTI; REXULTI; BREXPIPRAZOLE,BREXPIPRAZOLE,LU AF-41156,LU AF-41156,OPC-34712,REXULTI,REXULTI,BREXPIPRAZOLE,,,,,,,,,,,,,,,,,,,,,,,,,205422,BREXPIPRAZOLE,,,,,,,,,,,,,,,,,,,,,2015-07-10T00:00:00Z,2015,7,Rexulti,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; ALPHA 1B ADRENOCEPTOR ANTAGONIST; ALPHA 2C ADRENOCEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR PARTIAL AGONIST; DOPAMINE D3 RECEPTOR PARTIAL AGONIST,5-HT MODULATOR; ANTIDEPRESSANT; ANTIPSYCHOTIC; DOPAMINE MODULATOR,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205422,NDA,2014-07-11T00:00:00Z,fda,0,0,0,0,0,,otsuka,TYO: 4578,1,12023.5,13350.2,13344,13476.7,14733.1,13618.6,8285.8,1672.3,1672.3,,,,,IPO in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205422,238,299,295,659,Schizophrenia and other psychotic disorders,1,0
58,"ARIPIPRAZOLE (EXTENDED-RELEASE INTRAMUSCULAR, LINKERX, SCHIZOPHRENIA), ALKERMES","ALKS-9070; ALKS-9072; ARISTADA; ARISTADA; ARIPIPRAZOLE; ARIPIPRAZOLE (EXTENDED-RELEASE INJECTION, LINKERX, SCHIZOPHRENIA), ALKERMES; ARIPIPRAZOLE (EXTENDED-RELEASE INTRAMUSCULAR, LINKERX, SCHIZOPHRENIA), ALKERMES; ARIPIPRAZOLE LAUROXIL","ALKS-9070; ALKS-9072; ARISTADA; ARISTADA; ARIPIPRAZOLE; ARIPIPRAZOLE (EXTENDED-RELEASE INJECTION, LINKERX, SCHIZOPHRENIA), ALKERMES; ARIPIPRAZOLE (EXTENDED-RELEASE INTRAMUSCULAR, LINKERX, SCHIZOPHRENIA), ALKERMES; ARIPIPRAZOLE LAUROXIL","ARIPIPRAZOLE (EXTENDED-RELEASE INTRAMUSCULAR, LINKERX, SCHIZOPHRENIA), ALKERMES",ALKS-9070,ALKS-9072,ARISTADA,ARISTADA,ARIPIPRAZOLE,"ARIPIPRAZOLE (EXTENDED-RELEASE INJECTION, LINKERX, SCHIZOPHRENIA), ALKERMES","ARIPIPRAZOLE (EXTENDED-RELEASE INTRAMUSCULAR, LINKERX, SCHIZOPHRENIA), ALKERMES",ARIPIPRAZOLE LAUROXIL,,,,,,,,,,,,,,,,,,,,,,,207533,ARIPIPRAZOLE LAUROXIL,,,,,,,,,,,,,,,,,,,,,2015-10-05T00:00:00Z,2015,10,Aristada,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR PARTIAL AGONIST,ANTIPSYCHOTIC,INTRAMUSCULAR FORMULATION; MONTHLY DOSING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),207533,NDA,2014-08-22T00:00:00Z,fda,0,0,0,0,0,,alkermes,NASDAQ: ALKS,1,628.3,618.8,596.3,542.6,310.6,174,489.3,336.3,344.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207533,302,299,295,659,Schizophrenia and other psychotic disorders,1,0
564,"PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), JANSSEN","INVEGA; INVEGA SUSTENNA; INVEGA SUSTENNA (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES; INVEGA TRINZA; INVEGA TRINZA; TREVICTA; TREVICTA; PALIPERIDONE; PALIPERIDONE PALMITATE; PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES; PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), JANSSEN","INVEGA; INVEGA SUSTENNA; INVEGA SUSTENNA (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES; INVEGA TRINZA; INVEGA TRINZA; TREVICTA; TREVICTA; PALIPERIDONE; PALIPERIDONE PALMITATE; PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES; PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), JANSSEN","PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), JANSSEN",INVEGA,INVEGA SUSTENNA,"INVEGA SUSTENNA (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES",INVEGA TRINZA,INVEGA TRINZA,TREVICTA,TREVICTA,PALIPERIDONE,PALIPERIDONE PALMITATE,"PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), ALKERMES","PALIPERIDONE PALMITATE (3-MONTH FORMULATION, SCHIZOPHRENIA), JANSSEN",,,,,,,,,,,,,,,,,,,,207946,PALIPERIDONE PALMITATE,21999,PALIPERIDONE,22264,PALIPERIDONE PALMITATE,22264,PALIPERIDONE PALMITATE,,,,,,,,,,,,,,,2015-05-18T00:00:00Z,2015,5,Invega Trinza,schizophrenia,5-HT RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,INTRAMUSCULAR FORMULATION; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),207946,NDA,2014-11-18T00:00:00Z,fda,1,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,70074,74331,71312,67224,65030,61587,48619,9046,9046,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207946,310,299,295,659,Schizophrenia and other psychotic disorders,1,0
563,"PALIPERIDONE (ORAL, OROS), JOHNSON & JOHNSON","9-HYDROXYRISPERIDONE; INVEGA; INVEGA SR; JNS007ER; KSEPLION; PALIPERIDONE ER; R-76477; PALIPERIDONE; PALIPERIDONE (ORAL, OROS), JOHNSON & JOHNSON","9-HYDROXYRISPERIDONE; INVEGA; INVEGA SR; JNS007ER; KSEPLION; PALIPERIDONE ER; R-76477; PALIPERIDONE; PALIPERIDONE (ORAL, OROS), JOHNSON & JOHNSON","PALIPERIDONE (ORAL, OROS), JOHNSON & JOHNSON",9-HYDROXYRISPERIDONE,INVEGA,INVEGA SR,JNS007ER,KSEPLION,PALIPERIDONE ER,R-76477,PALIPERIDONE,"PALIPERIDONE (ORAL, OROS), JOHNSON & JOHNSON",,,,,,,,,,,,,,,,,,,,,,21999,PALIPERIDONE,,,,,,,,,,,,,,,,,,,,,2006-12-19T00:00:00Z,2006,12,Invega,schizophrenia,5-HT RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021999,NDA,2005-11-30T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,53324,50514,47348,41862,36298,32317,38267,7125,7125,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021999,432,299,295,659,Schizophrenia and other psychotic disorders,1,0
615,"QUETIAPINE FUMARATE (ONCE-DAILY SUSTAINED RELEASE TABLET), ASTRAZENECA","FK-949E; SEROQUEL ER; SEROQUEL SR; SEROQUEL XR; SEROQUEL XRO; XEROQUEL LP; QUETIAPINE; QUETIAPINE XR; QUETIAPINE FUMARATE; QUETIAPINE FUMARATE (ONCE-DAILY SUSTAINED RELEASE TABLET), ASTRAZENECA","FK-949E; SEROQUEL ER; SEROQUEL SR; SEROQUEL XR; SEROQUEL XRO; XEROQUEL LP; QUETIAPINE; QUETIAPINE XR; QUETIAPINE FUMARATE; QUETIAPINE FUMARATE (ONCE-DAILY SUSTAINED RELEASE TABLET), ASTRAZENECA","QUETIAPINE FUMARATE (ONCE-DAILY SUSTAINED RELEASE TABLET), ASTRAZENECA",FK-949E,SEROQUEL ER,SEROQUEL SR,SEROQUEL XR,SEROQUEL XRO,XEROQUEL LP,QUETIAPINE,QUETIAPINE XR,QUETIAPINE FUMARATE,"QUETIAPINE FUMARATE (ONCE-DAILY SUSTAINED RELEASE TABLET), ASTRAZENECA",,,,,,,,,,,,,,,,,,,,,22047,QUETIAPINE FUMARATE,22047,QUETIAPINE FUMARATE,,,,,,,,,,,,,,,,,,,2007-05-17T00:00:00Z,2007,5,Seroquel XR,schizophrenia,5-HT 2 RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIDEPRESSANT; ANTIPSYCHOTIC,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022047,NDA,2006-07-17T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,29559,26475,23950,21426,18849,17841,23555,4969,5240,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022047,452,299,295,659,Schizophrenia and other psychotic disorders,1,0
796,ZYPADHERA,"ZYPADHERA; ZYPREXA ADHERA; ZYPREXA RELPREVV; OLANZAPINE; OLANZAPINE (DEPOT INJECTION), ELI LILLY; OLANZAPINE LAI; OLANZAPINE PAMOATE","ZYPADHERA; ZYPREXA ADHERA; ZYPREXA RELPREVV; OLANZAPINE; OLANZAPINE (DEPOT INJECTION), ELI LILLY; OLANZAPINE LAI; OLANZAPINE PAMOATE",ZYPADHERA,ZYPADHERA,ZYPREXA ADHERA,ZYPREXA RELPREVV,OLANZAPINE,"OLANZAPINE (DEPOT INJECTION), ELI LILLY",OLANZAPINE LAI,OLANZAPINE PAMOATE,,,,,,,,,,,,,,,,,,,,,,,,22173,OLANZAPINE PAMOATE,,,,,,,,,,,,,,,,,,,,,2009-12-11T00:00:00Z,2009,12,Zyprexa Relprevv,schizophrenia,5-HT 2 RECEPTOR ANTAGONIST; DOPAMINE D1 RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST; DOPAMINE D4 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,INJECTABLE CONTROLLED RELEASE FORMULATION; INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),022173,NDA,2009-04-16T00:00:00Z,fda,0,0,0,0,0,,eli lilly,NYSE: LLY,1,21836,20371.9,18633.5,15691,14645.3,13857.9,17589,4326.5,4326.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022173,485,299,295,659,Schizophrenia and other psychotic disorders,1,0
373,ILOPERIDONE,FANAPT; FANAPTUM; FANAPTUM; FIAPTA; HP-873; ILO-522; P88-8991; P95-12113; ZOMARIL; ILOPERIDONE,FANAPT; FANAPTUM; FANAPTUM; FIAPTA; HP-873; ILO-522; P88-8991; P95-12113; ZOMARIL; ILOPERIDONE,ILOPERIDONE,FANAPT,FANAPTUM,FANAPTUM,FIAPTA,HP-873,ILO-522,P88-8991,P95-12113,ZOMARIL,ILOPERIDONE,,,,,,,,,,,,,,,,,,,,,22192,ILOPERIDONE,,,,,,,,,,,,,,,,,,,,,2009-05-06T00:00:00Z,2009,5,Fanapt,schizophrenia,5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022192,NDA,2007-09-27T00:00:00Z,fda,0,0,0,0,0,,vanda pharmaceuticals,NASDAQ: VNDA,1,4.5,,,,,,-5.1,5.5,13.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022192,490,299,295,659,Schizophrenia and other psychotic disorders,1,0
565,"PALIPERIDONE PALMITATE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON","INVEGA SUSTENNA; JNS-010; R-092670; SUSTENNA; XEPLION; PALIPERIDONE; PALIPERIDONE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON; PALIPERIDONE (INJECTABLE, NANOCRYSTAL), ELAN; PALIPERIDONE PALMITATE; PALIPERIDONE PALMITATE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON; PALIPERIDONE PALMITATE (INJECTABLE, NANOCRYSTAL), ELAN","INVEGA SUSTENNA; JNS-010; R-092670; SUSTENNA; XEPLION; PALIPERIDONE; PALIPERIDONE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON; PALIPERIDONE (INJECTABLE, NANOCRYSTAL), ELAN; PALIPERIDONE PALMITATE; PALIPERIDONE PALMITATE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON; PALIPERIDONE PALMITATE (INJECTABLE, NANOCRYSTAL), ELAN","PALIPERIDONE PALMITATE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON",INVEGA SUSTENNA,JNS-010,R-092670,SUSTENNA,XEPLION,PALIPERIDONE,"PALIPERIDONE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON","PALIPERIDONE (INJECTABLE, NANOCRYSTAL), ELAN",PALIPERIDONE PALMITATE,"PALIPERIDONE PALMITATE (DEPOT INJECTION, NANOCRYSTAL), JOHNSON & JOHNSON","PALIPERIDONE PALMITATE (INJECTABLE, NANOCRYSTAL), ELAN",,,,,,,,,,,,,,,,,,,,22264,PALIPERIDONE PALMITATE,,,,,,,,,,,,,,,,,,,,,2009-07-31T00:00:00Z,2009,7,Invega Sustenna,schizophrenia,5-HT RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,INTRAMUSCULAR FORMULATION; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),022264,NDA,2007-10-25T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61897,63747,61095,53324,50514,47348,43563,6986,6986,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022264,515,299,295,659,Schizophrenia and other psychotic disorders,1,0
60,"ARIPIPRAZOLE (INTRAMUSCULAR), OTSUKA/BMS","ABILIFY INJECTION (INTRAMUSCULAR, DEPRESSION/BIPOLAR MANIA), OTSUKA/BMS; IM ARIPIPRAZOLE; ARIPIPRAZOLE; ARIPIPRAZOLE (INTRAMUSCULAR), OTSUKA/BMS; INTRAMUSCULAR ARIPIPRAZOLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2006-09-20T00:00:00Z,2006,9,Abilify,schizophrenia,5-HT 1A RECEPTOR PARTIAL AGONIST; 5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR PARTIAL AGONIST,ANTIPSYCHOTIC,INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),021866,NDA,2005-11-29T00:00:00Z,fda,0,0,0,0,0,,otsuka,private,0,,,,,,,,,,,,,,IPO in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021866,640,299,295,659,Schizophrenia and other psychotic disorders,1,0
422,LEVOMILNACIPRAN,"5-HT ANTAGONIST/NOREPINEPHRINE UPTAKE INHIBITOR (DEPRESSION/ANXIETY), PIERRE FABRE; F-2695; F-2695 SR; FETZIMA; LEVOMILNACIPRAN; LEVOMILNACIPRAN HYDROCHLORIDE; MILNACIPRAN HYDROCHLORIDE (1S,2R)-ISOMER, PIERRE FABRE","5-HT ANTAGONIST/NOREPINEPHRINE UPTAKE INHIBITOR (DEPRESSION/ANXIETY), PIERRE FABRE; F-2695; F-2695 SR; FETZIMA; LEVOMILNACIPRAN; LEVOMILNACIPRAN HYDROCHLORIDE; MILNACIPRAN HYDROCHLORIDE (1S,2R)-ISOMER, PIERRE FABRE",LEVOMILNACIPRAN,"5-HT ANTAGONIST/NOREPINEPHRINE UPTAKE INHIBITOR (DEPRESSION/ANXIETY), PIERRE FABRE",F-2695,F-2695 SR,FETZIMA,LEVOMILNACIPRAN,LEVOMILNACIPRAN HYDROCHLORIDE,"MILNACIPRAN HYDROCHLORIDE (1S,2R)-ISOMER, PIERRE FABRE",,,,,,,,,,,,,,,,,,,,,,,,204168,LEVOMILNACIPRAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-07-25T00:00:00Z,2013,7,Fetzima,major depressive disorder,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,CAPSULE FORMULATION; CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY,matched (3),204168,NDA,2012-09-25T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,3371.4,3341.9,4635.3,4308.4,4060.6,3863.8,2682.2,809.6,836.6,,,,,acquired by actavis (now allergan plc) in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204168,186,4898,296,657,Mood disorders,1,0
790,VORTIOXETINE HYDROBROMIDE,BRINTELLIX; LU-AA21004; TRINTELLIX; VORTIOXETINE; VORTIOXETINE HYDROBROMIDE; VORTIOXETINE HYDROCHLORIDE,BRINTELLIX; LU-AA21004; TRINTELLIX; VORTIOXETINE; VORTIOXETINE HYDROBROMIDE; VORTIOXETINE HYDROCHLORIDE,VORTIOXETINE HYDROBROMIDE,BRINTELLIX,LU-AA21004,TRINTELLIX,VORTIOXETINE,VORTIOXETINE HYDROBROMIDE,VORTIOXETINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,204447,VORTIOXETINE HYDROBROMIDE,,,,,,,,,,,,,,,,,,,,,2013-09-30T00:00:00Z,2013,9,Trintellix,major depressive disorder,5-HT 1A RECEPTOR AGONIST; 5-HT 1B RECEPTOR PARTIAL AGONIST; 5-HT 1D RECEPTOR ANTAGONIST; 5-HT 3 RECEPTOR ANTAGONIST; 5-HT 7 RECEPTOR ANTAGONIST; SEROTONIN TRANSPORTER INHIBITOR,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; ANTIPSYCHOTIC; ANXIOLYTIC; NOOTROPIC AGENT,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204447,NDA,2012-10-02T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15739.7,18156.3,19052,17491.2,15722.4,16561.7,11337.5,101,3147,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204447,202,4898,296,657,Mood disorders,1,0
198,"DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), OSMOTICA PHARMACEUTICAL","KHEDEZLA; DESVENLAFAXINE; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), OSMOTICA PHARMACEUTICAL","KHEDEZLA; DESVENLAFAXINE; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), OSMOTICA PHARMACEUTICAL","DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), OSMOTICA PHARMACEUTICAL",KHEDEZLA,DESVENLAFAXINE,"DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), OSMOTICA PHARMACEUTICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,204683,DESVENLAFAXINE,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,,,,,,,,,,,,,,,2013-07-10T00:00:00Z,2013,7,Khedezla,major depressive disorder,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204683,NDA,2012-09-13T00:00:00Z,fda,0,0,0,0,0,,osmotica pharmaceutical,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204683,211,4898,296,657,Mood disorders,1,0
197,"DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/SUN","DESVENLAFAXINE; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/RANBAXY; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/SUN","DESVENLAFAXINE; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/RANBAXY; DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/SUN","DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/SUN",DESVENLAFAXINE,"DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/RANBAXY","DESVENLAFAXINE (EXTENDED-RELEASE TABLET, DEPRESSION), ALEMBIC/SUN",,,,,,,,,,,,,,,,,,,,,,,,,,,,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,,,,,,,,,,,,,,,2013-03-04T00:00:00Z,2013,3,Desvenlafaxine,major depressive disorder,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204150,NDA,2012-02-29T00:00:00Z,fda,0,0,0,0,0,,alembic pharmaceuticals,NSE: APLLTD,1,280,287.9,359.6,,,,141.2,13.7,13.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204150,230,4898,296,657,Mood disorders,1,0
196,DESVENLAFAXINE,DVS-233; ELLEFORE; KASTAN; PF-05212375; PRISTIQ; WY-45233; WY-45494; DESVENLAFAXINE; DESVENLAFAXINE SUCCINATE,DVS-233; ELLEFORE; KASTAN; PF-05212375; PRISTIQ; WY-45233; WY-45494; DESVENLAFAXINE; DESVENLAFAXINE SUCCINATE,DESVENLAFAXINE,DVS-233,ELLEFORE,KASTAN,PF-05212375,PRISTIQ,WY-45233,WY-45494,DESVENLAFAXINE,DESVENLAFAXINE SUCCINATE,,,,,,,,,,,,,,,,,,,,,,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,205208,DESVENLAFAXINE FUMARATE,21992,DESVENLAFAXINE SUCCINATE,,,,,,,,,,,,,,,2008-02-29T00:00:00Z,2008,2,Pristiq,major depressive disorder,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021992,NDA,2005-12-22T00:00:00Z,fda,0,0,0,0,0,,wyeth,NYSE: WYE,1,22833.9,22399.8,20350.7,18755.8,17358,15850.6,16828.6,3340.08,3373.2,,,,,acquired by Pfizer in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021992,429,4898,296,657,Mood disorders,1,0
120,"BUPROPION (ENHANCED-ABSORPTION SALT, DEPRESSION), BIOVAIL","APLENZIN; BVF-033; AMFEBUTAMONE; BUPROPION; BUPROPION (ENHANCED-ABSORPTION SALT, DEPRESSION), BIOVAIL; BUPROPION HYDROBROMIDE","APLENZIN; BVF-033; AMFEBUTAMONE; BUPROPION; BUPROPION (ENHANCED-ABSORPTION SALT, DEPRESSION), BIOVAIL; BUPROPION HYDROBROMIDE","BUPROPION (ENHANCED-ABSORPTION SALT, DEPRESSION), BIOVAIL",APLENZIN,BVF-033,AMFEBUTAMONE,BUPROPION,"BUPROPION (ENHANCED-ABSORPTION SALT, DEPRESSION), BIOVAIL",BUPROPION HYDROBROMIDE,,,,,,,,,,,,,,,,,,,,,,,,,22108,BUPROPION HYDROBROMIDE,,,,,,,,,,,,,,,,,,,,,2008-04-23T00:00:00Z,2008,4,Aplenzin,major depressive disorder,DOPAMINE RECEPTOR AGONIST,ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL ABSORPTION ENHANCER; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022108,NDA,2006-09-27T00:00:00Z,fda,0,0,0,0,0,,biovail laboratories,TSX: BVF,1,,,,,,,,,,,,,,acquired by valeant in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022108,469,4898,296,657,Mood disorders,1,0
63,ASENAPINE,ME-2136; MK-8274; ORG-5222; SCH-900274; SAPHRIS; SYCREST; ASENAPINE; ASENAPINE MALEATE,ME-2136; MK-8274; ORG-5222; SCH-900274; SAPHRIS; SYCREST; ASENAPINE; ASENAPINE MALEATE,ASENAPINE,ME-2136,MK-8274,ORG-5222,SCH-900274,SAPHRIS,SYCREST,ASENAPINE,ASENAPINE MALEATE,,,,,,,,,,,,,,,,,,,,,,,22117,ASENAPINE MALEATE,,,,,,,,,,,,,,,,,,,,,2009-08-13T00:00:00Z,2009,8,Saphris,bipolar disorder,5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D1 RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC,BUCCAL FORMULATION SYSTEMIC; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC,matched (3),022117,NDA,2009-02-12T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,27428,18502,12690,4643,,,20024,5613,5845,18052,2009-09-30T00:00:00Z,2009,,acquired by schering plough in 2007; subsidiary of merck as of 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022117,472,653,296,657,Mood disorders,1,0
770,"VALPROIC ACID (DELAYED RELEASE), NOVEN/BANNER","STAVZOR; VALPROIC ACID; VALPROIC ACID (DELAYED RELEASE), NOVEN/BANNER; VALPROIC ACID (DELAYED RELEASE, SOFTGEL), BANNER PHARMACAPS","STAVZOR; VALPROIC ACID; VALPROIC ACID (DELAYED RELEASE), NOVEN/BANNER; VALPROIC ACID (DELAYED RELEASE, SOFTGEL), BANNER PHARMACAPS","VALPROIC ACID (DELAYED RELEASE), NOVEN/BANNER",STAVZOR,VALPROIC ACID,"VALPROIC ACID (DELAYED RELEASE), NOVEN/BANNER","VALPROIC ACID (DELAYED RELEASE, SOFTGEL), BANNER PHARMACAPS",,,,,,,,,,,,,,,,,,,,,,,,,,,22152,VALPROIC ACID,,,,,,,,,,,,,,,,,,,,,2008-07-29T00:00:00Z,2008,7,Stavzor,bipolar disorder,GABA TRANSAMINASE INHIBITOR; HISTONE DEACETYLASE-1 INHIBITOR,ANTICONVULSANT AGENT,CAPSULE FORMULATION; ENTERIC COATED FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022152,NDA,2006-09-20T00:00:00Z,fda,0,0,0,0,0,,banner pharmacaps,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022152,480,653,296,657,Mood disorders,1,0
412,"LAMOTRIGINE (ORALLY DISINTEGRATING TABLET), GSK","BW-430C ODT; EUR-1048; GI-267119; LAMICTAL ODT; LAMICTAL ORALLY DISINTEGRATING TABLETS; LAMOTRIN; LAMOTRIGINE; LAMOTRIGINE (ORALLY DISINTEGRATING TABLET), GSK","BW-430C ODT; EUR-1048; GI-267119; LAMICTAL ODT; LAMICTAL ORALLY DISINTEGRATING TABLETS; LAMOTRIN; LAMOTRIGINE; LAMOTRIGINE (ORALLY DISINTEGRATING TABLET), GSK","LAMOTRIGINE (ORALLY DISINTEGRATING TABLET), GSK",BW-430C ODT,EUR-1048,GI-267119,LAMICTAL ODT,LAMICTAL ORALLY DISINTEGRATING TABLETS,LAMOTRIN,LAMOTRIGINE,"LAMOTRIGINE (ORALLY DISINTEGRATING TABLET), GSK",,,,,,,,,,,,,,,,,,,,,,,22251,LAMOTRIGINE,,,,,,,,,,,,,,,,,,,,,2009-05-08T00:00:00Z,2009,5,Lamictal Odt,bipolar i disorder,SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT; ANTIDEPRESSANT; ANTIPSYCHOTIC; GLUTAMATE RELEASE INHIBITOR; NEUROPROTECTANT,FORMULATION ORAL TASTE-MASKING; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022251,NDA,2007-11-28T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022251,511,3114,296,657,Mood disorders,1,0
782,VILAZODONE,"659746; EMD-68843; EMD-86006; EMD-95750; SB-659746-A; SSRI/5HT-1A PARTIAL AGONIST (DEPRESSION), CLINICAL DATA; SSRI/5HT1A PARTIAL AGONIST (DEPRESSION), MERCK KGAA/GLAXOSMITHKLINE; VIIBRYD; VILAZODONE; VILAZODONE HYDROCHLORIDE","659746; EMD-68843; EMD-86006; EMD-95750; SB-659746-A; SSRI/5HT-1A PARTIAL AGONIST (DEPRESSION), CLINICAL DATA; SSRI/5HT1A PARTIAL AGONIST (DEPRESSION), MERCK KGAA/GLAXOSMITHKLINE; VIIBRYD; VILAZODONE; VILAZODONE HYDROCHLORIDE",VILAZODONE,659746,EMD-68843,EMD-86006,EMD-95750,SB-659746-A,"SSRI/5HT-1A PARTIAL AGONIST (DEPRESSION), CLINICAL DATA","SSRI/5HT1A PARTIAL AGONIST (DEPRESSION), MERCK KGAA/GLAXOSMITHKLINE",VIIBRYD,VILAZODONE,VILAZODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,22567,VILAZODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-01-21T00:00:00Z,2011,1,Viibryd,major depressive disorder,5-HT 1A RECEPTOR PARTIAL AGONIST,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; ANXIOLYTIC,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022567,NDA,2010-03-22T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,4635.3,17.1,3.2,-13.9,33.3,20.4,3326,797.7,797.7,0,2011-03-31T00:00:00Z,2011,,acquired by forest labs in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022567,603,4898,296,657,Mood disorders,1,0
312,"FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), JAZZ","FLUVOX CR; LUVOX CR; CONTROLLED-RELEASE FLUVOXAMINE; FLUVOXAMINE; FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), JAZZ; FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), SOLVAY; FLUVOXAMINE CR","FLUVOX CR; LUVOX CR; CONTROLLED-RELEASE FLUVOXAMINE; FLUVOXAMINE; FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), JAZZ; FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), SOLVAY; FLUVOXAMINE CR","FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), JAZZ",FLUVOX CR,LUVOX CR,CONTROLLED-RELEASE FLUVOXAMINE,FLUVOXAMINE,"FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), JAZZ","FLUVOXAMINE (ORAL CONTROLLED-RELEASE, SODAS), SOLVAY",FLUVOXAMINE CR,,,,,,,,,,,,,,,,,,,,,,,,22033,FLUVOXAMINE MALEATE,,,,,,,,,,,,,,,,,,,,,2008-02-28T00:00:00Z,2008,2,Luvox CR,anxiety disorder,,5-HT UPTAKE INHIBITOR; ANXIOLYTIC,CAPSULE FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022033,NDA,2006-04-28T00:00:00Z,fda,0,0,0,0,0,,solvay pharmaceuticals,EBR: SOLB,1,9489.3,13978,12402.2,10142.1,9844.3,9524.8,1627.9,190,190,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022033,446,25,300,651,Anxiety disorders,3,0
69,AVANAFIL,"PDE 5 INHIBITOR (SEXUAL DYSFUNCTION), TANABE/VIVUS; SPEDRA; STENDRA; TA-1790; VI-0162; ZEPEED; AVANAFIL","PDE 5 INHIBITOR (SEXUAL DYSFUNCTION), TANABE/VIVUS; SPEDRA; STENDRA; TA-1790; VI-0162; ZEPEED; AVANAFIL",AVANAFIL,"PDE 5 INHIBITOR (SEXUAL DYSFUNCTION), TANABE/VIVUS",SPEDRA,STENDRA,TA-1790,VI-0162,ZEPEED,AVANAFIL,,,,,,,,,,,,,,,,,,,,,,,,202276,AVANAFIL,,,,,,,,,,,,,,,,,,,,,2012-04-27T00:00:00Z,2012,4,Stendra,erectile dysfunction,PDE 5 INHIBITOR,VASODILATOR,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202276,NDA,2011-06-29T00:00:00Z,fda,0,0,0,0,0,,vivus,NASDAQ: VVUS,1,2,,,31.4,83.7,54.7,1.8,31.2,31.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202276,109,186,302,670,Miscellaneous mental health disorders,2,0
294,FLIBANSERIN,ADDYI; BIMT-17; BIMT-17BS; GIROSA; FLIBANSERIN; FLIBANSERIN HYDROCHLORIDE,ADDYI; BIMT-17; BIMT-17BS; GIROSA; FLIBANSERIN; FLIBANSERIN HYDROCHLORIDE,FLIBANSERIN,ADDYI,BIMT-17,BIMT-17BS,GIROSA,FLIBANSERIN,FLIBANSERIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,22526,FLIBANSERIN,,,,,,,,,,,,,,,,,,,,,2015-08-18T00:00:00Z,2015,8,Addyi,hypoactive sexual desire disorder,5-HT 1A RECEPTOR AGONIST; 5-HT 2A RECEPTOR ANTAGONIST,ANTIDEPRESSANT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022526,NDA,2009-10-27T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,10442,,,,,,7996,334,334,,,2015,,acquired by valeant in 2015,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022526,591,2039,302,670,Miscellaneous mental health disorders,2,0
676,"SODIUM NITRITE AND SODIUM THIOSULFATE REGIMEN (INTRAVENOUS, CYANIDE POISONING), HOPE PHARMACEUTICAL","NITHIODOTE; SODIUM NITRITE + SODIUM THIOSULFATE PENTAHYDRATE; SODIUM NITRITE AND SODIUM THIOSULFATE REGIMEN (INTRAVENOUS, CYANIDE POISONING), HOPE PHARMACEUTICAL","NITHIODOTE; SODIUM NITRITE + SODIUM THIOSULFATE PENTAHYDRATE; SODIUM NITRITE AND SODIUM THIOSULFATE REGIMEN (INTRAVENOUS, CYANIDE POISONING), HOPE PHARMACEUTICAL","SODIUM NITRITE AND SODIUM THIOSULFATE REGIMEN (INTRAVENOUS, CYANIDE POISONING), HOPE PHARMACEUTICAL",NITHIODOTE,SODIUM NITRITE + SODIUM THIOSULFATE PENTAHYDRATE,"SODIUM NITRITE AND SODIUM THIOSULFATE REGIMEN (INTRAVENOUS, CYANIDE POISONING), HOPE PHARMACEUTICAL",,,,,,,,,,,,,,,,,,,,,,,,,,,,201444,SODIUM NITRITE; SODIUM THIOSULFATE,203922,SODIUM NITRITE,203922,SODIUM NITRITE,203922,SODIUM NITRITE,,,,,,,,,,,,,,,2011-01-14T00:00:00Z,2011,1,Nithiodote,intoxication,HEMOGLOBIN MODULATOR,ANTIDOTE,DRUG COMBINATION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),201444,NDA,2010-05-21T00:00:00Z,fda,0,0,0,0,0,,hope pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201444,86,752,303,660,Alcohol-related disorders,1,0
507,"NALTREXONE (ONCE-MONTHLY CONTROLLED-RELEASE, MEDISORB), ALKERMES","VIVITREX; VIVITROL; XR-NTX; NALTREXONE; NALTREXONE (ONCE-MONTHLY CONTROLLED-RELEASE, MEDISORB), ALKERMES","VIVITREX; VIVITROL; XR-NTX; NALTREXONE; NALTREXONE (ONCE-MONTHLY CONTROLLED-RELEASE, MEDISORB), ALKERMES","NALTREXONE (ONCE-MONTHLY CONTROLLED-RELEASE, MEDISORB), ALKERMES",VIVITREX,VIVITROL,XR-NTX,NALTREXONE,"NALTREXONE (ONCE-MONTHLY CONTROLLED-RELEASE, MEDISORB), ALKERMES",,,,,,,,,,,,,,,,,,,,,,,,,,21897,NALTREXONE,,,,,,,,,,,,,,,,,,,,,2006-04-13T00:00:00Z,2006,4,Vivitrol,alcoholism,OPIOID RECEPTOR ANTAGONIST; OPIOID RECEPTOR MU ANTAGONIST,,CONTROLLED RELEASE FORMULATION; INTRAMUSCULAR FORMULATION; MICROPARTICLE FORMULATION; MONTHLY DOSING; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),021897,NDA,2005-03-31T00:00:00Z,fda,1,0,0,0,0,,alkermes,NASDAQ: ALKS,1,228.8,136,69.2,35.3,47.6,51.3,186.1,111.2,111.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021897,403,11,303,660,Alcohol-related disorders,1,0
590,"PHENTOLAMINE MESYLATE (ANESTHESIA REVERSAL), NOVALAR","NV-101, NOVALAR; ORAVERSE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHENTOLAMINE MESYLATE (ANESTHESIA REVERSAL), NOVALAR","NV-101, NOVALAR; ORAVERSE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHENTOLAMINE MESYLATE (ANESTHESIA REVERSAL), NOVALAR","PHENTOLAMINE MESYLATE (ANESTHESIA REVERSAL), NOVALAR","NV-101, NOVALAR",ORAVERSE,PHENTOLAMINE,PHENTOLAMINE MESYLATE,"PHENTOLAMINE MESYLATE (ANESTHESIA REVERSAL), NOVALAR",,,,,,,,,,,,,,,,,,,,,,,,,,22159,PHENTOLAMINE MESYLATE,,,,,,,,,,,,,,,,,,,,,2008-05-09T00:00:00Z,2008,5,Oraverse,intoxication,ALPHA ADRENOCEPTOR ANTAGONIST,VASODILATOR,PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),022159,NDA,2007-04-09T00:00:00Z,fda,0,0,0,0,0,,novalar pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022159,482,752,303,660,Alcohol-related disorders,1,0
504,"NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), ADAPT PHARMA","LT-20; NARCAN; NALOXONE; NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), ADAPT PHARMA; NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), LIGHTLAKE / NIDA; TAKE-HOME EMERGENCY NALOXONE, ADAPT PHARMA; TAKE-HOME EMERGENCY NALOXONE, LIGHTLAKE","LT-20; NARCAN; NALOXONE; NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), ADAPT PHARMA; NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), LIGHTLAKE / NIDA; TAKE-HOME EMERGENCY NALOXONE, ADAPT PHARMA; TAKE-HOME EMERGENCY NALOXONE, LIGHTLAKE","NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), ADAPT PHARMA",LT-20,NARCAN,NALOXONE,"NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), ADAPT PHARMA","NALOXONE (NASAL SPRAY, OPIATE OVERDOSE), LIGHTLAKE / NIDA","TAKE-HOME EMERGENCY NALOXONE, ADAPT PHARMA","TAKE-HOME EMERGENCY NALOXONE, LIGHTLAKE",,,,,,,,,,,,,,,,,,,,,,,,16636,NALOXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-11-18T00:00:00Z,2015,11,Narcan,opiate dependence,OPIOID RECEPTOR ANTAGONIST,,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208411,NDA,2015-07-17T00:00:00Z,fda,1,0,1,0,0,,adapt pharma,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411,64,243,304,661,Substance-related disorders,1,0
119,"BUPRENORPHINE + NALOXONE (OPIOID DEPENDENCE), OREXO","OX-219; ZUBSOLV; BUPRENORPHINE + NALOXONE; BUPRENORPHINE + NALOXONE (OPIOID DEPENDENCE), OREXO","OX-219; ZUBSOLV; BUPRENORPHINE + NALOXONE; BUPRENORPHINE + NALOXONE (OPIOID DEPENDENCE), OREXO","BUPRENORPHINE + NALOXONE (OPIOID DEPENDENCE), OREXO",OX-219,ZUBSOLV,BUPRENORPHINE + NALOXONE,"BUPRENORPHINE + NALOXONE (OPIOID DEPENDENCE), OREXO",,,,,,,,,,,,,,,,,,,,,,,,,,,204242,BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-07-03T00:00:00Z,2013,7,Zubsolv,opiate dependence,MU OPIOID PARTIAL AGONIST; OPIOID PARTIAL AGONIST; OPIOID RECEPTOR ANTAGONIST; OPIOID RECEPTOR KAPPA ANTAGONIST,,BUCCAL FORMULATION SYSTEMIC; DRUG COMBINATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC,matched (3),204242,NDA,2012-09-05T00:00:00Z,fda,0,0,0,0,0,,orexo AB,STO: ORX,1,66.8,50.1,29.1,31.3,33,29.7,62.2,37,37,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204242,187,243,304,661,Substance-related disorders,1,0
116,"BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN/ BRAEBURN/ KNIGHT","PROBUPHINE; BUPRENORPHINE; BUPRENORPHINE (PRONEURA DELIVERY SYSTEM), TITAN; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), BRAEBURN/ KNIGHT; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN/ BRAEBURN/ KNIGHT; BUPRENORPHINE HYDROCHLORIDE","PROBUPHINE; BUPRENORPHINE; BUPRENORPHINE (PRONEURA DELIVERY SYSTEM), TITAN; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), BRAEBURN/ KNIGHT; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN; BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN/ BRAEBURN/ KNIGHT; BUPRENORPHINE HYDROCHLORIDE","BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN/ BRAEBURN/ KNIGHT",PROBUPHINE,BUPRENORPHINE,"BUPRENORPHINE (PRONEURA DELIVERY SYSTEM), TITAN","BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), BRAEBURN/ KNIGHT","BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN","BUPRENORPHINE (SUSTAINED RELEASE/SC IMPLANT, PRONEURA), TITAN/ BRAEBURN/ KNIGHT",BUPRENORPHINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,204442,BUPRENORPHINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2016-05-26T00:00:00Z,2016,5,Probuphine,opiate dependence,MU OPIOID PARTIAL AGONIST; ORL1 RECEPTOR AGONIST,ANALGESIC,SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS DRUG IMPLANT; SUBCUTANEOUS FORMULATION,matched (3),204442,NDA,2012-10-27T00:00:00Z,fda,1,0,0,0,0,,titan pharmaceuticals,NASDAQ: TTNP,1,15.1,1.7,3.6,10.5,7.1,4.1,8.9,,6.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204442,201,243,304,661,Substance-related disorders,1,0
118,"BUPRENORPHINE + NALOXONE (HIGH DOSE, BUCCAL (BEMA), OPIOID DEPENDENCE), BIODELIVERY SCIENCES","BNX; BUNAVAIL; BUPRENORPHINE + NALOXONE; BUPRENORPHINE + NALOXONE (HIGH DOSE, BUCCAL (BEMA), OPIOID DEPENDENCE), BIODELIVERY SCIENCES","BNX; BUNAVAIL; BUPRENORPHINE + NALOXONE; BUPRENORPHINE + NALOXONE (HIGH DOSE, BUCCAL (BEMA), OPIOID DEPENDENCE), BIODELIVERY SCIENCES","BUPRENORPHINE + NALOXONE (HIGH DOSE, BUCCAL (BEMA), OPIOID DEPENDENCE), BIODELIVERY SCIENCES",BNX,BUNAVAIL,BUPRENORPHINE + NALOXONE,"BUPRENORPHINE + NALOXONE (HIGH DOSE, BUCCAL (BEMA), OPIOID DEPENDENCE), BIODELIVERY SCIENCES",,,,,,,,,,,,,,,,,,,,,,,,,,,205637,BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-06-06T00:00:00Z,2014,6,Bunavail,opiate dependence,MU OPIOID PARTIAL AGONIST,,BUCCAL FORMULATION SYSTEMIC; DRUG COMBINATION; QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSMUCOSAL FORMULATION,matched (3),205637,NDA,2013-08-06T00:00:00Z,fda,0,0,0,0,0,,biodelivery sciences,NASDAQ: BDSI,1,26.2,8.6,54.6,3.3,3.4,62.8,-13,,34.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205637,247,243,304,661,Substance-related disorders,1,0
773,VARENICLINE,"CP 526555-18; CP-526555; CHAMPIX; CHANTIX; ALPHA4/BETA2 NICOTINIC RECEPTOR PARTIAL AGONIST, PFIZER; VARENICLINE; VARENICLINE TARTRATE","CP 526555-18; CP-526555; CHAMPIX; CHANTIX; ALPHA4/BETA2 NICOTINIC RECEPTOR PARTIAL AGONIST, PFIZER; VARENICLINE; VARENICLINE TARTRATE",VARENICLINE,CP 526555-18,CP-526555,CHAMPIX,CHANTIX,"ALPHA4/BETA2 NICOTINIC RECEPTOR PARTIAL AGONIST, PFIZER",VARENICLINE,VARENICLINE TARTRATE,,,,,,,,,,,,,,,,,,,,,,,,21928,VARENICLINE TARTRATE,,,,,,,,,,,,,,,,,,,,,2006-05-10T00:00:00Z,2006,5,Chantix,nicotine dependence,NICOTINIC ACH RECEPTOR ALPHA 4 SUBUNIT MODULATOR; NICOTINIC ACH RECEPTOR BETA 2 SUBUNIT MODULATOR; NICOTINIC ACH RECEPTOR PARTIAL AGONIST; NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR,,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021928,NDA,2005-11-09T00:00:00Z,fda,1,0,0,0,0,,pfizer,NYSE: PFE,1,48371,47405,48988,44736,32294,29024,41123,7423,7599,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021928,411,235,305,661,Substance-related disorders,3,0
448,"LOXAPINE (INHALED (STACCATO), ACUTE AGITATION), ALEXZA","ALXZ-004; AZ-004; ADASUVE; STACCATO LOXAPINE; LOXAPINE; LOXAPINE (INHALED (STACCATO), ACUTE AGITATION), ALEXZA","ALXZ-004; AZ-004; ADASUVE; STACCATO LOXAPINE; LOXAPINE; LOXAPINE (INHALED (STACCATO), ACUTE AGITATION), ALEXZA","LOXAPINE (INHALED (STACCATO), ACUTE AGITATION), ALEXZA",ALXZ-004,AZ-004,ADASUVE,STACCATO LOXAPINE,LOXAPINE,"LOXAPINE (INHALED (STACCATO), ACUTE AGITATION), ALEXZA",,,,,,,,,,,,,,,,,,,,,,,,,22549,LOXAPINE,,,,,,,,,,,,,,,,,,,,,2012-12-21T00:00:00Z,2012,12,Adasuve,agitation,5-HT 2A RECEPTOR ANTAGONIST; DOPAMINE D2 RECEPTOR ANTAGONIST,ANTIPSYCHOTIC; ANXIOLYTIC,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC,matched (3),022549,NDA,2009-12-11T00:00:00Z,fda,0,0,0,0,0,,alexza pharmaceuticals,NASDAQ: ALXA,1,4.07,5.66,42.876,9.514,0.486,,-17.779,,21.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022549,598,3609,307,670,Miscellaneous mental health disorders,3,0
305,"FLUOXETINE (ORAL TABLET, DEPRESSION), EDGEMONT","EDG-003; FLUOXETINE; FLUOXETINE (ORAL TABLET, DEPRESSION), EDGEMONT","EDG-003; FLUOXETINE; FLUOXETINE (ORAL TABLET, DEPRESSION), EDGEMONT","FLUOXETINE (ORAL TABLET, DEPRESSION), EDGEMONT",EDG-003,FLUOXETINE,"FLUOXETINE (ORAL TABLET, DEPRESSION), EDGEMONT",,,,,,,,,,,,,,,,,,,,,,,,,,,,202133,FLUOXETINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-10-06T00:00:00Z,2011,10,fluoxetine,depression,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202133,NDA,2010-12-09T00:00:00Z,fda,0,0,0,0,0,,edgemont pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202133,103,93,311,657,Mood disorders,1,0
663,"SELEGILINE TRANSDERMAL SYSTEM, MYLAN","EMSAM; ELDEPRYL TDS; STS, SOMERSET; SELEGILINE; SELEGILINE HYDROCHLORIDE; SELEGILINE TRANSDERMAL PATCH (DEPRESSION), SOMERSET/BMS; SELEGILINE TRANSDERMAL SYSTEM, MYLAN","EMSAM; ELDEPRYL TDS; STS, SOMERSET; SELEGILINE; SELEGILINE HYDROCHLORIDE; SELEGILINE TRANSDERMAL PATCH (DEPRESSION), SOMERSET/BMS; SELEGILINE TRANSDERMAL SYSTEM, MYLAN","SELEGILINE TRANSDERMAL SYSTEM, MYLAN",EMSAM,ELDEPRYL TDS,"STS, SOMERSET",SELEGILINE,SELEGILINE HYDROCHLORIDE,"SELEGILINE TRANSDERMAL PATCH (DEPRESSION), SOMERSET/BMS","SELEGILINE TRANSDERMAL SYSTEM, MYLAN",,,,,,,,,,,,,,,,,,,,,,,,19334,SELEGILINE HYDROCHLORIDE,19334,SELEGILINE HYDROCHLORIDE,21336,SELEGILINE,,,,,,,,,,,,,,,,,2006-02-27T00:00:00Z,2006,2,Emsam,depression,MAO B INHIBITOR,ANTIDEPRESSANT; ANTIPARKINSONIAN; ANXIOLYTIC; NOOTROPIC AGENT,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021336,NDA,2001-05-24T00:00:00Z,fda,0,0,0,0,0,,mylan,NASDAQ: MYL,1,1257.2,1253.4,1360.7,1269.2,1104.1,846.7,627.6,101.4,102.4,,,,1,was 50% owned by mylan until bought out remaining shares in 2008,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021336,364,93,311,657,Mood disorders,1,0
754,"TRAZODONE (ORAL ONCE-DAILY, CONTRAMID), LABOPHARM","DDS-04A; OLEPTRO; TRAZODONE CONTRAMID; TRITTICO; TRAZODONE; TRAZODONE (ORAL ONCE-DAILY, CONTRAMID), LABOPHARM","DDS-04A; OLEPTRO; TRAZODONE CONTRAMID; TRITTICO; TRAZODONE; TRAZODONE (ORAL ONCE-DAILY, CONTRAMID), LABOPHARM","TRAZODONE (ORAL ONCE-DAILY, CONTRAMID), LABOPHARM",DDS-04A,OLEPTRO,TRAZODONE CONTRAMID,TRITTICO,TRAZODONE,"TRAZODONE (ORAL ONCE-DAILY, CONTRAMID), LABOPHARM",,,,,,,,,,,,,,,,,,,,,,,,,22411,TRAZODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-02-02T00:00:00Z,2010,2,Oleptro,depression,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT,ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022411,NDA,2008-09-18T00:00:00Z,fda,0,0,0,0,0,,labopharm,TSX: DDS,1,29.5,23.5,17.9,19.2,13.6,2.8,13.9,,9.6,,,,,acquired by paladin labs in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022411,555,93,311,657,Mood disorders,1,0
122,"BUPROPION HYDROCHLORIDE (ORAL EXTENDED-RELEASE, VERSATAB), INTELGENX","CPI-300; FORFIVO XL; INT-0004/2006; INT-004; INT-004/06; BUPROPION; BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), CARY PHARMACEUTICALS/INTELGENX; BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), INTELGENX; BUPROPION HYDROCHLORIDE; BUPROPION HYDROCHLORIDE (ORAL EXTENDED-RELEASE, VERSATAB), INTELGENX","CPI-300; FORFIVO XL; INT-0004/2006; INT-004; INT-004/06; BUPROPION; BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), CARY PHARMACEUTICALS/INTELGENX; BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), INTELGENX; BUPROPION HYDROCHLORIDE; BUPROPION HYDROCHLORIDE (ORAL EXTENDED-RELEASE, VERSATAB), INTELGENX","BUPROPION HYDROCHLORIDE (ORAL EXTENDED-RELEASE, VERSATAB), INTELGENX",CPI-300,FORFIVO XL,INT-0004/2006,INT-004,INT-004/06,BUPROPION,"BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), CARY PHARMACEUTICALS/INTELGENX","BUPROPION (ORAL EXTENDED-RELEASE, VERSATAB, DEPRESSION), INTELGENX",BUPROPION HYDROCHLORIDE,"BUPROPION HYDROCHLORIDE (ORAL EXTENDED-RELEASE, VERSATAB), INTELGENX",,,,,,,,,,,,,,,,,,,,,22497,BUPROPION HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-11-10T00:00:00Z,2011,11,Forfivo XL,depression,DOPAMINE RECEPTOR AGONIST; NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST,ANTIDEPRESSANT; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022497,NDA,2009-03-31T00:00:00Z,fda,0,0,0,0,0,,intelgenx,OTCMKTS: IGXT,1,0.4,0.9,1.3,0.9,0.8,0.3,0.4,1.3,1.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022497,577,93,311,657,Mood disorders,1,0
478,"METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE ORAL SUSPENSION, ADHD), NEXTWAVE","NWP-06; QUILLIVANT XR; METHYLPHENIDATE; METHYLPHENIDATE (EXTENDED-RELEASE LIQUID SUSPENSION, ADHD), NEXTWAVE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE ORAL SUSPENSION, ADHD), NEXTWAVE","NWP-06; QUILLIVANT XR; METHYLPHENIDATE; METHYLPHENIDATE (EXTENDED-RELEASE LIQUID SUSPENSION, ADHD), NEXTWAVE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE ORAL SUSPENSION, ADHD), NEXTWAVE","METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE ORAL SUSPENSION, ADHD), NEXTWAVE",NWP-06,QUILLIVANT XR,METHYLPHENIDATE,"METHYLPHENIDATE (EXTENDED-RELEASE LIQUID SUSPENSION, ADHD), NEXTWAVE",METHYLPHENIDATE HYDROCHLORIDE,"METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE ORAL SUSPENSION, ADHD), NEXTWAVE",,,,,,,,,,,,,,,,,,,,,,,,,202100,METHYLPHENIDATE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2012-09-27T00:00:00Z,2012,9,Quillvant XR,attention deficit hyperactivity disorder,ALPHA 2 ADRENOCEPTOR AGONIST,DOPAMINE UPTAKE MODULATOR; PSYCHOMODULATOR,FORMULATION POWDER; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202100,NDA,2010-07-29T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,54657,,,,,,45164,6705,7482,,,,,acquired by pfizer in 2012,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202100,100,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
36,"AMFETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS","ADZENYS XR-ODT; NT-0202; AMFETAMINE; AMFETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS; AMPHETAMINE; AMPHETAMINE XR-ODT; AMPHETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS","ADZENYS XR-ODT; NT-0202; AMFETAMINE; AMFETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS; AMPHETAMINE; AMPHETAMINE XR-ODT; AMPHETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS","AMFETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS",ADZENYS XR-ODT,NT-0202,AMFETAMINE,"AMFETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS",AMPHETAMINE,AMPHETAMINE XR-ODT,"AMPHETAMINE POLISTIREX (EXTENDED RELEASE, ORALLY DISINTEGRATING TABLET, RDIM, ATTENTION DEFICIT HYPERACTIVITY DISORDER), NEOS",,,,,,,,,,,,,,,,,,,,,,,,204326,AMPHETAMINE,,,,,,,,,,,,,,,,,,,,,2016-01-27T00:00:00Z,2016,1,Adzenys XR-ODT,attention deficit hyperactivity disorder,ADRENOCEPTOR AGONIST,,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204326,NDA,2012-12-27T00:00:00Z,fda,0,0,0,0,0,,neos therapeutics,NASDAQ: NEOS,1,9.2,3.8,0.8,1,,,-2.3,12.2,12.2,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204326,193,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
479,"METHYLPHENIDATE HYDROCHLORIDE (ONCE-DAILY ORAL, ADHD), PURDUE PHARMA/RHODES PHARMACEUTICALS","APTENSIO XR; APTENSIO XR; BIPHENTIN; BIPHENTIN; MPH-MLR; MPH-MLR; METHYLPHENIDATE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (ONCE-DAILY ORAL, ADHD), PURDUE PHARMA/RHODES PHARMACEUTICALS","APTENSIO XR; APTENSIO XR; BIPHENTIN; BIPHENTIN; MPH-MLR; MPH-MLR; METHYLPHENIDATE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (ONCE-DAILY ORAL, ADHD), PURDUE PHARMA/RHODES PHARMACEUTICALS","METHYLPHENIDATE HYDROCHLORIDE (ONCE-DAILY ORAL, ADHD), PURDUE PHARMA/RHODES PHARMACEUTICALS",APTENSIO XR,APTENSIO XR,BIPHENTIN,BIPHENTIN,MPH-MLR,MPH-MLR,METHYLPHENIDATE,METHYLPHENIDATE HYDROCHLORIDE,"METHYLPHENIDATE HYDROCHLORIDE (ONCE-DAILY ORAL, ADHD), PURDUE PHARMA/RHODES PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,205831,METHYLPHENIDATE HYDROCHLORIDE,205831,METHYLPHENIDATE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2015-04-17T00:00:00Z,2015,4,Aptensio XR,attention deficit hyperactivity disorder,,PSYCHOSTIMULANT; UNSPECIFIED DRUG TARGET,CAPSULE FORMULATION; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205831,NDA,2014-06-18T00:00:00Z,fda,0,0,0,0,0,,rhodes pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205831,259,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
477,"METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE/PFIZER","NWP-09; QUILLICHEW ER; QUILLICHEW ER; METHYLPHENIDATE; METHYLPHENIDATE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE/PFIZER","NWP-09; QUILLICHEW ER; QUILLICHEW ER; METHYLPHENIDATE; METHYLPHENIDATE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE; METHYLPHENIDATE HYDROCHLORIDE; METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE/PFIZER","METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE/PFIZER",NWP-09,QUILLICHEW ER,QUILLICHEW ER,METHYLPHENIDATE,"METHYLPHENIDATE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE",METHYLPHENIDATE HYDROCHLORIDE,"METHYLPHENIDATE HYDROCHLORIDE (EXTENDED-RELEASE CHEWABLE TABLET, ADHD), NEXTWAVE/PFIZER",,,,,,,,,,,,,,,,,,,,,,,,207960,METHYLPHENIDATE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-12-04T00:00:00Z,2015,12,Quillichew ER,attention deficit hyperactivity disorder,ALPHA 2 ADRENOCEPTOR AGONIST,DOPAMINE UPTAKE MODULATOR; PSYCHOMODULATOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207960,NDA,2015-02-04T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,48851,49605,51584,54657,61035,65165,39490,7646,7690,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207960,315,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
43,AMPHETAMINE,"DYANAVEL XR; DYANAVEL XR; TRI-102; TRI-102-ADD-001; AMFETAMINE; AMPHETAMINE; AMPHETAMINE (EXTENDED-RELEASE ORAL SUSPENSION/LIQUIXR, ADHD), TRIS","DYANAVEL XR; DYANAVEL XR; TRI-102; TRI-102-ADD-001; AMFETAMINE; AMPHETAMINE; AMPHETAMINE (EXTENDED-RELEASE ORAL SUSPENSION/LIQUIXR, ADHD), TRIS",AMPHETAMINE,DYANAVEL XR,DYANAVEL XR,TRI-102,TRI-102-ADD-001,AMFETAMINE,AMPHETAMINE,"AMPHETAMINE (EXTENDED-RELEASE ORAL SUSPENSION/LIQUIXR, ADHD), TRIS",,,,,,,,,,,,,,,,,,,,,,,,208147,AMPHETAMINE,208147,AMPHETAMINE,,,,,,,,,,,,,,,,,,,2015-10-19T00:00:00Z,2015,10,Dynavel XR,attention deficit hyperactivity disorder,ADRENOCEPTOR AGONIST,HYPOGLYCEMIC AGENT; NEUROPROTECTANT,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208147,NDA,2014-12-18T00:00:00Z,fda,0,0,0,0,0,,tris pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208147,330,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
476,"METHYLPHENIDATE (TRANSDERMAL), SHIRE/NOVEN","DAYTRANA; MTS; METHYPATCH; SPD-485; METHYLPHENIDATE; METHYLPHENIDATE (TRANSDERMAL), SHIRE/NOVEN; TRANSDERMAL METHYLPHENIDATE, SHIRE/ NOVEN","DAYTRANA; MTS; METHYPATCH; SPD-485; METHYLPHENIDATE; METHYLPHENIDATE (TRANSDERMAL), SHIRE/NOVEN; TRANSDERMAL METHYLPHENIDATE, SHIRE/ NOVEN","METHYLPHENIDATE (TRANSDERMAL), SHIRE/NOVEN",DAYTRANA,MTS,METHYPATCH,SPD-485,METHYLPHENIDATE,"METHYLPHENIDATE (TRANSDERMAL), SHIRE/NOVEN","TRANSDERMAL METHYLPHENIDATE, SHIRE/ NOVEN",,,,,,,,,,,,,,,,,,,,,,,,21514,METHYLPHENIDATE,,,,,,,,,,,,,,,,,,,,,2006-04-06T00:00:00Z,2006,4,Daytrana,attention deficit hyperactivity disorder,ALPHA 2 ADRENOCEPTOR MODULATOR,CNS MODULATOR; DOPAMINE UPTAKE INHIBITOR; NOREPINEPHRINE UPTAKE INHIBITOR; PSYCHOMODULATOR,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TRANSDERMAL FORMULATION,matched (3),021514,NDA,2000-06-27T00:00:00Z,fda,0,0,0,0,0,,noven pharmaceuticals,NASDAQ: NOVN,1,60.7,52.5,45.9,43.2,55.4,45.9,24.2,11.5,11.5,,,,,acquired by hisamitsu in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021514,371,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
437,LISDEXAMFETAMINE,"ADUVANZ; ELVANSE; LDX; LDX-2; NRP-104; S-877489; SPD-489; TYVENSE; VENVANSE; VYVANSE; DEXTROAMPHETAMINE PRODRUG (ADHD), NEW RIVER; DEXTROAMPHETAMINE PRODRUG (ADHD), SHIRE; LISDEXAMFETAMINE; LISDEXAMFETAMINE DIMESYLATE","ADUVANZ; ELVANSE; LDX; LDX-2; NRP-104; S-877489; SPD-489; TYVENSE; VENVANSE; VYVANSE; DEXTROAMPHETAMINE PRODRUG (ADHD), NEW RIVER; DEXTROAMPHETAMINE PRODRUG (ADHD), SHIRE; LISDEXAMFETAMINE; LISDEXAMFETAMINE DIMESYLATE",LISDEXAMFETAMINE,ADUVANZ,ELVANSE,LDX,LDX-2,NRP-104,S-877489,SPD-489,TYVENSE,VENVANSE,VYVANSE,"DEXTROAMPHETAMINE PRODRUG (ADHD), NEW RIVER","DEXTROAMPHETAMINE PRODRUG (ADHD), SHIRE",LISDEXAMFETAMINE,LISDEXAMFETAMINE DIMESYLATE,,,,,,,,,,,,,,,,,21977,LISDEXAMFETAMINE DIMESYLATE,,,,,,,,,,,,,,,,,,,,,2007-02-23T00:00:00Z,2007,2,Vyvanse,attention deficit hyperactivity disorder,,ANTIDEPRESSANT; CNS MODULATOR; DOPAMINE RELEASE STIMULATOR; DOPAMINE UPTAKE INHIBITOR; NORADRENALINE RELEASE STIMULATOR; NOREPINEPHRINE UPTAKE INHIBITOR; PSYCHOSTIMULANT,BUCCAL FORMULATION SYSTEMIC; CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021977,NDA,2005-12-06T00:00:00Z,fda,0,0,0,0,0,,shire,NASDAQ: SHPG,1,2436.3,34.3,,,,,2116,544.6,544.6,,,2007,,acquired by shire in 2007,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021977,422,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
342,"GUANFACINE HYDROCHLORIDE (EXTENDED-RELEASE, ORAL, ATTENTION DEFICIT HYPERACTIVITY DISEASE/ ADHD), SHIRE","CONNEXYN; CONNEXYN; INTUNIV; INTUNIV XR; S-877503; S-877503; SHP-503; SPD-503; GUANFACINE; GUANFACINE HYDROCHLORIDE; GUANFACINE HYDROCHLORIDE (EXTENDED-RELEASE, ORAL, ATTENTION DEFICIT HYPERACTIVITY DISEASE/ ADHD), SHIRE","CONNEXYN; CONNEXYN; INTUNIV; INTUNIV XR; S-877503; S-877503; SHP-503; SPD-503; GUANFACINE; GUANFACINE HYDROCHLORIDE; GUANFACINE HYDROCHLORIDE (EXTENDED-RELEASE, ORAL, ATTENTION DEFICIT HYPERACTIVITY DISEASE/ ADHD), SHIRE","GUANFACINE HYDROCHLORIDE (EXTENDED-RELEASE, ORAL, ATTENTION DEFICIT HYPERACTIVITY DISEASE/ ADHD), SHIRE",CONNEXYN,CONNEXYN,INTUNIV,INTUNIV XR,S-877503,S-877503,SHP-503,SPD-503,GUANFACINE,GUANFACINE HYDROCHLORIDE,"GUANFACINE HYDROCHLORIDE (EXTENDED-RELEASE, ORAL, ATTENTION DEFICIT HYPERACTIVITY DISEASE/ ADHD), SHIRE",,,,,,,,,,,,,,,,,,,,22037,GUANFACINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-09-02T00:00:00Z,2009,9,Intuniv,attention deficit hyperactivity disorder,ALPHA 2A ADRENOCEPTOR AGONIST,ANXIOLYTIC; NORADRENALINE RELEASE MODULATOR; PSYCHOMODULATOR,DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022037,NDA,2006-08-24T00:00:00Z,fda,0,0,0,0,0,,shire,NASDAQ: SHPG,1,3007.7,3022.2,2436.3,1796.5,1599.3,1363.2,2631.7,639.9,639.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022037,448,34,314,652,"Attention-deficit, conduct, and disruptive behavior disorders",1,0
707,TASIMELTEON,"BMS-214778; HETLIOZ; MA-1; VEC-162; DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), BRISTOL-MYERS SQUIBB; DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), VANDA; TASIMELTEON","BMS-214778; HETLIOZ; MA-1; VEC-162; DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), BRISTOL-MYERS SQUIBB; DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), VANDA; TASIMELTEON",TASIMELTEON,BMS-214778,HETLIOZ,MA-1,VEC-162,"DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), BRISTOL-MYERS SQUIBB","DUAL MT1/MT2 MELATONIN RECEPTOR AGONIST (ORAL, INSOMNIA), VANDA",TASIMELTEON,,,,,,,,,,,,,,,,,,,,,,,,205677,TASIMELTEON,,,,,,,,,,,,,,,,,,,,,2014-01-31T00:00:00Z,2014,1,Hetlioz,circadian rhythm sleep disorder,MELATONIN MT1 AGONIST; MELATONIN MT2 AGONIST,ANTIDEPRESSANT; HYPNOTIC,CAPSULE FORMULATION; LIQUID FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205677,NDA,2013-05-31T00:00:00Z,fda,1,0,0,1,0,,vanda pharmaceuticals,NASDAQ: VNDA,1,50.2,33.9,32.7,31.3,35.7,4.5,48.6,19.2,19.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205677,249,2392,327,259,Residual codes; unclassified,3,0
61,ARMODAFINIL,"CEP-10953; NUVIGIL; R-ISOMER MODAFINIL, CEPHALON; R-MODAFINIL; ARMODAFINIL","CEP-10953; NUVIGIL; R-ISOMER MODAFINIL, CEPHALON; R-MODAFINIL; ARMODAFINIL",ARMODAFINIL,CEP-10953,NUVIGIL,"R-ISOMER MODAFINIL, CEPHALON",R-MODAFINIL,ARMODAFINIL,,,,,,,,,,,,,,,,,,,,,,,,,,21875,ARMODAFINIL,,,,,,,,,,,,,,,,,,,,,2007-06-15T00:00:00Z,2007,6,Nuvigil,obstructive sleep apnea,ALPHA 1 ADRENOCEPTOR AGONIST; DOPAMINE TRANSPORTER INHIBITOR,PSYCHOSTIMULANT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY; TABLET FORMULATION,matched (3),021875,NDA,2005-03-31T00:00:00Z,fda,0,0,0,0,0,,cephalon,NASDAQ: CEPH,1,1772.6,1764.1,1211.9,1015.4,714.8,506.9,1426.9,369.1,369.1,,,,,acquired by teva in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021875,398,3519,327,259,Residual codes; unclassified,3,0
296,FLORBETAPIR (18F),"18F PET RADIODIAGNOSTICS (VMAT-2, PARKINSON'S/DLB/DIABETES/AD), AVID; 18F FLORPIRAMINE; 18F-AV-138; 18F-AV-144; 18F-AV-19; 18F-AV-45; 18F-FLORBETAPIR; AV-138; AV-138-[18F]; AV-144; AV-144-[18F]; AV-15-[18F]; AV-19; AV-19-[18F]; AV-45; AMIVIDDO; AMYVID; FLUORINE-18-AV-45; FLORBETAPIR (18F); FLORBETAPIR F-18; FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES / DIABETES WITH BETA CELL MASS IN PANCREAS), AVID; FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES), AVID","18F PET RADIODIAGNOSTICS (VMAT-2, PARKINSON'S/DLB/DIABETES/AD), AVID; 18F FLORPIRAMINE; 18F-AV-138; 18F-AV-144; 18F-AV-19; 18F-AV-45; 18F-FLORBETAPIR; AV-138; AV-138-[18F]; AV-144; AV-144-[18F]; AV-15-[18F]; AV-19; AV-19-[18F]; AV-45; AMIVIDDO; AMYVID; FLUORINE-18-AV-45; FLORBETAPIR (18F); FLORBETAPIR F-18; FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES / DIABETES WITH BETA CELL MASS IN PANCREAS), AVID; FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES), AVID",FLORBETAPIR (18F),"18F PET RADIODIAGNOSTICS (VMAT-2, PARKINSON'S/DLB/DIABETES/AD), AVID",18F FLORPIRAMINE,18F-AV-138,18F-AV-144,18F-AV-19,18F-AV-45,18F-FLORBETAPIR,AV-138,AV-138-[18F],AV-144,AV-144-[18F],AV-15-[18F],AV-19,AV-19-[18F],AV-45,AMIVIDDO,AMYVID,FLUORINE-18-AV-45,FLORBETAPIR (18F),FLORBETAPIR F-18,"FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES / DIABETES WITH BETA CELL MASS IN PANCREAS), AVID","FLUORINE-18 PET RADIODIAGNOSTICS (VESICULAR MONOAMINE TRANSPORTER, PARKINSON'S/DEMENTIA WITH LEWY BODIES), AVID",,,,,,,,,202008,FLORBETAPIR F-18,,,,,,,,,,,,,,,,,,,,,2012-04-06T00:00:00Z,2012,4,Amyvid,alzheimers disease,BETA AMYLOID MODULATOR,CNS DIAGNOSTIC AGENT; PET CONTRAST AGENT; RADIODIAGNOSTIC,IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),202008,NDA,2011-10-07T00:00:00Z,fda,1,0,0,0,0,,eli lilly,NYSE: LLY,1,22603.4,24286.5,23076,,,,17806.9,5278.1,5278.1,,,2010,,acquired by Eli Lilly in 2010,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202008,94,14,331,81,Other hereditary and degenerative nervous system conditions,3,0
295,FLORBETABEN (18F),"18F AND 123I PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID; 18F-4-FLUORO-L-ORNITHINE; 18F-AV-1; 18F-AV-1/ZK; 18F-BAY-94-9172; 18F-FLORBETABEN; 18F-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID; 4-[18F]FLUORO-L-ORNITHINE; 4-FLUORO-L-ORNITHINE-[18F]; AV-1-[18F]; BAY-94-9172-[18F]; FLUORINE-18-4-FLUORO-L-ORNITHINE; NEURACEQ; ZK-6013443; FLORBETABEN (18F); FLORBETABEN F18; FLUORINE-18 AND IODINE-123 PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID; FLUORINE-18-AV-1/ZK; FLUORINE-18-FLORBETABEN; FLUORINE-18-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID","18F AND 123I PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID; 18F-4-FLUORO-L-ORNITHINE; 18F-AV-1; 18F-AV-1/ZK; 18F-BAY-94-9172; 18F-FLORBETABEN; 18F-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID; 4-[18F]FLUORO-L-ORNITHINE; 4-FLUORO-L-ORNITHINE-[18F]; AV-1-[18F]; BAY-94-9172-[18F]; FLUORINE-18-4-FLUORO-L-ORNITHINE; NEURACEQ; ZK-6013443; FLORBETABEN (18F); FLORBETABEN F18; FLUORINE-18 AND IODINE-123 PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID; FLUORINE-18-AV-1/ZK; FLUORINE-18-FLORBETABEN; FLUORINE-18-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID",FLORBETABEN (18F),"18F AND 123I PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID",18F-4-FLUORO-L-ORNITHINE,18F-AV-1,18F-AV-1/ZK,18F-BAY-94-9172,18F-FLORBETABEN,"18F-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID",4-[18F]FLUORO-L-ORNITHINE,4-FLUORO-L-ORNITHINE-[18F],AV-1-[18F],BAY-94-9172-[18F],FLUORINE-18-4-FLUORO-L-ORNITHINE,NEURACEQ,ZK-6013443,FLORBETABEN (18F),FLORBETABEN F18,"FLUORINE-18 AND IODINE-123 PET RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S), UNIVERSITY OF PENNSYLVANIA/AVID",FLUORINE-18-AV-1/ZK,FLUORINE-18-FLORBETABEN,"FLUORINE-18-STILBENE RADIODIAGNOSTICS (BETA-AMYLOID, ALZHEIMER'S) UNIVERSITY OF PENNSYLVANIA/AVID",,,,,,,,,,,204677,FLORBETABEN F-18,,,,,,,,,,,,,,,,,,,,,2014-03-19T00:00:00Z,2014,3,Neuraceq,alzheimers disease,BETA AMYLOID MODULATOR,CNS DIAGNOSTIC AGENT; NEOPLASM DIAGNOSTIC AGENT; PET CONTRAST AGENT; RADIODIAGNOSTIC,IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING,matched (3),204677,NDA,2012-12-21T00:00:00Z,fda,0,0,0,0,0,,piramal imaging,NSEI: PEL,1,785.4,697.5,599.9,374.2,645.6,768.3,533.3,45.8,45.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204677,210,14,331,81,Other hereditary and degenerative nervous system conditions,3,0
462,"MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ALLLERGAN","ADS-8704; ARIMENDA; MDX-8704; NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ ACTAVIS; NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ FOREST; NAMZARIC; MEMANTINE ER + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/FOREST; MEMANTINE HYDROCHLORIDE + DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ACTAVIS; MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ALLLERGAN","ADS-8704; ARIMENDA; MDX-8704; NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ ACTAVIS; NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ FOREST; NAMZARIC; MEMANTINE ER + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/FOREST; MEMANTINE HYDROCHLORIDE + DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ACTAVIS; MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ALLLERGAN","MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ALLLERGAN",ADS-8704,ARIMENDA,MDX-8704,"NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ ACTAVIS","NAMENDA XR + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ FOREST",NAMZARIC,"MEMANTINE ER + DONEPEZIL (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/FOREST",MEMANTINE HYDROCHLORIDE + DONEPEZIL HYDROCHLORIDE,"MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ACTAVIS","MEMANTINE HYDROCHLORIDE ER + DONEPEZIL HYDROCHLORIDE (EXTENDED RELEASE FORMULATION, DEMENTIA), ADAMAS/ALLLERGAN",,,,,,,,,,,,,,,,,,,,,206439,DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE,22525,MEMANTINE HYDROCHLORIDE,22525,MEMANTINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,2014-12-23T00:00:00Z,2014,12,Namzaric,alzheimers disease,ACETYLCHOLINESTERASE INHIBITOR; NMDA RECEPTOR ANTAGONIST,NEUROPROTECTANT; NOOTROPIC AGENT,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),206439,NDA,2014-02-26T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,3646.9,3094,4547.76,4390.13,4157.39,3848.37,2914.51,759.708,788.3,4518,2014-06-30T00:00:00Z,2014,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206439,282,14,331,81,Other hereditary and degenerative nervous system conditions,3,0
461,"MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ALLERGAN/MERZ","NAMENDA XR; MEMANTINE; MEMANTINE ER; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ACTAVIS/MERZ; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ALLERGAN/MERZ; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), FOREST/MERZ; MEMANTINE, ADAMAS PHARMACEUTICALS; MEMANTINE, NEUROMOLECULAR","NAMENDA XR; MEMANTINE; MEMANTINE ER; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ACTAVIS/MERZ; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ALLERGAN/MERZ; MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), FOREST/MERZ; MEMANTINE, ADAMAS PHARMACEUTICALS; MEMANTINE, NEUROMOLECULAR","MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ALLERGAN/MERZ",NAMENDA XR,MEMANTINE,MEMANTINE ER,"MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ACTAVIS/MERZ","MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), ALLERGAN/MERZ","MEMANTINE HYDROCHLORIDE (EXTENDED RELEASE), FOREST/MERZ","MEMANTINE, ADAMAS PHARMACEUTICALS","MEMANTINE, NEUROMOLECULAR",,,,,,,,,,,,,,,,,,,,,,,22525,MEMANTINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-06-21T00:00:00Z,2010,6,Namenda XR,alzheimers disease,NMDA RECEPTOR ANTAGONIST,NEUROPROTECTANT; NOOTROPIC AGENT,BEAD FORMULATION; CAPSULE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022525,NDA,2009-08-20T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,4308.4,4060.6,3863.8,3621.4,3242.3,2808.7,3343.2,984.7,984.7,,,,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022525,590,14,331,81,Other hereditary and degenerative nervous system conditions,3,0
134,"CARBIDOPA + LEVODOPA (CONTROLLED RELEASE, PARKINSONS DISEASE), IMPAX/GLAXOSMITHKLINE","587124; 587124; GSK-587124; IPX-066; NUMIENT; NUMIENT; PATROME; RYTARY; CARBIDOPA + LEVODOPA; CARBIDOPA + LEVODOPA (CONTROLLED RELEASE, PARKINSONS DISEASE), IMPAX/GLAXOSMITHKLINE","587124; 587124; GSK-587124; IPX-066; NUMIENT; NUMIENT; PATROME; RYTARY; CARBIDOPA + LEVODOPA; CARBIDOPA + LEVODOPA (CONTROLLED RELEASE, PARKINSONS DISEASE), IMPAX/GLAXOSMITHKLINE","CARBIDOPA + LEVODOPA (CONTROLLED RELEASE, PARKINSONS DISEASE), IMPAX/GLAXOSMITHKLINE",587124,587124,GSK-587124,IPX-066,NUMIENT,NUMIENT,PATROME,RYTARY,CARBIDOPA + LEVODOPA,"CARBIDOPA + LEVODOPA (CONTROLLED RELEASE, PARKINSONS DISEASE), IMPAX/GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,203312,CARBIDOPA; LEVODOPA,,,,,,,,,,,,,,,,,,,,,2015-01-07T00:00:00Z,2015,1,Rytary,parkinsons disease,DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR AGONIST,ANTIPARKINSONIAN; NEUROPROTECTANT,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203312,NDA,2011-12-20T00:00:00Z,fda,0,0,0,0,0,,impax,NASDAQ: IPXL,1,860.5,596,511.5,581.7,512.9,849.5,367.7,66,70.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203312,149,255,332,79,Parkinson`s disease,2,0
421,"LEVODOPA + CARBIDOPA (INTESTINAL SUSPENSION GEL, PARKINSON'S DISEASE), ABBVIE","ABT-SLV-187; DUODOPA; DUOPA; LCIG; SLV-187; CARBIDOPA + LEVODOPA; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; LEVODOPA + CARBIDOPA (INTESTINAL SUSPENSION GEL, PARKINSON'S DISEASE), ABBVIE","ABT-SLV-187; DUODOPA; DUOPA; LCIG; SLV-187; CARBIDOPA + LEVODOPA; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA; LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY; LEVODOPA + CARBIDOPA (INTESTINAL SUSPENSION GEL, PARKINSON'S DISEASE), ABBVIE","LEVODOPA + CARBIDOPA (INTESTINAL SUSPENSION GEL, PARKINSON'S DISEASE), ABBVIE",ABT-SLV-187,DUODOPA,DUOPA,LCIG,SLV-187,CARBIDOPA + LEVODOPA,"CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE","CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT","CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA","CARBIDOPA + LEVODOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY","CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA","CO-CARELDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY","LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBVIE","LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), ABBOTT","LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), NEOPHARMA","LEVODOPA + CARBIDOPA (INTESTINAL GEL, PARKINSON'S DISEASE), SOLVAY","LEVODOPA + CARBIDOPA (INTESTINAL SUSPENSION GEL, PARKINSON'S DISEASE), ABBVIE",,,,,,,,,,,,,,203952,CARBIDOPA; LEVODOPA,,,,,,,,,,,,,,,,,,,,,2015-01-09T00:00:00Z,2015,1,duopa,parkinsons disease,DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR AGONIST,ANTIPARKINSONIAN,DRUG COMBINATION; GEL FORMULATION; INFUSION; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),203952,NDA,2013-05-28T00:00:00Z,fda,0,0,1,1,0,,abbvie,NYSE: ABBV,1,22859,19960,18790,18380,17444,15638,18620,4101,4285,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203952,174,255,332,79,Parkinson`s disease,2,0
654,SAFINAMIDE,"FCE-26743; ME-2125; NW-1015; PNU-151774E; XADAGO; XADAGO; ZP-034; DOPAMINE REUPTAKE/MAO-B/GLUTAMATE RELEASE INHIBITOR (ORAL, PARKINSON'S DISEASE), MERCK SERONO/NEWRON; SAFINAMIDE; SAFINAMIDE MESYLATE","FCE-26743; ME-2125; NW-1015; PNU-151774E; XADAGO; XADAGO; ZP-034; DOPAMINE REUPTAKE/MAO-B/GLUTAMATE RELEASE INHIBITOR (ORAL, PARKINSON'S DISEASE), MERCK SERONO/NEWRON; SAFINAMIDE; SAFINAMIDE MESYLATE",SAFINAMIDE,FCE-26743,ME-2125,NW-1015,PNU-151774E,XADAGO,XADAGO,ZP-034,"DOPAMINE REUPTAKE/MAO-B/GLUTAMATE RELEASE INHIBITOR (ORAL, PARKINSON'S DISEASE), MERCK SERONO/NEWRON",SAFINAMIDE,SAFINAMIDE MESYLATE,,,,,,,,,,,,,,,,,,,,,207145,SAFINAMIDE,,,,,,,,,,,,,,,,,,,,,2017-03-21T00:00:00Z,2017,3,Xadago,parkinsons disease,CALCIUM CHANNEL MODULATOR; DOPAMINE RECEPTOR AGONIST; MAO B INHIBITOR; SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT; ANTIPARKINSONIAN; DOPAMINE UPTAKE INHIBITOR; GLUTAMATE RELEASE INHIBITOR; NEUROPROTECTANT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207145,NDA,2015-12-29T00:00:00Z,fda,0,0,0,0,0,,newron pharmaceuticals,SWX: NWRN,1,,7.1,2.6,1.9,4.9,11.8,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207145,296,255,332,79,Parkinson`s disease,2,0
662,"SELEGILINE (FAST-ACTING, ZYDIS), SCHERER/ELAN","OTRASEL; XILOPAR; ZELAPAR; ZYDIS SELEGILINE; ZYDIS SELEGILINE HCL; SELEGILINE; SELEGILINE (FAST-ACTING, ZYDIS), CARDINAL HEALTH/ELAN; SELEGILINE (FAST-ACTING, ZYDIS), SCHERER/ELAN; SELEGILINE HYDROCHLORIDE","OTRASEL; XILOPAR; ZELAPAR; ZYDIS SELEGILINE; ZYDIS SELEGILINE HCL; SELEGILINE; SELEGILINE (FAST-ACTING, ZYDIS), CARDINAL HEALTH/ELAN; SELEGILINE (FAST-ACTING, ZYDIS), SCHERER/ELAN; SELEGILINE HYDROCHLORIDE","SELEGILINE (FAST-ACTING, ZYDIS), SCHERER/ELAN",OTRASEL,XILOPAR,ZELAPAR,ZYDIS SELEGILINE,ZYDIS SELEGILINE HCL,SELEGILINE,"SELEGILINE (FAST-ACTING, ZYDIS), CARDINAL HEALTH/ELAN","SELEGILINE (FAST-ACTING, ZYDIS), SCHERER/ELAN",SELEGILINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,19334,SELEGILINE HYDROCHLORIDE,19334,SELEGILINE HYDROCHLORIDE,21479,SELEGILINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,2006-06-14T00:00:00Z,2006,6,Zelapar,parkinsons disease,MAO B INHIBITOR,ANTIPARKINSONIAN; NEUROPROTECTANT,BUCCAL FORMULATION SYSTEMIC; QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021479,NDA,2002-03-29T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,1067.7,938.3,879.2,811.8,788,583.3,838.9,77.8,95.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021479,370,255,332,79,Parkinson`s disease,2,0
623,RASAGILINE,AGN-1135; AGILECT; AZILECT; LU-00-773; R-CPAI; R-HPAI; R-MPAI; S-PAI; TV-1012; TVP-101; TVP-1012; TVP-1022; RASAGILINE; RASAGILINE MESYLATE; RASAGILINE RATIOPHARM,AGN-1135; AGILECT; AZILECT; LU-00-773; R-CPAI; R-HPAI; R-MPAI; S-PAI; TV-1012; TVP-101; TVP-1012; TVP-1022; RASAGILINE; RASAGILINE MESYLATE; RASAGILINE RATIOPHARM,RASAGILINE,AGN-1135,AGILECT,AZILECT,LU-00-773,R-CPAI,R-HPAI,R-MPAI,S-PAI,TV-1012,TVP-101,TVP-1012,TVP-1022,RASAGILINE,RASAGILINE MESYLATE,RASAGILINE RATIOPHARM,,,,,,,,,,,,,,,,21641,RASAGILINE MESYLATE,,,,,,,,,,,,,,,,,,,,,2006-05-16T00:00:00Z,2006,5,Azilect,parkinsons disease,MAO B INHIBITOR,ANTIPARKINSONIAN,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021641,NDA,2003-09-05T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,8408,5250,4799,3276.4,2518.6,2077.4,4259,495,495,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021641,377,255,332,79,Parkinson`s disease,2,0
647,"ROTIGOTINE (TRANSDERMAL PATCH, PARKINSON'S/RESTLESS LEGS SYNDROME), UCB","(-)-N-0437; LEGANTO; N-0923; NEUPRO; NEUPRO PATCH; PARKINSONS PATCH, DISCOVERY THERAPEUTICS/SCHWARZ; SPM-962; ROTIGOTINE; ROTIGOTINE (TRANSDERMAL PATCH, PARKINSON'S/RESTLESS LEGS SYNDROME), UCB; ROTIGOTINE CDS","(-)-N-0437; LEGANTO; N-0923; NEUPRO; NEUPRO PATCH; PARKINSONS PATCH, DISCOVERY THERAPEUTICS/SCHWARZ; SPM-962; ROTIGOTINE; ROTIGOTINE (TRANSDERMAL PATCH, PARKINSON'S/RESTLESS LEGS SYNDROME), UCB; ROTIGOTINE CDS","ROTIGOTINE (TRANSDERMAL PATCH, PARKINSON'S/RESTLESS LEGS SYNDROME), UCB",(-)-N-0437,LEGANTO,N-0923,NEUPRO,NEUPRO PATCH,"PARKINSONS PATCH, DISCOVERY THERAPEUTICS/SCHWARZ",SPM-962,ROTIGOTINE,"ROTIGOTINE (TRANSDERMAL PATCH, PARKINSON'S/RESTLESS LEGS SYNDROME), UCB",ROTIGOTINE CDS,,,,,,,,,,,,,,,,,,,,,21829,ROTIGOTINE,,,,,,,,,,,,,,,,,,,,,2007-05-09T00:00:00Z,2007,5,Neupro,parkinsons disease,5-HT RECEPTOR AGONIST; ADRENOCEPTOR AGONIST; DOPAMINE D1 RECEPTOR AGONIST; DOPAMINE D2 RECEPTOR AGONIST; DOPAMINE D3 RECEPTOR AGONIST; DOPAMINE D4 RECEPTOR AGONIST; DOPAMINE D5 RECEPTOR AGONIST,ANTIPARKINSONIAN,DRUG COATING; PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021829,NDA,2005-01-19T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,5295.05,3366.1,2773.04,2552.13,4251.41,3081.75,3901.93,1150.72,1150.72,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829,391,255,332,79,Parkinson`s disease,2,0
644,"ROPINIROLE (EXTENDED RELEASE, GEOMATRIX, PARKINSON'S DISEASE), GLAXOSMITHKLINE","REQUIP (ONCE-DAILY), GLAXOSMITHKLINE; REQUIP (ONCE-DAILY), SKYEPHARMA; REQUIP LP; REQUIP XL 24 HOUR ER; REQUIP ORAL EXTENDED RELEASE TABLETS; REQUIP 24HR; REQUIP DEPOT; REQUIP MODUTAB; REQUIP PD; REQUIP PR; REQUIP PROLIB; REQUIP XL; REQUIP PROLONGED RELEASE TABLETS; ROPINIROLE; ROPINIROLE (GEOMATRIX), SKYPHARMA; ROPINIROLE (EXTENDED RELEASE, GEOMATRIX, PARKINSON'S DISEASE), GLAXOSMITHKLINE; ROPINIROLE (ONCE-DAILY), GLAXOSMITHKLINE; ROPINIROLE (ONCE-DAILY), SKYEPHARMA; ROPINIROLE PR","REQUIP (ONCE-DAILY), GLAXOSMITHKLINE; REQUIP (ONCE-DAILY), SKYEPHARMA; REQUIP LP; REQUIP XL 24 HOUR ER; REQUIP ORAL EXTENDED RELEASE TABLETS; REQUIP 24HR; REQUIP DEPOT; REQUIP MODUTAB; REQUIP PD; REQUIP PR; REQUIP PROLIB; REQUIP XL; REQUIP PROLONGED RELEASE TABLETS; ROPINIROLE; ROPINIROLE (GEOMATRIX), SKYPHARMA; ROPINIROLE (EXTENDED RELEASE, GEOMATRIX, PARKINSON'S DISEASE), GLAXOSMITHKLINE; ROPINIROLE (ONCE-DAILY), GLAXOSMITHKLINE; ROPINIROLE (ONCE-DAILY), SKYEPHARMA; ROPINIROLE PR","ROPINIROLE (EXTENDED RELEASE, GEOMATRIX, PARKINSON'S DISEASE), GLAXOSMITHKLINE","REQUIP (ONCE-DAILY), GLAXOSMITHKLINE","REQUIP (ONCE-DAILY), SKYEPHARMA",REQUIP LP,REQUIP XL 24 HOUR ER,REQUIP ORAL EXTENDED RELEASE TABLETS,REQUIP 24HR,REQUIP DEPOT,REQUIP MODUTAB,REQUIP PD,REQUIP PR,REQUIP PROLIB,REQUIP XL,REQUIP PROLONGED RELEASE TABLETS,ROPINIROLE,"ROPINIROLE (GEOMATRIX), SKYPHARMA","ROPINIROLE (EXTENDED RELEASE, GEOMATRIX, PARKINSON'S DISEASE), GLAXOSMITHKLINE","ROPINIROLE (ONCE-DAILY), GLAXOSMITHKLINE","ROPINIROLE (ONCE-DAILY), SKYEPHARMA",ROPINIROLE PR,,,,,,,,,,,,22008,ROPINIROLE HYDROCHLORIDE,22008,ROPINIROLE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2008-06-13T00:00:00Z,2008,6,Requip XL,parkinsons disease,DOPAMINE D2 RECEPTOR AGONIST,ANTIPARKINSONIAN,ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022008,NDA,2007-02-09T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35480.4,45147.6,45499.1,37229.2,38293.2,37593.1,27064.9,5108.18,5363.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022008,439,255,332,79,Parkinson`s disease,2,0
604,"PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM","MIRAPEX ER; MIRAPEX LA; PRAMIPEXOLE HYDROCHLORIDE; SIFROL ER; PRAMIPEXOLE; PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM; PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM/ SAMIL; PRAMIPEXOLEM DIHYDROCHLORIDE","MIRAPEX ER; MIRAPEX LA; PRAMIPEXOLE HYDROCHLORIDE; SIFROL ER; PRAMIPEXOLE; PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM; PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM/ SAMIL; PRAMIPEXOLEM DIHYDROCHLORIDE","PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM",MIRAPEX ER,MIRAPEX LA,PRAMIPEXOLE HYDROCHLORIDE,SIFROL ER,PRAMIPEXOLE,"PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM","PRAMIPEXOLE (ORAL EXTENDED-RELEASE), BOEHRINGER INGELHEIM/ SAMIL",PRAMIPEXOLEM DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,22421,PRAMIPEXOLE DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-02-19T00:00:00Z,2010,2,Mirapex ER,parkinsons disease,DOPAMINE D3 RECEPTOR AGONIST,ANTIPARKINSONIAN,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022421,NDA,2008-10-23T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022421,558,255,332,79,Parkinson`s disease,2,0
4,ABOBOTULINUMTOXINA,AZZALURE; CNT-52120; DYSLOR; DYSPORT; DYSPORT NEXT GENERATION; DYSPORT RU; RELOXIN; ABOBOTULINUMTOXINA; BOTULIN TOXINS; BOTULINUM TOXINS,AZZALURE; CNT-52120; DYSLOR; DYSPORT; DYSPORT NEXT GENERATION; DYSPORT RU; RELOXIN; ABOBOTULINUMTOXINA; BOTULIN TOXINS; BOTULINUM TOXINS,ABOBOTULINUMTOXINA,AZZALURE,CNT-52120,DYSLOR,DYSPORT,DYSPORT NEXT GENERATION,DYSPORT RU,RELOXIN,ABOBOTULINUMTOXINA,BOTULIN TOXINS,BOTULINUM TOXINS,,,,,,,,,,,,,,,,,,,,,125274,abobotulinumtoxinA,,,,,,,,,,,,,,,,,,,,,2009-04-29T00:00:00Z,2009,4,Dysport,cervical dystonia,ACETYLCHOLINE RECEPTOR ANTAGONIST,ACETYLCHOLINE RELEASE INHIBITOR; ANTI-INFLAMMATORY; NEUROMUSCULAR BLOCKING AGENT; VULNERARY AGENT,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INTRAMUSCULAR FORMULATION; LIQUID FORMULATION; NATURAL PRODUCT; PEPTIDE; TOXIN,matched (3),125274,BLA,2007-12-06T00:00:00Z,cortellis,0,0,0,1,0,,ipsen biopharm,EPA: IPN,1,1594.2,1450.6,1451.2,1247.3,1011.3,1103.2,1253.4,282.8,282.8,,,,,biomeasure changed name to ipsen,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125274,14,564,333,81,Other hereditary and degenerative nervous system conditions,2,0
376,INCOBOTULINUMTOXINA,"NT-201; XEOMIN; BOTULINUM TOXIN TYPE A; BOTULINUM TOXIN TYPE A EXTRACT (BLEPHAROSPASM), MERZ/BIOTECON; INCOBOTULINUMTOXINA","NT-201; XEOMIN; BOTULINUM TOXIN TYPE A; BOTULINUM TOXIN TYPE A EXTRACT (BLEPHAROSPASM), MERZ/BIOTECON; INCOBOTULINUMTOXINA",INCOBOTULINUMTOXINA,NT-201,XEOMIN,BOTULINUM TOXIN TYPE A,"BOTULINUM TOXIN TYPE A EXTRACT (BLEPHAROSPASM), MERZ/BIOTECON",INCOBOTULINUMTOXINA,,,,,,,,,,,,,,,,,,,,,,,,,,125360,incobotulinumtoxinA,,,,,,,,,,,,,,,,,,,,,2010-07-30T00:00:00Z,2010,7,Xeomin,blepharospasm,,ACETYLCHOLINE RELEASE INHIBITOR; ANALGESIC; NEUROMUSCULAR BLOCKING AGENT,INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; TOXIN,matched (3),125360,BLA,2009-07-01T00:00:00Z,fda,0,0,0,0,0,,merz pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125360,30,2239,333,81,Other hereditary and degenerative nervous system conditions,2,0
728,TETRABENAZINE,CHOREAZINE; MOTETIS; NITOMAN; TETMODIS; XENAZINE; TETRABENAZINE,CHOREAZINE; MOTETIS; NITOMAN; TETMODIS; XENAZINE; TETRABENAZINE,TETRABENAZINE,CHOREAZINE,MOTETIS,NITOMAN,TETMODIS,XENAZINE,TETRABENAZINE,,,,,,,,,,,,,,,,,,,,,,,,,21894,TETRABENAZINE,,,,,,,,,,,,,,,,,,,,,2008-08-15T00:00:00Z,2008,8,Xenazine,huntingtons chorea,SYNAPTIC VESICULAR AMINE TRANSPORTER INHIBITOR,MONOAMINE ANTAGONIST; MONOAMINE RELEASE MODULATOR,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021894,NDA,2005-09-23T00:00:00Z,fda,1,0,0,1,0,,biovail laboratories,TSX: BVF,1,,,,,,,,,,,,2008,,acquired by biovail in 2008,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021894,402,170,333,81,Other hereditary and degenerative nervous system conditions,2,0
319,GABAPENTIN ENACARBIL,"1838262; ASP-8825; GSK-1838262; GABAPENTIN-XP; HORIZANT; REGNITE; SOLZIRA; XP-10569; XP-11084; XP-11239; XP-12464; XP-13512; GABAPENTIN ENACARBIL; GABAPENTIN PRODRUGS, XENOPORT","1838262; ASP-8825; GSK-1838262; GABAPENTIN-XP; HORIZANT; REGNITE; SOLZIRA; XP-10569; XP-11084; XP-11239; XP-12464; XP-13512; GABAPENTIN ENACARBIL; GABAPENTIN PRODRUGS, XENOPORT",GABAPENTIN ENACARBIL,1838262,ASP-8825,GSK-1838262,GABAPENTIN-XP,HORIZANT,REGNITE,SOLZIRA,XP-10569,XP-11084,XP-11239,XP-12464,XP-13512,GABAPENTIN ENACARBIL,"GABAPENTIN PRODRUGS, XENOPORT",,,,,,,,,,,,,,,,,22399,GABAPENTIN ENACARBIL,,,,,,,,,,,,,,,,,,,,,2011-04-06T00:00:00Z,2011,4,Horizant,restless legs syndrome,CACNA2D3 CALCIUM CHANNEL SUBUNIT MODULATOR,ANALGESIC; ANTI-INFLAMMATORY; ANTICONVULSANT AGENT,CONTROLLED RELEASE FORMULATION; DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022399,NDA,2009-01-08T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,42629,44331.3,45825.1,35480.4,45147.6,45499.1,30685.7,6257.3,6467.29,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022399,548,1774,333,81,Other hereditary and degenerative nervous system conditions,2,0
279,"FENTANYL (SUBLINGUAL SPRAY, PAIN), INSYS THERAPEUTICS","FENTANYL SL SPRAY; SUBSYS; FENTANYL; FENTANYL (SUBLINGUAL SPRAY, PAIN), INSYS THERAPEUTICS","FENTANYL SL SPRAY; SUBSYS; FENTANYL; FENTANYL (SUBLINGUAL SPRAY, PAIN), INSYS THERAPEUTICS","FENTANYL (SUBLINGUAL SPRAY, PAIN), INSYS THERAPEUTICS",FENTANYL SL SPRAY,SUBSYS,FENTANYL,"FENTANYL (SUBLINGUAL SPRAY, PAIN), INSYS THERAPEUTICS",,,,,,,,,,,,,,,,,,,,,,,,,,,20195,FENTANYL CITRATE,202788,FENTANYL,,,,,,,,,,,,,,,,,,,2012-01-04T00:00:00Z,2012,1,Subsys,cancer pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,BUCCAL FORMULATION SYSTEMIC; FORMULATION AEROSOL; SMALL MOLECULE THERAPEUTIC,matched (3),202788,NDA,2011-03-04T00:00:00Z,fda,0,0,0,0,0,,insys therapeutics,NASDAQ: INSY,1,15.5,,,,,,7.8,6.3,6.3,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202788,128,3211,338,95,Other nervous system disorders,1,0
276,"FENTANYL (BUCCAL TRANSMUCOSAL, ORAVESCENT), CEPHALON","ACCELANYL; E-FEN BUCCAL; EFFENTORA; FENTORA; OVF; FENTANYL; FENTANYL (ORAVESCENT FORMULATION, OVF), CIMA LABS; FENTANYL (BUCCAL TRANSMUCOSAL, ORAVESCENT), CEPHALON; FENTANYL CITRATE","ACCELANYL; E-FEN BUCCAL; EFFENTORA; FENTORA; OVF; FENTANYL; FENTANYL (ORAVESCENT FORMULATION, OVF), CIMA LABS; FENTANYL (BUCCAL TRANSMUCOSAL, ORAVESCENT), CEPHALON; FENTANYL CITRATE","FENTANYL (BUCCAL TRANSMUCOSAL, ORAVESCENT), CEPHALON",ACCELANYL,E-FEN BUCCAL,EFFENTORA,FENTORA,OVF,FENTANYL,"FENTANYL (ORAVESCENT FORMULATION, OVF), CIMA LABS","FENTANYL (BUCCAL TRANSMUCOSAL, ORAVESCENT), CEPHALON",FENTANYL CITRATE,,,,,,,,,,,,,,,,,,,,,,19101,FENTANYL CITRATE,20195,FENTANYL CITRATE,21947,FENTANYL CITRATE,,,,,,,,,,,,,,,,,2006-09-25T00:00:00Z,2006,9,Fentora,cancer pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,BUCCAL FORMULATION SYSTEMIC; SMALL MOLECULE THERAPEUTIC; TRANSMUCOSAL FORMULATION,matched (3),021947,NDA,2005-08-31T00:00:00Z,fda,0,0,0,0,0,,cephalon,NASDAQ: CEPH,1,1764.1,1211.9,1015.4,714.8,506.9,262,1428,424.2,424.2,,,,,acquired by teva in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021947,417,3211,338,95,Other nervous system disorders,1,0
277,"FENTANYL (BUCCAL, BEMA), BIODELIVERY/MEDA","BEMA DRUG DELIVERY SYSTEM (FENTANYL), ARIUS/BIODELIVERY; BEMA DRUG DELIVERY SYSTEM (FENTANYL), ATRIX; BEMA DRUG DELIVERY SYSTEM (FENTANYL), QLT USA; BEMA FENTANYL; BREAKYL; BREAKYL START; ONSOLIS; PAINKYL; FENTANYL; FENTANYL (BUCCAL, BEMA), BIODELIVERY/MEDA; FENTANYL (TRANSMUCOSAL, BEMA), ATRIX; FENTANYL (TRANSMUCOSAL, BEMA), QLT USA","BEMA DRUG DELIVERY SYSTEM (FENTANYL), ARIUS/BIODELIVERY; BEMA DRUG DELIVERY SYSTEM (FENTANYL), ATRIX; BEMA DRUG DELIVERY SYSTEM (FENTANYL), QLT USA; BEMA FENTANYL; BREAKYL; BREAKYL START; ONSOLIS; PAINKYL; FENTANYL; FENTANYL (BUCCAL, BEMA), BIODELIVERY/MEDA; FENTANYL (TRANSMUCOSAL, BEMA), ATRIX; FENTANYL (TRANSMUCOSAL, BEMA), QLT USA","FENTANYL (BUCCAL, BEMA), BIODELIVERY/MEDA","BEMA DRUG DELIVERY SYSTEM (FENTANYL), ARIUS/BIODELIVERY","BEMA DRUG DELIVERY SYSTEM (FENTANYL), ATRIX","BEMA DRUG DELIVERY SYSTEM (FENTANYL), QLT USA",BEMA FENTANYL,BREAKYL,BREAKYL START,ONSOLIS,PAINKYL,FENTANYL,"FENTANYL (BUCCAL, BEMA), BIODELIVERY/MEDA","FENTANYL (TRANSMUCOSAL, BEMA), ATRIX","FENTANYL (TRANSMUCOSAL, BEMA), QLT USA",,,,,,,,,,,,,,,,,,,20195,FENTANYL CITRATE,22266,FENTANYL CITRATE,,,,,,,,,,,,,,,,,,,2009-07-16T00:00:00Z,2009,7,Onsolis,cancer pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022266,NDA,2007-10-31T00:00:00Z,fda,0,0,0,0,0,,biodelivery sciences,NASDAQ: BDSI,1,62.8,0.3,0.2,0.3,0.9,1.8,60.8,10.3,10.3,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022266,516,3211,338,95,Other nervous system disorders,1,0
275,"FENTANYL (BUCCAL SYSTEMIC, PAIN), KYOWA KIRIN/KYOWA","ABSTRAL; EN-3267; KW-2246; LUNALDIN; OX-20; RAPINYL; FENTANYL; FENTANYL (BUCCAL SYSTEMIC, PAIN), ENDO/KYOWA/PROSTRAKAN; FENTANYL (BUCCAL SYSTEMIC, PAIN), KYOWA KIRIN/KYOWA; FENTANYL (BUCCAL SYSTEMIC, PAIN), PROSTRAKAN/KYOWA; FENTANYL (SUBLINGUAL), DIABACT; FENTANYL (SUBLINGUAL), OREXO","ABSTRAL; EN-3267; KW-2246; LUNALDIN; OX-20; RAPINYL; FENTANYL; FENTANYL (BUCCAL SYSTEMIC, PAIN), ENDO/KYOWA/PROSTRAKAN; FENTANYL (BUCCAL SYSTEMIC, PAIN), KYOWA KIRIN/KYOWA; FENTANYL (BUCCAL SYSTEMIC, PAIN), PROSTRAKAN/KYOWA; FENTANYL (SUBLINGUAL), DIABACT; FENTANYL (SUBLINGUAL), OREXO","FENTANYL (BUCCAL SYSTEMIC, PAIN), KYOWA KIRIN/KYOWA",ABSTRAL,EN-3267,KW-2246,LUNALDIN,OX-20,RAPINYL,FENTANYL,"FENTANYL (BUCCAL SYSTEMIC, PAIN), ENDO/KYOWA/PROSTRAKAN","FENTANYL (BUCCAL SYSTEMIC, PAIN), KYOWA KIRIN/KYOWA","FENTANYL (BUCCAL SYSTEMIC, PAIN), PROSTRAKAN/KYOWA","FENTANYL (SUBLINGUAL), DIABACT","FENTANYL (SUBLINGUAL), OREXO",,,,,,,,,,,,,,,,,,,20195,FENTANYL CITRATE,22510,FENTANYL CITRATE,,,,,,,,,,,,,,,,,,,2011-01-07T00:00:00Z,2011,1,Abstral,cancer pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022510,NDA,2009-08-05T00:00:00Z,fda,0,0,0,0,0,,kyowa kirin,TSE: 4151,1,4467.4,156.5,127.6,81.7,90.6,75.3,2567.7,622.9,622.6,,,2011,,acquired by kyowa kirin in 2011,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022510,582,3211,338,95,Other nervous system disorders,1,0
278,"FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES / DEPOMED","LAZANDA; NASALFENT; PECFENT; FENTANYL; FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES; FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES / DEPOMED; FENTANYL CITRATE; FENTANYL CITRATE (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES","LAZANDA; NASALFENT; PECFENT; FENTANYL; FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES; FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES / DEPOMED; FENTANYL CITRATE; FENTANYL CITRATE (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES","FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES / DEPOMED",LAZANDA,NASALFENT,PECFENT,FENTANYL,"FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES","FENTANYL (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES / DEPOMED",FENTANYL CITRATE,"FENTANYL CITRATE (INTRANASAL/PECSYS, BREAKTHROUGH CANCER PAIN), ARCHIMEDES",,,,,,,,,,,,,,,,,,,,,,,19101,FENTANYL CITRATE,19115,FENTANYL CITRATE,20195,FENTANYL CITRATE,22569,FENTANYL CITRATE,,,,,,,,,,,,,,,2011-06-30T00:00:00Z,2011,6,Lazanda,cancer pain,OPIOID RECEPTOR AGONIST,ANALGESIC,FORMULATION AEROSOL; NASAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TRANSMUCOSAL FORMULATION,matched (3),022569,NDA,2009-08-30T00:00:00Z,fda,0,0,0,0,0,,archimedes pharma,private,0,,,,,,,,,,,,,,,1,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022569,604,3211,338,95,Other nervous system disorders,1,0
267,EXTAVIA,"EXTAVIA; INTERFERON BETA-1B, NOVARTIS; NVF-233","EXTAVIA; INTERFERON BETA-1B, NOVARTIS; NVF-233",EXTAVIA,EXTAVIA,"INTERFERON BETA-1B, NOVARTIS",NVF-233,,,,,,,,,,,,,,,,,,,,,,,,,,,,125290,INTERFERON BETA-1B,,,,,,,,,,,,,,,,,,,,,2009-08-14T00:00:00Z,2009,8,Extavia,multiple sclerosis,INTERFERON BETA LIGAND,IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125290,BLA,2008-05-26T00:00:00Z,cortellis,0,0,0,0,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125290,20,213,340,80,Multiple sclerosis,1,0
579,"PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN","BIIB-017; PEG-AVONEX; PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN; PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC; PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN; PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC; PLEGRIDY; PLEGRIDY PEN; PEGINTERFERON BETA-1A; PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN; PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN IDEC","BIIB-017; PEG-AVONEX; PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN; PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC; PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN; PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC; PLEGRIDY; PLEGRIDY PEN; PEGINTERFERON BETA-1A; PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN; PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN IDEC","PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN",BIIB-017,PEG-AVONEX,"PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN","PEGYLATED IFN BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC","PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN","PEGYLATED INTERFERON BETA 1-A (MULTIPLE SCLEROSIS), BIOGEN IDEC",PLEGRIDY,PLEGRIDY PEN,PEGINTERFERON BETA-1A,"PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN","PEGINTERFERON BETA-1A (MULTIPLE SCLEROSIS), BIOGEN IDEC",,,,,,,,,,,,,,,,,,,,125499,PEGINTERFERON BETA-1A,,,,,,,,,,,,,,,,,,,,,2014-08-15T00:00:00Z,2014,8,Plegridy,multiple sclerosis,INTERFERON BETA LIGAND,ANTICANCER; IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; PEGYLATED FORMULATION; PEPTIDE; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125499,BLA,2013-05-15T00:00:00Z,fda,0,0,1,0,0,,biogen,NASDAQ: BIIB,1,9703.3,6932.2,5514.86,5037.63,4716.42,4377.35,8532.3,1893.4,1893.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125499,48,213,340,80,Multiple sclerosis,1,0
723,TERIFLUNOMIDE,A-771726; AUBAGIO; HMR-1726; TERIFLUNOMIDE,A-771726; AUBAGIO; HMR-1726; TERIFLUNOMIDE,TERIFLUNOMIDE,A-771726,AUBAGIO,HMR-1726,TERIFLUNOMIDE,,,,,,,,,,,,,,,,,,,,,,,,,,,202992,TERIFLUNOMIDE,,,,,,,,,,,,,,,,,,,,,2012-09-12T00:00:00Z,2012,9,Aubagio,multiple sclerosis,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,ANTI-INFLAMMATORY; IMMUNOMODULATOR; PYRIMIDINE NUCLEOTIDE METABOLISM MODULATOR,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202992,NDA,2011-08-12T00:00:00Z,fda,0,0,0,0,0,,sanofi,NYSE: SNY,1,47408.5,45544.7,45640,44761,40266.9,42651,32806.4,6467.14,6467.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202992,137,213,340,80,Multiple sclerosis,1,0
212,DIMETHYL FUMARATE,"BG-00012; BG-12; FAG-201; PANACLAR; TECFIDERA; DIMETHYL FUMARATE; DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN; DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN IDEC; FUMARATE DERIVATIVE (SECOND-GENERATION, PSORIASIS), FUMAPHARM/BIOGEN; SECOND-GENERATION FUMARATE DERIVATIVE (PSORIASIS), FUMAPHARM/BIOGEN","BG-00012; BG-12; FAG-201; PANACLAR; TECFIDERA; DIMETHYL FUMARATE; DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN; DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN IDEC; FUMARATE DERIVATIVE (SECOND-GENERATION, PSORIASIS), FUMAPHARM/BIOGEN; SECOND-GENERATION FUMARATE DERIVATIVE (PSORIASIS), FUMAPHARM/BIOGEN",DIMETHYL FUMARATE,BG-00012,BG-12,FAG-201,PANACLAR,TECFIDERA,DIMETHYL FUMARATE,"DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN","DIMETHYL FUMARATE (ORAL, PSORIASIS), BIOGEN IDEC","FUMARATE DERIVATIVE (SECOND-GENERATION, PSORIASIS), FUMAPHARM/BIOGEN","SECOND-GENERATION FUMARATE DERIVATIVE (PSORIASIS), FUMAPHARM/BIOGEN",,,,,,,,,,,,,,,,,,,,,204063,DIMETHYL FUMARATE,,,,,,,,,,,,,,,,,,,,,2013-03-27T00:00:00Z,2013,3,Tecfidera,multiple sclerosis,KELCH LIKE ECH ASSOCIATED PROTEIN 1 MODULATOR; NUCLEAR ERYTHROID 2-RELATED FACTOR 2 STIMULATOR,IMMUNOMODULATOR; NEUROPROTECTANT,CAPSULE FORMULATION; ENTERIC COATED FORMULATION; MICROPARTICLE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),204063,NDA,2012-02-24T00:00:00Z,fda,0,0,0,0,0,,biogen,NASDAQ: BIIB,1,6932.2,5514.86,5037.63,4716.42,4377.35,4097.51,6074.5,1444.1,1455.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204063,181,213,340,80,Multiple sclerosis,1,0
270,"FAMPRIDINE (ORAL, SUSTAINED RELEASE, MULTIPLE SCLEROSIS/ SPINAL CORD INJURY), ACORDA/BIOGEN","4-AP; 4-AMINOPYRIDINE; AMAYA; AMPYRA; BIIB-041; EL-970; FAMPRIDINE SR; FAMPYRA; IPDAS (FAMPRIDINE); NEURELAN; DALFAMPRIDINE; DALFAMPRIDINE ER; FAMPRIDINE; FAMPRIDINE (ORAL, SUSTAINED RELEASE, MULTIPLE SCLEROSIS/ SPINAL CORD INJURY), ACORDA/BIOGEN; FAMPRIDINE PR","4-AP; 4-AMINOPYRIDINE; AMAYA; AMPYRA; BIIB-041; EL-970; FAMPRIDINE SR; FAMPYRA; IPDAS (FAMPRIDINE); NEURELAN; DALFAMPRIDINE; DALFAMPRIDINE ER; FAMPRIDINE; FAMPRIDINE (ORAL, SUSTAINED RELEASE, MULTIPLE SCLEROSIS/ SPINAL CORD INJURY), ACORDA/BIOGEN; FAMPRIDINE PR","FAMPRIDINE (ORAL, SUSTAINED RELEASE, MULTIPLE SCLEROSIS/ SPINAL CORD INJURY), ACORDA/BIOGEN",4-AP,4-AMINOPYRIDINE,AMAYA,AMPYRA,BIIB-041,EL-970,FAMPRIDINE SR,FAMPYRA,IPDAS (FAMPRIDINE),NEURELAN,DALFAMPRIDINE,DALFAMPRIDINE ER,FAMPRIDINE,"FAMPRIDINE (ORAL, SUSTAINED RELEASE, MULTIPLE SCLEROSIS/ SPINAL CORD INJURY), ACORDA/BIOGEN",FAMPRIDINE PR,,,,,,,,,,,,,,,,22250,DALFAMPRIDINE,,,,,,,,,,,,,,,,,,,,,2010-01-22T00:00:00Z,2010,1,Ampyra,multiple sclerosis,POTASSIUM CHANNEL INHIBITOR,ANTI-INFLAMMATORY; NEUROPROTECTANT,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022250,NDA,2009-04-22T00:00:00Z,fda,1,0,0,1,0,,acorda therapeutics,NASDAQ: ACOR,1,191,54.7,47.8,39.5,27.4,5.1,154.8,30.6,30.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022250,510,213,340,80,Multiple sclerosis,1,0
291,FINGOLIMOD,"FTY-720; FILOSIR; FYNEFTA; GILENIA; GILENYA; IMUSERA; TDI-132; FINGOLIMOD; FINGOLIMOD HYDROCHLORIDE; SPHINGOSINE-1-PHOSPHATE MODULATOR, NOVARTIS/MITSUBISHI TANABE PHARMA","FTY-720; FILOSIR; FYNEFTA; GILENIA; GILENYA; IMUSERA; TDI-132; FINGOLIMOD; FINGOLIMOD HYDROCHLORIDE; SPHINGOSINE-1-PHOSPHATE MODULATOR, NOVARTIS/MITSUBISHI TANABE PHARMA",FINGOLIMOD,FTY-720,FILOSIR,FYNEFTA,GILENIA,GILENYA,IMUSERA,TDI-132,FINGOLIMOD,FINGOLIMOD HYDROCHLORIDE,"SPHINGOSINE-1-PHOSPHATE MODULATOR, NOVARTIS/MITSUBISHI TANABE PHARMA",,,,,,,,,,,,,,,,,,,,,22527,FINGOLIMOD,22527,FINGOLIMOD,,,,,,,,,,,,,,,,,,,2010-09-21T00:00:00Z,2010,9,Gilenya,multiple sclerosis,CANNABINOID RECEPTOR ANTAGONIST; SPHINGOSINE-1-PHOSPHATE RECEPTOR-1 MODULATOR,ANTI-INFLAMMATORY; IMMUNOMODULATOR; NEUROPROTECTANT,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),022527,NDA,2009-12-18T00:00:00Z,fda,1,0,0,0,0,,novartis,NYSE: NVS,1,51561,45075,42535,38947,35105,29753,37456,8149,9070,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022527,592,213,340,80,Multiple sclerosis,1,0
181,"DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN","BIIB-019; DAC HYP; ZINBRYTA; ZINBRYTA; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN IDEC; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN IDEC; DACLIZUMAB HYP; DACLIZUMAB HIGH YIELD PROCESS; DACLIZUMAB BETA","BIIB-019; DAC HYP; ZINBRYTA; ZINBRYTA; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN IDEC; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN; DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN IDEC; DACLIZUMAB HYP; DACLIZUMAB HIGH YIELD PROCESS; DACLIZUMAB BETA","DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN",BIIB-019,DAC HYP,ZINBRYTA,ZINBRYTA,"DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN","DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBVIE/BIOGEN IDEC","DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN","DACLIZUMAB (HIGH-CONCENTRATION SC, MULTIPLE SCLEROSIS), ABBOTT/BIOGEN IDEC",DACLIZUMAB HYP,DACLIZUMAB HIGH YIELD PROCESS,DACLIZUMAB BETA,,,,,,,,,,,,,,,,,,,,761029,DACLIZUMAB,,,,,,,,,,,,,,,,,,,,,2016-05-27T00:00:00Z,2016,5,Zinbryta,multiple sclerosis,IL-2 ANTAGONIST; IL-2 RECEPTOR ALPHA SUBUNIT INHIBITOR,ANTI-INFLAMMATORY; IMMUNOSUPPRESSANT,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMANIZED; MONTHLY DOSING; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),761029,BLA,2015-02-27T00:00:00Z,fda,0,0,0,0,0,,biogen,NASDAQ: BIIB,1,11448.8,10763.8,9703.3,6932.2,5514.86,5037.63,10022.5,1973.3,1973.3,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761029,619,213,340,80,Multiple sclerosis,1,0
744,"TOPIRAMATE (ONCE-DAILY, EPILEPSY), SUPERNUS","SPN-538; TOPIRAMATE QD; TROKENDI XR; TROKESA; TOPIRAMATE; TOPIRAMATE (ONCE-DAILY, EPILEPSY), SUPERNUS","SPN-538; TOPIRAMATE QD; TROKENDI XR; TROKESA; TOPIRAMATE; TOPIRAMATE (ONCE-DAILY, EPILEPSY), SUPERNUS","TOPIRAMATE (ONCE-DAILY, EPILEPSY), SUPERNUS",SPN-538,TOPIRAMATE QD,TROKENDI XR,TROKESA,TOPIRAMATE,"TOPIRAMATE (ONCE-DAILY, EPILEPSY), SUPERNUS",,,,,,,,,,,,,,,,,,,,,,,,,201635,TOPIRAMATE,,,,,,,,,,,,,,,,,,,,,2013-08-16T00:00:00Z,2013,8,Trokendi XR,epilepsy,CARBONIC ANHYDRASE INHIBITOR; CARBONIC ANHYDRASE-II INHIBITOR; CARBONIC ANHYDRASE-IV INHIBITOR; GABA RECEPTOR AGONIST; NMDA RECEPTOR ANTAGONIST; SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT,CAPSULE FORMULATION; DAILY DOSING; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),201635,NDA,2011-01-13T00:00:00Z,fda,0,0,0,0,0,,supernus pharmaceuticals,NASDAQ: SUPN,1,12,1.5,0.8,0.1,37.9,8.9,10.9,17.2,17.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201635,88,119,345,83,Epilepsy; convulsions,1,0
158,"CLOBAZAM (LENNOX-GASTAUT SYNDROME/ANXIETY), LUNDBECK","ONFI; CLOBAZAM; CLOBAZAM (LENNOX-GASTAUT SYNDROME), LUNDBECK; CLOBAZAM (LENNOX-GASTAUT SYNDROME), OVATION; CLOBAZAM (LENNOX-GASTAUT SYNDROME/ANXIETY), LUNDBECK","ONFI; CLOBAZAM; CLOBAZAM (LENNOX-GASTAUT SYNDROME), LUNDBECK; CLOBAZAM (LENNOX-GASTAUT SYNDROME), OVATION; CLOBAZAM (LENNOX-GASTAUT SYNDROME/ANXIETY), LUNDBECK","CLOBAZAM (LENNOX-GASTAUT SYNDROME/ANXIETY), LUNDBECK",ONFI,CLOBAZAM,"CLOBAZAM (LENNOX-GASTAUT SYNDROME), LUNDBECK","CLOBAZAM (LENNOX-GASTAUT SYNDROME), OVATION","CLOBAZAM (LENNOX-GASTAUT SYNDROME/ANXIETY), LUNDBECK",,,,,,,,,,,,,,,,,,,,,,,,,,202067,CLOBAZAM,,,,,,,,,,,,,,,,,,,,,2011-10-21T00:00:00Z,2011,10,Onfi,lennox gastaut syndrome,BENZODIAZEPINE RECEPTOR AGONIST,ANTICONVULSANT AGENT; ANXIOLYTIC,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202067,NDA,2010-12-23T00:00:00Z,fda,0,0,0,1,0,,lundbeck,CPH: LUN,1,2797.6,2656.3,2647.7,2171.2,2186.7,1632,2253.4,445,580.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202067,98,3132,345,83,Epilepsy; convulsions,1,0
418,"LEVETIRACETAM (IV INFUSION), UCB","E KEPPRA; E KEPPRA (INJECTABLE), UCB; E KEPPRA IV DRIP INFUSION, UCB; KEPPRA (INJECTABLE), UCB; L-059-IV; UCB-L059; LEVETIRACETAM; LEVETIRACETAM (INJECTABLE), UCB; LEVETIRACETAM (INTRAVENOUS), UCB; LEVETIRACETAM (IV INFUSION), UCB","E KEPPRA; E KEPPRA (INJECTABLE), UCB; E KEPPRA IV DRIP INFUSION, UCB; KEPPRA (INJECTABLE), UCB; L-059-IV; UCB-L059; LEVETIRACETAM; LEVETIRACETAM (INJECTABLE), UCB; LEVETIRACETAM (INTRAVENOUS), UCB; LEVETIRACETAM (IV INFUSION), UCB","LEVETIRACETAM (IV INFUSION), UCB",E KEPPRA,"E KEPPRA (INJECTABLE), UCB","E KEPPRA IV DRIP INFUSION, UCB","KEPPRA (INJECTABLE), UCB",L-059-IV,UCB-L059,LEVETIRACETAM,"LEVETIRACETAM (INJECTABLE), UCB","LEVETIRACETAM (INTRAVENOUS), UCB","LEVETIRACETAM (IV INFUSION), UCB",,,,,,,,,,,,,,,,,,,,,202543,LEVETIRACETAM,,,,,,,,,,,,,,,,,,,,,2006-07-31T00:00:00Z,2006,7,Keppra,epilepsy,MUSCARINIC RECEPTOR AGONIST; SYNAPTIC VESICLE GLYCOPROTEIN 2A MODULATOR,ANTICONVULSANT AGENT,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021872,NDA,2004-12-20T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,3366.1,2773.04,2552.13,4251.41,3081.75,2552.87,2652.24,811.506,811.506,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021872,123,119,345,83,Epilepsy; convulsions,1,0
551,"OXCARBAZEPINE (ONCE-DAILY, ORAL EXTENDED RELEASE, EPILEPSY), SUPERNUS","EPLIGA; OXCARBAZEPINE QD; OXTELLAR XR; SPN-804; OXCARBAZEPINE; OXCARBAZEPINE (ONCE-DAILY, ORAL EXTENDED RELEASE, EPILEPSY), SUPERNUS","EPLIGA; OXCARBAZEPINE QD; OXTELLAR XR; SPN-804; OXCARBAZEPINE; OXCARBAZEPINE (ONCE-DAILY, ORAL EXTENDED RELEASE, EPILEPSY), SUPERNUS","OXCARBAZEPINE (ONCE-DAILY, ORAL EXTENDED RELEASE, EPILEPSY), SUPERNUS",EPLIGA,OXCARBAZEPINE QD,OXTELLAR XR,SPN-804,OXCARBAZEPINE,"OXCARBAZEPINE (ONCE-DAILY, ORAL EXTENDED RELEASE, EPILEPSY), SUPERNUS",,,,,,,,,,,,,,,,,,,,,,,,,202810,OXCARBAZEPINE,,,,,,,,,,,,,,,,,,,,,2012-10-19T00:00:00Z,2012,10,Oxtellar XR,epilepsy,SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT,DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202810,NDA,2011-12-19T00:00:00Z,fda,0,0,0,0,0,,supernus pharmaceuticals,NASDAQ: SUPN,1,1.5,0.8,0.1,37.9,8.9,4.2,1.5,23.5,23.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202810,130,119,345,83,Epilepsy; convulsions,1,0
584,PERAMPANEL,"AMPA ANTAGONIST (ORAL, MIGRAINE/PARKINSON'S DISEASE/EPILEPSY/MULTIPLE SCLEROSIS), EISAI; E-2007; FYCOMPA; MARS; MULTIPLE SCLEROSIS AMPA RECEPTOR SELECTIVE ANTAGONIST; PERAMPANEL","AMPA ANTAGONIST (ORAL, MIGRAINE/PARKINSON'S DISEASE/EPILEPSY/MULTIPLE SCLEROSIS), EISAI; E-2007; FYCOMPA; MARS; MULTIPLE SCLEROSIS AMPA RECEPTOR SELECTIVE ANTAGONIST; PERAMPANEL",PERAMPANEL,"AMPA ANTAGONIST (ORAL, MIGRAINE/PARKINSON'S DISEASE/EPILEPSY/MULTIPLE SCLEROSIS), EISAI",E-2007,FYCOMPA,MARS,MULTIPLE SCLEROSIS AMPA RECEPTOR SELECTIVE ANTAGONIST,PERAMPANEL,,,,,,,,,,,,,,,,,,,,,,,,,202834,PERAMPANEL,,,,,,,,,,,,,,,,,,,,,2012-10-22T00:00:00Z,2012,10,Fycompa,partial seizure,AMPA RECEPTOR ANTAGONIST,ANTICONVULSANT AGENT; NEUROPROTECTANT,DAILY DOSING; FILM COATING; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202834,NDA,2011-12-22T00:00:00Z,cortellis,0,0,0,0,0,,eisai,TYO: 4523,1,6644.7,8576.2,10014.4,8460.4,8530.6,6546.8,4653.5,1446.8,1446.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202834,134,3439,345,83,Epilepsy; convulsions,1,0
781,VIGABATRIN,GVG; M-071754; MDL-71754; RMI-71754; SABRIL; SABRILEX; VIGABATIN; GAMMA-VINYL-GABA; VIGABATRIN,GVG; M-071754; MDL-71754; RMI-71754; SABRIL; SABRILEX; VIGABATIN; GAMMA-VINYL-GABA; VIGABATRIN,VIGABATRIN,GVG,M-071754,MDL-71754,RMI-71754,SABRIL,SABRILEX,VIGABATIN,GAMMA-VINYL-GABA,VIGABATRIN,,,,,,,,,,,,,,,,,,,,,,20427,VIGABATRIN,,,,,,,,,,,,,,,,,,,,,2009-08-21T00:00:00Z,2009,8,Sabril,complex partial seizure,GABA TRANSAMINASE INHIBITOR,ANTICONVULSANT AGENT,FILM COATING; FORMULATION POWDER; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),020427,NDA,2007-12-28T00:00:00Z,fda,1,0,0,1,0,,lundbeck,CPH: LUN,1,2647.7,2171.2,2186.7,1632,1440,1771.6,2136.4,615.6,615.6,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020427,189,3440,345,83,Epilepsy; convulsions,1,0
743,"TOPIRAMATE (EXTENDED-RELEASE, EPILEPSY), UPSHER-SMITH","QUDEXY XR; USL-255; TOPIRAMATE (EXTENDED-RELEASE, EPILEPSY), UPSHER-SMITH","QUDEXY XR; USL-255; TOPIRAMATE (EXTENDED-RELEASE, EPILEPSY), UPSHER-SMITH","TOPIRAMATE (EXTENDED-RELEASE, EPILEPSY), UPSHER-SMITH",QUDEXY XR,USL-255,"TOPIRAMATE (EXTENDED-RELEASE, EPILEPSY), UPSHER-SMITH",,,,,,,,,,,,,,,,,,,,,,,,,,,,205122,TOPIRAMATE,,,,,,,,,,,,,,,,,,,,,2014-03-11T00:00:00Z,2014,3,Qudexy XR,epilepsy,GABA RECEPTOR AGONIST; NMDA RECEPTOR ANTAGONIST; SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT,CAPSULE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205122,NDA,2013-02-11T00:00:00Z,fda,0,0,0,0,0,,upsher-smith laboratories,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205122,227,119,345,83,Epilepsy; convulsions,1,0
108,BRIVARACETAM,BRIVIACT; BRIVIACT; BRIVIACT CV; BRIVIACT CV; BRIVLERA; BRIVLERA; RIKELTA; RIKELTA; UCB-100406-1; UCB-34714; UCB-42145; BRIVARACETAM,BRIVIACT; BRIVIACT; BRIVIACT CV; BRIVIACT CV; BRIVLERA; BRIVLERA; RIKELTA; RIKELTA; UCB-100406-1; UCB-34714; UCB-42145; BRIVARACETAM,BRIVARACETAM,BRIVIACT,BRIVIACT,BRIVIACT CV,BRIVIACT CV,BRIVLERA,BRIVLERA,RIKELTA,RIKELTA,UCB-100406-1,UCB-34714,UCB-42145,BRIVARACETAM,,,,,,,,,,,,,,,,,,,205836,BRIVARACETAM,205836,BRIVARACETAM,,,,,,,,,,,,,,,,,,,2016-02-18T00:00:00Z,2016,2,Briviact,partial seizure,EPOXIDE HYDROLASE INHIBITOR; SYNAPTIC VESICLE GLYCOPROTEIN 2A MODULATOR,ANTICONVULSANT AGENT; NOOTROPIC AGENT,FILM COATING; INFUSION; INTRAVENOUS FORMULATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),205836,NDA,2014-11-19T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,4410.43,4209.61,4047.69,4314.54,4564.57,4216.95,3141.56,1076.74,1076.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205836,262,3439,345,83,Epilepsy; convulsions,1,0
419,"LEVETIRACETAM (ODT/ZIPDOSE, EPILEPSY), APRECIA","SPRITAM; SPRITAM; LEVETIRACETAM; LEVETIRACETAM (ODT/ZIPDOSE, EPILEPSY), APRECIA; UNDISCLOSED CNS THERAPEUTIC (ODT/ZIPDOSE, CNS DISORDERS), APRECIA","SPRITAM; SPRITAM; LEVETIRACETAM; LEVETIRACETAM (ODT/ZIPDOSE, EPILEPSY), APRECIA; UNDISCLOSED CNS THERAPEUTIC (ODT/ZIPDOSE, CNS DISORDERS), APRECIA","LEVETIRACETAM (ODT/ZIPDOSE, EPILEPSY), APRECIA",SPRITAM,SPRITAM,LEVETIRACETAM,"LEVETIRACETAM (ODT/ZIPDOSE, EPILEPSY), APRECIA","UNDISCLOSED CNS THERAPEUTIC (ODT/ZIPDOSE, CNS DISORDERS), APRECIA",,,,,,,,,,,,,,,,,,,,,,,,,,202543,LEVETIRACETAM,207958,LEVETIRACETAM,207958,LEVETIRACETAM,,,,,,,,,,,,,,,,,2015-07-31T00:00:00Z,2015,7,Spritam,epilepsy,ACETYLCHOLINE RECEPTOR AGONIST; MUSCARINIC RECEPTOR AGONIST; SYNAPTIC VESICLE GLYCOPROTEIN 2A MODULATOR,ANTICONVULSANT AGENT; NEUROPROTECTANT; NOOTROPIC AGENT,ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC,matched (3),207958,NDA,2014-10-01T00:00:00Z,fda,0,0,0,0,0,,aprecia pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207958,314,119,345,83,Epilepsy; convulsions,1,0
649,RUFINAMIDE,BANZEL; CGP-33101; E-2080; INOVELON; INOVERON; RUF-331; SYN-111; XILEP; RUFINAMIDE,BANZEL; CGP-33101; E-2080; INOVELON; INOVERON; RUF-331; SYN-111; XILEP; RUFINAMIDE,RUFINAMIDE,BANZEL,CGP-33101,E-2080,INOVELON,INOVERON,RUF-331,SYN-111,XILEP,RUFINAMIDE,,,,,,,,,,,,,,,,,,,,,,21911,RUFINAMIDE,,,,,,,,,,,,,,,,,,,,,2008-11-14T00:00:00Z,2008,11,Banzel,lennox gastaut syndrome,GABA B RECEPTOR ANTAGONIST; SODIUM CHANNEL INHIBITOR,ANALGESIC; ANTICONVULSANT AGENT; ANXIOLYTIC; PSYCHOMODULATOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021911,NDA,2005-11-17T00:00:00Z,fda,0,0,0,1,0,,eisai,TYO: 4523,1,8530.6,6546.8,5478,4907.5,5131,4594.2,6859.8,1706.7,1706.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021911,407,3132,345,83,Epilepsy; convulsions,1,0
650,"RUFINAMIDE (ORAL SUSPENSION), EISAI","BANZEL; BANZEL (ORAL SUSPENSION), EISAI; INOVELON; RUFINAMIDE (ORAL SUSPENSION), EISAI","BANZEL; BANZEL (ORAL SUSPENSION), EISAI; INOVELON; RUFINAMIDE (ORAL SUSPENSION), EISAI","RUFINAMIDE (ORAL SUSPENSION), EISAI",BANZEL,"BANZEL (ORAL SUSPENSION), EISAI",INOVELON,"RUFINAMIDE (ORAL SUSPENSION), EISAI",,,,,,,,,,,,,,,,,,,,,,,,,,,21911,RUFINAMIDE,,,,,,,,,,,,,,,,,,,,,2011-03-03T00:00:00Z,2011,3,Banzel (oral suspension),lennox gastaut syndrome,GABA B RECEPTOR ANTAGONIST; SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT,FILM COATING; ORAL FORMULATION; ORAL LIQUID FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION,matched (3),201367,NDA,2010-04-30T00:00:00Z,fda,0,0,0,0,0,,eisai,TYO: 4523,1,8576.2,10014.4,8460.4,8530.6,6546.8,5478,6369.6,505.1,505.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201367,408,3132,345,83,Epilepsy; convulsions,1,0
411,"LAMOTRIGINE (EXTENDED RELEASE), GLAXOSMITHKLINE","LAMICTAL; LAMICTAL XR; LAMOTRIGINE; LAMOTRIGINE (EXTENDED RELEASE), GLAXOSMITHKLINE","LAMICTAL; LAMICTAL XR; LAMOTRIGINE; LAMOTRIGINE (EXTENDED RELEASE), GLAXOSMITHKLINE","LAMOTRIGINE (EXTENDED RELEASE), GLAXOSMITHKLINE",LAMICTAL,LAMICTAL XR,LAMOTRIGINE,"LAMOTRIGINE (EXTENDED RELEASE), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,20241,LAMOTRIGINE,22115,LAMOTRIGINE,,,,,,,,,,,,,,,,,,,2009-05-29T00:00:00Z,2009,5,Lamictal XR,epilepsy,SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT; ANTIPSYCHOTIC; GLUTAMATE RELEASE INHIBITOR; NEUROPROTECTANT,ENTERIC COATED FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022115,NDA,2006-11-22T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022115,471,119,345,83,Epilepsy; convulsions,1,0
410,LACOSAMIDE,ADD-243037; SPM-927; SPM-929; SPM-965; VIMPAT; ERLOSAMIDE; HARKOSERIDE; LACOSAMIDE,ADD-243037; SPM-927; SPM-929; SPM-965; VIMPAT; ERLOSAMIDE; HARKOSERIDE; LACOSAMIDE,LACOSAMIDE,ADD-243037,SPM-927,SPM-929,SPM-965,VIMPAT,ERLOSAMIDE,HARKOSERIDE,LACOSAMIDE,,,,,,,,,,,,,,,,,,,,,,,22253,LACOSAMIDE,,,,,,,,,,,,,,,,,,,,,2008-10-28T00:00:00Z,2008,10,Vimpat,partial seizure,DIHYDROPYRIMIDINASE RELATED PROTEIN 2 MODULATOR; SODIUM CHANNEL MODULATOR,ANTICONVULSANT AGENT,FILM COATING; FORMULATION POWDER; INFUSION; INTRAVENOUS FORMULATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),022253,NDA,2007-09-28T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,5031.79,5295.05,3366.1,2773.04,2552.13,4251.41,3430.45,1071.75,1071.75,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022253,513,3439,345,83,Epilepsy; convulsions,1,0
417,"LEVETIRACETAM (EXTENDED RELEASE FORMULATION), UCB","KEPPRA XR; MONAVRI XR; LEVETIRACETAM; LEVETIRACETAM (EXTENDED RELEASE FORMULATION), UCB","KEPPRA XR; MONAVRI XR; LEVETIRACETAM; LEVETIRACETAM (EXTENDED RELEASE FORMULATION), UCB","LEVETIRACETAM (EXTENDED RELEASE FORMULATION), UCB",KEPPRA XR,MONAVRI XR,LEVETIRACETAM,"LEVETIRACETAM (EXTENDED RELEASE FORMULATION), UCB",,,,,,,,,,,,,,,,,,,,,,,,,,,202543,LEVETIRACETAM,22285,LEVETIRACETAM,,,,,,,,,,,,,,,,,,,2008-09-12T00:00:00Z,2008,9,Keppra XR,epilepsy,MUSCARINIC RECEPTOR AGONIST; SYNAPTIC VESICLE GLYCOPROTEIN 2A MODULATOR,ANTICONVULSANT AGENT,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022285,NDA,2007-11-13T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,5031.79,5295.05,3366.1,2773.04,2552.13,4251.41,3430.45,1071.75,1071.75,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022285,520,119,345,83,Epilepsy; convulsions,1,0
632,RETIGABINE,ADD-230001; AWD21-360; D-20443; D-23129; GKE-841; GW-582892; POTIGA; TROBALT; EZOGABINE; RETIGABINE; RETIGABINE IR,ADD-230001; AWD21-360; D-20443; D-23129; GKE-841; GW-582892; POTIGA; TROBALT; EZOGABINE; RETIGABINE; RETIGABINE IR,RETIGABINE,ADD-230001,AWD21-360,D-20443,D-23129,GKE-841,GW-582892,POTIGA,TROBALT,EZOGABINE,RETIGABINE,RETIGABINE IR,,,,,,,,,,,,,,,,,,,,22345,EZOGABINE,,,,,,,,,,,,,,,,,,,,,2011-06-10T00:00:00Z,2011,6,Potiga,epilepsy,GABA A RECEPTOR AGONIST; KCNQ VOLTAGE-GATED POTASSIUM CHANNEL STIMULATOR,ANTICONVULSANT AGENT,FILM COATING; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022345,NDA,2009-10-30T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,2427.5,1181.2,820.4,757.2,842.8,1067.7,1790.6,65.7,65.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022345,535,119,345,83,Epilepsy; convulsions,1,0
254,ESLICARBAZEPINE ACETATE,APTIOM; BIA-2-005; BIA-2-059; BIA-2-093; EXALIEF; SEP-0002093; STEDESA; ZEBINIX; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE,APTIOM; BIA-2-005; BIA-2-059; BIA-2-093; EXALIEF; SEP-0002093; STEDESA; ZEBINIX; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE,ESLICARBAZEPINE ACETATE,APTIOM,BIA-2-005,BIA-2-059,BIA-2-093,EXALIEF,SEP-0002093,STEDESA,ZEBINIX,ESLICARBAZEPINE,ESLICARBAZEPINE ACETATE,,,,,,,,,,,,,,,,,,,,,22416,ESLICARBAZEPINE ACETATE,,,,,,,,,,,,,,,,,,,,,2013-11-08T00:00:00Z,2013,11,Aptiom,partial seizure,VOLTAGE GATED SODIUM CHANNEL INHIBITOR,ANTICONVULSANT AGENT,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022416,NDA,2009-03-29T00:00:00Z,fda,0,0,0,0,0,,dainippon sumitomo,TSE: 4506,1,3452.2,4097.7,4729.8,4601.2,2856.3,1292.3,2754.7,678,678,1312.8,2009-06-30T00:00:00Z,2009,,formerly Sepracor; acquired by Dainippon Sumitomo pharma in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022416,556,3439,345,83,Epilepsy; convulsions,1,0
693,"SUMATRIPTAN SUCCINATE (INTRANASAL, MIGRAINE), OPTINOSE","AVP-825, OTSUKA; ONZETRA XSAIL; ONZETRA XSAIL; SUMATRIPTAN; SUMATRIPTAN (BREATH POWERED INTRANASAL, MIGRAINE), AVANIR; SUMATRIPTAN (INTRANASAL, MIGRAINE), OPTINOSE; SUMATRIPTAN SUCCINATE; SUMATRIPTAN SUCCINATE (INTRANASAL, MIGRAINE), OPTINOSE","AVP-825, OTSUKA; ONZETRA XSAIL; ONZETRA XSAIL; SUMATRIPTAN; SUMATRIPTAN (BREATH POWERED INTRANASAL, MIGRAINE), AVANIR; SUMATRIPTAN (INTRANASAL, MIGRAINE), OPTINOSE; SUMATRIPTAN SUCCINATE; SUMATRIPTAN SUCCINATE (INTRANASAL, MIGRAINE), OPTINOSE","SUMATRIPTAN SUCCINATE (INTRANASAL, MIGRAINE), OPTINOSE","AVP-825, OTSUKA",ONZETRA XSAIL,ONZETRA XSAIL,SUMATRIPTAN,"SUMATRIPTAN (BREATH POWERED INTRANASAL, MIGRAINE), AVANIR","SUMATRIPTAN (INTRANASAL, MIGRAINE), OPTINOSE",SUMATRIPTAN SUCCINATE,"SUMATRIPTAN SUCCINATE (INTRANASAL, MIGRAINE), OPTINOSE",,,,,,,,,,,,,,,,,,,,,,,206099,SUMATRIPTAN SUCCINATE,,,,,,,,,,,,,,,,,,,,,2016-01-27T00:00:00Z,2016,1,Onzetra Xsail,migraine,5-HT 1B RECEPTOR AGONIST; 5-HT 1D RECEPTOR AGONIST,ANALGESIC,CAPSULE FORMULATION; INHALANT FORMULATION; NASAL SYSTEMIC FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC,matched (3),206099,NDA,2014-01-27T00:00:00Z,fda,0,0,0,0,0,,otsuka,TYO: 4578,1,10240.2,12023.5,13350.2,85.6,50.6,15.8,6759.9,1446,1446,153.333333333333,2014-09-30T00:00:00Z,2014,,acquired by otsuka in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206099,269,210,346,84,Headache; including migraine,2,0
692,"SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GLAXOSMITHKLINE","TREXIMA; TREXIMET; SUMATRIPTAN + NAPROXEN SODIUM; SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), ARALEZ/GSK; SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), POZEN/GSK; SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GSK; SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GLAXOSMITHKLINE; SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GSK; SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GLAXOSMITHKLINE","TREXIMA; TREXIMET; SUMATRIPTAN + NAPROXEN SODIUM; SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), ARALEZ/GSK; SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), POZEN/GSK; SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GSK; SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GLAXOSMITHKLINE; SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GSK; SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GLAXOSMITHKLINE","SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GLAXOSMITHKLINE",TREXIMA,TREXIMET,SUMATRIPTAN + NAPROXEN SODIUM,"SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), ARALEZ/GSK","SUMATRIPTAN + NAPROXEN SODIUM (MT-400 TECHNOLOGY), POZEN/GSK","SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GSK","SUMATRIPTAN + NAPROXEN SODIUM, ARALEZ/GLAXOSMITHKLINE","SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GSK","SUMATRIPTAN + NAPROXEN SODIUM, POZEN/GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,21926,NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE,,,,,,,,,,,,,,,,,,,,,2008-04-15T00:00:00Z,2008,4,Treximet,migraine,5-HT 1B RECEPTOR AGONIST; 5-HT 1D RECEPTOR AGONIST,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY; VASOCONSTRICTOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021926,NDA,2005-08-05T00:00:00Z,fda,0,0,0,0,0,,aralez pharmaceuticals,NASDAQ: POZN,1,66.1,53.4,13.5,28.6,23.1,3.7,66.1,61.9,61.9,,,,,pozen changed name to aralez after acquiring tribute in 2016,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021926,410,210,346,84,Headache; including migraine,2,0
207,"DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/ DEPOMED/ TRIBUTE","CAMBIA; CATAFAST; PRO-513; VOLTFAST; DICHLOFENAC; DICLOFENAC; DICLOFENAC POTASSIUM; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/ DEPOMED/ TRIBUTE; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/NAUTILUS NEUROSCIENCES; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/PROETHIC; DICLOFENAC-K","CAMBIA; CATAFAST; PRO-513; VOLTFAST; DICHLOFENAC; DICLOFENAC; DICLOFENAC POTASSIUM; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/ DEPOMED/ TRIBUTE; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/NAUTILUS NEUROSCIENCES; DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/PROETHIC; DICLOFENAC-K","DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/ DEPOMED/ TRIBUTE",CAMBIA,CATAFAST,PRO-513,VOLTFAST,DICHLOFENAC,DICLOFENAC,DICLOFENAC POTASSIUM,"DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/ DEPOMED/ TRIBUTE","DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/NAUTILUS NEUROSCIENCES","DICLOFENAC POTASSIUM (IMMEDIATE-RELEASE, ORAL POWDER), NOVARTIS/PROETHIC",DICLOFENAC-K,,,,,,,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,22165,DICLOFENAC POTASSIUM,,,,,,,,,,,,,,,,,,,2009-06-17T00:00:00Z,2009,6,Cambia,migraine,CYCLOOXYGENASE 2 INHIBITOR,ANALGESIC; ANTI-INFLAMMATORY; NON-STEROIDAL ANTI-INFLAMMATORY,FORMULATION POWDER; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022165,NDA,2007-09-27T00:00:00Z,fda,0,0,0,0,0,,kowa pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022165,484,210,346,84,Headache; including migraine,2,0
691,"SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ENDO","INTRAJECT SUMATRIPTAN; SUMAVEL DOSEPRO; SUMATRIPTAN; SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ARADIGM; SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ENDO; SUMATRIPTAN DOSEPRO","INTRAJECT SUMATRIPTAN; SUMAVEL DOSEPRO; SUMATRIPTAN; SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ARADIGM; SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ENDO; SUMATRIPTAN DOSEPRO","SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ENDO",INTRAJECT SUMATRIPTAN,SUMAVEL DOSEPRO,SUMATRIPTAN,"SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ARADIGM","SUMATRIPTAN (NEEDLELESS DELIVERY, INTRAJECT), ENDO",SUMATRIPTAN DOSEPRO,,,,,,,,,,,,,,,,,,,,,,,,,22239,SUMATRIPTAN SUCCINATE,,,,,,,,,,,,,,,,,,,,,2009-07-15T00:00:00Z,2009,7,Sumavel Dosepro,migraine,5-HT 1B RECEPTOR AGONIST; 5-HT 1D RECEPTOR AGONIST,ANALGESIC; VASOCONSTRICTOR,SMALL MOLECULE THERAPEUTIC; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),022239,NDA,2009-01-14T00:00:00Z,fda,0,0,0,0,0,,zogenix,private,0,,,,,,,,21.4,21.4,,,,,IPO in 2010,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022239,507,210,346,84,Headache; including migraine,2,0
133,"CAPSAICIN DERMAL PATCH, NEUROGESX/ASTELLAS","NGX-4010; QUTENZA; TRANSACIN; TRANSDOLOR; CAPSAICIN; CAPSAICIN DERMAL PATCH, NEUROGESX/ASTELLAS","NGX-4010; QUTENZA; TRANSACIN; TRANSDOLOR; CAPSAICIN; CAPSAICIN DERMAL PATCH, NEUROGESX/ASTELLAS","CAPSAICIN DERMAL PATCH, NEUROGESX/ASTELLAS",NGX-4010,QUTENZA,TRANSACIN,TRANSDOLOR,CAPSAICIN,"CAPSAICIN DERMAL PATCH, NEUROGESX/ASTELLAS",,,,,,,,,,,,,,,,,,,,,,,,,22395,CAPSAICIN,,,,,,,,,,,,,,,,,,,,,2009-11-16T00:00:00Z,2009,11,Qutenza,neuropathic pain,VANILLOID VR1 AGONIST,ANALGESIC,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),022395,NDA,2008-10-13T00:00:00Z,fda,0,0,0,1,0,,neurogesx,NASDAQ: NGSX,1,2,,,,,,2,11.1,11.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022395,546,1295,349,95,Other nervous system disorders,3,0
512,"NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), AVADEL PHARMACEUTICALS","BLOXIVERZ; NEOSTIGMINE METHYLSULFATE; NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), AVADEL PHARMACEUTICALS; NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), FLAMEL","BLOXIVERZ; NEOSTIGMINE METHYLSULFATE; NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), AVADEL PHARMACEUTICALS; NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), FLAMEL","NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), AVADEL PHARMACEUTICALS",BLOXIVERZ,NEOSTIGMINE METHYLSULFATE,"NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), AVADEL PHARMACEUTICALS","NEOSTIGMINE METHYLSULFATE (INTRAVENOUS, NEUROMUSCULAR BLOCKADE), FLAMEL",,,,,,,,,,,,,,,,,,,,,,,,,,,203629,NEOSTIGMINE METHYLSULFATE,203629,NEOSTIGMINE METHYLSULFATE,203629,NEOSTIGMINE METHYLSULFATE,203629,NEOSTIGMINE METHYLSULFATE,204078,NEOSTIGMINE METHYLSULFATE,,,,,,,,,,,,,2013-05-31T00:00:00Z,2013,5,Bloxiverz,neuromuscular blockade,CHOLINESTERASE INHIBITOR,,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204078,NDA,2012-07-31T00:00:00Z,fda,0,0,0,0,0,,avadel,NASDAQ: AVDL,1,4.2,7.5,,,,,-12.3,,22.2,,,2012,,"acquired by Flamel tech, now Avadel, in 2012",,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204078,182,3501,358,95,Other nervous system disorders,1,0
79,"BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), PIRAMAL","GABLOFEN; GABLOFEN; BACLOFEN; BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), MALLINCKRODT; BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), PIRAMAL","GABLOFEN; GABLOFEN; BACLOFEN; BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), MALLINCKRODT; BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), PIRAMAL","BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), PIRAMAL",GABLOFEN,GABLOFEN,BACLOFEN,"BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), MALLINCKRODT","BACLOFEN (INTRATHECAL, SPASTICITY/COMPLEX REGIONAL PAIN SYNDROME), PIRAMAL",,,,,,,,,,,,,,,,,,,,,,,,,,22462,BACLOFEN,22462,BACLOFEN,,,,,,,,,,,,,,,,,,,2010-11-19T00:00:00Z,2010,11,Gablofen,muscle hypertonia,GABA B RECEPTOR AGONIST,ANALGESIC,INTRATHECAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022462,NDA,2009-03-27T00:00:00Z,fda,0,0,0,0,0,,CNS therapeutics,private,0,,,,,,,,,,,,,,acquired by malinckrodt in 2012,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022462,570,913,358,95,Other nervous system disorders,1,0
260,ETEPLIRSEN,"AVI-4225; AVI-4658; EXONDYS 51; EXONDYS 51; ANTISENSE THERAPY (ESPRIT, MUSCULAR DYSTROPHY), SAREPTA THERAPEUTICS; ETEPLIRSEN; MUSCULAR DYSTROPHY THERAPY (ESPRIT), AVI BIOPHARMA/ERCOLE BIOTECH","AVI-4225; AVI-4658; EXONDYS 51; EXONDYS 51; ANTISENSE THERAPY (ESPRIT, MUSCULAR DYSTROPHY), SAREPTA THERAPEUTICS; ETEPLIRSEN; MUSCULAR DYSTROPHY THERAPY (ESPRIT), AVI BIOPHARMA/ERCOLE BIOTECH",ETEPLIRSEN,AVI-4225,AVI-4658,EXONDYS 51,EXONDYS 51,"ANTISENSE THERAPY (ESPRIT, MUSCULAR DYSTROPHY), SAREPTA THERAPEUTICS",ETEPLIRSEN,"MUSCULAR DYSTROPHY THERAPY (ESPRIT), AVI BIOPHARMA/ERCOLE BIOTECH",,,,,,,,,,,,,,,,,,,,,,,,206488,ETEPLIRSEN,,,,,,,,,,,,,,,,,,,,,2016-09-19T00:00:00Z,2016,9,Exondys 51,duchenne dystrophy,DYSTROPHIN STIMULATOR,ANTISENSE OLIGONUCLEOTIDE INHIBITOR,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAMUSCULAR FORMULATION; INTRAVENOUS FORMULATION; OLIGONUCLEOTIDE ANTISENSE; RNA TECHNOLOGY,matched (3),206488,NDA,2015-06-26T00:00:00Z,fda,1,1,1,1,0,,sarepta therapeutics,NASDAQ: SRPT,1,5.4,1.3,9.8,14.2,37.3,47,-180.7,,188.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206488,284,2020,359,95,Other nervous system disorders,1,0
621,RANIBIZUMAB,"AMD-FAB; LUCENTIS; NUOSHIDE; RFB-002; RG-3645; Y0317; ANTI-VEGF ANTIBODY FRAGMENT, GENENTECH; RANIBIZUMAB; RHUFAB V2","AMD-FAB; LUCENTIS; NUOSHIDE; RFB-002; RG-3645; Y0317; ANTI-VEGF ANTIBODY FRAGMENT, GENENTECH; RANIBIZUMAB; RHUFAB V2",RANIBIZUMAB,AMD-FAB,LUCENTIS,NUOSHIDE,RFB-002,RG-3645,Y0317,"ANTI-VEGF ANTIBODY FRAGMENT, GENENTECH",RANIBIZUMAB,RHUFAB V2,,,,,,,,,,,,,,,,,,,,,,125156,RANIBIZUMAB,,,,,,,,,,,,,,,,,,,,,2006-06-30T00:00:00Z,2006,6,Lucentis,wet age related macular degeneration,VEGF RECEPTOR ANTAGONIST; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTICANCER MONOCLONAL ANTIBODY; ANTICANCER PROTEIN KINASE INHIBITOR; OCULAR ANTINEOVASCULARISATION AGENT; OPHTHALMOLOGICAL AGENT,ANTIBODY; ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; INJECTABLE FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; OPHTHALMIC FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; PROTEIN RECOMBINANT; SOLUTION,matched (3),125156,BLA,2005-12-29T00:00:00Z,fda,1,0,0,0,0,,genentech,NASDAQ: DNA,1,9284,6633,4621,3300.3,2583.7,2044,7918,1588,1773,,,,,acquired by roche in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125156,7,3354,362,87,Retinal detachments; defects; vascular occlusion; and retinopathy,1,0
17,"AFLIBERCEPT (INTRAVITREAL, WET AMD, MACULAR EDEMA, DIABETIC RETINOPATHY), REGENERON/BAYER","BAY-86-5321; EYLEA; VEGF TRAP-EYE; VEGF TRAP-EYE DISEASE; VEGF TRAP (INTRAVITREAL, AMD), REGENERON; VEGF TRAP (INTRAVITREAL, AGE-RELATED MACULAR DEGENERATION), REGENERON; AFLIBERCEPT; AFLIBERCEPT (INTRAVITREAL, WET AMD, MACULAR EDEMA, DIABETIC RETINOPATHY), REGENERON/BAYER","BAY-86-5321; EYLEA; VEGF TRAP-EYE; VEGF TRAP-EYE DISEASE; VEGF TRAP (INTRAVITREAL, AMD), REGENERON; VEGF TRAP (INTRAVITREAL, AGE-RELATED MACULAR DEGENERATION), REGENERON; AFLIBERCEPT; AFLIBERCEPT (INTRAVITREAL, WET AMD, MACULAR EDEMA, DIABETIC RETINOPATHY), REGENERON/BAYER","AFLIBERCEPT (INTRAVITREAL, WET AMD, MACULAR EDEMA, DIABETIC RETINOPATHY), REGENERON/BAYER",BAY-86-5321,EYLEA,VEGF TRAP-EYE,VEGF TRAP-EYE DISEASE,"VEGF TRAP (INTRAVITREAL, AMD), REGENERON","VEGF TRAP (INTRAVITREAL, AGE-RELATED MACULAR DEGENERATION), REGENERON",AFLIBERCEPT,"AFLIBERCEPT (INTRAVITREAL, WET AMD, MACULAR EDEMA, DIABETIC RETINOPATHY), REGENERON/BAYER",,,,,,,,,,,,,,,,,,,,,,,125387,AFLIBERCEPT,,,,,,,,,,,,,,,,,,,,,2011-11-18T00:00:00Z,2011,11,Eylea,wet age related macular degeneration,PLACENTA GROWTH FACTOR LIGAND INHIBITOR; VEGF-A LIGAND INHIBITOR,ANGIOGENESIS INHIBITOR; ANTICANCER; OCULAR ANTINEOVASCULARISATION AGENT,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; IMMUNOGLOBULIN-G; INJECTABLE FORMULATION; OPHTHALMIC FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; PROTEIN FUSION; PROTEIN RECOMBINANT; RECEPTOR FUSION; SOLUTION,matched (3),125387,BLA,2011-02-17T00:00:00Z,fda,1,0,0,0,0,,regeneron pharmaceuticals,NASDAQ: REGN,1,445.8,459.1,379.3,238.5,125,63.4,-87.9,,529.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125387,33,3354,362,87,Retinal detachments; defects; vascular occlusion; and retinopathy,1,0
530,"OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS/ALCON","A-01016; JETREA; MIVI; MICROPLASMIN FOR VITREOUS INJECTION III, THROMBOGENICS; THR-409; MICROPLASMINOGEN; OCRIPLASMIN; OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS; OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS/ALCON; RECOMBINANT HUMAN MICROPLASMIN; RECOMBINANT HUMAN MICROPLASMIN (OPHTHALMIC), THROMBOGENICS","A-01016; JETREA; MIVI; MICROPLASMIN FOR VITREOUS INJECTION III, THROMBOGENICS; THR-409; MICROPLASMINOGEN; OCRIPLASMIN; OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS; OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS/ALCON; RECOMBINANT HUMAN MICROPLASMIN; RECOMBINANT HUMAN MICROPLASMIN (OPHTHALMIC), THROMBOGENICS","OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS/ALCON",A-01016,JETREA,MIVI,"MICROPLASMIN FOR VITREOUS INJECTION III, THROMBOGENICS",THR-409,MICROPLASMINOGEN,OCRIPLASMIN,"OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS","OCRIPLASMIN (OPHTHALMIC), THROMBOGENICS/ALCON",RECOMBINANT HUMAN MICROPLASMIN,"RECOMBINANT HUMAN MICROPLASMIN (OPHTHALMIC), THROMBOGENICS",,,,,,,,,,,,,,,,,,,,125422,OCRIPLASMIN,,,,,,,,,,,,,,,,,,,,,2012-10-17T00:00:00Z,2012,10,Jetrea,macular disease,ALPHA-2 ANTIPLASMIN INHIBITOR; COLLAGEN ANTAGONIST; FIBRONECTIN INHIBITOR; LAMININ ANTAGONIST; PLASMIN STIMULATOR,FIBRINOLYSIS STIMULATOR; OPHTHALMOLOGICAL AGENT,BIOLOGICAL THERAPEUTIC; INJECTABLE FORMULATION; OPHTHALMIC FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; PROTEIN RECOMBINANT; RECOMBINANT ENZYME; SOLUTION,matched (3),125422,BLA,2012-04-16T00:00:00Z,fda,1,0,0,1,0,,thrombogenics,EBR: THR,1,99,3.2,8.3,6,42.5,2.2,94.9,21.2,26.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125422,38,3206,362,87,Retinal detachments; defects; vascular occlusion; and retinopathy,1,0
199,"DEXAMETHASONE (SUSTAINED RELEASE OPHTHALMIC), ALLERGAN/SANWA","OZURDEX; POSURDEX; SK-0503; DEXAMETHASONE; DEXAMETHASONE (OPHTHALMIC), OCULEX; DEXAMETHASONE (SUSTAINED RELEASE OPHTHALMIC), ALLERGAN/SANWA; INTRAOCULAR DDS (UVEITIS), OCULEX","OZURDEX; POSURDEX; SK-0503; DEXAMETHASONE; DEXAMETHASONE (OPHTHALMIC), OCULEX; DEXAMETHASONE (SUSTAINED RELEASE OPHTHALMIC), ALLERGAN/SANWA; INTRAOCULAR DDS (UVEITIS), OCULEX","DEXAMETHASONE (SUSTAINED RELEASE OPHTHALMIC), ALLERGAN/SANWA",OZURDEX,POSURDEX,SK-0503,DEXAMETHASONE,"DEXAMETHASONE (OPHTHALMIC), OCULEX","DEXAMETHASONE (SUSTAINED RELEASE OPHTHALMIC), ALLERGAN/SANWA","INTRAOCULAR DDS (UVEITIS), OCULEX",,,,,,,,,,,,,,,,,,,,,,,,22315,DEXAMETHASONE,,,,,,,,,,,,,,,,,,,,,2009-06-17T00:00:00Z,2009,6,Ozurdex,retinal venous occlusion,,CORTICOSTEROID AGONIST; OPHTHALMOLOGICAL AGENT; STEROIDAL ANTI-INFLAMMATORY,OPHTHALMIC DRUG IMPLANT; OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; SUSTAINED RELEASE FORMULATION,matched (3),022315,NDA,2008-12-23T00:00:00Z,fda,1,0,1,0,0,,allergan inc,NYSE: AGN,1,4503.6,4403.4,3938.9,3063.3,2342.6,2058.9,3772.9,684.9,820.1,,,,,This firm is Allergan inc which was acquired in 2015 by actavis which later changed name to Allergan Plc; note they use same stock ticker NYSE: AGN,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022315,530,2656,362,87,Retinal detachments; defects; vascular occlusion; and retinopathy,1,0
702,TAFLUPROST,AFP-168; DE-085; MK-2452; SAFLUTAN; TAFLOTAN; TAPROS; TAPROS MINI; ZIOPTAN; TAFLUPROST,AFP-168; DE-085; MK-2452; SAFLUTAN; TAFLOTAN; TAPROS; TAPROS MINI; ZIOPTAN; TAFLUPROST,TAFLUPROST,AFP-168,DE-085,MK-2452,SAFLUTAN,TAFLOTAN,TAPROS,TAPROS MINI,ZIOPTAN,TAFLUPROST,,,,,,,,,,,,,,,,,,,,,,202514,TAFLUPROST,,,,,,,,,,,,,,,,,,,,,2012-02-10T00:00:00Z,2012,2,Zioptan,open angle glaucoma,FP PROSTANOID AGONIST; PGF2 ALPHA AGONIST,ANTIHYPERTENSIVE; TOPICAL ANTIGLAUCOMA AGENT,OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),202514,NDA,2011-01-07T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,47267,48047,45987,27428,23850,24197.7,31009,7911,7968,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202514,122,3147,365,88,Glaucoma,1,0
107,"BRINZOLAMIDE + BRIMONIDINE (OPHTHALMIC, GLAUCOMA/OCULAR HYPERTENSION), ALCON","SIMBRINZA; BRINZOLAMIDE + BRIMONIDE; BRINZOLAMIDE + BRIMONIDINE (OPHTHALMIC, GLAUCOMA/OCULAR HYPERTENSION), ALCON","SIMBRINZA; BRINZOLAMIDE + BRIMONIDE; BRINZOLAMIDE + BRIMONIDINE (OPHTHALMIC, GLAUCOMA/OCULAR HYPERTENSION), ALCON","BRINZOLAMIDE + BRIMONIDINE (OPHTHALMIC, GLAUCOMA/OCULAR HYPERTENSION), ALCON",SIMBRINZA,BRINZOLAMIDE + BRIMONIDE,"BRINZOLAMIDE + BRIMONIDINE (OPHTHALMIC, GLAUCOMA/OCULAR HYPERTENSION), ALCON",,,,,,,,,,,,,,,,,,,,,,,,,,,,204251,BRIMONIDINE TARTRATE; BRINZOLAMIDE,,,,,,,,,,,,,,,,,,,,,2013-04-19T00:00:00Z,2013,4,Simbrinza,open angle glaucoma,ALPHA 2 ADRENOCEPTOR AGONIST; CARBONIC ANHYDRASE INHIBITOR,TOPICAL ANTIGLAUCOMA AGENT,DRUG COMBINATION; OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION,matched (3),204251,NDA,2012-06-19T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,52716,51971,59375,7179,6499,6294,36177,8946,9681,,,2011,,acquired by novartis in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204251,188,3147,365,88,Glaucoma,1,0
106,"BRIMONIDINE + TIMOLOL (OPHTHALMIC), ALLERGAN","COMBIGAN; BRIMONIDINE + TIMOLOL; BRIMONIDINE + TIMOLOL (INTRAOCULAR PRESSURE/GLAUCOMA), ALLERGAN; BRIMONIDINE + TIMOLOL (OPHTHALMIC), ALLERGAN","COMBIGAN; BRIMONIDINE + TIMOLOL; BRIMONIDINE + TIMOLOL (INTRAOCULAR PRESSURE/GLAUCOMA), ALLERGAN; BRIMONIDINE + TIMOLOL (OPHTHALMIC), ALLERGAN","BRIMONIDINE + TIMOLOL (OPHTHALMIC), ALLERGAN",COMBIGAN,BRIMONIDINE + TIMOLOL,"BRIMONIDINE + TIMOLOL (INTRAOCULAR PRESSURE/GLAUCOMA), ALLERGAN","BRIMONIDINE + TIMOLOL (OPHTHALMIC), ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,,,,21398,BRIMONIDINE TARTRATE; TIMOLOL MALEATE,,,,,,,,,,,,,,,,,,,,,2007-10-30T00:00:00Z,2007,10,Combigan,ocular hypertension,ALPHA 2 ADRENOCEPTOR AGONIST; BETA ADRENOCEPTOR ANTAGONIST,,DRUG COMBINATION; OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),021398,NDA,2001-09-17T00:00:00Z,fda,0,0,0,0,0,,allergan inc,NYSE: AGN,1,3938.9,3063.3,2342.6,2058.9,1771.4,1425.3,3269.2,646.1,646.1,,,,,This firm is Allergan inc which was acquired in 2015 by actavis which later changed name to Allergan Plc; note they use same stock ticker NYSE: AGN,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021398,367,240,365,88,Glaucoma,1,0
90,"BEPOTASTINE (OPHTHALMIC), SENJU/ISTA","BEPREVE; TALION EYE DROPS, SENJU/ISTA/DONG-A; BEPOTASTINE; BEPOTASTINE (OPHTHALMIC), SENJU/ISTA; BEPOTASTINE BESILATE; BEPOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA; BEPOTASTINE BESYLATE; BETOTASTINE BESILATE; BETOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA","BEPREVE; TALION EYE DROPS, SENJU/ISTA/DONG-A; BEPOTASTINE; BEPOTASTINE (OPHTHALMIC), SENJU/ISTA; BEPOTASTINE BESILATE; BEPOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA; BEPOTASTINE BESYLATE; BETOTASTINE BESILATE; BETOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA","BEPOTASTINE (OPHTHALMIC), SENJU/ISTA",BEPREVE,"TALION EYE DROPS, SENJU/ISTA/DONG-A",BEPOTASTINE,"BEPOTASTINE (OPHTHALMIC), SENJU/ISTA",BEPOTASTINE BESILATE,"BEPOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA",BEPOTASTINE BESYLATE,BETOTASTINE BESILATE,"BETOTASTINE BESILATE (OPHTHALMIC), SENJU/ISTA",,,,,,,,,,,,,,,,,,,,,,22288,BEPOTASTINE BESILATE,,,,,,,,,,,,,,,,,,,,,2009-09-08T00:00:00Z,2009,9,Bepreve,allergic conjunctivitis,HISTAMINE H1 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY; EOSINOPHIL MIGRATION INHIBITOR; MAST CELL DEGRANULATION INHIBITOR; OPHTHALMOLOGICAL AGENT,DAILY DOSING; OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022288,NDA,2008-11-12T00:00:00Z,fda,0,0,0,0,0,,ista pharmaceuticals,NASDAQ: ISTA,1,110.6,83.1,58.9,33,10.7,1.9,83.4,24.9,24.9,,,,,acquired by bausch + lomb in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022288,522,2438,365,88,Glaucoma,1,0
496,"MITOMYCIN (OPHTHALMIC), MOBIUS THERAPEUTICS","MITOMYCIN C; MITOSOL; OPTOMYCIN; ANTIFIBROTIC AGENT DELIVERY SYSTEM (CORNEAL DISEASE), MOBIUS THERAPEUTICS; MITOMYCIN; MITOMYCIN (OPHTHALMIC), MOBIUS THERAPEUTICS; MITOMYCIN C (OPHTHALMIC), MOBIUS THERAPEUTICS","MITOMYCIN C; MITOSOL; OPTOMYCIN; ANTIFIBROTIC AGENT DELIVERY SYSTEM (CORNEAL DISEASE), MOBIUS THERAPEUTICS; MITOMYCIN; MITOMYCIN (OPHTHALMIC), MOBIUS THERAPEUTICS; MITOMYCIN C (OPHTHALMIC), MOBIUS THERAPEUTICS","MITOMYCIN (OPHTHALMIC), MOBIUS THERAPEUTICS",MITOMYCIN C,MITOSOL,OPTOMYCIN,"ANTIFIBROTIC AGENT DELIVERY SYSTEM (CORNEAL DISEASE), MOBIUS THERAPEUTICS",MITOMYCIN,"MITOMYCIN (OPHTHALMIC), MOBIUS THERAPEUTICS","MITOMYCIN C (OPHTHALMIC), MOBIUS THERAPEUTICS",,,,,,,,,,,,,,,,,,,,,,,,22572,MITOMYCIN,,,,,,,,,,,,,,,,,,,,,2012-02-07T00:00:00Z,2012,2,Mitosol,glaucoma surgical procedure,,FIBROSUPPRESSANT; OPHTHALMOLOGICAL AGENT,OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022572,NDA,2010-06-21T00:00:00Z,fda,0,0,0,1,0,,mobius therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022572,606,3516,365,88,Glaucoma,1,0
752,"TRANSEPITHELIAL RIBOFLAVIN (PARACEL/CORNEAL CROSS-LINKING/OPHTHALMIC LIQUID FORMULATION, KERATOCONUS/CORNEAL ECTASIA), AVEDRO","PHOTREXA; PHOTREXA; PHOTREXA VISCOUS; VIBEX; RIBOFLAVIN; RIBOFLAVIN-5-PHOSPHATE; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS), ISTITUTO LASER MICROCHIRURGIA OCULARE; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS/CORNEAL ECTASIA), AVEDRO; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/CORNEAL CROSS-LINKING/OPHTHALMIC LIQUID FORMULATION, KERATOCONUS/CORNEAL ECTASIA), AVEDRO","PHOTREXA; PHOTREXA; PHOTREXA VISCOUS; VIBEX; RIBOFLAVIN; RIBOFLAVIN-5-PHOSPHATE; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS), ISTITUTO LASER MICROCHIRURGIA OCULARE; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS/CORNEAL ECTASIA), AVEDRO; TRANSEPITHELIAL RIBOFLAVIN (PARACEL/CORNEAL CROSS-LINKING/OPHTHALMIC LIQUID FORMULATION, KERATOCONUS/CORNEAL ECTASIA), AVEDRO","TRANSEPITHELIAL RIBOFLAVIN (PARACEL/CORNEAL CROSS-LINKING/OPHTHALMIC LIQUID FORMULATION, KERATOCONUS/CORNEAL ECTASIA), AVEDRO",PHOTREXA,PHOTREXA,PHOTREXA VISCOUS,VIBEX,RIBOFLAVIN,RIBOFLAVIN-5-PHOSPHATE,"TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS), ISTITUTO LASER MICROCHIRURGIA OCULARE","TRANSEPITHELIAL RIBOFLAVIN (PARACEL/ CORNEAL CROSS-LINKING, KERATOCONUS/CORNEAL ECTASIA), AVEDRO","TRANSEPITHELIAL RIBOFLAVIN (PARACEL/CORNEAL CROSS-LINKING/OPHTHALMIC LIQUID FORMULATION, KERATOCONUS/CORNEAL ECTASIA), AVEDRO",,,,,,,,,,,,,,,,,,,,,,203324,RIBOFLAVIN 5'-PHOSPHATE SODIUM,203324,RIBOFLAVIN 5'-PHOSPHATE SODIUM,203324,RIBOFLAVIN 5'-PHOSPHATE SODIUM,,,,,,,,,,,,,,,,,2016-04-15T00:00:00Z,2016,4,Photrexa,keratoconus,,OPHTHALMOLOGICAL AGENT; VITAMIN B2,OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),203324,NDA,2013-09-16T00:00:00Z,fda,1,0,0,1,0,,avedro,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203324,151,2519,371,91,Other eye disorders,1,0
21,ALCAFTADINE,"H1 ANTAGONIST (OPHTHALMIC, CONJUNCTIVITIS), JANSSEN/VISTAKON; LASTACAFT; R-89674; ALCAFTADINE","H1 ANTAGONIST (OPHTHALMIC, CONJUNCTIVITIS), JANSSEN/VISTAKON; LASTACAFT; R-89674; ALCAFTADINE",ALCAFTADINE,"H1 ANTAGONIST (OPHTHALMIC, CONJUNCTIVITIS), JANSSEN/VISTAKON",LASTACAFT,R-89674,ALCAFTADINE,,,,,,,,,,,,,,,,,,,,,,,,,,,22134,ALCAFTADINE,,,,,,,,,,,,,,,,,,,,,2010-07-28T00:00:00Z,2010,7,Lastacaft,conjunctivitis,HISTAMINE H1 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY; OPHTHALMOLOGICAL AGENT,OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022134,NDA,2009-09-28T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61587,61897,63747,61095,53324,50514,42795,6844,6844,,,,,acquired in 80's,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022134,477,77,372,91,Other eye disorders,2,0
93,BESIFLOXACIN,"BOL-303224-A; BESIVANCE; ISV-403; OPTURA; SS-732; SS-734; SS-734 (OPHTHALMIC), INSITE; ANTIBACTERIAL OPHTHALMICOLOGIVAL AGENT (CONJUNCTIVITIS), BAUSCH & LOMB; BESIFLOXACIN; BESIFLOXACIN HYDROCHLORIDE; BESIFLOXACIN HYDROCHLORIDE (OPHTHALMIC), INSITE; FLUOROQUINOLONE ANTIBIOTIC (OPHTHALMIC FORMULATION, DURASITE), BAUSCH & LOMB","BOL-303224-A; BESIVANCE; ISV-403; OPTURA; SS-732; SS-734; SS-734 (OPHTHALMIC), INSITE; ANTIBACTERIAL OPHTHALMICOLOGIVAL AGENT (CONJUNCTIVITIS), BAUSCH & LOMB; BESIFLOXACIN; BESIFLOXACIN HYDROCHLORIDE; BESIFLOXACIN HYDROCHLORIDE (OPHTHALMIC), INSITE; FLUOROQUINOLONE ANTIBIOTIC (OPHTHALMIC FORMULATION, DURASITE), BAUSCH & LOMB",BESIFLOXACIN,BOL-303224-A,BESIVANCE,ISV-403,OPTURA,SS-732,SS-734,"SS-734 (OPHTHALMIC), INSITE","ANTIBACTERIAL OPHTHALMICOLOGIVAL AGENT (CONJUNCTIVITIS), BAUSCH & LOMB",BESIFLOXACIN,BESIFLOXACIN HYDROCHLORIDE,"BESIFLOXACIN HYDROCHLORIDE (OPHTHALMIC), INSITE","FLUOROQUINOLONE ANTIBIOTIC (OPHTHALMIC FORMULATION, DURASITE), BAUSCH & LOMB",,,,,,,,,,,,,,,,,,,22308,BESIFLOXACIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-05-28T00:00:00Z,2009,5,Besivance,conjunctivitis,I-KAPPA B KINASE MODULATOR; INTERLEUKIN-1 BETA LIGAND INHIBITOR; NUCLEAR FACTOR KAPPA B INHIBITOR,ANTI-INFLAMMATORY; OPHTHALMOLOGICAL ANTIBACTERIAL,ANTIBIOTIC; OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),022308,NDA,2008-05-30T00:00:00Z,fda,0,0,0,0,0,,bausch & lomb,private,0,,,,,,,,,,,,,,owned by private equity firm; acquired by valeant  pharma in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022308,527,77,372,91,Other eye disorders,2,0
408,"KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE  (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS","OMS-302; OMIDRIA; ANTIINFLAMMATORY + MYDRIATIC AGENT (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS; KETOROLAC + PHENYLEPHRINE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS; KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE; KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS","OMS-302; OMIDRIA; ANTIINFLAMMATORY + MYDRIATIC AGENT (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS; KETOROLAC + PHENYLEPHRINE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS; KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE; KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS","KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE  (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS",OMS-302,OMIDRIA,"ANTIINFLAMMATORY + MYDRIATIC AGENT (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS","KETOROLAC + PHENYLEPHRINE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS",KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE,"KETOROLAC TROMETHAMINE + PHENYLEPHRINE HYDROCHLORIDE (OPHTHALMOLOGICAL, MYDRIASIS MAINTENANCE), OMEROS",,,,,,,,,,,,,,,,,,,,,,,,,205388,KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-05-30T00:00:00Z,2014,5,Omidria,ocular pain,ALPHA 1 ADRENOCEPTOR AGONIST; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE INHIBITOR,ANALGESIC; MYDRIATIC AGENT; NON-STEROIDAL ANTI-INFLAMMATORY; PG SYNTHESIS INHIBITOR,DRUG COMBINATION; INJECTABLE FORMULATION; LOCAL FORMULATION UNSPECIFIED; OPHTHALMIC FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),205388,NDA,2013-07-30T00:00:00Z,fda,0,0,0,0,0,,omeros,NASDAQ: OMER,1,0.5,1.6,6,4.5,2.1,1.4,-26.2,21.2,47.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205388,235,3762,379,91,Other eye disorders,2,0
154,"CIPROFLOXACIN + FLUOCINOLONE ACETONIDE (EAR DROP, EXTERNAL OTITIS), SALVAT","CETRAXAL PLUS; DF-289 + DF-277; DUOXAL; OTIXAL; OTOVEL; CIPROFLOXACIN + FLUOCINOLONE ACETONIDE; CIPROFLOXACIN + FLUOCINOLONE ACETONIDE (EAR DROP, EXTERNAL OTITIS), SALVAT","CETRAXAL PLUS; DF-289 + DF-277; DUOXAL; OTIXAL; OTOVEL; CIPROFLOXACIN + FLUOCINOLONE ACETONIDE; CIPROFLOXACIN + FLUOCINOLONE ACETONIDE (EAR DROP, EXTERNAL OTITIS), SALVAT","CIPROFLOXACIN + FLUOCINOLONE ACETONIDE (EAR DROP, EXTERNAL OTITIS), SALVAT",CETRAXAL PLUS,DF-289 + DF-277,DUOXAL,OTIXAL,OTOVEL,CIPROFLOXACIN + FLUOCINOLONE ACETONIDE,"CIPROFLOXACIN + FLUOCINOLONE ACETONIDE (EAR DROP, EXTERNAL OTITIS), SALVAT",,,,,,,,,,,,,,,,,,,,,,,,208251,CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE,,,,,,,,,,,,,,,,,,,,,2016-04-29T00:00:00Z,2016,4,Otovel,otitis externa,,ANTIBACTERIAL; CORTICOSTEROID AGONIST,DRUG COMBINATION; OTIC FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208251,NDA,2015-06-30T00:00:00Z,fda,0,0,0,0,0,,laboratorios salvat,private,0,,58.1,55,62,52.9,55.2,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208251,334,3242,380,94,Other ear and sense organ disorders,1,0
153,"CIPROFLOXACIN (INTRATYMPANIC SUSTAINED RELEASE GEL, OTITIS MEDIA), OTONOMY","AURIPRO; OTO-201; OTO-203; OTIPRIO; OTIPRIO; CIPROFLOXACIN; CIPROFLOXACIN (INTRATYMPANIC SUSTAINED RELEASE GEL, OTITIS MEDIA), OTONOMY","AURIPRO; OTO-201; OTO-203; OTIPRIO; OTIPRIO; CIPROFLOXACIN; CIPROFLOXACIN (INTRATYMPANIC SUSTAINED RELEASE GEL, OTITIS MEDIA), OTONOMY","CIPROFLOXACIN (INTRATYMPANIC SUSTAINED RELEASE GEL, OTITIS MEDIA), OTONOMY",AURIPRO,OTO-201,OTO-203,OTIPRIO,OTIPRIO,CIPROFLOXACIN,"CIPROFLOXACIN (INTRATYMPANIC SUSTAINED RELEASE GEL, OTITIS MEDIA), OTONOMY",,,,,,,,,,,,,,,,,,,,,,,,207986,CIPROFLOXACIN,,,,,,,,,,,,,,,,,,,,,2015-12-10T00:00:00Z,2015,12,Otiprio,otitis media,DNA GYRASE INHIBITOR; TOPOISOMERASE IV INHIBITOR,ANTIBACTERIAL; BACTERIAL NUCLEIC ACID SYNTHESIS INHIBITOR,ANTIBIOTIC; INJECTABLE FORMULATION; OTIC GEL FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),207986,NDA,2015-02-25T00:00:00Z,fda,0,0,0,0,0,,otonomy,NASDAQ: OTIC,1,,,,,,,,38.8,38.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207986,317,394,382,92,Otitis media and related conditions,1,0
28,"ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE (ORAL, HYPERTENSION), NOVARTIS","AMTURNIDE; CGP-60536 + AMLODIPINE + HYDROCHLOROTHIAZIDE; CGP60536B + AMLODIPINE + HYDROCHLOROTHIAZIDE; RASILAMLO HCT; RASILEZ + AMLODIPINE + HYDROCHLOROTHIAZIDE; RASITRIO; RASITRIO HCT; SPP-100 + AMLODIPINE + HYDROCHLOROTHIAZIDE; TEKTURNA + AMLODIPINE + HYDROCHLOROTHIAZIDE; ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE; ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE (ORAL, HYPERTENSION), NOVARTIS","AMTURNIDE; CGP-60536 + AMLODIPINE + HYDROCHLOROTHIAZIDE; CGP60536B + AMLODIPINE + HYDROCHLOROTHIAZIDE; RASILAMLO HCT; RASILEZ + AMLODIPINE + HYDROCHLOROTHIAZIDE; RASITRIO; RASITRIO HCT; SPP-100 + AMLODIPINE + HYDROCHLOROTHIAZIDE; TEKTURNA + AMLODIPINE + HYDROCHLOROTHIAZIDE; ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE; ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE (ORAL, HYPERTENSION), NOVARTIS","ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE (ORAL, HYPERTENSION), NOVARTIS",AMTURNIDE,CGP-60536 + AMLODIPINE + HYDROCHLOROTHIAZIDE,CGP60536B + AMLODIPINE + HYDROCHLOROTHIAZIDE,RASILAMLO HCT,RASILEZ + AMLODIPINE + HYDROCHLOROTHIAZIDE,RASITRIO,RASITRIO HCT,SPP-100 + AMLODIPINE + HYDROCHLOROTHIAZIDE,TEKTURNA + AMLODIPINE + HYDROCHLOROTHIAZIDE,ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE,"ALISKIREN + AMLODIPINE + HYDROCHLOROTHIAZIDE (ORAL, HYPERTENSION), NOVARTIS",,,,,,,,,,,,,,,,,,,,200045,ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE,,,,,,,,,,,,,,,,,,,,,2010-12-21T00:00:00Z,2010,12,Amturnide,hypertension,CALCIUM CHANNEL INHIBITOR; RENIN INHIBITOR,ANTIARTERIOSCLEROTIC; ANTIDIURETIC; ANTIHYPERTENSIVE; CARDIAC AGENT,DRUG COMBINATION; ORAL FORMULATION; PEPTIDOMIMETIC; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200045,NDA,2010-02-25T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,51561,45075,42535,38947,35105,29753,37456,8149,9070,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200045,68,178,401,98,Essential hypertension,2,0
537,"OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO","CS-8635; KONVERGE PLUS; SEVIKAR PLUS; SEVIKAR HCT; TRIBENZOR; TRISEVIKAR; AMLODIPINE + HYDROCHLOROTHIAZIDE + OLMESARTAN; AMLODIPINE + OLMESARTAN + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO; OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO","CS-8635; KONVERGE PLUS; SEVIKAR PLUS; SEVIKAR HCT; TRIBENZOR; TRISEVIKAR; AMLODIPINE + HYDROCHLOROTHIAZIDE + OLMESARTAN; AMLODIPINE + OLMESARTAN + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO; OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO","OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO",CS-8635,KONVERGE PLUS,SEVIKAR PLUS,SEVIKAR HCT,TRIBENZOR,TRISEVIKAR,AMLODIPINE + HYDROCHLOROTHIAZIDE + OLMESARTAN,"AMLODIPINE + OLMESARTAN + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO","OLMESARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE (HYPERTENSION), DAIICHI SANKYO",,,,,,,,,,,,,,,,,,,,,,200175,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL,,,,,,,,,,,,,,,,,,,,,2010-07-23T00:00:00Z,2010,7,Tribenzor,hypertension,ANGIOTENSIN II AT-1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE; DIURETIC AGENT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200175,NDA,2009-09-30T00:00:00Z,fda,0,0,0,0,0,,daiichi sankyo,TYO: 4568,1,12010.8,10100.3,8954.8,7992.4,8001.4,7189.7,8579.1,2348.2,2348.2,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200175,71,178,401,98,Essential hypertension,2,0
75,"AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA/ ARBOR","EDARBI; IPREZIV; TAK-491; ANGIOTENSIN RECEPTOR II ANTAGONIST (HYPERTENSION), TAKEDA PHARMACEUTICALS; AZILSARTAN KAMEDOXOMIL; AZILSARTAN KAMEDOXOMIL (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL; AZILSARTAN MEDOXOMIL POTASSIUM; AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA/ ARBOR","EDARBI; IPREZIV; TAK-491; ANGIOTENSIN RECEPTOR II ANTAGONIST (HYPERTENSION), TAKEDA PHARMACEUTICALS; AZILSARTAN KAMEDOXOMIL; AZILSARTAN KAMEDOXOMIL (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL; AZILSARTAN MEDOXOMIL POTASSIUM; AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA/ ARBOR","AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA/ ARBOR",EDARBI,IPREZIV,TAK-491,"ANGIOTENSIN RECEPTOR II ANTAGONIST (HYPERTENSION), TAKEDA PHARMACEUTICALS",AZILSARTAN KAMEDOXOMIL,"AZILSARTAN KAMEDOXOMIL (HYPERTENSION), TAKEDA",AZILSARTAN MEDOXOMIL,AZILSARTAN MEDOXOMIL POTASSIUM,"AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA","AZILSARTAN MEDOXOMIL POTASSIUM (HYPERTENSION), TAKEDA/ ARBOR",,,,,,,,,,,,,,,,,,,,,200796,AZILSARTAN KAMEDOXOMIL,,,,,,,,,,,,,,,,,,,,,2011-02-25T00:00:00Z,2011,2,Edarbi,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST,ANTIHYPERTENSIVE,ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200796,NDA,2010-04-22T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,19052,17491.2,15722.4,16561.7,12303.5,10759.3,14010.4,-3.4,3751.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200796,80,178,401,98,Essential hypertension,2,0
76,"AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA/ ARBOR","EDARBYCLOR; TAK-491 + CHLORTHALIDONE; TAK-491 + CHLORTHALIDONE (HYPERTENSION), TAKEDA; TAK-491CLD; AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE; AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL + CHLORTHALIDONE; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA/ ARBOR","EDARBYCLOR; TAK-491 + CHLORTHALIDONE; TAK-491 + CHLORTHALIDONE (HYPERTENSION), TAKEDA; TAK-491CLD; AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE; AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL + CHLORTHALIDONE; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA; AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA/ ARBOR","AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA/ ARBOR",EDARBYCLOR,TAK-491 + CHLORTHALIDONE,"TAK-491 + CHLORTHALIDONE (HYPERTENSION), TAKEDA",TAK-491CLD,AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE,"AZILSARTAN KAMEDOXOMIL + CHLORTHALIDONE (HYPERTENSION), TAKEDA",AZILSARTAN MEDOXOMIL + CHLORTHALIDONE,AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE,"AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA","AZILSARTAN MEDOXOMIL POTASSIUM + CHLORTHALIDONE (HYPERTENSION), TAKEDA/ ARBOR",,,,,,,,,,,,,,,,,,,,,202331,AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE,,,,,,,,,,,,,,,,,,,,,2011-12-20T00:00:00Z,2011,12,Edarbyclor,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST,ANTIHYPERTENSIVE; DIURETIC AGENT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202331,NDA,2011-02-24T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,19052,17491.2,15722.4,16561.7,12303.5,10759.3,14010.4,-3.4,3751.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202331,114,178,401,98,Essential hypertension,2,0
585,"PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/SYMPLMED","ACERYCAL; ARMIXXAM; COVERAM; COVERSICAL; PRESTALIA; PRESTANCE; PRESTARIUM-CO; PRESTERAM; S-05985; VIACORAM; XOMA-985; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/SYMPLMED; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/XOMA","ACERYCAL; ARMIXXAM; COVERAM; COVERSICAL; PRESTALIA; PRESTANCE; PRESTARIUM-CO; PRESTERAM; S-05985; VIACORAM; XOMA-985; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/SYMPLMED; PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/XOMA","PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/SYMPLMED",ACERYCAL,ARMIXXAM,COVERAM,COVERSICAL,PRESTALIA,PRESTANCE,PRESTARIUM-CO,PRESTERAM,S-05985,VIACORAM,XOMA-985,PERINDOPRIL ARGININE + AMLODIPINE BESYLATE,"PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER","PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/SYMPLMED","PERINDOPRIL ARGININE + AMLODIPINE BESYLATE (HYPERTENSION), SERVIER/XOMA",,,,,,,,,,,,,,,,205003,AMLODIPINE BESYLATE; PERINDOPRIL ARGININE,,,,,,,,,,,,,,,,,,,,,2015-01-21T00:00:00Z,2015,1,Prestalia,hypertension,ACE INHIBITOR; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205003,NDA,2014-03-21T00:00:00Z,fda,0,0,0,0,0,,symplmed pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205003,223,178,401,98,Essential hypertension,2,0
510,"NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ALLERGAN","BYSTOLIC + VALSARTAN; BYSTOLIC + VALSARTAN; BYVALSON; BYVALSON; NEBIVOLOL + VALSARTAN; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ACTAVIS; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ALLERGAN; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), FOREST LABORATORIES","BYSTOLIC + VALSARTAN; BYSTOLIC + VALSARTAN; BYVALSON; BYVALSON; NEBIVOLOL + VALSARTAN; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ACTAVIS; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ALLERGAN; NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), FOREST LABORATORIES","NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ALLERGAN",BYSTOLIC + VALSARTAN,BYSTOLIC + VALSARTAN,BYVALSON,BYVALSON,NEBIVOLOL + VALSARTAN,"NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ACTAVIS","NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), ALLERGAN","NEBIVOLOL + VALSARTAN (ORAL, HYPERTENSION), FOREST LABORATORIES",,,,,,,,,,,,,,,,,,,,,,,206302,NEBIVOLOL HYDROCHLORIDE; VALSARTAN,,,,,,,,,,,,,,,,,,,,,2016-06-03T00:00:00Z,2016,6,Byvalson,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST; BETA 1 ADRENOCEPTOR ANTAGONIST; BETA 3 ADRENOCEPTOR AGONIST,ANTIHYPERTENSIVE,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206302,NDA,2014-02-23T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,14570.6,12688.1,3646.9,3094,4547.76,4390.13,12741.1,2578.8,2575.7,4518,2014-06-30T00:00:00Z,2014,,acquired by actavis (now allergan plc) in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206302,275,178,401,98,Essential hypertension,2,0
438,"LISINOPRIL (ORAL SOLUTION, PEDIATRIC HYPERTENSION), SILVERGATE PHARMACEUTICALS","QBRELIS; QBRELIS; LISINOPRIL; LISINOPRIL (ORAL SOLUTION, PEDIATRIC HYPERTENSION), SILVERGATE PHARMACEUTICALS","QBRELIS; QBRELIS; LISINOPRIL; LISINOPRIL (ORAL SOLUTION, PEDIATRIC HYPERTENSION), SILVERGATE PHARMACEUTICALS","LISINOPRIL (ORAL SOLUTION, PEDIATRIC HYPERTENSION), SILVERGATE PHARMACEUTICALS",QBRELIS,QBRELIS,LISINOPRIL,"LISINOPRIL (ORAL SOLUTION, PEDIATRIC HYPERTENSION), SILVERGATE PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,208401,LISINOPRIL,208401,LISINOPRIL,,,,,,,,,,,,,,,,,,,2016-07-29T00:00:00Z,2016,7,Qbrelis,hypertension,ACE INHIBITOR,ANTIHYPERTENSIVE,ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),208401,NDA,2015-06-30T00:00:00Z,fda,0,0,0,0,0,,silvergate pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208401,341,178,401,98,Essential hypertension,2,0
246,"ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION/SYMPTOMATIC HEART FAILURE/ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION), SILVERGATE PHARMACEUTICALS","ENALAPED; EPANED; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION), SILVERGATE PHARMACEUTICALS; ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION/SYMPTOMATIC HEART FAILURE/ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION), SILVERGATE PHARMACEUTICALS","ENALAPED; EPANED; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION), SILVERGATE PHARMACEUTICALS; ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION/SYMPTOMATIC HEART FAILURE/ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION), SILVERGATE PHARMACEUTICALS","ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION/SYMPTOMATIC HEART FAILURE/ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION), SILVERGATE PHARMACEUTICALS",ENALAPED,EPANED,ENALAPRIL,ENALAPRIL MALEATE,"ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION), SILVERGATE PHARMACEUTICALS","ENALAPRIL MALEATE (POWDER FOR ORAL SOLUTION, HYPERTENSION/SYMPTOMATIC HEART FAILURE/ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION), SILVERGATE PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,208686,ENALAPRIL MALEATE,,,,,,,,,,,,,,,,,,,,,2013-08-13T00:00:00Z,2013,8,Epaned Kit,hypertension,ACE INHIBITOR,ANTIHYPERTENSIVE,FORMULATION POWDER; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),204308,NDA,2012-08-09T00:00:00Z,fda,0,0,0,0,0,,silvergate pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204308,352,178,401,98,Essential hypertension,2,0
509,NEBIVOLOL,BYSTOLIC; HYPOLOC; LOBIVON; LOBIVON-PLUS; ME-3255; NEBILET; NEBILOX; R-065824; R-65824; R-67555; DL-NEBIVOLOL; NEBIVOLOL,BYSTOLIC; HYPOLOC; LOBIVON; LOBIVON-PLUS; ME-3255; NEBILET; NEBILOX; R-065824; R-65824; R-67555; DL-NEBIVOLOL; NEBIVOLOL,NEBIVOLOL,BYSTOLIC,HYPOLOC,LOBIVON,LOBIVON-PLUS,ME-3255,NEBILET,NEBILOX,R-065824,R-65824,R-67555,DL-NEBIVOLOL,NEBIVOLOL,,,,,,,,,,,,,,,,,,,21742,NEBIVOLOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2007-12-17T00:00:00Z,2007,12,Bystolic,hypertension,BETA 1 ADRENOCEPTOR ANTAGONIST; BETA 3 ADRENOCEPTOR AGONIST,ANTIHYPERTENSIVE; VASODILATOR,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021742,NDA,2004-04-30T00:00:00Z,fda,0,0,0,0,0,,mylan,NASDAQ: MYL,1,2666,1440.2,1249.1,1270.3,1394.9,1198.1,1118.7,182.9,182.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021742,382,178,401,98,Essential hypertension,2,0
482,"METOPROLOL EXTENDED RELEASE + HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA","DUTOPROL; TOPROL XL/HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA; METOPROLOL + HYDROCHLOROTHIAZIDE; METOPROLOL EXTENDED RELEASE + HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA","DUTOPROL; TOPROL XL/HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA; METOPROLOL + HYDROCHLOROTHIAZIDE; METOPROLOL EXTENDED RELEASE + HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA","METOPROLOL EXTENDED RELEASE + HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA",DUTOPROL,"TOPROL XL/HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA",METOPROLOL + HYDROCHLOROTHIAZIDE,"METOPROLOL EXTENDED RELEASE + HYDROCHLOROTHIAZIDE TABLET (HYPERTENSION), ASTRAZENECA",,,,,,,,,,,,,,,,,,,,,,,,,,,19962,METOPROLOL SUCCINATE,21956,HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE,,,,,,,,,,,,,,,,,,,2006-08-28T00:00:00Z,2006,8,Dutoprol,hypertension,BETA 1 ADRENOCEPTOR ANTAGONIST,ANTIHYPERTENSIVE; DIURETIC AGENT,DRUG COMBINATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021956,NDA,2005-10-28T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,26475,23950,21426,18849,17841,16222,20916,3885,3902,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021956,419,178,401,98,Essential hypertension,2,0
26,ALISKIREN,CGP-60536; CGP-62198; CGP-62198A; CGP60536B; CGS-60536; ENVIAGE; RASILEZ; RAZILEZ; RIPRAZO; SPP-100; SPRIMEO; TEKTURNA; ALISKIREN; ALISKIREN FUMARATE,CGP-60536; CGP-62198; CGP-62198A; CGP60536B; CGS-60536; ENVIAGE; RASILEZ; RAZILEZ; RIPRAZO; SPP-100; SPRIMEO; TEKTURNA; ALISKIREN; ALISKIREN FUMARATE,ALISKIREN,CGP-60536,CGP-62198,CGP-62198A,CGP60536B,CGS-60536,ENVIAGE,RASILEZ,RAZILEZ,RIPRAZO,SPP-100,SPRIMEO,TEKTURNA,ALISKIREN,ALISKIREN FUMARATE,,,,,,,,,,,,,,,,,21985,ALISKIREN HEMIFUMARATE,,,,,,,,,,,,,,,,,,,,,2007-03-05T00:00:00Z,2007,3,Tekturna,hypertension,RENIN INHIBITOR,ANTIARTERIOSCLEROTIC; ANTIHYPERTENSIVE,ORAL FORMULATION; PEPTIDOMIMETIC; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021985,NDA,2006-02-10T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,38947,35105,29753,27277,24930,20877,28342,6430,6430,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021985,425,178,401,98,Essential hypertension,2,0
771,"VALSARTAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS","CVAA-489; COPALIA; DAFIRO; DIOVAN + AMLODIPINE BESYLATE; DIOVAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS; EXFORGE; EXFORGE OD; EXFORGE OD; IMPRIDA; VAA-489; VALSARTAN + AMLODIPINE BESYLATE; VALSARTAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS","CVAA-489; COPALIA; DAFIRO; DIOVAN + AMLODIPINE BESYLATE; DIOVAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS; EXFORGE; EXFORGE OD; EXFORGE OD; IMPRIDA; VAA-489; VALSARTAN + AMLODIPINE BESYLATE; VALSARTAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS","VALSARTAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS",CVAA-489,COPALIA,DAFIRO,DIOVAN + AMLODIPINE BESYLATE,"DIOVAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS",EXFORGE,EXFORGE OD,EXFORGE OD,IMPRIDA,VAA-489,VALSARTAN + AMLODIPINE BESYLATE,"VALSARTAN + AMLODIPINE BESYLATE (ORAL), NOVARTIS",,,,,,,,,,,,,,,,,,,21990,AMLODIPINE BESYLATE; VALSARTAN,,,,,,,,,,,,,,,,,,,,,2007-06-20T00:00:00Z,2007,6,Exforge,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021990,NDA,2006-02-22T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,38947,35105,29753,27277,24930,20877,28342,6430,6430,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021990,427,178,401,98,Essential hypertension,2,0
139,"CARVEDILOL PHOSPHATE (EXTENDED RELEASE, MICROPUMP), GLAXOSMITHKLINE","COREG CR; CARVEDILOL; CARVEDILOL PHOSPHATE; CARVEDILOL PHOSPHATE (EXTENDED RELEASE, MICROPUMP), GLAXOSMITHKLINE","COREG CR; CARVEDILOL; CARVEDILOL PHOSPHATE; CARVEDILOL PHOSPHATE (EXTENDED RELEASE, MICROPUMP), GLAXOSMITHKLINE","CARVEDILOL PHOSPHATE (EXTENDED RELEASE, MICROPUMP), GLAXOSMITHKLINE",COREG CR,CARVEDILOL,CARVEDILOL PHOSPHATE,"CARVEDILOL PHOSPHATE (EXTENDED RELEASE, MICROPUMP), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,22012,CARVEDILOL PHOSPHATE,,,,,,,,,,,,,,,,,,,,,2006-10-20T00:00:00Z,2006,10,Coreg CR,hypertension,ALPHA ADRENOCEPTOR ANTAGONIST; BETA 1 ADRENOCEPTOR ANTAGONIST,ANTIHYPERTENSIVE; CARDIOPROTECTANT,CAPSULE FORMULATION; DAILY DOSING; DRUG COATING; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022012,NDA,2005-12-21T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45499.1,37229.2,38293.2,37593.1,34140.7,29797.2,35684.2,6772.46,6772.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022012,441,178,401,98,Essential hypertension,2,0
538,"OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE  (HYPERTENSION), DAIICHI SANKYO","AZOR; KONVERGE; SEVIKAR; ZOLNOR; OLMESARTAN + AMLODIPINE (HYPERTENSION), DAIICHI SANKYO; OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE (HYPERTENSION), DAIICHI SANKYO","AZOR; KONVERGE; SEVIKAR; ZOLNOR; OLMESARTAN + AMLODIPINE (HYPERTENSION), DAIICHI SANKYO; OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE (HYPERTENSION), DAIICHI SANKYO","OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE  (HYPERTENSION), DAIICHI SANKYO",AZOR,KONVERGE,SEVIKAR,ZOLNOR,"OLMESARTAN + AMLODIPINE (HYPERTENSION), DAIICHI SANKYO",OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE,"OLMESARTAN MEDOXOMIL + AMLODIPINE BESYLATE (HYPERTENSION), DAIICHI SANKYO",,,,,,,,,,,,,,,,,,,,,,,,22100,AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL,,,,,,,,,,,,,,,,,,,,,2007-09-26T00:00:00Z,2007,9,Azor,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022100,NDA,2006-12-08T00:00:00Z,fda,0,0,0,0,0,,daiichi sankyo,TYO: 4568,1,7992.4,8001.4,7189.7,5690.1,5576.1,4795.5,5861.2,1524.5,405.2,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022100,465,178,401,98,Essential hypertension,2,0
29,ALISKIREN + HYDROCHLOROTHIAZIDE,ENVIAGE HCT; RASILEZ D; RASILEZ HCT; RIPRAZO HCT; SPRIMEO HCT; TEKTURNA HCT; ALISKIREN + HYDROCHLOROTHIAZIDE,ENVIAGE HCT; RASILEZ D; RASILEZ HCT; RIPRAZO HCT; SPRIMEO HCT; TEKTURNA HCT; ALISKIREN + HYDROCHLOROTHIAZIDE,ALISKIREN + HYDROCHLOROTHIAZIDE,ENVIAGE HCT,RASILEZ D,RASILEZ HCT,RIPRAZO HCT,SPRIMEO HCT,TEKTURNA HCT,ALISKIREN + HYDROCHLOROTHIAZIDE,,,,,,,,,,,,,,,,,,,,,,,,22107,ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE,,,,,,,,,,,,,,,,,,,,,2008-01-18T00:00:00Z,2008,1,Tekturna HCT,hypertension,RENIN INHIBITOR,ANTIHYPERTENSIVE; DIURETIC AGENT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022107,NDA,2007-03-19T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,42535,38947,35105,29753,27277,24930,31170,6902,7217,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022107,468,178,401,98,Essential hypertension,2,0
155,CLEVIDIPINE,CLEVELOX; CLEVIPREX; H-152/81; H-324/38; CLEVIDIPINE; CLEVIDIPINE BUTYRATE,CLEVELOX; CLEVIPREX; H-152/81; H-324/38; CLEVIDIPINE; CLEVIDIPINE BUTYRATE,CLEVIDIPINE,CLEVELOX,CLEVIPREX,H-152/81,H-324/38,CLEVIDIPINE,CLEVIDIPINE BUTYRATE,,,,,,,,,,,,,,,,,,,,,,,,,22156,CLEVIDIPINE,,,,,,,,,,,,,,,,,,,,,2008-08-01T00:00:00Z,2008,8,Cleviprex,hypertension,CALCIUM CHANNEL INHIBITOR L-TYPE,ANTIHYPERTENSIVE; VASODILATOR,INFUSION; INJECTABLE EMULSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022156,NDA,2007-07-02T00:00:00Z,fda,0,0,0,0,0,,the medicines company,NASDAQ: MDCO,1,348.2,257.5,214,150.2,144.3,85.6,259.8,84.3,84.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022156,481,178,401,98,Essential hypertension,2,0
40,AMLODIPINE BESYLATE + VALSARTAN + HYDROCHLOROTHIAZIDE,"COPALIA HCT; DAFIRO HCT; EJOCIA HCT; EXFORGE HCT; IMPRIDA HCT; AMLODIPINE BESYLATE + VALSARTAN + HYDROCHLOROTHIAZIDE; VALSARTAN + AMLODIPINE BESYLATE + HYDROCHLOROTHIAZIDE (ORAL), NOVARTIS","COPALIA HCT; DAFIRO HCT; EJOCIA HCT; EXFORGE HCT; IMPRIDA HCT; AMLODIPINE BESYLATE + VALSARTAN + HYDROCHLOROTHIAZIDE; VALSARTAN + AMLODIPINE BESYLATE + HYDROCHLOROTHIAZIDE (ORAL), NOVARTIS",AMLODIPINE BESYLATE + VALSARTAN + HYDROCHLOROTHIAZIDE,COPALIA HCT,DAFIRO HCT,EJOCIA HCT,EXFORGE HCT,IMPRIDA HCT,AMLODIPINE BESYLATE + VALSARTAN + HYDROCHLOROTHIAZIDE,"VALSARTAN + AMLODIPINE BESYLATE + HYDROCHLOROTHIAZIDE (ORAL), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,22026,AMLODIPINE BESYLATE,22026,AMLODIPINE BESYLATE,22314,AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN,,,,,,,,,,,,,,,,,2009-04-30T00:00:00Z,2009,4,Exforge HCT,hypertension,ANGIOTENSIN II RECEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE; DIURETIC AGENT,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022314,NDA,2008-06-30T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022314,529,178,401,98,Essential hypertension,2,0
39,AMLODIPINE + TELMISARTAN,"MICAMLO COMBINATION TABLETS AP; MICAMLO COMBINATION TABLETS BP; ONDUARP; TWYNSTA; AMLODIPINE + TELMISARTAN; TELMISARTAN + AMLODIPINE (HYPERTENSION), BOEHRINGER INGELHEIM; TELMISARTAN + AMLODIPINE, GLAXO","MICAMLO COMBINATION TABLETS AP; MICAMLO COMBINATION TABLETS BP; ONDUARP; TWYNSTA; AMLODIPINE + TELMISARTAN; TELMISARTAN + AMLODIPINE (HYPERTENSION), BOEHRINGER INGELHEIM; TELMISARTAN + AMLODIPINE, GLAXO",AMLODIPINE + TELMISARTAN,MICAMLO COMBINATION TABLETS AP,MICAMLO COMBINATION TABLETS BP,ONDUARP,TWYNSTA,AMLODIPINE + TELMISARTAN,"TELMISARTAN + AMLODIPINE (HYPERTENSION), BOEHRINGER INGELHEIM","TELMISARTAN + AMLODIPINE, GLAXO",,,,,,,,,,,,,,,,,,,,,,,,22401,AMLODIPINE BESYLATE; TELMISARTAN,,,,,,,,,,,,,,,,,,,,,2009-10-16T00:00:00Z,2009,10,Twynsta,hypertension,ANGIOTENSIN II AT-1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR,ANTIHYPERTENSIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022401,NDA,2008-12-18T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022401,549,178,401,98,Essential hypertension,2,0
159,"CLONIDINE (ORALXR+ EXTENDED-RELEASE, HYPERTENSION), NEXTWAVE","NAL-8208; NEXICLON XR; CLONIDINE; CLONIDINE (ORALXR+ EXTENDED-RELEASE, HYPERTENSION), NEXTWAVE","NAL-8208; NEXICLON XR; CLONIDINE; CLONIDINE (ORALXR+ EXTENDED-RELEASE, HYPERTENSION), NEXTWAVE","CLONIDINE (ORALXR+ EXTENDED-RELEASE, HYPERTENSION), NEXTWAVE",NAL-8208,NEXICLON XR,CLONIDINE,"CLONIDINE (ORALXR+ EXTENDED-RELEASE, HYPERTENSION), NEXTWAVE",,,,,,,,,,,,,,,,,,,,,,,,,,,22499,CLONIDINE,,,,,,,,,,,,,,,,,,,,,2009-12-03T00:00:00Z,2009,12,Nexiclon XR,hypertension,ALPHA ADRENOCEPTOR AGONIST,ANTIHYPERTENSIVE,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022499,NDA,2009-01-13T00:00:00Z,fda,0,0,0,0,0,,tris pharma,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022499,578,178,401,98,Essential hypertension,2,0
27,"ALISKIREN + AMLODIPINE (ORAL, HYPERTENSION), NOVARTIS","CGP-60536 + AMLODIPINE; CGP60536B + AMLODIPINE; RASILAMLO; RASILEZ + AMLODIPINE; SPA-100; SPP-100 + AMLODIPINE; TEKAMLO; TEKTURNA + AMLODIPINE; ALISKIREN + AMLODIPINE; ALISKIREN + AMLODIPINE (ORAL, HYPERTENSION), NOVARTIS","CGP-60536 + AMLODIPINE; CGP60536B + AMLODIPINE; RASILAMLO; RASILEZ + AMLODIPINE; SPA-100; SPP-100 + AMLODIPINE; TEKAMLO; TEKTURNA + AMLODIPINE; ALISKIREN + AMLODIPINE; ALISKIREN + AMLODIPINE (ORAL, HYPERTENSION), NOVARTIS","ALISKIREN + AMLODIPINE (ORAL, HYPERTENSION), NOVARTIS",CGP-60536 + AMLODIPINE,CGP60536B + AMLODIPINE,RASILAMLO,RASILEZ + AMLODIPINE,SPA-100,SPP-100 + AMLODIPINE,TEKAMLO,TEKTURNA + AMLODIPINE,ALISKIREN + AMLODIPINE,"ALISKIREN + AMLODIPINE (ORAL, HYPERTENSION), NOVARTIS",,,,,,,,,,,,,,,,,,,,,22545,ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE,,,,,,,,,,,,,,,,,,,,,2010-08-26T00:00:00Z,2010,8,Tekamlo,hypertension,CALCIUM CHANNEL INHIBITOR; RENIN INHIBITOR,ANTIARTERIOSCLEROTIC; ANTIHYPERTENSIVE; CARDIAC AGENT,DRUG COMBINATION; ORAL FORMULATION; PEPTIDOMIMETIC; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022545,NDA,2009-10-28T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,51561,45075,42535,38947,35105,29753,37456,8149,9070,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022545,597,178,401,98,Essential hypertension,2,0
160,"CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/DEARMPHARMA","CLONIBID; CLONICEL; CLONIDINE XR; JENLOGA XR; KAPVAY; NAL-8208; CLONIDINE; CLONIDINE (SUSTAINED-RELEASE, ADHD), ADDRENEX; CLONIDINE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), ADDRENEX; CLONIDINE (SUSTAINED-RELEASE, HYPERTENSION), ADDRENEX; CLONIDINE HYDROCHLORIDE; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/ALVOGEN KOREA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/DEARMPHARMA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), CONCORDIA/DEARMPHARMA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), SHIONOGI","CLONIBID; CLONICEL; CLONIDINE XR; JENLOGA XR; KAPVAY; NAL-8208; CLONIDINE; CLONIDINE (SUSTAINED-RELEASE, ADHD), ADDRENEX; CLONIDINE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), ADDRENEX; CLONIDINE (SUSTAINED-RELEASE, HYPERTENSION), ADDRENEX; CLONIDINE HYDROCHLORIDE; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/ALVOGEN KOREA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/DEARMPHARMA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), CONCORDIA/DEARMPHARMA; CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), SHIONOGI","CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/DEARMPHARMA",CLONIBID,CLONICEL,CLONIDINE XR,JENLOGA XR,KAPVAY,NAL-8208,CLONIDINE,"CLONIDINE (SUSTAINED-RELEASE, ADHD), ADDRENEX","CLONIDINE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), ADDRENEX","CLONIDINE (SUSTAINED-RELEASE, HYPERTENSION), ADDRENEX",CLONIDINE HYDROCHLORIDE,"CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/ALVOGEN KOREA","CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD), CONCORDIA/DEARMPHARMA","CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), CONCORDIA/DEARMPHARMA","CLONIDINE HYDROCHLORIDE (SUSTAINED-RELEASE, ADHD/HYPERTENSION), SHIONOGI",,,,,,,,,,,,,,,,22331,CLONIDINE HYDROCHLORIDE,22499,CLONIDINE,,,,,,,,,,,,,,,,,,,2009-09-29T00:00:00Z,2009,9,Jenloga,hypertension,ALPHA 2 ADRENOCEPTOR AGONIST,ANTIHYPERTENSIVE; PSYCHOMODULATOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022331,NDA,2008-02-15T00:00:00Z,fda,0,0,0,0,0,,shionogi,TYO: 4507,1,2677.9,,,,,,1926.6,481.6,481.6,,,2009,,acquired by shionogi in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022331,628,178,401,98,Essential hypertension,2,0
252,"EPTIFIBATIDE FOLLOW-ON BIOLOGIC, USV","EPTIFIBATIDE; EPTIFIBATIDE FOLLOW-ON BIOLOGIC, USV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-11-03T00:00:00Z,2014,11,,myocardial infarction,GP IIB IIIA ANTAGONIST,COAGULATION INHIBITOR; PLATELET AGGREGATION INHIBITOR,BIOLOGICAL THERAPEUTIC; FOLLOW ON BIOLOGICAL PRODUCT; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,using only (2),not identified,not identified,,,,,,,,,USV,private,0,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,656,224,410,100,Acute myocardial infarction,1,0
132,CANGRELOR,AR-C 69931MY; AR-C69931; AR-C69931MX; KENGREAL; KENGREAL; KENGREXAL; KENGREXAL; CANGRELOR; CANGRELOR TETRASODIUM,AR-C 69931MY; AR-C69931; AR-C69931MX; KENGREAL; KENGREAL; KENGREXAL; KENGREXAL; CANGRELOR; CANGRELOR TETRASODIUM,CANGRELOR,AR-C 69931MY,AR-C69931,AR-C69931MX,KENGREAL,KENGREAL,KENGREXAL,KENGREXAL,CANGRELOR,CANGRELOR TETRASODIUM,,,,,,,,,,,,,,,,,,,,,,204958,CANGRELOR,204958,CANGRELOR,,,,,,,,,,,,,,,,,,,2015-06-22T00:00:00Z,2015,6,Kengreal,coronary thrombosis,P2Y12 PURINOCEPTOR ANTAGONIST,PLATELET AGGREGATION INHIBITOR,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204958,NDA,2014-12-23T00:00:00Z,fda,0,0,0,0,0,,the medicines company,NASDAQ: MDCO,1,309,659.7,624.6,558.6,484.7,437.6,192.7,123.6,146.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958,222,1587,411,101,Coronary atherosclerosis and other heart disease,1,0
605,PRASUGREL,AZ-11703072; CS-747; CS-747S; CSS-747; EFFIENT; EFIENT; LY-640315; R-100364; R-100932; R-106583; R-118443; R-119251; R-125690; R-138727; R-95913; R-99224; PRASUGREL; PRASUGREL HYDROCHLORIDE,AZ-11703072; CS-747; CS-747S; CSS-747; EFFIENT; EFIENT; LY-640315; R-100364; R-100932; R-106583; R-118443; R-119251; R-125690; R-138727; R-95913; R-99224; PRASUGREL; PRASUGREL HYDROCHLORIDE,PRASUGREL,AZ-11703072,CS-747,CS-747S,CSS-747,EFFIENT,EFIENT,LY-640315,R-100364,R-100932,R-106583,R-118443,R-119251,R-125690,R-138727,R-95913,R-99224,PRASUGREL,PRASUGREL HYDROCHLORIDE,,,,,,,,,,,,,22307,PRASUGREL HYDROCHLORIDE,22307,PRASUGREL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2009-07-10T00:00:00Z,2009,7,Effient,acute coronary syndrome,P2Y12 PURINOCEPTOR ANTAGONIST,PLATELET AGGREGATION INHIBITOR,FILM COATING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022307,NDA,2007-12-26T00:00:00Z,fda,1,0,0,0,0,,eli lilly,NYSE: LLY,1,21836,20371.9,18633.5,15691,14645.3,13857.9,17589,4326.5,4326.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022307,526,3258,411,101,Coronary atherosclerosis and other heart disease,1,0
734,TICAGRELOR,"AR-C124910XX; AR-C126532; AZD-6140; AXCER; BRILINTA; BRILIQUE; P2T RECEPTOR ANTAGONIST (ARTERIAL THROMBOSIS), ASTRAZENECA; POSSIA; TICAGRELOR","AR-C124910XX; AR-C126532; AZD-6140; AXCER; BRILINTA; BRILIQUE; P2T RECEPTOR ANTAGONIST (ARTERIAL THROMBOSIS), ASTRAZENECA; POSSIA; TICAGRELOR",TICAGRELOR,AR-C124910XX,AR-C126532,AZD-6140,AXCER,BRILINTA,BRILIQUE,"P2T RECEPTOR ANTAGONIST (ARTERIAL THROMBOSIS), ASTRAZENECA",POSSIA,TICAGRELOR,,,,,,,,,,,,,,,,,,,,,,22433,TICAGRELOR,,,,,,,,,,,,,,,,,,,,,2011-07-20T00:00:00Z,2011,7,Brilinta,acute coronary syndrome,P2Y12 PURINOCEPTOR ANTAGONIST,PLATELET AGGREGATION INHIBITOR,FILM COATING; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022433,NDA,2009-11-13T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,33591,33269,32804,31601,29559,26475,27488,4506,5523,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022433,562,3258,411,101,Coronary atherosclerosis and other heart disease,1,0
519,"NITROGLYCERIN (SUBLINGUAL, ANGINA PECTORIS), G POHL-BOSKAMP/ESPERO PHARMACEUTICALS","GONITRO; GONITRO; NITROGLYCERIN; NITROGLYCERIN (SUBLINGUAL, ANGINA PECTORIS), G POHL-BOSKAMP/ESPERO PHARMACEUTICALS","GONITRO; GONITRO; NITROGLYCERIN; NITROGLYCERIN (SUBLINGUAL, ANGINA PECTORIS), G POHL-BOSKAMP/ESPERO PHARMACEUTICALS","NITROGLYCERIN (SUBLINGUAL, ANGINA PECTORIS), G POHL-BOSKAMP/ESPERO PHARMACEUTICALS",GONITRO,GONITRO,NITROGLYCERIN,"NITROGLYCERIN (SUBLINGUAL, ANGINA PECTORIS), G POHL-BOSKAMP/ESPERO PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,18531,NITROGLYCERIN,18531,NITROGLYCERIN,18531,NITROGLYCERIN,208424,NITROGLYCERIN,208424,NITROGLYCERIN,,,,,,,,,,,,,2016-06-08T00:00:00Z,2016,6,GoNitro,angina,,NO AGONIST; VASODILATOR,BUCCAL FORMULATION SYSTEMIC; FORMULATION POWDER; SMALL MOLECULE THERAPEUTIC,matched (3),208424,NDA,2015-08-06T00:00:00Z,fda,0,0,0,0,0,,espero pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208424,342,23,413,101,Coronary atherosclerosis and other heart disease,1,0
622,RANOLAZINE,CVT-303; GS-9668; KEG-1295; LATIXA; RS-43285; RS-43285-193; RANEXA; RANOLAZINE; RANOLAZINE HYDROCHLORIDE,CVT-303; GS-9668; KEG-1295; LATIXA; RS-43285; RS-43285-193; RANEXA; RANOLAZINE; RANOLAZINE HYDROCHLORIDE,RANOLAZINE,CVT-303,GS-9668,KEG-1295,LATIXA,RS-43285,RS-43285-193,RANEXA,RANOLAZINE,RANOLAZINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,21526,RANOLAZINE,,,,,,,,,,,,,,,,,,,,,2006-01-27T00:00:00Z,2006,1,Ranexa,angina,UNSPECIFIED SODIUM CHANNEL INHIBITOR,CLASS I ANTIARRHYTHMIC AGENT,CONTROLLED RELEASE FORMULATION; DAILY DOSING; FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021526,NDA,2002-12-27T00:00:00Z,fda,0,0,0,0,0,,cv therapeutics,NASDAQ: CVTX,1,36.8,19,20.4,11.3,5.3,6.8,-101.2,,135.3,,,,,acquired by gilead sciences in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021526,372,23,413,101,Coronary atherosclerosis and other heart disease,1,0
41,"AMMONIA N-13 INJECTION (CARDIAC PET IMAGING), FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH","AMMONIA N-13 INJECTION (CARDIAC PET IMAGING), FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH","AMMONIA N-13 INJECTION (CARDIAC PET IMAGING), FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH","AMMONIA N-13 INJECTION (CARDIAC PET IMAGING), FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH","AMMONIA N-13 INJECTION (CARDIAC PET IMAGING), FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22119,AMMONIA N-13,,,,,,,,,,,,,,,,,,,,,2007-08-23T00:00:00Z,2007,8,Ammonia N 13,coronary artery disease,,CARDIOVASCULAR DIAGNOSTIC AGENT; PET CONTRAST AGENT; RADIODIAGNOSTIC,IMAGING; INTRAVENOUS FORMULATION; RADIOLABELING,matched (3),022119,NDA,2006-10-16T00:00:00Z,fda,0,0,0,0,0,,feinstein institute for medical research,private,0,,,,,,,,,,,,,,non-profit institution,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022119,474,80,414,101,Coronary atherosclerosis and other heart disease,3,0
627,REGADENOSON,"CVT-2995; CVT-3032; CVT-3033; CVT-3127; CVT-3146; LEXISCAN; RAPISCAN; ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), CV THERAPEUTICS; ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), GILEAD PALO ALTO; REGADENOSON","CVT-2995; CVT-3032; CVT-3033; CVT-3127; CVT-3146; LEXISCAN; RAPISCAN; ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), CV THERAPEUTICS; ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), GILEAD PALO ALTO; REGADENOSON",REGADENOSON,CVT-2995,CVT-3032,CVT-3033,CVT-3127,CVT-3146,LEXISCAN,RAPISCAN,"ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), CV THERAPEUTICS","ADENOSINE A2A AGONISTS (CARDIOVASCULAR DISEASE), GILEAD PALO ALTO",REGADENOSON,,,,,,,,,,,,,,,,,,,,,22161,REGADENOSON,,,,,,,,,,,,,,,,,,,,,2008-04-10T00:00:00Z,2008,4,Lexiscan,coronary artery disease,ADENOSINE A2A RECEPTOR AGONIST,ANTIHYPERTENSIVE; CARDIOVASCULAR DIAGNOSTIC AGENT; IMAGING AGENT; VASODILATOR,IMAGING; INFUSION; INTRAVENOUS FORMULATION; SOLUTION,matched (3),022161,NDA,2007-05-14T00:00:00Z,fda,0,0,0,0,0,,cv therapeutics,NASDAQ: CVTX,1,154.5,82.8,36.8,19,20.4,11.3,60,,75.1,,,,,acquired by gilead sciences in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022161,483,80,414,101,Coronary atherosclerosis and other heart disease,3,0
638,RIVAROXABAN,"BAY-59-7939; FACTOR XA INHIBITOR (THROMBOSIS), BAYER/ ORTHO-MCNEIL; JNJ-39039039; XARELTO; RIVAROXABAN","BAY-59-7939; FACTOR XA INHIBITOR (THROMBOSIS), BAYER/ ORTHO-MCNEIL; JNJ-39039039; XARELTO; RIVAROXABAN",RIVAROXABAN,BAY-59-7939,"FACTOR XA INHIBITOR (THROMBOSIS), BAYER/ ORTHO-MCNEIL",JNJ-39039039,XARELTO,RIVAROXABAN,,,,,,,,,,,,,,,,,,,,,,,,,,22406,RIVAROXABAN,,,,,,,,,,,,,,,,,,,,,2011-07-01T00:00:00Z,2011,7,Xarelto,lung embolism,FACTOR XA ANTAGONIST,ANTI-INFLAMMATORY; ANTIARRHYTHMIC AGENT; COAGULATION INHIBITOR,FILM COATING; FORMULATION POWDER; GRANULE; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022406,NDA,2008-07-28T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,65030,61587,61897,63747,61095,53324,44757,7548,7548,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022406,552,1078,415,103,Pulmonary heart disease,2,0
757,"TREPROSTINIL DIOLAMINE (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS","ORENICELL; ORENICELL; ORENILEFT; ORENILEFT; ORENIPLUS; ORENIPLUS; ORENITRAM; UT-15 (ORAL), UNITED THERAPEUTICS; UT-15C; UT-15C SR; TREPROSTINIL; TREPROSTINIL (ORAL, ENSOTROL), UNITED THERAPEUTICS; TREPROSTINIL (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS; TREPROSTINIL DIETHANOLAMINE; TREPROSTINIL DIOLAMINE; TREPROSTINIL DIOLAMINE (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS","ORENICELL; ORENICELL; ORENILEFT; ORENILEFT; ORENIPLUS; ORENIPLUS; ORENITRAM; UT-15 (ORAL), UNITED THERAPEUTICS; UT-15C; UT-15C SR; TREPROSTINIL; TREPROSTINIL (ORAL, ENSOTROL), UNITED THERAPEUTICS; TREPROSTINIL (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS; TREPROSTINIL DIETHANOLAMINE; TREPROSTINIL DIOLAMINE; TREPROSTINIL DIOLAMINE (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS","TREPROSTINIL DIOLAMINE (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS",ORENICELL,ORENICELL,ORENILEFT,ORENILEFT,ORENIPLUS,ORENIPLUS,ORENITRAM,"UT-15 (ORAL), UNITED THERAPEUTICS",UT-15C,UT-15C SR,TREPROSTINIL,"TREPROSTINIL (ORAL, ENSOTROL), UNITED THERAPEUTICS","TREPROSTINIL (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS",TREPROSTINIL DIETHANOLAMINE,TREPROSTINIL DIOLAMINE,"TREPROSTINIL DIOLAMINE (ORAL, PULMONARY ARTERIAL HYPERTENSION), UNITED THERAPEUTICS",,,,,,,,,,,,,,,203496,TREPROSTINIL DIOLAMINE,,,,,,,,,,,,,,,,,,,,,2013-12-20T00:00:00Z,2013,12,Orenitram,pulmonary artery hypertension,PROSTACYCLIN AGONIST,ANTIHYPERTENSIVE; PLATELET AGGREGATION INHIBITOR; SMOOTH MUSCLE CELL PROLIFERATION INHIBITOR; VASODILATOR,ORAL FORMULATION; ORAL LIQUID FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),203496,NDA,2011-12-23T00:00:00Z,fda,0,0,0,0,0,,united therapeutics,NASDAQ: UTHR,1,1117,916.1,743.2,592.9,358.9,281.5,985.9,299.3,299.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203496,160,3510,416,103,Pulmonary heart disease,1,0
454,MACITENTAN,ACT-064992; ACT-132577; ACTELION-1; OPSUMIT; ZEPENDO; ZEPENDO; APROCITENTAN; MACITENTAN,ACT-064992; ACT-132577; ACTELION-1; OPSUMIT; ZEPENDO; ZEPENDO; APROCITENTAN; MACITENTAN,MACITENTAN,ACT-064992,ACT-132577,ACTELION-1,OPSUMIT,ZEPENDO,ZEPENDO,APROCITENTAN,MACITENTAN,,,,,,,,,,,,,,,,,,,,,,,204410,MACITENTAN,,,,,,,,,,,,,,,,,,,,,2013-10-18T00:00:00Z,2013,10,Opsumit,pulmonary artery hypertension,ENDOTHELIN ET-A ANTAGONIST; ENDOTHELIN ET-B ANTAGONIST,ANTICANCER; ANTIHYPERTENSIVE,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204410,NDA,2012-10-19T00:00:00Z,fda,0,0,0,1,0,,actelion pharmaceuticals,VTX: ATLN,1,2005.3,1887.8,1921.5,2064.6,1712.3,1385,1318.4,,455.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204410,197,3510,416,103,Pulmonary heart disease,1,0
637,RIOCIGUAT,"ADEMPAS; BAY-63-2521; RIOCIGUAT; SGC STIMULATOR (PULMONARY HYPERTENSION), BAYER; SOLUBLE GUANYLATE CYCLASE STIMULATOR (PULMONARY HYPERTENSION), BAYER","ADEMPAS; BAY-63-2521; RIOCIGUAT; SGC STIMULATOR (PULMONARY HYPERTENSION), BAYER; SOLUBLE GUANYLATE CYCLASE STIMULATOR (PULMONARY HYPERTENSION), BAYER",RIOCIGUAT,ADEMPAS,BAY-63-2521,RIOCIGUAT,"SGC STIMULATOR (PULMONARY HYPERTENSION), BAYER","SOLUBLE GUANYLATE CYCLASE STIMULATOR (PULMONARY HYPERTENSION), BAYER",,,,,,,,,,,,,,,,,,,,,,,,,,204819,RIOCIGUAT,,,,,,,,,,,,,,,,,,,,,2013-10-08T00:00:00Z,2013,10,Adempas,chronic thromboembolic pulmonary hypertension,GUANYLATE CYCLASE STIMULATOR,ANTI-INFLAMMATORY; ANTIHYPERTENSIVE; VASODILATOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204819,NDA,2013-02-08T00:00:00Z,fda,1,0,0,1,0,,bayer,ETR: BAYN,1,55301.2,52397.7,47454.4,47050.6,44669.3,45997.3,28539.6,4691.87,4690.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204819,218,3513,416,103,Pulmonary heart disease,1,0
664,SELEXIPAG,"ACT-293987; ACT-333679; ACT-33679; MRE-269; MRE-304; NS-304; PGI2 RECEPTOR AGONIST (PULMONARY HYPERTENSION), ACETLION/NIPPON SHINYAKU; UPTRAVI; PROSTACYCLIN RECEPTOR AGONISTS (VASCULAR DISEASE), NIPPON SHINYAKU; SELEXIPAG","ACT-293987; ACT-333679; ACT-33679; MRE-269; MRE-304; NS-304; PGI2 RECEPTOR AGONIST (PULMONARY HYPERTENSION), ACETLION/NIPPON SHINYAKU; UPTRAVI; PROSTACYCLIN RECEPTOR AGONISTS (VASCULAR DISEASE), NIPPON SHINYAKU; SELEXIPAG",SELEXIPAG,ACT-293987,ACT-333679,ACT-33679,MRE-269,MRE-304,NS-304,"PGI2 RECEPTOR AGONIST (PULMONARY HYPERTENSION), ACETLION/NIPPON SHINYAKU",UPTRAVI,"PROSTACYCLIN RECEPTOR AGONISTS (VASCULAR DISEASE), NIPPON SHINYAKU",SELEXIPAG,,,,,,,,,,,,,,,,,,,,,207947,SELEXIPAG,,,,,,,,,,,,,,,,,,,,,2015-12-21T00:00:00Z,2015,12,Uptravi,pulmonary artery hypertension,IP PROSTANOID RECEPTOR AGONIST; PROSTACYCLIN AGONIST,ANTIHYPERTENSIVE; VASODILATOR,FILM COATING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207947,NDA,2014-12-22T00:00:00Z,fda,0,0,0,1,0,,actelion pharmaceuticals,VTX: ATLN,1,2042.6,1971,2005.3,1887.8,1921.5,2064.6,1403.7,,463.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207947,311,3510,416,103,Pulmonary heart disease,1,0
35,AMBRISENTAN,BSF-208075; BSF-302146; BSF-420627; GSK-1325760A; GSK-132576A; GSK-132576A; LU-208075; LU-208075; LU-302146; LETAIRIS; LETAIRIS; VOLIBRIS; AMBRISENTAN,BSF-208075; BSF-302146; BSF-420627; GSK-1325760A; GSK-132576A; GSK-132576A; LU-208075; LU-208075; LU-302146; LETAIRIS; LETAIRIS; VOLIBRIS; AMBRISENTAN,AMBRISENTAN,BSF-208075,BSF-302146,BSF-420627,GSK-1325760A,GSK-132576A,GSK-132576A,LU-208075,LU-208075,LU-302146,LETAIRIS,LETAIRIS,VOLIBRIS,AMBRISENTAN,,,,,,,,,,,,,,,,,,22081,AMBRISENTAN,,,,,,,,,,,,,,,,,,,,,2007-06-15T00:00:00Z,2007,6,Letairis,pulmonary artery hypertension,ENDOTHELIN ET-A ANTAGONIST,ANTIHYPERTENSIVE; SYNERGIST; VASODILATOR,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022081,NDA,2006-12-13T00:00:00Z,fda,1,0,1,1,0,,gilead sciences,NASDAQ: GILD,1,4230.05,3026.14,2028.4,1324.62,867.864,466.79,3461.27,591.026,591,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022081,461,3510,416,103,Pulmonary heart disease,1,0
756,"TREPROSTINIL (INHALED, SUSTAINED-RELEASE), UNITED THERAPEUTICS/ARADIGM","TYVASO; TYVASO-ILD; TYVASO-ILD; VIVETA; VIVETA; TREPROSTINIL; TREPROSTINIL (AERX), UNITED THERAPEUTICS/ARADIGM; TREPROSTINIL (INHALED, SUSTAINED-RELEASE), UNITED THERAPEUTICS/ARADIGM","TYVASO; TYVASO-ILD; TYVASO-ILD; VIVETA; VIVETA; TREPROSTINIL; TREPROSTINIL (AERX), UNITED THERAPEUTICS/ARADIGM; TREPROSTINIL (INHALED, SUSTAINED-RELEASE), UNITED THERAPEUTICS/ARADIGM","TREPROSTINIL (INHALED, SUSTAINED-RELEASE), UNITED THERAPEUTICS/ARADIGM",TYVASO,TYVASO-ILD,TYVASO-ILD,VIVETA,VIVETA,TREPROSTINIL,"TREPROSTINIL (AERX), UNITED THERAPEUTICS/ARADIGM","TREPROSTINIL (INHALED, SUSTAINED-RELEASE), UNITED THERAPEUTICS/ARADIGM",,,,,,,,,,,,,,,,,,,,,,,22387,TREPROSTINIL,,,,,,,,,,,,,,,,,,,,,2009-07-30T00:00:00Z,2009,7,Tyvaso,pulmonary artery hypertension,PROSTACYCLIN AGONIST,ANTIHYPERTENSIVE; VASODILATOR,INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; SUSTAINED RELEASE FORMULATION,matched (3),022387,NDA,2008-06-27T00:00:00Z,fda,0,0,0,0,0,,united therapeutics,NASDAQ: UTHR,1,358.9,281.5,210.9,159.6,115.9,73.6,318,120.4,120.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022387,544,3510,416,103,Pulmonary heart disease,1,0
251,"EPOPROSTENOL (IMPROVED STABILITY INTRAVENOUS, PULMONARY ARTERIAL HYPERTENSION), ACTELION","ACT-385781A; CARIPUL; EPOPROSTENOL ACT; EPOPROSTENOL FOR INJECTION; VELETRI (EPOPROSTENOL FOR INJECTION); EPOPROSTENOL; EPOPROSTENOL (IMPROVED STABILITY INTRAVENOUS, PULMONARY ARTERIAL HYPERTENSION), ACTELION; EPOPROSTENOL (IMPROVED STABILITY INTRAVENOUS, PULMONARY ARTERIAL HYPERTENSION), ACTELION/SCIDOSE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-06-27T00:00:00Z,2008,6,Veletri,pulmonary artery hypertension,PROSTACYCLIN AGONIST,ANTIHYPERTENSIVE; PLATELET AGGREGATION INHIBITOR; VASODILATOR,FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,using only (2),022260,NDA,2007-08-24T00:00:00Z,fda,0,0,0,0,0,,generamedix,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022260,655,3510,416,103,Pulmonary heart disease,1,0
38,"AMIODARONE (INTRAVENOUS, CAPTISOL-ENABLED, ARRHYTHMIA), PRISM PHARMACEUTICALS","NEXTERONE; NEXTERONE INJECTION; NEXTERONE PREMIXED INJECTION; PM-101, PRISM PHARMACEUTICALS; AMIODARONE; AMIODARONE (INTRAVENOUS, CAPTISOL-ENABLED, ARRHYTHMIA), PRISM PHARMACEUTICALS; AMIODARONE (IV, CAPTISOL-ENABLED, ARRHYTHMIA), BAXTER; AMIODARONE HYDROCHLORIDE; CARDIOVASCULAR AGENT (INTRAVENOUS), BAXTER; CARDIOVASCULAR AGENT (INTRAVENOUS), PRISM PHARMACEUTICALS","NEXTERONE; NEXTERONE INJECTION; NEXTERONE PREMIXED INJECTION; PM-101, PRISM PHARMACEUTICALS; AMIODARONE; AMIODARONE (INTRAVENOUS, CAPTISOL-ENABLED, ARRHYTHMIA), PRISM PHARMACEUTICALS; AMIODARONE (IV, CAPTISOL-ENABLED, ARRHYTHMIA), BAXTER; AMIODARONE HYDROCHLORIDE; CARDIOVASCULAR AGENT (INTRAVENOUS), BAXTER; CARDIOVASCULAR AGENT (INTRAVENOUS), PRISM PHARMACEUTICALS","AMIODARONE (INTRAVENOUS, CAPTISOL-ENABLED, ARRHYTHMIA), PRISM PHARMACEUTICALS",NEXTERONE,NEXTERONE INJECTION,NEXTERONE PREMIXED INJECTION,"PM-101, PRISM PHARMACEUTICALS",AMIODARONE,"AMIODARONE (INTRAVENOUS, CAPTISOL-ENABLED, ARRHYTHMIA), PRISM PHARMACEUTICALS","AMIODARONE (IV, CAPTISOL-ENABLED, ARRHYTHMIA), BAXTER",AMIODARONE HYDROCHLORIDE,"CARDIOVASCULAR AGENT (INTRAVENOUS), BAXTER","CARDIOVASCULAR AGENT (INTRAVENOUS), PRISM PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,21594,AMIODARONE HYDROCHLORIDE,21594,AMIODARONE HYDROCHLORIDE,22325,AMIODARONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,2008-12-24T00:00:00Z,2008,12,Nexterone,ventricular tachycardia,UNSPECIFIED POTASSIUM CHANNEL INHIBITOR,CLASS III ANTIARRHYTHMIC AGENT,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022325,NDA,2008-02-21T00:00:00Z,fda,0,0,0,0,0,,prism pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022325,1,1554,427,106,Cardiac dysrhythmias,2,0
685,"SOTALOL HYDROCHLORIDE (ORAL SOLUTION, PEDIATRIC VENTRICULAR ARRHYTHMIA/ATRIAL FLUTTER/ATRIAL FIBRILLATION), ARBOR PHARMACEUTICALS","SOTYLIZE; SOTALOL; SOTALOL HYDROCHLORIDE; SOTALOL HYDROCHLORIDE (ORAL SOLUTION, PEDIATRIC VENTRICULAR ARRHYTHMIA/ATRIAL FLUTTER/ATRIAL FIBRILLATION), ARBOR PHARMACEUTICALS; SOTALOL HYDROCHLORIDE (PEDIATRIC VENTRICULAR ARRHYTHMIA), ARBOR PHARMACEUTICALS","SOTYLIZE; SOTALOL; SOTALOL HYDROCHLORIDE; SOTALOL HYDROCHLORIDE (ORAL SOLUTION, PEDIATRIC VENTRICULAR ARRHYTHMIA/ATRIAL FLUTTER/ATRIAL FIBRILLATION), ARBOR PHARMACEUTICALS; SOTALOL HYDROCHLORIDE (PEDIATRIC VENTRICULAR ARRHYTHMIA), ARBOR PHARMACEUTICALS","SOTALOL HYDROCHLORIDE (ORAL SOLUTION, PEDIATRIC VENTRICULAR ARRHYTHMIA/ATRIAL FLUTTER/ATRIAL FIBRILLATION), ARBOR PHARMACEUTICALS",SOTYLIZE,SOTALOL,SOTALOL HYDROCHLORIDE,"SOTALOL HYDROCHLORIDE (ORAL SOLUTION, PEDIATRIC VENTRICULAR ARRHYTHMIA/ATRIAL FLUTTER/ATRIAL FIBRILLATION), ARBOR PHARMACEUTICALS","SOTALOL HYDROCHLORIDE (PEDIATRIC VENTRICULAR ARRHYTHMIA), ARBOR PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,205108,SOTALOL HYDROCHLORIDE,22306,SOTALOL HYDROCHLORIDE,22306,SOTALOL HYDROCHLORIDE,22306,SOTALOL HYDROCHLORIDE,22306,SOTALOL HYDROCHLORIDE,,,,,,,,,,,,,2014-10-22T00:00:00Z,2014,10,Sotylize,ventricular arrhythmia,BETA ADRENOCEPTOR ANTAGONIST,ANTIARRHYTHMIC AGENT; CLASS II ANTIARRHYTHMIC AGENT; CLASS III ANTIARRHYTHMIC AGENT,ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205108,NDA,2013-12-23T00:00:00Z,fda,0,0,0,0,0,,arbor pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205108,225,3095,427,106,Cardiac dysrhythmias,2,0
224,DRONEDARONE,MULTAC; MULTAQ; SR-33589; SR-35021; DRONEDARONE,MULTAC; MULTAQ; SR-33589; SR-35021; DRONEDARONE,DRONEDARONE,MULTAC,MULTAQ,SR-33589,SR-35021,DRONEDARONE,,,,,,,,,,,,,,,,,,,,,,,,,,22425,DRONEDARONE HYDROCHLORIDE,22425,DRONEDARONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2009-07-01T00:00:00Z,2009,7,Multaq,atrial fibrillation,ADRENOCEPTOR ANTAGONIST; CALCIUM CHANNEL INHIBITOR; POTASSIUM CHANNEL INHIBITOR; SODIUM CHANNEL INHIBITOR,CARDIAC AGENT; CLASS III ANTIARRHYTHMIC AGENT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022425,NDA,2008-06-27T00:00:00Z,fda,1,0,0,0,0,,sanofi,NYSE: SNY,1,44761,40266.9,42651,38911.4,33775.2,21301.1,33271.2,6629.88,6629.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022425,559,1542,427,106,Cardiac dysrhythmias,2,0
397,IVABRADINE HYDROCHLORIDE,CORALAN; CORAXAN; CORLANOR; CORLANOR; CORLENTOR; LANCORA; LANCORA; ONO-1162; PROCOLARAN; PROCORALAN; S-15544; S-16257; S-16260; S-18982; IVABRADINE; IVABRADINE HYDROCHLORIDE,CORALAN; CORAXAN; CORLANOR; CORLANOR; CORLENTOR; LANCORA; LANCORA; ONO-1162; PROCOLARAN; PROCORALAN; S-15544; S-16257; S-16260; S-18982; IVABRADINE; IVABRADINE HYDROCHLORIDE,IVABRADINE HYDROCHLORIDE,CORALAN,CORAXAN,CORLANOR,CORLANOR,CORLENTOR,LANCORA,LANCORA,ONO-1162,PROCOLARAN,PROCORALAN,S-15544,S-16257,S-16260,S-18982,IVABRADINE,IVABRADINE HYDROCHLORIDE,,,,,,,,,,,,,,,206143,IVABRADINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-04-15T00:00:00Z,2015,4,Corlanor,cardiac failure,HCN POTASSIUM-SODIUM CHANNEL INHIBITOR,SINO-ATRIAL NODE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206143,NDA,2014-06-27T00:00:00Z,fda,1,0,1,0,0,,amgen,NASDAQ: AMGN,1,21662,20063,18676,17265,15582,15053,17487,4006,4160,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206143,271,55,428,108,Congestive heart failure; nonhypertensive,1,0
653,SACUBITRIL + VALSARTAN TRISODIUM HEMIPENTAHYDRATE,"AHU-377 + VALSARTAN TRISODIUM HEMIPENTAHYDRATE; ENTRESTO; ENTRESTO; LCZ-696; LCZ-696A; LCZ-696A; NEPARVIS; NEPARVIS; ANTIHYPERTENSIVE (NEP INHIBITOR), NOVARTIS; SACUBITRIL + VALSARTAN TRISODIUM HEMIPENTAHYDRATE","AHU-377 + VALSARTAN TRISODIUM HEMIPENTAHYDRATE; ENTRESTO; ENTRESTO; LCZ-696; LCZ-696A; LCZ-696A; NEPARVIS; NEPARVIS; ANTIHYPERTENSIVE (NEP INHIBITOR), NOVARTIS; SACUBITRIL + VALSARTAN TRISODIUM HEMIPENTAHYDRATE",SACUBITRIL + VALSARTAN TRISODIUM HEMIPENTAHYDRATE,AHU-377 + VALSARTAN TRISODIUM HEMIPENTAHYDRATE,ENTRESTO,ENTRESTO,LCZ-696,LCZ-696A,LCZ-696A,NEPARVIS,NEPARVIS,"ANTIHYPERTENSIVE (NEP INHIBITOR), NOVARTIS",SACUBITRIL + VALSARTAN TRISODIUM HEMIPENTAHYDRATE,,,,,,,,,,,,,,,,,,,,,207620,SACUBITRIL; VALSARTAN,,,,,,,,,,,,,,,,,,,,,2015-07-07T00:00:00Z,2015,7,Entresto,cardiac failure,ANGIOTENSIN II RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; NEUTRAL ENDOPEPTIDASE INHIBITOR,ANTIHYPERTENSIVE; BNP MODULATOR; CARDIOPROTECTANT; HYPERTENSIVE,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207620,NDA,2014-12-17T00:00:00Z,fda,1,0,1,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207620,304,55,428,108,Congestive heart failure; nonhypertensive,1,0
8,"ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN/ ESPERO","ASACARD; DURLAZA; NHP-544C; NHP-554C; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN/ ESPERO; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), FLAMEL/NEW HAVEN; ASPIRIN; ASPIRIN (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI","ASACARD; DURLAZA; NHP-544C; NHP-554C; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN/ ESPERO; ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), FLAMEL/NEW HAVEN; ASPIRIN; ASPIRIN (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI","ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN/ ESPERO",ASACARD,DURLAZA,NHP-544C,NHP-554C,ACETYLSALICYLIC ACID,"ACETYLSALICYLIC ACID (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI","ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN","ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), AVADEL/NEW HAVEN/ ESPERO","ACETYLSALICYLIC ACID (ORAL CONTROLLED RELEASE, MICROPUMP, CARDIOVASCULAR DISEASE), FLAMEL/NEW HAVEN",ASPIRIN,"ASPIRIN (CONTROLLED RELEASE, MICROPUMP), FLAMEL/RHEI",,,,,,,,,,,,,,,,,,,,200671,ASPIRIN,203697,ASPIRIN,,,,,,,,,,,,,,,,,,,2015-09-04T00:00:00Z,2015,9,Durlaza,cardiovascular disease,CYCLOOXYGENASE INHIBITOR,ANALGESIC; CARDIOVASCULAR AGENT; NON-STEROIDAL ANTI-INFLAMMATORY,CAPSULE FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),200671,NDA,2014-09-05T00:00:00Z,fda,0,0,0,0,0,,new haven pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200671,76,57,429,104,Other and ill-defined heart disease,3,0
690,"SULPHUR HEXAFLUORIDE MICROBUBBLE ULTRASOUND AGENT, BRACCO","BR-1; LUMASON; SF6 MICROBUBBLE ULTRASOUND AGENT, BRACO; SONOVUE; SULFUR HEXAFLUORIDE; SULPHUR HEXAFLUORIDE MICROBUBBLE ULTRASOUND AGENT, BRACCO","BR-1; LUMASON; SF6 MICROBUBBLE ULTRASOUND AGENT, BRACO; SONOVUE; SULFUR HEXAFLUORIDE; SULPHUR HEXAFLUORIDE MICROBUBBLE ULTRASOUND AGENT, BRACCO","SULPHUR HEXAFLUORIDE MICROBUBBLE ULTRASOUND AGENT, BRACCO",BR-1,LUMASON,"SF6 MICROBUBBLE ULTRASOUND AGENT, BRACO",SONOVUE,SULFUR HEXAFLUORIDE,"SULPHUR HEXAFLUORIDE MICROBUBBLE ULTRASOUND AGENT, BRACCO",,,,,,,,,,,,,,,,,,,,,,,,,203684,SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES,,,,,,,,,,,,,,,,,,,,,2014-10-10T00:00:00Z,2014,10,Lumason,cardiovascular disease,,CARDIOVASCULAR DIAGNOSTIC AGENT; GASTROINTESTINAL DIAGNOSTIC AGENT; NEOPLASM DIAGNOSTIC AGENT; ULTRASOUND CONTRAST AGENT,IMAGING; LIPOSOME FORMULATION INJECTABLE; SUSPENSION,matched (3),203684,NDA,2011-12-21T00:00:00Z,fda,0,0,0,0,0,,bracco diagnostics,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203684,168,57,429,104,Other and ill-defined heart disease,3,0
516,"NIMODIPINE (ORAL SOLUTION, SUBARACHNOID HEMORRHAGE), ARBOR PHARMACEUTICALS","AR-02; NYMALIZE; NIMODIPINE; NIMODIPINE (ORAL SOLUTION, SUBARACHNOID HEMORRHAGE), ARBOR PHARMACEUTICALS","AR-02; NYMALIZE; NIMODIPINE; NIMODIPINE (ORAL SOLUTION, SUBARACHNOID HEMORRHAGE), ARBOR PHARMACEUTICALS","NIMODIPINE (ORAL SOLUTION, SUBARACHNOID HEMORRHAGE), ARBOR PHARMACEUTICALS",AR-02,NYMALIZE,NIMODIPINE,"NIMODIPINE (ORAL SOLUTION, SUBARACHNOID HEMORRHAGE), ARBOR PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,203340,NIMODIPINE,,,,,,,,,,,,,,,,,,,,,2013-05-10T00:00:00Z,2013,5,Nymalize,brain hemorrhage,CALCIUM CHANNEL INHIBITOR,NEUROPROTECTANT; VASODILATOR,ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203340,NDA,2012-11-20T00:00:00Z,fda,1,0,1,1,0,,arbor pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203340,152,315,431,109,Acute cerebrovascular disease,1,0
321,GADOFOSVESET,ABLAVAR; ANGIOMARK; MS-325; VASOVIST; ZK-236018; GADOFOSVESET; GADOFOSVESET TRISODIUM,ABLAVAR; ANGIOMARK; MS-325; VASOVIST; ZK-236018; GADOFOSVESET; GADOFOSVESET TRISODIUM,GADOFOSVESET,ABLAVAR,ANGIOMARK,MS-325,VASOVIST,ZK-236018,GADOFOSVESET,GADOFOSVESET TRISODIUM,,,,,,,,,,,,,,,,,,,,,,,,21711,GADOFOSVESET TRISODIUM,,,,,,,,,,,,,,,,,,,,,2008-12-22T00:00:00Z,2008,12,Ablavar,peripheral vascular disease,ALBUMIN MODULATOR,CARDIOVASCULAR DIAGNOSTIC AGENT; ENDOCRINE DIAGNOSTIC AGENT; MRI IMAGING AGENT; NEOPLASM DIAGNOSTIC AGENT,IMAGING; INTRAVENOUS FORMULATION,matched (3),021711,NDA,2008-06-30T00:00:00Z,fda,0,0,0,0,0,,epix pharmaceuticals,NASDAQ: EPIX,1,28.6,15,6,7.2,12.3,13.5,-19.1,,46.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021711,379,260,443,115,Aortic; peripheral; and visceral artery aneurysms,3,0
49,ANTITHROMBIN ALFA,"AT-III, GTC GENZYME/SUMITOMO; ATRYN; ACLOTINE; ANTITHROMBIN ALFA; RHAT-III, GTC BIOTHERAPEUTICS; RHAT-III, REVO BIOLOGICS; TRANSGENIC ANTITHROMBIN III, GTC BIOTHERAPEUTICS; TRANSGENIC ANTITHROMBIN III, GENZYME/SUMITOMO; TRANSGENIC ANTITHROMBIN III, REVO BIOLOGICS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-02-06T00:00:00Z,2009,2,Atryn,thrombosis,ANTITHROMBIN III,ANTI-INFLAMMATORY; ANTIHYPERTENSIVE; ANTIVIRAL; VULNERARY AGENT,BIOLOGICAL THERAPEUTIC; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; TRANSGENIC ANIMAL,using only (2),125284,BLA,2008-02-04T00:00:00Z,cortellis,1,0,1,1,0,,LFB,private,0,538.4,16.7,13.9,6.1,4.2,6.6,236.1,108.8,108.8,2.8,2010-01-03T00:00:00Z,2009,,acquired by LFB in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125284,639,1076,453,118,Phlebitis; thrombophlebitis and thromboembolism,1,0
597,"POLIDOCANOL ENDOVENOUS MICROFOAM (IV, VARICOSIS), BTG","VARISOLVE PEM; VARISOLVE PEM; VARITHENA; POLIDOCANOL; POLIDOCANOL ENDOVENOUS MICROFOAM (IV, VARICOSIS), BTG","VARISOLVE PEM; VARISOLVE PEM; VARITHENA; POLIDOCANOL; POLIDOCANOL ENDOVENOUS MICROFOAM (IV, VARICOSIS), BTG","POLIDOCANOL ENDOVENOUS MICROFOAM (IV, VARICOSIS), BTG",VARISOLVE PEM,VARISOLVE PEM,VARITHENA,POLIDOCANOL,"POLIDOCANOL ENDOVENOUS MICROFOAM (IV, VARICOSIS), BTG",,,,,,,,,,,,,,,,,,,,,,,,,,205098,POLIDOCANOL,,,,,,,,,,,,,,,,,,,,,2013-11-25T00:00:00Z,2013,11,Varithena,varicosis,,UNSPECIFIED DRUG TARGET; VASCULAR AGENT,INJECTABLE EMULSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205098,NDA,2013-02-01T00:00:00Z,fda,0,0,0,0,0,,BTG international,LSE: BTG,1,442.1,376.7,290.2,162.5,162.3,118.6,299.9,72.6,83,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205098,224,741,454,119,Varicose veins of lower extremity,1,0
370,IDARUCIZUMAB,"BI-655075; BI-655075; PRAXBIND; PRAXBIND; PRIZBIND; PRIZBIND; ADABI-FAB; ANTI-DABIGATRAN ANTIBODY (BLOOD CLOTTING DISORDER), BOEHRINGER INGELHEIM; DABIGATRAN ETEXILATE NEUTRALIZER, BOEHRINGER INGELHEIM; DABIGATRAN-NEUTRALIZING FAB, BOEHRINGER INGELHEIM; DABIGATRAN-NEUTRALIZING HUMANIZED ANTIBODY FRAGMENT, BOEHRINGER INGELHEIM; IDARUCIZUMAB","BI-655075; BI-655075; PRAXBIND; PRAXBIND; PRIZBIND; PRIZBIND; ADABI-FAB; ANTI-DABIGATRAN ANTIBODY (BLOOD CLOTTING DISORDER), BOEHRINGER INGELHEIM; DABIGATRAN ETEXILATE NEUTRALIZER, BOEHRINGER INGELHEIM; DABIGATRAN-NEUTRALIZING FAB, BOEHRINGER INGELHEIM; DABIGATRAN-NEUTRALIZING HUMANIZED ANTIBODY FRAGMENT, BOEHRINGER INGELHEIM; IDARUCIZUMAB",IDARUCIZUMAB,BI-655075,BI-655075,PRAXBIND,PRAXBIND,PRIZBIND,PRIZBIND,ADABI-FAB,"ANTI-DABIGATRAN ANTIBODY (BLOOD CLOTTING DISORDER), BOEHRINGER INGELHEIM","DABIGATRAN ETEXILATE NEUTRALIZER, BOEHRINGER INGELHEIM","DABIGATRAN-NEUTRALIZING FAB, BOEHRINGER INGELHEIM","DABIGATRAN-NEUTRALIZING HUMANIZED ANTIBODY FRAGMENT, BOEHRINGER INGELHEIM",IDARUCIZUMAB,,,,,,,,,,,,,,,,,,,761025,IDARUCIZUMAB,,,,,,,,,,,,,,,,,,,,,2015-10-16T00:00:00Z,2015,10,Praxbind,bleeding,,ANTIDOTE; COAGULATION STIMULATOR; UNSPECIFIED DRUG TARGET,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; HUMANIZED ANTIBODY; INFUSION; INTRAVENOUS FORMULATION; SOLUTION,matched (3),761025,BLA,2015-02-19T00:00:00Z,fda,1,1,0,1,1,2014-06-26T00:00:00Z,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761025,618,552,456,121,Other diseases of veins and lymphatics,3,0
163,COAGADEX,"COAGADEX; HUMAN COAGULATION FACTOR X (FACTOR X DEFICIENCY), BPL; PLASMA-DERIVED HUMAN FACTOR X",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-10-20T00:00:00Z,2015,10,Coagadex,bleeding,FACTOR X AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; BLOOD CONSTITUENTS; PARENTERAL FORMULATION UNSPECIFIED; PEPTIDE,using only (2),125506,BLA,2013-07-15T00:00:00Z,cortellis,1,0,1,1,0,,bio products laboratory,private,0,152.3,170.8,159.8,162,143.5,,2.4,,,,,,,owned by bain capital private equity,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125506,649,552,456,121,Other diseases of veins and lymphatics,3,0
286,"FIBRINOGEN + THROMBIN (COLLAGEN PATCH, BLEEDING), TAKEDA/ BAXTER/ HIKMA/ HYUNDAI/ CSL","TACHOCOMB S; TACHOSIL; FIBRINOGEN + THROMBIN; FIBRINOGEN + THROMBIN (COLLAGEN PATCH, BLEEDING), TAKEDA PHARMACEUTICALS INTERNATIONAL; FIBRINOGEN + THROMBIN (COLLAGEN PATCH, BLEEDING), TAKEDA/ BAXTER/ HIKMA/ HYUNDAI/ CSL",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-04-05T00:00:00Z,2010,4,TachoSil,bleeding,FACTOR I STIMULATOR; FACTOR IIA AGONIST,COAGULATION STIMULATOR,DRUG COATING; DRUG COMBINATION; PATCH FORMULATION; PEPTIDE; SMALL MOLECULE THERAPEUTIC; SPONGE FORMULATION; TRANSDERMAL FORMULATION,using only (2),125351,BLA,2009-06-05T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,17491.2,15722.4,16561.7,12303.5,10759.3,10070.7,13730.4,-237.6,3395.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125351,659,552,456,121,Other diseases of veins and lymphatics,3,0
287,"FIBRINOGEN + THROMBIN MICROCAPSULES (HEMORRHAGE), PROFIBRIX/INNOVATA","ATP-201; FIBROCAPS; PRO-0510; PRO-0601; RAPLIXA; RAPLIXA; RAPLIXASPRAY; FIBRIN SEALANT; FIBRINOGEN + THROMBIN; FIBRINOGEN + THROMBIN MICROCAPSULES (HEMORRHAGE), PROFIBRIX/INNOVATA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-04-30T00:00:00Z,2015,4,Raplixa,bleeding,FACTOR I STIMULATOR; FACTOR IIA AGONIST,COAGULATION STIMULATOR,DERMATOLOGICAL FORMULATION; DRUG COMBINATION; FORMULATION POWDER; LOCAL FORMULATION UNSPECIFIED; MICROCAPSULE FORMULATION; ORAL FORMULATION; POWDER FORMULATION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,using only (2),125523,BLA,2014-04-03T00:00:00Z,cortellis,0,0,0,0,0,,the medicines company,NASDAQ: MDCO,1,309,659.7,624.6,,,,192.7,123.6,146.1,,,2013,,acquired by medicines co in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125523,660,552,456,121,Other diseases of veins and lymphatics,3,0
354,"HUMAN THROMBIN (FROZEN, SURGICAL BLEEDING), OMRIX","EVITHROM; HUMAN THROMBIN (FROZEN, SURGICAL BLEEDING), OMRIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-08-27T00:00:00Z,2007,8,Evithrom,bleeding,FACTOR IIA AGONIST,COAGULATION STIMULATOR,BIOLOGICAL THERAPEUTIC; LIQUID-BASED FORMULATION TECHNOLOGY; LOCAL FORMULATION UNSPECIFIED; PEPTIDE; TRANSDERMAL FORMULATION,using only (2),125217,BLA,2006-11-06T00:00:00Z,cortellis,0,0,0,0,0,,OMRIX biopharmaceuticals,NASDAQ: OMRI,1,61.7,63.8,27.5,19.9,14.9,12.2,24,4.5,4.5,,,,,acquired by J&J in 2008; publicly traded as of 2007,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125217,684,552,456,121,Other diseases of veins and lymphatics,3,0
731,"THROMBIN + FIBRINOGEN MATRIX PATCH (SURGICAL BLEEDING), OMRIX/ETHICON","BIOLOGICAL HEMOSTATIC DRESSING; EVARREST; FIBRIN FLEECE; FIBRIN PAD; FIBRIN PATCH; FLEECE FIBRIN PATCH; FIBRIN MATRIX PATCH (SURGICAL BLEEDING), OMRIX/ETHICON; FIBRINOGEN + THROMBIN; FIBRINOGEN, OMRIX/ETHICON; THROMBIN + FIBRINOGEN MATRIX PATCH (SURGICAL BLEEDING), OMRIX/ETHICON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-12-05T00:00:00Z,2012,12,Evarrest,bleeding,FACTOR IIA AGONIST; FACTOR IA AGONIST,COAGULATION STIMULATOR,GLYCOPROTEIN; MATRIX FORMULATION; PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,using only (2),125392,BLA,2010-11-19T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,67224,65030,61587,61897,63747,61095,45566,7665,7665,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125392,724,552,456,121,Other diseases of veins and lymphatics,3,0
733,THROMBIN ALFA,"RECOTHROM; THROMBIN (SYNTHETIC HUMAN); HUMAN THROMBIN (RECOMBINANT, GLYCOSYLATED); RTHROMBIN; RH THROMBIN, ZYMOGENETICS; RHTHROMBIN; THROMBIN ALFA; THROMBIN, ZYMOGENETICS; THROMBIN, TOPICAL (RECOMBINANT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-01-17T00:00:00Z,2008,1,Recothrom,bleeding,COAGULATION FACTOR AGONIST; FACTOR IIA AGONIST; PLATELET ACTIVATING FACTOR RECEPTOR AGONIST,COAGULATION STIMULATOR; HEMOSTASIS PATHWAY MODULATOR,BIOLOGICAL THERAPEUTIC; DERMATOLOGICAL FORMULATION; FORMULATION POWDER; FREEZE DRYING; LOCAL FORMULATION UNSPECIFIED; PROTEIN RECOMBINANT; TRANSDERMAL FORMULATION,using only (2),125248,BLA,2006-12-15T00:00:00Z,fda,0,0,0,0,0,,zymogenetics,NASDAQ: ZGEN,1,74,38.5,25.4,42.9,35.7,26,-58.4,,139.1,,,,,acquired by BMS in 2010,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125248,725,552,456,121,Other diseases of veins and lymphatics,3,0
225,DROXIDOPA,"DOPS; L-DOPS; L-THREO DOPS; L-DIHYDROXYPHENYLSERINE; L-THREO-3,4-DIHYDROXYPHENYLSERINE; NORTHERA; SM-5688; DROXIDOPA; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA/ SUMITOMO; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), H LUNDBECK A/S","DOPS; L-DOPS; L-THREO DOPS; L-DIHYDROXYPHENYLSERINE; L-THREO-3,4-DIHYDROXYPHENYLSERINE; NORTHERA; SM-5688; DROXIDOPA; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA/ SUMITOMO; SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), H LUNDBECK A/S",DROXIDOPA,DOPS,L-DOPS,L-THREO DOPS,L-DIHYDROXYPHENYLSERINE,"L-THREO-3,4-DIHYDROXYPHENYLSERINE",NORTHERA,SM-5688,DROXIDOPA,"SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA","SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), CHELSEA/ SUMITOMO","SYNTHETIC PRECURSOR OF NOREPINEPHRINE (PARKINSON'S DISEASE, HYPOTENSION, FIBROMYALGIA), H LUNDBECK A/S",,,,,,,,,,,,,,,,,,,,203202,DROXIDOPA,,,,,,,,,,,,,,,,,,,,,2014-02-18T00:00:00Z,2014,2,Northera,orthostatic hypotension,ALPHA ADRENOCEPTOR AGONIST,HYPERTENSIVE; VASOCONSTRICTOR,CAPSULE FORMULATION; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),203202,NDA,2011-09-23T00:00:00Z,fda,1,1,1,1,0,,lundbeck,CPH: LUN,1,2189,,,,,,1512.9,437.1,473.1,,,2014,,acquired by lundbeck in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203202,145,1836,458,117,Other circulatory disease,2,0
591,"PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS","VAZCULEP; PHENYLEPHRINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS; PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES","VAZCULEP; PHENYLEPHRINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS; PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES","PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS",VAZCULEP,PHENYLEPHRINE HYDROCHLORIDE,"PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS","PHENYLEPHRINE HYDROCHLORIDE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES",,,,,,,,,,,,,,,,,,,,,,,,,,,203510,PHENYLEPHRINE HYDROCHLORIDE,203510,PHENYLEPHRINE HYDROCHLORIDE,203510,PHENYLEPHRINE HYDROCHLORIDE,203510,PHENYLEPHRINE HYDROCHLORIDE,204300,PHENYLEPHRINE HYDROCHLORIDE,,,,,,,,,,,,,2014-06-27T00:00:00Z,2014,6,Vazculep,hypotension,ALPHA 1 ADRENOCEPTOR AGONIST,HYPERTENSIVE,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204300,NDA,2013-02-08T00:00:00Z,fda,0,0,0,0,0,,avadel,NASDAQ: FLML,1,15,4.2,7.5,,,,-5.7,,17.3,,,2012,,"acquired by Flamel tech, now Avadel, in 2012",,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204300,191,408,458,117,Other circulatory disease,2,0
56,"ARGIPRESSIN  (INJECTION), PAR PHARMACEUTICAL","8-L-ARGININE VASOPRESSIN; VASOSTRICT; ARGIPRESSIN; ARGIPRESSIN (INJECTION), PAR PHARMACEUTICAL; VASOPRESSIN (INJECTION), PAR PHARMACEUTICAL; VASOPRESSIN HUMAN","8-L-ARGININE VASOPRESSIN; VASOSTRICT; ARGIPRESSIN; ARGIPRESSIN (INJECTION), PAR PHARMACEUTICAL; VASOPRESSIN (INJECTION), PAR PHARMACEUTICAL; VASOPRESSIN HUMAN","ARGIPRESSIN  (INJECTION), PAR PHARMACEUTICAL",8-L-ARGININE VASOPRESSIN,VASOSTRICT,ARGIPRESSIN,"ARGIPRESSIN (INJECTION), PAR PHARMACEUTICAL","VASOPRESSIN (INJECTION), PAR PHARMACEUTICAL",VASOPRESSIN HUMAN,,,,,,,,,,,,,,,,,,,,,,,,,204485,VASOPRESSIN,,,,,,,,,,,,,,,,,,,,,2014-04-17T00:00:00Z,2014,4,Vasostrict,hypotension,VASOPRESSIN RECEPTOR AGONIST,HYPERTENSIVE; VASOCONSTRICTOR,BIOLOGICAL THERAPEUTIC; INTRAVENOUS FORMULATION; PEPTIDE,matched (3),204485,NDA,2012-09-25T00:00:00Z,fda,0,0,0,0,0,,par pharmaceuticals,private,0,1308.6,1097.5,1050,926.1,1008.9,1193.2,673.8,119.1,119.1,,,,,publicly traded as NYSE: PRX until 2012,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204485,203,408,458,117,Other circulatory disease,2,0
249,"EPHEDRINE SULFATE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS","AKOVAZ; AKOVAZ; EPHEDRINE SULFATE; EPHEDRINE SULFATE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS; EPHEDRINE SULFATE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES","AKOVAZ; AKOVAZ; EPHEDRINE SULFATE; EPHEDRINE SULFATE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS; EPHEDRINE SULFATE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES","EPHEDRINE SULFATE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS",AKOVAZ,AKOVAZ,EPHEDRINE SULFATE,"EPHEDRINE SULFATE (IV, HYPOTENSION), AVADEL PHARMACEUTICALS","EPHEDRINE SULFATE (IV, HYPOTENSION), FLAMEL TECHNOLOGIES",,,,,,,,,,,,,,,,,,,,,,,,,,208289,EPHEDRINE SULFATE,208289,EPHEDRINE SULFATE,208609,EPHEDRINE SULFATE,208609,EPHEDRINE SULFATE,208609,EPHEDRINE SULFATE,208609,EPHEDRINE SULFATE,,,,,,,,,,,2016-04-29T00:00:00Z,2016,4,Akovaz,hypotension,ALPHA ADRENOCEPTOR AGONIST; BETA ADRENOCEPTOR AGONIST,HYPERTENSIVE,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208289,NDA,2015-06-30T00:00:00Z,fda,0,0,0,0,0,,avadel,NASDAQ: AVDL,1,150.2,173,15,4.2,7.5,32.6,102.4,,34.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208289,336,408,458,117,Other circulatory disease,2,0
358,HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE + PSEUDOEPHEDRINE HYDROCHLORIDE,ZUTRIPRO; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE + PSEUDOEPHEDRINE HYDROCHLORIDE,ZUTRIPRO; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE + PSEUDOEPHEDRINE HYDROCHLORIDE,HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE + PSEUDOEPHEDRINE HYDROCHLORIDE,ZUTRIPRO,HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE + PSEUDOEPHEDRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22439,CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-06-08T00:00:00Z,2011,6,Zutripro,common cold,ALPHA ADRENOCEPTOR AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST,ANTITUSSIVE; ANTIVIRAL,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022439,NDA,2008-11-06T00:00:00Z,fda,0,0,0,0,0,,cypress pharmaceutical,private,0,52.8,47.4,,,,,31.5,3.3,3.3,,,,,acquired by pernix in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022439,564,517,460,126,Other upper respiratory infections,1,0
42,"AMOXICILLIN (PULSATILE FORMULATION), SHIONOGI","APC-111; MOXATAG; AMOXICILLIN; AMOXICILLIN (PULSYS), ADVANCIS/PAR; AMOXICILLIN (PULSYS), MIDDLEBROOK/PAR; AMOXICILLIN (EXTENDED-RELEASE TABLETS), MIDDLEBROOK; AMOXICILLIN (PULSATILE FORMULATION), ADVANCIS/PAR; AMOXICILLIN (PULSATILE FORMULATION), SHIONOGI; AMOXICILLIN (PULSATILE FORMULATION), VICTORY PHARMA; AMOXICILLIN PULSYS","APC-111; MOXATAG; AMOXICILLIN; AMOXICILLIN (PULSYS), ADVANCIS/PAR; AMOXICILLIN (PULSYS), MIDDLEBROOK/PAR; AMOXICILLIN (EXTENDED-RELEASE TABLETS), MIDDLEBROOK; AMOXICILLIN (PULSATILE FORMULATION), ADVANCIS/PAR; AMOXICILLIN (PULSATILE FORMULATION), SHIONOGI; AMOXICILLIN (PULSATILE FORMULATION), VICTORY PHARMA; AMOXICILLIN PULSYS","AMOXICILLIN (PULSATILE FORMULATION), SHIONOGI",APC-111,MOXATAG,AMOXICILLIN,"AMOXICILLIN (PULSYS), ADVANCIS/PAR","AMOXICILLIN (PULSYS), MIDDLEBROOK/PAR","AMOXICILLIN (EXTENDED-RELEASE TABLETS), MIDDLEBROOK","AMOXICILLIN (PULSATILE FORMULATION), ADVANCIS/PAR","AMOXICILLIN (PULSATILE FORMULATION), SHIONOGI","AMOXICILLIN (PULSATILE FORMULATION), VICTORY PHARMA",AMOXICILLIN PULSYS,,,,,,,,,,,,,,,,,,,,,50813,AMOXICILLIN,,,,,,,,,,,,,,,,,,,,,2008-01-23T00:00:00Z,2008,1,Moxatag,pharyngitis,BETA LACTAMASE INHIBITOR,ANTIBACTERIAL,ANTIBIOTIC; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),050813,NDA,2007-03-23T00:00:00Z,fda,0,0,0,0,0,,middlebrook pharmaceuticals,NASDAQ: MBRK,1,8.8,10.5,4.8,16.8,11.4,3.6,7.2,11.3,19.1,,,,,filed for bankruptcy in 2010,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050813,616,453,462,126,Other upper respiratory infections,1,0
74,"AZELASTINE + FLUTICASONE (NASAL SPRAY, ALLERGIC RHINITIS), MEDA/CIPLA","AZECORT; DYLASTINE; DYMISTA; MP-2902; MP-AZEFLU; AZELASTINE + FLUTICASONE; AZELASTINE + FLUTICASONE (NASAL SPRAY, ALLERGIC RHINITIS), MEDA/CIPLA; AZELASTINE HYDROCHLORIDE + FLUTICASONE PROPIONATE","AZECORT; DYLASTINE; DYMISTA; MP-2902; MP-AZEFLU; AZELASTINE + FLUTICASONE; AZELASTINE + FLUTICASONE (NASAL SPRAY, ALLERGIC RHINITIS), MEDA/CIPLA; AZELASTINE HYDROCHLORIDE + FLUTICASONE PROPIONATE","AZELASTINE + FLUTICASONE (NASAL SPRAY, ALLERGIC RHINITIS), MEDA/CIPLA",AZECORT,DYLASTINE,DYMISTA,MP-2902,MP-AZEFLU,AZELASTINE + FLUTICASONE,"AZELASTINE + FLUTICASONE (NASAL SPRAY, ALLERGIC RHINITIS), MEDA/CIPLA",AZELASTINE HYDROCHLORIDE + FLUTICASONE PROPIONATE,,,,,,,,,,,,,,,,,,,,,,,202236,AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE,,,,,,,,,,,,,,,,,,,,,2012-05-01T00:00:00Z,2012,5,Dymista,seasonal allergic rhinitis,HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE C4 ANTAGONIST,ANTI-INFLAMMATORY; CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; DRUG COMBINATION; NASAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; STEROID; SUSPENSION,matched (3),202236,NDA,2011-04-01T00:00:00Z,fda,0,0,0,0,0,,meda pharmaceuticals,STO: MEDAA,1,1995.1,1872.7,1721.9,1842.8,1360.7,1259.1,1221,400.7,400.7,,,,,acquired by mylan in 2016,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202236,106,3202,477,134,Other upper respiratory disease,2,0
83,"BECLOMETHASONE DIPROPIONATE  (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA","BDP NASAL HFA; BDP NASAL HFA; BDP-HFA; QNASL; QNASL NASAL AEROSOL; QNASL NASAL AEROSOL; QNAZE; BECLOMETASONE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA; BECLOMETHASONE DIPROPIONATE; BECLOMETHASONE DIPROPIONATE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA; BECLOMETHASONE DIPROPIONATE (INTRANASAL, ALLERGIC RHINITIS), TEVA","BDP NASAL HFA; BDP NASAL HFA; BDP-HFA; QNASL; QNASL NASAL AEROSOL; QNASL NASAL AEROSOL; QNAZE; BECLOMETASONE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA; BECLOMETHASONE DIPROPIONATE; BECLOMETHASONE DIPROPIONATE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA; BECLOMETHASONE DIPROPIONATE (INTRANASAL, ALLERGIC RHINITIS), TEVA","BECLOMETHASONE DIPROPIONATE  (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA",BDP NASAL HFA,BDP NASAL HFA,BDP-HFA,QNASL,QNASL NASAL AEROSOL,QNASL NASAL AEROSOL,QNAZE,"BECLOMETASONE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA",BECLOMETHASONE DIPROPIONATE,"BECLOMETHASONE DIPROPIONATE (WATERLESS NASAL SPRAY, ALLERGIC RHINITIS), TEVA","BECLOMETHASONE DIPROPIONATE (INTRANASAL, ALLERGIC RHINITIS), TEVA",,,,,,,,,,,,,,,,,,,,202813,BECLOMETHASONE DIPROPIONATE,,,,,,,,,,,,,,,,,,,,,2012-03-23T00:00:00Z,2012,3,Qnasl,seasonal allergic rhinitis,GLUCOCORTICOID AGONIST,STEROIDAL ANTI-INFLAMMATORY,FORMULATION AEROSOL; NASAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),202813,NDA,2011-05-24T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,20317,18312,16121,13899,11085,9408,10715,1356,1283,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202813,132,3202,477,134,Other upper respiratory disease,2,0
541,"OLOPATADINE (NASAL SPRAY), ALCON","PATANASE; OLOPATADINE; OLOPATADINE (NASAL SPRAY), ALCON; OLOPATADINE HYDROCHLORIDE","PATANASE; OLOPATADINE; OLOPATADINE (NASAL SPRAY), ALCON; OLOPATADINE HYDROCHLORIDE","OLOPATADINE (NASAL SPRAY), ALCON",PATANASE,OLOPATADINE,"OLOPATADINE (NASAL SPRAY), ALCON",OLOPATADINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,,21861,OLOPATADINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2008-04-15T00:00:00Z,2008,4,Patanase,seasonal allergic rhinitis,HISTAMINE H1 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; NASAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),021861,NDA,2004-12-24T00:00:00Z,fda,0,0,0,0,0,,alcon,NYSE: ACL,1,6294,5599,4896.6,4368.5,3913.6,3406.9,48.19,619,635,,,,,acquired by novartis in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021861,396,3202,477,134,Other upper respiratory disease,2,0
151,"CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SUNOVION","OMNAIR; OMNARIS; OMNARIS HFA; OMNARIS NASAL SPRAY; TBN-15; ZETONNA; CICLESONIDE; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SEPRACOR; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SUNOVION; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/TEIJIN/SUNOVION","OMNAIR; OMNARIS; OMNARIS HFA; OMNARIS NASAL SPRAY; TBN-15; ZETONNA; CICLESONIDE; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SEPRACOR; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SUNOVION; CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/TEIJIN/SUNOVION","CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SUNOVION",OMNAIR,OMNARIS,OMNARIS HFA,OMNARIS NASAL SPRAY,TBN-15,ZETONNA,CICLESONIDE,"CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SEPRACOR","CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/SUNOVION","CICLESONIDE (NASAL/AEROSOL FORMULATION), ALTANA/TEIJIN/SUNOVION",,,,,,,,,,,,,,,,,,,,,202129,CICLESONIDE,22004,CICLESONIDE,,,,,,,,,,,,,,,,,,,2006-10-20T00:00:00Z,2006,10,Omnaris,allergic rhinitis,,CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY,FORMULATION AEROSOL; NASAL FORMULATION LOCAL; PRODRUG; SMALL MOLECULE THERAPEUTIC; STEROID; SUSPENSION,matched (3),022004,NDA,2005-12-21T00:00:00Z,fda,0,0,0,0,0,,altana,FWB: ALT,1,1707.8,1074.1,4011.4,3446.9,2735.9,2054.9,632.3,89.3,89.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022004,437,1107,477,134,Other upper respiratory disease,2,0
307,"FLUTICASONE FUROATE (NASAL, ALLERGIC RHINITIS), GSK","685698; ALLERMIST; AVAMYS; GW-685698; GW-685698X; VERAMYST; FLUTICASONE FUROATE; FLUTICASONE FUROATE (NASAL, ALLERGIC RHINITIS), GSK",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-04-27T00:00:00Z,2007,4,Flonase,allergic rhinitis,GLUCOCORTICOID AGONIST,ANTI-INFLAMMATORY; RESPIRATORY SYSTEM AGENT,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; MICROPARTICLE FORMULATION; NASAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; STEROID; SUSPENSION,using only (2),022051,NDA,2006-06-15T00:00:00Z,cortellis,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,45147.6,45499.1,37229.2,38293.2,37593.1,34140.7,34800.8,6433.47,6612.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022051,663,1107,477,134,Other upper respiratory disease,2,0
338,"GRASS-POLLEN ALLERGEN IMMUNOTHERAPY (SUBLINGUAL TABLET), STALLERGENES/PALADIN LABS/GREER LAB","ORALAIR; ORALAIR GRASSES; SLIT (GRASS POLLEN ALLERGY), STALLERGENES/PALADIN LABS; GRASS-POLLEN ALLERGEN IMMUNOTHERAPY (SUBLINGUAL TABLET), STALLERGENES/PALADIN LABS/GREER LAB",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-04-01T00:00:00Z,2014,4,Oralair,allergic rhinitis,,ALLERGEN; ANTI-INFLAMMATORY; THERAPEUTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; PEPTIDE; TABLET FORMULATION,using only (2),125471,BLA,2012-12-18T00:00:00Z,fda,0,0,0,0,0,,stallergenes,private,0,304.2,341.7,316.2,301.8,290.3,276.6,233.7,31.8,56.1,,,,,IPO in 2015,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125471,672,1107,477,134,Other upper respiratory disease,2,0
339,GRAZAX,"ALK GRASS TABLET; GRASTEK; GRAZAX; MK-7243; SCH-697243; BIOLOGICAL GRASS POLLEN ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO; BIOLOGICAL GRASS POLLEN ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO/SCHERING-PLOUGH; GRASS AIT; GRASS POLLEN ALLERGY DESENSITIZATION TABLET, ALK-ABELLO; GRASS POLLEN ALLERGY DESENSITIZATION TABLET, ALK-ABELLO/SCHERING-PLOUGH; IMMUNOTHERAPY (GRASS POLLEN), ALK-ABELLO/SCHERING-PLOUGH; SUBLINGUAL TABLET-BASED IMMUNOTHERAPY (GRASS POLLEN ALLERGIES), SCHERING-PLOUGH/ALK-ABELLO",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-04-11T00:00:00Z,2014,4,Grastek,seasonal allergic rhinitis,,ALLERGEN; ANTI-INFLAMMATORY; IMMUNOMODULATOR; PROPHYLACTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; BUCCAL FORMULATION SYSTEMIC; NATURAL PRODUCT; ORAL FORMULATION; QUICK RELEASE FORMULATION; TABLET FORMULATION,using only (2),125473,BLA,2013-01-25T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125473,673,3202,477,134,Other upper respiratory disease,2,0
495,MITIZAX,"ACARIZAX; ALK HDM SLIT-DROPS; ALK HDM SLIT-TABLET; ALK HDM TABLET; AVANZ MITE MIX; HDM AIT; HDM SLIT-TABLET; MITICURE; MK-8237; MITIZAX; ODACTRA; SCH-900237; SLITONE ULTRA HDM; TO-203; ALLERGY IMMUNOTHERAPY TABLET (DUST MITE ALLERGIES), MERCK & CO/ALK ABELLO; ALLERGY IMMUNOTHERAPY TABLET (DUST MITE ALLERGIES), MERCK & CO/ALK ABELLO/TORII; ALLERGY IMMUNOTHERAPY TABLET (DUST MITE ALLERGIES), SCHERING-PLOUGH/ALK-ABELLO; BIOLOGICAL HOUSE DUST MITE ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO; BIOLOGICAL HOUSE DUST MITE ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO/SCHERING-PLOUGH; HOUSE DUST MITE ALLERGY DESENSITIZATION TABLET, ALK-ABELLO; HOUSE DUST MITE ALLERGY DESENSITIZATION TABLET, ALK-ABELLO/SCHERING-PLOUGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2017-03-01T00:00:00Z,2017,3,Odactra,allergic rhinitis,,ALLERGEN; ANTI-INFLAMMATORY; IMMUNOMODULATOR; THERAPEUTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; BUCCAL FORMULATION SYSTEMIC; DAILY DOSING; ORAL FORMULATION; PEPTIDE; QUICK RELEASE FORMULATION; SOLUTION; TABLET FORMULATION,using only (2),125592,BLA,2016-02-09T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,37736,39807,39498,42237,44033,47267,26232,7184,7184,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125592,699,1107,477,134,Other upper respiratory disease,2,0
497,MK-3641,"AIT (RAGWEED ALLERGY), SCHERING-PLOUGH/ALK-ABELLO; ALK RAGWEED TABLET; AMB-A-1-U; MK-3641; RAGWEED AIT; RAGWITEK; SCH-039641; SCH-39641; ALLERGY IMMUNOTHERAPY TABLET (RAGWEED ALLERGIES), MERCK & CO/ALK ABELLO; ALLERGY IMMUNOTHERAPY TABLET (RAGWEED ALLERGIES), SCHERING-PLOUGH/ALK-ABELLO; BIOLOGICAL RAGWEED ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO; BIOLOGICAL RAGWEED ALLERGEN (SUBLINGUAL, ZYDIS), ALK-ABELLO/SCHERING-PLOUGH; RAGWEED ALLERGY DESENSITIZATION TABLET, ALK-ABELLO; RAGWEED ALLERGY DESENSITIZATION TABLET, ALK-ABELLO/SCHERING-PLOUGH",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-04-17T00:00:00Z,2014,4,Ragwitek,seasonal allergic rhinitis,,ALLERGEN; IMMUNOMODULATOR; PROPHYLACTIC VACCINE,ANTIGEN; BIOLOGICAL THERAPEUTIC; BUCCAL FORMULATION SYSTEMIC; NATURAL PRODUCT; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; TABLET FORMULATION,using only (2),125478,BLA,2013-03-11T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125478,700,3202,477,134,Other upper respiratory disease,2,0
607,PREVNAR 13,"11VPNC, PFIZER; 11VPNC, WYETH-LEDERLE; 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, PFIZER; 13VPNC, PFIZER; 13VPNC, WYETH-LEDERLE; PCV-13; PF-05208760; PREVENAR 13; PREVNAR 13; PREVNAR 13 ADULT; PREVNAR 13 INFANT; MULTIVALENT PNEUMOCOCCAL VACCINES, WYETH; MULTIVALENT PNEUMOCOCCAL VACCINES, WYETH-LEDERLE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-02-24T00:00:00Z,2010,2,Prevnar 13,streptococcus pneumoniae infection,,ANTI-INFLAMMATORY; PROPHYLACTIC VACCINE; SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PROTEIN CONJUGATED; SUSPENSION,using only (2),125324,BLA,2009-03-31T00:00:00Z,fda,1,0,1,0,0,,pfizer,NYSE: PFE,1,65165,49269,22833.9,22399.8,20350.7,18755.8,17358,9431,8681,22144.2,2009-06-30T00:00:00Z,2009,,acquired by Pfizer in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125324,710,313,482,122,Pneumonia (except that caused by tuberculosis or sexually transmitted disease),1,0
583,"PERAMIVIR (INTRAVENOUS, INFLUENZA VIRUS INFECTION), UNIVERSITY OF ALABAMA/BIOCRYST","ALPIVAB; ALPIVAB; PERAMIFLU; PERAMIFLU; RAPIACTA; RAPIVAB; RAPIVAB; S-021812; S-021812; S-021812 (IV, INFLUENZA VIRUS INFECTION), SHIONOGI; PERAMIVIR; PERAMIVIR (USAN); PERAMIVIR (INTRAVENOUS, INFLUENZA VIRUS INFECTION), UNIVERSITY OF ALABAMA/BIOCRYST","ALPIVAB; ALPIVAB; PERAMIFLU; PERAMIFLU; RAPIACTA; RAPIVAB; RAPIVAB; S-021812; S-021812; S-021812 (IV, INFLUENZA VIRUS INFECTION), SHIONOGI; PERAMIVIR; PERAMIVIR (USAN); PERAMIVIR (INTRAVENOUS, INFLUENZA VIRUS INFECTION), UNIVERSITY OF ALABAMA/BIOCRYST","PERAMIVIR (INTRAVENOUS, INFLUENZA VIRUS INFECTION), UNIVERSITY OF ALABAMA/BIOCRYST",ALPIVAB,ALPIVAB,PERAMIFLU,PERAMIFLU,RAPIACTA,RAPIVAB,RAPIVAB,S-021812,S-021812,"S-021812 (IV, INFLUENZA VIRUS INFECTION), SHIONOGI",PERAMIVIR,PERAMIVIR (USAN),"PERAMIVIR (INTRAVENOUS, INFLUENZA VIRUS INFECTION), UNIVERSITY OF ALABAMA/BIOCRYST",,,,,,,,,,,,,,,,,,206426,PERAMIVIR,,,,,,,,,,,,,,,,,,,,,2014-12-19T00:00:00Z,2014,12,Rapivab,influenza virus infection,EXO-ALPHA SIALIDASE INHIBITOR,ANTIVIRAL; INFLUENZA VIRUS REPLICATION INHIBITOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),206426,NDA,2013-12-19T00:00:00Z,fda,0,0,1,0,0,,biocryst pharmaceuticals,NASDAQ: BCRX,1,13.608,17.331,26.293,19.643,62.381,74.59,-38.31,,51.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206426,281,191,487,123,Influenza,1,0
297,FLUAD,"ADIUGRIP; AGRIPPAL S1/MF-59 INFLUENZA VACCINE, CHIRON VACCINES; AGRIPPAL S1/MF-59 INFLUENZA VACCINE, NOVARTIS VACCINES & DIAGNOSTICS; BEGRIVAC; CHIROMAS; FLUAD; FLUAD PEDIATRIC; INFLUPOZZI ADIUVATO; INFLUENZA VACCINE, CHIRON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-11-24T00:00:00Z,2015,11,Fluad,influenza virus infection,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125510,BLA,2014-11-25T00:00:00Z,fda,0,1,0,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125510,661,191,487,123,Influenza,1,0
299,FLUBLOK,"ASP-7374; FLUBLOK; UMN-05; UMN-0502; VAXSYN (INFLUENZA), PSC; INFLUENZA VACCINE (RHA), PROTEIN SCIENCES CORP; INFLUENZA VACCINE (RECOMBINANT HEMAGGLUTININS), PROTEIN SCIENCES CORP; INFLUENZA VACCINE, MICROGENESYS; INFLUENZA VACCINE, PROTEIN SCIENCES CORP; VACCINE (INFLUENZA), PROTEIN SCIENCES CORP",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-01-16T00:00:00Z,2013,1,Flublok,influenza virus infection,,PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; PROTEIN RECOMBINANT,using only (2),125285,BLA,2008-04-18T00:00:00Z,fda,1,0,1,0,0,,protein sciences,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125285,662,191,487,123,Influenza,1,0
309,FLUVAX,"AFLURIA; ENZIRA; FLUVAX; NILGRIP; VACCINE (INFLUENZA), CSL LTD",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-09-28T00:00:00Z,2007,9,Afluria,influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125254,BLA,2007-03-30T00:00:00Z,cortellis,1,1,0,0,0,,CSL Behring,ASX: CSL,1,2991.4,2341.7,1900,1895.2,979.9,776.3,1371.7,171.5,171.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125254,664,191,487,123,Influenza,1,0
310,FLUVIRAL,"FLULAVAL; FLULAVAL TR; FLULAVAL TRIVALENT; FLUVIRAL; FLUVIRAL S/F; GSK-1557482A; SPD-707; INFLUENZA VIRUS VACCINE (INJECTABLE), SHIRE/ID BIOMEDICAL/GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2006-10-05T00:00:00Z,2006,10,FluLaval,influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION; SUSPENSION,using only (2),125163,BLA,2006-03-23T00:00:00Z,cortellis,0,1,1,0,0,,glaxosmithkline,NYSE: GSK,1,45499.1,37229.2,38293.2,37593.1,34140.7,29797.2,35684.2,6772.46,6772.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125163,665,191,487,123,Influenza,1,0
311,FLUVIRIN A(H1N1),"FLUVIRIN A(H1N1); H1N1 PANDEMIC INFLUENZA A VACCINE (UNADJUVANTED EGG-BASED), NOVARTIS; H1N1 PANDEMIC INFLUENZA A VACCINE (UNADJUVANTED EGG-BASED), SEQIRUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-09-15T00:00:00Z,2009,9,Fluvirin,influenza virus infection,,PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),1750,BLA,,,0,0,0,0,0,,novartis,NYSE: NVS,1,45075,42535,38947,35105,29753,27277,32845,7374,7469,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=1750,666,191,487,123,Influenza,1,0
343,"H1N1 PANDEMIC INFLUENZA VACCINE (AS03 ADJUVANTED) 1, GLAXOSMITHKLINE","GSK-2340269A; GSK-2340272A; GSK-2340273A; GSK-2340274A; GSK2592984A; H1N1 PANDEMIC INFLUENZA VACCINE (AS03 ADJUVANTED) 1, GLAXOSMITHKLINE; H1N1 PANDEMIC INFLUENZA VACCINE 1 (AS03 ADJUVANTED), GSK; PANDEMRIX (H1N1); INFLUENZA VACCINES (INTRAMUSCULAR, INFLUENZA VIRUS INFECTION), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-11-10T00:00:00Z,2009,11,"H1N1 vaccine, GlaxoSmithKline",influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; EMULSION FORMULATION; INTRAMUSCULAR FORMULATION,using only (2),not identified,BLA,,,,,,,,,glaxosmithkline,NYSE: GSK,1,45825.1,35480.4,45147.6,45499.1,37229.2,38293.2,34346.2,6382.36,6632.7,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,675,191,487,123,Influenza,1,0
345,"H1N1 PANDEMIC INFLUENZA VACCINE (US MARKET), SANOFI PASTEUR","H1N1 PANDEMIC INFLUENZA VACCINE (US MARKET), SANOFI PASTEUR; INACTIVATED H1N1 INFLUENZA VACCINE (INTRAMUSCULAR, US MARKET), SANOFI PASTEUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2009-09-15T00:00:00Z,2009,9,"H1N1 vaccine, Sanofi Pasteur",influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),not identified,BLA,,,,,,,,,sanofi,NYSE: SNY,1,44761,40266.9,42651,38911.4,33775.2,21301.1,33271.2,6629.88,6629.9,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,676,191,487,123,Influenza,1,0
346,"H5N1 INFLUENZA VACCINE (SPLIT WHOLE VIRUS), GLAXOSMITHKLINE","AREPANRIX H5N1; D-PAN; GSK-1557484A; GSK-1562902A; H5N1 INFLUENZA VACCINE (SPLIT WHOLE VIRUS), GLAXOSMITHKLINE; PANDEMRIX; PREPANDRIX; PUMARIX; Q-PAN; Q-PAN H5N1; AVIAN INFLUENZA VACCINE (SPLIT WHOLE VIRUS), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2013-11-22T00:00:00Z,2013,11,"Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted",influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125419,BLA,2012-02-22T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125419,677,191,487,123,Influenza,1,0
347,"H5N1 INFLUENZA VACCINE, SANOFI PASTEUR","EMERFLU; H5N1 INFLUENZA VACCINE, AVENTIS PASTEUR; H5N1 INFLUENZA VACCINE, SANOFI PASTEUR; AVIAN INFLUENZA VACCINE, AVENTIS PASTEUR; AVIAN INFLUENZA VACCINE, SANOFI PASTEUR",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-04-17T00:00:00Z,2007,4,Emerflu,influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),not identified,BLA,,,,,,,,,sanofi,NYSE: SNY,1,42651,38911.4,33775.2,21301.1,10143.7,7811.22,31595.1,6625.39,6625.4,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,678,191,487,123,Influenza,1,0
546,OPTAFLU,"FLUCELVAX; OPTAFLU; INFLUENZA VACCINE (CELL CULTURE), CSL; INFLUENZA VACCINE (CELL CULTURE), CHIRON; INFLUENZA VACCINE (CELL CULTURE), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-11-20T00:00:00Z,2012,11,Flucelvax,influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; INTRAMUSCULAR FORMULATION,using only (2),125408,BLA,2011-11-22T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,51971,59375,51561,45075,42535,38947,36385,8465,8588,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125408,706,191,487,123,Influenza,1,0
613,"QUADRIVALENT INFLUENZA VACCINE (CELL-BASED), SEQIRUS","FLUCELVAX QIV; FLUCELVAX QUADRIVALENT; QUADRIVALENT INFLUENZA VACCINE (CELL-BASED), CSL; QUADRIVALENT INFLUENZA VACCINE (CELL-BASED), NOVARTIS VACCINES; QUADRIVALENT INFLUENZA VACCINE (CELL-BASED), SEQIRUS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-05-23T00:00:00Z,2016,5,Flucelvax Quadrivalent,influenza virus infection,,INACTIVATED VIRAL VACCINE; PROPHYLACTIC VACCINE; PROTEIN SUBUNIT VACCINE,BIOLOGICAL THERAPEUTIC; SYSTEMIC FORMULATION UNSPECIFIED,using only (2),125408,BLA,2015-04-24T00:00:00Z,fda,0,0,0,0,0,,CSL,ASX: CSL,1,6452,5843.1,53634,52716,51971,59375,3272.5,616.9,616.9,50359,2015-12-31T00:00:00Z,2015,,seqiris formed as subsidiary of CSL after they acquired novartis's influenza vaccine business in 2015; Use novartis lagged revenues for 2011-2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125408,713,191,487,123,Influenza,1,0
12,ACLIDINIUM BROMIDE,"BRETARIS; BRETARIS GENUAIR; EKLIRA; EKLIRA GENUAIR; KRP-AB-1102; LAS-34273; LAS-35783; TUDORZA GENUAIR; TUDORZA PRESSAIR; ACLIDINIUM BROMIDE; MUSCARINIC M3 ANTAGONIST (MDPI), ALMIRALL; MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/ACTAVIS/KYORIN; MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/FOREST/KYORIN","BRETARIS; BRETARIS GENUAIR; EKLIRA; EKLIRA GENUAIR; KRP-AB-1102; LAS-34273; LAS-35783; TUDORZA GENUAIR; TUDORZA PRESSAIR; ACLIDINIUM BROMIDE; MUSCARINIC M3 ANTAGONIST (MDPI), ALMIRALL; MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/ACTAVIS/KYORIN; MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/FOREST/KYORIN",ACLIDINIUM BROMIDE,BRETARIS,BRETARIS GENUAIR,EKLIRA,EKLIRA GENUAIR,KRP-AB-1102,LAS-34273,LAS-35783,TUDORZA GENUAIR,TUDORZA PRESSAIR,ACLIDINIUM BROMIDE,"MUSCARINIC M3 ANTAGONIST (MDPI), ALMIRALL","MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/ACTAVIS/KYORIN","MUSCARINIC M3 ANTAGONIST (INHALED, DRY POWDER), ALMIRALL/FOREST/KYORIN",,,,,,,,,,,,,,,,,,202450,ACLIDINIUM BROMIDE,,,,,,,,,,,,,,,,,,,,,2012-07-23T00:00:00Z,2012,7,Tudorza Pressair,chronic obstructive pulmonary disease,MUSCARINIC M3 RECEPTOR ANTAGONIST,BRONCHODILATOR; SYNERGIST,INHALANT FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),202450,NDA,2011-06-23T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,3341.9,4635.3,4308.4,4060.6,3863.8,3621.4,2653,937.2,937.2,,,,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202450,120,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
539,OLODATEROL,BI-1744-BS; BI-1744-CL; STRIVERDI RESPIMAT; OLODATEROL; OLODATEROL HYDROCHLORIDE,BI-1744-BS; BI-1744-CL; STRIVERDI RESPIMAT; OLODATEROL; OLODATEROL HYDROCHLORIDE,OLODATEROL,BI-1744-BS,BI-1744-CL,STRIVERDI RESPIMAT,OLODATEROL,OLODATEROL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,203108,OLODATEROL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-07-31T00:00:00Z,2014,7,Striverdi Respimat,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST,BRONCHODILATOR; RESPIRATORY SYSTEM AGENT,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; INHALANT FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; SUSTAINED RELEASE FORMULATION; TRANSDERMAL FORMULATION,matched (3),203108,NDA,2012-05-14T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203108,142,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
767,"UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE","573719 + 642444 (COPD, INHALANT), GLAXOSMITHKLINE; ANORO; ANORO ELLIPTA; GSK-573719 + GSK-642444 (COPD, INHALANT), GLAXOSMITHKLINE; GSK-573719 + VILANTEROL (COPD, INHALANT), GSK/THERAVANCE; LAVENTAIR; UMEC + GW-642444-M; UMEC/VI; ZEPHYR; UMECLIDINIUM + VILANTEROL (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE; UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE; UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE","573719 + 642444 (COPD, INHALANT), GLAXOSMITHKLINE; ANORO; ANORO ELLIPTA; GSK-573719 + GSK-642444 (COPD, INHALANT), GLAXOSMITHKLINE; GSK-573719 + VILANTEROL (COPD, INHALANT), GSK/THERAVANCE; LAVENTAIR; UMEC + GW-642444-M; UMEC/VI; ZEPHYR; UMECLIDINIUM + VILANTEROL (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE; UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE; UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE","UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE","573719 + 642444 (COPD, INHALANT), GLAXOSMITHKLINE",ANORO,ANORO ELLIPTA,"GSK-573719 + GSK-642444 (COPD, INHALANT), GLAXOSMITHKLINE","GSK-573719 + VILANTEROL (COPD, INHALANT), GSK/THERAVANCE",LAVENTAIR,UMEC + GW-642444-M,UMEC/VI,ZEPHYR,"UMECLIDINIUM + VILANTEROL (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE",UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE,"UMECLIDINIUM BROMIDE + VILANTEROL TRIFENATATE (COPD, INHALANT), GLAXOSMITHKLINE/THERAVANCE",,,,,,,,,,,,,,,,,,,203975,UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE,,,,,,,,,,,,,,,,,,,,,2013-12-18T00:00:00Z,2013,12,Anoro Ellipta,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST; MUSCARINIC RECEPTOR ANTAGONIST,BRONCHODILATOR,DRUG COMBINATION; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC,matched (3),203975,NDA,2012-12-18T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203975,176,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
308,"FLUTICASONE FUROATE + VILANTEROL TRIFENATATE  (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE","BREO; BREO ELLIPTA; ELLIPTA; GW-642444M + GW-685698X, GLAXOSMITHKLINE; GW-642444M + FLUTICASONE FUROATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; GW-685698X + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; RELOVAIR; RELOVAIR ELLIPTA; RELOVAIR HORIZON (444 + 698, COPD/ASTHMA), GSK; RELVAR; RELVAR ELLIPTA; REVINTY ELLIPTA; FLUTICASONE FUROATE + 642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + GSK-642444M; FLUTICASONE FUROATE + GSK-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + VILANTEROL TRIFENATATE; FLUTICASONE FUROATE + VILANTEROL TRIFENATATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE; FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE","BREO; BREO ELLIPTA; ELLIPTA; GW-642444M + GW-685698X, GLAXOSMITHKLINE; GW-642444M + FLUTICASONE FUROATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; GW-685698X + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; RELOVAIR; RELOVAIR ELLIPTA; RELOVAIR HORIZON (444 + 698, COPD/ASTHMA), GSK; RELVAR; RELVAR ELLIPTA; REVINTY ELLIPTA; FLUTICASONE FUROATE + 642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + GSK-642444M; FLUTICASONE FUROATE + GSK-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + VILANTEROL TRIFENATATE; FLUTICASONE FUROATE + VILANTEROL TRIFENATATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE; FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE; FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE","FLUTICASONE FUROATE + VILANTEROL TRIFENATATE  (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",BREO,BREO ELLIPTA,ELLIPTA,"GW-642444M + GW-685698X, GLAXOSMITHKLINE","GW-642444M + FLUTICASONE FUROATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE","GW-685698X + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",RELOVAIR,RELOVAIR ELLIPTA,"RELOVAIR HORIZON (444 + 698, COPD/ASTHMA), GSK",RELVAR,RELVAR ELLIPTA,REVINTY ELLIPTA,"FLUTICASONE FUROATE + 642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",FLUTICASONE FUROATE + GSK-642444M,"FLUTICASONE FUROATE + GSK-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE","FLUTICASONE FUROATE + GW-642444M (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",FLUTICASONE FUROATE + VILANTEROL TRIFENATATE,"FLUTICASONE FUROATE + VILANTEROL TRIFENATATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE,"FLUTICASONE FUROATE + VILANTEROL TRIPHENYL ACETATE (ORAL INHALANT, ASTHMA/COPD), GLAXOSMITHKLINE",,,,,,,,,,,204275,FLUTICASONE FUROATE; VILANTEROL TRIFENATATE,,,,,,,,,,,,,,,,,,,,,2013-05-10T00:00:00Z,2013,5,Breo Ellipta,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST; GLUCOCORTICOID AGONIST,ANTI-INFLAMMATORY; BRONCHODILATOR,DRUG COMBINATION; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),204275,NDA,2012-07-11T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,43907.9,42959.8,42629,44331.3,45825.1,35480.4,29646.3,6498.8,6498.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204275,190,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
766,UMECLIDINIUM BROMIDE,"573719; ENCRUSE ELLIPTA; GSK-573719; INCRUSE; INCRUSE ELLIPTA; ROLUFTA; UMEC; MUSCARINIC ANTAGONIST (INHALANT FORMULATION, COPD), GLAXOSMITHKLINE; UMECLIDINIUM; UMECLIDINIUM BROMIDE","573719; ENCRUSE ELLIPTA; GSK-573719; INCRUSE; INCRUSE ELLIPTA; ROLUFTA; UMEC; MUSCARINIC ANTAGONIST (INHALANT FORMULATION, COPD), GLAXOSMITHKLINE; UMECLIDINIUM; UMECLIDINIUM BROMIDE",UMECLIDINIUM BROMIDE,573719,ENCRUSE ELLIPTA,GSK-573719,INCRUSE,INCRUSE ELLIPTA,ROLUFTA,UMEC,"MUSCARINIC ANTAGONIST (INHALANT FORMULATION, COPD), GLAXOSMITHKLINE",UMECLIDINIUM,UMECLIDINIUM BROMIDE,,,,,,,,,,,,,,,,,,,,,205382,UMECLIDINIUM BROMIDE,205382,UMECLIDINIUM BROMIDE,,,,,,,,,,,,,,,,,,,2014-04-30T00:00:00Z,2014,4,Incruse Ellipta,chronic obstructive pulmonary disease,MUSCARINIC RECEPTOR ANTAGONIST,BRONCHODILATOR,INHALANT FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),205382,NDA,2013-04-29T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35854.4,43907.9,42959.8,42629,44331.3,45825.1,24441.7,5376.76,5376.76,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205382,233,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
540,"OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE L (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM","BI-1744-CL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM; SPIOLTO RESPIMAT; SPIOLTO RESPIMAT; STIOLTO RESPIMAT; STIOLTO RESPIMAT; VAHELVA RESPIMAT; VAHELVA RESPIMAT; OLODATEROL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM; OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE; OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE L (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM; TIOTROPIUM + OLODATEROL (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM","BI-1744-CL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM; SPIOLTO RESPIMAT; SPIOLTO RESPIMAT; STIOLTO RESPIMAT; STIOLTO RESPIMAT; VAHELVA RESPIMAT; VAHELVA RESPIMAT; OLODATEROL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM; OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE; OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE L (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM; TIOTROPIUM + OLODATEROL (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM","OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE L (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM","BI-1744-CL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM",SPIOLTO RESPIMAT,SPIOLTO RESPIMAT,STIOLTO RESPIMAT,STIOLTO RESPIMAT,VAHELVA RESPIMAT,VAHELVA RESPIMAT,"OLODATEROL + TIOTROPIUM BROMIDE (INHALED, COPD), BOEHRINGER INGELHEIM",OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE,"OLODATEROL HYDROCHLORIDE + TIOTROPIUM BROMIDE MONOHYDRATE L (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM","TIOTROPIUM + OLODATEROL (RESPIMAT SOFT MIST/INHALED, COPD), BOEHRINGER INGELHEIM",,,,,,,,,,,,,,,,,,,,206756,OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE,,,,,,,,,,,,,,,,,,,,,2015-05-21T00:00:00Z,2015,5,Stiolto Respimat,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY; BRONCHODILATOR; RESPIRATORY SYSTEM AGENT,AEROSOL FORMULATION INHALANT; DAILY DOSING; DRUG COMBINATION; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),206756,NDA,2014-05-22T00:00:00Z,fda,0,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206756,289,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
316,"FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE (INHALED, COPD), PEARL","BEVESPI AEROSPHERE; BEVESPI AEROSPHERE; GFF-MDI; GFF-MDI; PT-001 + PT-005; PT-003; PT-003 GFF; FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE; FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE (INHALED, COPD), PEARL; RESPIRATORY AGENT (INHALED), PEARL THERAPEUTICS","BEVESPI AEROSPHERE; BEVESPI AEROSPHERE; GFF-MDI; GFF-MDI; PT-001 + PT-005; PT-003; PT-003 GFF; FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE; FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE (INHALED, COPD), PEARL; RESPIRATORY AGENT (INHALED), PEARL THERAPEUTICS","FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE (INHALED, COPD), PEARL",BEVESPI AEROSPHERE,BEVESPI AEROSPHERE,GFF-MDI,GFF-MDI,PT-001 + PT-005,PT-003,PT-003 GFF,FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE,"FORMOTEROL FUMARATE + GLYCOPYRRONIUM BROMIDE (INHALED, COPD), PEARL","RESPIRATORY AGENT (INHALED), PEARL THERAPEUTICS",,,,,,,,,,,,,,,,,,,,,208294,FORMOTEROL FUMARATE; GLYCOPYRROLATE,208294,FORMOTEROL FUMARATE; GLYCOPYRROLATE,,,,,,,,,,,,,,,,,,,2016-04-25T00:00:00Z,2016,4,Bevespi Aerosphere,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST; MUSCARINIC RECEPTOR ANTAGONIST,BRONCHODILATOR,AEROSOL FORMULATION INHALANT; DRUG COMBINATION; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),208294,NDA,2015-06-25T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,23002,24708,26547,25806,,,19006,5679,5809,,,2013,,acquired by astrazeneca in 2013,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208294,337,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
54,ARFORMOTEROL,"(R,R)-FORMOTEROL; BROVANA; R,R-EFORMOTEROL; ARFORMOTEROL; ARFORMOTEROL TARTRATE","(R,R)-FORMOTEROL; BROVANA; R,R-EFORMOTEROL; ARFORMOTEROL; ARFORMOTEROL TARTRATE",ARFORMOTEROL,"(R,R)-FORMOTEROL",BROVANA,"R,R-EFORMOTEROL",ARFORMOTEROL,ARFORMOTEROL TARTRATE,,,,,,,,,,,,,,,,,,,,,,,,,,21912,ARFORMOTEROL TARTRATE,,,,,,,,,,,,,,,,,,,,,2006-10-06T00:00:00Z,2006,10,Brovana,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST,BRONCHODILATOR,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; STEREOCHEMISTRY,matched (3),021912,NDA,2005-12-08T00:00:00Z,fda,0,0,0,0,0,,sunovion pharmaceuticals,NASDAQ: SEPR,1,1183.1,801.1,380.9,344,239,152.1,1078.4,163.5,163.5,,,,,formerly Sepracor; acquired by Dainippon Sumitomo pharma in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021912,409,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
377,INDACATEROL,"ARBEELA BREEZHALER; ARCAPTA NEOHALER; HIROBRIZ BREEZHALER; ONBREZ BREEZHALER; ONBREZ INHALATION CAPSULES; ONBRIZE; OSLIF BREEZHALER; QAB-149; QAB-149 (CONCEPT-1 DEVICE), NOVARTIS/SKYEPHARMA; QAB-149 (MDDPI), NOVARTIS/SKYEPHARMA; QAB-149 (MDDPI), SKYEPHARMA/NOVARTIS; QAB-149 (DRY POWDER INHALANT), NOVARTIS/SKYEPHARMA; QAB-149 (INHALED), NOVARTIS; QAB-149 (INHALED, DPI), NOVARTIS/SKYEPHARMA; QAB-149 (INHALED, SKYEHALER/SKYEPROTECT), NOVARTIS/SKYEPHARMA; QAB-149-AFA; INDACATEROL; INDACATEROL MALEATE","ARBEELA BREEZHALER; ARCAPTA NEOHALER; HIROBRIZ BREEZHALER; ONBREZ BREEZHALER; ONBREZ INHALATION CAPSULES; ONBRIZE; OSLIF BREEZHALER; QAB-149; QAB-149 (CONCEPT-1 DEVICE), NOVARTIS/SKYEPHARMA; QAB-149 (MDDPI), NOVARTIS/SKYEPHARMA; QAB-149 (MDDPI), SKYEPHARMA/NOVARTIS; QAB-149 (DRY POWDER INHALANT), NOVARTIS/SKYEPHARMA; QAB-149 (INHALED), NOVARTIS; QAB-149 (INHALED, DPI), NOVARTIS/SKYEPHARMA; QAB-149 (INHALED, SKYEHALER/SKYEPROTECT), NOVARTIS/SKYEPHARMA; QAB-149-AFA; INDACATEROL; INDACATEROL MALEATE",INDACATEROL,ARBEELA BREEZHALER,ARCAPTA NEOHALER,HIROBRIZ BREEZHALER,ONBREZ BREEZHALER,ONBREZ INHALATION CAPSULES,ONBRIZE,OSLIF BREEZHALER,QAB-149,"QAB-149 (CONCEPT-1 DEVICE), NOVARTIS/SKYEPHARMA","QAB-149 (MDDPI), NOVARTIS/SKYEPHARMA","QAB-149 (MDDPI), SKYEPHARMA/NOVARTIS","QAB-149 (DRY POWDER INHALANT), NOVARTIS/SKYEPHARMA","QAB-149 (INHALED), NOVARTIS","QAB-149 (INHALED, DPI), NOVARTIS/SKYEPHARMA","QAB-149 (INHALED, SKYEHALER/SKYEPROTECT), NOVARTIS/SKYEPHARMA",QAB-149-AFA,INDACATEROL,INDACATEROL MALEATE,,,,,,,,,,,,,22383,INDACATEROL MALEATE,,,,,,,,,,,,,,,,,,,,,2011-07-01T00:00:00Z,2011,7,Arcapta Neohaler,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST,ANTI-INFLAMMATORY; BRONCHODILATOR,CAPSULE FORMULATION; DAILY DOSING; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC,matched (3),022383,NDA,2008-12-15T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,59375,51561,45075,42535,38947,35105,40804,9332,10172,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022383,542,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
640,ROFLUMILAST,APTA-2217; B9302-107; BY-217; BYK-20869; DALIRESP; DALVEZA; DAXAS; LIBERTEK; XEVEX; ROFLUMILAST; ROFLUMIST,APTA-2217; B9302-107; BY-217; BYK-20869; DALIRESP; DALVEZA; DAXAS; LIBERTEK; XEVEX; ROFLUMILAST; ROFLUMIST,ROFLUMILAST,APTA-2217,B9302-107,BY-217,BYK-20869,DALIRESP,DALVEZA,DAXAS,LIBERTEK,XEVEX,ROFLUMILAST,ROFLUMIST,,,,,,,,,,,,,,,,,,,,22522,ROFLUMILAST,,,,,,,,,,,,,,,,,,,,,2011-02-28T00:00:00Z,2011,2,Daliresp,chronic obstructive pulmonary disease,PDE 4 INHIBITOR,ANTI-INFLAMMATORY; ANTIPSYCHOTIC; BRONCHODILATOR,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022522,NDA,2009-07-15T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,4635.3,4308.4,4060.6,3863.8,3621.4,3242.3,3617.2,723.9,723.9,,,,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022522,587,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
333,"GLYCOPYRRONIUM BROMIDE + INDACATEROL MALEATE (INHALED), NOVARTIS","AD-237 + QAB-149 FIXED DOSE COMBINATION (INHALED), NOVARTIS; AD-237 + INDACATEROL FIXED DOSE COMBINATION (INHLAED), NOVARTIS; NVA-237 + QAB-149 FIXED DOSE COMBINATION (INHALED), NOVARTIS; NVA-237 + QAB-149-AFA; NVA-237 + INDACATEROL FIXED DOSE COMBINATION (INHALED), NOVARTIS; NVF-239; QVA-149; QVA-149A; SEQUADRA; SEQUADRA; ULTIBRO BREEZHALER; ULTIBRO BREEZHALER; ULUNAR BREEZHALER; ULUNAR BREEZHALER; UTIBRON NEOHALER; UTIBRON NEOHALER; XOTERNA BREEZHALER; XOTERNA BREEZHALER; GLYCOPYRRONIUM BROMIDE + QAB-149 FIXED DOSE COMBINATION (INHLAED), NOVARTIS; GLYCOPYRRONIUM BROMIDE + INDACATEROL MALEATE; GLYCOPYRRONIUM BROMIDE + INDACATEROL MALEATE (INHALED), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2015-10-29T00:00:00Z,2015,10,Utibron Neohaler,chronic obstructive pulmonary disease,BETA 2 ADRENOCEPTOR AGONIST; MUSCARINIC RECEPTOR ANTAGONIST,BRONCHODILATOR; RESPIRATORY SYSTEM AGENT,DAILY DOSING; DRUG COMBINATION; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,using only (2),207930,NDA,2014-12-29T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207930,671,1185,491,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
315,"FORMOTEROL FUMARATE (INHALED NEBULIZED, COPD), MYLAN","PERFOROMIST; EFORMOTEROL; FORMOTEROL; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE (USAN); FORMOTEROL FUMARATE (INHALED NEBULIZED, COPD), MYLAN; FORMOTEROL FUMARATE DIHYDRATE","PERFOROMIST; EFORMOTEROL; FORMOTEROL; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE (USAN); FORMOTEROL FUMARATE (INHALED NEBULIZED, COPD), MYLAN; FORMOTEROL FUMARATE DIHYDRATE","FORMOTEROL FUMARATE (INHALED NEBULIZED, COPD), MYLAN",PERFOROMIST,EFORMOTEROL,FORMOTEROL,FORMOTEROL FUMARATE,FORMOTEROL FUMARATE (USAN),"FORMOTEROL FUMARATE (INHALED NEBULIZED, COPD), MYLAN",FORMOTEROL FUMARATE DIHYDRATE,,,,,,,,,,,,,,,,,,,,,,,,22007,FORMOTEROL FUMARATE,,,,,,,,,,,,,,,,,,,,,2007-05-11T00:00:00Z,2007,5,Perforomist,emphysema,BETA 2 ADRENOCEPTOR AGONIST,BRONCHODILATOR; RESPIRATORY SYSTEM AGENT,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022007,NDA,2006-06-28T00:00:00Z,fda,0,0,0,0,0,,mylan,NASDAQ: MYL,1,1611.8,22636,22011.9,22972.8,22485.9,21445.8,843.7,103.7,103.7,24197.7,2007-12-31T00:00:00Z,2007,,dey pharma acquired by mylan from merck in 2007; merck lagged revenues,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022007,438,111,492,127,Chronic obstructive pulmonary disease and bronchiectasis,1,0
465,MEPOLIZUMAB,240563; 240563; BOSATRIA; NUCALA; NUCALA; SB-240563; MEPOLIZUMAB,240563; 240563; BOSATRIA; NUCALA; NUCALA; SB-240563; MEPOLIZUMAB,MEPOLIZUMAB,240563,240563,BOSATRIA,NUCALA,NUCALA,SB-240563,MEPOLIZUMAB,,,,,,,,,,,,,,,,,,,,,,,,125526,MEPOLIZUMAB,,,,,,,,,,,,,,,,,,,,,2015-11-04T00:00:00Z,2015,11,Nucala,asthma,IL-5 ANTAGONIST,ANTI-INFLAMMATORY; ANTICANCER; BRONCHODILATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125526,BLA,2014-11-04T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35279.5,35854.4,43907.9,42959.8,42629,44331.3,23270.9,4702.85,5250,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125526,56,31,493,128,Asthma,1,0
306,"FLUTICASONE FUROATE (INHALED, RESPIRATORY DISORDERS), GLAXOSMITHKLINE","ARNUITY; ARNUITY ELLIPTA; GW-685698X; FLUTICASONE FUROATE; FLUTICASONE FUROATE (INHALED, RESPIRATORY DISORDERS), GLAXOSMITHKLINE","ARNUITY; ARNUITY ELLIPTA; GW-685698X; FLUTICASONE FUROATE; FLUTICASONE FUROATE (INHALED, RESPIRATORY DISORDERS), GLAXOSMITHKLINE","FLUTICASONE FUROATE (INHALED, RESPIRATORY DISORDERS), GLAXOSMITHKLINE",ARNUITY,ARNUITY ELLIPTA,GW-685698X,FLUTICASONE FUROATE,"FLUTICASONE FUROATE (INHALED, RESPIRATORY DISORDERS), GLAXOSMITHKLINE",,,,,,,,,,,,,,,,,,,,,,,,,,205625,FLUTICASONE FUROATE,,,,,,,,,,,,,,,,,,,,,2014-08-20T00:00:00Z,2014,8,Arnuity Ellipta,asthma,GLUCOCORTICOID AGONIST,RESPIRATORY SYSTEM AGENT; STEROIDAL ANTI-INFLAMMATORY,DAILY DOSING; INHALANT FORMULATION; ORAL FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),205625,NDA,2013-10-22T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,35854.4,43907.9,42959.8,42629,44331.3,45825.1,24441.7,5376.76,5376.76,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205625,246,31,493,128,Asthma,1,0
150,"CICLESONIDE (METERED DOSE INHALER), NYCOMED","ALVESCO; ALVESCO HFA; BTR-15; BTR-15K; BY-9010; CIC-AP; XRP-1526; CICLESONIDE; CICLESONIDE (METERED DOSE INHALER), NYCOMED","ALVESCO; ALVESCO HFA; BTR-15; BTR-15K; BY-9010; CIC-AP; XRP-1526; CICLESONIDE; CICLESONIDE (METERED DOSE INHALER), NYCOMED","CICLESONIDE (METERED DOSE INHALER), NYCOMED",ALVESCO,ALVESCO HFA,BTR-15,BTR-15K,BY-9010,CIC-AP,XRP-1526,CICLESONIDE,"CICLESONIDE (METERED DOSE INHALER), NYCOMED",,,,,,,,,,,,,,,,,,,,,,21658,CICLESONIDE,,,,,,,,,,,,,,,,,,,,,2008-01-10T00:00:00Z,2008,1,Alvesco,asthma,GLUCOCORTICOID AGONIST,STEROIDAL ANTI-INFLAMMATORY,AEROSOL FORMULATION INHALANT; INHALANT FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),021658,NDA,2003-12-22T00:00:00Z,fda,0,0,0,0,0,,nycomed,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021658,378,31,493,128,Asthma,1,0
113,"BUDESONIDE + FORMOTEROL FUMARATE, ASTRAZENECA","BUDESONIDE-FORMOTEROL MIXT, ASTRAZENECA; SYMBICORT; SYMBICORT FORTE TURBUHALER; SYMBICORT RAPIHALER; SYMBICORT SMART; SYMBICORT TURBOHALER; SYMBICORT TURBUHALER; SYMBICORT PMDI; BUDESONIDE + FORMOTEROL FUMARATE; BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE; BUDESONIDE + FORMOTEROL FUMARATE, ASTRAZENECA; BUDESONIDE + FORMOTEROL, ASTRAZENECA","BUDESONIDE-FORMOTEROL MIXT, ASTRAZENECA; SYMBICORT; SYMBICORT FORTE TURBUHALER; SYMBICORT RAPIHALER; SYMBICORT SMART; SYMBICORT TURBOHALER; SYMBICORT TURBUHALER; SYMBICORT PMDI; BUDESONIDE + FORMOTEROL FUMARATE; BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE; BUDESONIDE + FORMOTEROL FUMARATE, ASTRAZENECA; BUDESONIDE + FORMOTEROL, ASTRAZENECA","BUDESONIDE + FORMOTEROL FUMARATE, ASTRAZENECA","BUDESONIDE-FORMOTEROL MIXT, ASTRAZENECA",SYMBICORT,SYMBICORT FORTE TURBUHALER,SYMBICORT RAPIHALER,SYMBICORT SMART,SYMBICORT TURBOHALER,SYMBICORT TURBUHALER,SYMBICORT PMDI,BUDESONIDE + FORMOTEROL FUMARATE,BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE,"BUDESONIDE + FORMOTEROL FUMARATE, ASTRAZENECA","BUDESONIDE + FORMOTEROL, ASTRAZENECA",,,,,,,,,,,,,,,,,,,21929,BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE,,,,,,,,,,,,,,,,,,,,,2006-07-21T00:00:00Z,2006,7,Symbicort,asthma,BETA 2 ADRENOCEPTOR AGONIST,BRONCHODILATOR; CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY,AEROSOL FORMULATION INHALANT; DRUG COMBINATION; INHALANT FORMULATION; MICROPARTICLE FORMULATION; POWDER FORMULATION INHALANT; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),021929,NDA,2005-09-23T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,26475,23950,21426,18849,17841,16222,20916,3885,3902,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021929,412,31,493,128,Asthma,1,0
791,"ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CHIESI USA INC/SKYEPHARMA","ZYFLO CR; ZILEUTON; ZILEUTON (GEOMATRIX), SKYEPHARMA/ABBOTT; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CHIESI USA INC/SKYEPHARMA; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CORNERSTONE THERAPEUTICS/SKYEPHARMA; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CRITICAL THERAPEUTICS/SKYEPHARMA; ZILEUTON CR","ZYFLO CR; ZILEUTON; ZILEUTON (GEOMATRIX), SKYEPHARMA/ABBOTT; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CHIESI USA INC/SKYEPHARMA; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CORNERSTONE THERAPEUTICS/SKYEPHARMA; ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CRITICAL THERAPEUTICS/SKYEPHARMA; ZILEUTON CR","ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CHIESI USA INC/SKYEPHARMA",ZYFLO CR,ZILEUTON,"ZILEUTON (GEOMATRIX), SKYEPHARMA/ABBOTT","ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CHIESI USA INC/SKYEPHARMA","ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CORNERSTONE THERAPEUTICS/SKYEPHARMA","ZILEUTON (ORAL CONTROLLED-RELEASE, GEOMATRIX), CRITICAL THERAPEUTICS/SKYEPHARMA",ZILEUTON CR,,,,,,,,,,,,,,,,,,,,,,,,22052,ZILEUTON,,,,,,,,,,,,,,,,,,,,,2007-05-30T00:00:00Z,2007,5,Zyflo CR,asthma,5-LIPOXYGENASE INHIBITOR; LEUKOTRIENE C4 SYNTHASE INHIBITOR; LEUKOTRIENE E4 ANTAGONIST,ANTI-INFLAMMATORY; BRONCHODILATOR; LEUKOTRIENE B4 SYNTHESIS INHIBITOR; LEUKOTRIENE D4 SYNTHESIS MODULATOR,FILM COATING; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),022052,NDA,2006-07-30T00:00:00Z,fda,0,0,0,0,0,,critical therapeutics,NASDAQ: CRTX,1,12.9,13,6.2,4.4,1,,8.6,21,21.7,,,,,acquired by cornerstone biopharma in 2008,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022052,454,31,493,128,Asthma,1,0
498,"MOMETASONE + FORMOTEROL (INHALED, ASTHMA), MERCK & CO","DULERA; MFF-258; MK-0887A; SCH-418131; ZENHALE; MOMETASONE + FORMOTEROL; MOMETASONE + FORMOTEROL (INHALED, ASTHMA), MERCK & CO; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), MERCK & CO/NOVARTIS; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH/NOVARTIS; MOMETASONE FUROATE + FORMOTEROL; MOMETASONE FUROATE + FORMOTEROL FUMARATE","DULERA; MFF-258; MK-0887A; SCH-418131; ZENHALE; MOMETASONE + FORMOTEROL; MOMETASONE + FORMOTEROL (INHALED, ASTHMA), MERCK & CO; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), MERCK & CO/NOVARTIS; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH; MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH/NOVARTIS; MOMETASONE FUROATE + FORMOTEROL; MOMETASONE FUROATE + FORMOTEROL FUMARATE","MOMETASONE + FORMOTEROL (INHALED, ASTHMA), MERCK & CO",DULERA,MFF-258,MK-0887A,SCH-418131,ZENHALE,MOMETASONE + FORMOTEROL,"MOMETASONE + FORMOTEROL (INHALED, ASTHMA), MERCK & CO","MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), MERCK & CO/NOVARTIS","MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH","MOMETASONE + FORMOTEROL (INHALED, ASTHMA/COPD), SCHERING-PLOUGH/NOVARTIS",MOMETASONE FUROATE + FORMOTEROL,MOMETASONE FUROATE + FORMOTEROL FUMARATE,,,,,,,,,,,,,,,,,,,22518,FORMOTEROL FUMARATE; MOMETASONE FUROATE,,,,,,,,,,,,,,,,,,,,,2010-06-22T00:00:00Z,2010,6,Dulera,asthma,BETA 2 ADRENOCEPTOR AGONIST,BRONCHODILATOR; CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY,AEROSOL FORMULATION INHALANT; DRUG COMBINATION; INHALANT FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),022518,NDA,2009-05-21T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,45987,27428,18502,12690,10594,9508,12084,3529,3529,18052,2009-09-30T00:00:00Z,2009,,acquired by merck in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022518,585,31,493,128,Asthma,1,0
630,RESLIZUMAB,"CDP-835; CEP-38072; CTX-55700; CINQAERO; CINQAERO; CINQAIR; CINQAIR; CINQUIL; DCP-835; SCH-5570; SCH-55700; ANTI-IL-5 THERAPY, CEPTION; ANTI-IL-5 THERAPY, SCHERING PLOUGH/CELLTECH; ANTI-INTERLEUKIN-5 MAB, CEPTION; ANTI-INTERLEUKIN-5 MAB, SCHERING-PLOUGH/CELLTECH; RESLIZUMAB","CDP-835; CEP-38072; CTX-55700; CINQAERO; CINQAERO; CINQAIR; CINQAIR; CINQUIL; DCP-835; SCH-5570; SCH-55700; ANTI-IL-5 THERAPY, CEPTION; ANTI-IL-5 THERAPY, SCHERING PLOUGH/CELLTECH; ANTI-INTERLEUKIN-5 MAB, CEPTION; ANTI-INTERLEUKIN-5 MAB, SCHERING-PLOUGH/CELLTECH; RESLIZUMAB",RESLIZUMAB,CDP-835,CEP-38072,CTX-55700,CINQAERO,CINQAERO,CINQAIR,CINQAIR,CINQUIL,DCP-835,SCH-5570,SCH-55700,"ANTI-IL-5 THERAPY, CEPTION","ANTI-IL-5 THERAPY, SCHERING PLOUGH/CELLTECH","ANTI-INTERLEUKIN-5 MAB, CEPTION","ANTI-INTERLEUKIN-5 MAB, SCHERING-PLOUGH/CELLTECH",RESLIZUMAB,,,,,,,,,,,,,,,761033,RESLIZUMAB,,,,,,,,,,,,,,,,,,,,,2016-03-23T00:00:00Z,2016,3,Cinqair,asthma,IL-5 ANTAGONIST; INTERLEUKIN-5 LIGAND INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; CHEMOTAXIS MODULATOR; EOSINOPHIL MIGRATION MODULATOR,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; MONTHLY DOSING; PROTEIN RECOMBINANT,matched (3),761033,BLA,2015-03-29T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,21903,19652,20272,20314,20317,18312,12242,2111,1688,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761033,621,31,493,128,Asthma,1,0
517,NINTEDANIB,"BIBF-1120; BIBF-1120 ES; FGF/PDGF/VEGF RECEPTOR KINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM; OFEB; OFEB; OFEV; VARGATEF; ANGIOKINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM; INTEDANIB; NINTEDANIB; NINTEDANIB ESYLATE; NINTEDANIB ETHANESULFONATE; NINTEDANIB ETHANESULFONATE; NINTEDANIB ETHANESULFONATE","BIBF-1120; BIBF-1120 ES; FGF/PDGF/VEGF RECEPTOR KINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM; OFEB; OFEB; OFEV; VARGATEF; ANGIOKINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM; INTEDANIB; NINTEDANIB; NINTEDANIB ESYLATE; NINTEDANIB ETHANESULFONATE; NINTEDANIB ETHANESULFONATE; NINTEDANIB ETHANESULFONATE",NINTEDANIB,BIBF-1120,BIBF-1120 ES,"FGF/PDGF/VEGF RECEPTOR KINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM",OFEB,OFEB,OFEV,VARGATEF,"ANGIOKINASE INHIBITORS (CANCER), BOEHRINGER INGELHEIM",INTEDANIB,NINTEDANIB,NINTEDANIB ESYLATE,NINTEDANIB ETHANESULFONATE,NINTEDANIB ETHANESULFONATE,NINTEDANIB ETHANESULFONATE,,,,,,,,,,,,,,,,,205832,NINTEDANIB ESYLATE,,,,,,,,,,,,,,,,,,,,,2014-10-15T00:00:00Z,2014,10,Ofev,idiopathic pulmonary fibrosis,FGF RECEPTOR ANTAGONIST; FGF1 RECEPTOR ANTAGONIST; FGF2 RECEPTOR ANTAGONIST; FGF3 RECEPTOR ANTAGONIST; PDGF RECEPTOR ALPHA ANTAGONIST; PDGF RECEPTOR ANTAGONIST; PDGF RECEPTOR BETA ANTAGONIST; VEGF RECEPTOR ANTAGONIST; VEGF-1 RECEPTOR ANTAGONIST; VEGF-2 RECEPTOR ANTAGONIST; VEGF-3 RECEPTOR ANTAGONIST,ANGIOGENESIS INHIBITOR; ANTI-INFLAMMATORY; ANTICANCER; ANTICANCER PROTEIN KINASE INHIBITOR; FIBROSUPPRESSANT,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205832,NDA,2014-05-02T00:00:00Z,fda,1,0,1,1,1,2014-07-16T00:00:00Z,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205832,260,3771,516,133,Other lower respiratory disease,1,0
594,PIRFENIDONE,"AMR-69; DESKAR; ESBRIET; PIRESPA; RG-6062; RO-0220912; S-7701; P38 MAP KINASE INHIBITOR (ORAL, FIBROSIS/ MULTIPLE SCLEROSIS), MARNAC/ INTERMUNE; PIRFENIDONE","AMR-69; DESKAR; ESBRIET; PIRESPA; RG-6062; RO-0220912; S-7701; P38 MAP KINASE INHIBITOR (ORAL, FIBROSIS/ MULTIPLE SCLEROSIS), MARNAC/ INTERMUNE; PIRFENIDONE",PIRFENIDONE,AMR-69,DESKAR,ESBRIET,PIRESPA,RG-6062,RO-0220912,S-7701,"P38 MAP KINASE INHIBITOR (ORAL, FIBROSIS/ MULTIPLE SCLEROSIS), MARNAC/ INTERMUNE",PIRFENIDONE,,,,,,,,,,,,,,,,,,,,,,22535,PIRFENIDONE,,,,,,,,,,,,,,,,,,,,,2014-10-15T00:00:00Z,2014,10,Esbriet,idiopathic pulmonary fibrosis,PDGF RECEPTOR ANTAGONIST; TGF BETA ANTAGONIST; P38 MAP KINASE INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; COLLAGEN SYNTHESIS INHIBITOR; FIBROSUPPRESSANT; TNF ALPHA SYNTHESIS INHIBITOR,CAPSULE FORMULATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022535,NDA,2009-11-04T00:00:00Z,fda,1,0,1,1,1,2014-07-07T00:00:00Z,roche,SIX: ROG,1,50199.3,70.3,26.2,5.4,239.3,48.7,37134.6,9040,9961.1,228.2,2014-06-30T00:00:00Z,2014,,acquired by roche in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022535,594,3771,516,133,Other lower respiratory disease,1,0
332,"GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), MERZ","CUVPOSA; CUVPOSA; FHPC-02; GLYCOPYRROLATE; GLYCOPYRROLATE (EXCESSIVE SALIVARY PRODUCTION), SCIELE PHARMA; GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SCIELE PHARMA; GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SHIONOGI PHARMA; GLYCOPYRROLATE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), MERZ; GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA","CUVPOSA; CUVPOSA; FHPC-02; GLYCOPYRROLATE; GLYCOPYRROLATE (EXCESSIVE SALIVARY PRODUCTION), SCIELE PHARMA; GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SCIELE PHARMA; GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SHIONOGI PHARMA; GLYCOPYRROLATE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), MERZ; GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA","GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), MERZ",CUVPOSA,CUVPOSA,FHPC-02,GLYCOPYRROLATE,"GLYCOPYRROLATE (EXCESSIVE SALIVARY PRODUCTION), SCIELE PHARMA","GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SCIELE PHARMA","GLYCOPYRROLATE (NEUROLOGICAL DISEASE-ASSOCIATED DROOLING), SHIONOGI PHARMA","GLYCOPYRROLATE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA",GLYCOPYRRONIUM BROMIDE,"GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), MERZ","GLYCOPYRRONIUM BROMIDE (ORAL, EXCESSIVE SALIVARY PRODUCTION), SHIONOGI PHARMA",,,,,,,,,,,,,,,,,,,,22571,GLYCOPYRROLATE,22571,GLYCOPYRROLATE,,,,,,,,,,,,,,,,,,,2010-07-28T00:00:00Z,2010,7,Cuvposa,sialorrhea,ACETYLCHOLINE RECEPTOR ANTAGONIST,,ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022571,NDA,2009-09-26T00:00:00Z,fda,0,0,0,1,0,,shionogi,TYO: 4507,1,2979.8,2299.4,2148.8,1700.1,1671.7,1859.4,2163.8,554.3,554.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022571,605,2222,527,137,Diseases of mouth; excluding dental,1,0
200,"DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA","DEXILANT; DEXILANT DR; DEXILANT DR; DEXILANT SOLUTAB; DEXILANT SOLUTAB; DEXIVANT; DEXIVANT; DEXLANSOPRAZOLE MR; KAPIDEX; T-168390; TAK-390; TAK-390MR; TAK-390MR OD; DEXLANSOPRAZOLE; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA/TAP; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL; DEXLANSOPRAZOLE MR; LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAP/FLAMEL; LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL","DEXILANT; DEXILANT DR; DEXILANT DR; DEXILANT SOLUTAB; DEXILANT SOLUTAB; DEXIVANT; DEXIVANT; DEXLANSOPRAZOLE MR; KAPIDEX; T-168390; TAK-390; TAK-390MR; TAK-390MR OD; DEXLANSOPRAZOLE; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA/TAP; DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL; DEXLANSOPRAZOLE MR; LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAP/FLAMEL; LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL","DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA",DEXILANT,DEXILANT DR,DEXILANT DR,DEXILANT SOLUTAB,DEXILANT SOLUTAB,DEXIVANT,DEXIVANT,DEXLANSOPRAZOLE MR,KAPIDEX,T-168390,TAK-390,TAK-390MR,TAK-390MR OD,DEXLANSOPRAZOLE,"DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA","DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE), TAKEDA/TAP","DEXLANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL",DEXLANSOPRAZOLE MR,"LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAP/FLAMEL","LANSOPRAZOLE (ORAL CONTROLLED-RELEASE, MICROPUMP), TAKEDA/TAP/FLAMEL",,,,,,,,,,,208025,LANSOPRAZOLE,208025,LANSOPRAZOLE,208056,DEXLANSOPRAZOLE,22287,DEXLANSOPRAZOLE,22287,DEXLANSOPRAZOLE,,,,,,,,,,,,,2009-01-30T00:00:00Z,2009,1,Dexilant,gastroesophageal reflux,H+ K+ ATPASE INHIBITOR,GASTRIC SECRETION INHIBITOR,CAPSULE FORMULATION; CONTROLLED RELEASE FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY,matched (3),022287,NDA,2007-12-28T00:00:00Z,fda,0,0,0,0,0,,takeda pharmaceuticals,TYO: 4502,1,15722.4,16561.7,12303.5,10759.3,10070.7,10838.9,12683.2,-1808.2,1341.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022287,521,1243,530,138,Esophageal disorders,3,0
255,"ESOMEPRAZOLE STRONTIUM (ORAL, ULCER), HANMI","ESOMEZOL; ESOMEZOLE; ESOMEPRAZOLE; ESOMEPRAZOLE STRONTIUM; ESOMEPRAZOLE STRONTIUM (ORAL, ULCER), HANMI; ESOMEPRAZOLE STRONTIUM TETRAHYDRATE","ESOMEZOL; ESOMEZOLE; ESOMEPRAZOLE; ESOMEPRAZOLE STRONTIUM; ESOMEPRAZOLE STRONTIUM (ORAL, ULCER), HANMI; ESOMEPRAZOLE STRONTIUM TETRAHYDRATE","ESOMEPRAZOLE STRONTIUM (ORAL, ULCER), HANMI",ESOMEZOL,ESOMEZOLE,ESOMEPRAZOLE,ESOMEPRAZOLE STRONTIUM,"ESOMEPRAZOLE STRONTIUM (ORAL, ULCER), HANMI",ESOMEPRAZOLE STRONTIUM TETRAHYDRATE,,,,,,,,,,,,,,,,,,,,,,,,,202342,ESOMEPRAZOLE STRONTIUM,202342,ESOMEPRAZOLE STRONTIUM,202342,ESOMEPRAZOLE STRONTIUM,202342,ESOMEPRAZOLE STRONTIUM,202342,ESOMEPRAZOLE STRONTIUM,,,,,,,,,,,,,2013-08-06T00:00:00Z,2013,8,Esomeprazole strontium delayed-release,stomach ulcer,H+ K+ ATPASE INHIBITOR,ACID PUMP INHIBITOR ANTIULCERANT PRODUCT; ANTIBACTERIAL; ANTICANCER,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202342,NDA,2010-10-15T00:00:00Z,fda,0,0,0,0,0,,hanmi pharmaceutical,KRX: 128940,1,691.6,633.7,522.3,602,,,394.2,90,90,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202342,115,805,531,139,Gastroduodenal ulcer (except hemorrhage),2,0
543,"OMEPRAZOLE AND BICARBONATE (ORAL CAPSULES), SANTARUS/GSK/NORGINE","RAPINEX CAPSULES; SAN-15; ZEGERID CAPSULES; ZEGERID CHEWABLE TABLETS; OMEPRAZOLE; OMEPRAZOLE (IMMEDIATE-RELEASE (2)), SANTARUS; OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SALIX/GSK; OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SANTARUS/GSK; OMEPRAZOLE AND BICARBONATE (ORAL CAPSULES), SANTARUS/GSK/NORGINE; OMEPRAZOLE/SODIUM BICARBONATE/MAGNESIUM HYDROXIDE (IMMEDIATE-RELEASE BUFFERED TABLET), SANTARUS","RAPINEX CAPSULES; SAN-15; ZEGERID CAPSULES; ZEGERID CHEWABLE TABLETS; OMEPRAZOLE; OMEPRAZOLE (IMMEDIATE-RELEASE (2)), SANTARUS; OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SALIX/GSK; OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SANTARUS/GSK; OMEPRAZOLE AND BICARBONATE (ORAL CAPSULES), SANTARUS/GSK/NORGINE; OMEPRAZOLE/SODIUM BICARBONATE/MAGNESIUM HYDROXIDE (IMMEDIATE-RELEASE BUFFERED TABLET), SANTARUS","OMEPRAZOLE AND BICARBONATE (ORAL CAPSULES), SANTARUS/GSK/NORGINE",RAPINEX CAPSULES,SAN-15,ZEGERID CAPSULES,ZEGERID CHEWABLE TABLETS,OMEPRAZOLE,"OMEPRAZOLE (IMMEDIATE-RELEASE (2)), SANTARUS","OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SALIX/GSK","OMEPRAZOLE (ORAL TABLET/CAPSULES, ESOPHAGITIS/DUODENAL ULCER/STOMACH ULCER/GASTROINTESTINAL REFLUX), SANTARUS/GSK","OMEPRAZOLE AND BICARBONATE (ORAL CAPSULES), SANTARUS/GSK/NORGINE","OMEPRAZOLE/SODIUM BICARBONATE/MAGNESIUM HYDROXIDE (IMMEDIATE-RELEASE BUFFERED TABLET), SANTARUS",,,,,,,,,,,,,,,,,,,,,22032,OMEPRAZOLE,22032,OMEPRAZOLE,22032,OMEPRAZOLE,22032,OMEPRAZOLE,22032,OMEPRAZOLE,22032,OMEPRAZOLE,22032,OMEPRAZOLE,,,,,,,,,2006-02-27T00:00:00Z,2006,2,Omeprazole,stomach ulcer,H+ K+ ATPASE INHIBITOR,ACID PUMP INHIBITOR ANTIULCERANT PRODUCT,CAPSULE FORMULATION; FORMULATION POWDER; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021849,NDA,2005-04-26T00:00:00Z,fda,0,0,0,0,0,,santarus,NASDAQ: SNTS,1,49.2,26.5,1.3,,8,,37.9,7.6,7.6,,,,,acquired by salix in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021849,445,805,531,139,Gastroduodenal ulcer (except hemorrhage),2,0
390,"IOHEXOL (DISSOLVABLE POWDER FORMULATION), INTERPHARMA PRAHA","ORALTAG; IOHEXOL; IOHEXOL (DISSOLVABLE POWDER FORMULATION), INTERPHARMA PRAHA","ORALTAG; IOHEXOL; IOHEXOL (DISSOLVABLE POWDER FORMULATION), INTERPHARMA PRAHA","IOHEXOL (DISSOLVABLE POWDER FORMULATION), INTERPHARMA PRAHA",ORALTAG,IOHEXOL,"IOHEXOL (DISSOLVABLE POWDER FORMULATION), INTERPHARMA PRAHA",,,,,,,,,,,,,,,,,,,,,,,,,,,,205383,IOHEXOL,,,,,,,,,,,,,,,,,,,,,2015-03-26T00:00:00Z,2015,3,Oraltag,gastrointestinal disease,,GASTROINTESTINAL DIAGNOSTIC AGENT; X-RAY CONTRAST MEDIUM,FORMULATION POWDER; IMAGING; ORAL FORMULATION; SOLUTION,matched (3),205383,NDA,2013-03-11T00:00:00Z,fda,0,0,0,0,0,,otsuka,TYO: 4578,1,12023.5,13350.2,13344,13476.7,14733.1,13618.6,8285.8,1672.3,1672.3,,,2008,,acquired by otsuka in 2008,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205383,234,129,536,141,Other disorders of stomach and duodenum,2,0
146,CERTOLIZUMAB PEGOL,CDP-870; CIMZIA; PERSTYMAB; CERTOLIZUMAB PEGOL,CDP-870; CIMZIA; PERSTYMAB; CERTOLIZUMAB PEGOL,CERTOLIZUMAB PEGOL,CDP-870,CIMZIA,PERSTYMAB,CERTOLIZUMAB PEGOL,,,,,,,,,,,,,,,,,,,,,,,,,,,125160,CERTOLIZUMAB PEGOL,,,,,,,,,,,,,,,,,,,,,2008-04-22T00:00:00Z,2008,4,Cimzia,crohns disease,TNF ALPHA LIGAND INHIBITOR; TNF ANTAGONIST; TNF BINDING AGENT,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; MONOCLONAL ANTIBODY HUMANIZED; PEGYLATED FORMULATION; PROTEIN CONJUGATED; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125160,BLA,2006-03-02T00:00:00Z,cortellis,0,0,0,0,0,,UCB,EBR: UCB,1,5031.79,5295.05,3366.1,2773.04,2552.13,4251.41,3430.45,1071.75,1071.75,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125160,8,84,555,144,Regional enteritis and ulcerative colitis,1,0
776,VEDOLIZUMAB,"ENTYVIO; KINTELLES; KYNTELES; LDP-02; MLN-0002; MLN-02; ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, LEUKOSITE; ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, MILLENNIUM/GENENTECH; INTEGRIN ANTAGONISTS, MILLENNIUM/GENENTECH; VEDOLIZUMAB","ENTYVIO; KINTELLES; KYNTELES; LDP-02; MLN-0002; MLN-02; ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, LEUKOSITE; ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, MILLENNIUM/GENENTECH; INTEGRIN ANTAGONISTS, MILLENNIUM/GENENTECH; VEDOLIZUMAB",VEDOLIZUMAB,ENTYVIO,KINTELLES,KYNTELES,LDP-02,MLN-0002,MLN-02,"ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, LEUKOSITE","ANTI ALPHA-4/BETA-7 INTEGRIN ANTIBODY, MILLENNIUM/GENENTECH","INTEGRIN ANTAGONISTS, MILLENNIUM/GENENTECH",VEDOLIZUMAB,,,,,,,,,,,,,,,,,,,,,125476,VEDOLIZUMAB,,,,,,,,,,,,,,,,,,,,,2014-05-20T00:00:00Z,2014,5,Entyvio,crohns disease,INTEGRIN ALPHA-4/BETA-7 ANTAGONIST; MADCAM INHIBITOR,ANTI-INFLAMMATORY; ANTIBACTERIAL; ANTICANCER MONOCLONAL ANTIBODY; ANTIVIRAL; GASTROINTESTINAL SYSTEM AGENT; IMMUNOSUPPRESSANT,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; SUBCUTANEOUS FORMULATION,matched (3),125476,BLA,2013-06-20T00:00:00Z,fda,1,0,1,0,0,,takeda pharmaceuticals,TYO: 4502,1,14563.6,15739.7,18156.3,19052,17491.2,15722.4,10245.4,2976.4,2943.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125476,44,84,555,144,Regional enteritis and ulcerative colitis,1,0
111,"BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/FERRING/SALIX","BUDESONIDE MMX; CB-01-02; CORTIMENT; CORTIMENT MMX; UCERIS; ULTESA; BUDESONIDE; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/FERRING/SALIX; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/SANTARUS; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC, ULCERATIVE COLITIS), COSMO/FERRING","BUDESONIDE MMX; CB-01-02; CORTIMENT; CORTIMENT MMX; UCERIS; ULTESA; BUDESONIDE; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/FERRING/SALIX; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/SANTARUS; BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC, ULCERATIVE COLITIS), COSMO/FERRING","BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/FERRING/SALIX",BUDESONIDE MMX,CB-01-02,CORTIMENT,CORTIMENT MMX,UCERIS,ULTESA,BUDESONIDE,"BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/FERRING/SALIX","BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC (MMX), ULCERATIVE COLITIS), COSMO/SANTARUS","BUDESONIDE (ORAL CONTROLLED-RELEASE GASTROINTESTINAL-SPECIFIC, ULCERATIVE COLITIS), COSMO/FERRING",,,,,,,,,,,,,,,,,,,,,203634,BUDESONIDE,,,,,,,,,,,,,,,,,,,,,2013-01-14T00:00:00Z,2013,1,Uceris tablet,ulcerative colitis,,ANTI-INFLAMMATORY; CORTICOSTEROID AGONIST; GASTROINTESTINAL SYSTEM AGENT,CONTROLLED RELEASE FORMULATION; ENTERIC COATED FORMULATION; LOCAL FORMULATION UNSPECIFIED; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; TABLET FORMULATION,matched (3),203634,NDA,2012-12-14T00:00:00Z,fda,0,0,0,0,0,,santarus,NASDAQ: SNTS,1,384.5,218,118.8,125.4,172.5,130.2,265.3,26.9,26.9,,,,,acquired by salix in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203634,166,337,556,144,Regional enteritis and ulcerative colitis,1,0
112,"BUDESONIDE (RECTAL FOAM, ULCERATIVE COLITIS), DR FALK PHARMA/SALIX/AJINOMOTO/EA PHARMA","AJG-511; AJG-511; BUDENOFALK; BUDENOFALK; UCERIS; BUDESONIDE; BUDESONIDE (RECTAL FOAM, ULCERATIVE COLITIS), DR FALK PHARMA/SALIX/AJINOMOTO/EA PHARMA","AJG-511; AJG-511; BUDENOFALK; BUDENOFALK; UCERIS; BUDESONIDE; BUDESONIDE (RECTAL FOAM, ULCERATIVE COLITIS), DR FALK PHARMA/SALIX/AJINOMOTO/EA PHARMA","BUDESONIDE (RECTAL FOAM, ULCERATIVE COLITIS), DR FALK PHARMA/SALIX/AJINOMOTO/EA PHARMA",AJG-511,AJG-511,BUDENOFALK,BUDENOFALK,UCERIS,BUDESONIDE,"BUDESONIDE (RECTAL FOAM, ULCERATIVE COLITIS), DR FALK PHARMA/SALIX/AJINOMOTO/EA PHARMA",,,,,,,,,,,,,,,,,,,,,,,,203634,BUDESONIDE,,,,,,,,,,,,,,,,,,,,,2014-10-07T00:00:00Z,2014,10,Uceris rectal foam,ulcerative proctitis,GLUCOCORTICOID AGONIST,STEROIDAL ANTI-INFLAMMATORY,RECTAL FOAM FORMULATION; RECTAL FORMULATION; RECTAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),205613,NDA,2013-11-15T00:00:00Z,fda,0,0,0,0,0,,salix pharmaceuticals,NASDAQ: SLXP,1,1133.5,913.8,735.4,540.5,337,232.9,833,170.3,170.3,,,,,acquired by valeant in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205613,167,3035,556,144,Regional enteritis and ulcerative colitis,1,0
469,"MESALAZINE (ORAL DELAYED-RELEASE), ALLERGAN","DELZICOL; MESALAMINE; MESALAMINE (DELAYED-RELEASE), ALLERGAN; MESALAMINE (DELAYED-RELEASE), WARNER CHILCOTT; MESALAZINE; MESALAZINE (DELAYED-RELEASE), WARNER CHILCOTT; MESALAZINE (ORAL DELAYED-RELEASE), ALLERGAN","DELZICOL; MESALAMINE; MESALAMINE (DELAYED-RELEASE), ALLERGAN; MESALAMINE (DELAYED-RELEASE), WARNER CHILCOTT; MESALAZINE; MESALAZINE (DELAYED-RELEASE), WARNER CHILCOTT; MESALAZINE (ORAL DELAYED-RELEASE), ALLERGAN","MESALAZINE (ORAL DELAYED-RELEASE), ALLERGAN",DELZICOL,MESALAMINE,"MESALAMINE (DELAYED-RELEASE), ALLERGAN","MESALAMINE (DELAYED-RELEASE), WARNER CHILCOTT",MESALAZINE,"MESALAZINE (DELAYED-RELEASE), WARNER CHILCOTT","MESALAZINE (ORAL DELAYED-RELEASE), ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,204412,MESALAMINE,,,,,,,,,,,,,,,,,,,,,2013-02-01T00:00:00Z,2013,2,Delzicol,ulcerative colitis,CYCLOOXYGENASE INHIBITOR; LIPOXYGENASE MODULATOR,ANTI-INFLAMMATORY; GASTROINTESTINAL SYSTEM AGENT,CAPSULE FORMULATION; CONTROLLED RELEASE FORMULATION; LOCAL FORMULATION UNSPECIFIED; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204412,NDA,2012-07-31T00:00:00Z,fda,1,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,2602.5,2541,2728,2947,1435.8,938.1,1137.1,190.2,191.3,2409.33333333333,2013-09-30T00:00:00Z,2013,,acquired by actavis (now allergan plc) in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204412,198,337,556,144,Regional enteritis and ulcerative colitis,1,0
470,"MESALAZINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC","GED-0001; LIALDA; MD-0901; MMX MESALAMINE; MESAVANCE; MESAVANCOL; MEZAVANT; MEZAVANT XL; SPD-476; MESALAMINE; MESALAMINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC; MESALAZINE; MESALAZINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC; MESALAZINE MMX; MULTI-MATRIX 5-ASA, GIULIANI/SHIRE","GED-0001; LIALDA; MD-0901; MMX MESALAMINE; MESAVANCE; MESAVANCOL; MEZAVANT; MEZAVANT XL; SPD-476; MESALAMINE; MESALAMINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC; MESALAZINE; MESALAZINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC; MESALAZINE MMX; MULTI-MATRIX 5-ASA, GIULIANI/SHIRE","MESALAZINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC",GED-0001,LIALDA,MD-0901,MMX MESALAMINE,MESAVANCE,MESAVANCOL,MEZAVANT,MEZAVANT XL,SPD-476,MESALAMINE,"MESALAMINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC",MESALAZINE,"MESALAZINE (ORAL SUSTAINED RELEASE, MMX), GIULIANI/SHIRE/MOCHIDA/PACIFIC",MESALAZINE MMX,"MULTI-MATRIX 5-ASA, GIULIANI/SHIRE",,,,,,,,,,,,,,,,22000,MESALAMINE,,,,,,,,,,,,,,,,,,,,,2007-01-16T00:00:00Z,2007,1,Lialda,ulcerative colitis,,ANTI-INFLAMMATORY; GASTROINTESTINAL SYSTEM AGENT; NON-STEROIDAL ANTI-INFLAMMATORY; UNSPECIFIED DRUG TARGET,CONTROLLED RELEASE FORMULATION; DAILY DOSING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),022000,NDA,2005-12-21T00:00:00Z,fda,0,0,0,0,0,,shire,NASDAQ: SHPG,1,2436.3,1796.5,1599.3,1363.2,1331.48,1121.1,2116,544.6,544.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022000,433,337,556,144,Regional enteritis and ulcerative colitis,1,0
34,ALVIMOPAN,"ADL-08-0011; ADL-2698; ADL-8-2698; ENTEREG; ENTEREGA; ENTRAREG; L 8-2698; LY-246736; SB-767905; ALVIMOPAN; ALVIMOPAN (USAN); ALVIMOPAN DIHYDRATE; MU-OPIOID ANTAGONIST, ADOLOR; OPIATE ANTAGONIST, ADOLOR","ADL-08-0011; ADL-2698; ADL-8-2698; ENTEREG; ENTEREGA; ENTRAREG; L 8-2698; LY-246736; SB-767905; ALVIMOPAN; ALVIMOPAN (USAN); ALVIMOPAN DIHYDRATE; MU-OPIOID ANTAGONIST, ADOLOR; OPIATE ANTAGONIST, ADOLOR",ALVIMOPAN,ADL-08-0011,ADL-2698,ADL-8-2698,ENTEREG,ENTEREGA,ENTRAREG,L 8-2698,LY-246736,SB-767905,ALVIMOPAN,ALVIMOPAN (USAN),ALVIMOPAN DIHYDRATE,"MU-OPIOID ANTAGONIST, ADOLOR","OPIATE ANTAGONIST, ADOLOR",,,,,,,,,,,,,,,,,21775,ALVIMOPAN,21775,ALVIMOPAN,,,,,,,,,,,,,,,,,,,2008-05-20T00:00:00Z,2008,5,Entereg,ileus,OPIOID RECEPTOR MU ANTAGONIST,GASTROINTESTINAL SYSTEM AGENT,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021775,NDA,2007-08-09T00:00:00Z,fda,0,0,1,0,0,,adolor,NASDAQ: ADLR,1,49.5,9.1,15.1,15.7,25.5,20.7,22,25.4,52.7,,,,,acquired by cubist pharma in 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021775,385,1519,560,145,Intestinal obstruction without hernia,1,0
433,LINACLOTIDE,"ASP-0456; CONSTELLA; LINZESS; MD-1100; MM-416775; MM-419447; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/ACTAVIS; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/FOREST; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), LABORATORIOS ALMIRALL; LINACLOTIDE; LINACLOTIDE ACETATE","ASP-0456; CONSTELLA; LINZESS; MD-1100; MM-416775; MM-419447; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/ACTAVIS; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/FOREST; GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), LABORATORIOS ALMIRALL; LINACLOTIDE; LINACLOTIDE ACETATE",LINACLOTIDE,ASP-0456,CONSTELLA,LINZESS,MD-1100,MM-416775,MM-419447,"GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/ACTAVIS","GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), IRONWOOD/FOREST","GUANYLATE CYCLASE TYPE-C RECEPTOR AGONIST (IBS-C/CIC), LABORATORIOS ALMIRALL",LINACLOTIDE,LINACLOTIDE ACETATE,,,,,,,,,,,,,,,,,,,,202811,LINACLOTIDE,,,,,,,,,,,,,,,,,,,,,2012-08-30T00:00:00Z,2012,8,Linzess,constipation,NATRIURETIC PEPTIDE RECEPTOR C AGONIST,ANTICANCER; GASTROPROKINETIC; LAXATIVE,BEAD FORMULATION; BIOLOGICAL THERAPEUTIC; CAPSULE FORMULATION; DRUG COATING; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; PEPTIDE; TABLET FORMULATION,matched (3),202811,NDA,2011-08-08T00:00:00Z,fda,0,0,0,0,0,,forest laboratories,NYSE: FRX,1,3341.9,4635.3,4308.4,4060.6,3863.8,3621.4,2653,937.2,937.2,,,,,acquired by actavis (now allergan plc) in 2014,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202811,131,404,564,155,Other gastrointestinal disorders,3,0
503,NALOXEGOL,"AZ-13337019 OXALATE; MOVANTIK; MOVENTIG; NKTR-118; NKTR-118 OXALATE; PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), ASTRAZENECA; PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), NEKTAR; NALOXEGOL; NALOXEGOL OXALATE","AZ-13337019 OXALATE; MOVANTIK; MOVENTIG; NKTR-118; NKTR-118 OXALATE; PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), ASTRAZENECA; PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), NEKTAR; NALOXEGOL; NALOXEGOL OXALATE",NALOXEGOL,AZ-13337019 OXALATE,MOVANTIK,MOVENTIG,NKTR-118,NKTR-118 OXALATE,"PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), ASTRAZENECA","PEG-NALOXOL (ORAL, OPIOID-INDUCED CONSTIPATION), NEKTAR",NALOXEGOL,NALOXEGOL OXALATE,,,,,,,,,,,,,,,,,,,,,,204760,NALOXEGOL OXALATE,,,,,,,,,,,,,,,,,,,,,2014-09-16T00:00:00Z,2014,9,Movantik,constipation,OPIOID RECEPTOR MU ANTAGONIST,ANALGESIC,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; PEGYLATED FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204760,NDA,2013-09-16T00:00:00Z,fda,0,0,0,0,0,,astrazeneca,NYSE: AZN,1,26547,25806,27973,33591,33269,32804,20812,5001,5438,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204760,214,404,564,155,Other gastrointestinal disorders,3,0
239,ELUXADOLINE DIHYDROCHLORIDE,"IBS AGENT (ORAL), FURIEX PHARMACEUTICALS; JNJ-27018966; MUDELTA; TRUBERZI; TRUBERZI; VIBERZI; VIBERZI; ELUXADOLINE; ELUXADOLINE DIHYDROCHLORIDE; OPIOID RECEPTOR MODULATOR (IBS-D), FURIEX PHARMACEUTICALS; OPIOID RECEPTOR MODULATOR (IBS-D), JANSSEN PHARMACEUTICA NV/ PPD; OPIOID RECEPTOR MODULATOR (DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME), JANSSEN PHARMACEUTICA NV/ PPD","IBS AGENT (ORAL), FURIEX PHARMACEUTICALS; JNJ-27018966; MUDELTA; TRUBERZI; TRUBERZI; VIBERZI; VIBERZI; ELUXADOLINE; ELUXADOLINE DIHYDROCHLORIDE; OPIOID RECEPTOR MODULATOR (IBS-D), FURIEX PHARMACEUTICALS; OPIOID RECEPTOR MODULATOR (IBS-D), JANSSEN PHARMACEUTICA NV/ PPD; OPIOID RECEPTOR MODULATOR (DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME), JANSSEN PHARMACEUTICA NV/ PPD",ELUXADOLINE DIHYDROCHLORIDE,"IBS AGENT (ORAL), FURIEX PHARMACEUTICALS",JNJ-27018966,MUDELTA,TRUBERZI,TRUBERZI,VIBERZI,VIBERZI,ELUXADOLINE,ELUXADOLINE DIHYDROCHLORIDE,"OPIOID RECEPTOR MODULATOR (IBS-D), FURIEX PHARMACEUTICALS","OPIOID RECEPTOR MODULATOR (IBS-D), JANSSEN PHARMACEUTICA NV/ PPD","OPIOID RECEPTOR MODULATOR (DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME), JANSSEN PHARMACEUTICA NV/ PPD",,,,,,,,,,,,,,,,,,,206940,ELUXADOLINE,,,,,,,,,,,,,,,,,,,,,2015-05-27T00:00:00Z,2015,5,Viberzi,diarrhea predominant irritable bowel syndrome,OPIOID RECEPTOR DELTA ANTAGONIST; OPIOID RECEPTOR KAPPA AGONIST; OPIOID RECEPTOR MU AGONIST,GASTROINTESTINAL SYSTEM AGENT,DRUG COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206940,NDA,2014-06-26T00:00:00Z,fda,1,0,1,0,0,,actavis (allergan plc),NYSE: AGN,1,12688.1,4676.5,70.999,40.508,4.49,8.983,11221.3,2067,2358.5,25.6,2014-03-31T00:00:00Z,2014,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206940,293,3863,564,155,Other gastrointestinal disorders,3,0
449,LUBIPROSTONE,AMITIZA; RU-0211; SPI-0211; LUBIPROSTONE,AMITIZA; RU-0211; SPI-0211; LUBIPROSTONE,LUBIPROSTONE,AMITIZA,RU-0211,SPI-0211,LUBIPROSTONE,,,,,,,,,,,,,,,,,,,,,,,,,,,21908,LUBIPROSTONE,,,,,,,,,,,,,,,,,,,,,2006-01-31T00:00:00Z,2006,1,Amitiza,constipation,VOLTAGE GATED CHLORIDE CHANNEL 2 STIMULATOR,GASTROPROKINETIC; LAXATIVE,CAPSULE FORMULATION; MICROPARTICLE FORMULATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021908,NDA,2005-03-31T00:00:00Z,fda,0,0,0,0,0,,sucampo pharmaceuticals,private,0,59.3,40.2,3.3,4.1,,,37.6,,19.2,,,,,IPO IN 2007,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021908,406,404,564,155,Other gastrointestinal disorders,3,0
474,"METHYLNALTREXONE BROMIDE (ORAL), SALIX","MNTX (ORAL), PROGENICS; MOA-728; RELISTOR; METHYLNALTREXONE; METHYLNALTREXONE (ORAL), PROGENICS; METHYLNALTREXONE (ORAL), PROGENICS/WYETH; METHYLNALTREXONE BROMIDE; METHYLNALTREXONE BROMIDE (ORAL), PROGENICS; METHYLNALTREXONE BROMIDE (ORAL), SALIX","MNTX (ORAL), PROGENICS; MOA-728; RELISTOR; METHYLNALTREXONE; METHYLNALTREXONE (ORAL), PROGENICS; METHYLNALTREXONE (ORAL), PROGENICS/WYETH; METHYLNALTREXONE BROMIDE; METHYLNALTREXONE BROMIDE (ORAL), PROGENICS; METHYLNALTREXONE BROMIDE (ORAL), SALIX","METHYLNALTREXONE BROMIDE (ORAL), SALIX","MNTX (ORAL), PROGENICS",MOA-728,RELISTOR,METHYLNALTREXONE,"METHYLNALTREXONE (ORAL), PROGENICS","METHYLNALTREXONE (ORAL), PROGENICS/WYETH",METHYLNALTREXONE BROMIDE,"METHYLNALTREXONE BROMIDE (ORAL), PROGENICS","METHYLNALTREXONE BROMIDE (ORAL), SALIX",,,,,,,,,,,,,,,,,,,,,,21964,METHYLNALTREXONE BROMIDE,,,,,,,,,,,,,,,,,,,,,2016-07-19T00:00:00Z,2016,7,Relistor,constipation,OPIOID RECEPTOR MU ANTAGONIST,,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208271,NDA,2015-06-19T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,9674,8200,1133.5,913.8,735.4,540.5,7101,421,421,,,2015,,acquired by valeant in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208271,420,404,564,155,Other gastrointestinal disorders,3,0
475,"METHYLNALTREXONE BROMIDE (SUBCUTANEOUS), PROGENICS/WYETH/ONO/SALIX","MNTX (SC), UNIVERSITY OF CHICAGO/PROGENICS; MOA-728; ONO-3849; RELISTOR (SUBCUTANEOUS), PROGENICS/PFIZER/ONO/SALIX; RELISTOR (SUBCUTANEOUS), PROGENICS/WYETH/ONO/SALIX; METHYLNALTREXONE; METHYLNALTREXONE (SUBCUTANEOUS), PROGENICS; METHYLNALTREXONE (SUBCUTANEOUS, CONSTIPATION), PROGENICS/PFIZER/ONO/SALIX; METHYLNALTREXONE (SUBCUTANEOUS, CONSTIPATION), PROGENICS/WYETH/ONO/SALIX; METHYLNALTREXONE BROMIDE; METHYLNALTREXONE BROMIDE (SUBCUTANEOUS), PROGENICS/WYETH/ONO/SALIX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-04-24T00:00:00Z,2008,4,Relistor,constipation,OPIOID RECEPTOR MU ANTAGONIST,LAXATIVE,SMALL MOLECULE THERAPEUTIC; SOLUTION; SUBCUTANEOUS FORMULATION,using only (2),021964,NDA,2007-03-30T00:00:00Z,fda,0,0,0,0,0,,progenics,NASDAQ: PGNX,1,67.7,75.6,69.9,9.5,9.6,7.5,-17.5,,85.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021964,698,404,564,155,Other gastrointestinal disorders,3,0
520,NITROGLYCERIN OINTMENT,ANOGESIC; CELLEGESIC; RECTIV; RECTOGESIC; RUITUOXI; RUITUOXI; NITROGLYCERIN; NITROGLYCERIN OINTMENT,ANOGESIC; CELLEGESIC; RECTIV; RECTOGESIC; RUITUOXI; RUITUOXI; NITROGLYCERIN; NITROGLYCERIN OINTMENT,NITROGLYCERIN OINTMENT,ANOGESIC,CELLEGESIC,RECTIV,RECTOGESIC,RUITUOXI,RUITUOXI,NITROGLYCERIN,NITROGLYCERIN OINTMENT,,,,,,,,,,,,,,,,,,,,,,,18531,NITROGLYCERIN,18531,NITROGLYCERIN,18531,NITROGLYCERIN,21359,NITROGLYCERIN,,,,,,,,,,,,,,,2011-06-21T00:00:00Z,2011,6,Rectiv,anus pain,,ANALGESIC; NO AGONIST; VASODILATOR,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; RECTAL FORMULATION; RECTAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021359,NDA,2001-06-22T00:00:00Z,fda,1,0,0,0,0,,kyowa kirin,TSE: 4151,1,4467.4,156.5,127.6,81.7,90.6,75.3,2567.7,622.9,622.6,,,2011,,acquired by kyowa kirin in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021359,366,3648,569,155,Other gastrointestinal disorders,6,0
528,OBETICHOLIC ACID,"6ECDCA; DSP-1747; FXR AGONISTS, INTERCEPT; INT-747; OCA, INTERCEPT; OCALIVA; OCALIVA; UPF-747; FARNESOID X RECEPTOR AGONISTS, INTERCEPT; OBETICHOLIC ACID","6ECDCA; DSP-1747; FXR AGONISTS, INTERCEPT; INT-747; OCA, INTERCEPT; OCALIVA; OCALIVA; UPF-747; FARNESOID X RECEPTOR AGONISTS, INTERCEPT; OBETICHOLIC ACID",OBETICHOLIC ACID,6ECDCA,DSP-1747,"FXR AGONISTS, INTERCEPT",INT-747,"OCA, INTERCEPT",OCALIVA,OCALIVA,UPF-747,"FARNESOID X RECEPTOR AGONISTS, INTERCEPT",OBETICHOLIC ACID,,,,,,,,,,,,,,,,,,,,,207999,OBETICHOLIC ACID,,,,,,,,,,,,,,,,,,,,,2016-05-27T00:00:00Z,2016,5,Ocaliva,primary biliary cirrhosis,FARNESOID X RECEPTOR AGONIST,ANTI-INFLAMMATORY; BILE ACID MODULATOR,DAILY DOSING; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207999,NDA,2015-06-27T00:00:00Z,fda,1,1,1,1,0,,intercept pharmaceuticals,NASDAQ: ICPT,1,25,2.8,1.7,1.6,2.4,1.8,25,153.9,153.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207999,319,1995,571,151,Other liver diseases,3,0
192,"DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM","DEFITELIO; DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM; DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM/SIGMA-TAU","DEFITELIO; DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM; DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM/SIGMA-TAU","DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM",DEFITELIO,"DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM","DEFIBROTIDE (IV, VENO-OCCLUSIVE DISEASE), GENTIUM/SIGMA-TAU",,,,,,,,,,,,,,,,,,,,,,,,,,,,208114,DEFIBROTIDE SODIUM,,,,,,,,,,,,,,,,,,,,,2016-03-30T00:00:00Z,2016,3,Defitelio,venous occlusive disease,,ANTICANCER; COAGULATION INHIBITOR; UNSPECIFIED DRUG TARGET; VASOPROTECTANT,BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION; OLIGONUCLEOTIDE,matched (3),208114,NDA,2015-07-30T00:00:00Z,fda,1,0,1,1,0,,jazz pharmaceuticals,NASDAQ: JAZZ,1,1488,1324.8,1172.9,872.4,586,272.3,1382.6,162.3,261.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208114,329,3413,573,151,Other liver diseases,2,0
569,"PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CHIESI USA INC","PANCRECARB; PERTZYE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CHIESI USA INC; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CORNERSTONE THERAPEUTICS INC","PANCRECARB; PERTZYE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CHIESI USA INC; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CORNERSTONE THERAPEUTICS INC","PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CHIESI USA INC",PANCRECARB,PERTZYE,"PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE","PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CHIESI USA INC","PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), DIGESTIVE CARE/CORNERSTONE THERAPEUTICS INC",,,,,,,,,,,,,,,,,,,,,,,,,,22175,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),,,,,,,,,,,,,,,,,,,,,2012-05-17T00:00:00Z,2012,5,Pertzye,exocrine pancreatic insufficiency,AMYLASE STIMULATOR; LIPASE STIMULATOR; PROTEASE STIMULATOR,,BIOLOGICAL THERAPEUTIC; CAPSULE FORMULATION; CONTROLLED RELEASE FORMULATION; ENTERIC COATED FORMULATION; ENZYME; ORAL FORMULATION,matched (3),022175,NDA,2008-10-27T00:00:00Z,fda,0,0,1,0,0,,digestive care inc,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022175,486,3233,577,152,Pancreatic disorders (not diabetes),1,0
570,"PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND","EUR-1008; EUR-1008; EUR-1008M; EUR-1008M; ENZEPI; ENZEPI; ZENPEP; ZENTASE; ZENTASE; PANCREATIC ENZYME REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND; PANCRELIPASE; PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS; PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND","EUR-1008; EUR-1008; EUR-1008M; EUR-1008M; ENZEPI; ENZEPI; ZENPEP; ZENTASE; ZENTASE; PANCREATIC ENZYME REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND; PANCRELIPASE; PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS; PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND","PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND",EUR-1008,EUR-1008,EUR-1008M,EUR-1008M,ENZEPI,ENZEPI,ZENPEP,ZENTASE,ZENTASE,"PANCREATIC ENZYME REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND",PANCRELIPASE,"PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS","PANCRELIPASE REPLACEMENT THERAPY (EXOCRINE PANCREATIC INSUFFICIENCY), EURAND",,,,,,,,,,,,,,,,,,22210,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),,,,,,,,,,,,,,,,,,,,,2009-08-27T00:00:00Z,2009,8,Zenpep,exocrine pancreatic insufficiency,AMYLASE STIMULATOR; PANCREATIC LIPASE STIMULATOR; UNSPECIFIED PROTEASE STIMULATOR,DIGESTION STIMULATOR,BIOLOGICAL THERAPEUTIC; CAPSULE FORMULATION; DRUG COMBINATION; ENTERIC COATED FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION,matched (3),022210,NDA,2007-12-14T00:00:00Z,fda,1,0,1,0,0,,eurand pharmaceuticals,NASDAQ: EURX,1,172.8,137.7,123.9,109.3,85.6,110,76,24.7,33.8,,,,,acquired by axcan in 2011; now part of allergan plc,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022210,498,3233,577,152,Pancreatic disorders (not diabetes),1,0
568,"PANCRELIPASE (DELAYED RELEASE, EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS","ULTRASE; ULTRESA; PANCRELIPASE; PANCRELIPASE (DELAYED RELEASE, EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS","ULTRASE; ULTRESA; PANCRELIPASE; PANCRELIPASE (DELAYED RELEASE, EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS","PANCRELIPASE (DELAYED RELEASE, EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS",ULTRASE,ULTRESA,PANCRELIPASE,"PANCRELIPASE (DELAYED RELEASE, EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS",,,,,,,,,,,,,,,,,,,,,,,,,,,22222,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),22222,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),,,,,,,,,,,,,,,,,,,2012-03-01T00:00:00Z,2012,3,Ultresa,exocrine pancreatic insufficiency,AMYLASE STIMULATOR; PANCREATIC LIPASE STIMULATOR; PROTEASE STIMULATOR,DIGESTION STIMULATOR,CAPSULE FORMULATION; DRUG COMBINATION; ENTERIC COATED FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022222,NDA,2007-09-28T00:00:00Z,fda,1,0,1,0,0,,aptalis pharma,private,0,615.1,470.4,,,,,470.9,72.6,72.6,,,,,acquired by forest labs in 2014; privately held by TPG capital beforehand,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022222,503,3233,577,152,Pancreatic disorders (not diabetes),1,0
567,PANCREAZE,"PANCREAZE; PANCREATIC ENZYMES (DELAYED RELEASE CAPSULE), JOHNSON & JOHNSON; PANCRELIPASE","PANCREAZE; PANCREATIC ENZYMES (DELAYED RELEASE CAPSULE), JOHNSON & JOHNSON; PANCRELIPASE",PANCREAZE,PANCREAZE,"PANCREATIC ENZYMES (DELAYED RELEASE CAPSULE), JOHNSON & JOHNSON",PANCRELIPASE,,,,,,,,,,,,,,,,,,,,,,,,,,,,22523,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),,,,,,,,,,,,,,,,,,,,,2010-04-12T00:00:00Z,2010,4,Pancreaze,exocrine pancreatic insufficiency,AMYLASE STIMULATOR; PANCREATIC LIPASE STIMULATOR; PROTEASE STIMULATOR,DIGESTION STIMULATOR,BIOLOGICAL THERAPEUTIC; CAPSULE FORMULATION; ENZYME; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION,matched (3),022523,NDA,2009-06-23T00:00:00Z,fda,0,0,1,0,0,,johnson and johnson,NYSE: JNJ,1,61587,61897,63747,61095,53324,50514,42795,6844,6844,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022523,588,3233,577,152,Pancreatic disorders (not diabetes),1,0
784,VIOKACE,"VIOKACE; VIOKASE; PANCRELIPASE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS","VIOKACE; VIOKASE; PANCRELIPASE; PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS",VIOKACE,VIOKACE,VIOKASE,PANCRELIPASE,"PANCRELIPASE (EXOCRINE PANCREATIC INSUFFICIENCY), APTALIS",,,,,,,,,,,,,,,,,,,,,,,,,,,22542,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),22542,PANCRELIPASE (AMYLASE;LIPASE;PROTEASE),,,,,,,,,,,,,,,,,,,2012-03-01T00:00:00Z,2012,3,Viokace,exocrine pancreatic insufficiency,AMYLASE STIMULATOR; PANCREATIC LIPASE STIMULATOR; PROTEASE STIMULATOR,DIGESTION STIMULATOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022542,NDA,2009-10-29T00:00:00Z,fda,0,0,0,0,0,,aptalis pharma,private,0,615.1,470.4,,,,,470.9,72.6,72.6,,,,,acquired by forest labs in 2014; privately held by TPG capital beforehand,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022542,595,3233,577,152,Pancreatic disorders (not diabetes),1,0
712,TEDUGLUTIDE,"ALX-0600; GLP-2, ALLELIX; GLP-2, NPS ALLELIX; GATTEX; REVESTIVE; SHP-633; [GLY2]GLP-2; GLUCAGON-LIKE PEPTIDE-2, ALLELIX; GLUCAGON-LIKE PEPTIDE-2, NPS ALLELIX; TEDUGLUTIDE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2012-12-21T00:00:00Z,2012,12,Gattex,short bowel syndrome,GLUCAGON-LIKE PEPTIDE 2 AGONIST,,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; PEPTIDE; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,using only (2),203441,NDA,2011-11-30T00:00:00Z,fda,0,0,0,1,0,,NPS pharmaceuticals,NASDAQ: NPSP,1,105.6,101.6,89.4,84.1,102.3,86.2,105.6,94.8,94.8,,,,,acquired by shire 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441,723,2168,579,155,Other gastrointestinal disorders,3,0
329,GLUCARPIDASE,"BLHP-011; CPG2, ENACT; CPG2, PROTHERICS; VORAXAZE; CARBOXYPEPTIDASE G2, BTG; CARBOXYPEPTIDASE G2, ENACT; CARBOXYPEPTIDASE G2, OHARA; GLUCARPIDASE; METHOTREXATE ANTIDOTE, BTG; METHOTREXATE ANTIDOTE, ENACT; METHOTREXATE ANTIDOTE, OHARA","BLHP-011; CPG2, ENACT; CPG2, PROTHERICS; VORAXAZE; CARBOXYPEPTIDASE G2, BTG; CARBOXYPEPTIDASE G2, ENACT; CARBOXYPEPTIDASE G2, OHARA; GLUCARPIDASE; METHOTREXATE ANTIDOTE, BTG; METHOTREXATE ANTIDOTE, ENACT; METHOTREXATE ANTIDOTE, OHARA",GLUCARPIDASE,BLHP-011,"CPG2, ENACT","CPG2, PROTHERICS",VORAXAZE,"CARBOXYPEPTIDASE G2, BTG","CARBOXYPEPTIDASE G2, ENACT","CARBOXYPEPTIDASE G2, OHARA",GLUCARPIDASE,"METHOTREXATE ANTIDOTE, BTG","METHOTREXATE ANTIDOTE, ENACT","METHOTREXATE ANTIDOTE, OHARA",,,,,,,,,,,,,,,,,,,,125327,GLUCARPIDASE,,,,,,,,,,,,,,,,,,,,,2012-01-17T00:00:00Z,2012,1,Voraxaze,nephrotoxicity,CARBOXYPEPTIDASE G2 STIMULATOR,ANTIDOTE,BIOLOGICAL THERAPEUTIC; CLONING TECHNOLOGY; FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; RECOMBINANT ENZYME,matched (3),125327,BLA,2008-11-20T00:00:00Z,cortellis,1,0,1,1,0,,BTG international,LSE: BTG,1,376.7,290.2,162.5,162.3,118.6,115.8,270.7,64.1,88.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125327,26,450,583,156,Nephritis; nephrosis; renal sclerosis,1,0
466,"MERCAPTAMINE (CYSTINOSIS), LEADIANT BIOSCIENCES","CYSTARAN; CYSTEAMINE; CYSTEAMINE HYDROCHLORIDE; CYSTEAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS; MERCAPTAMINE; MERCAPTAMINE (CYSTINOSIS), LEADIANT BIOSCIENCES; MERCAPTAMINE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS; MERCAPTAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS","CYSTARAN; CYSTEAMINE; CYSTEAMINE HYDROCHLORIDE; CYSTEAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS; MERCAPTAMINE; MERCAPTAMINE (CYSTINOSIS), LEADIANT BIOSCIENCES; MERCAPTAMINE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS; MERCAPTAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS","MERCAPTAMINE (CYSTINOSIS), LEADIANT BIOSCIENCES",CYSTARAN,CYSTEAMINE,CYSTEAMINE HYDROCHLORIDE,"CYSTEAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS",MERCAPTAMINE,"MERCAPTAMINE (CYSTINOSIS), LEADIANT BIOSCIENCES","MERCAPTAMINE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS","MERCAPTAMINE HYDROCHLORIDE (CYSTINOSIS), SIGMA-TAU PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,200740,CYSTEAMINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2012-10-02T00:00:00Z,2012,10,Cystaran,cystinosis,,OPHTHALMOLOGICAL AGENT; UNSPECIFIED DRUG TARGET,OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),200740,NDA,2010-03-03T00:00:00Z,fda,1,0,0,1,0,,sigma-tau pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200740,79,3072,588,161,Other diseases of kidney and ureters,1,0
259,"ETELCALCETIDE (SECONDARY HYPERPARATHYROIDISM), ONO/AMGEN","AMG-416; AMG-416; KAI-4169; KAI-4169; ONO-5163; ONO-5163; PARSABIV; PARSABIV; CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS; CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS; ETELCALCETIDE; ETELCALCETIDE HYDROCHLORIDE; PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS; PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS; VELCALCETIDE; VELCALCETIDE (SECONDARY HYPERPARATHYROIDISM), ONO/AMGEN; VELCALCETIDE HYDROCHLORIDE","AMG-416; AMG-416; KAI-4169; KAI-4169; ONO-5163; ONO-5163; PARSABIV; PARSABIV; CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS; CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS; ETELCALCETIDE; ETELCALCETIDE HYDROCHLORIDE; PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS; PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS; VELCALCETIDE; VELCALCETIDE (SECONDARY HYPERPARATHYROIDISM), ONO/AMGEN; VELCALCETIDE HYDROCHLORIDE","ETELCALCETIDE (SECONDARY HYPERPARATHYROIDISM), ONO/AMGEN",AMG-416,AMG-416,KAI-4169,KAI-4169,ONO-5163,ONO-5163,PARSABIV,PARSABIV,"CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS","CALCIUM-SENSING RECEPTOR AGONIST (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS",ETELCALCETIDE,ETELCALCETIDE HYDROCHLORIDE,"PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), KAI PHARMACEUTICALS","PROTEIN KINASE C MODULATOR (SECONDARY HYPERPARATHYROIDISM), ONO PHARMACEUTICALS",VELCALCETIDE,"VELCALCETIDE (SECONDARY HYPERPARATHYROIDISM), ONO/AMGEN",VELCALCETIDE HYDROCHLORIDE,,,,,,,,,,,,,,208325,ETELCALCETIDE,,,,,,,,,,,,,,,,,,,,,2017-02-07T00:00:00Z,2017,2,Parsabiv,secondary hyperparathyroidism,EXTRACELLULAR CALCIUM SENSING RECEPTOR AGONIST; PROTEIN KINASE C EPSILON INHIBITOR,,BIOLOGICAL THERAPEUTIC; INTRAVENOUS FORMULATION; PEPTIDE; SUSTAINED RELEASE FORMULATION,matched (3),208325,NDA,2015-08-24T00:00:00Z,fda,0,0,0,0,0,,amgen,NASDAQ: AMGN,1,21856,22991,24662,20063,18676,17265,17872,3076,3076,,,2012,,acquired by amgen in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208325,338,1665,588,161,Other diseases of kidney and ureters,1,0
553,"OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ALLERGAN/ DAEWOONG","AP-1034; ANTUROL; GELNIQUE 3%; OXYBUTYNIN; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ALLERGAN/ DAEWOONG; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ACTAVIS; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ALLERGAN; OXYBUTYNIN (GEL, ATD), ANTARES; OXYBUTYNIN (GEL, OVERACTIVE BLADDER), ANTARES/WATSON; OXYBUTYNIN GEL 3%","AP-1034; ANTUROL; GELNIQUE 3%; OXYBUTYNIN; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ALLERGAN/ DAEWOONG; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ACTAVIS; OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ALLERGAN; OXYBUTYNIN (GEL, ATD), ANTARES; OXYBUTYNIN (GEL, OVERACTIVE BLADDER), ANTARES/WATSON; OXYBUTYNIN GEL 3%","OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ALLERGAN/ DAEWOONG",AP-1034,ANTUROL,GELNIQUE 3%,OXYBUTYNIN,"OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ALLERGAN/ DAEWOONG","OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ACTAVIS","OXYBUTYNIN (3% GEL, OVERACTIVE BLADDER), ANTARES/ALLERGAN","OXYBUTYNIN (GEL, ATD), ANTARES","OXYBUTYNIN (GEL, OVERACTIVE BLADDER), ANTARES/WATSON",OXYBUTYNIN GEL 3%,,,,,,,,,,,,,,,,,,,,,202513,OXYBUTYNIN,,,,,,,,,,,,,,,,,,,,,2011-12-07T00:00:00Z,2011,12,Gelnique 3% (Anturol),overactive bladder,MUSCARINIC RECEPTOR ANTAGONIST,,SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),202513,NDA,2010-12-17T00:00:00Z,fda,0,0,0,0,0,,antares pharma,NASDAQ: ATRS,1,16.5,12.8,8.3,5.7,7.9,4.3,9.7,6.7,9.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202513,121,2376,596,162,Other diseases of bladder and urethra,3,0
494,MIRABEGRON,"BETANIS; BETMIGA; MYRBETRIQ; YM-178; YM-178 OCAS; YM-178 OCAS-M; YM-178 OCAS-X; BETA-3 ADRENOCEPTOR AGONISTS (DIABETES/OBESITY), YAMANOUCHI; MIRABEGRON; MIRABEGRON OCAS","BETANIS; BETMIGA; MYRBETRIQ; YM-178; YM-178 OCAS; YM-178 OCAS-M; YM-178 OCAS-X; BETA-3 ADRENOCEPTOR AGONISTS (DIABETES/OBESITY), YAMANOUCHI; MIRABEGRON; MIRABEGRON OCAS",MIRABEGRON,BETANIS,BETMIGA,MYRBETRIQ,YM-178,YM-178 OCAS,YM-178 OCAS-M,YM-178 OCAS-X,"BETA-3 ADRENOCEPTOR AGONISTS (DIABETES/OBESITY), YAMANOUCHI",MIRABEGRON,MIRABEGRON OCAS,,,,,,,,,,,,,,,,,,,,,202611,MIRABEGRON,,,,,,,,,,,,,,,,,,,,,2012-06-28T00:00:00Z,2012,6,Myrbetriq,overactive bladder,BETA 3 ADRENOCEPTOR AGONIST,,CONTROLLED RELEASE FORMULATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202611,NDA,2011-08-26T00:00:00Z,fda,0,0,0,0,0,,astellas pharma,TYO: 4503,1,11107,12783.1,11541,10522.6,10658.3,8783.5,7375.9,2194.8,2194.8,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202611,125,2376,596,162,Other diseases of bladder and urethra,3,0
284,FESOTERODINE FUMARATE,PF-00695838; PNU-200577; SPM-007; SPM-7605; SPM-8272; SPM-907; TOVIAZ; DESFESOTERODINE; FESOTERODINE; FESOTERODINE FUMARATE,PF-00695838; PNU-200577; SPM-007; SPM-7605; SPM-8272; SPM-907; TOVIAZ; DESFESOTERODINE; FESOTERODINE; FESOTERODINE FUMARATE,FESOTERODINE FUMARATE,PF-00695838,PNU-200577,SPM-007,SPM-7605,SPM-8272,SPM-907,TOVIAZ,DESFESOTERODINE,FESOTERODINE,FESOTERODINE FUMARATE,,,,,,,,,,,,,,,,,,,,,22030,FESOTERODINE FUMARATE,,,,,,,,,,,,,,,,,,,,,2008-10-31T00:00:00Z,2008,10,Toviaz,overactive bladder,MUSCARINIC M2 RECEPTOR ANTAGONIST,,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022030,NDA,2006-03-17T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,48296,48418,48371,47405,48988,44736,40929,7512,7945,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022030,444,2376,596,162,Other diseases of bladder and urethra,3,0
763,"TROSPIUM CHLORIDE (ORAL, EXTENDED RELEASE), ENDO/ALLERGAN","REGURIN XL; SANCTURA XR; SPASMOLYT DEPOT; URIVESC SR; TROSPIUM CHLORIDE; TROSPIUM CHLORIDE (EXTENDED RELEASE), INDEVUS/SHIRE; TROSPIUM CHLORIDE (ORAL, EXTENDED RELEASE), ENDO/ALLERGAN","REGURIN XL; SANCTURA XR; SPASMOLYT DEPOT; URIVESC SR; TROSPIUM CHLORIDE; TROSPIUM CHLORIDE (EXTENDED RELEASE), INDEVUS/SHIRE; TROSPIUM CHLORIDE (ORAL, EXTENDED RELEASE), ENDO/ALLERGAN","TROSPIUM CHLORIDE (ORAL, EXTENDED RELEASE), ENDO/ALLERGAN",REGURIN XL,SANCTURA XR,SPASMOLYT DEPOT,URIVESC SR,TROSPIUM CHLORIDE,"TROSPIUM CHLORIDE (EXTENDED RELEASE), INDEVUS/SHIRE","TROSPIUM CHLORIDE (ORAL, EXTENDED RELEASE), ENDO/ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,22103,TROSPIUM CHLORIDE,,,,,,,,,,,,,,,,,,,,,2007-08-03T00:00:00Z,2007,8,Sanctura XR,overactive bladder,MUSCARINIC RECEPTOR ANTAGONIST,,CAPSULE FORMULATION; DAILY DOSING; DRUG COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022103,NDA,2006-10-12T00:00:00Z,fda,0,0,0,0,0,,indevus pharmaceuticals,NASDAQ: IDEV,1,66.1,50.5,33.3,18.7,5.2,4.4,51.4,41.9,41.9,,,,,acquired by endo in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022103,466,2376,596,162,Other diseases of bladder and urethra,3,0
552,"OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ALLERGAN","GELNIQUE; OTG; OXYBUTYNIN; OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ACTAVIS; OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ALLERGAN; OXYBUTYNIN (GEL, OVERACTIVE BLADDER), WATSON; OXYBUTYNIN CHLORIDE; OXYBUTYNIN HYDROCHLORIDE","GELNIQUE; OTG; OXYBUTYNIN; OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ACTAVIS; OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ALLERGAN; OXYBUTYNIN (GEL, OVERACTIVE BLADDER), WATSON; OXYBUTYNIN CHLORIDE; OXYBUTYNIN HYDROCHLORIDE","OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ALLERGAN",GELNIQUE,OTG,OXYBUTYNIN,"OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ACTAVIS","OXYBUTYNIN (10% GEL, OVERACTIVE BLADDER), ALLERGAN","OXYBUTYNIN (GEL, OVERACTIVE BLADDER), WATSON",OXYBUTYNIN CHLORIDE,OXYBUTYNIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,22204,OXYBUTYNIN CHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-01-27T00:00:00Z,2009,1,Gelnique,overactive bladder,MUSCARINIC RECEPTOR ANTAGONIST,SMOOTH MUSCLE RELAXANT,SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),022204,NDA,2008-03-26T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,2793,2535.5,2496.7,1979.2,1646.2,1640.6,1196.2,197.3,197.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022204,496,2376,596,162,Other diseases of bladder and urethra,3,0
666,SILODOSIN,KMD-3213; RAPAFLO; SILODYX; THRUPAS; TRUPASS; URIEF; URIEF OD; URIEF OD; UROREC; YOULIFU; SILODOSIN,KMD-3213; RAPAFLO; SILODYX; THRUPAS; TRUPASS; URIEF; URIEF OD; URIEF OD; UROREC; YOULIFU; SILODOSIN,SILODOSIN,KMD-3213,RAPAFLO,SILODYX,THRUPAS,TRUPASS,URIEF,URIEF OD,URIEF OD,UROREC,YOULIFU,SILODOSIN,,,,,,,,,,,,,,,,,,,,22206,SILODOSIN,,,,,,,,,,,,,,,,,,,,,2008-10-08T00:00:00Z,2008,10,Rapaflo,prostate hyperplasia,ALPHA 1A ADRENOCEPTOR ANTAGONIST,SMOOTH MUSCLE RELAXANT,CAPSULE FORMULATION; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022206,NDA,2007-12-12T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,2535.5,2496.7,1979.2,1646.2,1640.6,1457.7,1032.7,170.1,170.1,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022206,497,1241,600,164,Hyperplasia of prostate,1,0
550,OSPEMIFENE,"FC-1271; FC-1271A; OPHENA; OSPHENA; SENSHIO; OSPEMIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX /SHIONOGI; SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX PHARMACEUTICALS","FC-1271; FC-1271A; OPHENA; OSPHENA; SENSHIO; OSPEMIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX /SHIONOGI; SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX PHARMACEUTICALS",OSPEMIFENE,FC-1271,FC-1271A,OPHENA,OSPHENA,SENSHIO,OSPEMIFENE,"SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX /SHIONOGI","SELECTIVE ESTROGEN RECEPTOR MODULATOR (ORAL TABLET, ATROPHY/OSTEOPOROSIS), QUATRX PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,203505,OSPEMIFENE,,,,,,,,,,,,,,,,,,,,,2013-02-26T00:00:00Z,2013,2,Osphena,dyspareunia,ESTROGEN RECEPTOR MODULATOR,,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203505,NDA,2012-04-26T00:00:00Z,fda,0,0,0,0,0,,shionogi,TYO: 4507,1,3003.4,3243.2,3407.3,2979.8,2299.4,2148.8,2169.2,562.9,562.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203505,161,2694,608,166,Other male genital disorders,2,0
606,"PREDNISONE (ORAL, DELAYED RELEASE), HORIZON/MUNDIPHARMA","LODOTRA; NP-01 (HORIZON); RAYOS; ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOMATRIX), MERCK/SKYEPHARMA/NITEC; ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOCLOCK), MERCK/SKYEPHARMA/NITEC; PREDNISONE; PREDNISONE (ORAL, DELAYED RELEASE), HORIZON/MUNDIPHARMA; PREDNISONE (ORAL, MODIFIED RELEASE), NITEC/SKYEPHARMA/MERCK KGAA","LODOTRA; NP-01 (HORIZON); RAYOS; ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOMATRIX), MERCK/SKYEPHARMA/NITEC; ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOCLOCK), MERCK/SKYEPHARMA/NITEC; PREDNISONE; PREDNISONE (ORAL, DELAYED RELEASE), HORIZON/MUNDIPHARMA; PREDNISONE (ORAL, MODIFIED RELEASE), NITEC/SKYEPHARMA/MERCK KGAA","PREDNISONE (ORAL, DELAYED RELEASE), HORIZON/MUNDIPHARMA",LODOTRA,NP-01 (HORIZON),RAYOS,"ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOMATRIX), MERCK/SKYEPHARMA/NITEC","ANTI-INFLAMMATORY (ORAL CONTROLLED-RELEASE, GEOCLOCK), MERCK/SKYEPHARMA/NITEC",PREDNISONE,"PREDNISONE (ORAL, DELAYED RELEASE), HORIZON/MUNDIPHARMA","PREDNISONE (ORAL, MODIFIED RELEASE), NITEC/SKYEPHARMA/MERCK KGAA",,,,,,,,,,,,,,,,,,,,,,,17109,PREDNISONE,17109,PREDNISONE,17109,PREDNISONE,17109,PREDNISONE,202020,PREDNISONE,,,,,,,,,,,,,2012-07-26T00:00:00Z,2012,7,Rayos,inflammatory disease,GLUCOCORTICOID AGONIST,ANTI-INFLAMMATORY; IMMUNOSUPPRESSANT; STEROIDAL ANTI-INFLAMMATORY,CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; TABLET FORMULATION,matched (3),202020,NDA,2011-09-26T00:00:00Z,fda,0,0,0,0,0,,horizon pharmaceuticals,NASDAQ: HZNP,1,18.8,6.9,2.4,,,,7,16.8,21.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202020,95,188,614,168,Inflammatory diseases of female pelvic organs,1,0
508,"NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/ARALEZ","PN-400; PN-40020; VIMOVO; NAPROXEN + ESOMEPRAZOLE; NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/ARALEZ; NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/POZEN; NAPROXEN + ESOMEPRAZOLE (OSTEOARTHRITIS/RHEUMATOID ARTHRITIS PAIN), ASTRAZENECA/POZEN; NAPROXEN + ESOMEPRAZOLE MAGNESIUM","PN-400; PN-40020; VIMOVO; NAPROXEN + ESOMEPRAZOLE; NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/ARALEZ; NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/POZEN; NAPROXEN + ESOMEPRAZOLE (OSTEOARTHRITIS/RHEUMATOID ARTHRITIS PAIN), ASTRAZENECA/POZEN; NAPROXEN + ESOMEPRAZOLE MAGNESIUM","NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/ARALEZ",PN-400,PN-40020,VIMOVO,NAPROXEN + ESOMEPRAZOLE,"NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/ARALEZ","NAPROXEN + ESOMEPRAZOLE (ORAL FIXED-DOSE COMBINATION, INFLAMMATORY PAIN), ASTRAZENECA/POZEN","NAPROXEN + ESOMEPRAZOLE (OSTEOARTHRITIS/RHEUMATOID ARTHRITIS PAIN), ASTRAZENECA/POZEN",NAPROXEN + ESOMEPRAZOLE MAGNESIUM,,,,,,,,,,,,,,,,,,,,,,,22511,ESOMEPRAZOLE MAGNESIUM; NAPROXEN,,,,,,,,,,,,,,,,,,,,,2010-04-30T00:00:00Z,2010,4,Vimovo,inflammatory disease,CYCLOOXYGENASE INHIBITOR; H+ K+ ATPASE INHIBITOR,ACID PUMP INHIBITOR ANTIULCERANT PRODUCT; ANALGESIC; GASTRIC SECRETION INHIBITOR; NON-STEROIDAL ANTI-INFLAMMATORY; PG SYNTHESIS INHIBITOR,CONTROLLED RELEASE FORMULATION; DRUG COMBINATION; ENTERIC COATED FORMULATION; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022511,NDA,2009-06-30T00:00:00Z,fda,0,0,0,0,0,,aralez pharmaceuticals,NASDAQ: POZN,1,68.5,32.2,66.1,53.4,13.5,28.6,68.5,22.7,22.7,,,,,pozen changed name to aralez after acquiring tribute in 2016,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022511,583,188,614,168,Inflammatory diseases of female pelvic organs,1,0
484,"METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ALLERGAN","NUVESSA; PRODUCT 55394; PRODUCT 55394; METRONIDAZOLE; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ACTAVIS; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ALLERGAN; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), VALEANT","NUVESSA; PRODUCT 55394; PRODUCT 55394; METRONIDAZOLE; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ACTAVIS; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ALLERGAN; METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), VALEANT","METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ALLERGAN",NUVESSA,PRODUCT 55394,PRODUCT 55394,METRONIDAZOLE,"METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ACTAVIS","METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), ALLERGAN","METRONIDAZOLE 1.3% (VAGINAL GEL, BACTERIAL VAGINOSIS), VALEANT",,,,,,,,,,,,,,,,,,,,,,,,18517,METRONIDAZOLE,18517,METRONIDAZOLE,18517,METRONIDAZOLE,18517,METRONIDAZOLE,18517,METRONIDAZOLE,205223,METRONIDAZOLE,,,,,,,,,,,2014-03-24T00:00:00Z,2014,3,Nuvessa,bacterial vaginosis,,ANTIBACTERIAL; UNSPECIFIED DRUG TARGET,SMALL MOLECULE THERAPEUTIC; VAGINAL GEL FORMULATION,matched (3),205223,NDA,2013-05-24T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,8200,5765.6,3480.4,2427.5,1181.2,820.4,5997,246,246,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205223,66,2240,616,168,Inflammatory diseases of female pelvic organs,1,0
514,"NEXT GENERATION TRANSDERMAL ESTROGEN (MENOPAUSAL SYMPTOMS), NOVEN","MINIVELLE; ESTRADIOL; NEXT GENERATION TRANSDERMAL ESTROGEN (MENOPAUSAL SYMPTOMS), NOVEN","MINIVELLE; ESTRADIOL; NEXT GENERATION TRANSDERMAL ESTROGEN (MENOPAUSAL SYMPTOMS), NOVEN","NEXT GENERATION TRANSDERMAL ESTROGEN (MENOPAUSAL SYMPTOMS), NOVEN",MINIVELLE,ESTRADIOL,"NEXT GENERATION TRANSDERMAL ESTROGEN (MENOPAUSAL SYMPTOMS), NOVEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,203752,ESTRADIOL,20538,ESTRADIOL,,,,,,,,,,,,,,,,,,,2012-10-29T00:00:00Z,2012,10,Minivelle,menopause,ESTROGEN RECEPTOR AGONIST,,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),203752,NDA,2011-12-29T00:00:00Z,fda,0,0,0,0,0,,hisamitsu,TYO: 4530,1,1713,1782.1,1604.6,1503.3,108.2,83.2,1100.5,55.7,55.7,108.8,2009-06-30T00:00:00Z,2009,,acquired by hisamitsu in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203752,169,1523,627,173,Menopausal disorders,1,0
447,"LOW DOSE PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN","BRISDELLE; LDMP; MESAFEM; LOW DOSE PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN; PAROXETINE; PAROXETINE MESYLATE; PAROXETINE MESYLATE (HOT FLASHES), JDS; PAROXETINE MESYLATE (HOT FLASHES), NOVEN; PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN","BRISDELLE; LDMP; MESAFEM; LOW DOSE PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN; PAROXETINE; PAROXETINE MESYLATE; PAROXETINE MESYLATE (HOT FLASHES), JDS; PAROXETINE MESYLATE (HOT FLASHES), NOVEN; PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN","LOW DOSE PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN",BRISDELLE,LDMP,MESAFEM,"LOW DOSE PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN",PAROXETINE,PAROXETINE MESYLATE,"PAROXETINE MESYLATE (HOT FLASHES), JDS","PAROXETINE MESYLATE (HOT FLASHES), NOVEN","PAROXETINE MESYLATE (ORAL, HOT FLASHES), NOVEN",,,,,,,,,,,,,,,,,,,,,,204516,PAROXETINE MESYLATE,,,,,,,,,,,,,,,,,,,,,2013-06-28T00:00:00Z,2013,6,Brisdelle,hot flashes,,5-HT UPTAKE INHIBITOR,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204516,NDA,2012-08-28T00:00:00Z,fda,0,0,0,0,0,,hisamitsu,TYO: 4530,1,1469.5,1713,1782.1,1604.6,1503.3,108.2,938.4,123.6,123.6,108.8,2009-06-30T00:00:00Z,2009,,acquired by hisamitsu in 2009; hisamitsu revenues reported for november 30 of each year,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204516,204,2529,627,173,Menopausal disorders,1,0
697,"SYNTHETIC CONJUGATED ESTROGEN (CREAM, VULVOVAGINAL ATROPHY), TEVA","BIJUVA; BITHENA; DR-2041; SCE-A VAGINAL CREAM; SYNTHETIC CONJUGATED ESTROGEN (CREAM, VULVOVAGINAL ATROPHY), TEVA; SYNTHETIC CONJUGATED ESTROGENS-A, BARR; SYNTHETIC CONJUGATED ESTROGENS-A, DURAMED","BIJUVA; BITHENA; DR-2041; SCE-A VAGINAL CREAM; SYNTHETIC CONJUGATED ESTROGEN (CREAM, VULVOVAGINAL ATROPHY), TEVA; SYNTHETIC CONJUGATED ESTROGENS-A, BARR; SYNTHETIC CONJUGATED ESTROGENS-A, DURAMED","SYNTHETIC CONJUGATED ESTROGEN (CREAM, VULVOVAGINAL ATROPHY), TEVA",BIJUVA,BITHENA,DR-2041,SCE-A VAGINAL CREAM,"SYNTHETIC CONJUGATED ESTROGEN (CREAM, VULVOVAGINAL ATROPHY), TEVA","SYNTHETIC CONJUGATED ESTROGENS-A, BARR","SYNTHETIC CONJUGATED ESTROGENS-A, DURAMED",,,,,,,,,,,,,,,,,,,,,,,,21788,"ESTROGENS, CONJUGATED SYNTHETIC A",21788,"ESTROGENS, CONJUGATED SYNTHETIC A",21788,"ESTROGENS, CONJUGATED SYNTHETIC A",21788,"ESTROGENS, CONJUGATED SYNTHETIC A",,,,,,,,,,,,,,,2008-11-28T00:00:00Z,2008,11,"synthetic conjugated estrogens, A vaginal cream",atrophic vaginitis,ESTROGEN RECEPTOR AGONIST,,EMULSION FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; VAGINAL CREAM FORMULATION,matched (3),021788,NDA,2004-06-25T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,11085,2500.6,1583.3,1047.4,1309.1,902.9,5973,786,786,2832,2008-09-30T00:00:00Z,2008,,acquired by teva in 2008,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021788,386,3848,627,173,Menopausal disorders,1,0
257,"ESTRADIOL GEL, ANTARES/ANI PHARMACEUTICALS","BIO-E-GEL; ELESTRIN; BIOIDENTICAL ESTRADIOL TRANSDERMAL GEL, ANTARES/BIOSANTE; ESTRADIOL; ESTRADIOL ADVANCED TRANSDERMAL DELIVERY (ATD) GEL, ANTARES/BIOSANTE; ESTRADIOL GEL, ANTARES/ANI PHARMACEUTICALS; ESTRADIOL GEL, ANTARES/BIOSANTE","BIO-E-GEL; ELESTRIN; BIOIDENTICAL ESTRADIOL TRANSDERMAL GEL, ANTARES/BIOSANTE; ESTRADIOL; ESTRADIOL ADVANCED TRANSDERMAL DELIVERY (ATD) GEL, ANTARES/BIOSANTE; ESTRADIOL GEL, ANTARES/ANI PHARMACEUTICALS; ESTRADIOL GEL, ANTARES/BIOSANTE","ESTRADIOL GEL, ANTARES/ANI PHARMACEUTICALS",BIO-E-GEL,ELESTRIN,"BIOIDENTICAL ESTRADIOL TRANSDERMAL GEL, ANTARES/BIOSANTE",ESTRADIOL,"ESTRADIOL ADVANCED TRANSDERMAL DELIVERY (ATD) GEL, ANTARES/BIOSANTE","ESTRADIOL GEL, ANTARES/ANI PHARMACEUTICALS","ESTRADIOL GEL, ANTARES/BIOSANTE",,,,,,,,,,,,,,,,,,,,,,,,20538,ESTRADIOL,21813,ESTRADIOL,,,,,,,,,,,,,,,,,,,2006-12-15T00:00:00Z,2006,12,Elestrin,hot flashes,ESTRADIOL AGONIST,,SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),021813,NDA,2006-02-16T00:00:00Z,fda,0,0,0,0,0,,biosante pharmaceuticals,NASDAQ: BPAX,1,14.4,0.3,0.1,0.1,2.8,1.8,10.9,3.9,3.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021813,389,2529,627,173,Menopausal disorders,1,0
256,"ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), ACRUX","ELLAVIE; ESTRADIOL MDTS; ESTRAMIST; EVAMIST; ESTRADIOL; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), ACRUX; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), KV/ACRUX; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), VIVUS/ACRUX","ELLAVIE; ESTRADIOL MDTS; ESTRAMIST; EVAMIST; ESTRADIOL; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), ACRUX; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), KV/ACRUX; ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), VIVUS/ACRUX","ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), ACRUX",ELLAVIE,ESTRADIOL MDTS,ESTRAMIST,EVAMIST,ESTRADIOL,"ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), ACRUX","ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), KV/ACRUX","ESTRADIOL (TRANSDERMAL SPRAY, MDTS/ACROSS), VIVUS/ACRUX",,,,,,,,,,,,,,,,,,,,,,,20538,ESTRADIOL,22014,ESTRADIOL,,,,,,,,,,,,,,,,,,,2007-07-27T00:00:00Z,2007,7,Evamist,hot flashes,ESTRADIOL AGONIST,,ABSORPTION ENHANCER TRANSDERMAL; AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),022014,NDA,2006-09-28T00:00:00Z,fda,0,0,0,0,0,,vivus,NASDAQ: VVUS,1,54.7,17.2,14.7,19.6,22.4,22.3,42.6,26.2,26.7,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022014,442,2529,627,173,Menopausal disorders,1,0
258,"ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ VERTICAL","DELIDOSE; DIVIGEL; GYNPOLAR GEL; SISARE-GEL MONO; USL-221; ESTRADIOL; ESTRADIOL TRANSDERMAL GEL (HRT), ORION; ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ UPSHER-SMITH; ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ VERTICAL; ESTROGEN GEL (HRT), ORION","DELIDOSE; DIVIGEL; GYNPOLAR GEL; SISARE-GEL MONO; USL-221; ESTRADIOL; ESTRADIOL TRANSDERMAL GEL (HRT), ORION; ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ UPSHER-SMITH; ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ VERTICAL; ESTROGEN GEL (HRT), ORION","ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ VERTICAL",DELIDOSE,DIVIGEL,GYNPOLAR GEL,SISARE-GEL MONO,USL-221,ESTRADIOL,"ESTRADIOL TRANSDERMAL GEL (HRT), ORION","ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ UPSHER-SMITH","ESTRADIOL TRANSDERMAL GEL (HRT), ORION/ POLA/ MOCHIDA/ VERTICAL","ESTROGEN GEL (HRT), ORION",,,,,,,,,,,,,,,,,,,,,20538,ESTRADIOL,22038,ESTRADIOL,,,,,,,,,,,,,,,,,,,2007-06-04T00:00:00Z,2007,6,Divigel,menopause,ESTRADIOL AGONIST,,SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),022038,NDA,2006-05-01T00:00:00Z,fda,0,0,0,0,0,,upsher-smith laboratories,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022038,449,1523,627,173,Menopausal disorders,1,0
82,"BAZEDOXIFENE + CONJUGATED ESTROGENS, PFIZER","APRELA; BZA/CE, PFIZER; BZA/CE, WYETH; DUAVEE; DUAVIVE; TSE-424 + PREMARIN, PFIZER; TSE-424 + PREMARIN, WYETH; TSE-424 + CONJUGATED ESTROGENS, PFIZER; TSE-424 + CONJUGATED ESTROGENS, WYETH; BAZEDOXIDENE/CE; BAZEDOXIFENE + PREMARIN; BAZEDOXIFENE + PREMARIN, PFIZER; BAZEDOXIFENE + PREMARIN, WYETH; BAZEDOXIFENE + CONJUGATED ESTROGENS; BAZEDOXIFENE + CONJUGATED ESTROGENS, PFIZER; BAZEDOXIFENE + CONJUGATED ESTROGENS, WYETH","APRELA; BZA/CE, PFIZER; BZA/CE, WYETH; DUAVEE; DUAVIVE; TSE-424 + PREMARIN, PFIZER; TSE-424 + PREMARIN, WYETH; TSE-424 + CONJUGATED ESTROGENS, PFIZER; TSE-424 + CONJUGATED ESTROGENS, WYETH; BAZEDOXIDENE/CE; BAZEDOXIFENE + PREMARIN; BAZEDOXIFENE + PREMARIN, PFIZER; BAZEDOXIFENE + PREMARIN, WYETH; BAZEDOXIFENE + CONJUGATED ESTROGENS; BAZEDOXIFENE + CONJUGATED ESTROGENS, PFIZER; BAZEDOXIFENE + CONJUGATED ESTROGENS, WYETH","BAZEDOXIFENE + CONJUGATED ESTROGENS, PFIZER",APRELA,"BZA/CE, PFIZER","BZA/CE, WYETH",DUAVEE,DUAVIVE,"TSE-424 + PREMARIN, PFIZER","TSE-424 + PREMARIN, WYETH","TSE-424 + CONJUGATED ESTROGENS, PFIZER","TSE-424 + CONJUGATED ESTROGENS, WYETH",BAZEDOXIDENE/CE,BAZEDOXIFENE + PREMARIN,"BAZEDOXIFENE + PREMARIN, PFIZER","BAZEDOXIFENE + PREMARIN, WYETH",BAZEDOXIFENE + CONJUGATED ESTROGENS,"BAZEDOXIFENE + CONJUGATED ESTROGENS, PFIZER","BAZEDOXIFENE + CONJUGATED ESTROGENS, WYETH",,,,,,,,,,,,,,,22247,"BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED",,,,,,,,,,,,,,,,,,,,,2013-10-03T00:00:00Z,2013,10,Duavee,menopause,ESTROGEN RECEPTOR AGONIST,ANTICANCER; BONE RESORPTION INHIBITOR,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022247,NDA,2012-09-26T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,51584,54657,61035,65165,49269,22833.9,22399.8,6551,6678,22144.2,2009-06-30T00:00:00Z,2009,,acquired by Pfizer in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022247,508,1523,627,173,Menopausal disorders,1,0
750,"TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE/FERRING","LYSTEDA; XP-12B; TRANEXAMIC ACID; TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE; TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE/FERRING; TRANEXAMIC ACID MR","LYSTEDA; XP-12B; TRANEXAMIC ACID; TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE; TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE/FERRING; TRANEXAMIC ACID MR","TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE/FERRING",LYSTEDA,XP-12B,TRANEXAMIC ACID,"TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE","TRANEXAMIC ACID (MODIFIED RELEASE), XANODYNE/FERRING",TRANEXAMIC ACID MR,,,,,,,,,,,,,,,,,,,,,,,,,22430,TRANEXAMIC ACID,,,,,,,,,,,,,,,,,,,,,2009-11-13T00:00:00Z,2009,11,Lysteda,menorrhagia,PLASMIN INHIBITOR,FIBRINOLYSIS INHIBITOR,CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022430,NDA,2009-01-30T00:00:00Z,fda,1,0,1,0,0,,xanodyne pharmaceuticals,private,0,,72.4,74.1,66.4,52.6,13.7,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022430,561,2051,627,173,Menopausal disorders,1,0
609,"PROGESTERONE (VAGINAL PESSARY), FERRING","ENDOMETRIN; FE-999-913; FE-999913; LUTINUS; PROGESTERONE; PROGESTERONE (VAGINAL PESSARY), FERRING","ENDOMETRIN; FE-999-913; FE-999913; LUTINUS; PROGESTERONE; PROGESTERONE (VAGINAL PESSARY), FERRING","PROGESTERONE (VAGINAL PESSARY), FERRING",ENDOMETRIN,FE-999-913,FE-999913,LUTINUS,PROGESTERONE,"PROGESTERONE (VAGINAL PESSARY), FERRING",,,,,,,,,,,,,,,,,,,,,,,,,22057,PROGESTERONE,9238,PROGESTERONE,9238,PROGESTERONE,9238,PROGESTERONE,,,,,,,,,,,,,,,2007-06-21T00:00:00Z,2007,6,Endometrin,female infertility,PROGESTERONE RECEPTOR AGONIST,,PESSARY; SMALL MOLECULE THERAPEUTIC; VAGINAL FORMULATION,matched (3),022057,NDA,2006-08-21T00:00:00Z,fda,0,0,0,0,0,,ferring pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022057,456,1080,628,174,Female infertility,1,0
222,DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE,"DICLECTIN; DICLEGIS; DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE; DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE (DELAYED-RELEASE, NAUSEA/VOMITING), DUCHESNAY","DICLECTIN; DICLEGIS; DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE; DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE (DELAYED-RELEASE, NAUSEA/VOMITING), DUCHESNAY",DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE,DICLECTIN,DICLEGIS,DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE,"DOXYLAMINE SUCCINATE + PYRIDOXINE HYDROCHLORIDE (DELAYED-RELEASE, NAUSEA/VOMITING), DUCHESNAY",,,,,,,,,,,,,,,,,,,,,,,,,,,21876,DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2013-04-08T00:00:00Z,2013,4,Diclegis,morning sickness,HISTAMINE RECEPTOR ANTAGONIST,ANTI-EMETIC; VITAMIN B6,DRUG COMBINATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021876,NDA,2004-12-17T00:00:00Z,fda,0,0,0,0,0,,duchesnay,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021876,399,1527,643,181,Other complications of pregnancy,1,0
363,"HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA","17ALPHA-HYDROXYPROGESTERONE CAPROATE; 17ALPHA-HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA; 17ALPHA-HYDROXYPROGESTERONE HEXANOATE; GESTIVA; MAKENA; MAKENA SQ; MAKENA SQ; HYDROXYPROGESTERONE CAPROATE; HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA; NATURALLY-OCCURING PROGESTERONE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA","17ALPHA-HYDROXYPROGESTERONE CAPROATE; 17ALPHA-HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA; 17ALPHA-HYDROXYPROGESTERONE HEXANOATE; GESTIVA; MAKENA; MAKENA SQ; MAKENA SQ; HYDROXYPROGESTERONE CAPROATE; HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA; NATURALLY-OCCURING PROGESTERONE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA","HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA",17ALPHA-HYDROXYPROGESTERONE CAPROATE,"17ALPHA-HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA",17ALPHA-HYDROXYPROGESTERONE HEXANOATE,GESTIVA,MAKENA,MAKENA SQ,MAKENA SQ,HYDROXYPROGESTERONE CAPROATE,"HYDROXYPROGESTERONE CAPROATE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA","NATURALLY-OCCURING PROGESTERONE (LONG-ACTING, PRETERM BIRTH PREVENTION), ADEZA",,,,,,,,,,,,,,,,,,,,,17439,HYDROXYPROGESTERONE CAPROATE,17439,HYDROXYPROGESTERONE CAPROATE,17439,HYDROXYPROGESTERONE CAPROATE,21945,HYDROXYPROGESTERONE CAPROATE,,,,,,,,,,,,,,,2011-02-03T00:00:00Z,2011,2,Makena,premature labor,PROGESTERONE RECEPTOR AGONIST,,INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),021945,NDA,2006-04-14T00:00:00Z,fda,1,1,1,1,0,,hologic,NASDAQ: HOLX,1,1789.3,1679.6,1637.1,1674.5,738.4,462.7,1119.9,116.7,116.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021945,415,455,644,184,Early or threatened labor,1,0
406,"KETOCONAZOLE (VERSAFOAM-HF), STIEFEL","EXTINA; KETACONAZOLE MOUSSE, STIEFEL LABORATORIES; KETOCONAZOLE; KETOCONAZOLE (VERSAFOAM-HF), CONNETICS; KETOCONAZOLE (VERSAFOAM-HF), STIEFEL; KETOCONAZOLE MOUSSE, CONNETICS","EXTINA; KETACONAZOLE MOUSSE, STIEFEL LABORATORIES; KETOCONAZOLE; KETOCONAZOLE (VERSAFOAM-HF), CONNETICS; KETOCONAZOLE (VERSAFOAM-HF), STIEFEL; KETOCONAZOLE MOUSSE, CONNETICS","KETOCONAZOLE (VERSAFOAM-HF), STIEFEL",EXTINA,"KETACONAZOLE MOUSSE, STIEFEL LABORATORIES",KETOCONAZOLE,"KETOCONAZOLE (VERSAFOAM-HF), CONNETICS","KETOCONAZOLE (VERSAFOAM-HF), STIEFEL","KETOCONAZOLE MOUSSE, CONNETICS",,,,,,,,,,,,,,,,,,,,,,,,,21738,KETOCONAZOLE,,,,,,,,,,,,,,,,,,,,,2007-06-12T00:00:00Z,2007,6,Extina,seborrheic dermatitis,,ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021738,NDA,2006-12-11T00:00:00Z,fda,0,0,0,0,0,,stiefel laboratories,private,0,,,,,,,,,,,,,,acquired by GSK in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021738,381,300,690,198,Other inflammatory condition of skin,1,0
405,"KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), AQUA","SEBAZOLE; XOLEGEL; KETOCONAZOLE; KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), AQUA; KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), BARRIER","SEBAZOLE; XOLEGEL; KETOCONAZOLE; KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), AQUA; KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), BARRIER","KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), AQUA",SEBAZOLE,XOLEGEL,KETOCONAZOLE,"KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), AQUA","KETOCONAZOLE (TRANSDERMAL, ONCE-DAILY), BARRIER",,,,,,,,,,,,,,,,,,,,,,,,,,21946,KETOCONAZOLE,,,,,,,,,,,,,,,,,,,,,2006-07-28T00:00:00Z,2006,7,Xolegel,seborrheic dermatitis,,DERMATOLOGICAL AGENT; ERGOSTEROL SYNTHESIS INHIBITOR; FUNGICIDE,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),021946,NDA,2005-09-28T00:00:00Z,fda,0,0,0,0,0,,barrier therapeutics,NASDAQ: BTRX,1,6.738,2.54,0.897,0.367,,,5.307,25.895,25.895,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021946,416,300,690,198,Other inflammatory condition of skin,1,0
195,"DESONIDE (TOPICAL, VERSAFOAM), AQUA PHARMACEUTICALS","DESILUX; VERDESO; DESONIDE; DESONIDE (TOPICAL, VERSAFOAM), AQUA PHARMACEUTICALS; DESONIDE (TOPICAL, VERSAFOAM), CONNETICS","DESILUX; VERDESO; DESONIDE; DESONIDE (TOPICAL, VERSAFOAM), AQUA PHARMACEUTICALS; DESONIDE (TOPICAL, VERSAFOAM), CONNETICS","DESONIDE (TOPICAL, VERSAFOAM), AQUA PHARMACEUTICALS",DESILUX,VERDESO,DESONIDE,"DESONIDE (TOPICAL, VERSAFOAM), AQUA PHARMACEUTICALS","DESONIDE (TOPICAL, VERSAFOAM), CONNETICS",,,,,,,,,,,,,,,,,,,,,,,,,,17010,DESONIDE,21978,DESONIDE,,,,,,,,,,,,,,,,,,,2006-09-19T00:00:00Z,2006,9,Verdeso,atopic dermatitis,,CORTICOSTEROID AGONIST; DERMATOLOGICAL AGENT,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),021978,NDA,2005-11-18T00:00:00Z,fda,0,0,0,0,0,,stiefel laboratories,private,0,,176.4,143.2,75.2,52.8,34.1,137.6,34.9,,147.6,2006-09-30T00:00:00Z,2006,,acquired by stiefel in 2006,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021978,423,1102,691,253,Allergic reactions,1,0
105,"BRIMONIDINE (TOPICAL GEL, ERYTHEMA), GALDERMA","CD-07805/47; COL-118; MIRVASO; ONRELTEA; SR-101; BRIMONIDINE; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), COLLAGENEX; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), GALDERMA; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), SANSROSA","CD-07805/47; COL-118; MIRVASO; ONRELTEA; SR-101; BRIMONIDINE; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), COLLAGENEX; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), GALDERMA; BRIMONIDINE (TOPICAL GEL, ERYTHEMA), SANSROSA","BRIMONIDINE (TOPICAL GEL, ERYTHEMA), GALDERMA",CD-07805/47,COL-118,MIRVASO,ONRELTEA,SR-101,BRIMONIDINE,"BRIMONIDINE (TOPICAL GEL, ERYTHEMA), COLLAGENEX","BRIMONIDINE (TOPICAL GEL, ERYTHEMA), GALDERMA","BRIMONIDINE (TOPICAL GEL, ERYTHEMA), SANSROSA",,,,,,,,,,,,,,,,,,,,,,204708,BRIMONIDINE TARTRATE,,,,,,,,,,,,,,,,,,,,,2013-08-23T00:00:00Z,2013,8,Mirvaso,erythema,ALPHA 2 ADRENOCEPTOR AGONIST,DERMATOLOGICAL AGENT; VASOCONSTRICTOR,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204708,NDA,2012-10-25T00:00:00Z,fda,0,0,0,0,0,,nestle,VTX: NESN,1,103731.6,98227.3,89622.3,94204.2,97159,96894.4,49704.7,1687.8,1687.8,,,,1,joint venture of nestle and loreal; wholly owned by nestle as of 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204708,213,2024,695,198,Other inflammatory condition of skin,1,0
399,"IVERMECTIN (TOPICAL CREAM, ROSACEA), GALDERMA","CD-5024; CD-5024; ROSIVER; SOOLANTRA; SOOLANTRA; VASTREKA; IVERMECTIN; IVERMECTIN (TOPICAL CREAM, ROSACEA), GALDERMA","CD-5024; CD-5024; ROSIVER; SOOLANTRA; SOOLANTRA; VASTREKA; IVERMECTIN; IVERMECTIN (TOPICAL CREAM, ROSACEA), GALDERMA","IVERMECTIN (TOPICAL CREAM, ROSACEA), GALDERMA",CD-5024,CD-5024,ROSIVER,SOOLANTRA,SOOLANTRA,VASTREKA,IVERMECTIN,"IVERMECTIN (TOPICAL CREAM, ROSACEA), GALDERMA",,,,,,,,,,,,,,,,,,,,,,,206255,IVERMECTIN,,,,,,,,,,,,,,,,,,,,,2014-12-19T00:00:00Z,2014,12,Soolantra,rosacea,,ANTI-INFLAMMATORY; ANTIPARASITIC; DERMATOLOGICAL AGENT; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,matched (3),206255,NDA,2013-12-20T00:00:00Z,fda,0,0,0,0,0,,nestle,VTX: NESN,1,92479,103731.6,98227.3,89622.3,94204.2,97159,44608.2,1638.9,1638.9,,,,,joint venture of nestle and loreal; wholly owned by nestle as of 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206255,273,2164,695,198,Other inflammatory condition of skin,1,0
220,"DOXYCYCLINE (ONCE-DAILY, ORAL CONTROLLED RELEASE), COLLAGENEX","APPRILON; COL-101; ORACEA; PERIOSTAT (ONCE-DAILY FORMULATION), COLLAGENEX; PERIOSTAT MR; DOXYCYCLINE; DOXYCYCLINE (ONCE-DAILY, ORAL CONTROLLED RELEASE), COLLAGENEX","APPRILON; COL-101; ORACEA; PERIOSTAT (ONCE-DAILY FORMULATION), COLLAGENEX; PERIOSTAT MR; DOXYCYCLINE; DOXYCYCLINE (ONCE-DAILY, ORAL CONTROLLED RELEASE), COLLAGENEX","DOXYCYCLINE (ONCE-DAILY, ORAL CONTROLLED RELEASE), COLLAGENEX",APPRILON,COL-101,ORACEA,"PERIOSTAT (ONCE-DAILY FORMULATION), COLLAGENEX",PERIOSTAT MR,DOXYCYCLINE,"DOXYCYCLINE (ONCE-DAILY, ORAL CONTROLLED RELEASE), COLLAGENEX",,,,,,,,,,,,,,,,,,,,,,,,50805,DOXYCYCLINE,,,,,,,,,,,,,,,,,,,,,2006-05-26T00:00:00Z,2006,5,Oracea,rosacea,COLLAGENASE INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER; TETRACYCLINE,CAPSULE FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),050805,NDA,2005-07-29T00:00:00Z,fda,0,0,0,0,0,,collagenex pharmaceuticals,NASDAQ: CGPI,1,26.4,26.4,52.1,52.9,44.6,35.2,20.9,15.1,15.4,,,,,acquired by galderma in 2008,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050805,613,2164,695,198,Other inflammatory condition of skin,1,0
769,USTEKINUMAB,"CNTO-1275; STELARA; ANTI-IL-12/IL-23 MAB (INFLAMMATORY DISORDERS), CENTOCOR; ANTI-IL-12P40/IL-23P40 MAB (INFLAMMATORY DISORDERS), CENTOCOR; USTEKINUMAB","CNTO-1275; STELARA; ANTI-IL-12/IL-23 MAB (INFLAMMATORY DISORDERS), CENTOCOR; ANTI-IL-12P40/IL-23P40 MAB (INFLAMMATORY DISORDERS), CENTOCOR; USTEKINUMAB",USTEKINUMAB,CNTO-1275,STELARA,"ANTI-IL-12/IL-23 MAB (INFLAMMATORY DISORDERS), CENTOCOR","ANTI-IL-12P40/IL-23P40 MAB (INFLAMMATORY DISORDERS), CENTOCOR",USTEKINUMAB,,,,,,,,,,,,,,,,,,,,,,,,,,125261,USTEKINUMAB,,,,,,,,,,,,,,,,,,,,,2009-09-25T00:00:00Z,2009,9,Stelara,psoriasis,IL-12 ANTAGONIST; IL-23 ANTAGONIST,ANTI-INFLAMMATORY; HYPOGLYCEMIC AGENT,BIOLOGICAL THERAPEUTIC; CELL CULTURE; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; SUBCUTANEOUS FORMULATION,matched (3),125261,BLA,2007-11-28T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61897,63747,61095,53324,50514,47348,43563,6986,6986,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125261,12,281,696,198,Other inflammatory condition of skin,1,0
661,SECUKINUMAB,"AIN-457; AIN-457A; COSENTYX; IL-17A MONOCLONAL ANTIBODY (RHEUMATOID ARTHRITIS), NOVARTIS; ZAFREZ; ANTI-IL-17A MAB (RHEUMATOID ARTHRITIS), NOVARTIS; SECUKINUMAB","AIN-457; AIN-457A; COSENTYX; IL-17A MONOCLONAL ANTIBODY (RHEUMATOID ARTHRITIS), NOVARTIS; ZAFREZ; ANTI-IL-17A MAB (RHEUMATOID ARTHRITIS), NOVARTIS; SECUKINUMAB",SECUKINUMAB,AIN-457,AIN-457A,COSENTYX,"IL-17A MONOCLONAL ANTIBODY (RHEUMATOID ARTHRITIS), NOVARTIS",ZAFREZ,"ANTI-IL-17A MAB (RHEUMATOID ARTHRITIS), NOVARTIS",SECUKINUMAB,,,,,,,,,,,,,,,,,,,,,,,,125504,SECUKINUMAB,,,,,,,,,,,,,,,,,,,,,2015-01-21T00:00:00Z,2015,1,Cosentyx,psoriasis,IL-17 ANTAGONIST,ANTI-INFLAMMATORY; ANTICANCER ANTIBODY; SYSTEMIC ANTIPSORIATIC PRODUCT,BIOLOGICAL THERAPEUTIC; CELL CULTURE TECHNIQUE; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; MONOCLONAL ANTIBODY HUMAN; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125504,BLA,2013-10-24T00:00:00Z,fda,0,0,0,0,0,,novartis,NYSE: NVS,1,50359,53634,52716,51971,59375,51561,33234,8781,9472,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504,49,281,696,198,Other inflammatory condition of skin,1,0
403,IXEKIZUMAB,"LY-2439821; TALTZ; TALTZ; TALTZ SUBCUTANEOUS INJECTION 80MG AUTO-INJECTOR; TALTZ SUBCUTANEOUS INJECTION 80MG SYRINGE; ANTI IL-17 ANTIBODY (RHEUMATOID ARTHRITIS, AUTOIMMUNE INFLAMMATION), ELI LILLY; IXEKIZUMAB","LY-2439821; TALTZ; TALTZ; TALTZ SUBCUTANEOUS INJECTION 80MG AUTO-INJECTOR; TALTZ SUBCUTANEOUS INJECTION 80MG SYRINGE; ANTI IL-17 ANTIBODY (RHEUMATOID ARTHRITIS, AUTOIMMUNE INFLAMMATION), ELI LILLY; IXEKIZUMAB",IXEKIZUMAB,LY-2439821,TALTZ,TALTZ,TALTZ SUBCUTANEOUS INJECTION 80MG AUTO-INJECTOR,TALTZ SUBCUTANEOUS INJECTION 80MG SYRINGE,"ANTI IL-17 ANTIBODY (RHEUMATOID ARTHRITIS, AUTOIMMUNE INFLAMMATION), ELI LILLY",IXEKIZUMAB,,,,,,,,,,,,,,,,,,,,,,,,125521,IXEKIZUMAB,,,,,,,,,,,,,,,,,,,,,2016-03-22T00:00:00Z,2016,3,Taltz,psoriasis,IL-17 ANTAGONIST,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125521,BLA,2015-03-23T00:00:00Z,fda,0,0,0,0,0,,eli lilly,NYSE: LLY,1,21222.1,19958.7,19615.6,23113.1,22603.4,24286.5,15567.2,5243.9,5243.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521,54,281,696,198,Other inflammatory condition of skin,1,0
52,APREMILAST,"CC-10004; CC-110004; CDC-104; OTEZLA; APREMILAST; LEAD SELCID (2), CELGENE; SELCID (COPD), CELGENE","CC-10004; CC-110004; CDC-104; OTEZLA; APREMILAST; LEAD SELCID (2), CELGENE; SELCID (COPD), CELGENE",APREMILAST,CC-10004,CC-110004,CDC-104,OTEZLA,APREMILAST,"LEAD SELCID (2), CELGENE","SELCID (COPD), CELGENE",,,,,,,,,,,,,,,,,,,,,,,,205437,APREMILAST,,,,,,,,,,,,,,,,,,,,,2014-03-21T00:00:00Z,2014,3,Otezla,psoriatic arthritis,PDE 4 INHIBITOR,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT; TOPICAL ANTIPRURITIC PRODUCT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205437,NDA,2013-03-20T00:00:00Z,fda,0,0,0,0,0,,celgene,NASDAQ: CELG,1,7670.4,6493.9,5506.7,4842.1,3625.7,2689.9,6779.4,1796.3,2301.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205437,240,1781,696,198,Other inflammatory condition of skin,1,0
94,"BETAMETHASONE DIPROPIONATE (TOPICAL SPRAY, PSORIASIS), PROMIUS PHARMA","DFD-01; SERNIVO; SERNIVO; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE (TOPICAL SPRAY, PSORIASIS), PROMIUS PHARMA","DFD-01; SERNIVO; SERNIVO; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE (TOPICAL SPRAY, PSORIASIS), PROMIUS PHARMA","BETAMETHASONE DIPROPIONATE (TOPICAL SPRAY, PSORIASIS), PROMIUS PHARMA",DFD-01,SERNIVO,SERNIVO,BETAMETHASONE DIPROPIONATE,"BETAMETHASONE DIPROPIONATE (TOPICAL SPRAY, PSORIASIS), PROMIUS PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,19136,BETAMETHASONE DIPROPIONATE,19136,BETAMETHASONE DIPROPIONATE,19136,BETAMETHASONE DIPROPIONATE,208079,BETAMETHASONE DIPROPIONATE,,,,,,,,,,,,,,,2016-02-05T00:00:00Z,2016,2,Sernivo,psoriasis,,CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY; TOPICAL ANTIPSORIATIC PRODUCT,AEROSOL FORMULATION DERMATOLOGICAL; DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),208079,NDA,2015-04-06T00:00:00Z,fda,0,0,0,0,0,,promius pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208079,325,281,696,198,Other inflammatory condition of skin,1,0
126,"CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE, LEO","DAIVOBET; DAIVOBET GEL; DOVOBET; LEO-80185; LEO-90105; TACLONEX; TACLONEX SCALP; XAMIOL; CALCIPOTRIENE + BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE (GEL FORMULATION), LEO; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE, LEO","DAIVOBET; DAIVOBET GEL; DOVOBET; LEO-80185; LEO-90105; TACLONEX; TACLONEX SCALP; XAMIOL; CALCIPOTRIENE + BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE (GEL FORMULATION), LEO; CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE, LEO","CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE, LEO",DAIVOBET,DAIVOBET GEL,DOVOBET,LEO-80185,LEO-90105,TACLONEX,TACLONEX SCALP,XAMIOL,CALCIPOTRIENE + BETAMETHASONE DIPROPIONATE,CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE,"CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE (GEL FORMULATION), LEO","CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE, LEO",,,,,,,,,,,,,,,,,,,21852,BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE,,,,,,,,,,,,,,,,,,,,,2006-01-09T00:00:00Z,2006,1,Taclonex,psoriasis,,CORTICOSTEROID AGONIST; IMMUNOMODULATOR; KERATINOCYTE INHIBITOR; STEROIDAL ANTI-INFLAMMATORY; TOPICAL ANTIPSORIATIC PRODUCT; VITAMIN D ANALOG,DERMATOLOGICAL FORMULATION; DRUG COMBINATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC; STEROID; SUSPENSION; TRANSDERMAL FORMULATION; TRANSDERMAL GEL FORMULATION,matched (3),021852,NDA,2005-03-09T00:00:00Z,fda,0,0,0,0,0,,leo pharma,private,0,537.1,,,,,,304.3,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021852,394,281,696,198,Other inflammatory condition of skin,1,0
127,"CALCITRIOL (OINTMENT), GALDERMA","SILKIS; VECTICAL; CALCITRIOL; CALCITRIOL (OINTMENT), GALDERMA; CALCITRIOL, BIO-TECHNOLOGY GENERAL; VITAMIN D3 METABOLITE, BTGC","SILKIS; VECTICAL; CALCITRIOL; CALCITRIOL (OINTMENT), GALDERMA; CALCITRIOL, BIO-TECHNOLOGY GENERAL; VITAMIN D3 METABOLITE, BTGC","CALCITRIOL (OINTMENT), GALDERMA",SILKIS,VECTICAL,CALCITRIOL,"CALCITRIOL (OINTMENT), GALDERMA","CALCITRIOL, BIO-TECHNOLOGY GENERAL","VITAMIN D3 METABOLITE, BTGC",,,,,,,,,,,,,,,,,,,,,,,,,22087,CALCITRIOL,,,,,,,,,,,,,,,,,,,,,2009-01-23T00:00:00Z,2009,1,Vectical,psoriasis,VITAMIN D3 RECEPTOR AGONIST,TOPICAL ANTIPSORIATIC PRODUCT,DERMATOLOGICAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022087,NDA,2007-12-21T00:00:00Z,fda,0,0,0,0,0,,nestle,VTX: NESN,1,97159,96894.4,94884.9,80723.1,69299.5,74211.4,55170,1310.9,1310.9,,,,1,joint venture of nestle and loreal; wholly owned by nestle as of 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022087,462,281,696,198,Other inflammatory condition of skin,1,0
125,"CALCIPOTRIOL (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL","STF-115469; SORILUX; SORILUX FOAM; U-0267; CALCIPOTRIENE; CALCIPOTRIENE (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL; CALCIPOTRIOL; CALCIPOTRIOL (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL; TOPICAL ANTIPSORIATIC (EMULSION), STIEFEL","STF-115469; SORILUX; SORILUX FOAM; U-0267; CALCIPOTRIENE; CALCIPOTRIENE (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL; CALCIPOTRIOL; CALCIPOTRIOL (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL; TOPICAL ANTIPSORIATIC (EMULSION), STIEFEL","CALCIPOTRIOL (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL",STF-115469,SORILUX,SORILUX FOAM,U-0267,CALCIPOTRIENE,"CALCIPOTRIENE (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL",CALCIPOTRIOL,"CALCIPOTRIOL (DERMATOLOGICAL FOAM, PSORIASIS), STIEFEL","TOPICAL ANTIPSORIATIC (EMULSION), STIEFEL",,,,,,,,,,,,,,,,,,,,,,22563,CALCIPOTRIENE,,,,,,,,,,,,,,,,,,,,,2010-10-06T00:00:00Z,2010,10,Sorilux,psoriasis,VITAMIN D3 RECEPTOR AGONIST,TOPICAL ANTIPSORIATIC PRODUCT,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; FORMULATION AEROSOL; SMALL MOLECULE THERAPEUTIC,matched (3),022563,NDA,2009-12-18T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,44331.3,45825.1,,,,,32308.5,5992.7,6959.2,,,2009,,acquired by GSK in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022563,602,281,696,198,Other inflammatory condition of skin,1,0
109,BRODALUMAB,"AMG-827; KHK-4827; KHK-4827; LUMICEF; LUMICEF; MEDI-6365; SILIQ; SILIQ; ANTI-IL-17 MAB (RHEUMATOID ARTHRITIS), AMGEN; BRODALUMAB","AMG-827; KHK-4827; KHK-4827; LUMICEF; LUMICEF; MEDI-6365; SILIQ; SILIQ; ANTI-IL-17 MAB (RHEUMATOID ARTHRITIS), AMGEN; BRODALUMAB",BRODALUMAB,AMG-827,KHK-4827,KHK-4827,LUMICEF,LUMICEF,MEDI-6365,SILIQ,SILIQ,"ANTI-IL-17 MAB (RHEUMATOID ARTHRITIS), AMGEN",BRODALUMAB,,,,,,,,,,,,,,,,,,,,,761032,BRODALUMAB,,,,,,,,,,,,,,,,,,,,,2017-02-15T00:00:00Z,2017,2,Siliq,psoriasis,INTERLEUKIN RECEPTOR 17A ANTAGONIST,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMAN; SUBCUTANEOUS FORMULATION,matched (3),761032,BLA,2015-11-16T00:00:00Z,fda,0,0,0,0,0,,valeant pharmaceuticals,NYSE: VRX,1,8436,9674,10442,8200,5765.6,3480.4,6052,384,384,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761032,620,281,696,198,Other inflammatory condition of skin,1,0
380,"INGENOL MEBUTATE (TOPICAL), PEPLIN","3-ANGELOYL INGENOL; 3-INGENYL ANGELATE; PEP-001; PEP-005; PEP-005 (TOPICAL), PEPLIN; PEP-005 TOPICAL; PEP-005-007; PICATO; INGENOL 3-ANGELATE; INGENOL MEBUTATE; INGENOL MEBUTATE (TOPICAL), PEPLIN; PROTEIN KINASE C INHIBITOR (TOPICAL FORMULATION), PEPLIN/ALLERGAN; TOPICAL ANTICANCER COMPOUND, PEPLIN","3-ANGELOYL INGENOL; 3-INGENYL ANGELATE; PEP-001; PEP-005; PEP-005 (TOPICAL), PEPLIN; PEP-005 TOPICAL; PEP-005-007; PICATO; INGENOL 3-ANGELATE; INGENOL MEBUTATE; INGENOL MEBUTATE (TOPICAL), PEPLIN; PROTEIN KINASE C INHIBITOR (TOPICAL FORMULATION), PEPLIN/ALLERGAN; TOPICAL ANTICANCER COMPOUND, PEPLIN","INGENOL MEBUTATE (TOPICAL), PEPLIN",3-ANGELOYL INGENOL,3-INGENYL ANGELATE,PEP-001,PEP-005,"PEP-005 (TOPICAL), PEPLIN",PEP-005 TOPICAL,PEP-005-007,PICATO,INGENOL 3-ANGELATE,INGENOL MEBUTATE,"INGENOL MEBUTATE (TOPICAL), PEPLIN","PROTEIN KINASE C INHIBITOR (TOPICAL FORMULATION), PEPLIN/ALLERGAN","TOPICAL ANTICANCER COMPOUND, PEPLIN",,,,,,,,,,,,,,,,,,202833,INGENOL MEBUTATE,,,,,,,,,,,,,,,,,,,,,2012-01-23T00:00:00Z,2012,1,Picato,keratosis,PROTEIN KINASE C INHIBITOR,ANTICANCER PROTEIN KINASE INHIBITOR; ANTIVIRAL; TOPICAL DERMATOLOGICAL ANTIVIRAL PRODUCT,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; NATURAL PRODUCT; SMALL MOLECULE THERAPEUTIC,matched (3),202833,NDA,2011-03-25T00:00:00Z,fda,0,0,0,0,0,,leo pharma,private,0,1106.4,1029,978.4,822.4,610.7,584.8,515,,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202833,133,1057,702,200,Other skin disorders,1,0
37,"AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA","5-AMINOLEVULINIC ACID; 5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), ASAT; 5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA; ALA; AMELUZ; BF-200 ALA; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA","5-AMINOLEVULINIC ACID; 5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), ASAT; 5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA; ALA; AMELUZ; BF-200 ALA; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA","AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA",5-AMINOLEVULINIC ACID,"5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), ASAT","5-AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA",ALA,AMELUZ,BF-200 ALA,AMINOLEVULINIC ACID,"AMINOLEVULINIC ACID (NANOCOLLOIDAL), BIOFRONTERA",,,,,,,,,,,,,,,,,,,,,,,208081,AMINOLEVULINIC ACID HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2016-05-10T00:00:00Z,2016,5,Ameluz,keratosis,PROTOPORPHYRINOGEN OXIDASE MODULATOR,ANTICANCER; ANTIVIRAL; PHOTOSENSITIZER; TOPICAL DERMATOLOGICAL ANTIVIRAL PRODUCT,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; EMULSION DERMATOLOGICAL; NANOPARTICLE FORMULATION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC,matched (3),208081,NDA,2015-07-10T00:00:00Z,fda,0,0,0,0,0,,biofrontera bioscience,ETR: B8F,1,6.5,4.5,3.8,4.3,4.5,0.7,4.7,4.9,4.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208081,326,1057,702,200,Other skin disorders,1,0
14,"ADAPALENE 0.3% + BENZOYL PEROXIDE 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES","CD-0271 0.3% + CD-1579 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES; EPIDUO FORTE; ADAPALENE 0.3% + BENZOYL PEROXIDE 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES","CD-0271 0.3% + CD-1579 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES; EPIDUO FORTE; ADAPALENE 0.3% + BENZOYL PEROXIDE 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES","ADAPALENE 0.3% + BENZOYL PEROXIDE 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES","CD-0271 0.3% + CD-1579 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES",EPIDUO FORTE,"ADAPALENE 0.3% + BENZOYL PEROXIDE 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,207917,ADAPALENE; BENZOYL PEROXIDE,,,,,,,,,,,,,,,,,,,,,2015-07-15T00:00:00Z,2015,7,Epiduo Forte,acne vulgaris,,TOPICAL ANTI-ACNE PRODUCT; TOPICAL DERMATOLOGICAL ANTIBACTERIAL PRODUCT; UNSPECIFIED DRUG TARGET,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; DRUG COMBINATION; SMALL MOLECULE THERAPEUTIC,matched (3),207917,NDA,2014-09-19T00:00:00Z,fda,0,0,0,0,0,,nestle,VTX: NESN,1,88975.3,92479,103731.6,98227.3,89622.3,94204.2,44299.4,1676,1676,,,,,joint venture of nestle and loreal; wholly owned by nestle as of 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207917,308,3040,706,200,Other skin disorders,1,0
395,"ISOTRETINOIN (ORAL), CIPHER PHARMACEUTICALS","ABSORICA; CIP-ISOTRETINOIN; EPURIS; LISACNE-CIP; ISOTRETINOIN; ISOTRETINOIN (ORAL), CIPHER PHARMACEUTICALS","ABSORICA; CIP-ISOTRETINOIN; EPURIS; LISACNE-CIP; ISOTRETINOIN; ISOTRETINOIN (ORAL), CIPHER PHARMACEUTICALS","ISOTRETINOIN (ORAL), CIPHER PHARMACEUTICALS",ABSORICA,CIP-ISOTRETINOIN,EPURIS,LISACNE-CIP,ISOTRETINOIN,"ISOTRETINOIN (ORAL), CIPHER PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,21951,ISOTRETINOIN,,,,,,,,,,,,,,,,,,,,,2012-05-25T00:00:00Z,2012,5,Absorica,acne,RETINOIC ACID RECEPTOR AGONIST,VITAMIN A AGONIST,CAPSULE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021951,NDA,2005-06-27T00:00:00Z,fda,0,0,0,0,0,,cipher pharmaceuticals,TSX: CPH,1,8.5,3.5,5.4,3,1.3,0.5,7,,1.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021951,418,3,706,200,Other skin disorders,1,0
157,"CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL, ACNE), DOW/MEDICIS","ACNATAC; ACNATAC; ACNEX; IDP-121; TRECLINAC; ZIANA; CLINDAMYCIN PHOSPHATE + TRETINOIN; CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL, ACNE), DOW/MEDICIS","ACNATAC; ACNATAC; ACNEX; IDP-121; TRECLINAC; ZIANA; CLINDAMYCIN PHOSPHATE + TRETINOIN; CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL, ACNE), DOW/MEDICIS","CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL, ACNE), DOW/MEDICIS",ACNATAC,ACNATAC,ACNEX,IDP-121,TRECLINAC,ZIANA,CLINDAMYCIN PHOSPHATE + TRETINOIN,"CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL, ACNE), DOW/MEDICIS",,,,,,,,,,,,,,,,,,,,,,,50648,CLINDAMYCIN PHOSPHATE,50648,CLINDAMYCIN PHOSPHATE,50648,CLINDAMYCIN PHOSPHATE,50802,CLINDAMYCIN PHOSPHATE; TRETINOIN,,,,,,,,,,,,,,,2006-11-07T00:00:00Z,2006,11,Ziana,acne vulgaris,RETINOIC ACID RECEPTOR MODULATOR,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; RIBOSOME BINDING AGENT; TOPICAL DERMATOLOGICAL ANTIBACTERIAL PRODUCT,ANTIBIOTIC; DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; DRUG COMBINATION; SMALL MOLECULE THERAPEUTIC,matched (3),050802,NDA,2004-02-06T00:00:00Z,fda,0,0,0,0,0,,medicis pharmaceutical,NYSE: MRX,1,393.2,361.1,257.1,209.3,177,137.1,347.1,161.8,161.8,,,,,acquired by valeant in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050802,611,3040,706,200,Other skin disorders,1,0
156,"CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK","CTGEL; IDP-121; VELTIN; W-0265; CLINDAMYCIN + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK; CLINDAMYCIN PHOSPHATE + TRETINOIN; CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK; FIXED-COMBINATION GEL (ACNE VULGARIS), STIEFEL LABORATORITES","CTGEL; IDP-121; VELTIN; W-0265; CLINDAMYCIN + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK; CLINDAMYCIN PHOSPHATE + TRETINOIN; CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK; FIXED-COMBINATION GEL (ACNE VULGARIS), STIEFEL LABORATORITES","CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK",CTGEL,IDP-121,VELTIN,W-0265,"CLINDAMYCIN + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK",CLINDAMYCIN PHOSPHATE + TRETINOIN,"CLINDAMYCIN PHOSPHATE + TRETINOIN (TOPICAL GEL, ACNE), STIEFEL/GSK","FIXED-COMBINATION GEL (ACNE VULGARIS), STIEFEL LABORATORITES",,,,,,,,,,,,,,,,,,,,,,,50648,CLINDAMYCIN PHOSPHATE,50648,CLINDAMYCIN PHOSPHATE,50648,CLINDAMYCIN PHOSPHATE,50803,CLINDAMYCIN PHOSPHATE; TRETINOIN,,,,,,,,,,,,,,,2010-07-16T00:00:00Z,2010,7,Veltin,acne vulgaris,RETINOIC ACID RECEPTOR ANTAGONIST,BACTERIAL PROTEIN SYNTHESIS INHIBITOR; MACROLIDE ANTIBIOTIC; RIBOSOME BINDING AGENT; TOPICAL DERMATOLOGICAL ANTIBACTERIAL PRODUCT,DERMATOLOGICAL FORMULATION; DERMATOLOGICAL GEL FORMULATION; DRUG COMBINATION; SMALL MOLECULE THERAPEUTIC,matched (3),050803,NDA,2004-08-23T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,44331.3,45825.1,,,,,32308.5,5992.7,6959.2,,,2009,,acquired by GSK in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050803,612,3040,706,200,Other skin disorders,1,0
490,"MINOCYCLINE HYDROCHLORIDE (EXTENDED-RELEASE, ACNE), MEDICIS","SOLODYN; MINOCYCLINE; MINOCYCLINE ER; MINOCYCLINE HCL (EXTENDED-RELEASE, ACNE), MEDICIS; MINOCYCLINE HYDROCHLORIDE; MINOCYCLINE HYDROCHLORIDE (EXTENDED-RELEASE, ACNE), MEDICIS","SOLODYN; MINOCYCLINE; MINOCYCLINE ER; MINOCYCLINE HCL (EXTENDED-RELEASE, ACNE), MEDICIS; MINOCYCLINE HYDROCHLORIDE; MINOCYCLINE HYDROCHLORIDE (EXTENDED-RELEASE, ACNE), MEDICIS","MINOCYCLINE HYDROCHLORIDE (EXTENDED-RELEASE, ACNE), MEDICIS",SOLODYN,MINOCYCLINE,MINOCYCLINE ER,"MINOCYCLINE HCL (EXTENDED-RELEASE, ACNE), MEDICIS",MINOCYCLINE HYDROCHLORIDE,"MINOCYCLINE HYDROCHLORIDE (EXTENDED-RELEASE, ACNE), MEDICIS",,,,,,,,,,,,,,,,,,,,,,,,,50451,MINOCYCLINE HYDROCHLORIDE,50451,MINOCYCLINE HYDROCHLORIDE,50451,MINOCYCLINE HYDROCHLORIDE,50451,MINOCYCLINE HYDROCHLORIDE,50808,MINOCYCLINE HYDROCHLORIDE,,,,,,,,,,,,,2006-05-08T00:00:00Z,2006,5,Solodyn,acne vulgaris,BIFUNCTIONAL AMINOACYL TRNA SYNTHETASE INHIBITOR,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT; TETRACYCLINE,ANTIBIOTIC; DRUG COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),050808,NDA,2005-06-30T00:00:00Z,fda,0,0,0,0,0,,medicis pharmaceutical,NYSE: MRX,1,393.2,361.1,257.1,209.3,177,137.1,347.1,161.8,161.8,,,,,acquired by valeant in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050808,614,3040,706,200,Other skin disorders,1,0
13,"ADAPALENE + BENZOYL PEROXIDE (TOPICAL GEL, ACNE), GALDERMA","CD-0271 0.1% + CD-1579 2.5% (TOPICAL GEL, ACNE VULGARIS), GALDERMA LABORATORIES; DIFFERIN GEL; EPIDUO GEL; GK-530G; TACTUO; ADAPALENE + BENZOYL PEROXIDE; ADAPALENE + BENZOYL PEROXIDE (TOPICAL GEL, ACNE), GALDERMA; TACTUOBEN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-12-08T00:00:00Z,2008,12,Epiduo,acne,RETINOIC ACID RECEPTOR AGONIST,ANTI-INFLAMMATORY; ANTIBACTERIAL; SYSTEMIC DERMATOLOGICAL ANTIBACTERIAL PRODUCT; TOPICAL ANTI-ACNE PRODUCT,DRUG COMBINATION; GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),022320,NDA,2008-02-08T00:00:00Z,fda,0,0,0,0,0,,nestle,VTX: NESN,1,96894.4,94884.9,80723.1,69299.5,74211.4,71065.4,53886.6,1277.4,1277.4,,,,1,joint venture of nestle and loreal; wholly owned by nestle as of 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022320,634,3,706,200,Other skin disorders,1,0
420,LEVOCETIRIZINE,"(-)-CETIRIZINE; (-)-CETIRIZINE, SEPRACOR; GSK-2074687; UCB-28556; XUSAL; XYZAL; XYZAL SYRUP; XYZEM; ZYXEM; LEVOCETIRIZINE; LEVOCETIRIZINE DIHYDROCHLORIDE","(-)-CETIRIZINE; (-)-CETIRIZINE, SEPRACOR; GSK-2074687; UCB-28556; XUSAL; XYZAL; XYZAL SYRUP; XYZEM; ZYXEM; LEVOCETIRIZINE; LEVOCETIRIZINE DIHYDROCHLORIDE",LEVOCETIRIZINE,(-)-CETIRIZINE,"(-)-CETIRIZINE, SEPRACOR",GSK-2074687,UCB-28556,XUSAL,XYZAL,XYZAL SYRUP,XYZEM,ZYXEM,LEVOCETIRIZINE,LEVOCETIRIZINE DIHYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,22064,LEVOCETIRIZINE DIHYDROCHLORIDE,22429,CETIRIZINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2007-05-25T00:00:00Z,2007,5,Xyzal,urticaria,HISTAMINE H1 RECEPTOR ANTAGONIST,ANTI-INFLAMMATORY; TOPICAL ANTIPRURITIC PRODUCT,FILM COATING; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; STEREOCHEMISTRY; TABLET FORMULATION,matched (3),022064,NDA,2006-07-24T00:00:00Z,fda,0,0,0,0,0,,UCB,EBR: UCB,1,5295.05,3366.1,2773.04,2552.13,4251.41,3081.75,3901.93,1150.72,1150.72,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022064,458,340,708,253,Allergic reactions,1,0
86,BELIMUMAB,"BENLYSTA; GSK-1550188; HGS-1006; LYMPHOSTAT-B; ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS; ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS / GSK; ANTIBODY (AUTOIMMUNE DISEASE), HGS; ANTIBODY (IMMUNOSUPRESSANT), HGS; BELIMUMAB","BENLYSTA; GSK-1550188; HGS-1006; LYMPHOSTAT-B; ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS; ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS / GSK; ANTIBODY (AUTOIMMUNE DISEASE), HGS; ANTIBODY (IMMUNOSUPRESSANT), HGS; BELIMUMAB",BELIMUMAB,BENLYSTA,GSK-1550188,HGS-1006,LYMPHOSTAT-B,"ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS","ANTI-BLYS ANTIBODY (RHEUMATOID ARTHRITIS / SYSTEMIC LUPUS ERYTHEMATOSUS), HGS / GSK","ANTIBODY (AUTOIMMUNE DISEASE), HGS","ANTIBODY (IMMUNOSUPRESSANT), HGS",BELIMUMAB,,,,,,,,,,,,,,,,,,,,,,125370,BELIMUMAB,,,,,,,,,,,,,,,,,,,,,2011-03-09T00:00:00Z,2011,3,Benlysta,systemic lupus erythematosus,B-LYMPHOCYTE STIMULATOR LIGAND INHIBITOR,ANTICANCER; ANTICANCER MONOCLONAL ANTIBODY; IMMUNOMODULATOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMAN; SUBCUTANEOUS FORMULATION,matched (3),125370,BLA,2010-06-09T00:00:00Z,fda,1,0,1,0,0,,human genome sciences,NASDAQ: HGSI,1,131,157.4,275.7,48.4,41.9,25.8,-172.5,,225.2,,,,,acquired by GSK in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125370,31,318,710,210,Systemic lupus erythematosus and connective tissue disorders,2,0
729,"TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS","KOVACAINE MIST; KOVANAZE; LOCAL ANESTHESTIC (NASAL SPRAY), ST RENATUS; TETRACAINE + OXYMETAZOLINE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS; TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS","KOVACAINE MIST; KOVANAZE; LOCAL ANESTHESTIC (NASAL SPRAY), ST RENATUS; TETRACAINE + OXYMETAZOLINE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS; TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS","TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS",KOVACAINE MIST,KOVANAZE,"LOCAL ANESTHESTIC (NASAL SPRAY), ST RENATUS","TETRACAINE + OXYMETAZOLINE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS",TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE,"TETRACAINE HYDROCHLORIDE + OXYMETAZOLINE HYDROCHLORIDE (NASAL SPRAY, LOCAL ANESTHESIA), ST RENATUS",,,,,,,,,,,,,,,,,,,,,,,,,208032,OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE,208135,TETRACAINE HYDROCHLORIDE,208135,TETRACAINE HYDROCHLORIDE,208135,TETRACAINE HYDROCHLORIDE,,,,,,,,,,,,,,,2016-06-29T00:00:00Z,2016,6,Kovanaze,topical anesthesia,SODIUM CHANNEL INHIBITOR,LOCAL ANESTHETIC; VASOCONSTRICTOR,DRUG COMBINATION; NASAL FORMULATION LOCAL; SMALL MOLECULE THERAPEUTIC,matched (3),208032,NDA,2015-05-29T00:00:00Z,fda,0,0,0,0,0,,st. renatus,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208032,321,328,710,210,Systemic lupus erythematosus and connective tissue disorders,2,0
430,"LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), CRESCITA","FLEXICAINE; PLIAGLIS; S-CAINE PEEL; TETRAPEEL; ZS-2001; LIDOCAINE + TETRACAINE; LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), CRESCITA; LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), NUVO","FLEXICAINE; PLIAGLIS; S-CAINE PEEL; TETRAPEEL; ZS-2001; LIDOCAINE + TETRACAINE; LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), CRESCITA; LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), NUVO","LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), CRESCITA",FLEXICAINE,PLIAGLIS,S-CAINE PEEL,TETRAPEEL,ZS-2001,LIDOCAINE + TETRACAINE,"LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), CRESCITA","LIDOCAINE + TETRACAINE (LOCAL ANESTHESIA), NUVO",,,,,,,,,,,,,,,,,,,,,,,21717,LIDOCAINE; TETRACAINE,,,,,,,,,,,,,,,,,,,,,2006-06-29T00:00:00Z,2006,6,Pliaglis,topical anesthesia,SODIUM CHANNEL INHIBITOR,ANALGESIC; LOCAL ANESTHETIC,DERMATOLOGICAL FORMULATION; DRUG COMBINATION; EMULSION DERMATOLOGICAL; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021717,NDA,2003-11-14T00:00:00Z,fda,0,0,0,0,0,,ZARS pharma,private,0,7.6,2.9,6.5,,,,7.6,12.2,12.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021717,380,328,710,210,Systemic lupus erythematosus and connective tissue disorders,2,0
428,"LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), LEE'S/ POWDER/ MARATHON","3268; ALGRX-3268; POWDERJECT LIDOCAINE; ZINGO; DERMAL POWDERJECT LIDOCAINE; LIDOCAINE; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ALGORX; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ANESIVA; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), CORGENTECH; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), LEE'S/ POWDER/ MARATHON; LIDOCAINE DERMAL, POWDERJECT; LIDOCAINE, POWDERJECT/CHIROSCIENCE","3268; ALGRX-3268; POWDERJECT LIDOCAINE; ZINGO; DERMAL POWDERJECT LIDOCAINE; LIDOCAINE; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ALGORX; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ANESIVA; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), CORGENTECH; LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), LEE'S/ POWDER/ MARATHON; LIDOCAINE DERMAL, POWDERJECT; LIDOCAINE, POWDERJECT/CHIROSCIENCE","LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), LEE'S/ POWDER/ MARATHON",3268,ALGRX-3268,POWDERJECT LIDOCAINE,ZINGO,DERMAL POWDERJECT LIDOCAINE,LIDOCAINE,"LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ALGORX","LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), ANESIVA","LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), CORGENTECH","LIDOCAINE (TRANSDERMAL HIGH VELOCITY, POWDERJECT), LEE'S/ POWDER/ MARATHON","LIDOCAINE DERMAL, POWDERJECT","LIDOCAINE, POWDERJECT/CHIROSCIENCE",,,,,,,,,,,,,,,,,,,22114,LIDOCAINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2007-08-16T00:00:00Z,2007,8,Zingo,topical anesthesia,SODIUM CHANNEL INHIBITOR,ANALGESIC; LOCAL ANESTHETIC,INTRADERMAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION; TRANSDERMAL HIGH VELOCITY PARTICLE FORMULATION,matched (3),022114,NDA,2006-11-21T00:00:00Z,fda,0,0,0,0,0,,anesiva,NASDAQ: ANSV,1,0.051,0.089,,,0.1,0.149,-23.21,,23.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022114,470,328,710,210,Systemic lupus erythematosus and connective tissue disorders,2,0
114,"BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS/MARUHO","DUR-843; DEPOBUPIVACAINE; EXPAREL; SKY-0402; BUPIVACAINE; BUPIVACAINE (DEPOFOAM), PACIRA PHARMACEUTICALS; BUPIVACAINE (DEPOFOAM), SKYEPHARMA/MARUHO; BUPIVACAINE (CONTROLLED RELEASE, DEPOFOAM), PACIRA; BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS/MARUHO; BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), SKYEPHARMA/MARUHO; BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS; BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), SKYEPHARMA; BUPIVACAINE HYDROCHLORIDE","DUR-843; DEPOBUPIVACAINE; EXPAREL; SKY-0402; BUPIVACAINE; BUPIVACAINE (DEPOFOAM), PACIRA PHARMACEUTICALS; BUPIVACAINE (DEPOFOAM), SKYEPHARMA/MARUHO; BUPIVACAINE (CONTROLLED RELEASE, DEPOFOAM), PACIRA; BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS/MARUHO; BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), SKYEPHARMA/MARUHO; BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS; BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), SKYEPHARMA; BUPIVACAINE HYDROCHLORIDE","BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS/MARUHO",DUR-843,DEPOBUPIVACAINE,EXPAREL,SKY-0402,BUPIVACAINE,"BUPIVACAINE (DEPOFOAM), PACIRA PHARMACEUTICALS","BUPIVACAINE (DEPOFOAM), SKYEPHARMA/MARUHO","BUPIVACAINE (CONTROLLED RELEASE, DEPOFOAM), PACIRA","BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS/MARUHO","BUPIVACAINE (EXTENDED RELEASE/DEPOFOAM, POSTOPERATIVE PAIN), SKYEPHARMA/MARUHO","BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), PACIRA PHARMACEUTICALS","BUPIVACAINE (LIPOSOMAL, POSTOPERATIVE PAIN), SKYEPHARMA",BUPIVACAINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,18053,BUPIVACAINE HYDROCHLORIDE,22046,BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE,22496,BUPIVACAINE,,,,,,,,,,,,,,,,,2011-10-28T00:00:00Z,2011,10,Exparel,topical anesthesia,SODIUM CHANNEL INHIBITOR,ANALGESIC; LOCAL ANESTHETIC,LIPOSOME FORMULATION; SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION; SUSPENSION; SUSTAINED RELEASE FORMULATION,matched (3),022496,NDA,2010-09-28T00:00:00Z,fda,0,0,0,0,0,,pacira pharmaceuticals,NASDAQ: PCRX,1,15.7,14.6,15,13.9,8.3,6.9,-15.9,,14.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022496,576,328,710,210,Systemic lupus erythematosus and connective tissue disorders,2,0
738,"TOCILIZUMAB (INTRAVENOUS), ROCHE/CHUGAI","ACTEMRA; IL-6 RECEPTOR MAB, CHUGAI; MR16-1; MRA; R-1569; RG-1569; RO-4877533; ROACTEMRA; ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI; ATLIZUMAB; HPM-1; TOCILIZUMAB; TOCILIZUMAB (INTRAVENOUS), ROCHE/CHUGAI","ACTEMRA; IL-6 RECEPTOR MAB, CHUGAI; MR16-1; MRA; R-1569; RG-1569; RO-4877533; ROACTEMRA; ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI; ATLIZUMAB; HPM-1; TOCILIZUMAB; TOCILIZUMAB (INTRAVENOUS), ROCHE/CHUGAI","TOCILIZUMAB (INTRAVENOUS), ROCHE/CHUGAI",ACTEMRA,"IL-6 RECEPTOR MAB, CHUGAI",MR16-1,MRA,R-1569,RG-1569,RO-4877533,ROACTEMRA,"ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI",ATLIZUMAB,HPM-1,TOCILIZUMAB,"TOCILIZUMAB (INTRAVENOUS), ROCHE/CHUGAI",,,,,,,,,,,,,,,,,,125276,TOCILIZUMAB,,,,,,,,,,,,,,,,,,,,,2010-01-08T00:00:00Z,2010,1,Actemra (intravenous),rheumatoid arthritis,IL-6 ANTAGONIST; IL-6 RECEPTOR MODULATOR,ANALGESIC; ANTI-INFLAMMATORY; ANTICANCER MONOCLONAL ANTIBODY; ANTIHYPERTENSIVE,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125276,BLA,2007-11-19T00:00:00Z,fda,0,0,0,0,0,,roche,SIX: ROG,1,52624.4,49411.7,13418,11724,9284,6633,38603.2,9711,10731,,,2009,,acquired by roche in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276,15,291,714,202,Rheumatoid arthritis and related disease,1,0
739,"TOCILIZUMAB (SUBCUTANEOUS), ROCHE/CHUGAI","ACTEMRA; IL-6 RECEPTOR MAB, CHUGAI; MRA; MRA-SC; R-1569; RG-1569; RO-4877533; ROACTEMRA; ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI; ATLIZUMAB; TOCILIZUMAB; TOCILIZUMAB (SUBCUTANEOUS), ROCHE/CHUGAI","ACTEMRA; IL-6 RECEPTOR MAB, CHUGAI; MRA; MRA-SC; R-1569; RG-1569; RO-4877533; ROACTEMRA; ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI; ATLIZUMAB; TOCILIZUMAB; TOCILIZUMAB (SUBCUTANEOUS), ROCHE/CHUGAI","TOCILIZUMAB (SUBCUTANEOUS), ROCHE/CHUGAI",ACTEMRA,"IL-6 RECEPTOR MAB, CHUGAI",MRA,MRA-SC,R-1569,RG-1569,RO-4877533,ROACTEMRA,"ANTI-INTERLEUKIN-6 RECEPTOR MAB, CHUGAI",ATLIZUMAB,TOCILIZUMAB,"TOCILIZUMAB (SUBCUTANEOUS), ROCHE/CHUGAI",,,,,,,,,,,,,,,,,,,125276,TOCILIZUMAB,,,,,,,,,,,,,,,,,,,,,2013-10-21T00:00:00Z,2013,10,Actemra (subcutaneous),rheumatoid arthritis,IL-6 ANTAGONIST; IL-6 RECEPTOR MODULATOR,ANTI-INFLAMMATORY,BIOLOGICAL THERAPEUTIC; MONOCLONAL ANTIBODY HUMANIZED; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,matched (3),125472,BLA,2012-12-21T00:00:00Z,fda,0,0,0,0,0,,roche,SIX: ROG,1,54589.6,51820.8,47194.8,52624.4,49411.7,13418,40688.4,9832.7,10409.9,,,2009,,acquired by roche in 2009,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125472,16,291,714,202,Rheumatoid arthritis and related disease,1,0
335,"GOLIMUMAB (IV INFUSION), JOHNSON & JOHNSON","SIMPONI; SIMPONI ARIA; SIMPONI ARIA; GOLIMUMAB; GOLIMUMAB (IV INFUSION), JOHNSON & JOHNSON","SIMPONI; SIMPONI ARIA; SIMPONI ARIA; GOLIMUMAB; GOLIMUMAB (IV INFUSION), JOHNSON & JOHNSON","GOLIMUMAB (IV INFUSION), JOHNSON & JOHNSON",SIMPONI,SIMPONI ARIA,SIMPONI ARIA,GOLIMUMAB,"GOLIMUMAB (IV INFUSION), JOHNSON & JOHNSON",,,,,,,,,,,,,,,,,,,,,,,,,,125289,GOLIMUMAB,125433,GOLIMUMAB,,,,,,,,,,,,,,,,,,,2013-07-18T00:00:00Z,2013,7,Simponi Aria,rheumatoid arthritis,TNF ALPHA LIGAND INHIBITOR,ANTI-INFLAMMATORY,INFUSION; INTRAVENOUS FORMULATION; MONOCLONAL ANTIBODY; SMALL MOLECULE THERAPEUTIC,matched (3),125433,BLA,2012-09-18T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,71312,67224,65030,61587,61897,63747,49070,8183,8183,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125433,41,291,714,202,Rheumatoid arthritis and related disease,1,0
741,"TOFACITINIB (ORAL, INFLAMMATION), PFIZER","CP-690550; JAK-3 INHIBITOR (RA/TRANSPLANT REJECTION), PFIZER; JAQUINUS; XELJANZ; JANUS KINASE-3 INHIBITOR (RHEUMATOID ARTHRITIS/TRANSPLANT REJECTION), PFIZER; TASOCITINIB; TASOCITINIB CITRATE; TOFACITINIB; TOFACITINIB (ORAL, INFLAMMATION), PFIZER","CP-690550; JAK-3 INHIBITOR (RA/TRANSPLANT REJECTION), PFIZER; JAQUINUS; XELJANZ; JANUS KINASE-3 INHIBITOR (RHEUMATOID ARTHRITIS/TRANSPLANT REJECTION), PFIZER; TASOCITINIB; TASOCITINIB CITRATE; TOFACITINIB; TOFACITINIB (ORAL, INFLAMMATION), PFIZER","TOFACITINIB (ORAL, INFLAMMATION), PFIZER",CP-690550,"JAK-3 INHIBITOR (RA/TRANSPLANT REJECTION), PFIZER",JAQUINUS,XELJANZ,"JANUS KINASE-3 INHIBITOR (RHEUMATOID ARTHRITIS/TRANSPLANT REJECTION), PFIZER",TASOCITINIB,TASOCITINIB CITRATE,TOFACITINIB,"TOFACITINIB (ORAL, INFLAMMATION), PFIZER",,,,,,,,,,,,,,,,,,,,,,203214,TOFACITINIB CITRATE,,,,,,,,,,,,,,,,,,,,,2012-11-06T00:00:00Z,2012,11,Xeljanz,rheumatoid arthritis,JAK TYROSINE KINASE INHIBITOR; JAK1 TYROSINE KINASE INHIBITOR; JAK3 TYROSINE KINASE INHIBITOR,ANTI-INFLAMMATORY; GASTROINTESTINAL SYSTEM AGENT; SYSTEMIC ANTIPSORIATIC PRODUCT,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),203214,NDA,2011-10-21T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,54657,61035,65165,49269,48296,48418,45164,6705,7482,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203214,146,291,714,202,Rheumatoid arthritis and related disease,1,0
472,"METHOTREXATE (SC/MEDI-JET, RHEUMATOID ARTHRITIS/PSORIASIS), ANTARES PHARMA","OTREXUP; VIBEX MTX; METHOTREXATE; METHOTREXATE (VIBEX, SC, RHEUMATOID ARTHRITIS/AUTOIMMUNE DISEASE), ANTARES PHARMA; METHOTREXATE (SC/MEDI-JET, RHEUMATOID ARTHRITIS/PSORIASIS), ANTARES PHARMA","OTREXUP; VIBEX MTX; METHOTREXATE; METHOTREXATE (VIBEX, SC, RHEUMATOID ARTHRITIS/AUTOIMMUNE DISEASE), ANTARES PHARMA; METHOTREXATE (SC/MEDI-JET, RHEUMATOID ARTHRITIS/PSORIASIS), ANTARES PHARMA","METHOTREXATE (SC/MEDI-JET, RHEUMATOID ARTHRITIS/PSORIASIS), ANTARES PHARMA",OTREXUP,VIBEX MTX,METHOTREXATE,"METHOTREXATE (VIBEX, SC, RHEUMATOID ARTHRITIS/AUTOIMMUNE DISEASE), ANTARES PHARMA","METHOTREXATE (SC/MEDI-JET, RHEUMATOID ARTHRITIS/PSORIASIS), ANTARES PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,204824,METHOTREXATE,8085,METHOTREXATE SODIUM,,,,,,,,,,,,,,,,,,,2013-10-11T00:00:00Z,2013,10,Otrexup,juvenile rheumatoid arthritis,DHFR INHIBITOR,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT,SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION,matched (3),204824,NDA,2012-12-14T00:00:00Z,fda,0,0,0,0,0,,antares pharma,NASDAQ: ATRS,1,20.6,22.6,16.5,12.8,8.3,5.7,11.4,15.3,17.5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204824,220,3003,714,202,Rheumatoid arthritis and related disease,1,0
471,"METHOTREXATE (SC, RHEUMATOID ARTHRITIS/POLY-ARTICULAR-COURSE JUVENILE RA/PSORIASIS), MEDAC PHARMA","MPI-2505; RASUVO; METHOTREXATE; METHOTREXATE (SC, RHEUMATOID ARTHRITIS), MEDAC PHARMA; METHOTREXATE (SC, RHEUMATOID ARTHRITIS/POLY-ARTICULAR-COURSE JUVENILE RA/PSORIASIS), MEDAC PHARMA","MPI-2505; RASUVO; METHOTREXATE; METHOTREXATE (SC, RHEUMATOID ARTHRITIS), MEDAC PHARMA; METHOTREXATE (SC, RHEUMATOID ARTHRITIS/POLY-ARTICULAR-COURSE JUVENILE RA/PSORIASIS), MEDAC PHARMA","METHOTREXATE (SC, RHEUMATOID ARTHRITIS/POLY-ARTICULAR-COURSE JUVENILE RA/PSORIASIS), MEDAC PHARMA",MPI-2505,RASUVO,METHOTREXATE,"METHOTREXATE (SC, RHEUMATOID ARTHRITIS), MEDAC PHARMA","METHOTREXATE (SC, RHEUMATOID ARTHRITIS/POLY-ARTICULAR-COURSE JUVENILE RA/PSORIASIS), MEDAC PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,205776,METHOTREXATE,8085,METHOTREXATE SODIUM,,,,,,,,,,,,,,,,,,,2014-07-10T00:00:00Z,2014,7,Rasuvo,juvenile rheumatoid arthritis,DHFR INHIBITOR,ANTI-INFLAMMATORY,SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION,matched (3),205776,NDA,2013-09-10T00:00:00Z,fda,0,0,0,0,0,,medac pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205776,255,3003,714,202,Rheumatoid arthritis and related disease,1,0
740,"TOFACITINIB (ORAL MODIFIED RELEASE), PFIZER","XELJANZ (ONCE-DAILY FORMULATION), PFIZER; XELJANZ XR; TOFACITINIB; TOFACITINIB (ONCE-DAILY ORAL FORMULATION, RA), PFIZER; TOFACITINIB (ORAL MODIFIED RELEASE), PFIZER; TOFACITINIB QD MR (ONCE-DAILY MODIFIED RELEASE FORMULATION), PFIZER","XELJANZ (ONCE-DAILY FORMULATION), PFIZER; XELJANZ XR; TOFACITINIB; TOFACITINIB (ONCE-DAILY ORAL FORMULATION, RA), PFIZER; TOFACITINIB (ORAL MODIFIED RELEASE), PFIZER; TOFACITINIB QD MR (ONCE-DAILY MODIFIED RELEASE FORMULATION), PFIZER","TOFACITINIB (ORAL MODIFIED RELEASE), PFIZER","XELJANZ (ONCE-DAILY FORMULATION), PFIZER",XELJANZ XR,TOFACITINIB,"TOFACITINIB (ONCE-DAILY ORAL FORMULATION, RA), PFIZER","TOFACITINIB (ORAL MODIFIED RELEASE), PFIZER","TOFACITINIB QD MR (ONCE-DAILY MODIFIED RELEASE FORMULATION), PFIZER",,,,,,,,,,,,,,,,,,,,,,,,,208246,TOFACITINIB CITRATE,,,,,,,,,,,,,,,,,,,,,2016-02-23T00:00:00Z,2016,2,Xeljanz XR,rheumatoid arthritis,JAK1 TYROSINE KINASE INHIBITOR; JAK3 TYROSINE KINASE INHIBITOR,ANTI-INFLAMMATORY,CONTROLLED RELEASE FORMULATION; DAILY DOSING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),208246,NDA,2015-04-24T00:00:00Z,fda,0,0,0,0,0,,pfizer,NYSE: PFE,1,52824,48851,49605,51584,54657,61035,40899,7838,7872,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208246,333,291,714,202,Rheumatoid arthritis and related disease,1,0
366,"IBUPROFEN + FAMOTIDINE (ORAL/TABLET, PAIN/ARTHRITIS/GASTRIC ULCER), HORIZON","DUEXA; DUEXIS; DUEXIS; HZN-501; HZT-501; IBUPROFEN + FAMOTIDINE; IBUPROFEN + FAMOTIDINE (ORAL/TABLET, PAIN/ARTHRITIS/GASTRIC ULCER), HORIZON","DUEXA; DUEXIS; DUEXIS; HZN-501; HZT-501; IBUPROFEN + FAMOTIDINE; IBUPROFEN + FAMOTIDINE (ORAL/TABLET, PAIN/ARTHRITIS/GASTRIC ULCER), HORIZON","IBUPROFEN + FAMOTIDINE (ORAL/TABLET, PAIN/ARTHRITIS/GASTRIC ULCER), HORIZON",DUEXA,DUEXIS,DUEXIS,HZN-501,HZT-501,IBUPROFEN + FAMOTIDINE,"IBUPROFEN + FAMOTIDINE (ORAL/TABLET, PAIN/ARTHRITIS/GASTRIC ULCER), HORIZON",,,,,,,,,,,,,,,,,,,,,,,,22519,FAMOTIDINE; IBUPROFEN,,,,,,,,,,,,,,,,,,,,,2011-04-23T00:00:00Z,2011,4,Duexis,arthritis,HISTAMINE H2 RECEPTOR ANTAGONIST,ANALGESIC; ANTACID; GASTRIC SECRETION INHIBITOR; HISTAMINE H2 ANTAGONIST ANTIULCERANT PRODUCT; NON-STEROIDAL ANTI-INFLAMMATORY,DAILY DOSING; DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022519,NDA,2010-03-22T00:00:00Z,fda,0,0,0,0,0,,horizon pharmaceuticals,NASDAQ: HZNP,1,6.9,2.4,,,,,-0.3,15.4,19.1,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022519,586,28,714,202,Rheumatoid arthritis and related disease,1,0
203,"DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/ HORIZON PHARMA","MNK-395; NRI-1004; PENNSAID 2%; PENNSAID GEL; PENNSAID PLUS; PENNSAID VISCOUS SOLUTION; DICHLOFENAC; DICLOFENAC; DICLOFENAC (FAST PENETRATION FORMULATION), DIMETHAID; DICLOFENAC (FAST PENETRATION FORMULATION), NUVO; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), DIMETHAID; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/ HORIZON PHARMA; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/MALLINCKRODT; DICLOFENAC (FAST PENETRATION TOPICAL GEL FORMULATION), NUVO; OSTEOARTHRITIS THERAPY (FAST PENETRATION), DIMETHAID; OSTEOARTHRITIS THERAPY (FAST PENETRATION), NUVO","MNK-395; NRI-1004; PENNSAID 2%; PENNSAID GEL; PENNSAID PLUS; PENNSAID VISCOUS SOLUTION; DICHLOFENAC; DICLOFENAC; DICLOFENAC (FAST PENETRATION FORMULATION), DIMETHAID; DICLOFENAC (FAST PENETRATION FORMULATION), NUVO; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), DIMETHAID; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/ HORIZON PHARMA; DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/MALLINCKRODT; DICLOFENAC (FAST PENETRATION TOPICAL GEL FORMULATION), NUVO; OSTEOARTHRITIS THERAPY (FAST PENETRATION), DIMETHAID; OSTEOARTHRITIS THERAPY (FAST PENETRATION), NUVO","DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/ HORIZON PHARMA",MNK-395,NRI-1004,PENNSAID 2%,PENNSAID GEL,PENNSAID PLUS,PENNSAID VISCOUS SOLUTION,DICHLOFENAC,DICLOFENAC,"DICLOFENAC (FAST PENETRATION FORMULATION), DIMETHAID","DICLOFENAC (FAST PENETRATION FORMULATION), NUVO","DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), DIMETHAID","DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/ HORIZON PHARMA","DICLOFENAC (FAST PENETRATION TOPICAL FORMULATION), NUVO/MALLINCKRODT","DICLOFENAC (FAST PENETRATION TOPICAL GEL FORMULATION), NUVO","OSTEOARTHRITIS THERAPY (FAST PENETRATION), DIMETHAID","OSTEOARTHRITIS THERAPY (FAST PENETRATION), NUVO",,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,,,,,,,,,,,,,,,,,,,,,2014-01-16T00:00:00Z,2014,1,Pennsaid,osteoarthritis,CYCLOOXYGENASE INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,ABSORPTION ENHANCER TRANSDERMAL; GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204623,NDA,2012-05-04T00:00:00Z,fda,0,0,0,0,0,,mallinckrodt,NYSE: MNK,1,2310,2240.7,2056.5,2021.8,2047.6,,1266.4,177.2,177.2,,,,,reported revenue for 2011 and 2010 are for the 12 months prior to September of each year,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204623,327,245,715,203,Osteoarthritis,1,0
205,"DICLOFENAC (TOPICAL), NUVO","DIMETHAID-D; PENNSAID; PENNSAID 1.5%; DICHLOFENAC; DICLOFENAC; DICLOFENAC (TOPICAL), DIMETHAID; DICLOFENAC (TOPICAL), NUVO; DICLOFENAC (TOPICAL), NUVO/PALADIN; DICLOFENAC (TOPICAL, DIMETHYL SULFOXIDE (DMSO) CARRIER), NUVO","DIMETHAID-D; PENNSAID; PENNSAID 1.5%; DICHLOFENAC; DICLOFENAC; DICLOFENAC (TOPICAL), DIMETHAID; DICLOFENAC (TOPICAL), NUVO; DICLOFENAC (TOPICAL), NUVO/PALADIN; DICLOFENAC (TOPICAL, DIMETHYL SULFOXIDE (DMSO) CARRIER), NUVO","DICLOFENAC (TOPICAL), NUVO",DIMETHAID-D,PENNSAID,PENNSAID 1.5%,DICHLOFENAC,DICLOFENAC,"DICLOFENAC (TOPICAL), DIMETHAID","DICLOFENAC (TOPICAL), NUVO","DICLOFENAC (TOPICAL), NUVO/PALADIN","DICLOFENAC (TOPICAL, DIMETHYL SULFOXIDE (DMSO) CARRIER), NUVO",,,,,,,,,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,20947,DICLOFENAC SODIUM,,,,,,,,,,,,,,,,,,,2009-11-04T00:00:00Z,2009,11,Pennsaid,osteoarthritis,CYCLOOXYGENASE 2 INHIBITOR,ANALGESIC; LOCAL ANESTHETIC; NON-STEROIDAL ANTI-INFLAMMATORY,DERMATOLOGICAL FORMULATION; EMULSION DERMATOLOGICAL; LOCAL FORMULATION UNSPECIFIED; PHARMACEUTICAL CARRIER; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),020947,NDA,2001-08-07T00:00:00Z,fda,0,0,0,0,0,,nuvo research,TSX: NRI,1,36.9,8.7,7.3,3.6,4.3,5.3,31.3,8.3,8.3,,,,,"reported revenue for 2004 is for the 12 months prior to november 30, 2004",,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020947,358,245,715,203,Osteoarthritis,1,0
334,GOLIMUMAB,CNTO-148; SIMPONI; SYMPONI; GOLIMUMAB,CNTO-148; SIMPONI; SYMPONI; GOLIMUMAB,GOLIMUMAB,CNTO-148,SIMPONI,SYMPONI,GOLIMUMAB,,,,,,,,,,,,,,,,,,,,,,,,,,,125289,GOLIMUMAB,125289,GOLIMUMAB,,,,,,,,,,,,,,,,,,,2009-04-24T00:00:00Z,2009,4,Simponi,ankylosing spondylitis,TNF ALPHA LIGAND INHIBITOR,ANTI-INFLAMMATORY,BIOLOGICAL THERAPEUTIC; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY HUMAN; MONTHLY DOSING; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125289,BLA,2008-06-24T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61897,63747,61095,53324,50514,47348,43563,6986,6986,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125289,19,398,720,205,Spondylosis; intervertebral disc disorders; other back problems,2,0
379,"INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR/ORION","CT-P13; FLAMMEGIS; INFLECTRA; REMSIMA; INFLIXIMAB; INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR; INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR/ORION; INFLIXIMAB-DYYB","CT-P13; FLAMMEGIS; INFLECTRA; REMSIMA; INFLIXIMAB; INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR; INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR/ORION; INFLIXIMAB-DYYB","INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR/ORION",CT-P13,FLAMMEGIS,INFLECTRA,REMSIMA,INFLIXIMAB,"INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR","INFLIXIMAB BIOSIMILAR, CELLTRION/NIPPON KAYAKU/HOSPIRA/EGIS GYOGYSZERGYAR/ORION",INFLIXIMAB-DYYB,,,,,,,,,,,,,,,,,,,,,,,125544,INFLIXIMAB-DYYB,,,,,,,,,,,,,,,,,,,,,2016-04-05T00:00:00Z,2016,4,Inflectra,ankylosing spondylitis,TNF ALPHA LIGAND INHIBITOR; TNF BINDING AGENT,ANTI-INFLAMMATORY; SYSTEMIC ANTIPSORIATIC PRODUCT,BIOLOGICAL THERAPEUTIC; BIOSIMILAR PRODUCT; CHIMERIC MONOCLONAL ANTIBODY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT,matched (3),125544,BLA,2014-08-08T00:00:00Z,fda,0,0,0,0,0,,celltrion,KOSDAQ: 068270,1,557,512.8,431.6,214.3,329.3,240.4,329.4,54.3,54.3,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544,58,398,720,205,Spondylosis; intervertebral disc disorders; other back problems,2,0
169,"COLLAGENASE (INJECTABLE), ENDO/PFIZER","AA-4500; AK-160; CCH; CORDASE; EN-3835; LIPOLYSIN; PF-5076985; PEYRONIE'S DISEASE THERAPY, AUXILIUM PHARAMCEUTICALS; PLAQUASE; XIAFLEX; XIAPEX; CLOSTRIDIAL COLLAGENASE; COLLAGENASE (INJECTABLE), AUXILIUM/PFIZER; COLLAGENASE (INJECTABLE), ENDO/PFIZER; COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; INJECTABLE COLLAGENASE, BIOSPECIFICS/AUXILIUM","AA-4500; AK-160; CCH; CORDASE; EN-3835; LIPOLYSIN; PF-5076985; PEYRONIE'S DISEASE THERAPY, AUXILIUM PHARAMCEUTICALS; PLAQUASE; XIAFLEX; XIAPEX; CLOSTRIDIAL COLLAGENASE; COLLAGENASE (INJECTABLE), AUXILIUM/PFIZER; COLLAGENASE (INJECTABLE), ENDO/PFIZER; COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; INJECTABLE COLLAGENASE, BIOSPECIFICS/AUXILIUM","COLLAGENASE (INJECTABLE), ENDO/PFIZER",AA-4500,AK-160,CCH,CORDASE,EN-3835,LIPOLYSIN,PF-5076985,"PEYRONIE'S DISEASE THERAPY, AUXILIUM PHARAMCEUTICALS",PLAQUASE,XIAFLEX,XIAPEX,CLOSTRIDIAL COLLAGENASE,"COLLAGENASE (INJECTABLE), AUXILIUM/PFIZER","COLLAGENASE (INJECTABLE), ENDO/PFIZER",COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,"INJECTABLE COLLAGENASE, BIOSPECIFICS/AUXILIUM",,,,,,,,,,,,,,,125338,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,,,,,,,,,,,,,,,,,,,,,2010-02-02T00:00:00Z,2010,2,Xiaflex,dupuytren contracture,COLLAGEN I ANTAGONIST; COLLAGEN III ANTAGONIST; COLLAGENASE STIMULATOR,ANTICANCER,BIOLOGICAL THERAPEUTIC; ENZYME; FORMULATION POWDER; FREEZE DRYING; INTRADERMAL FORMULATION; PEPTIDE,matched (3),125338,BLA,2009-02-27T00:00:00Z,fda,1,0,0,1,0,,auxilium pharmaceuticals,private,0,211.4,164,125.4,95.7,68.5,42.8,165.6,48,48,,,,,acquired by endo in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125338,27,2672,728,211,Other connective tissue disease,1,0
527,NUSINERSEN,"ASO-10-27; BIIB-058; IONIS-SMNRX; ISIS-396443; ISIS-SMN RA; ISIS-SMNRX; ISIS-SMNRX, ISIS/BIOGEN; ISIS-SMNRX, ISIS/BIOGEN IDEC; SMN PROMOTER ACTIVATORS (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS; SMNRX; SMNRX; SPINRAZA; SPINRAZA; ANTISENSE OLIGONUCLEOTIDE (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS; ANTISENSE OLIGONUCLEOTIDES (SMA), GENZYME/ISIS; NUSINERSEN; SURVIVAL MOTOR NEURON PROMOTER (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS","ASO-10-27; BIIB-058; IONIS-SMNRX; ISIS-396443; ISIS-SMN RA; ISIS-SMNRX; ISIS-SMNRX, ISIS/BIOGEN; ISIS-SMNRX, ISIS/BIOGEN IDEC; SMN PROMOTER ACTIVATORS (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS; SMNRX; SMNRX; SPINRAZA; SPINRAZA; ANTISENSE OLIGONUCLEOTIDE (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS; ANTISENSE OLIGONUCLEOTIDES (SMA), GENZYME/ISIS; NUSINERSEN; SURVIVAL MOTOR NEURON PROMOTER (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS",NUSINERSEN,ASO-10-27,BIIB-058,IONIS-SMNRX,ISIS-396443,ISIS-SMN RA,ISIS-SMNRX,"ISIS-SMNRX, ISIS/BIOGEN","ISIS-SMNRX, ISIS/BIOGEN IDEC","SMN PROMOTER ACTIVATORS (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS",SMNRX,SMNRX,SPINRAZA,SPINRAZA,"ANTISENSE OLIGONUCLEOTIDE (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS","ANTISENSE OLIGONUCLEOTIDES (SMA), GENZYME/ISIS",NUSINERSEN,"SURVIVAL MOTOR NEURON PROMOTER (SPINAL MUSCULAR ATROPHY), GENZYME/ISIS",,,,,,,,,,,,,,209531,NUSINERSEN SODIUM,,,,,,,,,,,,,,,,,,,,,2016-12-23T00:00:00Z,2016,12,Spinraza,spinal muscular atrophy,,ANTISENSE OLIGONUCLEOTIDE INHIBITOR; NEUROPROTECTANT; SMN2 GENE MODULATOR,BIOLOGICAL THERAPEUTIC; INTRATHECAL FORMULATION; OLIGONUCLEOTIDE ANTISENSE,matched (3),209531,NDA,2016-09-23T00:00:00Z,fda,1,0,1,1,0,,biogen,NASDAQ: BIIB,1,11448.8,10763.8,9703.3,6932.2,5514.86,5037.63,10022.5,1973.3,1973.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209531,359,727,728,211,Other connective tissue disease,1,0
176,CYCLOBENZAPRINE HYDROCHLORIDE (EXTENDED-RELEASE DIFFUCAPS FORMULATION) CEPHALON,"AMRIX (EXTENDED RELEASE); BONELAX ER; EUR-1002; CYCLOBENZAPRINE; CYCLOBENZAPRINE (EXTENDED RELEASE, MUSCLE SPASM) CEPHALON/EURAND; CYCLOBENZAPRINE HYDROCHLORIDE; CYCLOBENZAPRINE HYDROCHLORIDE (EXTENDED RELEASE, MUSCLE SPASM) CEPHALON; CYCLOBENZAPRINE HYDROCHLORIDE (EXTENDED-RELEASE DIFFUCAPS FORMULATION) CEPHALON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2007-02-01T00:00:00Z,2007,2,Amrix,muscle spasm,,CENTRALLY-ACTING MUSCLE RELAXANT; UNSPECIFIED DRUG TARGET,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),021777,NDA,2004-04-29T00:00:00Z,cortellis,0,0,0,0,0,,akorn,NASDAQ: AKRX,1,1162.2,775.3,504.7,413.5,248.4,95.7,783,7.9,7.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021777,651,358,728,211,Other connective tissue disease,1,0
459,"MELOXICAM (SOLUMATRIX/ARTHRITIS), ICEUTICA","IP-045; IP-045; VIVLODEX; VIVLODEX; MELOXICAM; MELOXICAM (SOLUMATRIX/ARTHRITIS), ICEUTICA; MELOXICAM NANOFORMULATION CAPSULES (ARTHRITIS), ICEUTICA","IP-045; IP-045; VIVLODEX; VIVLODEX; MELOXICAM; MELOXICAM (SOLUMATRIX/ARTHRITIS), ICEUTICA; MELOXICAM NANOFORMULATION CAPSULES (ARTHRITIS), ICEUTICA","MELOXICAM (SOLUMATRIX/ARTHRITIS), ICEUTICA",IP-045,IP-045,VIVLODEX,VIVLODEX,MELOXICAM,"MELOXICAM (SOLUMATRIX/ARTHRITIS), ICEUTICA","MELOXICAM NANOFORMULATION CAPSULES (ARTHRITIS), ICEUTICA",,,,,,,,,,,,,,,,,,,,,,,,207233,MELOXICAM,,,,,,,,,,,,,,,,,,,,,2015-10-22T00:00:00Z,2015,10,Vivlodex,musculoskeletal pain,CYCLOOXYGENASE 2 INHIBITOR,ANALGESIC; ANTI-INFLAMMATORY; NON-STEROIDAL ANTI-INFLAMMATORY; PG SYNTHESIS INHIBITOR,CAPSULE FORMULATION; NANOPARTICLE FORMULATION ORAL; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),207233,NDA,2014-12-23T00:00:00Z,fda,0,0,0,0,0,,iroko pharmaceuticals,private,0,,,,,,,,,,,,,,publicly traded stock is defunct since 2013; company still in business,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207233,298,2440,729,211,Other connective tissue disease,1,0
488,MILNACIPRAN,DALCIPRAN; F-2207; F-2641; IMPULSOR; IXEL; IXEL CAP; JONCIA; LIXEL; SAVELLA; TOLEDOMIN; MILNACIPRAN; MILNACIPRAN HYDROCHLORIDE,DALCIPRAN; F-2207; F-2641; IMPULSOR; IXEL; IXEL CAP; JONCIA; LIXEL; SAVELLA; TOLEDOMIN; MILNACIPRAN; MILNACIPRAN HYDROCHLORIDE,MILNACIPRAN,DALCIPRAN,F-2207,F-2641,IMPULSOR,IXEL,IXEL CAP,JONCIA,LIXEL,SAVELLA,TOLEDOMIN,MILNACIPRAN,MILNACIPRAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,22256,MILNACIPRAN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-01-14T00:00:00Z,2009,1,Savella,fibromyalgia,,5-HT UPTAKE INHIBITOR; ANTIDEPRESSANT; MUSCLE RELAXANT; NOREPINEPHRINE UPTAKE INHIBITOR,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022256,NDA,2007-12-18T00:00:00Z,fda,0,0,0,0,0,,cypress bioscience,NASDAQ: CYPB,1,27.3,16.7,13.4,4.3,8.4,14.4,13.4,,12,,,,,acquired by ramius llc in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022256,514,2527,729,211,Other connective tissue disease,1,0
194,DENOSUMAB,"AMG-162; PRALIA; PROLIA; RANK-L ANTAGONIST (MONOCLONAL ANTIBODY), AMGEN; RANMARK; XGEVA; ANTI-RANK-L MAB (BONE DISEASES, RHEUMATOID ARTHRITIS), AMGEN; DENOSUMAB","AMG-162; PRALIA; PROLIA; RANK-L ANTAGONIST (MONOCLONAL ANTIBODY), AMGEN; RANMARK; XGEVA; ANTI-RANK-L MAB (BONE DISEASES, RHEUMATOID ARTHRITIS), AMGEN; DENOSUMAB",DENOSUMAB,AMG-162,PRALIA,PROLIA,"RANK-L ANTAGONIST (MONOCLONAL ANTIBODY), AMGEN",RANMARK,XGEVA,"ANTI-RANK-L MAB (BONE DISEASES, RHEUMATOID ARTHRITIS), AMGEN",DENOSUMAB,,,,,,,,,,,,,,,,,,,,,,,125320,DENOSUMAB,125320,DENOSUMAB,125320,DENOSUMAB,,,,,,,,,,,,,,,,,2010-06-01T00:00:00Z,2010,6,Prolia,osteoporosis,IMMUNOGLOBULIN G2 ANTAGONIST; NF KAPPA B INHIBITOR STIMULATOR; OSTEOCLAST DIFFERENTIATION FACTOR ANTAGONIST; OSTEOCLAST DIFFERENTIATION FACTOR LIGAND INHIBITOR; TNFSF11 GENE INHIBITOR,ANTI-INFLAMMATORY; ANTICANCER MONOCLONAL ANTIBODY; BONE RESORPTION INHIBITOR; METASTASIS INHIBITOR,BIOLOGICAL THERAPEUTIC; CELL CULTURE; DNA TECHNOLOGY; IMMUNOGLOBULIN-G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUMAN; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),125320,BLA,2008-12-19T00:00:00Z,fda,0,0,0,0,0,,amgen,NASDAQ: AMGN,1,15053,14642,15003,14771,14268,12430,12833,2894,2922,,,,,,1,listed in cancer drug file with brand name xgeva,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320,24,246,733,212,Other bone disease and musculoskeletal deformities,3,0
23,"ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/ AHN-GOOK/ HIKMA/ ABIOGEN/ LACER/ ATRAL","AGB-P1; AVALENT; BINOSTO; EX-101; STEOVESS; ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/ AHN-GOOK/ HIKMA/ ABIOGEN/ LACER/ ATRAL; ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL; ALENDRONATE SODIUM; ALENDRONIC ACID; ALENDRONIC ACID (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL","AGB-P1; AVALENT; BINOSTO; EX-101; STEOVESS; ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/ AHN-GOOK/ HIKMA/ ABIOGEN/ LACER/ ATRAL; ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL; ALENDRONATE SODIUM; ALENDRONIC ACID; ALENDRONIC ACID (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL","ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/ AHN-GOOK/ HIKMA/ ABIOGEN/ LACER/ ATRAL",AGB-P1,AVALENT,BINOSTO,EX-101,STEOVESS,"ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/ AHN-GOOK/ HIKMA/ ABIOGEN/ LACER/ ATRAL","ALENDRONATE (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL",ALENDRONATE SODIUM,ALENDRONIC ACID,"ALENDRONIC ACID (EFFERVESCENT, OSTEOPOROSIS), EFFRX/TAKEDA PHARMACEUTICALS INTERNATIONAL",,,,,,,,,,,,,,,,,,,,,202344,ALENDRONATE SODIUM,,,,,,,,,,,,,,,,,,,,,2012-03-12T00:00:00Z,2012,3,Binosto,male osteoporosis,,BONE RESORPTION INHIBITOR; CALCIUM METABOLIC INHIBITOR; OSTEOCLAST INHIBITOR,FORMULATION ORAL TASTE-MASKING; ORAL FORMULATION; ORAL LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),202344,NDA,2010-12-21T00:00:00Z,fda,0,0,0,0,0,,effRx pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202344,117,2548,733,212,Other bone disease and musculoskeletal deformities,3,0
66,"ATELVIA (OSTEOPOROSIS, WARNER CHILCOTT)","ATELVIA; ATELVIA (OSTEOPOROSIS, WARNER CHILCOTT)","ATELVIA; ATELVIA (OSTEOPOROSIS, WARNER CHILCOTT)","ATELVIA (OSTEOPOROSIS, WARNER CHILCOTT)",ATELVIA,"ATELVIA (OSTEOPOROSIS, WARNER CHILCOTT)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,22560,RISEDRONATE SODIUM,,,,,,,,,,,,,,,,,,,,,2010-10-08T00:00:00Z,2010,10,Atelvia,postmenopausal osteoporosis,,BONE RESORPTION INHIBITOR; OSTEOCLAST INHIBITOR,CONTROLLED RELEASE FORMULATION; ENTERIC COATED FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022560,NDA,2009-09-24T00:00:00Z,fda,0,0,0,0,0,,warner chilcott,NASDAQ: WCRX,1,2974,1435.8,938.1,899.6,754.5,515.3,2587,147,147,,,,,acquired by actavis (now allergan plc) in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022560,600,2549,733,212,Other bone disease and musculoskeletal deformities,3,0
71,"AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ALLERGAN","AVYCAZ; CAZ-104; CAZ-AVI; NXL-104 + CEFTAZIDIME (IV, URINARY TRACT INFECTION), NOVEXEL; ZAVICEFTA; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ACTAVIS; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ALLERGAN; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/FOREST LABORATORIES; BETA-LACTAMASE INHIBITOR PLUS BETA-LACTAM ANTIBIOTICS (INTRAVENOUS, GRAM NEGATIVE INFECTION), NOVEXEL; CEFTAZIDIME + AVE-1330A; CEFTAZIDIME + NXL-104; CEFTAZIDIME + AVIBACTAM SODIUM","AVYCAZ; CAZ-104; CAZ-AVI; NXL-104 + CEFTAZIDIME (IV, URINARY TRACT INFECTION), NOVEXEL; ZAVICEFTA; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ACTAVIS; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ALLERGAN; AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/FOREST LABORATORIES; BETA-LACTAMASE INHIBITOR PLUS BETA-LACTAM ANTIBIOTICS (INTRAVENOUS, GRAM NEGATIVE INFECTION), NOVEXEL; CEFTAZIDIME + AVE-1330A; CEFTAZIDIME + NXL-104; CEFTAZIDIME + AVIBACTAM SODIUM","AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ALLERGAN",AVYCAZ,CAZ-104,CAZ-AVI,"NXL-104 + CEFTAZIDIME (IV, URINARY TRACT INFECTION), NOVEXEL",ZAVICEFTA,"AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ACTAVIS","AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/ALLERGAN","AVIBACTAM SODIUM + CEFTAZIDIME (IV, URINARY TRACT INFECTION), ASTRAZENECA/FOREST LABORATORIES","BETA-LACTAMASE INHIBITOR PLUS BETA-LACTAM ANTIBIOTICS (INTRAVENOUS, GRAM NEGATIVE INFECTION), NOVEXEL",CEFTAZIDIME + AVE-1330A,CEFTAZIDIME + NXL-104,CEFTAZIDIME + AVIBACTAM SODIUM,,,,,,,,,,,,,,,,,,,206494,AVIBACTAM SODIUM; CEFTAZIDIME,,,,,,,,,,,,,,,,,,,,,2015-02-25T00:00:00Z,2015,2,Avycaz,urinary tract infection,BETA LACTAMASE INHIBITOR,BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN,ANTIBIOTIC; DRUG COMBINATION; FORMULATION POWDER; INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),206494,NDA,2014-06-25T00:00:00Z,fda,1,0,1,0,0,,actavis (allergan plc),NYSE: AGN,1,12688.1,3646.9,3094,4547.76,4390.13,4157.39,11221.3,2067,2358.5,4518,2014-06-30T00:00:00Z,2014,,acquired by actavis (now allergan plc) in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206494,285,1009,760,224,Other perinatal conditions,3,0
431,"LIDOCAINE GEL (OPHTHALMIC FORMULATION, OCULAR ANESTHESIA), AKORN","AK-1015; AKTEN; LIDOCAINE; LIDOCAINE GEL (OPHTHALMIC FORMULATION, OCULAR ANESTHESIA), AKORN","AK-1015; AKTEN; LIDOCAINE; LIDOCAINE GEL (OPHTHALMIC FORMULATION, OCULAR ANESTHESIA), AKORN","LIDOCAINE GEL (OPHTHALMIC FORMULATION, OCULAR ANESTHESIA), AKORN",AK-1015,AKTEN,LIDOCAINE,"LIDOCAINE GEL (OPHTHALMIC FORMULATION, OCULAR ANESTHESIA), AKORN",,,,,,,,,,,,,,,,,,,,,,,,,,,22221,LIDOCAINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2008-10-07T00:00:00Z,2008,10,Akten,anesthesia,,ANESTHETIC; UNSPECIFIED DRUG TARGET,OPHTHALMIC FORMULATION; OPHTHALMIC GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022221,NDA,2007-06-29T00:00:00Z,fda,0,0,0,0,0,,akorn,NASDAQ: AKRX,1,93.6,52.9,71.3,44.5,50.7,45.5,26.6,6.8,6.8,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022221,502,19,763,224,Other perinatal conditions,1,0
450,"LUCINACTANT (LIQUID INSTILLATE), WINDTREE THERAPEUTICS/ESTEVE","KL4; KL4 PULMONARY SURFACTANT; KL4-SURFACTANT; SURFAXIN; SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES; SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE; SURFAXIN LS; LUCINACTANT; LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES; LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE; LUCINACTANT (LIQUID INSTILLATE), WINDTREE THERAPEUTICS/ESTEVE; SINAPULTIDE; SINAPULTIDE + LIPIDS","KL4; KL4 PULMONARY SURFACTANT; KL4-SURFACTANT; SURFAXIN; SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES; SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE; SURFAXIN LS; LUCINACTANT; LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES; LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE; LUCINACTANT (LIQUID INSTILLATE), WINDTREE THERAPEUTICS/ESTEVE; SINAPULTIDE; SINAPULTIDE + LIPIDS","LUCINACTANT (LIQUID INSTILLATE), WINDTREE THERAPEUTICS/ESTEVE",KL4,KL4 PULMONARY SURFACTANT,KL4-SURFACTANT,SURFAXIN,"SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES","SURFAXIN (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE",SURFAXIN LS,LUCINACTANT,"LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES","LUCINACTANT (LIQUID INSTILLATE), DISCOVERY LABORATORIES/ESTEVE","LUCINACTANT (LIQUID INSTILLATE), WINDTREE THERAPEUTICS/ESTEVE",SINAPULTIDE,SINAPULTIDE + LIPIDS,,,,,,,,,,,,,,,,,,21746,LUCINACTANT,,,,,,,,,,,,,,,,,,,,,2012-03-06T00:00:00Z,2012,3,Surfaxin,neonatal respiratory distress syndrome,BONE MORPHOGENETIC PROTEIN-10 LIGAND INHIBITOR; BONE MORPHOGENETIC PROTEIN-15 LIGAND INHIBITOR; LUNG SURFACTANT ASSOCIATED PROTEIN B STIMULATOR,ANTI-INFLAMMATORY; RESPIRATORY SYSTEM AGENT; SURFACTANT,BIOLOGICAL THERAPEUTIC; FREEZE DRYING; LIPID; LIQUID-BASED FORMULATION TECHNOLOGY; LOCAL FORMULATION UNSPECIFIED; PROTEIN RECOMBINANT; SUSPENSION; SYSTEMIC FORMULATION UNSPECIFIED,matched (3),021746,NDA,2004-04-13T00:00:00Z,fda,0,0,1,0,0,,discovery laboratories,NASDAQ: DSCO,1,0.2,0.6,,,4.6,,-21.4,,21.6,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021746,384,2563,770,224,Other perinatal conditions,2,0
561,"OXYMORPHONE IR, ENDO","EN-3203; OPANA; IMMEDIATE RELEASE OXYMORPHONE, ENDO; OXYMORPHONE; OXYMORPHONE IR, ENDO; OXYMORPHONE HYDROCHLORIDE","EN-3203; OPANA; IMMEDIATE RELEASE OXYMORPHONE, ENDO; OXYMORPHONE; OXYMORPHONE IR, ENDO; OXYMORPHONE HYDROCHLORIDE","OXYMORPHONE IR, ENDO",EN-3203,OPANA,"IMMEDIATE RELEASE OXYMORPHONE, ENDO",OXYMORPHONE,"OXYMORPHONE IR, ENDO",OXYMORPHONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,11707,OXYMORPHONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2006-06-22T00:00:00Z,2006,6,Opana IR,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021611,NDA,2002-12-20T00:00:00Z,fda,0,0,0,0,0,,endo pharmaceuticals,NASDAQ: ENDP,1,909.659,820.164,615.1,595.608,398.973,251.979,700.77,86.629,86.629,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021611,3,20,780,259,Residual codes; unclassified,11,0
706,"TAPENTADOL (SUSTAINED RELEASE, PAIN) J&J PRD/GRUNENTHAL","CG-5503 ER; CG-5503 PR; JNS-024 ER; NUCYNTA ER; NUCYNTA SR; PALEXIA DEPOT; PALEXIA DEPOT; PALEXIA LP; PALEXIA LP; PALEXIA SR; PALEXIA SR; PALEXIA RETARD; PALEXIA RETARD; TAPENTA; TAPENTA; YANTIL RETARD; YANTIL SR; YANTIL SR; TAPENTADOL; TAPENTADOL (SUSTAINED RELEASE, PAIN) J&J PRD/GRUNENTHAL; TAPENTADOL ER; TAPENTADOL PR; TAPENTADOL HYDROCHLORIDE","CG-5503 ER; CG-5503 PR; JNS-024 ER; NUCYNTA ER; NUCYNTA SR; PALEXIA DEPOT; PALEXIA DEPOT; PALEXIA LP; PALEXIA LP; PALEXIA SR; PALEXIA SR; PALEXIA RETARD; PALEXIA RETARD; TAPENTA; TAPENTA; YANTIL RETARD; YANTIL SR; YANTIL SR; TAPENTADOL; TAPENTADOL (SUSTAINED RELEASE, PAIN) J&J PRD/GRUNENTHAL; TAPENTADOL ER; TAPENTADOL PR; TAPENTADOL HYDROCHLORIDE","TAPENTADOL (SUSTAINED RELEASE, PAIN) J&J PRD/GRUNENTHAL",CG-5503 ER,CG-5503 PR,JNS-024 ER,NUCYNTA ER,NUCYNTA SR,PALEXIA DEPOT,PALEXIA DEPOT,PALEXIA LP,PALEXIA LP,PALEXIA SR,PALEXIA SR,PALEXIA RETARD,PALEXIA RETARD,TAPENTA,TAPENTA,YANTIL RETARD,YANTIL SR,YANTIL SR,TAPENTADOL,"TAPENTADOL (SUSTAINED RELEASE, PAIN) J&J PRD/GRUNENTHAL",TAPENTADOL ER,TAPENTADOL PR,TAPENTADOL HYDROCHLORIDE,,,,,,,,200533,TAPENTADOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-08-25T00:00:00Z,2011,8,Nucynta ER,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),200533,NDA,2009-11-30T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,65030,61587,61897,63747,61095,53324,44757,7548,7548,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200533,73,20,780,259,Residual codes; unclassified,11,0
559,"OXYCODONE HYDROCHLORIDE (ODT, IMMEDIATE-RELEASE, ORAL TASTE-MASKED/FLASHTAB, PAIN), ETHYPHARM","OXYNORMORO; OXYCODONE; OXYCODONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE (ODT, IMMEDIATE-RELEASE, ORAL TASTE-MASKED/FLASHTAB, PAIN), ETHYPHARM","OXYNORMORO; OXYCODONE; OXYCODONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE (ODT, IMMEDIATE-RELEASE, ORAL TASTE-MASKED/FLASHTAB, PAIN), ETHYPHARM","OXYCODONE HYDROCHLORIDE (ODT, IMMEDIATE-RELEASE, ORAL TASTE-MASKED/FLASHTAB, PAIN), ETHYPHARM",OXYNORMORO,OXYCODONE,OXYCODONE HYDROCHLORIDE,"OXYCODONE HYDROCHLORIDE (ODT, IMMEDIATE-RELEASE, ORAL TASTE-MASKED/FLASHTAB, PAIN), ETHYPHARM",,,,,,,,,,,,,,,,,,,,,,,,,,,200534,OXYCODONE HYDROCHLORIDE,200534,OXYCODONE HYDROCHLORIDE,200534,OXYCODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,2011-06-30T00:00:00Z,2011,6,Oxynormoro,pain,OPIOID RECEPTOR AGONIST,ANALGESIC,FORMULATION ORAL TASTE-MASKING; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),not identified,NDA,,,0,0,0,0,0,,ethypharm,private,0,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,74,20,780,259,Residual codes; unclassified,11,0
555,"OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), EGALET CORP","ACUROX; ACUROX (WITHOUT NIACIN), KING/ACURA; LTX-01; LTX-02; OXAYDO; OXAYDO; OXECTA; OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), ACURA/KING; OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), EGALET CORP; OXYCODONE HCL; OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/KING; OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/PFIZER; OXYCODONE HYDROCHLORIDE","ACUROX; ACUROX (WITHOUT NIACIN), KING/ACURA; LTX-01; LTX-02; OXAYDO; OXAYDO; OXECTA; OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), ACURA/KING; OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), EGALET CORP; OXYCODONE HCL; OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/KING; OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/PFIZER; OXYCODONE HYDROCHLORIDE","OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), EGALET CORP",ACUROX,"ACUROX (WITHOUT NIACIN), KING/ACURA",LTX-01,LTX-02,OXAYDO,OXAYDO,OXECTA,"OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), ACURA/KING","OXYCODONE (IMMEDIATE RELEASE, ABUSE DETERRENT, AVERSION), EGALET CORP",OXYCODONE HCL,"OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/KING","OXYCODONE HCL (IMMEDIATE-RELEASE TABLET, PAIN), ACURA/PFIZER",OXYCODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,200534,OXYCODONE HYDROCHLORIDE,202080,OXYCODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2011-06-17T00:00:00Z,2011,6,Oxaydo,pain,OPIOID RECEPTOR AGONIST; OPIOID RECEPTOR MU AGONIST,ANALGESIC,ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),202080,NDA,2010-12-17T00:00:00Z,fda,1,0,0,0,0,,pfizer,NYSE: PFE,1,61035,65165,1776.5,1565.1,2136.9,1988.5,49335,8004,8681,1501.73333333333,2010-09-30T00:00:00Z,2010,,acquired by pfizer in 2010,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202080,99,20,780,259,Residual codes; unclassified,11,0
355,"HYDROCODONE (ORAL ABUSE-RESISTANT (BEADTEK), CONTROLLED-RELEASE (SODAS)), PERNIX","ZX-002; ZOHYDRO; ZOHYDRO ER; HYDROCODONE; HYDROCODONE (ORAL ABUSE-RESISTANT (BEADTEK), CONTROLLED-RELEASE (SODAS)), PERNIX; HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE (ORAL CONTROLLED-RELEASE, SODAS, PAIN), ELAN/ZOGENIX","ZX-002; ZOHYDRO; ZOHYDRO ER; HYDROCODONE; HYDROCODONE (ORAL ABUSE-RESISTANT (BEADTEK), CONTROLLED-RELEASE (SODAS)), PERNIX; HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE (ORAL CONTROLLED-RELEASE, SODAS, PAIN), ELAN/ZOGENIX","HYDROCODONE (ORAL ABUSE-RESISTANT (BEADTEK), CONTROLLED-RELEASE (SODAS)), PERNIX",ZX-002,ZOHYDRO,ZOHYDRO ER,HYDROCODONE,"HYDROCODONE (ORAL ABUSE-RESISTANT (BEADTEK), CONTROLLED-RELEASE (SODAS)), PERNIX",HYDROCODONE BITARTRATE,"HYDROCODONE BITARTRATE (ORAL CONTROLLED-RELEASE, SODAS, PAIN), ELAN/ZOGENIX",,,,,,,,,,,,,,,,,,,,,,,,202880,HYDROCODONE BITARTRATE,,,,,,,,,,,,,,,,,,,,,2013-10-25T00:00:00Z,2013,10,Zohydro ER,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,CAPSULE FORMULATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),202880,NDA,2012-04-30T00:00:00Z,fda,0,0,0,0,0,,zogenix,NASDAQ: ZGNX,1,33,44.3,37.6,23.4,,,10.5,8.4,8.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202880,135,20,780,259,Residual codes; unclassified,11,0
557,"OXYCODONE + PARACETAMOL (ORAL, ACUFORM, PAIN), MALLINCKRODT","COV-795; MNK-795; XARTEMIS XR; OXYCODONE + ACETAMINOPHEN; OXYCODONE + ACETAMINOPHEN (ORAL, ACUFORM, PAIN), MALLINCKRODT; OXYCODONE + PARACETAMOL; OXYCODONE + PARACETAMOL (ORAL, ACUFORM, PAIN), MALLINCKRODT; PARACETAMOL + OPIOID AGONISTS (ACUFORM, PAIN), MALLINCKRODT","COV-795; MNK-795; XARTEMIS XR; OXYCODONE + ACETAMINOPHEN; OXYCODONE + ACETAMINOPHEN (ORAL, ACUFORM, PAIN), MALLINCKRODT; OXYCODONE + PARACETAMOL; OXYCODONE + PARACETAMOL (ORAL, ACUFORM, PAIN), MALLINCKRODT; PARACETAMOL + OPIOID AGONISTS (ACUFORM, PAIN), MALLINCKRODT","OXYCODONE + PARACETAMOL (ORAL, ACUFORM, PAIN), MALLINCKRODT",COV-795,MNK-795,XARTEMIS XR,OXYCODONE + ACETAMINOPHEN,"OXYCODONE + ACETAMINOPHEN (ORAL, ACUFORM, PAIN), MALLINCKRODT",OXYCODONE + PARACETAMOL,"OXYCODONE + PARACETAMOL (ORAL, ACUFORM, PAIN), MALLINCKRODT","PARACETAMOL + OPIOID AGONISTS (ACUFORM, PAIN), MALLINCKRODT",,,,,,,,,,,,,,,,,,,,,,,204031,ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-03-11T00:00:00Z,2014,3,Xartemis XR,pain,OPIOID RECEPTOR AGONIST,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,DRUG COMBINATION; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204031,NDA,2013-05-24T00:00:00Z,fda,1,0,0,0,0,,mallinckrodt,NYSE: MNK,1,2310,2240.7,2056.5,2021.8,2047.6,,1266.4,177.2,177.2,,,,,reported revenue for 2011 and 2010 are for the 12 months prior to September of each year,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204031,178,20,780,259,Residual codes; unclassified,11,0
696,SUVOREXANT,BELSOMRA; MK-4305; SUVOREXANT,BELSOMRA; MK-4305; SUVOREXANT,SUVOREXANT,BELSOMRA,MK-4305,SUVOREXANT,,,,,,,,,,,,,,,,,,,,,,,,,,,,204569,SUVOREXANT,,,,,,,,,,,,,,,,,,,,,2014-08-13T00:00:00Z,2014,8,Belsomra,insomnia,OREXIN 1 RECEPTOR ANTAGONIST; OREXIN 2 RECEPTOR ANTAGONIST,HYPNOTIC,FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),204569,NDA,2012-08-30T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,42237,44033,47267,48047,45987,27428,27051,6532,7131,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569,205,750,780,259,Residual codes; unclassified,11,0
204,"DICLOFENAC (SOLUMATRIX/CAPSULE, DENTAL/OSTEOARTHRITIC PAIN), IROKO/ICEUTICA","IP-880; ZORVOLEX; DICLOFENAC; DICLOFENAC (SOLUMATRIX/CAPSULE, DENTAL/OSTEOARTHRITIC PAIN), IROKO/ICEUTICA","IP-880; ZORVOLEX; DICLOFENAC; DICLOFENAC (SOLUMATRIX/CAPSULE, DENTAL/OSTEOARTHRITIC PAIN), IROKO/ICEUTICA","DICLOFENAC (SOLUMATRIX/CAPSULE, DENTAL/OSTEOARTHRITIC PAIN), IROKO/ICEUTICA",IP-880,ZORVOLEX,DICLOFENAC,"DICLOFENAC (SOLUMATRIX/CAPSULE, DENTAL/OSTEOARTHRITIC PAIN), IROKO/ICEUTICA",,,,,,,,,,,,,,,,,,,,,,,,,,,204592,DICLOFENAC,20809,DICLOFENAC SODIUM,,,,,,,,,,,,,,,,,,,2013-10-18T00:00:00Z,2013,10,Zorvolex,pain,,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY; UNSPECIFIED DRUG TARGET,CAPSULE FORMULATION; NANOPARTICLE FORMULATION ORAL; ORAL FORMULATION; ORAL GEL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204592,NDA,2012-12-20T00:00:00Z,fda,0,0,0,0,0,,iroko pharmaceuticals,private,0,,,,,,,,,,,,,,publicly traded stock is defunct since 2013; company still in business,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204592,206,20,780,259,Residual codes; unclassified,11,0
378,"INDOMETHACIN (SOLUMATRIX/CAPSULE, DENTAL PAIN), IROKO/ICEUTICA","IP-940; NAL-1207; TIVORBEX; INDOMETACIN; INDOMETHACIN; INDOMETHACIN (SOLUMATRIX/CAPSULE, DENTAL PAIN), IROKO/ICEUTICA","IP-940; NAL-1207; TIVORBEX; INDOMETACIN; INDOMETHACIN; INDOMETHACIN (SOLUMATRIX/CAPSULE, DENTAL PAIN), IROKO/ICEUTICA","INDOMETHACIN (SOLUMATRIX/CAPSULE, DENTAL PAIN), IROKO/ICEUTICA",IP-940,NAL-1207,TIVORBEX,INDOMETACIN,INDOMETHACIN,"INDOMETHACIN (SOLUMATRIX/CAPSULE, DENTAL PAIN), IROKO/ICEUTICA",,,,,,,,,,,,,,,,,,,,,,,,,18690,INDOMETHACIN,18690,INDOMETHACIN,18690,INDOMETHACIN,18690,INDOMETHACIN,204768,INDOMETHACIN,,,,,,,,,,,,,2014-02-24T00:00:00Z,2014,2,Tivorbex,pain,,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY; PROSTAGLANDIN METABOLISM MODULATOR,CAPSULE FORMULATION; NANOPARTICLE FORMULATION ORAL; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204768,NDA,2013-04-30T00:00:00Z,fda,0,0,0,0,0,,iroko pharmaceuticals,private,0,,,,,,,,,,,,,,publicly traded stock is defunct since 2013; company still in business,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204768,215,20,780,259,Residual codes; unclassified,11,0
554,"OXYCODONE (FORMULATED WITH ABUSE-DETERRENT NALOXONE, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA","OXN PR; TARGIN; TARGINACT; TARGINIQ; TARGINIQ ER; OPIOID AGONIST (FORMULATED WITH ABUSE-DETERRENT OPIOID ANTAGONIST, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA; OXN; OXYCODONE (FORMULATED WITH ABUSE-DETERRENT NALOXONE, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA","OXN PR; TARGIN; TARGINACT; TARGINIQ; TARGINIQ ER; OPIOID AGONIST (FORMULATED WITH ABUSE-DETERRENT OPIOID ANTAGONIST, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA; OXN; OXYCODONE (FORMULATED WITH ABUSE-DETERRENT NALOXONE, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA","OXYCODONE (FORMULATED WITH ABUSE-DETERRENT NALOXONE, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA",OXN PR,TARGIN,TARGINACT,TARGINIQ,TARGINIQ ER,"OPIOID AGONIST (FORMULATED WITH ABUSE-DETERRENT OPIOID ANTAGONIST, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA",OXN,"OXYCODONE (FORMULATED WITH ABUSE-DETERRENT NALOXONE, PROLONGED RELEASE TABLET, PAIN), MUNDIPHARMA",,,,,,,,,,,,,,,,,,,,,,,205777,NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-07-23T00:00:00Z,2014,7,Targiniq,pain,OPIOID RECEPTOR AGONIST,ANALGESIC,DRUG COMBINATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),205777,NDA,2013-09-22T00:00:00Z,fda,0,0,0,0,0,,purdue pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205777,256,20,780,259,Residual codes; unclassified,11,0
115,"BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY/ ENDO","BEMA BUPRENORPHINE; BEMA LA; BEMA LONG ACTING; BELBUCA; BELBUCA; EN-3409; BUPRENORPHINE; BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY; BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY/ ENDO; BUPRENORPHINE HYDROCHLORIDE; OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY; OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY/ ENDO PHARMACEUTICALS","BEMA BUPRENORPHINE; BEMA LA; BEMA LONG ACTING; BELBUCA; BELBUCA; EN-3409; BUPRENORPHINE; BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY; BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY/ ENDO; BUPRENORPHINE HYDROCHLORIDE; OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY; OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY/ ENDO PHARMACEUTICALS","BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY/ ENDO",BEMA BUPRENORPHINE,BEMA LA,BEMA LONG ACTING,BELBUCA,BELBUCA,EN-3409,BUPRENORPHINE,"BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY","BUPRENORPHINE (BUCCAL, BEMA), BIODELIVERY/ ENDO",BUPRENORPHINE HYDROCHLORIDE,"OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY","OPIOID ANALGESIC (BUCCAL, BEMA, PAIN), BIODELIVERY/ ENDO PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,207932,BUPRENORPHINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2015-10-23T00:00:00Z,2015,10,Belbuca,pain,MU OPIOID PARTIAL AGONIST; OPIOID RECEPTOR KAPPA ANTAGONIST,ANALGESIC,BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSMUCOSAL FORMULATION,matched (3),207932,NDA,2014-12-23T00:00:00Z,fda,0,0,0,0,0,,endo pharmaceuticals,NASDAQ: ENDP,1,3268.72,2380.68,2124.68,2815.74,2524.92,1716.23,1425.53,102.197,102.197,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207932,309,20,780,259,Residual codes; unclassified,11,0
558,"OXYCODONE EXTENDED-RELEASE (ORAL, DETERX, CHRONIC PAIN), COLLEGIUM PHARMACEUTICALS","COL-003; COL-003; XTAMPZA ER; XTAMPZA ER; OXYCODONE; OXYCODONE (ORAL/SUSTAINED-RELEASE/DETERX, PAIN), COLLEGIUM; OXYCODONE DETERX; OXYCODONE EXTENDED-RELEASE (ORAL, DETERX, CHRONIC PAIN), COLLEGIUM PHARMACEUTICALS","COL-003; COL-003; XTAMPZA ER; XTAMPZA ER; OXYCODONE; OXYCODONE (ORAL/SUSTAINED-RELEASE/DETERX, PAIN), COLLEGIUM; OXYCODONE DETERX; OXYCODONE EXTENDED-RELEASE (ORAL, DETERX, CHRONIC PAIN), COLLEGIUM PHARMACEUTICALS","OXYCODONE EXTENDED-RELEASE (ORAL, DETERX, CHRONIC PAIN), COLLEGIUM PHARMACEUTICALS",COL-003,COL-003,XTAMPZA ER,XTAMPZA ER,OXYCODONE,"OXYCODONE (ORAL/SUSTAINED-RELEASE/DETERX, PAIN), COLLEGIUM",OXYCODONE DETERX,"OXYCODONE EXTENDED-RELEASE (ORAL, DETERX, CHRONIC PAIN), COLLEGIUM PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,208090,OXYCODONE,,,,,,,,,,,,,,,,,,,,,2016-04-26T00:00:00Z,2016,4,Xtampza ER,pain,OPIOID RECEPTOR AGONIST,ANALGESIC,CAPSULE FORMULATION; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),208090,NDA,2014-12-12T00:00:00Z,fda,0,0,1,0,0,,collegium pharmaceuticals,NASDAQ: COLL,1,1.7,,,,,,1.5,14.9,14.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208090,328,20,780,259,Residual codes; unclassified,11,0
361,"HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/NEUROMED","AP-77; DILAUDID CR; EXALGO; JURNISTA; JURNISTA ER; NMED-1077; OROS (HYDROMORPHONE); HYDROMORPHONE; HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/ABBOTT; HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/NEUROMED; HYDROMORPHONE, ALZA/TDC","AP-77; DILAUDID CR; EXALGO; JURNISTA; JURNISTA ER; NMED-1077; OROS (HYDROMORPHONE); HYDROMORPHONE; HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/ABBOTT; HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/NEUROMED; HYDROMORPHONE, ALZA/TDC","HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/NEUROMED",AP-77,DILAUDID CR,EXALGO,JURNISTA,JURNISTA ER,NMED-1077,OROS (HYDROMORPHONE),HYDROMORPHONE,"HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/ABBOTT","HYDROMORPHONE (ORAL CONTROLLED-RELEASE, OROS), ALZA/NEUROMED","HYDROMORPHONE, ALZA/TDC",,,,,,,,,,,,,,,,,,,,200403,HYDROMORPHONE HYDROCHLORIDE,21217,HYDROMORPHONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2010-03-01T00:00:00Z,2010,3,Exalgo,pain,OPIOID RECEPTOR AGONIST,ANALGESIC,DAILY DOSING; ORAL CONTROLLED RELEASE FORMULATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),021217,NDA,1999-12-28T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,61587,61897,63747,61095,53324,50514,42795,6844,6844,,,2001,,acquired by J&J in 2001,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021217,361,20,780,259,Residual codes; unclassified,11,0
206,"DICLOFENAC (TRANSDERMAL PATCH), PFIZER","FLECTOR; DICHLOFENAC; DICLOFENAC; DICLOFENAC (TRANSDERMAL PATCH), ALPHARMA; DICLOFENAC (TRANSDERMAL PATCH), PFIZER; DICLOFENAC EPOLAMINE; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH), ALPHARMA; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), INSTITUT BIOCHIMIQUE; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), NOVARTIS","FLECTOR; DICHLOFENAC; DICLOFENAC; DICLOFENAC (TRANSDERMAL PATCH), ALPHARMA; DICLOFENAC (TRANSDERMAL PATCH), PFIZER; DICLOFENAC EPOLAMINE; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH), ALPHARMA; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), INSTITUT BIOCHIMIQUE; DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), NOVARTIS","DICLOFENAC (TRANSDERMAL PATCH), PFIZER",FLECTOR,DICHLOFENAC,DICLOFENAC,"DICLOFENAC (TRANSDERMAL PATCH), ALPHARMA","DICLOFENAC (TRANSDERMAL PATCH), PFIZER",DICLOFENAC EPOLAMINE,"DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH), ALPHARMA","DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), INSTITUT BIOCHIMIQUE","DICLOFENAC EPOLAMINE (TRANSDERMAL PATCH, PAIN), NOVARTIS",,,,,,,,,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,21234,DICLOFENAC EPOLAMINE,,,,,,,,,,,,,,,,,,,2007-01-31T00:00:00Z,2007,1,Flector,pain,CYCLOOXYGENASE INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,LOCAL FORMULATION UNSPECIFIED; PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021234,NDA,2000-12-18T00:00:00Z,fda,0,0,0,0,0,,institut biochimique,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021234,362,20,780,259,Residual codes; unclassified,11,0
117,"BUPRENORPHINE (TRANSDERMAL PATCH, PAIN), GRUNENTHAL/ MUNDIPHARMA","BTDS; BUTRANS; NORSPAN; SOVENOR; TTS BUPRENORPHINE, GRUNENTHAL/MUNDIPHARMA; TRANSTEC; TRANSTEC PRO; BUPRENORPHINE; BUPRENORPHINE (TRANSDERMAL PATCH, PAIN), GRUNENTHAL/ MUNDIPHARMA; BUPRENORPHINE TDS (PAIN), GRUENENTHAL/MUNDIPHARMA; TRANSDERMAL THERAPEUTIC SYSTEM (BUPRENORPHINE), GRUNENTHAL/MUNDIPHARMA; TRANSDERMAL THERAPEUTIC SYSTEM (PAIN), GRUNENTHAL/MUNDIPHARMA","BTDS; BUTRANS; NORSPAN; SOVENOR; TTS BUPRENORPHINE, GRUNENTHAL/MUNDIPHARMA; TRANSTEC; TRANSTEC PRO; BUPRENORPHINE; BUPRENORPHINE (TRANSDERMAL PATCH, PAIN), GRUNENTHAL/ MUNDIPHARMA; BUPRENORPHINE TDS (PAIN), GRUENENTHAL/MUNDIPHARMA; TRANSDERMAL THERAPEUTIC SYSTEM (BUPRENORPHINE), GRUNENTHAL/MUNDIPHARMA; TRANSDERMAL THERAPEUTIC SYSTEM (PAIN), GRUNENTHAL/MUNDIPHARMA","BUPRENORPHINE (TRANSDERMAL PATCH, PAIN), GRUNENTHAL/ MUNDIPHARMA",BTDS,BUTRANS,NORSPAN,SOVENOR,"TTS BUPRENORPHINE, GRUNENTHAL/MUNDIPHARMA",TRANSTEC,TRANSTEC PRO,BUPRENORPHINE,"BUPRENORPHINE (TRANSDERMAL PATCH, PAIN), GRUNENTHAL/ MUNDIPHARMA","BUPRENORPHINE TDS (PAIN), GRUENENTHAL/MUNDIPHARMA","TRANSDERMAL THERAPEUTIC SYSTEM (BUPRENORPHINE), GRUNENTHAL/MUNDIPHARMA","TRANSDERMAL THERAPEUTIC SYSTEM (PAIN), GRUNENTHAL/MUNDIPHARMA",,,,,,,,,,,,,,,,,,,21306,BUPRENORPHINE,,,,,,,,,,,,,,,,,,,,,2010-06-30T00:00:00Z,2010,6,Butrans,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021306,NDA,2000-11-03T00:00:00Z,fda,0,0,0,0,0,,purdue pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021306,363,20,780,259,Residual codes; unclassified,11,0
280,"FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), JOHNSON & JOHNSON","E-TRANS FENTANYL, ALZA; E-TRANS FENTANYL, INCLINE THERAPEUTICS; E-TRANS FENTANYL, JOHNSON & JOHNSON; IONSYS; SYB P-1501; TRANSFENTA; FENTANYL; FENTANYL (TRANSDERMAL, E-TRANS), ALZA; FENTANYL (TRANSDERMAL, E-TRANS), INCLINE THERAPEUTICS; FENTANYL (TRANSDERMAL, E-TRANS), JOHNSON & JOHNSON; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), ALZA; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), INCLINE THERAPEUTICS; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), JOHNSON & JOHNSON; FENTANYL ETS; FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM","E-TRANS FENTANYL, ALZA; E-TRANS FENTANYL, INCLINE THERAPEUTICS; E-TRANS FENTANYL, JOHNSON & JOHNSON; IONSYS; SYB P-1501; TRANSFENTA; FENTANYL; FENTANYL (TRANSDERMAL, E-TRANS), ALZA; FENTANYL (TRANSDERMAL, E-TRANS), INCLINE THERAPEUTICS; FENTANYL (TRANSDERMAL, E-TRANS), JOHNSON & JOHNSON; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), ALZA; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), INCLINE THERAPEUTICS; FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), JOHNSON & JOHNSON; FENTANYL ETS; FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM","FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), JOHNSON & JOHNSON","E-TRANS FENTANYL, ALZA","E-TRANS FENTANYL, INCLINE THERAPEUTICS","E-TRANS FENTANYL, JOHNSON & JOHNSON",IONSYS,SYB P-1501,TRANSFENTA,FENTANYL,"FENTANYL (TRANSDERMAL, E-TRANS), ALZA","FENTANYL (TRANSDERMAL, E-TRANS), INCLINE THERAPEUTICS","FENTANYL (TRANSDERMAL, E-TRANS), JOHNSON & JOHNSON","FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), ALZA","FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), INCLINE THERAPEUTICS","FENTANYL (TRANSDERMAL, HOSPITALIZED PATIENTS), JOHNSON & JOHNSON",FENTANYL ETS,FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM,,,,,,,,,,,,,,,,20195,FENTANYL CITRATE,21338,FENTANYL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2006-05-22T00:00:00Z,2006,5,Ionsys,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,ABSORPTION ENHANCER TRANSDERMAL; PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),021338,NDA,2003-09-23T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,53324,50514,47348,41862,36298,32317,38267,7125,7125,1192.4,2001-03-31T00:00:00Z,2001,,acquired by J&J in 2001,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021338,365,20,780,259,Residual codes; unclassified,11,0
560,"OXYMORPHONE ER, ENDO","EN-3202; OPANA ER; EXTENDED RELEASE ORAL OXYMORPHONE, ENDO/PENWEST; OXYMORPHONE; OXYMORPHONE (ORAL CONTROLLED RELEASE, INTAC), ENDO/GRUNENTHAL; OXYMORPHONE (ORAL CONTROLLED RELEASE, TIMERX), ENDO/PENWEST; OXYMORPHONE ER, ENDO; OXYMORPHONE HYDROCHLORIDE","EN-3202; OPANA ER; EXTENDED RELEASE ORAL OXYMORPHONE, ENDO/PENWEST; OXYMORPHONE; OXYMORPHONE (ORAL CONTROLLED RELEASE, INTAC), ENDO/GRUNENTHAL; OXYMORPHONE (ORAL CONTROLLED RELEASE, TIMERX), ENDO/PENWEST; OXYMORPHONE ER, ENDO; OXYMORPHONE HYDROCHLORIDE","OXYMORPHONE ER, ENDO",EN-3202,OPANA ER,"EXTENDED RELEASE ORAL OXYMORPHONE, ENDO/PENWEST",OXYMORPHONE,"OXYMORPHONE (ORAL CONTROLLED RELEASE, INTAC), ENDO/GRUNENTHAL","OXYMORPHONE (ORAL CONTROLLED RELEASE, TIMERX), ENDO/PENWEST","OXYMORPHONE ER, ENDO",OXYMORPHONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,21610,OXYMORPHONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2006-06-22T00:00:00Z,2006,6,Opana ER,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021610,NDA,2002-12-19T00:00:00Z,cortellis,0,0,0,0,0,,endo pharmaceuticals,NASDAQ: ENDP,1,909.659,820.164,615.1,595.608,398.973,251.979,700.77,86.629,86.629,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021610,374,20,780,259,Residual codes; unclassified,11,0
748,"TRAMADOL HYDROCHLORIDE (ONCE-DAILY, CONTRAMID), LABOPHARM","CONTRAMAL UNO; CONTRAMAL UNO; CONTRAMID (TRAMADOL), LABOPHARM; DOLPAR; DUROTRAM XR; DUROTRAM XR; MONOALGIC L.P; MONOALGIC L.P; NS-24; NS-24; NOAX UNO; NOAX UNO; ONETRAM; RYZOLT; TRADOREC XL; TRADOREC XL; TRAMACONTI CR; TRAMACONTI CR; TRAMADEX-OD; TRAMADEX-OD; TRAMADOLOR; TRAMADOLOR EINMAL TAEGLICH; TRAMADOLOR EINMAL TAEGLICH; TRIDURAL; TRIDURAL; UNITRAMA; TRAMADOL; TRAMADOL (ONCE-DAILY, CONTRAMID), LABOPHARM; TRAMADOL HYDROCHLORIDE; TRAMADOL HYDROCHLORIDE (ONCE-DAILY, CONTRAMID), LABOPHARM","CONTRAMAL UNO; CONTRAMAL UNO; CONTRAMID (TRAMADOL), LABOPHARM; DOLPAR; DUROTRAM XR; DUROTRAM XR; MONOALGIC L.P; MONOALGIC L.P; NS-24; NS-24; NOAX UNO; NOAX UNO; ONETRAM; RYZOLT; TRADOREC XL; TRADOREC XL; TRAMACONTI CR; TRAMACONTI CR; TRAMADEX-OD; TRAMADEX-OD; TRAMADOLOR; TRAMADOLOR EINMAL TAEGLICH; TRAMADOLOR EINMAL TAEGLICH; TRIDURAL; TRIDURAL; UNITRAMA; TRAMADOL; TRAMADOL (ONCE-DAILY, CONTRAMID), LABOPHARM; TRAMADOL HYDROCHLORIDE; TRAMADOL HYDROCHLORIDE (ONCE-DAILY, CONTRAMID), LABOPHARM","TRAMADOL HYDROCHLORIDE (ONCE-DAILY, CONTRAMID), LABOPHARM",CONTRAMAL UNO,CONTRAMAL UNO,"CONTRAMID (TRAMADOL), LABOPHARM",DOLPAR,DUROTRAM XR,DUROTRAM XR,MONOALGIC L.P,MONOALGIC L.P,NS-24,NS-24,NOAX UNO,NOAX UNO,ONETRAM,RYZOLT,TRADOREC XL,TRADOREC XL,TRAMACONTI CR,TRAMACONTI CR,TRAMADEX-OD,TRAMADEX-OD,TRAMADOLOR,TRAMADOLOR EINMAL TAEGLICH,TRAMADOLOR EINMAL TAEGLICH,TRIDURAL,TRIDURAL,UNITRAMA,TRAMADOL,"TRAMADOL (ONCE-DAILY, CONTRAMID), LABOPHARM",TRAMADOL HYDROCHLORIDE,"TRAMADOL HYDROCHLORIDE (ONCE-DAILY, CONTRAMID), LABOPHARM",21745,TRAMADOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2008-12-30T00:00:00Z,2008,12,Ryzolt,pain,OPIOID RECEPTOR MU AGONIST,5-HT UPTAKE INHIBITOR; ANALGESIC; NOREPINEPHRINE UPTAKE INHIBITOR,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021745,NDA,2005-11-25T00:00:00Z,fda,0,0,0,0,0,,labopharm,TSX: DDS,1,17.9,19.2,13.6,2.8,1.2,0.5,-5.7,,20.5,,,,,acquired by paladin labs in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021745,383,20,780,259,Residual codes; unclassified,11,0
793,"ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), MEDA","EDLUAR; OX-22; SUBLINOX; ZOLPEDUAR; INSOMNIA THERAPY, OREXO; ZOLPIDEM; ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), MEDA; ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), OREXO; ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), MEDA; ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), OREXO","EDLUAR; OX-22; SUBLINOX; ZOLPEDUAR; INSOMNIA THERAPY, OREXO; ZOLPIDEM; ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), MEDA; ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), OREXO; ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), MEDA; ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), OREXO","ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), MEDA",EDLUAR,OX-22,SUBLINOX,ZOLPEDUAR,"INSOMNIA THERAPY, OREXO",ZOLPIDEM,"ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), MEDA","ZOLPIDEM (SUBLINGUAL TABLET, INSOMNIA), OREXO","ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), MEDA","ZOLPIDEM TARTRATE (SUBLINGUAL TABLET, INSOMNIA), OREXO",,,,,,,,,,,,,,,,,,,,,21997,ZOLPIDEM TARTRATE,,,,,,,,,,,,,,,,,,,,,2009-03-13T00:00:00Z,2009,3,Edluar,insomnia,GABA A RECEPTOR ALPHA-1 SUBUNIT MODULATOR,HYPNOTIC,BUCCAL FORMULATION SYSTEMIC; ORAL FORMULATION; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC,matched (3),021997,NDA,2008-05-14T00:00:00Z,fda,0,0,0,0,0,,daiichi jitsugyo,TYO: 8059,1,860.2,1515.6,1179,997.6,974.3,1089.5,181.3,,1.7,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021997,431,750,780,259,Residual codes; unclassified,11,0
218,"DOXEPIN HYDROCHLORIDE (LOW-DOSE ORAL, INSOMNIA), SOMAXON","SO-101; SILENOR; DOXEPIN; DOXEPIN (LOW-DOSE ORAL, INSOMNIA), SOMAXON; DOXEPIN (ORAL, INSOMNIA), SOMAXON; DOXEPIN HYDROCHLORIDE; DOXEPIN HYDROCHLORIDE (LOW-DOSE ORAL, INSOMNIA), SOMAXON","SO-101; SILENOR; DOXEPIN; DOXEPIN (LOW-DOSE ORAL, INSOMNIA), SOMAXON; DOXEPIN (ORAL, INSOMNIA), SOMAXON; DOXEPIN HYDROCHLORIDE; DOXEPIN HYDROCHLORIDE (LOW-DOSE ORAL, INSOMNIA), SOMAXON","DOXEPIN HYDROCHLORIDE (LOW-DOSE ORAL, INSOMNIA), SOMAXON",SO-101,SILENOR,DOXEPIN,"DOXEPIN (LOW-DOSE ORAL, INSOMNIA), SOMAXON","DOXEPIN (ORAL, INSOMNIA), SOMAXON",DOXEPIN HYDROCHLORIDE,"DOXEPIN HYDROCHLORIDE (LOW-DOSE ORAL, INSOMNIA), SOMAXON",,,,,,,,,,,,,,,,,,,,,,,,16987,DOXEPIN HYDROCHLORIDE,16987,DOXEPIN HYDROCHLORIDE,16987,DOXEPIN HYDROCHLORIDE,22036,DOXEPIN HYDROCHLORIDE,,,,,,,,,,,,,,,2010-03-17T00:00:00Z,2010,3,Silenor,insomnia,HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR ANTAGONIST,HYPNOTIC,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022036,NDA,2008-01-31T00:00:00Z,fda,0,0,0,0,0,,somaxon pharmaceuticals,NASDAQ: SOMX,1,1.4,,,,,,1.1,3.6,3.6,,,,,acquired by pernix in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022036,447,750,780,259,Residual codes; unclassified,11,0
794,"ZOLPIDEM TARTRATE (SUBLINGUAL, INSOMNIA), NOVADEL/ECR","ZOLPIMIST; ZOLPIDEM; ZOLPIDEM (BUCCAL, INSOMNIA), NOVADEL; ZOLPIDEM (SUBLINGUAL, INSOMNIA), NOVADEL/ECR; ZOLPIDEM TARTRATE (SUBLINGUAL, INSOMNIA), NOVADEL/ECR","ZOLPIMIST; ZOLPIDEM; ZOLPIDEM (BUCCAL, INSOMNIA), NOVADEL; ZOLPIDEM (SUBLINGUAL, INSOMNIA), NOVADEL/ECR; ZOLPIDEM TARTRATE (SUBLINGUAL, INSOMNIA), NOVADEL/ECR","ZOLPIDEM TARTRATE (SUBLINGUAL, INSOMNIA), NOVADEL/ECR",ZOLPIMIST,ZOLPIDEM,"ZOLPIDEM (BUCCAL, INSOMNIA), NOVADEL","ZOLPIDEM (SUBLINGUAL, INSOMNIA), NOVADEL/ECR","ZOLPIDEM TARTRATE (SUBLINGUAL, INSOMNIA), NOVADEL/ECR",,,,,,,,,,,,,,,,,,,,,,,,,,22196,ZOLPIDEM TARTRATE,,,,,,,,,,,,,,,,,,,,,2008-12-19T00:00:00Z,2008,12,Zolpimist,insomnia,BENZODIAZEPINE RECEPTOR AGONIST,HYPNOTIC,BUCCAL FORMULATION SYSTEMIC; FORMULATION AEROSOL UNSPECIFIED; SMALL MOLECULE THERAPEUTIC,matched (3),022196,NDA,2007-11-20T00:00:00Z,fda,0,0,0,0,0,,novadel pharma,OTCPK: NVDL,1,0.4,0.5,5,0.4,0.5,,0.4,3.9,3.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022196,491,750,780,259,Residual codes; unclassified,11,0
208,"DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), DEPOMED","LYNXORB; PROSORB-D; XP-21L; ZIPSOR; DICLOFENAC; DICLOFENAC POTASSIUM; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), AAIPHARMA; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), DEPOMED; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), XANODYNE","LYNXORB; PROSORB-D; XP-21L; ZIPSOR; DICLOFENAC; DICLOFENAC POTASSIUM; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), AAIPHARMA; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), DEPOMED; DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), XANODYNE","DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), DEPOMED",LYNXORB,PROSORB-D,XP-21L,ZIPSOR,DICLOFENAC,DICLOFENAC POTASSIUM,"DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), AAIPHARMA","DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), DEPOMED","DICLOFENAC POTASSIUM (ORAL, PROSORB, PAIN), XANODYNE",,,,,,,,,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,22202,DICLOFENAC POTASSIUM,,,,,,,,,,,,,,,,,,,2009-06-16T00:00:00Z,2009,6,Zipsor,pain,CYCLOOXYGENASE INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022202,NDA,2007-09-21T00:00:00Z,fda,0,0,0,0,0,,xanodyne pharmaceuticals,private,0,,72.4,74.1,66.4,52.6,13.7,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022202,495,20,780,259,Residual codes; unclassified,11,0
211,"DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), ALCON","DUREZOL; SJE-2079; ST-601; DIFLUPREDNATE; DIFLUPREDNATE (OPHTHALMIC EMULSION), SENJU; DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), ALCON; DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), SIRION; OPHTHALMIC EMULSION (DIFLUPREDNATE), SENJU; OPHTHALMIC EMULSION (DIFLUPREDNATE), SIRION","DUREZOL; SJE-2079; ST-601; DIFLUPREDNATE; DIFLUPREDNATE (OPHTHALMIC EMULSION), SENJU; DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), ALCON; DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), SIRION; OPHTHALMIC EMULSION (DIFLUPREDNATE), SENJU; OPHTHALMIC EMULSION (DIFLUPREDNATE), SIRION","DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), ALCON",DUREZOL,SJE-2079,ST-601,DIFLUPREDNATE,"DIFLUPREDNATE (OPHTHALMIC EMULSION), SENJU","DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), ALCON","DIFLUPREDNATE (OPHTHALMIC EMULSION, OCULAR INFLAMMATION/PAIN ), SIRION","OPHTHALMIC EMULSION (DIFLUPREDNATE), SENJU","OPHTHALMIC EMULSION (DIFLUPREDNATE), SIRION",,,,,,,,,,,,,,,,,,,,,,22212,DIFLUPREDNATE,,,,,,,,,,,,,,,,,,,,,2008-06-23T00:00:00Z,2008,6,Durezol,pain,GLUCOCORTICOID AGONIST,OPHTHALMOLOGICAL CORTICOSTEROID; STEROIDAL ANTI-INFLAMMATORY,EMULSION FORMULATION; OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),022212,NDA,2007-12-21T00:00:00Z,fda,1,0,0,0,0,,sirion therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022212,500,20,780,259,Residual codes; unclassified,11,0
705,TAPENTADOL,"CG-5503; CG-5503 IR; JNS-024; NUCYNTA; NUCYNTA IR; PALEXIA; PALEXIA IR; PALEXIS; R-331333; YANTIL; TAPENTADOL; TAPENTADOL (IMMEDIATE RELEASE, PAIN) J&J PRD/GRUNENTHAL; TAPENTADOL IR; TAPENTADOL HYDROCHLORIDE","CG-5503; CG-5503 IR; JNS-024; NUCYNTA; NUCYNTA IR; PALEXIA; PALEXIA IR; PALEXIS; R-331333; YANTIL; TAPENTADOL; TAPENTADOL (IMMEDIATE RELEASE, PAIN) J&J PRD/GRUNENTHAL; TAPENTADOL IR; TAPENTADOL HYDROCHLORIDE",TAPENTADOL,CG-5503,CG-5503 IR,JNS-024,NUCYNTA,NUCYNTA IR,PALEXIA,PALEXIA IR,PALEXIS,R-331333,YANTIL,TAPENTADOL,"TAPENTADOL (IMMEDIATE RELEASE, PAIN) J&J PRD/GRUNENTHAL",TAPENTADOL IR,TAPENTADOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,22304,TAPENTADOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2008-12-24T00:00:00Z,2008,12,Nucynta,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC; NOREPINEPHRINE UPTAKE INHIBITOR,FILM COATING; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; TABLET FORMULATION,matched (3),022304,NDA,2008-01-22T00:00:00Z,fda,0,0,0,0,0,,johnson and johnson,NYSE: JNJ,1,63747,61095,53324,50514,47348,41862,45236,7577,7577,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022304,525,20,780,259,Residual codes; unclassified,11,0
500,"MORPHINE (ORAL, SUSTAINED-RELEASE, FORMULATED WITH ABUSE-DETERRENT NALTREXONE), PFIZER","ALO-01; EMBEDA; KADIAN NT; PF-06412528; ABUSE-RESISTANT SUSTAINED-RELEASED MORPHINE (PAIN), KING; MORPHINE (ORAL, SUSTAINED-RELEASE, FORMULATED WITH ABUSE-DETERRENT NALTREXONE), PFIZER","ALO-01; EMBEDA; KADIAN NT; PF-06412528; ABUSE-RESISTANT SUSTAINED-RELEASED MORPHINE (PAIN), KING; MORPHINE (ORAL, SUSTAINED-RELEASE, FORMULATED WITH ABUSE-DETERRENT NALTREXONE), PFIZER","MORPHINE (ORAL, SUSTAINED-RELEASE, FORMULATED WITH ABUSE-DETERRENT NALTREXONE), PFIZER",ALO-01,EMBEDA,KADIAN NT,PF-06412528,"ABUSE-RESISTANT SUSTAINED-RELEASED MORPHINE (PAIN), KING","MORPHINE (ORAL, SUSTAINED-RELEASE, FORMULATED WITH ABUSE-DETERRENT NALTREXONE), PFIZER",,,,,,,,,,,,,,,,,,,,,,,,,22321,MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2009-08-13T00:00:00Z,2009,8,Embeda,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,CAPSULE FORMULATION; ORAL FORMULATION; PELLET; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),022321,NDA,2008-06-30T00:00:00Z,fda,1,0,0,0,0,,king pharmaceuticals,NYSE: ALO,1,1776.5,1565.1,722.4,653.8,553.6,513.3,1153.7,98.7,98.7,666.8,2008-09-30T00:00:00Z,2008,,acquired by king pharmaceuticals in 2008,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022321,531,20,780,259,Residual codes; unclassified,11,0
792,"ZOLPIDEM TARTRATE (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE","INTERMEZZO; ZOLPIDEM; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSORAL; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE; ZOLPIDEM TARTRATE (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE","INTERMEZZO; ZOLPIDEM; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSORAL; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT; ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE; ZOLPIDEM TARTRATE (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE","ZOLPIDEM TARTRATE (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE",INTERMEZZO,ZOLPIDEM,"ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSORAL","ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT","ZOLPIDEM (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE","ZOLPIDEM TARTRATE (LOW-DOSE SUBLINGUAL TABLET, INSOMNIA), TRANSCEPT/ PURDUE",,,,,,,,,,,,,,,,,,,,,,,,,22328,ZOLPIDEM TARTRATE,,,,,,,,,,,,,,,,,,,,,2011-11-23T00:00:00Z,2011,11,Intermezzo,insomnia,GABA A RECEPTOR AGONIST,HYPNOTIC,BUCCAL FORMULATION SYSTEMIC; ORAL ABSORPTION ENHANCER; ORALLY DISINTEGRATING TABLET; SMALL MOLECULE THERAPEUTIC,matched (3),022328,NDA,2011-09-27T00:00:00Z,fda,0,0,0,0,0,,transcept pharmaceuticals,NASDAQ: TSPT,1,18,12.5,5.2,,,,7.3,,11.3,,,,,acquired by paratek in 2014,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022328,532,750,780,259,Residual codes; unclassified,11,0
365,"IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND/ PHEBRA/ DB PHARM/ ALVEDA/ GLORIA/ PT. SOHO INDUSTRI PHARMASI/ SANDOR MEDICAIDS/ GRIFOLS","AMELIOR; CALDOLOR; IBUPROFEN; IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND; IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND/ PHEBRA/ DB PHARM/ ALVEDA/ GLORIA/ PT. SOHO INDUSTRI PHARMASI/ SANDOR MEDICAIDS/ GRIFOLS","AMELIOR; CALDOLOR; IBUPROFEN; IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND; IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND/ PHEBRA/ DB PHARM/ ALVEDA/ GLORIA/ PT. SOHO INDUSTRI PHARMASI/ SANDOR MEDICAIDS/ GRIFOLS","IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND/ PHEBRA/ DB PHARM/ ALVEDA/ GLORIA/ PT. SOHO INDUSTRI PHARMASI/ SANDOR MEDICAIDS/ GRIFOLS",AMELIOR,CALDOLOR,IBUPROFEN,"IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND","IBUPROFEN (INJECTABLE, PAIN/FEVER), CUMBERLAND/ PHEBRA/ DB PHARM/ ALVEDA/ GLORIA/ PT. SOHO INDUSTRI PHARMASI/ SANDOR MEDICAIDS/ GRIFOLS",,,,,,,,,,,,,,,,,,,,,,,,,,22348,IBUPROFEN,,,,,,,,,,,,,,,,,,,,,2009-06-11T00:00:00Z,2009,6,Caldolor,pain,CYCLOOXYGENASE INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022348,NDA,2008-12-03T00:00:00Z,fda,1,0,0,0,0,,cumberland pharmaceuticals,NASDAQ: CPIX,1,43.5,35.1,28.1,17.8,10.7,12,39.4,5,5,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022348,536,20,780,259,Residual codes; unclassified,11,0
747,"TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/MEDICAL FUTURES","CIP-TRAMADOL (EXTENDED RELEASE), CIPHER/GALEPHAR; CIP-TRAMADOL ER; CONZIP; CONZIPA; DURELA; DURELAA; ULTRAGESIC; TRAMADOL; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/MEDICAL FUTURES; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/TRIBUTE PHARMACEUTICALS CANADA; TRAMADOL (SUSTAINED RELEASE), CIPHER/GALEPHAR","CIP-TRAMADOL (EXTENDED RELEASE), CIPHER/GALEPHAR; CIP-TRAMADOL ER; CONZIP; CONZIPA; DURELA; DURELAA; ULTRAGESIC; TRAMADOL; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/MEDICAL FUTURES; TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/TRIBUTE PHARMACEUTICALS CANADA; TRAMADOL (SUSTAINED RELEASE), CIPHER/GALEPHAR","TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/MEDICAL FUTURES","CIP-TRAMADOL (EXTENDED RELEASE), CIPHER/GALEPHAR",CIP-TRAMADOL ER,CONZIP,CONZIPA,DURELA,DURELAA,ULTRAGESIC,TRAMADOL,"TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER","TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/MEDICAL FUTURES","TRAMADOL (ONCE-DAILY, SUSTAINED-RELEASE, ORAL), CIPHER/VERTICAL PHARMACEUTICALS/TRIBUTE PHARMACEUTICALS CANADA","TRAMADOL (SUSTAINED RELEASE), CIPHER/GALEPHAR",,,,,,,,,,,,,,,,,,,22370,TRAMADOL HYDROCHLORIDE,22370,TRAMADOL HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2010-05-07T00:00:00Z,2010,5,Conzip,pain,OPIOID RECEPTOR MU AGONIST,ANALGESIC,CAPSULE FORMULATION; ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022370,NDA,2008-04-14T00:00:00Z,fda,0,0,0,0,0,,cipher pharmaceuticals,TSX: CPH,1,5.4,3,1.3,0.5,,,4.7,,12.9,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022370,540,20,780,259,Residual codes; unclassified,11,0
407,"KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), EGALET","COX-1/COX-2 INHIBITOR (INTRANASAL, PAIN), ROXRO PHARMA; ROX-888; SPRIX; KETOROLAC; KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), EGALET; KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), ROXRO PHARMA; NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC, ROXRO PHARMA","COX-1/COX-2 INHIBITOR (INTRANASAL, PAIN), ROXRO PHARMA; ROX-888; SPRIX; KETOROLAC; KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), EGALET; KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), ROXRO PHARMA; NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC, ROXRO PHARMA","KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), EGALET","COX-1/COX-2 INHIBITOR (INTRANASAL, PAIN), ROXRO PHARMA",ROX-888,SPRIX,KETOROLAC,"KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), EGALET","KETOROLAC TROMETHAMINE (INTRANASAL, PAIN), ROXRO PHARMA","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC, ROXRO PHARMA",,,,,,,,,,,,,,,,,,,,,,,,22382,KETOROLAC TROMETHAMINE,,,,,,,,,,,,,,,,,,,,,2010-05-14T00:00:00Z,2010,5,Sprix,pain,CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,NASAL SYSTEMIC FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022382,NDA,2008-12-05T00:00:00Z,fda,0,0,0,0,0,,roxro pharma,private,0,,,,,,,,,,,,,,acquired by daiichi sankyo 2011,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022382,541,20,780,259,Residual codes; unclassified,11,0
177,"CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), HOSPIRA","DIC-075V; DYLOJECT; SB-701; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), HOSPIRA; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), JAVELIN; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), JAVELIN; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR/INJECTABLE, PAIN), SHIMODA BIOTECH; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), JAVELIN; DICHLOFENAC; DICLOFENAC","DIC-075V; DYLOJECT; SB-701; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), HOSPIRA; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), JAVELIN; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), JAVELIN; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR/INJECTABLE, PAIN), SHIMODA BIOTECH; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), IDDS; CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), JAVELIN; DICHLOFENAC; DICLOFENAC","CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), HOSPIRA",DIC-075V,DYLOJECT,SB-701,"CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), HOSPIRA","CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), IDDS","CYCLODEXTRIN-COMBINED DICLOFENAC (INJECTABLE), JAVELIN","CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), IDDS","CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR), JAVELIN","CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAMUSCULAR/INJECTABLE, PAIN), SHIMODA BIOTECH","CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), IDDS","CYCLODEXTRIN-COMBINED DICLOFENAC (INTRAVENOUS), JAVELIN",DICHLOFENAC,DICLOFENAC,,,,,,,,,,,,,,,,,,20809,DICLOFENAC SODIUM,22396,DICLOFENAC SODIUM,,,,,,,,,,,,,,,,,,,2014-12-23T00:00:00Z,2014,12,Dyloject,pain,CYCLOOXYGENASE INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY,INTRAMUSCULAR FORMULATION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022396,NDA,2009-12-02T00:00:00Z,fda,0,0,0,0,0,,hospira,NYSE: HSP,1,4463.7,4002.8,4092.1,4057.1,3917.2,3.8,1653.7,344.3,382.3,1.2,2010-03-31T00:00:00Z,2010,,acquired by hospira in 2010,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022396,547,20,780,259,Residual codes; unclassified,11,0
356,"HYDROCODONE BITARTRATE (EXTENDED-RELEASE, ABUSE-DETERRENT FORMULATION, PAIN), PURDUE PHARMA","HYSINGLA ER; HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE (EXTENDED-RELEASE, ABUSE-DETERRENT FORMULATION, PAIN), PURDUE PHARMA",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-11-20T00:00:00Z,2014,11,Hysingla ER,pain,OPIOID RECEPTOR AGONIST,ANALGESIC,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,using only (2),206627,NDA,2014-04-26T00:00:00Z,fda,1,0,0,0,0,,purdue pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206627,685,20,780,259,Residual codes; unclassified,11,0
556,"OXYCODONE (SUSTAINED RELEASE, TAMPER RESISTANT), PURDUE","OXYCONTIN NEO; OXYCODONE; OXYCODONE (SUSTAINED RELEASE, REFORMULATED), PURDUE; OXYCODONE (SUSTAINED RELEASE, TAMPER RESISTANT), PURDUE; REFORMULATED OXYCONTIN",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2010-04-05T00:00:00Z,2010,4,Oxycontin,pain,OPIOID RECEPTOR AGONIST; OPIOID RECEPTOR MU AGONIST,ANALGESIC,FILM COATING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,using only (2),022272,NDA,2007-11-29T00:00:00Z,fda,1,0,0,0,0,,purdue pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022272,708,20,780,259,Residual codes; unclassified,11,0
667,SILTUXIMAB,"CNTO-328; MAB (IL-6), CENTOCOR; SYLVANT; CCLB8; MONOCLONAL ANTIBODY (IL-6), CENTOCOR; SILTUXIMAB","CNTO-328; MAB (IL-6), CENTOCOR; SYLVANT; CCLB8; MONOCLONAL ANTIBODY (IL-6), CENTOCOR; SILTUXIMAB",SILTUXIMAB,CNTO-328,"MAB (IL-6), CENTOCOR",SYLVANT,CCLB8,"MONOCLONAL ANTIBODY (IL-6), CENTOCOR",SILTUXIMAB,,,,,,,,,,,,,,,,,,,,,,,,,125496,SILTUXIMAB,,,,,,,,,,,,,,,,,,,,,2014-04-23T00:00:00Z,2014,4,Sylvant,castlemans disease,HEAT SHOCK PROTEIN INHIBITOR; IL-6 ANTAGONIST,ANTICANCER MONOCLONAL ANTIBODY,BIOLOGICAL THERAPEUTIC; CHIMERIC MONOCLONAL ANTIBODY; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION,matched (3),125496,BLA,2013-08-29T00:00:00Z,fda,1,0,0,1,0,,johnson and johnson,NYSE: JNJ,1,74331,71312,67224,65030,61587,61897,51585,8494,8494,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125496,47,1294,785,249,Shock,6,0
357,"HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE (COUGH), HAWTHORN PHARMACEUTICALS","VITUZ; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE (COUGH), HAWTHORN PHARMACEUTICALS","VITUZ; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE (COUGH), HAWTHORN PHARMACEUTICALS","HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE (COUGH), HAWTHORN PHARMACEUTICALS",VITUZ,HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE,"HYDROCODONE BITARTRATE + CHLORPHENIRAMINE MALEATE (COUGH), HAWTHORN PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,,204307,CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE,,,,,,,,,,,,,,,,,,,,,2013-02-20T00:00:00Z,2013,2,Vituz,cough,HISTAMINE H1 RECEPTOR ANTAGONIST,ANTITUSSIVE; ANTIVIRAL,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),204307,NDA,2012-04-24T00:00:00Z,fda,0,0,0,0,0,,pernix,NASDAQ: PTX,1,84.9,61.3,52.8,47.4,,,47.4,4.8,4.8,62.6666666666667,2012-09-30T00:00:00Z,2012,,acquired by pernix in 2012,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204307,192,82,786,133,Other lower respiratory disease,3,0
166,"CODEINE POLISTIREX + CHLORPHENIRAMINE POLISTIREX (EXTENDED-RELEASE ORAL SUSPENSION, COUGH), VERNALIS/TRIS","CCP-01; CCP-01; TUZISTRA XR; TUZISTRA XR; CODEINE + CHLORPHENIRAMINE; CODEINE POLISTIREX + CHLORPHENIRAMINE POLISTIREX (EXTENDED-RELEASE ORAL SUSPENSION, COUGH), VERNALIS/TRIS","CCP-01; CCP-01; TUZISTRA XR; TUZISTRA XR; CODEINE + CHLORPHENIRAMINE; CODEINE POLISTIREX + CHLORPHENIRAMINE POLISTIREX (EXTENDED-RELEASE ORAL SUSPENSION, COUGH), VERNALIS/TRIS","CODEINE POLISTIREX + CHLORPHENIRAMINE POLISTIREX (EXTENDED-RELEASE ORAL SUSPENSION, COUGH), VERNALIS/TRIS",CCP-01,CCP-01,TUZISTRA XR,TUZISTRA XR,CODEINE + CHLORPHENIRAMINE,"CODEINE POLISTIREX + CHLORPHENIRAMINE POLISTIREX (EXTENDED-RELEASE ORAL SUSPENSION, COUGH), VERNALIS/TRIS",,,,,,,,,,,,,,,,,,,,,,,,,207768,CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX,,,,,,,,,,,,,,,,,,,,,2015-04-30T00:00:00Z,2015,4,Tuzistra XR,cough,HISTAMINE H1 RECEPTOR ANTAGONIST; OPIOID RECEPTOR MODULATOR,ANTITUSSIVE; ANTIVIRAL,DRUG COMBINATION; ORAL FORMULATION; ORAL LIQUID FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),207768,NDA,2014-06-27T00:00:00Z,fda,0,0,0,0,0,,tris pharma,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207768,305,82,786,133,Other lower respiratory disease,3,0
359,HYDROCODONE BITARTRATE + PSEUDOEPHEDRINE HYDROCHLORIDE,REZIRA; HYDROCODONE BITARTRATE + PSEUDOEPHEDRINE HYDROCHLORIDE,REZIRA; HYDROCODONE BITARTRATE + PSEUDOEPHEDRINE HYDROCHLORIDE,HYDROCODONE BITARTRATE + PSEUDOEPHEDRINE HYDROCHLORIDE,REZIRA,HYDROCODONE BITARTRATE + PSEUDOEPHEDRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22442,HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2011-06-08T00:00:00Z,2011,6,Rezira,cough,ALPHA ADRENOCEPTOR AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST,ANTITUSSIVE; ANTIVIRAL,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022442,NDA,2008-11-06T00:00:00Z,fda,0,0,0,0,0,,cypress pharmaceutical,private,0,52.8,47.4,,,,,31.5,3.3,3.3,,,,,acquired by pernix in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022442,565,82,786,133,Other lower respiratory disease,3,0
288,FIDAXOMICIN,"ASP-2819; DIFICID; DIFICLIR; DIFIMICIN; OP-1118; OPT-80; PAR-101; R-TIACUMICIN B; FIDAXOMICIN; FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), CUBIST PHARMACEUTICALS; FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), OPTIMER","ASP-2819; DIFICID; DIFICLIR; DIFIMICIN; OP-1118; OPT-80; PAR-101; R-TIACUMICIN B; FIDAXOMICIN; FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), CUBIST PHARMACEUTICALS; FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), OPTIMER",FIDAXOMICIN,ASP-2819,DIFICID,DIFICLIR,DIFIMICIN,OP-1118,OPT-80,PAR-101,R-TIACUMICIN B,FIDAXOMICIN,"FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), CUBIST PHARMACEUTICALS","FIDAXOMICIN (ORAL SUSPENSION, C DIFFICILE INFECTION), OPTIMER",,,,,,,,,,,,,,,,,,,,201699,FIDAXOMICIN,,,,,,,,,,,,,,,,,,,,,2011-05-27T00:00:00Z,2011,5,Dificid,diarrhea,CYTOCHROME P450 REDUCTASE INHIBITOR; RNA POLYMERASE INHIBITOR,ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; MACROLIDE ANTIBIOTIC; RNA SYNTHESIS INHIBITOR; SYNERGIST,ANTIBIOTIC; FILM COATING; MACROLIDE; ORAL FORMULATION; ORAL SUSPENSION FORMULATION; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY; TABLET FORMULATION,matched (3),201699,NDA,2010-11-29T00:00:00Z,fda,1,0,1,0,0,,optimer pharmaceuticals,NASDAQ: OPTR,1,145,1.5,0.9,1,0.8,0.9,135.9,43.1,43.1,,,,,acquired by cubist in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201699,90,102,787,155,Other gastrointestinal disorders,2,0
173,CROFELEMER,"CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; FULYZAQ; MYTESI; MYTESI; PROVIR; SP-303; SP-303 (ORAL); TRN-002; TRN-002; CROFELEMER; CROFELEMER (ORAL), NAPO/TRINE/GLENMARK/ASIAPHARM; CROFELEMER (ORAL, DIARRHEA), NAPO/SALIX/GLENMARK/ASIAPHARM","CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; FULYZAQ; MYTESI; MYTESI; PROVIR; SP-303; SP-303 (ORAL); TRN-002; TRN-002; CROFELEMER; CROFELEMER (ORAL), NAPO/TRINE/GLENMARK/ASIAPHARM; CROFELEMER (ORAL, DIARRHEA), NAPO/SALIX/GLENMARK/ASIAPHARM",CROFELEMER,CRO-HIV,CRO-IBS,CRO-ID,CRO-PED,FULYZAQ,MYTESI,MYTESI,PROVIR,SP-303,SP-303 (ORAL),TRN-002,TRN-002,CROFELEMER,"CROFELEMER (ORAL), NAPO/TRINE/GLENMARK/ASIAPHARM","CROFELEMER (ORAL, DIARRHEA), NAPO/SALIX/GLENMARK/ASIAPHARM",,,,,,,,,,,,,,,,202292,CROFELEMER,,,,,,,,,,,,,,,,,,,,,2012-12-31T00:00:00Z,2012,12,Fulyzaq,diarrhea,ANOCTAMIN 1 INHIBITOR; CFTR INHIBITOR; CALCIUM ACTIVATED CHLORIDE CHANNEL INHIBITOR; CHLORIDE CHANNEL INHIBITOR,ANALGESIC; ANTI-INFLAMMATORY; ANTIDIARRHOEAL; ANTIVIRAL; GASTRIC SECRETION INHIBITOR,ENTERIC COATED FORMULATION; NATURAL PRODUCT; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION,matched (3),202292,NDA,2011-12-05T00:00:00Z,fda,1,0,1,0,0,,salix pharmaceuticals,NASDAQ: SLXP,1,735.4,540.5,337,232.9,178.8,235.8,610.8,85,85,,,,,acquired by valeant in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202292,110,102,787,155,Other gastrointestinal disorders,2,0
513,"NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN","AKYNZEO; NEPA; NEPA FDC; NETU-PALO FDC (ORAL/ CHEMOTHERAPY-INDUCED NAUSEA), HELSINN; NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN; NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN/ STA/ IS PHARMA/ TAIHO/ RIEMSER/ EISAI/ CJ/ VIFOR; PALONOSETRON + NETUPITANT; PALONOSETRON + NETUPITANT (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN","AKYNZEO; NEPA; NEPA FDC; NETU-PALO FDC (ORAL/ CHEMOTHERAPY-INDUCED NAUSEA), HELSINN; NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN; NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN/ STA/ IS PHARMA/ TAIHO/ RIEMSER/ EISAI/ CJ/ VIFOR; PALONOSETRON + NETUPITANT; PALONOSETRON + NETUPITANT (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN","NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN",AKYNZEO,NEPA,NEPA FDC,"NETU-PALO FDC (ORAL/ CHEMOTHERAPY-INDUCED NAUSEA), HELSINN","NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN","NETUPITANT + PALONOSETRON (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN/ STA/ IS PHARMA/ TAIHO/ RIEMSER/ EISAI/ CJ/ VIFOR",PALONOSETRON + NETUPITANT,"PALONOSETRON + NETUPITANT (ORAL, CHEMOTHERAPY-INDUCED NAUSEA), HELSINN",,,,,,,,,,,,,,,,,,,,,,,205718,NETUPITANT; PALONOSETRON HYDROCHLORIDE,208109,PALONOSETRON HYDROCHLORIDE,208109,PALONOSETRON HYDROCHLORIDE,,,,,,,,,,,,,,,,,2014-10-10T00:00:00Z,2014,10,Akynzeo,chemotherapy induced nausea and vomiting,5-HT 3 RECEPTOR ANTAGONIST; NK1 RECEPTOR ANTAGONIST,ANALGESIC; ANTI-EMETIC; GASTROINTESTINAL SYSTEM AGENT,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),205718,NDA,2013-09-27T00:00:00Z,fda,0,0,0,0,0,,helsinn,private,0,,,,,,,,,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205718,251,3847,787,155,Other gastrointestinal disorders,2,0
641,"ROLAPITANT (ORAL), TESARO","NK1 RECEPTOR ANTAGONISTS, SCHERING-PLOUGH; SCH-388714; SCH-425078; SCH-619734; SCH-714758; VARUBI; VARUBI; VARUBY; ROLAPITANT; ROLAPITANT (IV, EMESIS), SCHERING-PLOUGH; ROLAPITANT (ORAL), TESARO; ROLAPITANT (ORAL, EMESIS), SCHERING-PLOUGH; ROLAPITANT HYDROCHLORIDE","NK1 RECEPTOR ANTAGONISTS, SCHERING-PLOUGH; SCH-388714; SCH-425078; SCH-619734; SCH-714758; VARUBI; VARUBI; VARUBY; ROLAPITANT; ROLAPITANT (IV, EMESIS), SCHERING-PLOUGH; ROLAPITANT (ORAL), TESARO; ROLAPITANT (ORAL, EMESIS), SCHERING-PLOUGH; ROLAPITANT HYDROCHLORIDE","ROLAPITANT (ORAL), TESARO","NK1 RECEPTOR ANTAGONISTS, SCHERING-PLOUGH",SCH-388714,SCH-425078,SCH-619734,SCH-714758,VARUBI,VARUBI,VARUBY,ROLAPITANT,"ROLAPITANT (IV, EMESIS), SCHERING-PLOUGH","ROLAPITANT (ORAL), TESARO","ROLAPITANT (ORAL, EMESIS), SCHERING-PLOUGH",ROLAPITANT HYDROCHLORIDE,,,,,,,,,,,,,,,,,,206500,ROLAPITANT HYDROCHLORIDE,206500,ROLAPITANT HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,2015-09-01T00:00:00Z,2015,9,Varubi,chemotherapy induced nausea and vomiting,NK1 RECEPTOR ANTAGONIST,ANTI-EMETIC; ANTIDEPRESSANT; ANTITUSSIVE; ANXIOLYTIC,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206500,NDA,2014-09-05T00:00:00Z,fda,0,0,0,0,0,,tesaro,NASDAQ: TSRO,1,0.3,,,,,,0.3,155.4,155.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206500,286,3847,787,155,Other gastrointestinal disorders,2,0
545,"ONDANSETRON (THIN FILM, EMESIS), MIDATECH","ONDANSETRON ODFS; ZUPLENZ; ONDANSETRON; ONDANSETRON (THIN FILM, EMESIS), GALENA; ONDANSETRON (THIN FILM, EMESIS), MIDATECH; ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX; ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX/STRATIVA","ONDANSETRON ODFS; ZUPLENZ; ONDANSETRON; ONDANSETRON (THIN FILM, EMESIS), GALENA; ONDANSETRON (THIN FILM, EMESIS), MIDATECH; ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX; ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX/STRATIVA","ONDANSETRON (THIN FILM, EMESIS), MIDATECH",ONDANSETRON ODFS,ZUPLENZ,ONDANSETRON,"ONDANSETRON (THIN FILM, EMESIS), GALENA","ONDANSETRON (THIN FILM, EMESIS), MIDATECH","ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX","ONDANSETRON (THIN FILM, EMESIS), MONOSOL RX/STRATIVA",,,,,,,,,,,,,,,,,,,,,,,,22524,ONDANSETRON,,,,,,,,,,,,,,,,,,,,,2010-07-02T00:00:00Z,2010,7,Zuplenz,emesis,5-HT 3 RECEPTOR ANTAGONIST,ANTI-EMETIC,ORAL FORMULATION; QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022524,NDA,2009-04-07T00:00:00Z,fda,0,0,0,0,0,,par pharmaceuticals,NYSE: PRX,1,1008.9,1193.2,578.1,759.7,725.2,432.3,388,39.4,50.4,,,,,publicly traded as NYSE: PRX until 2012,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022524,589,110,787,155,Other gastrointestinal disorders,2,0
317,FOSAPREPITANT,EMEND IV; EMEND FOR INJECTION; IVEMEND; L-758298; MK-0517; MK-517; ONO-7847; PROEMEND; PROEMEND FOR INJECTION; C-9280; FOSAPREPITANT; FOSAPREPITANT DIMEGLUMINE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2008-01-25T00:00:00Z,2008,1,Emend for injection,chemotherapy induced nausea and vomiting,NK1 RECEPTOR ANTAGONIST,ANTI-EMETIC,FORMULATION POWDER; FREEZE DRYING; INFUSION; INTRAVENOUS FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC; SOLUTION,using only (2),022023,NDA,2006-03-31T00:00:00Z,fda,0,0,0,0,0,,merck,NYSE: MRK,1,23850,24197.7,22636,22011.9,22972.8,22485.9,18390,4677,4805,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022023,667,3847,787,155,Other gastrointestinal disorders,2,0
533,"OCTREOTIDE FOLLOW-ON BIOLOGIC, USV","OCTREOTIDE; OCTREOTIDE FOLLOW-ON BIOLOGIC, USV",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2014-11-03T00:00:00Z,2014,11,,diarrhea,SOMATOSTATIN RECEPTOR AGONIST,ANTIDIARRHOEAL; GROWTH HORMONE RELEASE INHIBITOR,BIOLOGICAL THERAPEUTIC; FOLLOW ON BIOLOGICAL PRODUCT; INTRAVENOUS FORMULATION; PROTEIN RECOMBINANT; SUBCUTANEOUS FORMULATION,using only (2),not identified,not identified,,,,,,,,,USV,private,0,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,704,102,787,155,Other gastrointestinal disorders,2,0
,DRONABINOL ORAL SOLUTION,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2016-07-01T00:00:00Z,2016,7,Syndros,chemotherapy induced nausea and vomiting,,,,,205525,NDA,2015-06-01T00:00:00Z,fda,0,0,0,0,0,,insys therapeutics,NASDAQ: INSY,1,242.3,330.3,219.1,99.3,15.5,,216.9,73.9,,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205525,733,3847,787,155,Other gastrointestinal disorders,2,0
227,"DUTASTERIDE + TAMSULOSIN (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE","AVODART + FLOMAX; AVODART + ALPHA BLOCKER (BPH), GSK; AVODART + TAMSULOSIN (BPH), GSK; COMBODART; DUODART; GI-198745; JALYN; DUTASTERIDE + ALPHA BLOCKER (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE; DUTASTERIDE + TAMSULOSIN (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE; TAMSULOSIN + DUTASTERIDE","AVODART + FLOMAX; AVODART + ALPHA BLOCKER (BPH), GSK; AVODART + TAMSULOSIN (BPH), GSK; COMBODART; DUODART; GI-198745; JALYN; DUTASTERIDE + ALPHA BLOCKER (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE; DUTASTERIDE + TAMSULOSIN (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE; TAMSULOSIN + DUTASTERIDE","DUTASTERIDE + TAMSULOSIN (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE",AVODART + FLOMAX,"AVODART + ALPHA BLOCKER (BPH), GSK","AVODART + TAMSULOSIN (BPH), GSK",COMBODART,DUODART,GI-198745,JALYN,"DUTASTERIDE + ALPHA BLOCKER (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE","DUTASTERIDE + TAMSULOSIN (BENIGN PROSTATIC HYPERPLASIA), GLAXOSMITHKLINE",TAMSULOSIN + DUTASTERIDE,,,,,,,,,,,,,,,,,,,,,22460,DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2010-06-14T00:00:00Z,2010,6,Jalyn,urinary dysfunction,5-ALPHA-REDUCTASE INHIBITOR; ALPHA 1A ADRENOCEPTOR ANTAGONIST,,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022460,NDA,2009-03-20T00:00:00Z,fda,0,0,0,0,0,,glaxosmithkline,NYSE: GSK,1,44331.3,45825.1,35480.4,45147.6,45499.1,37229.2,32308.5,5992.66,6959.2,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022460,569,483,788,163,Genitourinary symptoms and ill-defined conditions,2,0
202,"DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN), AVANIR PHARMACEUTICALS","ALS THERAPY, CENTER FOR NEUROLOGIC STUDY; AVP-923; AVP-923-20; AVP-923-30; AVP-923-45; NEURODEX; NUEDEXTA; NUEDEXTA; ZENVIA; DEXTROMETHORPHAN + QUINIDINE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN/CENTRAL NEUROPATHIC PAIN), AVANIR; DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE; DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN), AVANIR PHARMACEUTICALS","ALS THERAPY, CENTER FOR NEUROLOGIC STUDY; AVP-923; AVP-923-20; AVP-923-30; AVP-923-45; NEURODEX; NUEDEXTA; NUEDEXTA; ZENVIA; DEXTROMETHORPHAN + QUINIDINE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN/CENTRAL NEUROPATHIC PAIN), AVANIR; DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE; DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN), AVANIR PHARMACEUTICALS","DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN), AVANIR PHARMACEUTICALS","ALS THERAPY, CENTER FOR NEUROLOGIC STUDY",AVP-923,AVP-923-20,AVP-923-30,AVP-923-45,NEURODEX,NUEDEXTA,NUEDEXTA,ZENVIA,"DEXTROMETHORPHAN + QUINIDINE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN/CENTRAL NEUROPATHIC PAIN), AVANIR",DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE,"DEXTROMETHORPHAN HYDROBROMIDE + QUINIDINE SULFATE (ORAL, PSEUDOBULBAR AFFECT/ DIABETIC PERIPHERAL NEUROPATHIC PAIN), AVANIR PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,21879,DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE,,,,,,,,,,,,,,,,,,,,,2010-10-29T00:00:00Z,2010,10,Nuedexta,emotional lability,CYTOCHROME P450 2D6 INHIBITOR; NMDA RECEPTOR ANTAGONIST; NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST; OPIOID RECEPTOR SIGMA AGONIST 1,ANALGESIC; ANTIDEPRESSANT; PSYCHOMODULATOR,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021879,NDA,2006-01-27T00:00:00Z,fda,1,0,0,0,0,,avanir pharmaceuticals,NASDAQ: AVNR,1,3.2,3.9,6.6,9.2,9.2,23.9,3,12.1,13.7,,,,,acquired by otsuka in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021879,400,3093,799,259,Residual codes; unclassified,5,0
6,"ACETYLCYSTEINE (ACETAMINOPHEN-INDUCED LIVER DAMAGE), ARBOR PHARMACEUTICALS","AR-10; AR-10; CETYLEV; CETYLEV; N-ACETYL CYSTEINE; NAC; ACETYLCYSTEINE; ACETYLCYSTEINE (ACETAMINOPHEN-INDUCED LIVER DAMAGE), ARBOR PHARMACEUTICALS","AR-10; AR-10; CETYLEV; CETYLEV; N-ACETYL CYSTEINE; NAC; ACETYLCYSTEINE; ACETYLCYSTEINE (ACETAMINOPHEN-INDUCED LIVER DAMAGE), ARBOR PHARMACEUTICALS","ACETYLCYSTEINE (ACETAMINOPHEN-INDUCED LIVER DAMAGE), ARBOR PHARMACEUTICALS",AR-10,AR-10,CETYLEV,CETYLEV,N-ACETYL CYSTEINE,NAC,ACETYLCYSTEINE,"ACETYLCYSTEINE (ACETAMINOPHEN-INDUCED LIVER DAMAGE), ARBOR PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,207916,ACETYLCYSTEINE,,,,,,,,,,,,,,,,,,,,,2016-01-29T00:00:00Z,2016,1,Cetylev,paracetamol overdose,,PROTECTANT,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),207916,NDA,2015-03-30T00:00:00Z,fda,0,0,0,1,0,,arbor pharmaceuticals,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207916,307,3696,965,242,Poisoning by other medications and drugs,2,0
505,"NALOXONE HYDROCHLORIDE (AUTO-INJECTOR, OPIOID OVERDOSE), KALEO","EVZIO; NALOXONE; NALOXONE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE (AUTO-INJECTOR, OPIOID OVERDOSE), KALEO","EVZIO; NALOXONE; NALOXONE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE (AUTO-INJECTOR, OPIOID OVERDOSE), KALEO","NALOXONE HYDROCHLORIDE (AUTO-INJECTOR, OPIOID OVERDOSE), KALEO",EVZIO,NALOXONE,NALOXONE HYDROCHLORIDE,"NALOXONE HYDROCHLORIDE (AUTO-INJECTOR, OPIOID OVERDOSE), KALEO",,,,,,,,,,,,,,,,,,,,,,,,,,,205787,NALOXONE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2014-04-03T00:00:00Z,2014,4,Evzio,drug overdose,OPIOID RECEPTOR ANTAGONIST,,INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION,matched (3),205787,NDA,2013-12-20T00:00:00Z,fda,1,0,1,0,0,,kaleo,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205787,257,3691,968,242,Poisoning by other medications and drugs,1,0
675,"SODIUM NITRITE (INTRAVENOUS, SICKLE CELL DISEASE/MYOCARDIAL INFARCTION/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS","SODIUM NITRITE; SODIUM NITRITE (INTRAVENOUS, SICKLE CELL DISEASE/MYOCARDIAL INFARCTION/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS; SODIUM NITRITE (IV, SICKLE CELL/MI/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS","SODIUM NITRITE; SODIUM NITRITE (INTRAVENOUS, SICKLE CELL DISEASE/MYOCARDIAL INFARCTION/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS; SODIUM NITRITE (IV, SICKLE CELL/MI/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS","SODIUM NITRITE (INTRAVENOUS, SICKLE CELL DISEASE/MYOCARDIAL INFARCTION/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS",SODIUM NITRITE,"SODIUM NITRITE (INTRAVENOUS, SICKLE CELL DISEASE/MYOCARDIAL INFARCTION/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS","SODIUM NITRITE (IV, SICKLE CELL/MI/CEREBRAL VASOSPASM), HOPE PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,,,,,203922,SODIUM NITRITE,203922,SODIUM NITRITE,203922,SODIUM NITRITE,203922,SODIUM NITRITE,,,,,,,,,,,,,,,2012-02-14T00:00:00Z,2012,2,sodium nitrite injection,poison intoxication,,CARDIOPROTECTANT; NITRIC OXIDE DONOR; VASODILATOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),203922,NDA,2012-01-10T00:00:00Z,fda,0,0,0,0,0,,hope pharmaceuticals,private,0,,,,,,,,,,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203922,173,474,977,242,Poisoning by other medications and drugs,1,0
68,"ATROPINE + PRALIDOXIME CHLORIDE AUTOINJECTOR (NERVE AGENT POISONING), MERIDIAN MEDICAL TECHNOLOGIES","DUODOTE; ATROPINE + PRALIDOXIME CHLORIDE; ATROPINE + PRALIDOXIME CHLORIDE AUTOINJECTOR (NERVE AGENT POISONING), MERIDIAN MEDICAL TECHNOLOGIES","DUODOTE; ATROPINE + PRALIDOXIME CHLORIDE; ATROPINE + PRALIDOXIME CHLORIDE AUTOINJECTOR (NERVE AGENT POISONING), MERIDIAN MEDICAL TECHNOLOGIES","ATROPINE + PRALIDOXIME CHLORIDE AUTOINJECTOR (NERVE AGENT POISONING), MERIDIAN MEDICAL TECHNOLOGIES",DUODOTE,ATROPINE + PRALIDOXIME CHLORIDE,"ATROPINE + PRALIDOXIME CHLORIDE AUTOINJECTOR (NERVE AGENT POISONING), MERIDIAN MEDICAL TECHNOLOGIES",,,,,,,,,,,,,,,,,,,,,,,,,,,,21983,ATROPINE; PRALIDOXIME CHLORIDE,,,,,,,,,,,,,,,,,,,,,2006-09-28T00:00:00Z,2006,9,Duodote,poison intoxication,ACETYLCHOLINE RECEPTOR AGONIST; MUSCARINIC RECEPTOR AGONIST,,DRUG COMBINATION; INTRAMUSCULAR FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),021983,NDA,2006-03-24T00:00:00Z,fda,1,0,0,0,0,,meridian,NASDAQ: VIVO,1,112.2,99,80.3,67.9,61.7,54.8,67.1,5,5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021983,424,474,977,242,Poisoning by other medications and drugs,1,0
362,"HYDROXOCOBALAMIN (CYANIDE INTOXICATION), MERCK SANTE","CYANOKIT; HYDROXOCOBALAMIN; HYDROXOCOBALAMIN (CYANIDE INTOXICATION), MERCK SANTE; HYDROXOCOBALAMIN (SMOKE INHALATION), MERCK SANTE","CYANOKIT; HYDROXOCOBALAMIN; HYDROXOCOBALAMIN (CYANIDE INTOXICATION), MERCK SANTE; HYDROXOCOBALAMIN (SMOKE INHALATION), MERCK SANTE","HYDROXOCOBALAMIN (CYANIDE INTOXICATION), MERCK SANTE",CYANOKIT,HYDROXOCOBALAMIN,"HYDROXOCOBALAMIN (CYANIDE INTOXICATION), MERCK SANTE","HYDROXOCOBALAMIN (SMOKE INHALATION), MERCK SANTE",,,,,,,,,,,,,,,,,,,,,,,,,,,22041,HYDROXOCOBALAMIN,,,,,,,,,,,,,,,,,,,,,2006-12-15T00:00:00Z,2006,12,Cyanokit,poison intoxication,,ANTIDOTE; VITAMIN B12 AGONIST,INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022041,NDA,2006-06-16T00:00:00Z,fda,1,0,1,1,0,,merck,NYSE: MRK,1,22636,22011.9,22972.8,22485.9,21445.8,21199,17371.3,3963.6,4020.4,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022041,450,474,977,242,Poisoning by other medications and drugs,1,0
46,ANASCORP,"ALACRAMYN; ALACRAMYN NAMO; ANASCORP; SCORPION ANTIVENOM, RARE DISEASE THERAPEUTICS/ BIOCLON",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2011-08-04T00:00:00Z,2011,8,Anascorp,poison intoxication,,ANTIDOTE; UNSPECIFIED DRUG TARGET,ANTIBODY FRAGMENT; BIOLOGICAL THERAPEUTIC; INFUSION; INTRAVENOUS FORMULATION,using only (2),125335,BLA,2009-01-22T00:00:00Z,fda,1,0,0,1,0,,rare disease therapeutics,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125335,637,474,977,242,Poisoning by other medications and drugs,1,0
128,CALCIUM LEVOFOLINATE,(S)-LEUCOVORIN; FUSILEV; ISOVORIN; L-FOLINIC ACID; LFA; CALCIUM LEVOFOLINATE; LEVOFOLINIC ACID; LEVOLEUCOVORIN CALCIUM; LEVOLEUKOVORIN CALCIUM,(S)-LEUCOVORIN; FUSILEV; ISOVORIN; L-FOLINIC ACID; LFA; CALCIUM LEVOFOLINATE; LEVOFOLINIC ACID; LEVOLEUCOVORIN CALCIUM; LEVOLEUKOVORIN CALCIUM,CALCIUM LEVOFOLINATE,(S)-LEUCOVORIN,FUSILEV,ISOVORIN,L-FOLINIC ACID,LFA,CALCIUM LEVOFOLINATE,LEVOFOLINIC ACID,LEVOLEUCOVORIN CALCIUM,LEVOLEUKOVORIN CALCIUM,,,,,,,,,,,,,,,,,,,,,,20140,LEVOLEUCOVORIN CALCIUM,208723,LEVOLEUCOVORIN CALCIUM,208723,LEVOLEUCOVORIN CALCIUM,,,,,,,,,,,,,,,,,2008-03-07T00:00:00Z,2008,3,Fusilev,toxicity,,ANTICANCER ANTIMETABOLITE; FOLIC ACID ANALOG,FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),020140,NDA,2007-07-10T00:00:00Z,fda,0,0,0,1,0,,spectrum pharmaceuticals,NASDAQ: SPPI,1,28.7,7.7,5.1,0.6,0.3,1,27.5,26.7,21.8,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020140,85,735,989,243,Poisoning by nonmedicinal substances,1,0
201,"DEXRAZOXANE (EXTRAVASATION), APRICUS/KISSEI","KDX-0811; SAVENE; TOTECT; DEXRAZOXANE; DEXRAZOXANE (EXTRAVASATION), APRICUS/KISSEI; DEXRAZOXANE (EXTRAVASATION), ONXEO; DEXRAZOXANE (EXTRAVASATION), TOPOTARGET","KDX-0811; SAVENE; TOTECT; DEXRAZOXANE; DEXRAZOXANE (EXTRAVASATION), APRICUS/KISSEI; DEXRAZOXANE (EXTRAVASATION), ONXEO; DEXRAZOXANE (EXTRAVASATION), TOPOTARGET","DEXRAZOXANE (EXTRAVASATION), APRICUS/KISSEI",KDX-0811,SAVENE,TOTECT,DEXRAZOXANE,"DEXRAZOXANE (EXTRAVASATION), APRICUS/KISSEI","DEXRAZOXANE (EXTRAVASATION), ONXEO","DEXRAZOXANE (EXTRAVASATION), TOPOTARGET",,,,,,,,,,,,,,,,,,,,,,,,22025,DEXRAZOXANE HYDROCHLORIDE,,,,,,,,,,,,,,,,,,,,,2007-09-06T00:00:00Z,2007,9,Totect,toxicity,TOPOISOMERASE II INHIBITOR,ANTIDOTE; IRON CHELATOR,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022025,NDA,2006-01-31T00:00:00Z,fda,1,0,0,1,0,,topotarget,CPH: TOPO,1,8.8,8.1,12.5,3.2,,,3.7,25.3,25.3,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022025,443,735,989,243,Poisoning by nonmedicinal substances,1,0
183,"DANTROLENE SODIUM (HEAT STROKE/MALIGNANT HYPERTHERMIA), EAGLE PHARMACEUTICALS","EGL-4104; EGL-4104; EP-4104; RYANODEX; DANTROLENE; DANTROLENE SODIUM; DANTROLENE SODIUM (HEAT STROKE/MALIGNANT HYPERTHERMIA), EAGLE PHARMACEUTICALS","EGL-4104; EGL-4104; EP-4104; RYANODEX; DANTROLENE; DANTROLENE SODIUM; DANTROLENE SODIUM (HEAT STROKE/MALIGNANT HYPERTHERMIA), EAGLE PHARMACEUTICALS","DANTROLENE SODIUM (HEAT STROKE/MALIGNANT HYPERTHERMIA), EAGLE PHARMACEUTICALS",EGL-4104,EGL-4104,EP-4104,RYANODEX,DANTROLENE,DANTROLENE SODIUM,"DANTROLENE SODIUM (HEAT STROKE/MALIGNANT HYPERTHERMIA), EAGLE PHARMACEUTICALS",,,,,,,,,,,,,,,,,,,,,,,,205579,DANTROLENE SODIUM,,,,,,,,,,,,,,,,,,,,,2014-07-22T00:00:00Z,2014,7,Ryanodex,malignant hyperthermia,CALCIUM CHANNEL MODULATOR,MUSCLE RELAXANT,FORMULATION POWDER; FREEZE DRYING; INTRAVENOUS FORMULATION; NANOPARTICLE FORMULATION INJECTABLE; SMALL MOLECULE THERAPEUTIC; SUSPENSION,matched (3),205579,NDA,2014-01-21T00:00:00Z,fda,1,0,0,1,0,,eagle pharmaceuticals,NASDAQ: EGRX,1,19.6,17.7,2.5,9.5,,,8.9,18.6,18.6,,,,,IPO in 2014; revenues for 2011 and 2012 are for 12 months preceding september of that year,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205579,244,1834,995,244,Other injuries and conditions due to external causes,6,0
337,"GRANISETRON (TRANSDERMAL PATCH), KYOWA KIRIN","5-HT 3 ANTAGONISTS (ANTI-EMETIC PATCH), STRAKAN; 5-HT 3 ANTAGONISTS (TRANSDERMAL PATCH), PROSTRAKAN; SP-01, SOLASIA; SANCUSO; ANTI-EMETIC PATCH (5-HT 3 ANTAGONISTS), STRAKAN; ANTI-EMETIC PATCH, STRAKAN/LG LIFE SCIENCES; GRANISETRON; GRANISETRON (TRANSDERMAL PATCH), KYOWA KIRIN; GRANISETRON (TRANSDERMAL PATCH), PROSTRAKAN; TRANSDERMAL PATCH (5-HT 3 ANTAGONISTS), PROSTRAKAN","5-HT 3 ANTAGONISTS (ANTI-EMETIC PATCH), STRAKAN; 5-HT 3 ANTAGONISTS (TRANSDERMAL PATCH), PROSTRAKAN; SP-01, SOLASIA; SANCUSO; ANTI-EMETIC PATCH (5-HT 3 ANTAGONISTS), STRAKAN; ANTI-EMETIC PATCH, STRAKAN/LG LIFE SCIENCES; GRANISETRON; GRANISETRON (TRANSDERMAL PATCH), KYOWA KIRIN; GRANISETRON (TRANSDERMAL PATCH), PROSTRAKAN; TRANSDERMAL PATCH (5-HT 3 ANTAGONISTS), PROSTRAKAN","GRANISETRON (TRANSDERMAL PATCH), KYOWA KIRIN","5-HT 3 ANTAGONISTS (ANTI-EMETIC PATCH), STRAKAN","5-HT 3 ANTAGONISTS (TRANSDERMAL PATCH), PROSTRAKAN","SP-01, SOLASIA",SANCUSO,"ANTI-EMETIC PATCH (5-HT 3 ANTAGONISTS), STRAKAN","ANTI-EMETIC PATCH, STRAKAN/LG LIFE SCIENCES",GRANISETRON,"GRANISETRON (TRANSDERMAL PATCH), KYOWA KIRIN","GRANISETRON (TRANSDERMAL PATCH), PROSTRAKAN","TRANSDERMAL PATCH (5-HT 3 ANTAGONISTS), PROSTRAKAN",,,,,,,,,,,,,,,,,,,,,22198,GRANISETRON,,,,,,,,,,,,,,,,,,,,,2008-09-12T00:00:00Z,2008,9,Sancuso,chemotherapy-induced emesis,5-HT 3 RECEPTOR ANTAGONIST,ANTI-EMETIC,PATCH FORMULATION; SMALL MOLECULE THERAPEUTIC; TRANSDERMAL FORMULATION,matched (3),022198,NDA,2007-06-29T00:00:00Z,fda,0,0,0,0,0,,prostrakan,LSE: PSK,1,81.7,90.6,75.3,54.2,41.4,15.3,52.6,15.4,15.4,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022198,492,352,995,244,Other injuries and conditions due to external causes,6,0
689,SUGAMMADEX,"BRIDION; MK-8616; ORG-25169; ORG-25604; ORG-25819; ORG-25969; ORG-26276; SCH-900616; SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, MERCK; SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, ORGANON; SUGAMMADEX; SUGAMMADEX SODIUM","BRIDION; MK-8616; ORG-25169; ORG-25604; ORG-25819; ORG-25969; ORG-26276; SCH-900616; SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, MERCK; SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, ORGANON; SUGAMMADEX; SUGAMMADEX SODIUM",SUGAMMADEX,BRIDION,MK-8616,ORG-25169,ORG-25604,ORG-25819,ORG-25969,ORG-26276,SCH-900616,"SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, MERCK","SELECTIVE NEUROMUSCULAR-BLOCKING REVERSAL AGENTS, ORGANON",SUGAMMADEX,SUGAMMADEX SODIUM,,,,,,,,,,,,,,,,,,,22225,SUGAMMADEX SODIUM,,,,,,,,,,,,,,,,,,,,,2015-12-15T00:00:00Z,2015,12,Bridion,general anesthesia,,CHELATING AGENT; NEUROMUSCULAR BLOCKING AGENT ANTAGONIST,INTRAVENOUS FORMULATION; OLIGOSACCHARIDE; SMALL MOLECULE THERAPEUTIC; SOLUTION,matched (3),022225,NDA,2007-10-30T00:00:00Z,fda,1,0,0,0,0,,merck,NYSE: MRK,1,39498,42237,44033,47267,48047,45987,25075,6663,6641,,,,,acquired by schering plough in 2007; subsidiary of merck as of 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022225,505,2978,995,244,Other injuries and conditions due to external causes,6,0
336,"GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS), HERON THERAPEUTICS","APF-530; SUSTOL; GRANISETRON; GRANISETRON (BIOCHRONOMER), AP PHARMA/RHEI; GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS), HERON THERAPEUTICS; GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS, BIOCHRONOMER), AP PHARMA/RHEI; GRANISETRON (SUSTAINED RELEASE/SC), AP PHARMA","APF-530; SUSTOL; GRANISETRON; GRANISETRON (BIOCHRONOMER), AP PHARMA/RHEI; GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS), HERON THERAPEUTICS; GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS, BIOCHRONOMER), AP PHARMA/RHEI; GRANISETRON (SUSTAINED RELEASE/SC), AP PHARMA","GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS), HERON THERAPEUTICS",APF-530,SUSTOL,GRANISETRON,"GRANISETRON (BIOCHRONOMER), AP PHARMA/RHEI","GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS), HERON THERAPEUTICS","GRANISETRON (SUSTAINED RELEASE SUBCUTANEOUS, BIOCHRONOMER), AP PHARMA/RHEI","GRANISETRON (SUSTAINED RELEASE/SC), AP PHARMA",,,,,,,,,,,,,,,,,,,,,,,,22445,GRANISETRON,,,,,,,,,,,,,,,,,,,,,2016-08-09T00:00:00Z,2016,8,Sustol,chemotherapy-induced emesis,5-HT 3 RECEPTOR ANTAGONIST,ANTI-EMETIC,SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS FORMULATION; SUSTAINED RELEASE FORMULATION,matched (3),022445,NDA,2009-05-16T00:00:00Z,fda,0,0,0,0,0,,heron therapeutics,NASDAQ: HRTX,1,1.3,,,,,0.6,-95.2,,103.1,,,,,,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022445,566,352,995,244,Other injuries and conditions due to external causes,6,0
135,"CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA/FSC LABORATORIES","KARBINAL ER; TRI-046; CARBINOXAMINE; CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA; CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA/FSC LABORATORIES","KARBINAL ER; TRI-046; CARBINOXAMINE; CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA; CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA/FSC LABORATORIES","CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA/FSC LABORATORIES",KARBINAL ER,TRI-046,CARBINOXAMINE,"CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA","CARBINOXAMINE (EXTENDED RELEASE ORAL SUSPENSION, ALLERGY), TRIS PHARMA/FSC LABORATORIES",,,,,,,,,,,,,,,,,,,,,,,,,,22556,CARBINOXAMINE MALEATE,,,,,,,,,,,,,,,,,,,,,2013-03-28T00:00:00Z,2013,3,Karbinal ER,allergy,HISTAMINE RECEPTOR ANTAGONIST,,ORAL FORMULATION; ORAL SUSPENSION FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),022556,NDA,2010-12-07T00:00:00Z,fda,0,0,0,0,0,,tris pharma,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022556,599,12,995,244,Other injuries and conditions due to external causes,6,0
544,"ONDANSETRON (ORAL QUICK RELEASE, RAPIDFILM), APR/LABTEC/MONOSOL RX/BIOALLIANCE/SCICLONE","BA-030; SETOFILM; ONDANSETRON; ONDANSETRON (ORAL QUICK RELEASE, RAPIDFILM), APR/LABTEC/MONOSOL RX/BIOALLIANCE/SCICLONE; ONDANSETRON (ORAL THIN FILM, EMESIS), APR/LABTEC/BIOALLIANCE",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2011-01-12T00:00:00Z,2011,1,,chemotherapy-induced emesis,5-HT 3 RECEPTOR ANTAGONIST,ACETYLCHOLINE RELEASE STIMULATOR; ANTI-EMETIC,ORAL FORMULATION; ORAL QUICK RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,using only (2),not identified,not identified,,,,,,,,,applied pharma research,private,0,,,,,,,,,,,,,,,,,,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=not identified,705,352,995,244,Other injuries and conditions due to external causes,6,0
85,BELATACEPT,BMS-224818; L104EA29YIG; LEA-029; LEA-29Y; NULOJIX; BELATACEPT,BMS-224818; L104EA29YIG; LEA-029; LEA-29Y; NULOJIX; BELATACEPT,BELATACEPT,BMS-224818,L104EA29YIG,LEA-029,LEA-29Y,NULOJIX,BELATACEPT,,,,,,,,,,,,,,,,,,,,,,,,,125288,BELATACEPT,,,,,,,,,,,,,,,,,,,,,2011-06-15T00:00:00Z,2011,6,Nulojix,kidney transplant rejection,CYTOTOXIC T-LYMPHOCYTE PROTEIN-4 MODULATOR; T CELL SURFACE GLYCOPROTEIN CD28 INHIBITOR,IMMUNOSUPPRESSANT; LYMPHOCYTE INHIBITOR,BIOLOGICAL THERAPEUTIC; FORMULATION POWDER; FREEZE DRYING; IMMUNOGLOBULIN-G; INFUSION; INTRAVENOUS FORMULATION; PROTEIN FUSION,matched (3),125288,BLA,2009-06-30T00:00:00Z,fda,0,0,0,1,0,,bristol-myers squibb,NYSE: BMY,1,21244,19484,18808,17715,15617,16208,15721,3604,3811,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125288,18,2989,996,237,Complication of device; implant or graft,1,0
423,"LEVONORGESTEROL (3-YEAR INTRAUTERINE CONTRACEPTIVE SYSTEM), BAYER HEALTHCARE","JAYDESS; SKYLA; LEVONORGESTEROL (3-YEAR INTRAUTERINE CONTRACEPTIVE SYSTEM), BAYER HEALTHCARE; LEVONORGESTREL","JAYDESS; SKYLA; LEVONORGESTEROL (3-YEAR INTRAUTERINE CONTRACEPTIVE SYSTEM), BAYER HEALTHCARE; LEVONORGESTREL","LEVONORGESTEROL (3-YEAR INTRAUTERINE CONTRACEPTIVE SYSTEM), BAYER HEALTHCARE",JAYDESS,SKYLA,"LEVONORGESTEROL (3-YEAR INTRAUTERINE CONTRACEPTIVE SYSTEM), BAYER HEALTHCARE",LEVONORGESTREL,,,,,,,,,,,,,,,,,,,,,,,,,,,203159,LEVONORGESTREL,20627,LEVONORGESTREL,,,,,,,,,,,,,,,,,,,2013-01-09T00:00:00Z,2013,1,Skyla,female contraception,PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE,DRUG IMPLANT; IUD MEDICATED; SMALL MOLECULE THERAPEUTIC; STEREOCHEMISTRY; STEROID; VAGINAL FORMULATION,matched (3),203159,NDA,2011-12-09T00:00:00Z,fda,0,0,0,0,0,,bayer,ETR: BAYN,1,55301.2,52397.7,47454.4,47050.6,44669.3,45997.3,28539.6,4691.87,4690.5,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203159,143,1778,996,237,Complication of device; implant or graft,1,0
424,"LEVONORGESTREL + ETHINYL ESTRADIOL (CONTRACEPTIVE, ORAL), TEVA","DR-103; DR-1031; NORDETTE-21; NORDETTE-28; QUARTETTE; ETHINYLESTRADIOL + LEVONORGESTREL; LEVONORGESTREL + ETHINYL ESTRADIOL (CONTRACEPTIVE, ORAL), TEVA","DR-103; DR-1031; NORDETTE-21; NORDETTE-28; QUARTETTE; ETHINYLESTRADIOL + LEVONORGESTREL; LEVONORGESTREL + ETHINYL ESTRADIOL (CONTRACEPTIVE, ORAL), TEVA","LEVONORGESTREL + ETHINYL ESTRADIOL (CONTRACEPTIVE, ORAL), TEVA",DR-103,DR-1031,NORDETTE-21,NORDETTE-28,QUARTETTE,ETHINYLESTRADIOL + LEVONORGESTREL,"LEVONORGESTREL + ETHINYL ESTRADIOL (CONTRACEPTIVE, ORAL), TEVA",,,,,,,,,,,,,,,,,,,,,,,,18668,ETHINYL ESTRADIOL; LEVONORGESTREL,18782,ETHINYL ESTRADIOL; LEVONORGESTREL,204061,ETHINYL ESTRADIOL; LEVONORGESTREL,20627,LEVONORGESTREL,20627,LEVONORGESTREL,,,,,,,,,,,,,2013-03-28T00:00:00Z,2013,3,Quartette,female contraception,ESTROGEN RECEPTOR AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; TABLET FORMULATION,matched (3),204061,NDA,2012-05-30T00:00:00Z,fda,0,0,0,0,0,,teva pharmaceuticals,NYSE: TEVA,1,20314,20317,18312,16121,13899,11085,10716,1427,1422,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204061,180,1778,996,237,Complication of device; implant or graft,1,0
700,"TACROLIMUS (ORAL SUSTAINED-RELEASE), ASTELLAS","ADVAGRAF; ASTAGRAF XL; FK-506E; FK-506MR; GRACEPTOR; MR PROGRAF; MR TACROLIMUS, ASTELLAS; MR TACROLIMUS, FUJISAWA; MR-4; PROGRAF XL; MODIFIED RELEASE PROGRAF; TACROLIMUS; TACROLIMUS (MODIFIED-RELEASE), FUJISAWA; TACROLIMUS (ONCE-DAILY), ASTELLAS; TACROLIMUS (ONCE-DAILY), FUJISAWA; TACROLIMUS (ORAL MODIFIED-RELEASE), ASTELLAS; TACROLIMUS (ORAL PROLONGED-RELEASE), ASTELLAS; TACROLIMUS (ORAL SUSTAINED-RELEASE), ASTELLAS","ADVAGRAF; ASTAGRAF XL; FK-506E; FK-506MR; GRACEPTOR; MR PROGRAF; MR TACROLIMUS, ASTELLAS; MR TACROLIMUS, FUJISAWA; MR-4; PROGRAF XL; MODIFIED RELEASE PROGRAF; TACROLIMUS; TACROLIMUS (MODIFIED-RELEASE), FUJISAWA; TACROLIMUS (ONCE-DAILY), ASTELLAS; TACROLIMUS (ONCE-DAILY), FUJISAWA; TACROLIMUS (ORAL MODIFIED-RELEASE), ASTELLAS; TACROLIMUS (ORAL PROLONGED-RELEASE), ASTELLAS; TACROLIMUS (ORAL SUSTAINED-RELEASE), ASTELLAS","TACROLIMUS (ORAL SUSTAINED-RELEASE), ASTELLAS",ADVAGRAF,ASTAGRAF XL,FK-506E,FK-506MR,GRACEPTOR,MR PROGRAF,"MR TACROLIMUS, ASTELLAS","MR TACROLIMUS, FUJISAWA",MR-4,PROGRAF XL,MODIFIED RELEASE PROGRAF,TACROLIMUS,"TACROLIMUS (MODIFIED-RELEASE), FUJISAWA","TACROLIMUS (ONCE-DAILY), ASTELLAS","TACROLIMUS (ONCE-DAILY), FUJISAWA","TACROLIMUS (ORAL MODIFIED-RELEASE), ASTELLAS","TACROLIMUS (ORAL PROLONGED-RELEASE), ASTELLAS","TACROLIMUS (ORAL SUSTAINED-RELEASE), ASTELLAS",,,,,,,,,,,,,204096,TACROLIMUS,,,,,,,,,,,,,,,,,,,,,2013-07-19T00:00:00Z,2013,7,Astagraf XL,kidney transplant rejection,CALCINEURIN INHIBITOR,IMMUNOSUPPRESSANT; T-LYMPHOCYTE INHIBITOR,CAPSULE FORMULATION; DAILY DOSING; ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204096,NDA,2012-09-21T00:00:00Z,fda,0,0,0,0,0,,astellas pharma,TYO: 4503,1,10821,11107,12783.1,11541,10522.6,10658.3,7479.8,1730.4,1730.4,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204096,183,2989,996,237,Complication of device; implant or graft,1,0
525,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE, ALLERGAN","TAYTULLA; NORETHINDRONE + ETHINYL ESTRADIOL + FERROUS FUMARATE (ORAL/SOFTGEL, FEMALE CONTRACEPTION), ALLERGAN; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE, ALLERGAN","TAYTULLA; NORETHINDRONE + ETHINYL ESTRADIOL + FERROUS FUMARATE (ORAL/SOFTGEL, FEMALE CONTRACEPTION), ALLERGAN; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE, ALLERGAN","NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE, ALLERGAN",TAYTULLA,"NORETHINDRONE + ETHINYL ESTRADIOL + FERROUS FUMARATE (ORAL/SOFTGEL, FEMALE CONTRACEPTION), ALLERGAN",NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL + FERROUS FUMARATE, ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,,,,204426,ETHINYL ESTRADIOL; NORETHINDRONE ACETATE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,,,,,,,,,,,,,2013-04-19T00:00:00Z,2013,4,Taytulla,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE; OVULATION INHIBITOR,CAPSULE FORMULATION; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC,matched (3),204426,NDA,2012-06-21T00:00:00Z,fda,0,0,0,0,0,,actavis (allergan plc),NYSE: AGN,1,2602.5,2541,2728,2947,1435.8,938.1,1137.1,190.2,191.3,2409.33333333333,2013-09-30T00:00:00Z,2013,,acquired by actavis (now allergan plc) in 2013,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204426,199,1778,996,237,Complication of device; implant or graft,1,0
445,"LOTEPREDNOL ETABONATE (OPHTHALMIC GEL), BAUSCH & LOMB","LOTEMAX; LOTEMAX GEL; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE (OPHTHALMIC GEL), BAUSCH & LOMB","LOTEMAX; LOTEMAX GEL; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE (OPHTHALMIC GEL), BAUSCH & LOMB","LOTEPREDNOL ETABONATE (OPHTHALMIC GEL), BAUSCH & LOMB",LOTEMAX,LOTEMAX GEL,LOTEPREDNOL ETABONATE,"LOTEPREDNOL ETABONATE (OPHTHALMIC GEL), BAUSCH & LOMB",,,,,,,,,,,,,,,,,,,,,,,,,,,20583,LOTEPREDNOL ETABONATE,,,,,,,,,,,,,,,,,,,,,2012-09-28T00:00:00Z,2012,9,Lotemax,ocular inflammation,,ANALGESIC; CORTICOSTEROID AGONIST; STEROIDAL ANTI-INFLAMMATORY,OPHTHALMIC FORMULATION; OPHTHALMIC GEL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID,matched (3),202872,NDA,2011-11-29T00:00:00Z,fda,0,0,0,0,0,,bausch & lomb,private,0,3037.6,2845.4,2576.9,,,,1905.3,225.4,227.4,,,,,owned by private equity firm; acquired by valeant  pharma in 2013,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202872,258,686,996,237,Complication of device; implant or graft,1,0
698,"TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS/CHIESI","ENVARSUS; ENVARSUS XR; LCP-TACRO; TACROLIMUS; TACROLIMUS (IMPROVED TABLET FORMULATION), LIFECYCLE PHARMA; TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS; TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS/CHIESI","ENVARSUS; ENVARSUS XR; LCP-TACRO; TACROLIMUS; TACROLIMUS (IMPROVED TABLET FORMULATION), LIFECYCLE PHARMA; TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS; TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS/CHIESI","TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS/CHIESI",ENVARSUS,ENVARSUS XR,LCP-TACRO,TACROLIMUS,"TACROLIMUS (IMPROVED TABLET FORMULATION), LIFECYCLE PHARMA","TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS","TACROLIMUS (IMPROVED TABLET FORMULATION), VELOXIS/CHIESI",,,,,,,,,,,,,,,,,,,,,,,,206406,TACROLIMUS,,,,,,,,,,,,,,,,,,,,,2015-07-10T00:00:00Z,2015,7,Envarsus XR,kidney transplant rejection,CALCINEURIN INHIBITOR,IMMUNOSUPPRESSANT,ORAL FORMULATION; ORAL SUSTAINED RELEASE FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),206406,NDA,2013-12-28T00:00:00Z,fda,0,0,0,1,0,,veloxis pharmaceuticals,CPH: VELO,1,2.1,20.1,7,1.2,,0.3,-0.1,11.3,11.3,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206406,280,2989,996,237,Complication of device; implant or graft,1,0
446,"LOW CONCENTRATION BROMFENAC (DURASITE, INFLAMMATION/EYE PAIN), INSITE","BROMSITE; ISV-303; ISV-304; ANTI-INFLAMMATORY/ANALGESIC AGENTS (DURASITE, INFLAMMATION/EYE PAIN), INSITE; BROMFENAC; LOW CONCENTRATION BROMFENAC (DURASITE, INFLAMMATION/EYE PAIN), INSITE","BROMSITE; ISV-303; ISV-304; ANTI-INFLAMMATORY/ANALGESIC AGENTS (DURASITE, INFLAMMATION/EYE PAIN), INSITE; BROMFENAC; LOW CONCENTRATION BROMFENAC (DURASITE, INFLAMMATION/EYE PAIN), INSITE","LOW CONCENTRATION BROMFENAC (DURASITE, INFLAMMATION/EYE PAIN), INSITE",BROMSITE,ISV-303,ISV-304,"ANTI-INFLAMMATORY/ANALGESIC AGENTS (DURASITE, INFLAMMATION/EYE PAIN), INSITE",BROMFENAC,"LOW CONCENTRATION BROMFENAC (DURASITE, INFLAMMATION/EYE PAIN), INSITE",,,,,,,,,,,,,,,,,,,,,,,,,206911,BROMFENAC SODIUM,,,,,,,,,,,,,,,,,,,,,2016-04-08T00:00:00Z,2016,4,Bromsite,ocular inflammation,CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR,ANALGESIC; NON-STEROIDAL ANTI-INFLAMMATORY; OPHTHALMOLOGICAL AGENT,OPHTHALMIC FORMULATION; SMALL MOLECULE THERAPEUTIC; SUSTAINED RELEASE FORMULATION,matched (3),206911,NDA,2015-06-10T00:00:00Z,fda,0,0,0,0,0,,sun pharmaceutical,NSE: SUNPHARMA,1,4699.8,4021.2,8.2,15.3,21.6,15.9,2719.6,,236.6,7.6,2015-06-30T00:00:00Z,2015,,acquired by sun pharma in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206911,292,686,996,237,Complication of device; implant or graft,1,0
262,ETONOGESTREL,"IMPLANON; IMPLANON NXT; NEXPLANON; ORG-32222; ORG-3236; RADIOPAQUE IMPLANON; ETONOGESTREL; ETONOGESTREL CONTRACEPTIVE IMPLANT (RADIOPAQUE), ORGANON/SCHERING-PLOUGH; ETONOGESTREL CONTRACEPTIVE IMPLANT, ORGANON","IMPLANON; IMPLANON NXT; NEXPLANON; ORG-32222; ORG-3236; RADIOPAQUE IMPLANON; ETONOGESTREL; ETONOGESTREL CONTRACEPTIVE IMPLANT (RADIOPAQUE), ORGANON/SCHERING-PLOUGH; ETONOGESTREL CONTRACEPTIVE IMPLANT, ORGANON",ETONOGESTREL,IMPLANON,IMPLANON NXT,NEXPLANON,ORG-32222,ORG-3236,RADIOPAQUE IMPLANON,ETONOGESTREL,"ETONOGESTREL CONTRACEPTIVE IMPLANT (RADIOPAQUE), ORGANON/SCHERING-PLOUGH","ETONOGESTREL CONTRACEPTIVE IMPLANT, ORGANON",,,,,,,,,,,,,,,,,,,,,,21529,ETONOGESTREL,21529,ETONOGESTREL,,,,,,,,,,,,,,,,,,,2006-07-17T00:00:00Z,2006,7,Implanon,female contraception,PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE; OVULATION INHIBITOR,SMALL MOLECULE THERAPEUTIC; SUBCUTANEOUS DRUG IMPLANT,matched (3),021529,NDA,2003-09-30T00:00:00Z,fda,0,0,0,0,0,,organon,private,0,4643,,,,,,3145,781,781,,,,,acquired by schering plough in 2007; subsidiary of merck as of 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021529,373,1778,996,237,Complication of device; implant or graft,1,0
425,"LEVONORGESTREL + ETHINYLESTRADIOL (PLUS ETHINYLESTRADIOL TABLETS), BARR/PALADIN","DP3; DR-1011; DR-105; LO SEASONIQUE; SEASONIQUE; ETHINYLESTRADIOL + LEVONORGESTREL; EXTENDED REGIMEN ORAL CONTRACEPTIVE, BARR LABORATORIES; LEVONORGESTREL + ETHINYLESTRADIOL (PLUS ETHINYLESTRADIOL TABLETS), BARR/PALADIN","DP3; DR-1011; DR-105; LO SEASONIQUE; SEASONIQUE; ETHINYLESTRADIOL + LEVONORGESTREL; EXTENDED REGIMEN ORAL CONTRACEPTIVE, BARR LABORATORIES; LEVONORGESTREL + ETHINYLESTRADIOL (PLUS ETHINYLESTRADIOL TABLETS), BARR/PALADIN","LEVONORGESTREL + ETHINYLESTRADIOL (PLUS ETHINYLESTRADIOL TABLETS), BARR/PALADIN",DP3,DR-1011,DR-105,LO SEASONIQUE,SEASONIQUE,ETHINYLESTRADIOL + LEVONORGESTREL,"EXTENDED REGIMEN ORAL CONTRACEPTIVE, BARR LABORATORIES","LEVONORGESTREL + ETHINYLESTRADIOL (PLUS ETHINYLESTRADIOL TABLETS), BARR/PALADIN",,,,,,,,,,,,,,,,,,,,,,,20627,LEVONORGESTREL,20627,LEVONORGESTREL,21840,ETHINYL ESTRADIOL; LEVONORGESTREL,22262,ETHINYL ESTRADIOL; LEVONORGESTREL,,,,,,,,,,,,,,,2006-05-25T00:00:00Z,2006,5,Seasonique,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021840,NDA,2004-10-21T00:00:00Z,fda,0,0,0,0,0,,barr pharmaceuticals,NYSE: BRL,1,1583.3,1047.4,1309.1,902.9,1189,593.2,1064.9,180.9,180.9,,,,,acquired by teva in 2008,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021840,392,1778,996,237,Complication of device; implant or graft,1,0
426,"LEVONORGESTREL + ETHINYLESTRADIOL, PFIZER","ANYA; LIBREL; LYBREL; ETHINYLESTRADIOL + LEVONORGESTREL; LEVONORGESTREL + ETHINYLESTRADIOL, PFIZER; LEVONORGESTREL + ETHINYLESTRADIOL, WYETH","ANYA; LIBREL; LYBREL; ETHINYLESTRADIOL + LEVONORGESTREL; LEVONORGESTREL + ETHINYLESTRADIOL, PFIZER; LEVONORGESTREL + ETHINYLESTRADIOL, WYETH","LEVONORGESTREL + ETHINYLESTRADIOL, PFIZER",ANYA,LIBREL,LYBREL,ETHINYLESTRADIOL + LEVONORGESTREL,"LEVONORGESTREL + ETHINYLESTRADIOL, PFIZER","LEVONORGESTREL + ETHINYLESTRADIOL, WYETH",,,,,,,,,,,,,,,,,,,,,,,,,20627,LEVONORGESTREL,20627,LEVONORGESTREL,20627,LEVONORGESTREL,21864,ETHINYL ESTRADIOL; LEVONORGESTREL,21864,ETHINYL ESTRADIOL; LEVONORGESTREL,,,,,,,,,,,,,2007-05-22T00:00:00Z,2007,5,Lybrel,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),021864,NDA,2005-05-27T00:00:00Z,fda,0,0,0,0,0,,wyeth,NYSE: WYE,1,22399.8,20350.7,18755.8,17358,15850.6,14584,16330.5,3256.52,3256.8,,,,,acquired by Pfizer in 2009,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021864,397,1778,996,237,Complication of device; implant or graft,1,0
758,"TRIAMCINOLONE ACETONIDE (INJECTABLE, OCULAR INFLAMMATION), ALCON","TRIESENCE; VISAGEN; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE (INJECTABLE, OCULAR INFLAMMATION), ALCON; TRIAMCINOLONE ACETONIDE (INTRAOCULAR), REGENERA","TRIESENCE; VISAGEN; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE (INJECTABLE, OCULAR INFLAMMATION), ALCON; TRIAMCINOLONE ACETONIDE (INTRAOCULAR), REGENERA","TRIAMCINOLONE ACETONIDE (INJECTABLE, OCULAR INFLAMMATION), ALCON",TRIESENCE,VISAGEN,TRIAMCINOLONE ACETONIDE,"TRIAMCINOLONE ACETONIDE (INJECTABLE, OCULAR INFLAMMATION), ALCON","TRIAMCINOLONE ACETONIDE (INTRAOCULAR), REGENERA",,,,,,,,,,,,,,,,,,,,,,,,,,11601,TRIAMCINOLONE ACETONIDE,11601,TRIAMCINOLONE ACETONIDE,11601,TRIAMCINOLONE ACETONIDE,11601,TRIAMCINOLONE ACETONIDE,22048,TRIAMCINOLONE ACETONIDE,,,,,,,,,,,,,2007-11-29T00:00:00Z,2007,11,Triesence,ocular inflammation,,ANGIOGENESIS INHIBITOR; CORTICOSTEROID AGONIST,INJECTABLE FORMULATION; OPHTHALMIC FORMULATION; PARENTERAL FORMULATION UNSPECIFIED; SMALL MOLECULE THERAPEUTIC; STEROID; SUSPENSION,matched (3),022048,NDA,2007-05-25T00:00:00Z,fda,1,0,0,0,0,,alcon,NYSE: ACL,1,5599,4896.6,4368.5,3913.6,3406.9,3009,4225,564,579,,,,,acquired by novartis in 2011,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022048,453,686,996,237,Complication of device; implant or graft,1,0
210,"DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), BAYER SCHERING","BAY-86-5027; DUB-OC; E2; E2 PILL, SCHERING AG; E2/DNG PILL, SCHERING AG; NATAZIA; QLAIRA; SH-T00658ID; ZK-37659 + ZK-5104 (ORAL CONTRACEPTIVE), SCHERING AG; DIENOGEST + ESTRADIOL VALERATE; DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), BAYER SCHERING; DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), SCHERING AG","BAY-86-5027; DUB-OC; E2; E2 PILL, SCHERING AG; E2/DNG PILL, SCHERING AG; NATAZIA; QLAIRA; SH-T00658ID; ZK-37659 + ZK-5104 (ORAL CONTRACEPTIVE), SCHERING AG; DIENOGEST + ESTRADIOL VALERATE; DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), BAYER SCHERING; DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), SCHERING AG","DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), BAYER SCHERING",BAY-86-5027,DUB-OC,E2,"E2 PILL, SCHERING AG","E2/DNG PILL, SCHERING AG",NATAZIA,QLAIRA,SH-T00658ID,"ZK-37659 + ZK-5104 (ORAL CONTRACEPTIVE), SCHERING AG",DIENOGEST + ESTRADIOL VALERATE,"DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), BAYER SCHERING","DIENOGEST + ESTRADIOL VALERATE (ORAL CONTRACEPTIVE), SCHERING AG",,,,,,,,,,,,,,,,,,,22252,DIENOGEST; ESTRADIOL VALERATE,,,,,,,,,,,,,,,,,,,,,2010-05-06T00:00:00Z,2010,5,Natazia,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE; OVULATION INHIBITOR,DRUG COMBINATION; FILM COATING; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; STEROID; TABLET FORMULATION,matched (3),022252,NDA,2009-07-02T00:00:00Z,fda,0,0,0,0,0,,bayer,ETR: BAYN,1,47050.6,44669.3,45997.3,47291.9,38208.1,29259.7,24116.7,4093.87,4093.9,,,,,,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022252,512,1778,996,237,Complication of device; implant or graft,1,0
765,ULIPRISTAL,"CDB-2914; DVELLA; ELLA; ELLAONE; ESMYA; FIBRISTAL; HRP-2000; PGL-4001; RTI-3021-012; RTI-3021-022; UPA (ORAL, UTERINE FIBROIDS), HRA PHARMA/ POPULATION COUNCIL; UPA-UF; VA-2914; ULIPRISTAL; ULIPRISTAL ACETATE","CDB-2914; DVELLA; ELLA; ELLAONE; ESMYA; FIBRISTAL; HRP-2000; PGL-4001; RTI-3021-012; RTI-3021-022; UPA (ORAL, UTERINE FIBROIDS), HRA PHARMA/ POPULATION COUNCIL; UPA-UF; VA-2914; ULIPRISTAL; ULIPRISTAL ACETATE",ULIPRISTAL,CDB-2914,DVELLA,ELLA,ELLAONE,ESMYA,FIBRISTAL,HRP-2000,PGL-4001,RTI-3021-012,RTI-3021-022,"UPA (ORAL, UTERINE FIBROIDS), HRA PHARMA/ POPULATION COUNCIL",UPA-UF,VA-2914,ULIPRISTAL,ULIPRISTAL ACETATE,,,,,,,,,,,,,,,,22474,ULIPRISTAL ACETATE,,,,,,,,,,,,,,,,,,,,,2010-08-13T00:00:00Z,2010,8,Ella,female contraception,PROGESTERONE RECEPTOR MODULATOR,ANTICANCER; FEMALE CONTRACEPTIVE,ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022474,NDA,2009-10-14T00:00:00Z,fda,0,0,0,0,0,,HRA pharma,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022474,574,1778,996,237,Complication of device; implant or graft,1,0
523,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LO LOESTRIN FE), WARNER CHILCOTT","LO LOESTRIN FE; WC-3016; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LO LOESTRIN FE), WARNER CHILCOTT; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN","LO LOESTRIN FE; WC-3016; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LO LOESTRIN FE), WARNER CHILCOTT; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN","NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LO LOESTRIN FE), WARNER CHILCOTT",LO LOESTRIN FE,WC-3016,NORETHINDRONE ACETATE + ETHINYL ESTRADIOL,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LO LOESTRIN FE), WARNER CHILCOTT","NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,,,22501,FERROUS FUMARATE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,,,,,,,,,,,,,2010-10-21T00:00:00Z,2010,10,Lo Loestrin Fe,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE,DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022501,NDA,2009-03-26T00:00:00Z,fda,0,0,0,0,0,,warner chilcott,NASDAQ: WCRX,1,2974,1435.8,938.1,899.6,754.5,515.3,2587,147,147,,,,,acquired by actavis (now allergan plc) in 2013,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022501,579,1778,996,237,Complication of device; implant or graft,1,0
524,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN","GENERESS FE; WC-3026; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN","GENERESS FE; WC-3026; NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN","NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN",GENERESS FE,WC-3026,"NORETHINDRONE ACETATE + ETHINYL ESTRADIOL (LOW DOSE ORAL CONTRACEPTIVE), ALLERGAN",,,,,,,,,,,,,,,,,,,,,,,,,,,,22573,ETHINYL ESTRADIOL; NORETHINDRONE,22573,ETHINYL ESTRADIOL; NORETHINDRONE,,,,,,,,,,,,,,,,,,,2010-12-22T00:00:00Z,2010,12,Generess Fe,female contraception,ESTRADIOL AGONIST; PROGESTERONE RECEPTOR AGONIST,FEMALE CONTRACEPTIVE; OVULATION INHIBITOR,BUCCAL FORMULATION SYSTEMIC; DRUG COMBINATION; ORAL FORMULATION; SMALL MOLECULE THERAPEUTIC; TABLET FORMULATION,matched (3),022573,NDA,2009-11-25T00:00:00Z,fda,0,0,0,0,0,,warner chilcott,NASDAQ: WCRX,1,2974,1435.8,938.1,899.6,754.5,515.3,2587,147,147,,,,,acquired by actavis (now allergan plc) in 2013,,,1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022573,607,1778,996,237,Complication of device; implant or graft,1,0
77,"AZITHROMYCIN (OPHTHALMIC SUSTAINED RELEASE, DURASITE), INSITE","AZASITE; ISV-401; ANTIBIOTIC (DURASITE), INSITE; AZITHROMYCIN; AZITHROMYCIN (OPHTHALMIC SUSTAINED RELEASE, DURASITE), INSITE","AZASITE; ISV-401; ANTIBIOTIC (DURASITE), INSITE; AZITHROMYCIN; AZITHROMYCIN (OPHTHALMIC SUSTAINED RELEASE, DURASITE), INSITE","AZITHROMYCIN (OPHTHALMIC SUSTAINED RELEASE, DURASITE), INSITE",AZASITE,ISV-401,"ANTIBIOTIC (DURASITE), INSITE",AZITHROMYCIN,"AZITHROMYCIN (OPHTHALMIC SUSTAINED RELEASE, DURASITE), INSITE",,,,,,,,,,,,,,,,,,,,,,,,,,50809,AZITHROMYCIN,50809,AZITHROMYCIN,50809,AZITHROMYCIN,50810,AZITHROMYCIN,,,,,,,,,,,,,,,2007-04-27T00:00:00Z,2007,4,Azasite,ocular infection,,ANTI-INFLAMMATORY; ANTIBACTERIAL; BACTERIAL PROTEIN SYNTHESIS INHIBITOR; MACROLIDE ANTIBIOTIC; OPHTHALMOLOGICAL ANTIBACTERIAL; RIBOSOME BINDING AGENT,ANTIBIOTIC; OPHTHALMIC FORMULATION; OPHTHALMIC LIQUID FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; SUSTAINED RELEASE FORMULATION,matched (3),050810,NDA,2006-06-28T00:00:00Z,fda,0,0,0,0,0,,insite vision,OTCBB: INSV,1,23.8,,,0.5,0.1,,22.8,10.4,10.4,,,,,acquired by sun pharma in 2015,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050810,615,2546,996,237,Complication of device; implant or graft,1,0
178,DABIGATRAN ETEXILATE,BIBR-1048; BIBR-1048BS; BIBR-1048MS; BIBR-953; BIBR-953ZW; PRADAX; PRADAXA; PRAZAXA; RENDIX; DABIGATRAN; DABIGATRAN ETEXILATE; DABIGATRAN ETEXILATE MESYLATE,BIBR-1048; BIBR-1048BS; BIBR-1048MS; BIBR-953; BIBR-953ZW; PRADAX; PRADAXA; PRAZAXA; RENDIX; DABIGATRAN; DABIGATRAN ETEXILATE; DABIGATRAN ETEXILATE MESYLATE,DABIGATRAN ETEXILATE,BIBR-1048,BIBR-1048BS,BIBR-1048MS,BIBR-953,BIBR-953ZW,PRADAX,PRADAXA,PRAZAXA,RENDIX,DABIGATRAN,DABIGATRAN ETEXILATE,DABIGATRAN ETEXILATE MESYLATE,,,,,,,,,,,,,,,,,,,22512,DABIGATRAN ETEXILATE MESYLATE,22512,DABIGATRAN ETEXILATE MESYLATE,,,,,,,,,,,,,,,,,,,2010-10-19T00:00:00Z,2010,10,Pradaxa,stroke,FACTOR IIA ANTAGONIST; PROTEASE-ACTIVATED RECEPTOR-1 ANTAGONIST,ANTIARRHYTHMIC AGENT,CAPSULE FORMULATION; ORAL FORMULATION; PRODRUG; SMALL MOLECULE THERAPEUTIC,matched (3),022512,NDA,2009-12-15T00:00:00Z,fda,1,0,0,0,0,,boehringer ingelheim,private,0,,,,,,,,,,,,,,,,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022512,584,65,997,238,Complications of surgical procedures or medical care,1,0
596,PLERIXAFOR,AMD-3100; GZ316455; JM-3100; MOZOBIL; SDZ-SID-791; SID-791; PLERIXAFOR,AMD-3100; GZ316455; JM-3100; MOZOBIL; SDZ-SID-791; SID-791; PLERIXAFOR,PLERIXAFOR,AMD-3100,GZ316455,JM-3100,MOZOBIL,SDZ-SID-791,SID-791,PLERIXAFOR,,,,,,,,,,,,,,,,,,,,,,,,22311,PLERIXAFOR,,,,,,,,,,,,,,,,,,,,,2008-12-15T00:00:00Z,2008,12,Mozobil,bone marrow transplantation,CXCR4 CHEMOKINE ANTAGONIST; NEUROPLASTIN INHIBITOR,ANTICANCER; ANTIVIRAL,INFUSION; INTRAVENOUS FORMULATION; SMALL MOLECULE THERAPEUTIC; SOLUTION; SUBCUTANEOUS FORMULATION,matched (3),022311,NDA,2008-06-16T00:00:00Z,fda,1,0,0,1,0,,genzyme,NASDAQ: GENZ,1,4127.43,3813.52,3187.01,2734.84,2201.14,1713.87,3284.91,1294.41,1294.41,,,,,acquired by sanofi in 2011,1,,0,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022311,528,46,2042,,,0,
